<SEC-DOCUMENT>0001410578-22-000405.txt : 20220316
<SEC-HEADER>0001410578-22-000405.hdr.sgml : 20220316
<ACCEPTANCE-DATETIME>20220316165002
ACCESSION NUMBER:		0001410578-22-000405
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220316
DATE AS OF CHANGE:		20220316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		22745505

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>syn-20211231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8042.36810 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/16/2022 8:41:17 PM -->
      <!-- iXBRL Library version: 1.0.8042.36816 -->
      <!-- iXBRL Service Job ID: a89a5706-832d-41f6-8895-76a839143746 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:syn="http://www.syntheticbiologics.com/20211231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden__wOLoItMfEOut5trbqSU7g">121875042</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_3sfOX5zm_UaozPORX6pCRg">19011362</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityCentralIndexKey" id="Tc_aDIZG6t2n0GZwd5yvkuYTA_2_1">0000894158</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:CurrentFiscalYearEndDate" id="Tc_P_akI3DE1U26SA0hTdl8ZQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:DocumentFiscalYearFocus" id="Tc_WywGZbKdZEKPeSzBbDQ9WQ_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:DocumentFiscalPeriodFocus" id="Tc_zI_l_DiMgECyz19QANz4gg_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:AmendmentFlag" id="Tc_LmSysYKNIEGOs74P9jPmJg_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityRegistrantName" id="Hidden_BQvinvRxo0eTGbNdzdVEkw">Synthetic Biologics, Inc.</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" xs:nil="true" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_pHpHOTsQ8k6yuHhORq5anA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" xs:nil="true" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_ZQSm3RSFNUWe7-1pBlUnCQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_Fdq-HoAqqU2n8c5YodGVLg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="0" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_f4gZt4BnFEalpG9LgsR3Xw">120000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_e1t6MXX3JEGFq5wEFzIGlA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="0" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_amWeR7lJNkqz2tqB1vva4w">3973</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="INF" name="us-gaap:EarningsPerShareDiluted" id="Hidden_tNvE2AVdREediPDrorC8RQ">0.19</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="INF" name="us-gaap:EarningsPerShareDiluted" id="Hidden_7MwD_ebw_UmKjW6bRvU1Yw">0.66</ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" id="Hidden_YmEvW5Sg1kyNFgYcXmib7A">http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:AmendmentFlag" id="Narr_yl_iqzuwbE6YNxoKgQk5EA">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="syn-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tO6QgfwYmUKrmumFN_QdXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ZNP2PWLgIUK7spcejRs3hQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_26_2017_V_Q0QMOYikCPg8S4qD1ovg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zR9PSAiA3US5NsG8x7-7Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_vVcxs-TyVEOrQ1i7bBXI3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:FbrCapitalMarketsCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_IPq28Mt1gUW_3j_-pwfbiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_IfsKKTpoWkaVjjV1uYXCvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_e0SFi2g7CEyrvY0QNpCI5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_g8yBpnY3o0iFqkOSqvylXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_18_2016_To_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MDjl32aA7Eup2n9x0SL85A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-18</xbrli:startDate><xbrli:endDate>2016-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_tjgiVhZrI0OhzmtDQzO8PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HesMEARWFkamUpDQQXE38g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember__EXyzsLBqku0E4Q28xmdZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y8DpvdHRXUi1PZn6rztZ4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lizShvTQnU27DK8SmxrMjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember__lq54v75EEqpd9AIZOp9HA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oR9rstllEUaUPKUvptIWbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w6f6JU4750WKM1AQ8ouQ7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_nK4S9nYjdkezj6o91cTQfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TY4ik2aZpkKjKDPnPKTE7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FpJzkt3PvkCZCGFfIrDKyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VbneEhxFhkiVk48Qo2CSMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BD7rNLuWk0iEFQwVRkploA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YJu4vcU5tUaCOKLeOjoE9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E9oQZ01YbkmNNdN49AavHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M20NXTQpLkugL1IJr-5fEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_puysgE2QRkquEuEWCphmDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice710010200Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice41007000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice0004000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice710010200Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice41007000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice0004000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TmfP0gKxNEy5KmAuY3LXKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_syn_StockPlan2010Member_4D5WRURlwE63c5hlGLugSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_8UEIx49YJkWPUL6XsZYSRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockPlan2007Member_auU9NgALU0aCvHRUD6P_0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_17_2020_us-gaap_PlanNameAxis_syn_StockPlan2020Member_KiYSEy59102VWky5jzVKvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_2_2010_us-gaap_PlanNameAxis_syn_StockPlan2010Member_Zt_SyFnbm0e4SI86EXshXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_20_2007_us-gaap_PlanNameAxis_syn_StockPlan2007Member_sZjnQm5mlUKRuIz8LR01dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2007-03-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zVfa8-ihl0GXFzR6eyN9PA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZD4aLXU3F02Cocoebc69mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_EmployeesAndDirectorsMember_nY8Xr06tV0aNNWlTT_5fvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_EmployeesAndDirectorsMember_LECQK4-VqUWq2chzZjdaUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndDirectorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2007_To_3_20_2007_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_syn_StockPlan2007Member_6vT1SirORkqYa-QBH8UMpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2007-03-01</xbrli:startDate><xbrli:endDate>2007-03-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_YKWmzXomVU-N4eCGaM8B_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_XdJgrqbMT0ShQF0kRBhn7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_5_2018_To_9_5_2018_uBFbvYxH-EmzEpTcsw0I4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-05</xbrli:startDate><xbrli:endDate>2018-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_06odZ0po2U2Duco7oDcnHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_qOfAb8XKjEiqZKgjiMEWCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_mGRCO12RFEyXuQzUlkC0Ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_IzIuFnR8zEGM4rQkXo15Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_ZvDVzBKGkEueIM7aytJo4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputersAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_588QHXjz8kSla7aDWmJMXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_xIpjyVqOO0Og8SZMiELCjw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_ThDy-dV5AU6IEh4MuJpfGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputersAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_XRwkhJ_Dmk-8YpsoxAckVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_5WO4v6359U6n6BT9EUOLpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-11</xbrli:startDate><xbrli:endDate>2017-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_U6tWdREtxkuc90dTPJYBog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-JYGHuWq50WFYfi0Zl8OPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_BQ77y5ola0aDzP3L6mwvjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_XT6XJ5XjDUuV4c_EGi70aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_E07f6QbiCEq3peUEus5GHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_wVR9EwKxu0OMQoL-9aHnSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_16_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CBpL-RLdCE6YnRWt9ySuKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_2eCFDmHGOUmlUJq481sbrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_9_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_k_-xpTQWD0GCQdXycMKDSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bg6a5VAYZkmiWar8_qygxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-27</xbrli:startDate><xbrli:endDate>2021-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_27_2021_To_1_27_2021_DAGJFo-tVEioslNEUzr8Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-27</xbrli:startDate><xbrli:endDate>2021-01-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2020_To_12_23_2020_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_CEW0YNQQwU-z7FPuSvxFMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:Dr.SlimanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2020-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2017_To_11_30_2017_9RYWQN6O80iVs8ielspjNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9Xpcg3JLq0uiDoVj62uKQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-02</xbrli:startDate><xbrli:endDate>2013-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_GqTzjk6ZRUmQxuCuv8dWDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-12-02</xbrli:startDate><xbrli:endDate>2013-12-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2020Member_FiWLkKZ3vEKpx7yg9MiRzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeaseAgreementsMember_FPxvWRsyyEuHDdGJz_4XaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_syn_SeriesAAndSeriesBPreferredStockMember_fpL3K7hVwEiXTKmMFfDtbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syn:SeriesAAndSeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ConsolidationItemsAxis_srt_ConsolidationEliminationsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_DrPimentelsMember_0ZR0S_QqJE-CfP4OWtt76g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:DrPimentelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_lfF71se-CkmmyddDrmHIPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_DrPimentelsMember_6pUuXCugXk6NelClzj9WWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:DrPimentelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_cBapFdW9TUCTcjAUH7txKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_Ub1M_a5LVE-DkomejQsGNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_2hlEGz94m0y871onqyMQIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_X7OTRMegzEONug23YJ7vFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_ppvkWxwF4027bvy1U_yy0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_MRPkLh7Yjk6pd-zFujqF_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGuOmgQVFUWelRGFisfwCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:StevenAShallcrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_3_2022_To_1_3_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6rAbrvfSCUWGUsBaubIWMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:StevenAShallcrossMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2022-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2021_To_12_23_2021_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_ob3-lBLKQ0-1m3VgfFdc-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:Dr.SlimanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-23</xbrli:startDate><xbrli:endDate>2021-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_30_2020_To_12_30_2020_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_5Rwg92J14EiVYGDVwneJ0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:StevenAShallcrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-30</xbrli:startDate><xbrli:endDate>2020-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-11</xbrli:startDate><xbrli:endDate>2017-09-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_p7WYQOUTpUi11HMdW1VRjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_3Kn9Wj-M-U2EBcPcpa_-tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_UcLPi0nU_k-Nrovhui30Ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_I2ym8-ECqUmzrLIL8pB_FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_cCtXQSarIUqWy1ntHvFVqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_16_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_JKnuxTVzpU26lxfBbgZZXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_16_2020_CZ8bHk5Mp0ir4tpe8uIf9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B1Z-wDViY0io9Y60hJ5IyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_h58kDK3e0kC9mHm8SZusWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2018_zFSd_b_S1kyXW8-66Kwglw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_18_2016_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_us-gaap_SeriesAMember_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_JdtyyC7Z80SCunUZpuqFNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ZxaIHv3whUOoORl_cB5qNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-11-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_syn_MoneyMarketAccountsMember_RVHGBSefSU2di_Mp-C0IXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">syn:MoneyMarketAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_syn_MoneyMarketAccountsMember_sKG50uvlI0qAGAuG7zjYtg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">syn:MoneyMarketAccountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_BusinessAcquisitionAxis_syn_NewTechnologiesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WiHLxploBU2xe-zdv1Ih8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:NewTechnologiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_BusinessAcquisitionAxis_syn_GrifolsInnovationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4zfGfEAdcUanM58rCqi1Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:GrifolsInnovationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_CsW_sJTdhUmHG2HCpG3-rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_OptionMember_UcsU_7n8D0Gh9M_a12yMqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_p0e-bc-m1k-aY-9mEgL6FQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_OptionMember_w-qS4dRJ3U6O4DpjgVohSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_VjXYAcDWp02HBkXd6GYVAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_MCFQsLEw-UuxHL58RoxInQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_eQmeAnrjzk6zi6wV_bY3hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_ombmDTe2AkCAbJcUoj-n9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_-3VYIo1Se0a3VB9LflrxFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_thyNdGbiIUKfEg211NQAxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_15_2018_To_10_15_2018_us-gaap_ClassOfWarrantOrRightAxis_syn_OctoberTwoThousandEighteenWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_syn_UnderwrittenPublicOfferingMember_Kff7vF4eSUKF3WYZhsclQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:OctoberTwoThousandEighteenWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-15</xbrli:startDate><xbrli:endDate>2018-10-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_mAkr-3jFnkW2bbxcAR8RYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice1820Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_Y6KWsIfrY0W-AXmu4z1SHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice0.69TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_nGWIzttATUuENHWAb_1Gxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice0.69Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_7WfemUuB9kSDPnEwicRDoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_VMLlPD7ENUWWhTbFeid_mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice1820Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_8CxCH8oNkEm74aCXq-VOTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice0.69TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_Qfjmc-RTiEuH6kugXZ51Iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice0.69Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_26_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_MzByem4-e0OSJosV2hHEFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_ThirdYearMember_pDW3ZJBjLEOCTDy7Fvp73A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="syn:QuarterlyInstallmentsPaymentPeriodAxis">syn:ThirdYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_SecondYearMember_BTboTCNJsUKQRiy6cxkbug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="syn:QuarterlyInstallmentsPaymentPeriodAxis">syn:SecondYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_FirstYearMember__Bn5hy98mU6mfmfCN95quw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="syn:QuarterlyInstallmentsPaymentPeriodAxis">syn:FirstYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_ISVZPzMHc0Ggvc_ZgMPJ2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:FbrCapitalMarketsCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_84bpVptC1E-TU2cJmJR7uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Y8P_QWYzfky5T_au5O14bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember_OdBA1XZNCkSZ2xDmj4iqwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:PrevAbrLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_HRovq6U78E-v3Zs9fQPjlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_XDETk7h4EEaL0z0ltMNi8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_gGcNUhXIPkSw2CheAQJBxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_MCMoFtcreUerjsPb8Xr3IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-18</xbrli:startDate><xbrli:endDate>2016-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_qr4fxMiyiEuZKSyigooSJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-18</xbrli:startDate><xbrli:endDate>2016-11-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_QYEqV_MK-kaCxh0ejQsXbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_RegulatoryApprovalInAsianCountryMember_b29ls9jD-Eq0pdQkSHFuxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:RegulatoryApprovalInAsianCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-02</xbrli:startDate><xbrli:endDate>2012-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_PhaseIiiClinicalTrialsMember_lswYHCn0iEGpMO6RGGHoqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:PhaseIiiClinicalTrialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-02</xbrli:startDate><xbrli:endDate>2012-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_PhaseIClinicalTrialsMember_TUHpBF3yc0CkN3QUWLfWmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:PhaseIClinicalTrialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-02</xbrli:startDate><xbrli:endDate>2012-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_NdaSubmissionInUsMember_iAOhW_VZcEGqi0gmByMIAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:NdaSubmissionInUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-02</xbrli:startDate><xbrli:endDate>2012-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_EuropeanMedicinesAgencyApprovalMember_P8LwHIwz0kewI_WCPzgecA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:EuropeanMedicinesAgencyApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-02</xbrli:startDate><xbrli:endDate>2012-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2012_To_12_19_2012_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_gp7VGPemIUmMsNTJacOkog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-01</xbrli:startDate><xbrli:endDate>2012-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_AwBR-gCbEkOKHtktUYXQIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_uAjHlff2ZEySANOAcEoi0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_3SlaVldlt0uuxM4dd8Zq4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2018_To_9_5_2018_BLr1pn9j6UusGha5FDmjVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_7_2019_To_8_7_2019_us-gaap_TypeOfArrangementAxis_syn_ClinicalTrialAgreementMember_e8nSUVWVOUOzmBeVgBlJ_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:ClinicalTrialAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-07</xbrli:startDate><xbrli:endDate>2019-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2020_To_12_23_2020_lK-7ce7kgUKMLA_1odurJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-23</xbrli:startDate><xbrli:endDate>2020-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nYSwPr0VKkqWTeFT1i_ttQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_iWZnfq9DoESxxwMr9XQsEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3rOlqxEP0ybyVhLBiTYEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8-WgejdDaEqgy2EWOSkLzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B8SS6pik5UydvtJcCB9dlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_US3t8HW7-0GmoQhdLHyCwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_u3tJQ_TKWUKU4AV_VlfaIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_fJelKMiPik68kesEofzomQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z7S1T7sWPU-5mMUOHtvhAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p4kGNEYs-UaBwLK97CJoow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_10_2022_To_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nY9W9p5hLEOy0btQJThIaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-10</xbrli:startDate><xbrli:endDate>2022-03-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:OtherSecondIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:OtherFirstIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6abns4wbvk2nLNMGsIo3mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_5_2016_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_z5Ev0yENHUmoho2bPyB-eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:FbrCapitalMarketsCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_29_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_19H4jFVReE6xfC5K5cBF2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JT5YJdWctkSrgjj-7sNP_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYTAthCVn0yW8kcGh07aqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_2_2012_To_11_28_2012_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember__uZ5OPc6pka-czPBvUDXXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:PrevAbrLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-11-02</xbrli:startDate><xbrli:endDate>2012-11-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_MBsOhyAU1U-BqkratkUq7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_16_2022_umqElCEvQEmNaFMGvvZFPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000894158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_yMnlz8fE9U-5tR1qkqQKuA"><xbrli:measure>syn:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:3.88%;padding-right:3.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">  </b><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_dd18e481_e380_4139_8faf_ea34aa1b5e0a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:DocumentType" id="Narr_igEh-5p84UO6ixlkErH2Ag"><b style="font-size:8pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:DocumentAnnualReport" id="Narr_WJ8vzMZVtkirVRc3nGT5OA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;</span><b style="font-size:8pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:DocumentPeriodEndDate" id="Narr_rEh6dqkOcEiTsdAjXxoyzg"><b style="font-size:8pt;font-weight:bold;">December&#160;31, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:DocumentTransitionReport" id="Narr_i48lUAHvV0SW8fVE-anq2Q"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;</span><b style="font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityFileNumber" id="Narr_p9PKWbwcJUSLOaWvo30aCQ"><b style="font-size:8pt;font-weight:bold;">001-12584</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_BQvinvRxo0eTGbNdzdVEkw;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">SYNTHETIC BIOLOGICS,&#160;INC.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Exact Name of Registrant as Specified in Its Charter)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_553e8ab1_9844_4365_8f19_b12e26c893c8"></a><a id="Tc_ULC1GFvnOUqTnv1bbxSoIA_2_0"></a><a id="Tc_YlGkeq0NVE6E3KDh0fljSA_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityIncorporationStateCountryCode" id="Tc_H0HqScr_fUSM3MmATWvHmw_1_0"><b style="font-size:8pt;font-weight:bold;">Nevada</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityTaxIdentificationNumber" id="Tc_keeYmNuox0KPfx9V4LaaUA_1_2"><b style="font-size:8pt;font-weight:bold;">13-3808303</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(State or Other Jurisdiction of Incorporation or</i><br /><i style="font-style:italic;">Organization)</i></p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(I.R.S. Employer</i><br /><i style="font-style:italic;">Identification Number)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a0c6defb_d0d3_4684_9e7b_ef8ca244c3ac"></a><a id="Tc_VluVb6_g40iS9-Fk6vTK_A_1_0"></a><a id="Tc_zPUyBhgGq0yuHTEVKfJ9wg_2_0"></a><a id="Tc_54wIAnaSF0KU34p9koOPtg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.61%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityAddressAddressLine1" id="Narr_6vQPNIAUAEmAlDyNqBfM9g"><b style="font-size:8pt;font-weight:bold;">9605 Medical Center Drive, Ste. 270</b></ix:nonNumeric><span style="font-size:8pt;"><br /></span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityAddressCityOrTown" id="Narr_yIZKH3vYLEqFzWDSfx4Y2A"><b style="font-size:8pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityAddressCountry" id="Narr_Q627kfPO6UW73iK1hFEEQA"><b style="font-size:8pt;font-weight:bold;">MD</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityAddressPostalZipCode" id="Tc_mc1QBtnKwEWoGsAPoFaPnw_1_2"><b style="font-size:8pt;font-weight:bold;">20850</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Address of Principal Executive Offices)</i></p></td><td style="vertical-align:bottom;width:2.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Zip Code)</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;white-space:pre-wrap;"> (</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:CityAreaCode" id="Narr_xiNr4Q5EhEy4TwBBnlKBUA"><b style="font-size:8pt;font-weight:bold;">301</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:LocalPhoneNumber" id="Narr_vj1d6FK8ZUy8jQyBTT8wiQ"><b style="font-size:8pt;font-weight:bold;">417-4364</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b50fc6ff_9da0_4905_84dd_201d83f26684"></a><a id="Tc_TyycAwcscEuahOPib5-gcw_1_0"></a><a id="Tc_vNF6MvnvB0q2Ip1zZCpTTg_1_2"></a><a id="Tc_TJ630jGRSkKpvNP9e2Y18g_1_4"></a><a id="Tc_-IQc999GeE-txwR7Ri7lOw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:39.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:39.36%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:39.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:2.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:15.95%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:39.36%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:39.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:Security12bTitle" id="Tc_nFa-5Y7L7Ue1qvXQZ6iUYw_2_0"><span style="font-size:8pt;">Common Stock</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:15.95%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:TradingSymbol" id="Tc_uyg43PNvjUqKNEQ3YmQ1dg_2_2"><span style="font-size:8pt;">SYN</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:39.36%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:SecurityExchangeName" id="Narr_4hrRhqZiNUSj17XtFl6Nrg"><span style="font-size:8pt;">NYSE</span></ix:nonNumeric><span style="font-size:8pt;"> American</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="font-style:italic;font-weight:bold;white-space:pre-wrap;"> None</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-family:'Wingdings';font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_UGJcEqxqGkG5q2Edh691Eg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="font-size:8pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-family:'Wingdings';font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityVoluntaryFilers" id="Narr_G_TbGiV-mk2BKZjij_taAw"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Indicate by check mark whether the issuer: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityCurrentReportingStatus" id="Narr_r5ADZNlsSEOXcgWNBogkTw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-family:'Wingdings';font-size:8pt;"> </span><span style="font-size:8pt;">No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (section 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityInteractiveDataCurrent" id="Narr_KNsZDxfWJEOQAPfCKiajWQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-family:'Wingdings';font-size:8pt;"> </span><span style="font-size:8pt;">No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer, &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. (Check one):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1fd7cdd7_6d3d_4550_a38e_7245bd0650a6"></a><a id="Tc_rfR5tj6m4EKEZn8buDbllw_1_0"></a><a id="Tc_pTadd474gE6zgY1aaGN89A_1_1"></a><a id="Tc_XQHBijOrxEavSs3ct9dEKA_1_3"></a><a id="Tc_PJMxNfAtUEO-ut_1LeDHig_1_4"></a><a id="Tc_6voDfGTo9E6LFDc-oDQ66g_3_1"></a><a id="Tc_lItiAO_tvkiYGZfQ05qk2Q_3_3"></a><a id="Tc_mfKTTNOC7UiH5lz3EOHBzA_5_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large&#160;Accelerated&#160;Filer</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated&#160;Filer</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityFilerCategory" id="Tc_rR3FRUyZ9US2pKOyiqMYSg_3_0"><span style="font-size:8pt;">Non-accelerated&#160;Filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller&#160;Reporting&#160;Company</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntitySmallBusiness" id="Tc_w4M9TrN2Q0-fMau5grodrA_3_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:2pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:43.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityEmergingGrowthCompany" id="Tc_KifUZ1VHC0eEnjmAXIJ7Zg_5_4"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. &#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Segoe UI Symbol';font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:IcfrAuditorAttestationFlag" id="Narr_2BKukzij6kyRiEjTtb8lvw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 5pt 0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-family:'Wingdings';font-size:8pt;"> </span><span style="font-size:8pt;">No </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:EntityShellCompany" id="Narr_rdkwoj4LnEOmwR1Yn_KzQw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant as of June&#160;30, 2021, the last business day of the registrant&#8217;s recently completed second quarter, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2021_MBsOhyAU1U-BqkratkUq7w" decimals="-5" name="dei:EntityPublicFloat" id="Narr_L8Gt-6XhZ0mVBfyFbdogJQ">79.2</ix:nonFraction> million based on $0.60, the closing price of the registrant&#8217;s common stock as reported by the NYSE American on that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">As of March&#160;16, 2022, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_16_2022_umqElCEvQEmNaFMGvvZFPQ" decimals="0" name="dei:EntityCommonStockSharesOutstanding" id="Narr_M5izBwoGRkSNMCmZ5OmGNg">158,437,840</ix:nonFraction> shares of common stock outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 1pt 0pt;">Documents incorporated by reference: <b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:92.24%;border:0;margin:30pt 3.88% 30pt 3.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a9812f5d_ff70_4496_86ac_56ad7f997d79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">SYNTHETIC BIOLOGICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;10-K</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_146175"><span style="font-style:normal;font-weight:normal;">PART&#160;I.</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BusinessOverview_515891"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BusinessOverview_515891"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_830998"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_830998"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_955608"><span style="font-style:normal;font-weight:normal;">Item&#160;1B.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_955608"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">48</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_968497"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_968497"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">48</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_303884"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_303884"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_792475"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_792475"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_464332"><span style="font-style:normal;font-weight:normal;">PART&#160;II.</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_437170"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_437170"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">50</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;7.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">50</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item&#160;7A.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">55</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item&#160;9.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_509870"><span style="font-style:normal;font-weight:normal;">Item&#160;9A.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_509870"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">83</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_266663"><span style="font-style:normal;font-weight:normal;">Item&#160;9B.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_266663"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">I</span><span style="font-style:normal;font-weight:normal;">tem&#160;9C.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_87758"><span style="font-style:normal;font-weight:normal;">PART&#160;III.</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Item&#160;10.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_150315"><span style="font-style:normal;font-weight:normal;">Item&#160;11.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_150315"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">87</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item&#160;12.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">97</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item&#160;13.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Item&#160;14.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_978496"><span style="font-style:normal;font-weight:normal;">PART&#160;IV.</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">100</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item&#160;15.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">100</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_42441"><span style="font-style:normal;font-weight:normal;">Item&#160;16.</span></a></p></td><td style="vertical-align:top;width:83.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_42441"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">106</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0c30baea_eeeb_464f_9481_a36488ecc43a"></a><a id="PARTI_146175"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Special Note&#160;Regarding Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">This Annual Report on Form&#160;10-K (this &#8220;Annual Report&#8221;) contains forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that involve substantial risks and uncertainties. The forward-looking statements are contained principally in Part&#160;I, Item&#160;1. &#8220;Business,&#8221; Part&#160;I, Item&#160;1A. &#8220;Risk Factors,&#8221; and Part&#160;II, Item&#160;7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; but are also contained elsewhere in this Annual Report. In some cases you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; and similar expressions. These statements are based on our current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed, projected or implied in or by the forward-looking statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should refer to Item&#160;1A. &#8220;Risk Factors&#8221; section of this Annual Report for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. We do not undertake any obligation to update any forward-looking statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Unless the context requires otherwise, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;Synthetic Biologics,&#8221; refer to Synthetic Biologics,&#160;Inc. and its subsidiaries.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Summary Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following is a summary of the key risks relating to the Company. A more detailed description of each of the risks can be found below under Item 1A. Risk Factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to the Acquisition of VCN Biosciences, S.L.(&#8220;VCN&#8221;)</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The combined company may not experience the anticipated strategic benefits of the acquisition of VCN.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to successfully integrate the VCN businesses with our current management and structure.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We do not anticipate generating revenue from product or technology sales for many years.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In order to develop VCN products or technology we will have to devote significant resources to VCN products or technology and will need to raise additional capital to fully develop the newly acquired product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of our common stock following the acquisition of VCN may decline as a result of the acquisition.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our stockholders will experience substantial dilution from the issuance of the acquisition consideration.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Our Business</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need to raise additional capital to operate our business and our failure to obtain funding when needed may force us to delay, reduce or eliminate certain of our development programs or commercialization efforts.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The COVID-19 global health crisis has impacted and could continue to impact our planned operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Business disruptions could seriously harm our future revenue and fianncal conditions and increase costs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect to continue to incur significant operating and capital expenditures.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The actual amount of funds we will need to operate is subject to many risk factors, some of which are beyond our control.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently have no products approved for commercial sale, have no significant source of revenue and may never generate significant revenue.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To date we have not conducted any cancer research and development activities and there can be no assurance that we will successfully be able to do so.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In the past Oncolytic Viruses have experienced certain challenges</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our research and development efforts may not succeed in developing successful products and technologies, which may limit our ability to achieve profitability. </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to retain rights licensed to us by others to commercialize key products and may not be able to establish or maintain the relationships we need to develop, manufacture, and market our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may incur additional expenses in connection with our licenses and collaboration arrangements and our development of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Developments by competitors may render our products or technologies obsolete or non-competitive.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may seek to selectively establish collaborations, and, if we are unable to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the parties we depend on for supplying drug substance, raw materials for our product candidates and certain manufacturing-related services, are insufficient in quality or quantity, it may delay or impair our ability to develop, manufacture and market our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For the proposed Phase 2 clinical trial of VCN-01 &#160;in patients with PDAC, we plan to administer our clinical product candidate, VCN-01, in combination with other approved standard of care drugs. Any problems obtaining the standard of care drugs could result in a delay or interruption in our clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may fail to retain or recruit necessary personnel, and we may be unable to secure the services of consultants.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely extensively on our information technology systems which are vulnerable to damage and interruption.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any failure to maintain the security of information relating to our patients, customers, employees and suppliers, whether as a result of cybersecurity attacks or otherwise, could expose us to litigation, government enforcement actions and costly response measures, and could disrupt our operations and harm our reputation.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may face particular data protection, data security and privacy risks in connection with the European Union&#8217;s Global Data Protection Regulation and other privacy regulations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Risks</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we do not obtain the necessary regulatory approvals in the U.S. and/or other countries, we may not be able to develop or sell our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials are very expensive, time consuming, and difficult to design and implement.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The results of our clinical trials may not support our proposed product candidate claims and the results of preclinical studies and completed clinical trials are not necessarily predictive of future results.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Difficulties in enrolling, retaining, or completing patients in our clinical trials or delays in enrollment are expected to result in our clinical development activities being delayed or otherwise adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patients who are administered our product candidates may experience unexpected side effects or other safety risks that could cause a halt in clinical development, preclude approval or limit the commercial potential of the product candidate.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates, if approved for sale, may not gain acceptance among physicians, patients and the medical community.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on third parties, including researchers and sublicensees, who are not under our control. If these third parties do not successfully carry out their contractual duties or meet expected deadlines we may not be able to seek or obtain regulatory approval for, or commercialize our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently have no marketing, sales or distribution organization and have no experience in marketing products as a company.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reimbursement may not be available for our product candidates, which would impede sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Healthcare reform measures could hinder or prevent our product candidates&#8217; commercial success.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property Risks</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on patent applications and various regulatory exclusivities to protect some of our product candidates and our ability to compete may be limited or eliminated if we are not able to protect our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may incur substantial costs as a result of litigation or other proceedings relating to protecting our intellectual property rights, as well as costs associated with lawsuits.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we infringe the rights of others, we could be prevented from selling products or forced to pay damages.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><span style="font-style:italic;font-weight:bold;">Risks Related to Our Securities</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We cannot assure you that our common stock will be liquid or that it will remain listed on the NYSE American.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We expect to seek to raise additional capital in the future, which may be dilutive to stockholders or impose operational restrictions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Holders of our warrants issued in our October 2018 offering have no rights as common stockholders until they exercise their warrants and acquire our common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of our common stock has been and may continue to be volatile and adversely affected by various factors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our articles of incorporation and bylaws and Nevada law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline. We do not intend to pay dividends in the foreseeable future on our common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We do not intend to pay dividends in the foreseeable future on ur common stock.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Resales of our common stock in the public market by our stockholders may cause the market price of our common stock to fall.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The shares of common stock offered under our current Amended and Restated At The Market Issuance Sales Agreement may be sold in &#8220;at the market&#8221; offerings, and investors who buy shares at different times will likely pay different prices.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COVID-19 Update</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are continuing to assess the potential impact of the COVID-19 pandemic.&#160; We are in close contact with our clinical development partners in order to assess the&#160;impact of COVID-19 on our studies and current timelines and costs.&#160; While we currently do not anticipate any interruptions in our operations due to COVID-19, it is possible that if the COVID-19 pandemic persists for an extended period of time, we could experience significant disruptions to our clinical development timelines due to the COVID-19 pandemic, which would adversely affect our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In response to the spread of COVID-19 as well as public health directives and orders, we have implemented a number of measures designed to ensure employee safety and business continuity. We have limited access to our offices and are allowing our administrative employees to continue their work outside of our offices in order to support the community efforts to reduce the transmission of COVID-19 and protect employees, complying with guidance from federal, state and local government and health authorities. The full extent to which the COVID-19 outbreak will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted. The effects of the governmental orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e9a9ae37_d3ad_446f_a14a_c66b32a804a3"></a><a id="Item1BusinessOverview_515891"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1.&#160;&#160;&#160;&#160;</b><span style="font-style:italic;font-weight:bold;">Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Acquisition of VCN Biosciences, S.L</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 14, 2021, we entered into a Share Purchase Agreement (&#8220;Purchase Agreement&#8221;) with VCN Biosciences, S.L., a corporation organized under the laws of Spain (&#8220;VCN&#8221;) and the shareholders of VCN (the &#8220;Sellers&#8221;), which provided for our acquisition (the &#8220;Acquisition&#8221;) of all the outstanding shares of VCN (the &#8220;VCN Shares&#8221;) from the shareholders of VCN. VCN is a private, clinical-stage biopharmaceutical company developing new oncolytic adenoviruses for the treatment of cancer. VCN&#8217;s lead product candidate, VCN-01, is being studied in clinical trials for pancreatic cancer and retinoblastoma. The Acquisition was consummated on March 10 2022 and VCN became our wholly owned subsidiary. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the Purchase Agreement, as consideration for the purchase of the VCN Shares of capital stock, we paid $4,700,000 (the &#8220;Closing Cash Consideration&#8221;) to Grifols Innovation and New Technologies Limited (&#8220;Grifols&#8221;), the owner of approximately 86% of the equity of VCN, and issued to the remaining Sellers 26,395,303 shares of our common stock, $.001 par value (the &#8220;Closing Shares&#8221;), representing 19.99% of the outstanding shares of our common stock on December 14, 2021, the date of the Purchase Agreement. As </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">additional consideration for the purchase of the VCN Shares held by Grifols, we also agreed to make the following milestone payments to Grifols:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-weight:bold;">Milestone Payments</b></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;">US$3MM upon VCN-01 US IND Safe to Proceed pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;, or other&#160;<i style="font-style:italic;">first</i>&#160;indication)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;">US$2.75MM upon VCN-01 US IND Safe to Proceed &#8211; retinoblastoma (&#8220;RB&#8221;, or other&#160;<i style="font-style:italic;">second&#160;</i>indication)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;">US$3.25MM upon VCN-01 US first patient dosed&#8211; PDAC (or other&#160;<i style="font-style:italic;">first</i>&#160;indication) after receipt of VCN-01 US IND Safe to Proceed for PDAC being informed</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;">US$3.25MM upon VCN-01 US first patient dosed &#8211; RB (or other&#160;<i style="font-style:italic;">second&#160;</i>indication) after receipt of VCN-01 US IND Safe to Proceed for RB being informed</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;">US$6MM upon VCN-01 US Phase 2 trial meets the primary endpoint or if a Phase 2 trial is not conducted and only a Phase 3 trial is conducted then upon a Phase 3 being initiated &#8211; PDAC (or other&#160;<i style="font-style:italic;">first</i>&#160;indication)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;">US$8MM upon VCN-01 Pivotal Trial meeting the primary endpoint or upon BLA Submission &#8211; RB (or other&#160;<i style="font-style:italic;">second&#160;</i>indication)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;">US$12MM upon VCN-01 US Phase 3 trial meeting the primary endpoint or upon BLA Submission &#8211; PDAC (or other&#160;<i style="font-style:italic;">first</i>&#160;indication)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;">US$16MM upon VCN-01 BLA Approval &#8211; PDAC (or other&#160;<i style="font-style:italic;">first</i>&#160;indication)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 35.25pt;">US$16MM upon VCN-01 BLA Approval &#8211; RB (or other&#160;<i style="font-style:italic;">second&#160;</i>indication)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Purchase Agreement, at the Closing we assumed $2,400,000 of liabilities of VCN, which includes certain loans from the Spanish Government and the Catalan Government Agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Purchase Agreement contains customary representations, warranties and covenants of the Sellers and us. Subject to certain customary limitations, the Sellers have agreed to indemnify us and our officers and directors against certain losses related to, among other things, breaches of their representations and warranties, certain specified liabilities and the failure to perform covenants or obligations under the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Purchase Agreement we agreed to loan VCN up to $425,000 to help finance the costs of certain of VCN&#8217;s research and development activities. In addition, at Closing VCN and Grifols entered into a sublease agreement for the sublease by VCN of the laboratory and office space currently occupied by it as well as a transitional services agreement. We agreed as a post- Closing covenant to commit to fund VCN&#8217;s research and development programs, including but not limited to VCN-01 PDAC phase 2 trial, VCN-01 RB pivotal trial and necessary G&amp;A within a budgetary plan of approximately $27.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Upon effecting the Acquisition, on March 10, 2022 our pipeline is now expanded to include and focus on treatments of cancers. Our product pipeline has been expanded to include VCN&#8217;s lead product candidate, VCN-01, which is being studied in clinical trials for pancreatic cancer and retinoblastoma. In February 2022, VCN-01 received Orphan Drug Designation for the treatment of retinoblastoma from the U.S. Food &amp; Drug Administration (&#8220;FDA&#8221;). &#160;VCN-01 is designed to be administered systemically, intratumorally or intravitreally, either as a monotherapy or in combination with standard of care, to treat a wide variety of cancer indications. VCN-01 is designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment, Degrading the tumor stroma has been shown to improve access to the tumor by the virus and additional therapies such as chemo- and immuno-therapies. Importantly, degrading the stroma exposes tumor antigens, turning &#8220;cold&#8221; tumors &#8220;hot&#8221; and enabling a sustained anti-tumor immune response. VCN has the rights to four exclusive patents for proprietary technologies, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (&#8220;ICO-IDIBELL&#8221;), with a number of additional patents pending.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:203.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to the Acquisition, our main focus was on developing therapeutics designed to treat gastrointestinal (GI) diseases in areas of high unmet need. Our lead clinical development candidates in addition to our VCN product candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the GI tract to prevent microbiome damage, <i style="font-style:italic;">Clostridioides difficile</i> infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. We intend to continue with our clinical development partners to advance the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic HCT patients, and complete the Phase 1 program for SYN-020 intestinal IAP to support potential development in a number of significant clinical indications related to inflammation and gut barrier dysfunction. We have an option-license agreement with Massachusetts General Hospital (&#8220;MGH&#8221;) for intellectual property related to these SYN-020 indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of 2021, Washington University began enrollment and dosed our first patient in the first of three antibiotic cohorts for the Phase 1b/2a clinical trial of SYN-004 in adult HCT recipients (Q2 2021). At December 31 2021, 12 participants had been treated with at least one dose of the study drug and 8 were considered evaluable towards the primary endpoint.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the second quarter of 2021, we commenced and completed enrollment, dosing and observation in a Phase 1 single ascending dose (&#8220;SAD&#8221;) study of SYN-020 in healthy volunteers. Analyses of preliminary data from the Phase 1 SAD study of SYN-020 demonstrated that SYN-020 maintained a favorable safety profile and was well tolerated at all doses with no treatment related adverse events and no serious adverse events reported. During the third quarter of 2021, we commenced enrollment, dosing and observation in a Phase 1, multiple ascending dose (&#8220;MAD&#8221;) clinical trial of SYN-020 in healthy, adult volunteers. A data readout is anticipated during the second quarter of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Current Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="syn-20211231x10k001.jpg" alt="Graphic" style="display:inline-block;height:203.22pt;width:522.68pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">*Based on management&#8217;s current beliefs and expectations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">aGVHD</b> acute graft-vs-host disease; <b style="font-weight:bold;">allo-HCT</b> allogeneic hematopoietic cell transplant. <b style="font-weight:bold;">IAP</b> recombinant bovine intestinal alkaline phosphatase II. <b style="font-weight:bold;">CPI</b> immune checkpoint inhibitor. <b style="font-weight:bold;">Gem/Nab</b> Gemcitabine + Abraxane&#174; (nab-paclitaxel). <b style="font-weight:bold;">HNSCC</b> head and neck squamous cell carcinoma. <b style="font-weight:bold;">IV</b> intravenous. <b style="font-weight:bold;">IVit</b> intravitreal. <b style="font-weight:bold;">MAD</b> multiple ascending dose. <b style="font-weight:bold;">ODD</b> Orphan Drug Designation. <b style="font-weight:bold;">OV</b> oncolytic adenovirus engineered to selectively replicate in tumors and express hyaluronidase enzyme PH20. Additional products with preclinical proof-of-concept include SYN-006 (carbapenemase) to prevent aGVHD and infection by carbapenem resistant enterococci and SYN-007 (ribaxamase) DR to prevent antibiotic associated diarrhea with oral &#946;-lactam antibiotics. Depending on funding/partnership, SYN-004 may enter an FDA-agreed Phase 3 clinical trial for the treatment of Clostridioides difficile infection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our </b><b style="font-weight:bold;">Current Gastrointestinal (GI) and </b><b style="font-weight:bold;">Microbiome-Focused Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our SYN-004 (ribaxamase) and SYN-020 clinical programs are focused on the gastrointestinal tract (GI) and the gut microbiome, which is home to billions of microbial species and composed of a natural balance of both &#8220;good&#8221; beneficial species and potentially &#8220;bad&#8221; pathogenic species. When the natural balance or normal function of these microbial species is disrupted, a person&#8217;s health can be compromised. Disruption of the gut barrier is associated with a number of inflammatory and metabolic diseases. All of our programs are supported by our growing intellectual property portfolio. We are maintaining and building our patent portfolio through filing new patent applications; prosecuting existing applications; and licensing and acquiring new patents and patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">SYN-004 (ribaxamase)&#160;&#8212;&#160;Prevention of antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">SYN-004 (ribaxamase) is a proprietary oral capsule prophylactic therapy designed to degrade certain IV beta-lactam antibiotics excreted into the GI tract and thereby maintain the natural balance of the gut microbiome. Preventing beta-lactam damage to the gut microbiome has a range of potential therapeutic outcomes, including prevention of CDI, suppression of the overgrowth of pathogenic species (particularly antimicrobial-resistant organisms) and potentially reducing the incidence and/or severity of aGVHD in allogeneic hematopoietic cell transplant (HCT) patients. SYN-004 (ribaxamase) 75 mg capsules are intended to be administered orally while patients are administered certain IV beta-lactam antibiotics. The capsule dosage form is designed to release the SYN-004 (ribaxamase) enzyme into proximal small intestine, where it has been shown to degrade beta-lactam antibiotics in the GI tract without altering systemic antibiotic levels. Beta-lactam antibiotics are a mainstay in hospital infection management and include the commonly used penicillin and cephalosporin classes of antibiotics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clostridioides difficile Infection</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clostridioides difficile </i>(formerly known as <i style="font-style:italic;">Clostridium difficile </i>and often called <i style="font-style:italic;">C. difficile </i>or CDI) is a leading type of hospital acquired infection and is frequently associated with IV beta-lactam antibiotic treatment. The Centers for Disease Control and Prevention (CDC) identified <i style="font-style:italic;">C. difficile</i> as an &#8220;urgent public health threat,&#8221; particularly given its resistance to many drugs used to treat other infections. CDI is a major unintended risk associated with the prophylactic or therapeutic use of IV antibiotics, which may adversely alter the natural balance of microflora that normally protect the GI tract, leading to <i style="font-style:italic;">C. difficile</i> overgrowth and infection. Other risk factors for CDI include hospitalization, prolonged length of stay (estimated at 7&#160;days), underlying illness, and immune-compromising conditions including the administration of chemotherapy and advanced age. According to a paper published in BMC Infectious Diseases (Desai K et al. BMC Infect Dis. 2016; 16: 303) the economic cost of CDI was approximately $5.4 billion in 2016 ($4.7 billion in healthcare settings; $725 million in the community) in the U.S., mostly due to hospitalizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Limitations of Current Treatments and Market Opportunity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">CDI is a widespread and often drug resistant infectious disease. Approximately 20% of patients who have been diagnosed with CDI experience a recurrence of CDI within one to three months. Furthermore, controlling the spread of CDI has proven challenging, as the <i style="font-style:italic;">C. difficile</i> spores are easily transferred to patients via normal contact with healthcare personnel and with inanimate objects. There is currently no vaccine or approved product for the prevention of primary (incident) CDI. The current standard of care for primary CDI, as outlined by the Infectious Disease Society of America (IDSA), is to treat with powerful antibiotics such as fidaxomicin or vancomycin. Prolonged use of fidaxomicin and vancomycin has been shown to further exacerbate damage to the gut microbiome, leading to increased risk of CDI recurrence as well as the emergence of pathogenic and antimicrobial-resistant (AMR) organisms, such as vancomycin-resistant enterococci (VRE). AMR is a serious global threat and one which world leaders have begun to take action against. According to the European Society of Clinical Microbiology and Infections Disease (ECCMID), failure to address AMR could lead to a potential antibiotic Armageddon, resulting in 10 million deaths worldwide by 2050 and may cost as much as $100 trillion in worldwide economic output.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">According to a paper published in BMC Infectious Diseases (Desai K (2016) Epidemiological and economic burden of <i style="font-style:italic;">Clostridium difficile</i> in the United States: estimates from a modeling approach. BMC Infect Dis 16: 303), it is estimated that approximately 606,000 patients are infected with <i style="font-style:italic;">C. difficile</i> annually in the U.S., and it has been reported that approximately 44,500 deaths are attributable to CDI-associated complications each year. According to IMS Health Incorporated*, in 2016, the potential addressable market for SYN-004 (ribaxamase) included approximately 227 million doses of intravenous Penicillin and Cephalosporin antibiotics which were administered in the United States and which may contribute to the onset of CDI. Additional data derived from IMS Health Incorporated states that in 2016, the worldwide market for SYN-004 (ribaxamase)-addressable intravenous beta-lactam antibiotics was approximately </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">7.5 billion doses, which may represent a multi-billion-dollar market opportunity for us.&#160;If approved, SYN-004 (ribaxamase) would be the first therapeutic intervention indicated to prevent the onset of antibiotic-mediated primary CDI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 1a and 1b Clinical Trial Pharmacokinetic Data</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March&#160;2015, we reported supportive pharmacokinetic data from a Phase 1a clinical trial, which suggested that SYN-004 (ribaxamase) should have no effect on the IV antibiotic in the bloodstream, allowing the antibiotic to fight the primary infection. In February&#160;2015, we reported supportive topline results from a subsequent Phase 1b clinical trial of escalating doses of oral SYN-004 (ribaxamase), with no safety or tolerability issues reported at dose levels and dosing regimens that were equivalent to or exceeded those expected to be studied in subsequent clinical trials. The Phase 1a (40 participants) and 1b (24 participants) clinical trials of SYN-004 (ribaxamase) were initiated in December&#160;2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Two Phase 2a Clinical Trials: Topline Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December&#160;2015, we reported supportive topline results from our first Phase 2a clinical trial of SYN-004 (ribaxamase). The study demonstrated that SYN-004 (ribaxamase) successfully degraded IV ceftriaxone in the chyme of ten participants with ileostomies without affecting the levels of ceftriaxone in the bloodstream. In May&#160;2016, we reported supportive topline results from a second Phase 2a clinical trial of SYN-004 (ribaxamase) in 14 healthy participants with functioning ileostomies administered IV ceftriaxone with and without oral SYN-004 (ribaxamase). This second study demonstrated that the 150 mg dose of SYN-004 (ribaxamase), both alone and in the presence of the proton pump inhibitor (PPI), esomeprazole, degraded ceftriaxone excreted into the chyme resulting in ceftriaxone levels that were low or not-detectable. Ceftriaxone plasma concentrations in participants of the second study were not altered by SYN-004 (ribaxamase) in the presence or absence of an oral PPI, suggesting limited drug-drug interactions. The 150 mg dose of SYN-004 (ribaxamase) was well tolerated by all participants in this clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 2b Proof of Concept Clinical Trial Design&#160;&amp; Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September&#160;2015, we initiated a multicenter, randomized, placebo-controlled Phase 2b proof-of-concept clinical study in 412 patients (206 per group).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 5, 2017, we announced positive topline data from our Phase 2b proof-of-concept clinical trial intended to evaluate the ability of SYN-004 (ribaxamase) to prevent CDI, CDAD (<i style="font-style:italic;">C. difficile</i>-associated diarrhea) and AAD (antibiotic-associated diarrhea) in patients hospitalized for a lower respiratory tract infection and receiving IV ceftriaxone. Results from this study demonstrated that SYN-004 (ribaxamase) achieved its primary endpoint of significantly reducing CDI. Preliminary analysis of the data indicated seven confirmed cases of CDI in the placebo group compared to two cases in the SYN-004 (ribaxamase) treatment group. Patients receiving SYN-004 (ribaxamase) achieved a 71.4% relative risk reduction (p-value=0.045) in CDI rates compared to patients receiving placebo. SYN-004 (ribaxamase) treated patients also demonstrated a significant reduction in new colonization by vancomycin-resistant enterococci (VRE) compared to placebo (p-value=0.002). Results from this trial also demonstrated that patients administered ribaxamase in conjunction with IV-ceftriaxone demonstrated comparable cure rates (approximately 94%) for the treatment of primary infection compared to the placebo group. Results from this trial also demonstrated that the percentage of subjects reporting at least one treatment emergent adverse event (TEAE) was similar between SYN-004 (ribaxamase) and placebo treatment groups (40.8% vs 44.2%). Adverse events reported during this trial were comparable between treatment and placebo arms. Serious adverse events (SAEs) in the treatment arm, including fatal AEs, which exceeded those in the placebo arm, were not considered drug-related by investigators at the clinical sites, or by an independent third-party, each of whom determined SAEs were attributable to disparities in the underlying health and comorbidities between the groups.</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This information is an estimate derived from the use of information under license from the following IMS Health Incorporated information service: IMS Health Analytics for the full&#160;year 2016. IMS expressly reserves all rights, including rights of copying, distribution, and republication.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;6, 2016 we were awarded a government contract in the amount of $521,014 by the CDC&#8217;s Broad Agency Announcement (BAA) 2016-N-17812 to examine changes in the gut resistome of patients in our Phase 2b clinical study. Data generated under this contract are consistent with SYN-004&#8217;s (ribaxamase) mode of action of preserving the normal gut flora by degrading ceftriaxone in the upper GI tract of study participants treated with SYN-004 (ribaxamase). The data further demonstrated that SYN-004 (ribaxamase) significantly reduced the loss of microbial diversity, reduced overgrowth of opportunistically pathogenic species, and reduced the emergence of antimicrobial resistance (AMR) genes (such as VRE) caused by ceftriaxone treatment in SYN-004 (ribaxamase) treated patients compared to placebo.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Future Planning and Potential Regulatory Strategy for Prevention of Primary CDI</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;21, 2018, we announced results from our End-of-Phase 2 meeting with the FDA during which key elements of a Phase 3 clinical program were confirmed. Pursuant to the meeting, the FDA proposed criteria for Phase 3 clinical efficacy and safety which, if achieved, may support submission for marketing approval of SYN-004 (ribaxamase) on the basis of a single Phase 3 clinical trial. The proposed SYN-004 (ribaxamase) Phase 3 clinical program entails a single, global, event-driven clinical trial with a fixed maximum number of approximately 4,000 patients for total enrollment and evaluates the potential efficacy and safety of ribaxamase in a broad patient population by enrolling patients with a variety of underlying infections treated with a range of IV beta-lactam antibiotics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The proposed Phase 3 clinical trial incorporates co-primary safety and efficacy endpoints (mortality and the reduction in the incidence of CDI at one&#160;month after the last drug dose in the SYN-004 (ribaxamase) treatment group versus placebo,respectively). We expect the clinical development costs to complete this trial to be in excess of $80 million and anticipate initiating the Phase 3 clinical program only after securing additional potential financing via a strategic partnership.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acute Graft-Versus-Host-Disease in Allogeneic Hematopoietic Cell Transplant (allogeneic HCT) Recipients&#160;&amp; SYN-004 (ribaxamase)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In parallel with our clinical and regulatory efforts, we completed a Health Economics Outcomes Research (HEOR) study, which was conducted to generate key insights on how we can expect Health Care Practitioners, or HCPs, to evaluate patient access for SYN-004 (ribaxamase) while also providing a framework for potential reimbursement strategies. After evaluating findings from the study, we believe that there is significant potential value in exploring the development of SYN-004 (ribaxamase) in a narrower patient population where the incidence of the disease endpoint is high and the clinical development may be less costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe allogeneic hematopoietic cell transplant (HCT) recipients, who have a very high risk of CDI, VRE colonization and potentially fatal bacteremia, and acute-graft-vs-host disease (aGVHD), represent such a patient population. Published literature has demonstrated a strong association between these adverse outcomes and microbiome damage caused by IV beta-lactam antibiotics in these patients. Approximately 80-90% of HCT recipients receive IV beta-lactam antibiotics to treat febrile neutropenia. Penicillins and cephalosporins are first-line therapies in the USA and EU, whereas carbapenems are first-line in China. Antibiotic-mediated damage to the gut microbiome is strongly associated with GVHD, bloodstream infections, VRE bacteremia, transplant relapse, and increased mortality in HCT recipients, raising concern over the spectrum of antibiotics used during HCT.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">CDI occurs in up to 31% of HCT patients and is associated with GVHD and increased mortality. aGVHD occurs in 30-60% of allogeneic HCT recipients and is recognized as a primary contributor to morbidity and mortality in this patient population. In 2018, there were approximately 9,000 reported allogeneic HCT procedures in the USA, an estimated 19,800 procedures in Europe, 9,600 in China, and 3,500 in Japan. First-line treatments for aGVHD fail in more than 50% of patients and 2-year survival in patients with steroid refractory aGVHD is only 20%. At least one U.S. study found allogeneic HCT recipients who developed aGVHD had 3-times higher in-hospital mortality and almost 2-fold higher median hospital costs than patients who did not develop aGVHD. It has been reported that in-patient costs for allogeneic HCT in the USA range from $180,000-$300,000 depending on the disease severity. In 2014, all-cause costs for allogeneic HCT in the USA were greater than $600,000 per patient (up to 12&#160;months post-transplant). VRE infection is a persistent problem in HCT patients and VRE colonization after HCT has been associated with decreased patient survival.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 1b/2a Clinical Study in Allogeneic HCT Recipients</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August&#160;2019, we entered into a Clinical Trial Agreement (CTA) with the Washington University School of Medicine (Washington University) to conduct a Phase 1b/2a clinical trial of SYN-004 (ribaxamase). Under the terms of this agreement, we serve as the sponsor of the study and supply SYN-004 (ribaxamase). Dr.&#160;Erik R. Dubberke, Professor of Medicine and Clinical Director, Transplant Infectious Diseases at Washington University and a member of the SYN-004 (ribaxamase) steering committee serves as the principal investigator of the clinical trial in collaboration with his Washington University colleague Dr.&#160;Mark A. Schroeder, Associate Professor of Medicine, Division of Oncology, Bone Marrow Transplantation and Leukemia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On January&#160;7, 2020, we announced the receipt of official meeting minutes from the FDA following a Type-C meeting held on December&#160;2, 2019 at our request to discuss the development of SYN-004 (ribaxamase) for treatment of allogeneic HCT recipients who are administered IV beta-lactam antibiotics in response to fever. Based on the final meeting minutes, the Phase 1b/2a clinical trial will comprise a single center, randomized, double-blinded, placebo-controlled clinical trial of oral SYN-004 (ribaxamase) in up to 36 evaluable adult allogeneic HCT recipients. The goal of this study is to evaluate the safety, tolerability and potential absorption into the systemic circulation (if any) of oral SYN-004 (ribaxamase; 150 mg four times daily) administered to allogeneic HCT recipients who receive an IV carbapenem or beta-lactam antibiotic to treat fever. Study participants will be enrolled into three sequential cohorts </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">administered a different study-assigned IV antibiotic. Each cohort seeks to complete eight evaluable participants treated with SYN-004 (ribaxamase) and four evaluable participants treated with placebo. Safety and pharmacokinetic data for each cohort will be reviewed by an independent Data and Safety Monitoring Committee, which will make a recommendation on whether to proceed to the next IV antibiotic cohort. The study will also evaluate potential protective effects of SYN-004 on the gut microbiome as well as generate preliminary information on potential therapeutic benefits and patient outcomes of SYN-004 in allogeneic HCT recipients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On July&#160;30, 2020, we received written notification from the FDA informing us that they determined the Phase 1b/2a clinical program in adult allogeneic HCT recipients may proceed per the submitted clinical study protocol. On December&#160;22, 2020, we announced that we received approval from the Institutional Review Board (IRB) at Washington University to commence the Phase 1b/2a clinical trial of SYN-004. During the first quarter of 2021, Washington University began screening patients for enrollment of the first of three antibiotic cohorts in the Phase 1b/2a clinical trial of SYN-004 in allogeneic HCT recipients. On April 14, 2021, we announced that the first patient had been dosed in our Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) recipients for the prevention of acute graft-versus-host-disease (aGVHD. To date, we have dosed 14 patients (10 that are considered evaluable) in the study. If enrollment proceeds as planned, we may be positioned to announce as many as three interim data readouts during the next 12-18 months with the first one anticipated from the first antibiotic cohort towards the end of &#160;Q2 2022, pandemic conditions permitting, the second cohort during the first half of 2023 and the third cohort during the first half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to the unique challenges posed by the global COVID-19 pandemic, Washington University had previously halted the commencement of the Phase 1b/2a clinical trial and they continue to evaluate non-essential activities which may have a direct impact on the continuation of the ongoing clinical trial. Continuation of the Phase 1b/2a clinical trial including, but not limited to, the enrollment of new patients remains largely at the discretion of Washington University and is contingent upon their ability to conduct this clinical program free from the impact of COVID-19. We remain in close contact with Washington University and are actively monitoring the potential impact of COVID-19 on the clinical development plans of SYN-004 (ribaxamase) program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">SYN-020&#160;&#8212;&#160;Oral Intestinal Alkaline Phosphatase (IAP)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">SYN 020 is a quality-controlled, recombinant version of bovine Intestinal Alkaline Phosphatase (IAP) produced under cGMP conditions and formulated for oral delivery. The published literature indicates that IAP functions to diminish GI and systemic inflammation, tighten the gut barrier to diminish &#8220;leaky gut,&#8221; and promote a healthy microbiome. Despite its broad therapeutic potential, a key hurdle to commercialization has been the high cost of IAP manufacture which is commercially available for as much as $10,000 per gram. We believe we have developed technologies to traverse this hurdle and now have the ability to produce more than 3 grams per liter of SYN-020 for roughly a few hundred dollars per gram at commercial scale. Based on the known mechanisms as well as our own supporting animal model data, we intended to initially develop SYN-020 to mitigate the intestinal damage caused by radiation therapy that is routinely used to treat pelvic cancers. While we believe SYN-020 may play a pivotal role in addressing acute and long-term complications associated with radiation exposure to the GI tract, we have also begun planning for potential development of SYN-020 in large market indications with significant unmet medical needs. Such indications include celiac disease, non-alcoholic fatty liver disease (&#8220;NAFLD&#8221;), and indications to treat and prevent metabolic and inflammatory disorders associated with aging which are supported by our collaboration with Massachusetts General Hospital (&#8220;MGH&#8221;). Across the six major markets, the total prevalent cases of celiac disease are expected to increase from 5.8 million cases in 2013 to an expected 8.1 million cases in 2023, representing an annual growth rate of approximately 4%. During the same period, prevalent cases in the U.S. are expected to increase from 2.8 million in 2013 to an expected 4.3 million in 2023, representing a significant market opportunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 30, 2020, we submitted an IND application to the FDA in support of an initial indication for the treatment of radiation enteropathy secondary to pelvic cancer therapy. On July 30, 2020, we announced that we received a study-may-proceed letter from the FDA to conduct a Phase 1a single-ascending-dose (&#8220;SAD&#8221;) study in healthy volunteers designed to evaluate SYN-020 for safety, tolerability and pharmacokinetic parameters. On April 1, 2021, we announced that enrollment had commenced in the Phase 1 SAD clinical trial of SYN-020. On June 29, 2021, we announced that enrollment, patient dosing and observation had been completed in the Phase 1, open-label, SAD study of SYN-020. The SAD study enrolled 6 healthy adult volunteers into each of four cohorts with SYN-020 given orally as single doses ranging from 5 mg to 150 mg. Analyses of preliminary data demonstrated that SYN-020 maintained a favorable safety profile, was well tolerated at all dose levels, and no adverse events were attributed to the study drug. No serious adverse events were reported.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the third quarter of 2021 we initiated a Phase 1 clinical study evaluating multiple ascending doses (&#8220;MAD&#8221;) of SYN-020. On October 21, 2021 we announced that patient enrollment, dosing and observation commenced in the Phase 1 MAD of SYN-020. The Phase 1, placebo-controlled MAD study was designed to evaluate the safety, tolerability and biodistribution of SYN-020 upon repeated dosing and enrolled 8 healthy adult volunteers into each of four cohorts (32 total study participants) with SYN-020 given orally at doses </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">ranging from 5 mg to 75 mg twice daily for fourteen days. A safety review was conducted at the end of each cohort to determine whether progression into the next higher dose cohort was permissible. At this time, participant dosing and follow-up has been completed in all four cohorts and serum and fecal samples have been submitted for analysis of pharmacokinetic and pharmacodynamic (biomarker) endpoints. The study remains blinded; however, only sporadic mild adverse events were observed and there were no serious adverse events. A topline data readout of the Phase 1 MAD clinical study is anticipated during the second quarter of 2022. Both studies are intended to support the development of SYN-020 in multiple potential clinical indications including celiac disease, NAFLD, radiation enteritis, as well as indications supported by our collaboration with Massachusetts General Hospital. We anticipate commencement of at least one Phase 2 clinical trial in an indication to be announced during H2 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the second quarter of 2020, we announced that we entered into an agreement with Massachusetts General Hospital (&#39;MGH&#8221;) granting us an option for an exclusive license to intellectual property and technology related to the use of IAP to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases. During the second quarter of 2021, we announced an amendment to our option for an exclusive license agreement with MGH to include intellectual property and technology related to the use of SYN-020 to inhibit liver fibrosis in select diseases, including NAFLD. Research published by a team of investigators led by Richard Hodin, MD, Chief of the Massachusetts General Hospital Division of General and Gastrointestinal Surgery and Professor of Surgery, Harvard Medical School, evaluated long-term oral supplementation of IAP, including SYN-020, in mice. Dr. Hodin&#8217;s research demonstrated that IAP administration, starting at 10 months of age, slowed the microbiome changes, gut-barrier dysfunction, and gastrointestinal and systemic inflammation that normally accompany aging. Additionally, the IAP administration resulted in improved metabolic profiles in the aged mice, diminished frailty, and extended lifespan. Under the terms of the agreement, we are granted exclusive rights to negotiate a worldwide license with MGH to commercially develop SYN-020 to treat and prevent metabolic and inflammatory diseases associated with aging. If executed, we plan to use this license in the advancement of an expanded clinical development program for SYN-020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Current Oncology-Focused Pipeline (through the acquisition of VCN)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Oncolytic Viruses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our oncology platform is based on oncolytic virotherapy (&#8220;OV therapy&#8221;), which exploits the ability of certain viruses to kill tumor cells and trigger an anti-tumor immune response. &#160;This novel class of targeted anticancer agents has unique mechanisms of action compared to other cancer drugs. &#160;Oncolytic viruses exploit the fact that cancer cells contain mutations that cause them to lose growth control and form tumors. &#160;Once inside a tumor cell, oncolytic viruses exploit the tumor cell machinery to generate thousands of additional copies of the virus, which then kill the tumor cell and spread to neighboring cells, causing a chain reaction of cell killing. &#160;This infection by OVs also alerts the immune system, which can then attack the virus infected cells and the tumor cells to help destroy the tumor in some instances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our OV products are engineered to efficiently infect and selectively replicate to a high extent in tumor cells versus normal host cells, which enables intravenous delivery. By contrast, many other oncolytic viruses in clinical development today are administered by direct injection into the tumor. Intravenous delivery has the potential to expand the therapeutic effect of OVs because the virus can infect both the primary tumor and tumor metastases throughout the body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our first product, VCN-01, is a clinical stage oncolytic human adenovirus (common cold virus) that is modified to express an enzyme, hyaluronidase, that helps the virus and other molecules to penetrate the tumor. &#160;VCN-01 can be used alone or in combination with other cancer therapies such as chemotherapy and immunotherapy, for difficult to treat cancers. An expanding intellectual property portfolio supports our oncology programs, and because our products are characterized as biologics, they will be further protected by data and/or market exclusivity in major markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">VCN-01&#160;&#8212;&#160;An oncolytic human type-5 virus engineered for intravenous administration and to express a tumor matrix degrading enzyme (PH20, hyaluronidase) that facilitates the entry of therapeutics and immune cells into tumors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">VCN-01 is a genetically modified oncolytic adenovirus that has been engineered to contain four independent genetic modifications on the backbone of the wild-type human adenovirus serotype 5 (HAd5) genome. These modifications have been shown in preclinical and clinical studies to confer tumor selective replication and antitumor activity. VCN-01 was engineered to replicate in and kill virtually all cancer cells, to expose tumor neoantigens of lysed tumors, to increase tumor targeting, and to express PH20 hyaluronidase to enhance the penetration of virus, chemotherapy and immune cells into the tumor.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Malignant tumors are made up of tumor cells as well as significant supporting tissue known as tumor stroma. The tumor stroma supports the formation and growth of tumors and contains cells and other components that are required for robust tumor growth and metastasis. The stroma also forms an effective barrier to the entry of therapeutic agents such as chemotherapy and antibodies. &#160;VCN-01 is designed to overcome the stroma barrier problem by expressing the well-characterized stroma degrading enzyme PH20 hyaluronidase after it infects tumor cells. Expression of PH20 by VCN-01 degrades the hyaluronic acid within the tumor stroma and improves virus spread. Based upon the foregoing, we believe our oncolytic virus platform, exemplified by VCN-01, represents a new and potentially powerful form of therapy that combines tumor cell killing, anti-tumor immunity and stroma destruction after intravenous delivery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The VCN-01 product candidate is provided as a sterile liquid concentrate that is diluted for infusion or injection. The proposed therapeutic indication for VCN-01 is the treatment of solid tumors, as its selectivity mechanism relies on cellular properties shared by virtually all human tumor cells. Our initial indication for clinical development is unresectable metastatic pancreatic cancer, a disease for which there is currently no cure and only limited therapeutic options.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">VCN-01 has been evaluated in 72 patients across four Phase 1 clinical trials, including patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pancreatic Ductal Adenocarcinoma</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cancer of the pancreas consists of two main histological types: cancer that arises from the ductal (exocrine) cells of the pancreas or, much less often, cancers may arise from the endocrine compartment of the pancreas. Pancreatic Ductal Adenocarcinoma (&#8220;PDAC&#8221;) accounts for more than 90% of all pancreatic tumors. It can be located either in the head of the gland or in the body-tail. Pancreatic cancer usually gives metastases to liver and peritoneum. Other less common sites are lungs, brain, kidney and bone. Since in early stages the pancreatic cancer does not give any characteristic symptoms, patients visit their physician late. Progressive abdominal pain many times is the first symptom. On the other hand, neither truly effective conventional radiological tests that may identify the early disease, nor specific and sensitive diagnostic serum markers are available. Therefore, it is very common that the pancreatic cancer is diagnosed in its late stages (locally advanced non-metastatic or metastatic stage of the disease) when the radical resection and possibly curative treatment is not possible anymore. It&#8217;s generally assumed that only 10% of cases are resectable at presentation, whereas 30-40% of patients are diagnosed at local advanced/unresectable stage and 50-60% presents distant metastases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">PDAC Clinical Unmet need and Market Opportunity</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PDAC is one of the most fatal cancers accounting for the 3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup> highest cause of cancer-associated deaths in US and 4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> in the European Union. Despite significant research efforts, minimal progress has been achieved to date. The five-year overall survival rate is &lt; 10% and has not substantially improved over the last 30 years. Surgery is the only treatment that offers the prospect of long term-survival; however, the 5-year survival for the limited number of patients in whom resection is possible remains low (20 &#8211; 30 %). Patients with advanced disease are managed with chemotherapy. In recent years, the combination of gemcitabine with albumin-bound paclitaxel (GA), and the combination of folic acid, 5-fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) have emerged as the standard of care. However, the results are still very poor and new therapeutic interventions are needed. The increase is particularly evident in younger people and several studies anticipate that pancreatic cancer is expected to become the second leading cause of cancer-related death in the United States by 2030. The rising incidence of pancreatic cancer and its current economic burden place increased pressure to improve outcomes for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2011, the Committee for Orphan Medicinal Products (&#8220;COMP&#8221;) from the European Medicines Agency (&#8220;EMA&#8221;) recommended granting Orphan Medicinal Product Designation to VCN-01 for the treatment of pancreatic cancer and in June 2011, the European Commission confirmed the designation under Regulation (&#8220;EC&#8221;) No 141/2000 of the European Parliament and of the Council.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 1a/Proof of Concept Trial of VCN-01 by intratumor administration in PDAC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In September 2019, VCN presented a poster at the European Society for Molecular Oncology (&#8220;ESMO&#8221;) annual meeting describing initial mechanism of action data from a multicenter, Phase 1 dose escalation study of intratumoral (&#8220;IT&#8221;) VCN-01 administered to pancreatic cancer patients in combination with standard doses/schedules of either gemcitabine or nab-paclitaxel plus gemcitabine (&#8220;NCT02045589&#8221;). The study was conducted at three hospitals in Spain and 8 patients with confirmed histologic diagnosis of unresectable PDAC amenable to endoscopic ultrasound guided (&#8220;EUS)) injection were treated with 3 injections (coincident with 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> day of the chemotherapy cycles) at two different dose levels of VCN-01 (six patients had metastatic disease and two had locally advanced disease). The treatment regimen was generally well-tolerated; however, one patient died from severe intraabdominal fluid collection that was considered to be related to VCN-01 treatment Evaluation of virus pharmacokinetics and PH20 levels in serum were consistent </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">with strong virus replication in the tumors. This was supported by the presence of viral particles in tumor cells as assessed in paired tumor biopsies collected before and after treatment. Tumor stiffness was reduced in all VCN-01-injected lesions as measured by elastography. Disease stabilization of injected lesions was observed in 5 out of 6 patients although subsequent tumor progression was observed in most of the patients because of the appearance of new lesions or growth of distant, non-injected, metastatic lesions. This study provided encouraging mechanism of action data for VCN-01; however, intratumoral injection did not appear to deliver sufficiently high VCN-01 levels for effective delivery to non-injected tumors. We believe these results supported the evaluation of the safety/tolerability and potential efficacy of VCN-01 via intravenous administration in combination with chemotherapy and/or immunotherapies for the treatment of advanced PDAC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 1 Trial of intravenous VCN-01 with or without nab-paclitaxel plus gemcitabine in patients with solid tumors and PDAC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, we also presented a poster at the ESMO meeting describing initial data from a Phase I clinical trial whose aim was to find the maximum tolerated dose (MTD)/recommended phase II dose (&#8220;RP2D&#8221;) and identify dose-limiting toxicity(ies) (&#8220;DLT&#8221;) for intravenous VCN-01 administered to patients with advanced cancer (&#8220;NCT02045602&#8221;). This study was designed as a multicenter, open-label, dose-escalation phase I clinical trial of a single dose of intravenous VCN-01 alone (Part I, 16 patients with advanced refractory solid tumors) or in combination with nab-paclitaxel plus gemcitabine (Part II and III; patients with pancreatic adenocarcinoma). In Part II, 12 patients received VCN-01 dose concurrent with chemotherapy on day 1, whereas in Part III 14 additional patients received the dose of VCN-01seven days before chemotherapy. The RP2D was determined to be 1x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13</sup> viral particles (vp)/patient in Part I, 3.3x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup> vp/patient in Part II and 1x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13</sup> vp/patient in Part III. Based on its apparent safety profile and the absence of dose-limiting toxicities, 1x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13</sup> vp/patient using sequential dosing schedule was selected for further clinical development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pharmacokinetic data showed dose linearity, as well as relevant VCN-01 exposure. Analysis of VCN-01 clearance in patients enrolled in Part II did not show significant differences with respect to patients receiving VCN-01 as a single agent. VCN-01 viral genomes were detected in tumor tissue in 5 out of 6 biopsies. A second viral peak in plasma and increased hyaluronidase serum levels suggested replication after intravenous injection in all patients. Increased levels of immune biomarkers (IFN&#947;, sLAG3, IL-6, IL-10) were found after VCN-01 administration. In patients with pancreatic adenocarcinoma, the overall response rate (ORR) was 50% for Part II and 50% for Part III, as assessed by the investigators. Median progression free survival (PFS) for patients in Part III was 6.7 months, and median overall survival (OS) was 13.5 months. Eight patients (66.7%) survived more than 12 months. In addition, in April 2021, a subgroup analysis of patients at the RP2D (1.x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13</sup> vp/patient followed by nab-paclitaxel plus gemcitabine one week later, n=6) was conducted and showed an ORR of 83%, with a median PFS of 6.3 months and median OS of 20.8 months. Some VCN-01 treated patients appeared to benefit from late-onset responses. This form of delayed anti-tumor activity is not common with chemotherapy but is frequently observed with immunotherapies. We believe an immune mechanism of action associated with the oncolytic activity of VCN-01 may be the underlying explanation. VCN-01 appeared to convert the typically immunosuppressive tumor microenvironment of pancreatic adenocarcinomas into an enhanced inflammatory microenvironment (IDO, CD28, PD-1, CTL signature up-regulation, and collagen formation) after treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Future Planning and Potential Regulatory Strategy for development of VCN-01 in PDAC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are currently planning a Phase 2 clinical trial of systemically administered VCN-01 in PDAC patients and anticipate submission of the protocol to the FDA and EMA in Q2 2022. The proposed Phase 2 trial is expected to be an open-label, randomized study to test the efficacy of VCN-01 in combination with gemcitabine and nab-paclitaxel in patients with newly diagnosed metastatic pancreatic cancer. The study is expected to enroll 92 patients and be conducted at approximately 25 sites in the US and EU. &#160;Two doses of VCN-01 are planned in the treatment arm: the 1st dose will be administered on day 1, then one week later 3 cycles of gemcitabine and nab-paclitaxel as standard of care will be administered. The second VCN-01 dose will be administered after the third cycle of chemotherapy, followed by additional chemotherapy. Dr. Manuel Hidalgo, chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York-Presbyterian Hospital has been appointed as Principal Investigator. If the regulatory agencies allow us to proceed, initiation of recruitment is expected during Q4 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Retinoblastoma</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Retinoblastoma is a tumor that originates in the retina and it is the most common type of eye cancer in children. It occurs in approximately 1 / 14,000-1 / 18,000 live newborns and accounts for 15% of the tumors in the pediatric population &lt; 1 year old. The average age of pediatric patients at diagnosis is 2, and it rarely occurs in children older than 6. In the US, retinoblastoma shows an incidence rate of 3.3 per 1,000,000 with only about 200 to 300 children diagnosed per year according to the American Cancer Society. Bilateral retinoblastoma (Rb1 germinal mutation) represents 25-35% of the cases while unilateral retinoblastoma (sporadic mutation) accounts for 65-75%. While retinoblastoma is a highly curable disease, with a current disease-free survival rate of &gt;95%, the clinical challenge </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for those who treat retinoblastoma is to preserve life and to prevent the loss of an eye, blindness and other serious effects of treatment that reduce the patient&#8217;s life span or the quality of life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Current treatments are not without significant morbidity, which may include visual impairment and severe cosmetic deformity secondary to enucleation and/or irradiation of the orbital region. The use of intravenous chemotherapy and more recently intra-arterial and intravitreal chemotherapy have resulted in a significantly greater number of eyes preserved with fewer long-term effects compared to past treatments such as external radiation therapy. However, allowing patients with advanced intraocular disease to be treated conservatively, led to the appearance of a subgroup of patients with advanced intraocular disease who relapsed after an initial response. Most of these cases include those patients who present gross vitreous or subretinal seeding. Once the aforementioned treatments are exhausted, these patients rarely manage to preserve the eyes and vision and must be enucleated. The ocular preservation rate of these eyes with advanced disease is still less than 50%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February 2022, the FDA granted orphan drug designation to VCN-01 for the treatment of retinoblastoma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 1 Trial of intravitreal VCN-01 in patients with retinoblastoma</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the third quarter of 2017, VCN entered into a Clinical Trial Agreement with Hospital Sant Joan de D&#233;u (Barcelona, Spain) to conduct an investigator sponsored Phase 1 clinical study evaluating the safety and tolerability of two intravitreal injections of VCN-01 in patients with intraocular retinoblastoma refractory to systemic, intra-arterial or intravitreal chemotherapy, or radiotherapy, in whom enucleation was the only recommended treatment (NCT03284268). Patients received two doses of VCN-01 injected 14 days apart using a dose escalation regimen. At this time, the dose-escalation phase of the study has already been completed in 4 patients distributed in two cohorts (2 x 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">9</sup> vp/eye and 2 x 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">10</sup> vp/eye). VCN-01 was well tolerated to date after intravitreal administration, although some degree of intravitreal inflammation and associated turbidity were observed. Inflammation has been managed and potential turbidity minimized with local and systemic administration of anti-inflammatory drugs. VCN-01 does not appear to change the retinal function, and selective VCN-01 replication in retinoblastoma cells has been observed by immunohistochemical analysis. Replication within retinoblastoma tumors over time was detected and VCN-01 reduced the number of vitreous seeds in all patients treated at 2 x 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">10</sup> vp/eye (n=3). The investigator has reported that one patient treated with VCN-01 has had a complete regression lasting more than 30 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This study is currently ongoing and anticipated to be completed in the second half of 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">VCN-01 in combination with Immunomodulatory therapeutics</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based on the clinical and pre-clinical data described below, we believe that the effect of administration of VCN-01, can elicit an anti-tumor immune response that could potentiate the effects of VCN-01 and co-administered therapeutics. Biopsies from the Phase 1 trial of PDAC patients administered intravenous VCN-01 demonstrated lymphocyte (CD8+) infiltration and modulated levels of immune markers in tumors, including an induction of the PD1/PD-L1 expression in tumor tissue from some of the patients. Preclinical experiments demonstrated that VCN-01 significantly increased extravasation of an anti-PD-L1 antibody into subcutaneous xenograft tumors compared to non-treated (PBS) tumors and also that PH20 hyaluronidase improves the ingress of T-cells in animal models. Thus, we hypothesize that the administration of VCN-01 into the tumor will help to overcome the observed resistance to PD-L1 checkpoint inhibitors and to mesothelin-directed CAR-T cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 1 Trial of intravenous VCN-01 in Combination with Durvalumab in Subjects with Recurrent/ Metastatic SCCHN</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In February 2019, VCN entered into a Clinical Trial Agreement with Catalan Institute of Oncology (ICO) (Spain) to conduct an investigator sponsored Phase 1 clinical study to evaluate the safety, tolerability and RP2D of a single intravenous injection of VCN-01 combined with durvalumab in two administration regimens: VCN-01 concomitantly with durvalamab, or sequentially with durvalumab starting two weeks after VCN-01 administration (NCT03799744). The study is also designed to evaluate whether VCN-01 treatment can re-sensitize PD-(l)-1 refractory tumors to subsequent anti-PD-L1 therapy. Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune, which supplies the product for its use in the clinical study. This Phase I trial is a multicenter, open label, dose escalation study in patients with histologically confirmed head and neck squamous cell carcinoma from specific sites: oral cavity, oropharynx, larynx or hypopharynx that is recurrent/metastatic (R/M) and not amenable to curative therapy by surgery or radiation. In addition, all patients should have undergone prior exposure to anti-PD-(L) 1 and progressed. Patients are entered at each dose level, according to a planned dose escalation schedule. The treatment is a single intravenous VCN-01 dose combined with concomitant intravenous durvalumab (MEDI4736) 1500 mg Q4W (Arm I) or durvalumab starting two weeks after VCN-01 administration (&#8220;sequential schedule&#8221;; Arm II). Patient recruitment into Arm I and Arm II was performed concurrently. Only one single dose of VCN-01 is administered to each patient </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">during the trial. Durvalumab is administered Q4W until disease progression, unacceptable toxicity, withdrawal of consent, or another discontinuation criterion. Patient recruitment into the study was completed in February 2022 with a total of 18 patients enrolled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 1 Trial evaluating the safety and feasibility of huCART-meso cells when given in combination with VCN-01</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In July 2021, VCN entered into a Clinical Trial Agreement with the University of Pennsylvania (Philadelphia) to conduct an investigator sponsored Phase 1 clinical study to evaluate the safety, tolerability and feasibility of intravenous administration of VCN-01 in combination with lentiviral transduced huCART-meso cells (developed by the laboratory of Dr. Carl June) in patients with histologically confirmed unresectable or metastatic pancreatic adenocarcinoma and serous epithelial ovarian cancer (NCT05057715). This is a Phase I study evaluating the combination of VCN-01 when given in combination with lentiviral transduced huCART-meso cells in a dose-escalation design in two cohorts (N = 3-6), where patients will receive VCN-01 as a single IV infusion (at 3.3x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup> or 1x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13</sup> vp) on Day 0, followed by a single dose of 5x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">7</sup> huCART-meso cells on Day 14 via IV infusion. huCART-meso cells are modified T-cells targeting the mesothelin antigen, which is frequently expressed in multiple tumor types, particularly in pancreatic and ovarian cancers. Dr. June&#8217;s previous clinical studies have shown that huCART-meso cells encounter significant challenges in the tumor microenvironment, including immunosuppressive cells and soluble factors as well as metabolic restrictions. Initial VCN-01 clinical data from the studies described above suggest that administration of VCN-01 may increase tumor immunogenicity and improve access of the huCART-meso cells to tumor cells. &#160;This Phase I study will evaluate the safety and tolerability of the VCN-01 huCART-meso cell combination and test the hypothesis that administration of VCN-01 may enhance the potential antitumor effects of the co-administered huCART-meso cells . The trial is open but not yet recruiting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Phase 1 Trial evaluating the intravenous administration of VCN-01 in patients prior to surgical resection of high-grade brain tumors</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the second quarter of 2021, VCN entered into a Clinical Trial Agreement with the University of Leeds (UK) to sponsor a proof of concept Phase 1 clinical study to evaluate whether intravenously administered VCN-01 can cross the blood-brain barrier and infect the target brain tumor. This is an open-label, non-randomized, single center study of VCN-01 given intravenously at a dose of 1x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">13 </sup>virus particles to patients prior to planned surgery for recurrent high-grade primary or metastatic brain tumors. We believe that the intravenous delivery of anti-cancer therapy to brain tumors, if effective, may allow repeat dosing may enable the treatment of systemically disseminated brain metastases and may allow for reduction in the need to use neurosurgery to administer the drugs. This study aims to assess the presence of VCN-01 within the resected surgical specimen after systemic VCN-01 delivery and determine the safety of intravenous VCN-01 in patients with recurrent high-grade glioma or brain metastases. By confirming the presence of VCN-01 in high grade brain tumors following intravenous delivery, this study may pave the way for larger trials to study VCN-01 efficacy, both as a monotherapy and in combination with PD-1/PD-L1 blockade. This trial has already received approval from Medicines &amp; Healthcare Products Regulatory Agency (MHRA) from UK Government.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">SYN-006; SYN-007 and SYN-005</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, our research programs have been primarily directed to the development of GI acting products that have generated preclinical proof-of-concept with two pipeline products (SYN-006 and SYN-007) that expand the potential utility of our beta-lactamase strategy. SYN-007 is a specially formulated version of SYN-004 (ribaxamase) designed to degrade orally administered beta-lactam antibiotics to protect the gut microbiome from antibiotic-mediated dysbiosis. SYN-006 is a carbapenemase designed to degrade intravenous (IV) carbapenem antibiotics within the GI tract to maintain the natural balance of the gut microbiome for the prevention of CDI, overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR). Our SYN-005 monoclonal antibody program is intended to both treat and prevent pertussis. Our research programs may be expanded to include development of new oncolytic virus products and/or explore oncology applications of our existing products such as SYN-006 and SYN-020.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">VCN-11 </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">VCN-11 is a novel virus that we believe has the potential to extend our OV platform. &#160;VCN-11 has been engineered to contain all of the features of VCN-01 as well as an additional modification to include an albumin binding domain (ABD) in the virus capsid. &#160;The virus capsid is the target for neutralizing antibodies (NAbs) that are generated by the host immune system to destroy circulating viruses. &#160;The presence of an albumin binding domain, however, blocks the binding of most neutralizing antibodies, which allows the virus to reach the tumor following intravenous administration. &#160;This &#8220;albumin shield&#8221; works because human blood contains a large amount of albumin to coat the VCN-11 virus. &#160;Importantly, this coating of albumin appears to be displaced after the virus reaches tumor cells to infect them. In pre-clinical mouse studies to test the functionality of the &#8220;albumin shield&#8221;, mice pre-immunized with virus are able to completely neutralize an unmodified OV because they have a large concentration of neutralizing antibodies in their blood. &#160;By contrast, viruses containing the albumin binding domain such as VCN-11 are not neutralized and retain their ability to infect and destroy tumor cells. &#160;We believe these results support the further development of VCN-11 for tumors in which rapid multi-dosing may be beneficial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the second quarter of 2020, VCN had several interactions with Spanish regulatory authorities (AEMPS) to agree on the design of the non-clinical GLP toxicology and biodistribution studies that are required to support a first-in-human clinical trial for VCN-11.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In March 2021, preclinical data obtained with VCN-11 was published, showing that VCN-11 induced 450 times more cytotoxicity in tumor cells than in normal cells. VCN confirmed VCN-11 hyaluronidase production by measuring the activity of the PH20 enzyme with a hyaluronic acid-degradation assay, and by measuring PH20 activity in VCN-11 infected tumors in vivo. VCN-11 evaded NAbs from different sources and tumor targeting was demonstrated in the presence of high levels of NAbs in vivo, whereas the control virus without ABD was neutralized. VCN-11 showed a low toxicity profile in athymic nude mice and Syrian hamsters, allowing treatments with high doses and fractionated administrations without major toxicities (up to 1.2x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">11</sup>vp/mouse and 7.5x10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">11</sup>vp/hamster). VCN-11 increased ALT levels on day 3 within an acceptable range that returned to normal levels by day 9. Fractionated intravenous administration of VCN-11 (splitting the dose into two portions administered 4 h apart) appeared to improve VCN-11 circulation kinetics and tumor targeting. VCN-11 showed antitumor efficacy in the presence of NAbs against Ad5 and itself.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our programs are supported by growing patent estates. In total, Synthetic Biologics has over 95 U.S. and foreign patents and over 70 U.S. and foreign patents pending. VCN Biosciences, through assignment or exclusive licenses, controls over 25 U.S. and foreign patents and over 15 U.S. and foreign patents pending</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The SYN-004 (ribaxamase) program is supported by IP that is assigned to Synthetic Biologics, namely U.S. patents and foreign patents (in most major markets, e.g. Europe (including Germany, Great Britain and France), Japan, China and Canada, among others) and U.S. and foreign patents pending (in most major markets, e.g. Europe (including Germany, Great Britain and France), Japan, China and Canada, among others). For instance, U.S. Patent Nos. 8,894,994 and 9,587,234, which include claims to compositions of matter and pharmaceutical compositions of beta-lactamases, including SYN-004 (ribaxamase), have patent terms to at least 2031. Further, U.S. Patent 9,301,995 and 9,301,996, both of which will expire in 2031, cover various uses of beta-lactamases, including SYN-004 (ribaxamase), in protecting the microbiome, and U.S. Patent Nos. 9,290,754, 9,376,673, 9,404,103, 9,464,280, and 9,695,409 which will expire in at least 2035, covers further beta-lactamase compositions of matter related to SYN-004 (ribaxamase).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The SYN-020 (oral intestinal alkaline phosphatase (IAP)) program is supported by IP that is assigned to Synthetic Biologics, namely U.S. and foreign patent applications (in many major markets, e.g. Europe, China, Japan, Korea, Canada, and Australia). These patent applications, which cover various formulations, medical uses and manufacture of SYN-020, are expected to expire in 2038-2040, if granted, and without taking potential patent term extensions or patent term adjustment into account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The VCN-01 and VCN-11 programs are supported by patents and patent applications that are assigned to VCN Biosciences or exclusively licensed from Fundacio Privada Institut d&#39;Investigacio Biomedica de Bellvitge (IDIBELL), Institut Catala d&#39;Oncologia (ICO), and Hospital Sant Joan De Deu Barcelona. The patents and patent applications include U.S. patents and foreign patents (in most major markets, e.g. Europe, China, Japan, Korea, Canada, Israel, Mexico, Russia, and Australia) and U.S. and foreign patents pending (in most major markets, e.g. Europe, China, Korea, Canada, Mexico, and India). The patents and patent applications cover compositions of matter and pharmaceutical compositions of oncolytic adenoviruses and various medical uses of the same. For instance, U.S. Patent No. 10,316,065, which expires in 2030 without taking potential patent term extensions or patent term adjustment into account, provides composition of matter and pharmaceutical composition coverage for a genus of engineered oncolytic adenovirus suitable for the treatment of solid tumors. Other patents and patent applications, if granted, will provide protection to 2037 without taking potential patent term extensions or patent term adjustment into account.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our goal is to (i)&#160;obtain, maintain, and enforce patent protection for our products, formulations, processes, methods, and other proprietary technologies, (ii)&#160;preserve our trade secrets, and (iii)&#160;operate without infringing on the proprietary rights of other parties worldwide. We seek, where appropriate, the broadest intellectual property protection for product candidates, proprietary information, and proprietary technology through a combination of contractual arrangements and patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Current Collaborations (inclusive of our acquisition of VCN)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IDIBELL Technology Transfer Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 31, 2010, VCN entered into a Technology Transfer Agreement (the &#8220;Technology Transfer Agreement&#8221;) with the Bellvitge Biomedical Research Institute (&#8220;IDIBELL&#8221;) for the exclusive license of the right to use a Spanish patent number P200901201 titled &#8220;Oncolytic adenoviruses for treating cancer&#8221; which is co-owned by IDIBELL and Catalan Oncology Institute (&#8220;ICO&#8221;) for the term of the patent. The Technology Transfer Agreement provides that IDIBELL is entitled to a low single digit % royalty on the income collected by VCN from the utilization of products derived from the licensed technology, prior to applying any value-added tax, if any, and low single digit % royalty on other income received by VCN arising from the use of the licensed technology, including income related to sublicenses of the licensed technology to third parties and advance payments or payments made for goals that were met and/or services associated with the licensed technology. &#160;The Technology Transfer Agreement terminates upon the expiration of the patent rights and is subject to early termination by either party in the event of a breach by the other party of its obligations thereunder. In addition, IDIBELL has the right to revoke the license if VCN ceases business activities for a continuous year or ceases to utilize the technology subject of the Technology Transfer Agreement, uses the technology in violation of the principals of IDIBELL or ICO or stops maintaining the patent licensed under the Technology Transfer Agreement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">ICO Marketing License</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 16, 2009, VCN entered into a Contract to Grant a Marketing License (the &#8220;ICO License Agreement&#8221;) with the Catalan Institute of Oncology (the &#8220;ICO&#8221;) for a manufacturing and marketing license of a patent P200700665 titled &#8220;Adenovirus with mutations in the area of endoplasmic retention of protein E3-19k and their use in the treatment of cancer&#8221; in connection with a sublicense identified therein. The validity period of the license granted is unlimited with the only applicable limit being the patent&#8217;s own validity. The ICO License Agreement provides that the ICO is entitled to a royalty of low double digit % of the net value of the income from the concession of the identified sublicense and low double digit % on other lump sums received thereunder. VCN and its sublicensees have an obligation to o use all diligent and commercially reasonable efforts for the exploitation of the patent, otherwise, ICO may proceed to recover the license. The ICO License terminates upon the expiration of the patent rights and is subject to early termination by either party in the event of a breach by the other party of its obligations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">IDIBELL/ICO License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 4, 2016, VCN entered into a License Agreement (the &#8220;IDIBELL/ICO License Agreement&#8221;) with IDIBELL and the ICO, for the exclusive license of the right to use a family of patents whose priority application is European patent application EP 14 38 2162.7 titled &#8220;Adenovirus comprising an albumin-binding molety&#8221;. The License Agreement provides that IDIBELL and ICO, as licensors, are entitled to share a low single digit % royalty on the annual Net Sales (as defined in the IDIBELL/ICO License Agreement)collected by VCN from the utilization of products derived from the licensed technology and a royalty on sublicensing income received from the licensed technology at a rate of: low double digit % during the first 3 years following the effective date of the agreement, mid single digit % during the term of 3 to 7 years following the effective date and low single digit % thereafter. The IDIBELL/ICO License Agreement also provides for certain fixed payments, including a payment 25 days following the date of concession of the licensed patent in a minimum of three European jurisdictions and a payment 25 days following the date of concession of an American patent derived from the licensed patent. The IDIBELL/ICO License is for an indefinite term subject to early termination (i) by mutual agreement of the parties; (ii) by licensor in the event of at least two successive breaches or three alternate breaches calculated annually of the obligation to pay any consideration; (iii) by VCN at its discretion due to certain patent infringements of rights protected by the patents or due to the absence of protection of the patent in any countries in the territory which is worldwide or (iv) in the event of a breach by the other party of its obligations thereunder which are not remedied within thirty (30) days. In addition, the licensors have the right to revoke the IDIBELL/ICO License Agreement if VCN during a continuous period of two years abandons its research or development activities of the licensed patent or activities aimed at exploitation of the resulting products, VCN has undertaken no marketing whatsoever during the term of the IDIBELL/ICO License Agreement or uses the patent licensed for purposes other those as set forth in the IDIBELL/ICO License Agreement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Saint Joan De D&#233;u Collaboration and License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 15, 2016, VCN entered into a Collaboration Agreement to Conduct a Clinical Trial and Grant an Operating License (the &#8220;Collaboration and License Agreement&#8221;) with the Saint Joan De D&#233;u Hospital (the &#8220;Hospital&#8221;) and the Saint Joan De D&#233;u Foundation (the &#8220;Foundation&#8221;, and together with the Hospital, the &#8220;Institution&#8221;) regarding the conduct of a clinical trial to evaluate the safety and activity of VCN-01 in patients with refractory retinoblastoma. The Collaboration and License Agreement provides that if the trial results are positive and VCN is interested in continuing with the development of VCN-01 for the treatment of retinoblastoma; (a) the parties undertake to apply their best efforts to negotiate and, where appropriate, sign an agreement to collaborate in the development and execution of the following phases of the development of VCN-01 for the treatment of retinoblastoma; (b) the Institution shall grant to VCN an exclusive, worldwide and indefinite license to use and exploit the trial results and their possible patents exclusively for the treatment of retinoblastoma; (c) VCN shall pay the Foundation five hundred thousand Euros (&#8364;500,000), subject to reduction for any public and/or private economic aid that third parties may grant to the Institution for the conduct of the trial and/or any advance payments made by VCN before the end of the trial; (d) VCN shall pay the Foundation three hundred twenty thousand Euros (&#8364;320,000) once following the trial results a pivotal study, to be carried out by VCN, has been completed which allows it to obtain the marketing authorization of the product following from the results, which payment must be made within a maximum period of four (4) years from the date on which Institution has delivered the final report of the trial to VCN ; and (e) the parties will use their best efforts to negotiate and, where appropriate, sign a product supply agreement in order that the Hospital can use VCN-01 for compassionate use in the treatment of retinoblastoma. The Collaboration and License Agreement continues in force and effect until all obligations arising from the trial have been fulfilled, subject to early termination for a material breach by a party of any of their contractual and/or legal obligations, or, in the case of any other type of breach, when the breaching party has been asked in writing to remedy the breach and the breach is not cured within thirty (30) days from the date on which the written request was sent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Washington University School of Medicine in St. Louis Clinical Trial Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August&#160;7, 2019, we entered into a clinical trial agreement (&#8220;CTA&#8221;) with Washington University School of Medicine in St. Louis (&#8220;Washington University&#8221;) to conduct a Phase 1b/2a single-center, randomized, double-blinded, placebo-controlled clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of oral SYN-004 (ribaxamase) in up to 36 adult allogeneic hematopoietic cell transplant (HCT) recipients (the &#8220;Study&#8221;). Under the terms of the CTA, we will serve as the sponsor of the Study and supply SYN-004 (ribaxamase), as well as compensate Washington University for all research services to be provided in connection with the Study which is estimated to cost approximately $3,200,000. Dr.&#160;Erik R. Dubberke, Professor of Medicine and Clinical Director, Transplant Infectious Diseases at Washington University will serve as the principal investigator of the trial in collaboration with his Washington University colleague Dr.&#160;Mark A. Schroeder, Associate Professor of Medicine, Division of Oncology, Bone Marrow Transplantation and Leukemia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The CTA continues in effect until completion of all obligations under the CTA. Either party may terminate the CTA prior to completion of its obligations (i)&#160;if authorization of the study is withdrawn by the FDA; (ii)&#160;if the emergence of any adverse reaction or side effect with SYN-004 (ribaxamase) administered in the Study is of such magnitude or incidence in the opinion of either party to support termination; or (iii)&#160;upon a breach of the terms of the CTA if the breaching party fails to cure the breach within 30&#160;days after receipt of notice. We have the right to terminate the CTA (i)&#160;effective immediately if Washington University fails to perform the study in accordance with the terms of the protocol, the CTA or applicable laws or regulations or if Washington University or the principal investigator become debarred or (ii)&#160;upon 14&#160;days written notice and Washington University has the right to terminate the CTA upon 14&#160;days notice if the principal investigator becomes unable to perform or complete the Study and the parties have not, prior to the expiration of such fourteen (14) day period, agreed to an alternative principal investigator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Massachusetts General Hospital Exclusive Option License Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May&#160;27, 2020, we entered into an agreement with Massachusetts General Hospital (&#8220;MGH&#8221;) granting us an option for an exclusive license to intellectual property and technology related to the use of intestinal alkaline phosphatase (&#8220;IAP&#8221;) to maintain gastrointestinal (GI) and microbiome health, diminish systemic inflammation, and treat age-related diseases. If executed, we plan to use this license in the advancement of an expanded clinical development program for SYN-020, our proprietary recombinant version of bovine IAP currently in pre-clinical development. Under the terms of the agreement, we are granted exclusive rights to negotiate a worldwide license with MGH to commercially develop SYN-020 to treat and prevent metabolic and inflammatory diseases associated with aging. During the second quarter of 2021, we announced an amendment to our option for an exclusive license agreement with MGH to include intellectual property and technology related to the use of SYN-020 to inhibit liver fibrosis in select diseases, including NAFLD. To date, we have not exercised the option.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The University of Texas at Austin License Agreement and Sponsored Research Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December&#160;19, 2012, we entered into a Patent License Agreement (the &#8220;Texas License Agreement&#8221;) with UT Austin for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related to pertussis antibodies developed in the lab of Dr.&#160;Jennifer A. Maynard, Associate Professor of Chemical Engineering. In accordance with the terms of the Texas License Agreement we made the following payments to the UT Austin: a payment of past patent expenses, an annual payment of $50,000 per&#160;year commencing on the effective date through December&#160;31, 2014 and a $25,000 payment on December&#160;31, 2015. The Texas License Agreement also provides that UT Austin is entitled to milestone payments of $50,000 upon commencement of Phase 1 Clinical Trials, $100,000 upon commencement of Phase 3 Clinical Trials, $250,000 upon NDA submission in the United States, $100,000 upon European Medicines Agency approval and $100,000 upon regulatory approval in an Asian country. In addition, the University is entitled to a running royalty upon Net Product Sales and Net Service Sales (as defined in the Texas License Agreement and currently projected to be 2037 (not accounting for possible extensions)). The License Agreement terminates upon the expiration of the patent rights (as defined in the Texas License Agreement); provided, however that the Texas License Agreement is subject to early termination by us in our discretion and by the University for a breach of the Texas License Agreement by us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Texas License Agreement, we also entered into a Sponsored Research Agreement (the &#8220;Sponsored Research Agreement&#8221;) with the University pursuant to which the University will perform certain research work related to pertussis under the direction of Dr.&#160;Jennifer Maynard. All inventions conceived during such research shall be subject to the Texas License Agreement and we will obtain certain rights to patents and technology developed during the course of such research. We paid the University a fixed fee for the first&#160;year of $303,287 and the second and third&#160;years of $316,438 and $328,758, respectively. The Sponsored Research Agreement was amended on October&#160;22, 2015 to extend its termination date to January&#160;15, 2017: on September&#160;2, 2016 to extend the agreement until January&#160;15, 2018; on August&#160;22, 2017 to extend the agreement until January&#160;17, 2019;on August&#160;24, 2018 to extend the agreement until January&#160;21, 2021; and again on August&#160;18, 2020 which extended the agreement until January&#160;17, 2023; provided, however, the Sponsored Research Agreement is subject to early termination upon the written agreement of the parties, a default in the material obligations under the Sponsored Research Agreement which remain uncured for 60&#160;days after receipt of notice, automatically upon our bankruptcy or insolvency and by us in our sole discretion at any time after the one&#160;year anniversary of the date of execution thereof upon no less than 90&#160;days&#8217; notice. Upon a termination or due to a breach by the University, we will only be responsible for all reasonable expenses that do not exceed the fixed annual amount and that are incurred by the University prior to the termination date for services performed prior to the termination date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have an issued U.S. patent and patents pending in the U.S. and internationally (<i style="font-style:italic;">e.g.</i> Europe, China, Japan, Australia, and China) on compositions and uses of SYN-005 that are co-owned by UT Austin and ourselves or licensed to us, and we have an issued U.S. patent and patent applications on other pertussis mAbs licensed from UT Austin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">SYN-004 and SYN-020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product candidates SYN-004 and SYN-020 are biologics that can be readily synthesized by processes that we have developed; however, the manufacturing for our clinical programs, including SYN-004 and SYN-020 may require long lead times and is subject to potential COVID-19 related global supply chain interruptions. We do not own or operate manufacturing facilities for the production of these product candidates for preclinical and clinical activities. We rely on third-party contract manufacturers, and in most cases only one third-party, to manufacture critical raw materials, drug substance and final drug product for our research, preclinical development and clinical trial activities. Commercial quantities of any drugs we seek to develop will have to be manufactured in facilities and by processes that comply with the FDA and other regulations, and we plan to rely on third parties to manufacture commercial quantities of products we successfully develop through FDA approval. We believe we have sufficient quantities of SYN-004 and SYN-020 to complete our planned Phase 1b/2a clinical trial of SYN-004 and our planned Phase 1 clinical trials of SYN-020, and are working with qualified third-party vendors for the manufacture of additional quantities of SYN-004 and SYN-020 for potential future preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">VCN-01 &amp; VCN-11</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our oncolytic virus platform viruses (e.g. VCN-01, VCN-11) are biologics that can be readily synthesized by processes that we have developed in collaboration with Contract and Development Manufacturing Organizations (CDMOs) such as Thermo Fisher, BioReliance, GenIBET, and others. VCN does not own or operate manufacturing facilities for the production of our product candidates, VCN-01 and VCN-11 but it does produce and test viruses and virus processes at VCN facilities in Spain. VCN&#8217;s cell and virus seed </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">stocks and Master/Working banks for current and future production. Our cells for manufacturing are approved by and licensed from US regulatory authorities. Clinical and commercial supplies will be manufactured in facilities and by processes that comply with the FDA and other regulatory agency requirements. VCN plans to rely on third parties to manufacture commercial quantities of products that we successfully develop through regulatory approval. VCN has contracted with two CDMOs to provide what it believes are adequate clinical supplies for our planned clinical trials. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">VCN&#8217;s upstream and downstream processes for producing oncolytic viruses are well understood in the industry and use industry standard cell factories and single use bioreactors for manufacturing. &#160;All downstream purifications employ single-use columns and filters, and release testing is performed by third-party vendors using qualified or validated assays. Critical quality attributes and other product testing specifications for our clinical supplies are agreed to with regulatory authorities prior to release and use. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">VCN anticipates some delays in manufacturing due to COVID-19 impact on the supply chain. Its impact, if any, on the timing of future clinical trials is currently unknown.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2021 and 2020, we incurred approximately $7.8 million and $5.1 million, respectively, in research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the U.S., the formulation, manufacturing, packaging, storing, labeling, promotion, advertising, distribution and sale of our products are subject to regulation by various governmental agencies, including primarily the FDA. Our proposed activities may also be regulated by various agencies of the states, localities and foreign countries in which our proposed products may be manufactured, distributed and sold. The FDA, in particular, regulates the formulation, manufacture and labeling of prescription drugs, such as those that we intend to distribute. FDA regulations require us and our suppliers to meet relevant cGMP regulations for the preparation, packing, labeling, and storage of all drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing FDA regulation, including record-keeping requirements, reporting of adverse experiences, submitting periodic reports, drug sampling and distribution requirements, manufacturing or labeling changes, record-keeping requirements, and compliance with FDA promotion and advertising requirements. Drug manufacturers and their subcontractors are required to register their facilities with the FDA and state agencies, and are subject to periodic unannounced inspections for GMP compliance, imposing procedural and documentation requirements upon us and third-party manufacturers. Failure to comply with these regulations could result, among other things, in suspension of regulatory approval, recalls, suspension of production or injunctions, seizures, or civil or criminal sanctions. We cannot be certain that we or our present or future subcontractors will be able to comply with these regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA regulates prescription drug labeling and promotion activities in the United States. The FDA actively enforces regulations prohibiting the marketing of products for unapproved uses. The FDA permits the promotion of drugs for unapproved uses in certain circumstances, subject to stringent requirements. We and our product candidates are subject to a variety of state laws and regulations which may hinder our ability to market our products. Whether or not FDA approval has been obtained, approval by foreign regulatory authorities must be obtained prior to commencing clinical trials, and sales and marketing efforts in those countries. These approval procedures vary in complexity from country to country, and the processes may be longer or shorter than that required for FDA approval. We may incur significant costs to comply with these laws and regulations now or in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA, comparable foreign regulators and state and local pharmaceutical regulators impose substantial requirements upon clinical development, manufacture and marketing of pharmaceutical products. These and other entities regulate research and development and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising, and promotion of our products. The drug approval process required by the FDA under the Food, Drug, and Cosmetic Act and Public Health Service Act (for biologics) generally involves:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preclinical laboratory and animal tests;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission of an IND, prior to commencing human clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequate and well-controlled human clinical trials to establish safety and efficacy for intended use;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an NDA or BLA; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of an NDA or BLA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approval will be granted on a timely basis, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preclinical tests include laboratory evaluation of the product candidate, its chemistry, formulation and stability, and animal studies to assess potential safety and efficacy. Certain preclinical tests must be conducted in compliance with good laboratory practice regulations. Violations of these regulations can, in some cases, lead to invalidation of the studies, requiring them to be replicated. In some cases, long-term preclinical studies are conducted concurrently with clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will submit the preclinical test results, together with manufacturing information and analytical data, to the FDA as part of an IND, which must become effective before we begin human clinical trials. The IND automatically becomes effective 30&#160;days after filing, unless the FDA raises questions about conduct of the trials outlined in the IND and imposes a clinical hold, in which case, the IND sponsor and FDA must resolve the matters before clinical trials can begin. It is possible that our submission may not result in FDA authorization to commence clinical trials. The timing and requirements of IND review may differ from the FDA in other countries, potentially delaying study initiation at sites in those countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical trials must be supervised by qualified investigators in accordance with current good clinical practice (cGCP) regulations, which include informed consent requirements. Each study must be approved and monitored by the appropriate Institutional Review Boards (IRBs) or ethics committees (ECs) which are periodically informed of the study&#8217;s progress, adverse events and changes in research. Annual updates are submitted to the FDA and comparable foreign regulators (if required) with more frequent reporting if certain serious adverse events occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Human clinical trials of drug candidates typically have three sequential phases that may overlap:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Phase 1:&#160;&#160;&#160;The drug is initially tested in healthy human subjects or patients for safety, dosage tolerance, absorption, metabolism, distribution, and excretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Phase 2:&#160;&#160;&#160;The drug is studied in a limited patient population to identify possible adverse effects and safety risks, determine efficacy for specific diseases and establish dosage tolerance and optimal dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Phase 3:&#160;&#160;&#160;When Phase 2 evaluations demonstrate that a dosage range is effective with an acceptable safety profile, Phase 3 trials to further evaluate dosage, clinical efficacy and safety, are undertaken in an expanded patient population, often at geographically dispersed sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot be certain that we will successfully complete Phase 1, Phase 2, or Phase 3 testing of our product candidates within any specific time period, if at all. Furthermore, the FDA or comparable foreign regulator, an IRB/EC or the IND sponsor may suspend clinical trials at any time on various grounds, including a finding that subjects or patients are exposed to unacceptable health risk. Under the Pediatric Research Equity Act, we also must prepare, within 60&#160;days of an End of Phase 2 meeting, a pediatric study plan or request for waiver or deferral of pediatric studies in the indication under development. Concurrent with these trials and studies, we also develop chemistry and physical characteristics data and finalize a manufacturing process in accordance with cGMP requirements. The manufacturing process must conform to consistency and quality standards, and we must develop methods for testing the quality, purity, and potency of the final products. Appropriate packaging is selected and tested, and chemistry stability studies are conducted to demonstrate that the product does not undergo unacceptable deterioration over its shelf-life. Results of the foregoing are submitted to the FDA as part of an NDA (or BLA in case of biologic products) for marketing and commercial shipment approval. The FDA reviews each NDA or BLA submitted and may request additional information. A 60-day period after the sponsor&#8217;s submission of an NDA or BLA is used by the FDA to determine whether the application is sufficiently complete to permit substantive review, in which case the application is accepted for filing. The timing and requirements of NDA or BLA review may differ from the FDA in other countries,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Once the FDA accepts the NDA or BLA for filing, it begins its in-depth review. The FDA has substantial discretion in the approval process and may disagree with our interpretation of the data submitted or identify new concerns. The process may be significantly extended by requests for new information or clarification of information already submitted. As part of this review, the FDA may refer the application to an advisory committee, typically a panel of clinicians. Manufacturing establishments often are inspected prior to NDA or BLA approval to assure compliance with GMPs and with manufacturing commitments made in the application.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Submission of an NDA or BLA with clinical data requires payment of a substantial fee. In return, the FDA assigns a goal for review and decision on the application, in which the FDA may approve or deny the NDA or BLA, or issue a complete response letter outlining information needed to support approval, including a potential need for additional clinical data. Even if these data are submitted, the FDA may ultimately decide the NDA or BLA does not satisfy approval criteria. If the FDA approves the NDA or BLA, the product becomes available for marketing. Product approval may be withdrawn if regulatory compliance is not maintained or safety problems occur. The FDA may require post-marketing studies, also known as Phase 4 studies, as a condition of approval, and Risk Evaluation and Mitigation Strategies (REMS) requires surveillance programs to monitor approved products that have been commercialized. The agency has the power to require changes in labeling or prohibit further marketing based on the results of post-marketing surveillance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Satisfaction of these and other regulatory requirements typically takes several&#160;years, and the actual time required may vary substantially based upon the type, complexity and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve any of our products on a timely basis, if at all. Success in preclinical or early-stage clinical trials does not assure success in later-stage clinical trials. Data obtained from preclinical and clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval. Even if a product receives regulatory approval, the approval may be significantly limited to specific indications or uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even after regulatory approval is obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delays in obtaining, or failures to obtain regulatory approvals would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FDA&#8217;s or comparable foreign regulatory agency may change their policies, and additional government regulations may be enacted which could prevent or delay regulatory approval of our potential products. Increased attention to the containment of health care costs worldwide could result in new government regulations materially adverse to our business. We cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the U.S. or abroad.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Orphan Drug Act</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation must be requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the name of the sponsor, identity of the drug or biologic and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not shorten the duration of the regulatory review or approval process, but does provide certain advantages, such as a waiver of Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) fees, enhanced access to FDA staff and potential waiver of pediatric research requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full NDA, to market the same drug or biologic for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the application user fee. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Orphan Drug Designation is also available in Europe from the European Medicines Agency (EMA) and provides for 10 years of market exclusivity if granted. The requirements, costs and timing for obtaining and maintaining EMA Orphan Drug Designation differ from the FDA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Other Healthcare Laws and Compliance Requirements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the United States, the research, manufacturing, distribution, sale and promotion of drug products and medical devices are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the U.S. Department of Justice, state Attorneys General, and other state and local government agencies. The federal Anti-Kickback Statute prohibits any person, including a prescription drug manufacturer (or a party acting on its behalf), from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the furnishing, recommending or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. The federal False Claims Act imposes liability on any person or entity that, among other things, knowingly presents or causes to be presented, a false or fraudulent claim for payment by a federal healthcare program. The qui tam provisions of the False Claims Act allow a private individual to bring civil actions on behalf of the federal government alleging that the defendant has submitted a false claim to the federal government, and to share in any monetary recovery. In addition, various states have enacted anti-kickback statues and false claims laws analogous to the False Claims Act. Also, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) created several federal crimes, including healthcare fraud, and false statements relating to the delivery of or payments for healthcare benefits, items or services. HIPAA and its implementing regulations also established uniform federal standards for certain &#8220;covered entities&#8221; (healthcare providers, health plans and healthcare clearinghouses) governing the conduct of certain electronic healthcare transactions and protecting the security and privacy of protected health information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these and other laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government contracts, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to market any product outside of the United States, a company also must comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can initiate clinical trials or market products in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows the same lines as in the United States. It entails satisfactory completion of pharmaceutical development, nonclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the medicinal product for each proposed indication. It also requires the submission to relevant competent authorities for clinical trials authorization and to the EMA or to competent authorities in EU Member States for a marketing authorization application, or MAA, and granting of a marketing authorization by competent authorities in EU Member States or the European Commission before the product can be marketed and sold in the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data Privacy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Strict data privacy laws regulating the collection, transmission, storage and use of employee data and consumers&#8217; personally-identifying information are evolving in the European Union, U.S. and other jurisdictions in which we operate. Outside of the United States, the laws, regulations and standards in many jurisdictions apply broadly to the collection, use, and other processing of personal information. For example, in the European Union, the collection and use of personal data are governed by the provisions of the General Data Protection Regulation (the &#8220;GDPR&#8221;). The GDPR, together with national legislation, regulations and guidelines of the European Union. member states governing the processing of personal data, impose strict obligations on entities subject to the GDPR, including but not limited to: (i) accountability and transparency requirements, and enhanced requirements for obtaining valid consent from data subjects; (ii) obligations to consider data protection as any new products or services are developed and to limit the amount of personal data processed; (iii) obligations to comply with the data protection rights of data subjects; and (iv) obligations to report certain personal data breaches to governmental authorities and individuals. Data protection authorities from the different E.U. member states and other European countries may enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing European personal data. Failure to comply with the requirements of the GDPR and the related national data protection laws may result in significant monetary fines and other administrative penalties (the GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#8364;20 million, whichever is greater) as well as civil </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">liability claims from individuals whose personal data was processed. Additionally, expenses associated with compliance could reduce our operating margins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The GDPR also prohibits the transfer of personal data from the E.U. to countries outside of the E.U. unless made to a country deemed by the European Commission to provide adequate protection for personal data or accomplished by means of an approved data transfer mechanism (e.g., standard contractual clauses). Data protection authority guidance and enforcement actions that restrict companies&#8217; ability to transfer data may increase risk relating to data transfers or make it more difficult or impossible to transfer E.U. personal data to the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Competitive Environment</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The pharmaceutical and biotechnology industries are characterized by rapidly evolving technology and intense competition. Our competitors include major multi-national pharmaceutical companies and biotechnology companies developing both generic and proprietary therapies to treat serious diseases. Many of these companies are well-established and possess technical, human, research and development, financial, and sales and marketing resources significantly greater than ours. In addition, many of our potential competitors have formed strategic collaborations, partnerships and other types of joint ventures with larger, well established industry competitors that afford these companies potential research and development and commercialization advantages in the therapeutic areas we are currently pursuing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Academic research centers, governmental agencies and other public and private research organizations are also conducting and financing research activities which may produce products directly competitive to those being developed by us. In addition, many of these competitors may be able to obtain patent protection, obtain FDA and other regulatory approvals and begin commercial sales of their products before us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Companies that currently sell or are developing proprietary products for the prevention and treatment of <i style="font-style:italic;">C. difficile</i> infection include: Actelion Pharmaceutical Ltd., Artugen Therapeutics,&#160;Inc., AzurRx,&#160;Inc., Da Volterra, Deinove, Pfizer Inc., Merck&#160;&amp; Co. Inc., Merus B.V., Pfizer Inc., Rebiotix,&#160;Inc., Seres Therapeutics,&#160;Inc., Summit Therapeutics plc. and Vedanata Biosciences Inc. Companies that sell or are developing products for the treatment or prevention of acute graft-versus-host-disease (aGVHD) include: Amgen,&#160;Inc., Astellas Pharma, Janssen Biotech,&#160;Inc., Mallinckrodt plc, Novartis International AG, Pfizer,&#160;Inc. Roche AG and Takeda Pharmaceutical Company Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Only three oncolytic virus (OV) products have been approved in different global markets. Amgen Inc.&#8217;s Imlygic&#174; (T-VEC, OncoVEX) for melanoma (USA); Daiichi Sankyo Company, Limited&#8216;s DELYTACT&#174; for malignant glioma (Japan) and Shanghai Sunway Biotech Co., Ltd Oncorine&#174; for patients with late-stage refractory nasopharyngeal cancer (China).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">More than 60 companies have publicly identified that they are pursuing clinical development of different forms of OV products. Adenoviruses are the most commonly used viruses in these programs, with modified adenoviruses under development by companies including AdCure Bio LLC, Candel Therapeutics, Inc., CG Oncology, Inc., DNAtrix, Inc., EpicentRx, Inc., GeneMedicine, Co Ltd., IconOVir Bio, Inc., Lokon Pharma AB, Multivir, Inc., NewGenPharm Incorporation, Oncolys BioPharma, Inc., Orca Therapeutics B.V., PsiOxus Therapeutics Ltd, Shanghai Sunway Biotech Co., Ltd , Targovax Oy|Targovax ASA, Tessa Therapeutics, TILT Biotherapeutics, Ltd., and Valo Therapeutics Oy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">OV products have been or are being developed using other virus backbones, including: Coxsackie virus (Viralytics Ltd., Oncorus Inc.); herpes simplex virus (Amgen, Inc., Candel Therapeutics, Inc., Daiichi Sankyo Company Ltd., Oncorus, Inc., Replimune, Inc., Takara Bio, Inc., Wuhan Binhui Biotechnology Co., Ltd.); Maraba virus (Turnstone Biologics, Inc.); measles virus (Vyriad, Inc.); myxoma virus (OncoMyx Therapeutics, Inc.); parvovirus (Oryx GmbH &amp; Co. KG), reovirus (Oncolytics Biotech, Inc.); Seneca Valley virus (Seneca Therapeutics Inc., Oncorus Inc.); vesicular stomatitis virus (Vyriad, Inc.); and vaccinia viruses (Genelux Corporation, KaliVir Immunotherapeutics LLC, SillaJen, Inc., Transgene SA, Turnstone Biologics, Corp.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">OV companies that have identified pancreatic cancer or PDAC as a proposed clinical indication include Candel Therapeutics, Inc., GeneMedicine, Co Ltd., Lokon Pharma AB, NewGenPharm Incorporation, Oncolytics Biotech, Oryx GmbH &amp; Co. KG, V2ACT Therapeutics&#8482; LLC (a Genelux Corporation joint venture), and Wuhan Binhui Biotechnology Co., Ltd. OV companies that have identified retinoblastoma as a potential target indication include Seneca Therapeutics Inc. and Shanghai Sunway Biotech Co., Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">VCN OV products are designed to be systemically, intratumorally or intravitreally injected; selectively replicate only in tumor cells versus normal host cells; have reduced liver tropism compared to wild type adenovirus type 5; and express an enzyme (PH20) that </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">degrades the tumor stroma barrier. If confirmed in Phase 2 and later clinical trials, these features significantly differentiate VCN products from competing OVs and will enable VCN products to be co-administered with other therapeutic modalities such as chemotherapy and immune therapy to improve cancer treatment outcomes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Corporate History</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our predecessor, Sheffield Pharmaceuticals,&#160;Inc., was incorporated in 1986, and in 2006 engaged in a reverse merger with Pipex Therapeutics,&#160;Inc., a publicly-traded Delaware corporation formed in 2001. After the reverse merger, we changed our name to Pipex Pharmaceuticals,&#160;Inc., and in October&#160;2008 we changed our name to Adeona Pharmaceuticals,&#160;Inc. On October&#160;15, 2009, we engaged in a merger with a wholly owned subsidiary for the purpose of reincorporating in the State of Nevada. On February&#160;15, 2012, we changed our name to Synthetic Biologics,&#160;Inc. On August&#160;10, 2018, we effected a one for thirty-five reverse stock split of our authorized, issued and outstanding common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Human Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We believe that our success depends upon our ability to attract, develop and retain key personnel. Prior to the VCN Acquisition, we employed 9 individuals, all of whom were full-time employees, of which 5 were part of our research and clinical development team and clinical development team and 4 were part of our financial reporting and accounting team. As of March 16, 2022, we employed 16 &#160;individuals, all of whom are full-time employees, of which 5 were part of our research and clinical development team in the United States and six were part of VCN&#8217;s research and clinical development team located in Spain, one is part of VCN&#8217;s management team located in Spain and 4 were part of our financial reporting and accounting team located in the United States. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">A significant number of our management and professional employees have had prior experience with pharmaceutical, biotechnology or medical product companies. None of our employees in the United States are covered by collective bargaining agreements, and management considers relations with our employees to be in good standing. As is the usual situation in Spain, all the employees are currently covered by a collective bargaining system specific for the pharma sector. Although we continually seek to add additional talent to our work force, management believes that it has sufficient human capital to operate its business successfully.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Competitive Pay and Benefits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our compensation programs are designed to align the compensation of our employees with our performance and to provide the proper incentives to attract, retain and motivate employees to achieve superior results. The structure of our compensation programs balances incentive earnings for both short-term and long-term performance. Specifically:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we provide employee wages that are competitive and consistent with employee positions, skill levels, experience, knowledge and geographic location;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we engage nationally recognized outside compensation and benefits consulting firms to independently evaluate the effectiveness of our executive compensation and benefit programs and to provide benchmarking against our peers within the industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we align our executives&#8217; long-term equity compensation with our shareholders&#8217; interests by linking realizable pay with stock performance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all employees are eligible for health insurance, paid and unpaid leaves, a retirement plan and life and disability/accident coverage. We also offer a variety of voluntary benefits that allow employees to select the options that meet their needs, including flexible time-off, telemedicine, and unpaid parental leave.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Health and Safety</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The health and safety of our employees is our highest priority, and this is consistent with our operating philosophy. Accordingly, with the global spread of the ongoing novel coronavirus pandemic, we have implemented plans designed to address and mitigate the impact of the COVID-19 pandemic on the safety of our employees and our business, which include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding work from home flexibility;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adjusting attendance policies to encourage those who are sick to stay home;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increasing cleaning protocols across all locations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiating regular communication regarding impacts of the COVID-19 pandemic, including health and safety protocols and procedures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Properties</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our principal executive offices are located at 9605 Medical Center Drive, Suite&#160;270, Rockville, Maryland 20850. VCN personnel will continue to operate from laboratories and office space leased from Grifols at Avinguda de la Generalitat, 152, 08174 Sant Cugat del Vall&#232;s, Barcelona, Spain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additional information about Synthetic Biologics is contained at our website, <i style="font-style:italic;">www.syntheticbiologics.com</i>. Information contained on our website is not incorporated by reference into, and does not form any part of, this Annual Report on Form 10-K. We have included our website address as a factual reference and do not intend it to be an active link to our website. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations page of our internet website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (the &#8220;SEC&#8221;). The following Corporate Governance documents are also posted on our website: Code of Conduct, Code of Ethics for Financial Management and the Charters for the Audit Committee, Compensation Committee and Nominations Committee of the Board of Directors. Our phone number is (301) 417-4364 and our facsimile number is (301) 417-4367. The SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Commission. &#160;The address of that website is <i style="font-style:italic;">www.sec.gov</i><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_857c604d_2241_4b56_b97d_2293bbeeb58f"></a><a id="Item1ARiskFactors_830998"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk Factors</span><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1A.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing in our securities involves a high degree of risk. In addition to the risks related to our business set forth in this Annual Report and the other information included in this Annual Report, you should carefully consider the risks described below before purchasing our securities. Additional risks, uncertainties and other factors not presently known to us or that we currently deem immaterial may also impair our business operations.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISKS RELATED TO THE </b><b style="font-weight:bold;">ACQUISITION OF VCN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The combined company may not experience the anticipated strategic benefits of the Acquisition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">While we anticipate certain benefits from our Acquisition of VCN, we may not be able to realize the expected benefits. We may not be able to integrate the two businesses successfully, and we could assume unknown or contingent liabilities. The VCN intellectual property may not have the scientific value and commercial potential which we envision. Any failure of the Acquisition to meet our expectations could have a material negative effect on our results of operations. </span>There can be no assurance that the anticipated benefits of the Acquisition will materialize or that if they materialize will result in increased stockholder value or revenue stream to the combined company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may be unable to successfully integrate the VCN businesses with our current management and structure. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our failure to successfully complete the integration of VCN could have an adverse effect on our prospects, business activities, cash flow, financial condition, results of operations and stock price. Integration challenges may include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilating VCN&#8217;s technology and retaining personnel, especially in light of the fact that VCN&#8217;s operations are in Spain; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">estimating the capital, personnel and equipment required for VCN based on the historical experience of management with the businesses they are familiar with; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">minimizing potential adverse effects on existing business relationships. </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not anticipate generating revenue from VCN product or technology sales for many years. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not expect to derive revenue from the sale of VCN-01 for many years and there can be no assurance that regulatory approvals will be received or if received that they will be received when anticipated. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In order to develop VCN product or technology we will have to devote significant resources to VCN product or technology &#160;and will need to raise additional capital to fully develop the newly acquired product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">We have agreed to use reasonable efforts to commercialize VCN-01 and we agreed as a post- closing covenant to commit to fund VCN&#8217;s research and development programs, including but not limited to VCN-01 PDAC phase 2 clinical trial, VCN-01 RB pivotal trial and necessary G&amp;A within a budgetary plan of approximately $27.8 million. &#160;Obtaining requisite regulatory approvals for the clinical trials of VCN-01 are anticipated to require significant expenditures. We have incurred significant losses from operations to date and expect our expenses to increase in connection with our ongoing activities, and the addition of VCN&#8217;s activities. In order to fully develop the newly acquired VCN product candidates we will need to raise additional capital. There can be no assurance that funding will be available on acceptable terms on a timely basis, or at all. The various ways that we could raise capital carry potential risks. Any additional sources of financing will likely involve the issuance of our equity securities, which will have a dilutive effect on our stockholders. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our technologies or tests or grant licenses on terms that are not favorable to us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our common stock following the Acquisition may decline as a result of the Acquisition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The market price of our common stock may decline as a result of the Acquisition for a number of reasons including if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investors react negatively to the prospects of the post-Acquisition business and prospects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effect of the Acquisition on our business and prospects is not consistent with the expectations of financial or industry analysts; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the post-Acquisition company does not achieve the perceived benefits of the Acquisition as rapidly or to the extent anticipated by financial or industry analysts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our stockholders will experience substantial dilution from the issuance of the Acquisition consideration and may not realize a benefit from the Acquisition commensurate with the ownership dilution they will experience in connection with the Acquisition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our stockholders will experience substantial dilution from the issuance of the Acquisition consideration. If post-Acquisition we are unable to realize the full strategic and financial benefits currently anticipated from the Acquisition, our securityholders will have experienced substantial dilution of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent the post-merger company is able to realize only part of the strategic and financial benefits currently anticipated from the merger.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISKS RELATED TO OUR BUSINESS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We will need to raise additional capital to operate our business and our failure to obtain funding when needed may force us to delay, reduce or eliminate certain of our development programs or commercialization efforts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the&#160;year ended December&#160;31, 2021, our operating activities used net cash of approximately $12.9 million and as of December&#160;31, 2021 our cash and cash equivalents were $67.3 million. With the exception of the three&#160;months ended December&#160;31, 2017 and June&#160;30, 2010, we have experienced significant losses since inception and have a significant accumulated deficit. As of December&#160;31, 2021, our accumulated deficit totaled approximately $271.3 million on a consolidated basis. Pursuant to the Purchase Agreement, we have agreed to use reasonable efforts to commercialize VCN-01 and we agreed as a post- closing covenant to commit to fund VCN&#39;s research and development programs, including but not limited to VCN-01 PDAC phase 2 clinical trial, VCN-01 RB pivotal trial and necessary G&amp;A within a budgetary plan of approximately $27.8 million over the next three years. We expect to incur additional operating losses in the future and therefore expect our cumulative losses to increase. With the exception of the quarter ended June&#160;30, 2010, and limited laboratory revenues from Adeona Clinical Laboratory, which we sold in March&#160;2012, we have generated very minimal revenues. We </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">do not expect to derive revenue from any source in the near future until we or our potential partners successfully commercialize our products. We expect our expenses to increase in connection with our anticipated activities, particularly as we continue research and development, initiate and conduct clinical trials, and seek marketing approval for our product candidates. Until such time as we receive approval from the FDA and other regulatory authorities for our product candidates, we will not be permitted to sell our products and therefore will not have product revenues from the sale of products. For the foreseeable future we will have to fund all of our operations and capital expenditures from equity and debt offerings, cash on hand, licensing and collaboration fees and grants, if any.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We will need to raise additional capital to fund our operations and meet our current timelines and we cannot be certain that funding will be available on acceptable terms on a timely basis, or at all. Based on our current plans, our cash and cash equivalents will be sufficient to complete our planned later stage clinical trials of VCN-01, Phase 1a/2a clinical trial of SYN-004, our Phase 1 single-ascending and multiple-ascending dose clinical trials of SYN-020, and a potential Phase 2a clinical trial of SYN-020 but, may not be sufficient for post-Phase 2a future clinical programs for SYN-020 or additional trials of SYN-004, which are expected to require significant cash expenditures. In addition, based on the significant anticipated cost of a Phase 3 clinical program in a broad indication for SYN-004, we expect it will not be feasible for us to initiate and complete this trial at this time without a partner given the capital constraints tied to our current market cap and share price. Further development of VCN&#8217;s product candidates will require additional funding. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants that may impact our ability to conduct our business and also have a dilutive effect on our stockholders. A failure otherwise to secure additional funds when needed in the future whether through an equity or debt financing or a sufficient amount of capital without a strategic partnership could result in us being unable to complete planned preclinical and clinical trials or obtain approval of our product candidates from the FDA and other regulatory authorities. In addition, we could be forced to delay, discontinue or curtail product development, forego sales and marketing efforts, and forego licensing in attractive business opportunities. Our ability to raise capital through the sale of securities may be limited by the rules&#160;of the SEC and NYSE American that place limits on the number and dollar amount of securities that may be sold. There can be no assurances that we will be able to raise the funds needed, especially in light of the fact that our ability to sell securities registered on our registration statement on Form&#160;S-3 will be limited until such time the market value of our voting securities held by non-affiliates is $75 million or more. We also may be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 global health crisis has and could continue to impact our planned operations, including our clinical studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January&#160;2020, the World Health Organization declared a global pandemic for the novel strain of coronavirus, COVID-19. Since then, the COVID-19 coronavirus has spread to multiple countries, including throughout the United States. We have experienced disruptions that have impacted our business and clinical trials and expect to experience additional disruptions as the pandemic continues, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unwillingness of potential study participants to enroll in new clinical trials and/or visit healthcare facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">postponement of enrollment in our SYN-004 Phase 1b/2a clinical study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">postponement of the initiation of our SYN-020 Phase 2 studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical site visits by study participants and clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption in global shipping that may affect the manufacture and transport of clinical trial materials, such as investigational drug product used in our clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in local regulations as part of a response to the COVID-19 coronavirus outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delay in the timing of interactions with the FDA due to absenteeism by federal employees or by the diversion of their efforts and attention to approval of other therapeutics or other activities related to COVID-19.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">Our business and the business of the suppliers of our clinical product candidates has been and is expected to continue to be materially and adversely affected by the pandemic. While we are currently not experiencing material delays, such events could result in the delay or complete or partial closure of clinical trial sites or one or more manufacturing facilities which could impact our supply of our clinical product candidates. In addition, it could impact economies and financial markets, resulting in an economic downturn that could impact our ability to raise capital or slow down potential partnering relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In response to the spread of COVID-19 as well as public health directives and orders, we have implemented a number of measures designed to ensure employee safety and business continuity. We have limited access to our offices and are allowing our administrative employees to continue their work outside of our offices in order to support the community efforts to reduce the transmission of COVID-19 and protect employees, complying with guidance from federal, state and local government and health authorities. The effects of the governmental orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;">In addition, the COVID-19 outbreak could disrupt our operations due to absenteeism by infected or ill members of management or other employees, or absenteeism by members of management and other employees who elect not to come to work due to the illness affecting others in our office, or due to quarantines. The COVID-19 illness could also impact members of our Board of Directors resulting in absenteeism from meetings of the directors or committees of directors, and making it more difficult to convene the quorums of the full Board of Directors or its committees needed to conduct meetings for the management of our affairs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The global outbreak of the virus continues to rapidly evolve. The extent to which the virus may continue to impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. We do not yet know the full extent of potential delays or impacts on our business, operations, or the global economy as a whole. While the spread of COVID-19 may eventually be contained or mitigated, there is no guarantee that a future outbreak of this or any other widespread epidemics will not occur, or that the global economy will recover, either of which could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While we are currently not experiencing any delays, we have in the past experienced delays in clinical testing of our product candidates due to COVID-19 and may in the future experience other delays. These delays may result in the need for trials to be redesigned and may impact whether they will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the COVID-19 pandemic, delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial or in obtaining sufficient supplies of clinical trial materials. Manufacturing considerations for clinical development candidates may include an expected several month lead time following a decision to commence any clinical trial(s)&#160;and capacity considerations of our third-party contract manufacturers to provide clinical supply of our product candidates could cause delays in clinical trials. Furthermore, due to the COVID-19 pandemic, many manufacturers have been prioritizing the manufacture of COVD-19 related products, increasing the manufacturing lead times for non-COVID-19 related products. Many factors affect patient enrollment, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, competing clinical trials and new drugs approved for the conditions we are investigating. Clinical investigators will need to decide whether to offer their patients enrollment in clinical trials of our product candidates versus treating these patients with commercially available drugs that have established safety and efficacy profiles. Any delays in completing our clinical trials will increase our costs, slow down our product development and timeliness and approval process and delay our ability to generate revenue.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business</span><b style="font-weight:bold;"> </b><span style="font-style:italic;font-weight:bold;">disruptions</span><b style="font-weight:bold;"> </b><span style="font-style:italic;font-weight:bold;">could seriously harm our future revenue and financial condition and increase costs and expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our operations and those of our third-party suppliers and collaborators could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes or other extreme weather conditions, medical epidemics, labor disputes, war or other business interruptions. Any interruption could seriously harm our ability to timely proceed with any clinical programs or to supply product candidates for use in our clinical programs or during commercialization. For example, the current COVID-19 pandemic has, at points, caused an interruption in our clinical trial activities. Additionally, supply chain disruptions impact and may continue to impact our research activities. Moreover, at the end of 2021 and into 2022, tensions between the United States and Russia escalated when Russia amassed large numbers of military ground forces and support personnel on the Ukraine-Russia border and, in February 2022, Russia invaded Ukraine. In response, North Atlantic Treaty Organization, or NATO has deployed additional military forces to Eastern Europe and the Biden administration announced certain sanctions against Russia. The invasion of Ukraine and the retaliatory measures that have been taken, or could be taken in the future, by the United States, NATO, and other countries have created global security concerns that could result in a regional conflict and otherwise have a lasting impact on regional and global economies, any or all of which could disrupt our supply chain, and despite the fact that we currently do not plan any clinical trials in Eastern Europe, may adversely impact the cost and coduct of our international clinical trials of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to continue to incur significant operating and capital expenditures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other than with respect to the three&#160;months ended December&#160;31, 2017 and June&#160;30, 2010, we have a history of losses and we have incurred, and will continue to incur, substantial losses and negative operating cash flow. Even if we succeed in developing and commercializing one or more of our product candidates, we may still incur substantial losses for the foreseeable future and may not sustain profitability. We expect that later stage clinical trials, if conducted, including a Phase 3 clinical program of SYN-004 (ribaxamase) for the prevention of aGVHD or CDI, will enroll a greater number of patients than our prior clinical trials and will be more costly than our prior clinical trials. In addition, we anticipate a need for additional employees as we undertake later stage clinical trials. We have also incurred certain obligations pursuant to the terms of the Purchase Agreement including the assumption of $2.4 million of liabilities and have agreed to a post-closing covenant to commit to fund VCN&#8217;s research and development programs, including but not limited to VCN-01 PDAC phase 2 trial, VCN-01 RB pivotal trial and necessary G&amp;A within a budgetary plan of approximately $27.8 million. &#160;Further development of VCN&#8217;s product candidates will require additional expenditures. We also expect to continue to incur significant operating and capital expenditures and anticipate that our expenses will substantially increase in the foreseeable future as we do the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to undertake preclinical development and mid and late-stage clinical trials for our product candidates, including SYN-004 (ribaxamase), and SYN-020;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop our product candidates for commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implement additional internal systems and infrastructure;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">license or acquire additional technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lease additional or alternative office facilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture product for clinical trials and commercial use; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional personnel, including members of our management team.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may experience negative cash flow for the foreseeable future as we fund our development and clinical programs with capital expenditures. As a result, we will need to raise additional capital or generate significant revenues in order to achieve and maintain profitability. We may not be able to generate these revenues or achieve profitability in the future. Our failure to achieve or maintain profitability, which we do not anticipate will occur in the near future, could negatively impact the value of our common stock and underlying securities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The actual amount of funds we will need to operate is subject to many risk factors, some of which are beyond our control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These factors include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of our research activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and scope of our research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of our preclinical and clinical development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of the development efforts of parties with whom we have entered into research and development agreements and amount of funding received from partners and collaborators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain current research and development licensing arrangements and to establish new research and development and licensing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve our milestones under licensing arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with manufacturing-related services to produce materials for use in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in prosecuting and enforcing patent claims and other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs incurred to screen and enroll patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The costs and timing of regulatory approvals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have based our estimate on assumptions that may prove to be wrong. We may need to obtain additional funds sooner or in greater amounts than we currently anticipate. Potential sources of financing include strategic relationships, public or private sales of our shares or debt and other sources. Additionally, we may seek to access the public or private equity markets when conditions are favorable due to our long-term capital requirements. We do not have any committed sources of financing at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently have no products approved for commercial sale, have no significant source of revenue and may never generate significant revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue depends heavily on:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to raise additional capital on a timely basis to continue to fund our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration in current and future clinical trials that our lead product candidates, VCN-01 in PDAC and VCN-01 RB, SYN-004 (ribaxamase) and SYN-020, are safe and effective;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful manufacture and commercialization of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance of our products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All of our existing product candidates are in various stages of development and will require extensive additional clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment before they could provide us with any revenue. As a result, even if we successfully develop, achieve regulatory approval and commercialize our products, we may be unable to generate revenue for many&#160;years, if at all. We do not anticipate that we will generate revenue from product sales for at least several&#160;years, if at all. If we are unable to generate revenue from product sales, we will not become profitable, and we may be unable to continue our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">To date we have not conducted any cancer research and development activities and there can be no assurance that we will successfully be able to do so.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prior to the VCN Acquisition, our focus was on the microbiome and our research and development was focused primarily on therapeutics for various microbiome related diseases. &#160;Upon the VCN Acquisition, our focus has shifted to the use of oncolytic viruses to treat cancer. &#160;Although, we have members of management that have experience in this field, we may not be successful as a company with such focus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In the past Oncolytic Viruses have experienced certain safety challenges.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although current clinical trials of oncolytic virotherapies have supported their role as a potential treatment for cancer, there is the risk of uncontrolled replication <i style="font-style:italic;">in vivo</i> and possible transmission to patients&#39; contacts, such as other patients and health care workers. In recent years, clinical trials to address these concerns have been conducted. Any such transmission by VCN or a competitor would have an adverse impact on VCN&#8217;s future research and development efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our research and development efforts may not result in commercially successful products and technologies, which may limit our ability to achieve profitability. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We must continue to explore opportunities that may lead to new products and technologies. To accomplish this, we must commit substantial efforts, funds, and other resources to research and development. A high rate of failure is inherent in the research and development of new products and technologies. Any such expenditures that we make will be made without any assurance that our efforts will be successful. Failure can occur at any point in the process, including after significant funds have been invested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The success of our business currently depends on our development, approval and commercialization of our lead product candidates, VCN-01, SYN-004 (ribaxamase) and SYN-020. Our ongoing Phase 1b/2a clinical trial of SYN-004 for the prevention of aGVHD in allogeneic HCT recipients, &#160;our fully dosed Phase 1 single ascending and multiple ascending dose studies of SYN-020 and ongoing early-stage clinical trials of VCN-01 are not designed as registrational clinical trials and we currently do not have the necessary funding to complete any late stage registrational clinical trials. There are many uncertainties known and unknown that may affect the outcome of future clinical trials. All of our product candidates, including SYN-004 (ribaxamase), SYN-020 and VCN-01, will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. Regardless of whether our clinical trials are deemed to be successful, promising new product candidates may fail to reach the market or may only have limited commercial success because of efficacy or safety concerns, failure to achieve positive clinical outcomes, inability to obtain necessary regulatory approvals or satisfy regulatory criteria, limited scope of approved uses, excessive costs to manufacture, the failure to establish or maintain intellectual property rights, or infringement of the intellectual property rights of others. Failure to obtain regulatory approvals of SYN-004 (ribaxamase), SYN-020 or VCN-01 in a timely manner would have a material adverse impact on our business. Even if we successfully develop SYN-004 (ribaxamase), SYN-020, or VCN-01 or other new products or enhancements, they may be quickly rendered obsolete by changing customer preferences, changing industry standards, or competitors&#8217; innovations. Innovations may not be quickly accepted in the marketplace because of, among other things, entrenched patterns of clinical practice or uncertainty over third-party reimbursement. We cannot state with certainty when or whether any of our products under development will be launched, whether we will be able to develop, license, or otherwise acquire drug candidates or products, or whether any products will be commercially successful. Failure to launch successful new products or new indications for existing products may cause our products to become obsolete, which may limit our ability to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">or license, we will achieve the revenue or specific net income that justifies such transaction. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to retain rights licensed to us by others to commercialize key products and may not be able to establish or maintain the relationships we need to develop, manufacture, and market our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to our own patent applications, we also currently rely on licensing agreements with third party patent holders/licensors for our products. VCN has entered license agreements upon which its technology is dependent. We entered into an option agreement with MGH to enter into an exclusive license to intellectual property and technology related to the use of IAP to maintain GI and microbiome health, diminish systemic inflammation, and treat age-related diseases. There can be no assurance that we will be able to reach agreement on license terms or that the terms will be favorable to us. This license agreement is expected to require us to meet certain diligence requirements and timelines in order to keep the license agreement in effect. In addition, certain license agreements, including the one that may potentially be entered into with MGH, typically contain provisions requiring royalty free non-exclusive licenses to the U.S government if any federal funding was used to invent any of the patents being licensed. In the event we or our sublicensee are not able to meet our diligence requirements contained in the license agreement with MGH or any other license agreement, we may not be able to retain the rights granted under our agreement or renegotiate with our arrangement institution on reasonable terms, or at all. If any license were to terminate and we were to lose the right to commercialize our products, our business opportunity would be adversely affected. Furthermore, we currently have very limited product development capabilities, and limited marketing or sales capabilities. For us to research, develop, and test our product candidates, we would need to contract with outside researchers, in most cases those parties that did the original research and from whom we have licensed the technologies. Our agreement with UT Austin allows UT Austin to terminate its agreement if we fail to comply with the terms of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We can give no assurances that any of our issued patents licensed to us or any of our other patent applications will provide us with significant proprietary protection or be of commercial benefit to us. Furthermore, the issuance of a patent is not conclusive as to its validity or enforceability, nor does the issuance of a patent provide the patent holder with freedom to operate without infringing the patent rights of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may incur additional expenses in connection with our licenses and collaboration arrangements and our development of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our agreements with Washington University and MGH may require that we initiate certain studies and file or have accepted an NDA within a certain amount of time, each of which are costly and will require additional expenditures. Although all manufacturing, preclinical studies and human clinical trials are expensive and difficult to design and implement, costs associated with the manufacturing, research and development of biologic product candidates are generally greater in comparison to small molecule product candidates. Due to our small work force, we expect in future&#160;years to require additional personnel to support our later stage research and development efforts. Now that the Acquisition has been consummated, we will require additional employees to support those operations. In addition, we intend to commence manufacturing of SYN-004 (ribaxamase) and SYN-020 materials to support potential future clinical studies which will require us to incur additional expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because development activities in our collaborations are sometimes determined pursuant to joint steering committees, future development costs associated with these programs may be difficult to anticipate and may exceed our expectations. Our actual cash requirements may vary materially from our current expectations for a number of other factors that may include, but are not limited to, unanticipated technical challenges, enrollment challenges, changes in the focus and direction of our development activities or adjustments necessitated by changes in the competitive landscape in which we operate. If we are unable to continue to financially support such collaborations due to our own working capital constraints, we may be forced to delay our activities. If we are unable to obtain additional financing on terms acceptable to us or at all, we may be forced to seek licensing partners or discontinue development.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Developments by competitors may render our products or technologies obsolete or non-competitive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The pharmaceutical and biotechnology industries, including the monoclonal antibody industry, are characterized by rapidly evolving technology and intense competition. Our competitors include major multi-national pharmaceutical companies and biotechnology companies developing both generic and proprietary therapies to treat serious diseases. Many of our competitors have drugs that have already been commercialized and therefore benefit from being first to market their products. Many of these companies are well-established and possess technical, human, research and development, financial, and sales and marketing resources significantly greater than ours. In addition, many of our potential competitors have formed strategic collaborations, partnerships and other types of joint ventures with larger, well established industry competitors that afford these companies&#8217; potential research and development and commercialization advantages in the therapeutic areas we are currently pursuing. Academic research centers, governmental agencies and other public and private research organizations are also conducting and financing research activities which may produce products directly competitive to those being developed by us. In addition, many of these competitors may be able to obtain patent protection, obtain FDA and other regulatory approvals and begin commercial sales of their products before us, including for different indications of the same active ingredients that comprise our pipeline products. These competitors will compete with us in product sales as well as recruitment and retention of qualified scientific and management personnel, establishment of clinical trial sites and patient enrollment for clinical trials, as well as in the acquisition of technologies and technology licenses complementary to our programs or advantageous to our business. Companies that currently sell or are developing proprietary products for the prevention and treatment of <i style="font-style:italic;">C. difficile</i> infection include: Actelion Pharmaceutical&#160;Ltd.,Artugen Therapeutics,&#160;Inc., AzurRx,&#160;Inc., Da Volterra, Deinove, Merck&#160;&amp; Co.&#160;Inc., Merus B.V., Pfizer&#160;Inc., Rebiotix,&#160;Inc., Seres Therapeutics,&#160;Inc., Summit Therapeutics&#160;plc., and Vedanta Biosciences,&#160;Inc. Companies that sell or are developing products for the treatment or prevention of acute graft-versus-host-disease (aGVHD) include: Amgen,&#160;Inc., Astellas Pharma, Janssen Biotech,&#160;Inc., Mallinckrodt plc, Novartis International AG, Pfizer,&#160;Inc., Roche AG and Takeda Pharmaceutical Company Ltd. Companies that currently sell or are developing proprietary products for pertussis include: GlaxoSmithKline plc, Mitsubishi Tanabe Pharma Corporation and Sanofi S.A. AG. The infectious disease market is highly competitive with many generic and proprietary intravenous and oral formulations available to physicians and their patients. For our monoclonal antibodies, we currently do not expect to be able to deliver our infectious disease candidates via the oral route and may thus be limited to the in-patient and/or acute treatment setting. In addition, academic research centers may develop technologies that compete with our SYN-004, SYN-020, and SYN-005 products and our other technologies. Should clinicians or regulatory authorities view alternative therapeutic regiments as more effective than our products, this might delay or prevent us from obtaining regulatory approval for our products, or it might prevent us from obtaining favorable reimbursement rates from payers, such as Medicare, Medicaid, hospitals and private insurers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek to selectively establish collaborations, and, if we are unable to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our product development programs and the potential commercialization of our clinical product candidates will require substantial additional cash to fund expenses. For some of our product candidates (such as our planned phase 3 clinical trial of SYN-004) we may decide to collaborate with governmental entities or additional pharmaceutical and biotechnology companies for the development and potential commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with our product candidate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If the parties we depend on for supplying substance raw materials for our product candidates and certain manufacturing-related services do not timely supply these products and services in sufficient quality or quantity, it may delay or impair our ability to develop, manufacture and market our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on suppliers for the substance raw materials of our product candidates and third parties for manufacturing-related services to produce material that meets appropriate content, quality and stability standards and use in clinical trials of our products and, after approval, for commercial distribution. To succeed, clinical trials require adequate supplies of study material, which may be difficult or uneconomical to procure or manufacture and there can be no assurance that we will successfully procure such study material or even if procured, that we can do so in quantities and in a timely manner to allow our clinical trials to proceed as planned. We and our suppliers and vendors may not be able to (i)&#160;produce our study material to appropriate standards for use in clinical studies, (ii)&#160;perform under any definitive manufacturing, supply or service agreements with us, or (iii)&#160;remain in business for a sufficient time to successfully produce and market our product candidates. If we do not maintain important manufacturing and service relationships, we may fail to find a replacement supplier or required vendor or manufacturer which could delay or impair our ability to obtain regulatory approval for our products and substantially increase our costs or deplete profit margins, if any. If we do find replacement manufacturers and vendors, we may not be able to enter into agreements with them on terms and conditions favorable to us and there could be a substantial delay before a new facility could be qualified and registered with the FDA and foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The third-party manufacturers of the active pharmaceutical ingredient (API) and drug product for our lead product candidates, VCN -01, SYN-004 (ribaxamase) and SYN-020, are established cGMP manufacturers. For all other therapeutic areas, we have not yet established cGMP manufacturers for our biologic and drug candidates. We do not currently have definitive agreement with any third party vendor for the manufacture of SYN-004. We currently have only one manufacturer for each of our lead product candidates VCN-01, SYN-004 or SYN-020. Although we believe additional manufacturers are available, if either of our manufacturers were to limit or terminate production or otherwise fail to meet the quality or delivery requirements needed to satisfy the supply commitments, the process of locating and qualifying alternate sources could require up to several&#160;months, during which time our production could be delayed. Any curtailment in the availability of VCN-01, SYN-004 (ribaxamase) or SYN-020 could have a material adverse effect on our business, financial position and results of operations. In addition, because regulatory authorities must generally approve raw material sources for pharmaceutical products, changes in raw material suppliers may result in production delays or higher raw material costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The manufacture of our product candidates requires significant expertise and manufacturers may encounter difficulties in production, particularly in scaling up production. These problems include difficulties with production costs and yields, quality control, including stability of the product and quality assurance testing, shortages of qualified personnel, as well as compliance with federal, state and foreign regulations. We may experience longer than expected lead times with respect to the manufacture of clinical drug supply, which may result from the increase in manufacturing scale necessary to conduct our anticipated late-stage clinical trials and result in trial delays. Furthermore, due to the COVID-19 pandemic, many manufacturers have been prioritizing the manufacture of COVID-19 related products, increasing the manufacturing lead times for non-COVID-19 related products.In addition, any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials, increase the costs associated with conducting our clinical trials and, depending upon the period of delay, require us to commence new clinical trials at significant additional expense or to terminate a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are responsible for ensuring that each of our contract manufacturers comply with the cGMP requirements of the FDA and other regulatory authorities from which we seek to obtain product approval. While we oversee compliance, we do not have control over our manufacturers and their compliance with regulatory requirements. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The approval process for NDAs includes a review of the manufacturer&#8217;s compliance with cGMP requirements. We are responsible for regularly assessing a contract manufacturer&#8217;s compliance with cGMP requirements through record reviews and periodic audits and for ensuring that the contract manufacturer takes responsibility and corrective action for any identified deviations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis and at commercially reasonable prices, we may be unable to meet demand for any approved products and would lose potential revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">For the proposed Phase 2 clinical trial of VCN-01 &#160;in patients with PDAC, we plan to administer, our clinical product candidate, VCN-01, in combination with other approved standard of care drugs. Any problems obtaining the standard of care drugs could result in a delay or interruption in our clinical trials.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For each of our planned Phase 2 clinical trial of VCN-01 in patients with PDAC, &#160;we plan to administer VCN-01 in combination with already approved standard of care drug, gemcitabine/nab-paclitaxel, for which there has recently been a supply shortage. Therefore, our success will be dependent upon the continued use of and ability to obtain the standard of care drugs. We expect that in any other clinical trials we conduct for additional indications, our clinical product candidate will also be administered in combination with drugs owned by third parties. If any of the standard of care drugs that are used in our clinical trials are unavailable while the trials are continuing, the timeliness and commercialization costs could be impacted. In addition, if any of these other drugs are determined to have safety or efficacy problems, our clinical trials and commercialization efforts would be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may fail to retain or recruit necessary personnel, and we may be unable to secure the services of consultants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 16, 2022, we employed 16 full-time employees, including employees located at VCN&#39;s offices in Barcelona, Spain. We have also engaged clinical consultants to advise us on our clinical programs and regulatory consultants to advise us on our dealings with the FDA and other foreign regulatory authorities. Due to our small &#160;work force, we expect in future years to require additional personnel to support our later stage research and development efforts. Now that the Acquisition is consummated, we will require additional employees to support those operations. We have been and may be required to retain additional consultants and employees in order to fulfill our obligations under our licenses and collaborations for our development of SYN-004, SYN-020, VCN-01 and our agreements with Washington University and other collaborators. Our future performance will depend in part on our ability to successfully integrate newly hired officers into our management team and our ability to develop an effective working relationship among senior management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain of our directors, scientific advisors, and consultants serve as officers, directors, scientific advisors, or consultants of other biopharmaceutical or biotechnology companies that might be developing competitive products to ours. Other than corporate opportunities, none of our directors are obligated under any agreement or understanding with us to make any additional products or technologies available to us. Similarly, we can give no assurances, and we do not expect and stockholders should not expect, that any biomedical or pharmaceutical product or technology identified by any of our directors or affiliates in the future would be made available to us other than corporate opportunities. We can give no assurances that any such other companies will not have interests that are in conflict with our interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Losing key personnel or failing to recruit necessary additional personnel would impede our ability to attain our development objectives. There is intense competition for qualified personnel in the drug and biologic development areas, and we may not be able to attract and retain the qualified personnel we would need to develop our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on independent organizations, advisors, and consultants to perform certain services for us, including handling substantially all aspects of regulatory approval, clinical management, manufacturing, marketing, and sales. We expect that this will continue to be the case. Such services may not always be available to us on a timely basis when we need them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely extensively on our information technology systems and are vulnerable to damage&#160;and interruption.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely on our information technology systems and infrastructure to process transactions, summarize results and manage our business, including maintaining client and supplier information. Additionally, we utilize third parties, including cloud providers, to store, transfer and process data. Our information technology systems, as well as the systems of our suppliers and other partners, whose systems we do not control, are vulnerable to outages and an increasing risk of continually evolving deliberate intrusions to gain access to company sensitive information. Likewise, data security incidents and breaches by employees and others with or without permitted access to our systems pose a risk that sensitive data may be exposed to unauthorized persons or to the public. A cyber-attack or other significant disruption involving our information technology systems, or those of our vendors, suppliers and other partners, could also result in disruptions in critical systems, corruption or loss of data and theft of data, funds or intellectual property.&#160;&#160;We may be unable to prevent outages or security breaches in our systems.&#160;&#160;We remain potentially vulnerable to additional known or yet unknown threats as, in some instances, we, our suppliers and our other partners may be unaware of an incident or its magnitude and effects.&#160;&#160;We also face the risk that we expose our vendors or partners to cybersecurity attacks.&#160;&#160;Any or all of the foregoing could adversely affect our results of operations and our business reputation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any failure to maintain the security of information relating to our patients, customers, employees and suppliers, whether as a result of cybersecurity attacks or otherwise, could expose us to litigation, government enforcement actions and costly response measures, and could disrupt our operations and harm our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the pre-clinical and clinical development, sales and marketing of our products and services, we may from time to time transmit confidential information. We also have access to, collect or maintain private or confidential information regarding our clinical trials and the patients enrolled therein, employees, and suppliers, as well as our business. Cyberattacks are rapidly evolving and becoming increasingly sophisticated. It is possible that computer hackers and others might compromise our security measures, or security measures of those parties that we do business with now or in the future, and obtain the personal information of patients in our clinical trials, vendors, employees and suppliers or our business information. A security breach of any kind, including physical or electronic break-ins, computer viruses and attacks by hackers, employees or others, could expose us to risks of data loss, litigation, government enforcement actions, regulatory penalties and costly response measures, and could seriously disrupt our operations. Any resulting negative publicity could significantly harm our reputation, which could cause us to lose market share and have an adverse effect on our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may face particular data protection, data security and privacy risks in connection with the European Union&#8217;s Global Data Protection Regulation and other privacy regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Outside of the United States, the laws, regulations and standards in many jurisdictions apply broadly to the collection, use, and other processing of personal information. For example, in the European Union, the collection and use of personal data are governed by the provisions of the General Data Protection Regulation (the &#8220;GDPR&#8221;). The GDPR, together with national legislation, regulations and guidelines of the European Union. member states governing the processing of personal data, impose strict obligations on entities subject to the GDPR, including but not limited to: (i) accountability and transparency requirements, and enhanced requirements for obtaining valid consent from data subjects; (ii) obligations to consider data protection as any new products or services are developed and to limit the amount of personal data processed; (iii) obligations to comply with the data protection rights of data subjects; and (iv) obligations to report certain personal data breaches to governmental authorities and individuals. Data protection authorities from the different E.U. member states and other European countries may enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing European personal data. Failure to comply with the requirements of the GDPR and the related national data protection laws may result in significant monetary fines and other administrative penalties (the GDPR authorizes fines for certain violations of up to 4% of global annual revenue or &#8364;20 million, whichever is greater) as well as civil liability claims from individuals whose personal data was processed. Additionally, expenses associated with compliance could reduce our operating margins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The GDPR also prohibits the transfer of personal data from the E.U. to countries outside of the E.U. unless made to a country deemed by the European Commission to provide adequate protection for personal data or accomplished by means of an approved data transfer mechanism (e.g., standard contractual clauses). Data protection authority guidance and enforcement actions that restrict companies&#8217; ability to transfer data may increase risk relating to data transfers or make it more difficult or impossible to transfer E.U. personal data to the U.S.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REGULATORY RISKS </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we do not obtain the necessary regulatory approvals in the U.S. and/or other countries we will not be able to develop or sell our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot assure you that we will receive the approvals necessary to commercialize any of our product candidates or any product candidates we acquire or develop in the future. We will need FDA approval to commercialize our product candidates in the U.S. and approvals from the FDA-equivalent regulatory authorities in foreign jurisdictions to commercialize our product candidates in those jurisdictions. We will be required to conduct clinical trials that will be costly and we currently do not have the funding to complete any registrational clinical trials. We cannot predict whether our clinical trials will demonstrate the safety and efficacy of our product candidates or if the results of any clinical trials will be sufficient to advance to the next phase of development or for approval from the FDA (or equivalent foreign regulatory authorities). We also cannot predict whether our research and clinical approaches will result in drugs or therapeutics that the FDA considers safe and effective for the proposed indications. The FDA has substantial discretion in the drug approval process. The approval process may be delayed by changes in government regulation, future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may prevent or delay commercialization of, and our ability to derive product revenues from our product candidates; and diminish any competitive advantages that we may otherwise believe that we hold.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Even if we comply with all FDA (or equivalent foreign regulatory authorities) requests, the FDA may ultimately reject one or more of our NDAs or BLAs. We may never obtain regulatory clearance for any of our product candidates. Failure to obtain FDA approval of any of our product candidates will severely undermine our business by leaving us without a saleable product, and therefore without any source of revenues, until another product candidate can be developed. There is no guarantee that we will ever be able to develop or acquire another product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the FDA (or equivalent foreign regulatory authorities) may require us to conduct additional pre-clinical and clinical testing or to perform post-marketing studies, as a condition to granting marketing approval of a product. The results generated after approval could result in loss of marketing approval, changes in product labeling, and/or new or increased concerns about the side effects or efficacy of a product. The FDA has significant post-market authority, including the explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance with FDA-approved risk evaluation and mitigation strategies. The FDA&#8217;s exercise of its authority has in some cases resulted, and in the future could result, in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements and potential restrictions on sales of approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In foreign jurisdictions, we must also receive approval from the appropriate regulatory authorities before we can commercialize any products, which can be time consuming and costly. Foreign regulatory approval processes generally include all of the risks associated with the FDA approval procedures described above but processes, requirements and timelines for approval by these agencies may differ significantly from the FDA. There can be no assurance that we will receive the approvals necessary to commercialize our product candidate for sale outside the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the FDA approves any of our product candidates, the labeling, manufacturing, packaging, adverse event reporting, storage, advertising, promotion and record-keeping for our products will be subject to ongoing FDA requirements and continued regulatory oversight and review. Our drug manufacturers and subcontractors that we retain will be required to comply with FDA and other regulations. We may also be subject to additional FDA post-marketing obligations. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, suspension of regulatory approval, suspension of production, injunctions or civil or criminal sanctions. The subsequent discovery of previously unknown problems with any marketed product, including adverse events of unanticipated severity or frequency, may result in restrictions on the marketing of the product, and could include withdrawal of the product from the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials are very expensive, time-consuming, and difficult to design and implement.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Human clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. We estimate that clinical trials for our product candidates would take at least several&#160;years to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us to abandon or repeat clinical trials. Commencement and completion of clinical trials may be delayed by several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining an IND application with the FDA or foreign equivalent to commence clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identification of, and acceptable arrangements with, one or more clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining IRB or EC approval to commence clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen safety issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determination of dosing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lack of effectiveness during clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">slower than expected rates of patient recruitment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to monitor patients adequately during or after treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lower than expected rates of patient completion of clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain supply of our drug candidate in a timely manner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability or unwillingness of medical investigators to follow our clinical protocols; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unwillingness of the FDA or foreign equivalent, or IRBs to permit the clinical trials to be initiated.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, we, IRBs or the FDA or foreign equivalent may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or if IRBs /ECs or the FDA or foreign equivalent finds deficiencies in our submissions or conduct of our trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The results of our clinical trials may not support our product candidate claims and the results of preclinical studies and completed clinical trials are not necessarily predictive of future results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">To date, long-term safety and efficacy have not yet been demonstrated in clinical trials for any of our product candidates. Favorable results in our early studies or trials may not be repeated in later studies or trials as was the case with SYN-010. Even if our clinical trials are initiated and completed as planned, we cannot be certain that the results will support our product candidate claims. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful. Success in VCN&#8217;s Phase 1 PDAC clinical trial or Retinoblastoma clinical trial does not ensure success of VCN-01, especially in light of the small number of patients treated in those trials. Success of our predecessor P1A clinical product or positive topline data from our previous SYN-004 (ribaxamase) Phase 1 and Phase 2 clinical trials, does not ensure success of SYN-004 (ribaxamase). Furthermore, the FDA could determine that SYN-004 (ribaxamase) has not demonstrated safety and require additional clinical trials and safety data, despite positive results from our SYN-004 (ribaxamase) Phase 2b clinical trial and the determination by clinical sites investigators and an independent third party that the serious adverse events that occurred in the group that received SYN-004 in our Phase 2b clinical trial were not drug related. We cannot be sure that the results of later clinical trials would replicate the results of prior clinical trials and preclinical testing nor that they would satisfy the requirements of the FDA or other regulatory agencies. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products. Any such failure could cause us or our sublicensee to abandon a product candidate and might delay development of other product candidates. Preclinical and clinical results are frequently susceptible to varying interpretations that may delay, limit or prevent regulatory approvals or commercialization. Any delay in, or termination of, our clinical trials would delay our obtaining FDA approval for the affected product candidate and, ultimately, our ability to commercialize that product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Difficulties enrolling patients in our clinical trials or delays in enrollment are expected to result in our clinical development activities being delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Delays in patient enrollment may result in increased cost or may adversely affect timing or outcome of planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates. This can lead to delays in completion of clinical trials as well as additional expense for recruitment of patients. In addition, the COVID-19 pandemic may result in fewer technicians being available to conduct clinical testing for patients currently enrolled in our clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Patients who are administered our product candidates may experience unexpected side effects or other safety risks that could cause a halt in their clinical development, preclude approval of our product candidates or limit their commercial potential.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our clinical trials may be suspended at any time for a number of reasons. We may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition, the FDA or other regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the clinical trial patients. For example, the FDA or foreign equivalents could determine that VCN -01 or SYN-004 has not demonstrated safety, that adverse events are drug related and require additional clinical trials and safety data, despite positive results from VCN&#8217;s Phase 1 clinical trial or our SYN-004 Phase 2b clinical trial and the determination by clinical sites investigators and an independent third party that the adverse events that occurred in the group that received VCN-01 in VCN&#8217;s Phase 1 clinical trials or SYN-004 in our Phase 2b clinical trial were not drug related.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Administering any product candidate to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of our product candidates and could result in the FDA or other regulatory authorities denying further development or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">approval of our product candidates for any or all targeted indications. Ultimately, some or all of our product candidates may prove to be unsafe for human use. Moreover, we could be subject to significant liability if any volunteer or patient suffers, or appears to suffer, adverse health effects as a result of participating in our clinical trials. Any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could substantially increase commercialization costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates, if approved for sale, may not gain acceptance among physicians, patients and the medical community, thereby limiting our potential to generate revenues.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If one of our product candidates is approved for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of any approved product by physicians, healthcare professionals and third-party payors and our profitability and growth will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">demonstration of safety and efficacy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the practice guidelines and the standard of care for the targeted indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any adverse side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">budget impact of adoption of our product on relevant drug formularies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability, cost and potential advantages of alternative treatments, including less expensive generic drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing, reimbursement and cost effectiveness, which may be subject to regulatory control;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of our or any of our partners&#8217; sales and marketing strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product labeling or product insert required by the FDA or regulatory authority in other countries; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of adequate third-party insurance coverage or reimbursement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any product candidate that we develop does not provide a treatment regimen that is as beneficial as, or is perceived as being as beneficial as, the current standard of care or otherwise does not provide patient benefit, that product candidate, if approved for commercial sale by the FDA or other regulatory authorities, likely will not achieve market acceptance. Our ability to effectively promote and sell any approved products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price and our ability to obtain sufficient third-party coverage or reimbursement. If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, patients and third-party payors, our ability to generate revenues from that product would be substantially reduced. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources, may be constrained by FDA rules&#160;and policies on product promotion, and may never be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We depend on third parties, including researchers and sublicensees, who are not under our control. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to seek or obtain regulatory approval for or commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We and VCN depend on independent investigators and scientific collaborators, such as universities and medical institutions or private physician scientists, to advise us and to conduct our preclinical and clinical trials under agreements with us. These collaborators are not our employees and we cannot control the amount or timing of resources that they devote to our programs or the timing of their procurement of clinical-trial data or their compliance with applicable regulatory guidelines. Should any of these scientific inventors/advisors or those of our sublicensee become disabled or die unexpectedly, or should they fail to comply with applicable regulatory guidelines, we or our sublicensee may be forced to scale back or terminate development of that program. They may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking those programs ourselves. Failing to devote sufficient time and resources to our drug-development programs, or substandard performance and failure to comply with regulatory guidelines, could result in delay of any FDA applications and our commercialization of the drug candidate involved.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These collaborators may also have relationships with other commercial entities, some of which may compete with us. Our collaborators assisting our competitors could harm our competitive position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">With respect to our product candidate for pertussis in collaboration with UT Austin, we are dependent on its research laboratories as we have no such facilities or capabilities of our own. If any of the foregoing were to become inaccessible or terminated, it would be difficult for us to develop and commercialize our synthetic biologic product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have in the past and expect to have in the future agreements with third-party contract research organizations (CROs) under which we have delegated to the CROs the responsibility to coordinate and monitor the conduct of our SYN-004,SYN-020 and VCN-01 clinical trials and to manage data for our clinical programs. Our Phase 1b/2a clinical trial of SYN-004, Phase 1 clinical trials of SYN-020 and anticipated clinical trials for VCN-01 are being conducted by clinical sites over which we have little direct control. We, our CROs and our clinical sites are required to comply with current Good Clinical Practices, or cGCPs, regulations and guidelines issued by the FDA and by similar governmental authorities in other countries where we are conducting clinical trials. We have an ongoing obligation to monitor the activities conducted by our CROs and at our clinical sites to confirm compliance with these requirements. In the future, if we, our CROs or our clinical sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations and will require a large number of test subjects. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. If our CROs or investigator-sponsored clinical sites do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently have no marketing, sales or distribution organization and have no experience in marketing products as a company. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We currently have no marketing, sales or distribution capabilities and have no experience in marketing products. We may develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product in the United States or overseas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reimbursement may not be available for our product candidates, which would impede sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Market acceptance and sales of our product candidates may depend on coverage and reimbursement policies and health care reform measures. Decisions about formulary coverage as well as levels at which government authorities and third-party payers, such as private health insurers and health maintenance organizations, reimburse patients for the price they pay for our products as well as levels at which these payors pay directly for our products, where applicable, could affect whether we are able to commercialize these products. We cannot be sure that reimbursement will be available for any of our products. Also, we cannot be sure that coverage or reimbursement amounts will not reduce the demand for, or the price of, our products. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In recent&#160;years, officials have made numerous proposals to change the health care system in the United States. These proposals include measures that would limit or prohibit payments for certain medical treatments or subject the pricing of drugs to government control. In </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">addition, in many foreign countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to government control. If our products are or become subject to government regulation that limits or prohibits payment for our products, or that subjects the price of our products to governmental control, we may not be able to generate revenue, attain profitability or commercialize our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As a result of legislative proposals and the trend towards managed health care in the United States, third-party payors are increasingly attempting to contain health care costs by limiting both coverage and the level of reimbursement of new drugs. They may also impose strict prior authorization requirements and/or refuse to provide any coverage of uses of approved products for medical indications other than those for which the FDA or foreign equivalent has granted market approvals. As a result, significant uncertainty exists as to whether and how much third-party payors will reimburse patients for their use of newly-approved drugs, which in turn will put pressure on the pricing of drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Healthcare reform measures could hinder or prevent our product candidates&#8217; commercial success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The U.S. government and other governments have shown significant interest in pursuing continued healthcare reform. Any government-adopted reform measures could adversely impact the pricing of healthcare products and services in the United States or internationally and the amount of reimbursement available from governmental agencies or other third-party payors. The continuing efforts of the U.S. and foreign governments, insurance companies, managed care organizations and other payors of health care services to contain or reduce health care costs may adversely affect our ability to set prices for our products which we believe are fair, and our ability to generate revenues and achieve and maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">New laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to healthcare availability, methods of delivery or payment for products and services, or sales, marketing or pricing, may limit our potential revenue, and we may need to revise our research and development programs. The pricing and reimbursement environment may change in the future and become more challenging due to several reasons, including policies advanced by the current executive administration in the United States, new healthcare legislation or fiscal challenges faced by government health administration authorities. Specifically, in both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If product liability lawsuits are successfully brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability lawsuits related to the testing of our product candidates and will face an even greater risk if we sell our product candidates commercially. Currently, we are not aware of any anticipated product liability claims with respect to our product candidates. In the future, an individual may bring a liability claim against us if one of our product candidates causes, or merely appears to have caused, an injury. If we cannot successfully defend ourselves against the product liability claim, we may incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#8217;s attention from our primary business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize our product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have clinical trial liability insurance. We intend to expand our insurance coverage to include the sale of commercial products if marketing approval is obtained for our product candidates. Our current insurance coverage may prove insufficient to cover any liability claims brought against us. In addition, because of the increasing costs of insurance coverage, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy liabilities that may arise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">INTELLECTUAL PROPERTY RISKS</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We rely on patent applications and various regulatory exclusivities to protect some of our product candidates and our ability to compete may be limited or eliminated if we are not able to protect our products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The patent positions of pharmaceutical companies are uncertain and may involve complex legal and factual questions. We may incur significant expenses in protecting our intellectual property and defending or assessing claims with respect to intellectual property owned by others. Any patent or other infringement litigation by or against us could cause us to incur significant expenses and divert the attention of our management. Even for our issued patents, we do not have a guarantee of patent term restoration and marketing exclusivity of the ingredients for our drugs under the Hatch-Waxman Amendments, even if we are granted FDA approval of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Others may file patent applications or obtain patents on similar technologies or compounds that compete with our products. We cannot predict how broad the claims in any such patents or applications will be, and whether they will be allowed. Once claims have been issued, we cannot predict how they will be construed or enforced. We may infringe intellectual property rights of others without being aware of it. If another party claims we are infringing their technology, we could have to defend an expensive and time consuming lawsuit, pay a large sum if we are found to be infringing, or be prohibited from selling or licensing our products unless we obtain a license or redesign our product, which may not be possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also rely on trade secrets and proprietary know-how to develop and maintain our competitive position. Some of our current or former employees, consultants, scientific advisors, current or prospective corporate collaborators, may unintentionally or willfully disclose our confidential information to competitors or use our proprietary technology for their own benefit. Furthermore, enforcing a claim alleging the infringement of our trade secrets would be expensive and difficult to prove, making the outcome uncertain. Our competitors may also independently develop similar knowledge, methods, and know-how or gain access to our proprietary information through some other means.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, as well as costs associated with lawsuits.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If any other person files patent applications, or is issued patents, claiming technology also claimed by us in pending applications, we may be required to participate in interference proceedings in the U.S. Patent and Trademark Office to determine priority of invention. We, or our licensors, may also need to participate in interference proceedings involving our issued patents and pending applications of another entity. The European Patent Office and some national patent authorities have formal patent opposition processes where the validity of issued patents may be challenged. If a patent opposition is filed, we, or our licensors, may also need to participate in opposition proceedings involving our issued patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The intellectual property environment in the monoclonal antibody field is particularly complex, constantly evolving and highly fragmented. We have not conducted freedom-to-use patent searches on all aspects of our product candidates or potential product candidates, and we may be unaware of relevant patents and patent applications of third parties. In addition, the freedom-to-use patent searches that have been conducted may not have identified all relevant issued patents or pending patents. We cannot provide assurance that our proposed products in this area will not ultimately be held to infringe one or more valid claims owned by third parties which may exist or come to exist in the future or that in such case we will be able to obtain a license from such parties on acceptable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that the practice of our technologies will not conflict with the rights of others. In some foreign jurisdictions, we could become involved in opposition proceedings, either by opposing the validity of another&#8217;s foreign patent or by persons opposing the validity of our foreign patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We may also face frivolous litigation or lawsuits from various competitors or from litigious securities attorneys. The cost to us of any litigation or other proceeding relating to these areas, even if deemed frivolous or resolved in our favor, could be substantial and could </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">distract management from our business. Uncertainties resulting from initiation and continuation of any litigation could have a material adverse effect on our ability to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we infringe the rights of others, we could be prevented from selling products or forced to pay damages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our products, methods, processes, and other technologies are found to infringe the proprietary rights of other parties, we could be required to pay damages, or we may be required to cease using the technology or to license rights from the prevailing party. Any prevailing party may be unwilling to offer us a license on commercially acceptable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">RISKS RELATING TO OUR SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We cannot assure you that our common stock will be liquid or that it will remain listed on the NYSE American.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock is listed on the NYSE American. The NYSE American&#8217;s listing standards generally mandate that we meet certain requirements relating to stockholders&#8217; equity, stock price, market capitalization, aggregate market value of publicly held shares and distribution requirements. We cannot assure you that we will be able to maintain the continued listing standards of the NYSE American. The NYSE American requires companies to meet certain continued listing criteria including a minimum stockholders&#8217; equity of $6.0 million if an issuer has sustained losses from continuing operations and/or net losses in its five most recent&#160;years, as outlined in the NYSE American Company Guide. The NYSE American Company Guide also states that the NYSE normally will not consider removing from listing securities of an issuer if it is in compliance with all of the following:a total value of market capitalization of at least $50.0 million; 1,100,000 publicly-held shares; a market value of publicly held shares of at least $15.0 million; and 400 round lot shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If our common stock falls below $0.20 per share on a 30-trading-day average it will become subject to the continued listing evaluation and follow-up procedures set forth in Section&#160;1009 of the NYSE American Company Guide which could, among other things, result in initiation of immediate delisting procedures. In the event that we were to fail to meet the requirements of NYSE American per share price requirement or stockholders&#8217; equity requirement and we could not timely cure such deficiency, our listing could become subject to NYSE American continued listing evaluation and follow-up procedures, which could result in delisting procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We previously received notification from the NYSE American citing failure to comply with the minimum stockholders&#8217; equity continued listing standard as set forth in Part 10, Section 1003 of the Company Guide. Although in the past we have been able to cure previously cited deficiencies, there can be no assurance that we will continue to meet the NYSE American continued listing requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, in the future we may not be able to maintain minimum stockholders&#8217; equity and/or issue additional equity securities in exchange for cash or other assets, if available, to maintain certain minimum stockholders&#8217; equity required by the NYSE American. If we are delisted from the NYSE American then our common stock will trade, if at all, only on the over-the-counter market, such as the OTC Bulletin Board securities market, and then only if one or more registered broker-dealer market makers comply with quotation requirements. In addition, delisting of our common stock could depress our stock price, substantially limit liquidity of our common stock and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Delisting from the NYSE American could also have other negative results, including the potential loss of confidence by suppliers and employees, the loss of institutional investor interest and fewer business development opportunities. We cannot assure you that our common stock will be liquid or that it will remain listed on the NYSE American. A failure to regain compliance with the NYSE American stockholders&#8217; equity requirements or failure to continue to meet the other listing requirements could result in a de-listing of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We expect to seek to raise additional capital in the future, which may be dilutive to stockholders or impose operational restrictions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We expect to seek to raise additional capital in the future to help fund development of our proposed products. If we raise additional capital through the issuance of equity or of debt securities, the percentage ownership of our current stockholders will be reduced. We may also enter into strategic transactions, issue equity as consideration for acquisitions or part of license issue fees to our licensors, compensate consultants or settle outstanding payables using equity that may be dilutive. We are authorized to issue 200,000,000 shares of common stock, of which 158,437,840 shares of common stock were issued and outstanding as of March 16, 2022. At March 16, 2022, we had reserved 12,600,241 shares of common stock for issuance upon exercise of our outstanding options and warrants. In addition, at such date, we had 200,000 shares of our common stock reserved for future issuance under our equity incentive plans. If all of these securities were to be exercised, the total number of shares of our common stock that we would be required to issue is 12,800,241, which in addition to the 158,437,840 shares issued and outstanding, would leave 28,759,591 authorized but unissued shares of common stock. As a result of our limited number of authorized and unissued shares of common stock, we may have insufficient shares of common stock available to issue in connection with any future equity financing transactions or strategic transactions we may seek to undertake. At our </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">2021 Annual Meeting of Shareholders, we sought shareholder approval of an amendment to our Articles of Incorporation, as amended, to increase our authorized number of shares of common stock, which approval was not obtained. Accordingly, we anticipate taking steps, when appropriate, to increase our number of available shares which may have the effect of facilitating such transactions; however, there can be no assurance that we will be successful in obtaining the required approval for any such action.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share paid by existing stockholders, thereby subjecting such stockholders to dilution. Our stockholders may experience additional dilution in net book value per share and any additional equity securities may have rights, preferences and privileges senior to those of the holders of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by existing stockholders, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. In the event that we sell shares or other securities at prices below the exercise price of the warrants that we issued in our October&#160;2018 offering, the price protection anti-dilution provisions of the warrant provide that the exercise price of the warrants sold in our October&#160;2018 offering is to be reduced which may result in additional warrant exercises and additional dilution to stockholders as was the case in 2020 and during the first quarter of 2021 when we utilized our at-the-market facility and the warrant exercise price was reduced. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Holders of our warrants issued in our October&#160;2018 offering have no rights as common stockholders until they exercise their warrants and acquire our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Until the holders of the warrants we issued in our October&#160;2018 offering acquire shares of our common stock by exercising their warrants, the holders of the warrants have no rights as a stockholder with respect to the shares of common stock underlying their securities. Upon exercise of the warrants they will be entitled to the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Whether the outstanding warrants will have any value will depend on the market conditions for, and the price of, our common stock, which conditions will depend on factors related and unrelated to the success of our clinical development program, and cannot be predicted at this time. If our common stock price does not increase to an amount sufficiently above the exercise price of the warrants during the periods the warrants are exercisable, holders of warrants will be unable to recover any of their investment in the warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because there is no established public trading market for the October 2018 warrants we issued, the liquidity of each such security is limited. We do not expect a market to develop, nor do we intend to apply to list the warrants on any securities exchange. Upon exercise of the warrants, our stockholders will experience dilution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market price of our common stock has been and may continue to be volatile and adversely affected by various factors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our stock price has fluctuated in the past, has recently been volatile and may be volatile in the future. By way of example, on February&#160;8, 2021, the price of our common stock closed at $1.17 per share while on October&#160;18, 2021, our stock price closed at $0.4362 per share and on February 3, 2022, our stock price closed at $0.23 per share with no discernable announcements or developments by the company or third parties. We may incur rapid and substantial decreases in our stock price in the foreseeable future that are unrelated to our operating performance or prospects. In addition, the recent outbreak of the novel strain of coronavirus (COVID-19) has caused broad stock market and industry fluctuations. The stock market in general and the market for biotechnology and pharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may experience losses on their investment in our common stock. The market price of our common stock could fluctuate significantly in response to various factors and events, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">investor reaction to our business strategy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our continued compliance with the listing standards of the NYSE American;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our products;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of our efforts to acquire or in-license additional products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning our collaborations or partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patents or other proprietary rights, litigation matters and our ability to obtain patent protection for our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">declines in the market prices of stocks generally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, including those resulting from such events, or the prospect of such events, including war, terrorism and other international conflicts, such as the recent Russian invasion of Ukraine as well as continued and new sanctions against Russia, which restrict a wide range of trade and financial dealings with Russia and Russian persons, public health issues including health epidemics or pandemics, such as the recent outbreak of the novel coronavirus (COVID-19), and natural disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United States or elsewhere, could disrupt our operations, disrupt the operations of our suppliers or result in political or economic instability.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance. Further, recent increases are significantly inconsistent with any improvements in actual or expected operating performance, financial condition or other indicators of value. Since the stock price of our common stock has fluctuated in the past, has been recently volatile and may be volatile in the future, investors in our common stock could incur substantial losses. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management&#8217;s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.&#160;There can be no guarantee that our stock price will remain at current prices or that future sales of our common stock will not be at prices lower than those sold to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, recently, securities of certain companies have experienced significant and extreme&#160;volatility in stock price due to short sellers of shares of common stock, known as a &#8220;short squeeze.&#8221; &#160;These short squeezes have caused extreme volatility in those companies and in the market and have led the price per share of those companies to trade at a significantly inflated rate that is disconnected from the underlying value of the company. Many investors who have purchased shares in those companies at an inflated rate face the risk of losing a significant portion of their original investment as the price per share has declined steadily as interest in those stocks have abated. While we have no reason to believe our shares would be the target of a short squeeze, there can be no assurance that we won&#8217;t be in the future, and you may lose a significant portion or all of your investment if you purchase our shares at a rate that is significantly disconnected from our underlying value.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our articles of incorporation and bylaws and Nevada law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our articles of incorporation, as amended, our amended and restated bylaws and Nevada law could make it more difficult for a third party to acquire us, even if closing such a transaction would be beneficial to our stockholders. The Board of Directors could authorize the issuance of an additional series of preferred stock that would grant holders preferred rights to our assets upon liquidation, special voting rights, the right to receive dividends before dividends would be declared to common stockholders, and the right to the redemption of such shares, possibly together with a premium, prior to the redemption of the common stock. To the extent that we do issue additional preferred stock, the rights of holders of common stock could be impaired thereby, including without limitation, with respect to liquidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Provisions of our articles of incorporation, as amended and our amended and restated bylaws may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular, our articles of incorporation, as amended, and amended and restated bylaws, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide the board of directors with the ability to alter the bylaws without stockholder approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that vacancies on the board of directors may be filled by a majority of directors in office, although less than a quorum.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We do not intend to pay dividends in the foreseeable future on our common stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never paid cash dividends on our common stock. We currently intend to retain our future earnings, if any, to finance the operation and growth of our business and currently do not plan to pay any cash dividends in the foreseeable future. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if the market price of our common stock price appreciates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Resales of our common stock in the public market by our stockholders may cause the market price of our common stock to fall.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may issue common stock from time to time in connection with future offerings. Any issuance from time to time of new shares of our common stock, or our ability to issue shares of common stock in future offerings, could result in resales of our common stock by our current stockholders concerned about the potential dilution of their holdings. In turn, these resales could have the effect of depressing the market price for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The shares of common stock offered under our current Amended and Restated At The Market Issuance Sales Agreement may be sold in &#8220;at the market&#8221; offerings, and investors who buy shares at different times will likely pay different prices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Investors who purchase shares that are sold under our current Amended and Restated At The Market Issuance Sales Agreement at different times will likely pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold, and there is no minimum or maximum sales price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Investors may experience declines in the value of their shares as a result of share sales made at prices lower than the prices they paid.</p><a id="_cf0fc259_6bf5_4f5b_a8cd_db626b71d6e9"></a><a id="Item1BUnresolvedStaffComments_955608"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 1B.&#160;&#160;&#160;&#160;</b><span style="font-style:italic;font-weight:bold;">Unresolved Staff Comments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_68e795d3_2abf_41fa_b298_791cf3699aa0"></a><a id="Item2Properties_968497"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2.&#160;&#160;&#160;&#160;</b><span style="font-style:italic;font-weight:bold;">Properties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters are located in Rockville, Maryland, where we occupy approximately 10,363 square feet of office space under a lease agreement expiring December&#160;31, 2027, with&#160;monthly rent of $27,187. VCN currently leases approximately 4,946 square feet of office and lab space office space in Barcelona, Spain under a lease agreement with Grifols expiring October 2026, which an option to renew for an additional five years with monthly rent of 25,000 Euros per month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not own any real property. We believe that we have adequate space for our anticipated needs and that suitable additional space will be available at commercially reasonable prices as needed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dbab8961_4339_46a2_a390_d5b65aec3398"></a><a id="Item3LegalProceedings_303884"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 3.&#160;&#160;&#160;&#160;</b><span style="font-style:italic;font-weight:bold;">Legal Proceedings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p><a id="_18bb95aa_e9eb_48bf_a0a9_8889ef30cd38"></a><a id="Item4MineSafetyDisclosures_792475"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54.7pt;text-indent:-54.7pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 4.</b><span style="font-size:12pt;">&#160;&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Mine Safety Disclosures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_9e5fb212_8a10_47b6_a51e_5dd6bf39173e"></a><a id="PARTII_464332"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;II</b></p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 5.</b><span style="font-size:12pt;">&#160;&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock has traded on the NYSE American under the symbol &#8220;SYN&#8221; since February&#160;16, 2012. Prior to February&#160;16, 2012, our common stock traded under the symbol &#8220;AEN&#8221; since October&#160;16, 2008. The last price of our common stock as reported on the NYSE American on March&#160;14, 2022 was $0.231 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Dividend Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have never paid or declared any cash dividends on our common stock to date, and do not anticipate paying such cash dividends on our common stock in the foreseeable future. Whether we declare and pay dividends is determined by our Board of Directors at their discretion, subject to certain limitations imposed under Nevada corporate law. The timing, amount and form of dividends, if any, will depend on, among other things, our results of operations, financial condition, cash requirements and other factors deemed relevant by our Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Series&#160;A Preferred Stock, none of which remains outstanding, ranked senior to the shares of our common stock and shares of our Series&#160;B Preferred Stock with respect to dividend rights and holders of Series&#160;A Preferred Stock were entitled to a cumulative dividend at the rate of 2.0%&#160;per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series&#160;A Convertible Preferred Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Holders</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March&#160;16, 2022, we had approximately 288 stockholders of record of our common stock. This number does not include stockholders for whom shares are held in a &#8220;nominee&#8221; or &#8220;street&#8221; name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock Performance Graph</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is a smaller reporting company as defined by Rule&#160;12b-2 of the Exchange Act and is not required to provide the information required under this item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Equity Compensation Plan Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Part&#160;II&#8211;Item&#160;12 under the heading &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8212;Equity Compensation Plan Information&#8221; of this Annual Report on Form&#160;10-K for equity compensation plan information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Sales of Unregistered Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We did not sell any equity securities during the quarter ended December&#160;31, 2021 in transactions that were not registered under the Securities Act, other than as previously disclosed in our filings with the SEC.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Issuer Purchases of Equity Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There were no issuer purchases of equity securities during the&#160;year ended December&#160;31, 2021.</p><a id="_ccc574d5_2acb_43be_b967_729e27888fb5"></a><a id="Item6SelectedFinancialData_437170"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54.7pt;text-indent:-54.7pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item 6.</b><span style="font-size:12pt;">&#160;&#160;&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">[Reserved]</p><a id="_6d7cbee6_d530_4ba2_84e5_f105109bd0ad"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54.7pt;text-indent:-54.7pt;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Item 7.</b><span style="font-size:12pt;">&#160;&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with our audited financial statements and notes thereto for the&#160;years ended December&#160;31, 2021 and 2020 included elsewhere in this Annual Report. In addition to historical information, the following discussion contains certain forward-looking statements that involve risks, uncertainties and assumptions. Where possible, we have tried to identify these forward-looking statements by using words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;intends,&#8221; or similar expressions. Our actual results could differ materially from those expressed or implied by the forward-looking statements due to important factors and risks including, but not limited to, those set forth under &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Annual Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a diversified clinical-stage company developing therapeutics in ares of high unmet need. Prior to the Acqusiition fo VCN, our focus was on developing therapeutics designed to treat gastrointestinal (GI) diseases in areas of high unmet need which included. our lead clinical development candidates: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the GI tract to prevent microbiome damage, <i style="font-style:italic;">Clostridioides difficile</i> infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. Upon consummation of the Acquisition of VCN, described in more detail below, we are now also focused upon the development of &#160;new oncolytic adenovirus &#160;platform designed for intravenous and intravitreal delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient&#8217;s immune-system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We plan to explore and evaluate a range of strategic options, which may include: in-licensing opportunities; evaluation of potential acquisitions; or other potential strategic transactions. In the meantime, we remain focused on working with our clinical development partners to advance the planned Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) patients, and advancing the clinical development program for SYN-020 intestinal alkaline phosphatase (IAP) in multiple potential indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are continuing to assess the potential impact of the COVID-19 pandemic. We are in close contact with our clinical development partners in order to assess the impact of COVID-19 on our studies and current timelines and costs. While we currently do not anticipate any interruptions in our operations due to COVID-19, it is possible that if the COVID-19 pandemic persists for an extended period of time, we could experience significant disruptions to our clinical development timelines due to the COVID-19 pandemic, which would adversely affect our business, financial condition, results of operations and growth prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In response to the spread of COVID-19 as well as public health directives and orders, we have implemented a number of measures designed to ensure employee safety and business continuity. We have limited access to our offices and are allowing our administrative employees to continue their work outside of our offices in order to support the community efforts to reduce the transmission of COVID-19 and protect employees, complying with guidance from federal, state and local government and health authorities. The full extent to which the COVID-19 outbreak will directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted. The effects of the governmental orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Acquisition of VCN Biosciences, S.L</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 10, 2022, we completed our acquisition of all the outstanding shares of VCN (the &#8220;VCN Shares&#8221;) from the shareholders of VCN.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:203.22pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">VCN is a private, clinical-stage biopharmaceutical company developing new oncolytic adenoviruses for the treatment of cancer. VCN&#8217;s lead product candidate, VCN-01, is being studied in clinical trials for pancreatic cancer and retinoblastoma. VCN-01 is designed to be administered systemically, intratumorally or intravitreally, either as a monotherapy or in combination with standard of care, to treat a wide variety of cancer indications. VCN-01 is designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment, Degrading the tumor stroma has been shown to improve access to the tumor by the virus and additional therapies such as chemo- and immuno-therapies. Importantly, degrading the stroma exposes tumor antigens, turning &#8220;cold&#8221; tumors &#8220;hot&#8221; and enabling a sustained anti-tumor immune response. VCN has the rights to four exclusive patents for proprietary technologies, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional patents pending.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Our Current Product Pipeline</b></p><div style="clear:both;"></div><div style="clear:right;float:right;height:158.6pt;width:0pt;"></div><div style="clear:right;float:right;height:203.22pt;margin-left:9pt;margin-right:calc(50% - 247.84pt);width:495.68pt;z-index:251658240;"><div style="height:203.22pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:495.68pt;"><img src="syn-20211231x10k002.jpg" alt="Graphic" style="height:203.22pt;width:495.68pt;" /></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">*Based on management&#8217;s current beliefs and expectations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">aGVHD</b> acute graft-vs-host disease; <b style="font-weight:bold;">allo-HCT</b> allogeneic hematopoietic cell transplant. <b style="font-weight:bold;">IAP</b> recombinant bovine intestinal alkaline phosphatase II. <b style="font-weight:bold;">CPI</b> immune checkpoint inhibitor. <b style="font-weight:bold;">Gem/Nab</b> Gemcitabine + Abraxane&#174; (nab-paclitaxel). <b style="font-weight:bold;">HNSCC</b> head and neck squamous cell carcinoma. <b style="font-weight:bold;">IV</b> intravenous. <b style="font-weight:bold;">IVit</b> intravitreal. <b style="font-weight:bold;">MAD</b> multiple ascending dose. <b style="font-weight:bold;">ODD</b> Orphan Drug Designation. <b style="font-weight:bold;">OV </b>oncolytic adenovirus engineered to selectively replicate in tumors and express hyaluronidase enzyme PH20<b style="font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#185;Additional products with preclinical proof-of-concept include SYN-006 (carbapenemase) to prevent aGVHD and infection by carbapenem resistant enterococci and SYN-007 (ribaxamase) DR to prevent antibiotic associated diarrhea with oral &#946;-lactam antibiotics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#178;Depending on funding/partnership. SYN-004 may enter an FDA-agreed Phase 3 clinical trial for the treatment of Clostridioides difficile infection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#179;We have an option-license agreement with Massachusetts General Hospital to develop SYN-020 in several potential indications related to inflammation and gut barrier dysfunction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Financial Developments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">B Riley and AGP Securities Sales Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We entered into an Amended and Restated At Market Issuance Sales Agreement, dated February 9, 2021, with B. Riley Securities, Inc., or B. Riley, and A.G.P./Alliance Global Partners, or AGP and together with B. Riley, the sales agents (the &#8220;Amended and Restated ATM Sales Agreement&#8221;), which replaced the At Market Issuance Sales Agreement, dated August 5, 2016, with B. Riley Securities, Inc. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">(formerly known as B. Riley FBR, Inc.), as amended by amendment no. 1 thereto, dated May 7, 2018 (the &#8220;Original ATM Sales Agreement&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ending December 31, 2021, we sold approximately 78.7 million shares of our common stock and received net proceeds of approximately $66 million, pursuant to the Amended and Restated ATM Sales Agreement and during the year ended December 31, 2020 we sold approximately 9.2 million shares of our common stock and received net proceeds of approximately $3.4 million, pursuant to the Original ATM Sales Agreement and the Amended and Restated ATM Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;16, 2020, the exercise price of warrants issued by us in October&#160;2018 (the &#8220;2018 Warrants&#8221;) was reduced from $1.38 per Warrant per full share of the Company&#8217;s common stock, $0.001 par value per share, to $0.69 per 2018 Warrant per full share of common stock pursuant to the terms of the Warrants. The reduction was the result of the issuance of shares of common stock by the us through its &#8220;at the market offering&#8221; facility. An entry to reduce the income available to common shareholders was recorded for $880,000 to recognize the value of the effect of the change in exercise price. During January and February 2021, 11,655,747 2018 Warrants were exercised for cash proceeds of $8.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of our consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues and expenses, and related disclosures. We believe our estimates and assumptions are reasonable; however, actual results and the timing of the recognition of such amounts could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are accounting policies, each of which requires significant judgments and estimates on the part on management, that we believe are significant to the presentation of our consolidated financial statements. The most significant accounting estimates relate to research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Costs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We expense research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing&#160;costs, salaries, stock-based compensation and related employee costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of our product candidates. Research and development expenses include external contract research organization (&#8220;CRO&#8221;) services. We make payments to the CROs based on agreed upon terms and may include payments in advance of study services. We review and accrue CRO expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. At December&#160;31, 2021 and 2020, we have accrued CRO expenses of $0.7 million that are included in accrued expenses. As of December&#160;31, 2021, and 2020, we have prepaid CRO costs of $0.5 million that are included in prepaid expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Years Ended December&#160;31, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased to $6.5 million for the year ended December&#160;31, 2021, from $5.0 million for the year ended December&#160;31, 2020. This increase of 28.7% primarily comprised of increased consulting and legal costs related to the VCN acquisition, higher insurance costs, audit fees, and public relations expenses. &#160;The charge relating to stock-based compensation expense was $0.3 million for the year ended December&#160;31, 2021, compared to $0.3 million for the year ended December&#160;31, 2020. In addition, we expect general and administrative expenses to increase as we increase headcount due to the Acquisition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development expenses increased to $7.8 million for the year ended December&#160;31, 2021, from $5.1 million for the year ended December&#160;31, 2020. This increase of 53% is primarily the result of increased clinical trial expenses as we continued dosing patients in the Phase 1b/2a clinical trial of SYN-004, the dosing of healthy volunteers in the SAD and MAD Phase 1 clinical trials for SYN-020, and by higher indirect program costs for the year ended December 31, 2021, including an increase in manufacturing costs for SYN-020. &#160;We anticipate research and development expense to increase as our ongoing clinical trials continue to enroll patients. Research and development expenses also include a charge relating to non-cash stock-based compensation expense of $76,000 for the year ended December&#160;31, 2021, compared to $66,000 for the year ended December&#160;31, 2020. &#160;In addition, we expect research and development expenses to increase as we incur program costs for VCN&#8217;s product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth our research and development expenses directly related to our therapeutic areas for the years ended December&#160;31, 2021 and 2020. These direct expenses were external costs associated with preclinical studies and clinical trials. Indirect research and development costs related to employee costs, facilities, manufacturing, stock-based compensation and research and development support services are not directly allocated to specific drug candidates.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b>&#160;<b style="font-weight:bold;">31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December</b>&#160;<b style="font-weight:bold;">31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Therapeutic Areas</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">SYN-020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,431</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">SYN-004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,366</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 245</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">SYN-010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 430</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other therapeutic areas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 40</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total direct costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,807</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 715</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total indirect costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,993</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,416</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Total research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 7,800</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,131</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Total Other Income</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Other income was $6,000 for the year ended December&#160;31, 2021, compared to other income of $44,000 for the year ended December&#160;31, 2020. Other income for the year ended December&#160;31, 2021 and 2020 is primarily comprised of interest income from investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Loss</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our net loss for the year ended December&#160;31, 2021 was $14.3 million, or ($0.19) per common share, compared to $10.0 million, or ($0.66) per common share for the year ended December&#160;31, 2020. Net loss attributable to common stockholders for the year ended December&#160;31, 2021 was $23.2 million and excludes net loss attributable to non-controlling interest of $1,000, and includes the accretion of the Series&#160;B preferred stock deemed dividends of $1.5 million on converted shares and Series&#160;A preferred stock accrued dividends of $24,000 and the deemed dividend for the effect of the Series A preferred shares price adjustment of $7.4 million. Net loss attributable to common stockholders for the year ended December&#160;31, 2020 was $12.6 million, and excludes net loss attributable to non-controlling interest of $73,000 and includes the accretion of the Series&#160;B preferred stock deemed dividends of $1.4 million on converted shares, the effect of the warrant exercise price adjustment of $880,000 and Series&#160;A preferred stock accrued dividends of $254,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have experienced significant losses since inception, incurred negative cash flows from operations, and have a significant accumulated deficit. We have incurred an accumulated deficit of $271.3 million as of December&#160;31, 2021 and expect to continue to incur losses in the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our cash and cash equivalents totaled $67.3 million as of December&#160;31, 2021, an increase of $61.1 million from December&#160;31, 2020.&#160;During the year ended December&#160;31, 2021, the primary use of cash was for working capital requirements and operating activities which resulted in a net loss of $14.3 million for the year ended December&#160;31, 2021. From January through December 31, 2021, we have raised approximately $74 million from cash received via the exercise of the 2018 Warrants and sales of our common stock through the Original ATM Sales Agreement and the Amended and Restated ATM Sales Agreement. With the cash available in mid March 2022 of $57.1 million, we believe these resources will be sufficient to fund our operations through at least the end of the fourth quarter of 2023, including the $2.4 million of obligations we agreed to assume and the $27.8 million of research and development expenses we agreed to fund over the next three years.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. We are actively monitoring the global situation and its potential impact on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the future effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Although we are experiencing limited, if any, adverse impact to our financial stability stemming from the global economic slowdown, the overall disruption of global healthcare systems and other risks and uncertainties associated with the COVID-19 pandemic, including uncertainty regarding our clinical trial timelines, our business, financial condition, results of operations and growth prospects could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Historically, we have financed our operations primarily through public and private sales of our securities, and we expect to continue to seek and obtain additional capital in a similar manner. During the year ended December&#160;31, 2021, our only source of cash was from the exercise of the 2018 Warrants and sales of our common stock through the Original ATM Sales Agreement and the Amended and Restated ATM Sales Agreement discussed above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31, 2020, our only source of financing other than warrant exercises was from sales of 9.2&#160;million shares of our common stock utilizing our at-the-market offering program through the Original ATM Sales Agreement pursuant to which we received net proceeds of approximately $3.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will be able to continue to raise funds through the sale of shares of common stock through the Amended and Restated ATM Sales Agreement. If we raise funds by selling additional shares of common stock or other securities convertible into common stock, the ownership interest of our existing stockholders will be diluted. If we are not able to obtain funding for future clinical trials when needed, we will be unable to carry out our business plan and we will be forced to delay the initiation of future clinical trials until such time as we obtain adequate financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have committed, and expect to continue to commit, substantial capital in order to implement our business strategy, including our planned product development efforts, preparation for our planned clinical trials, and performance of clinical trials and our research and discovery efforts. We believe our cash position of $57.1 million in mid March&#160;2022 is sufficient to fund our operations through at least the end of the fourth quarter of 2023, including continuation of our ongoing Phase 1b/2a clinical study of SYN-004 (ribaxamase) in allogeneic HCT recipients for the prevention of aGVHD, as well as our planned Phase 1 and Phase 2 clinical programs for SYN-020 and to fund our committed obligations under the Purchase Agreement for the VCN Acquisition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Following the anticipated completion of our ongoing Phase 1b/2a clinical study of SYN-004 (ribaxamase) in allogeneic HCT recipients, the Phase 1 SAD and MAD clinical studies and planned Phase 2a clinical trial of SYN-020, we will need to obtain additional funds for future clinical trials. We anticipate that our future clinical trials will be much larger in size and require larger cash expenditures than the aforementioned clinical programs. We do not have any committed sources of financing for future clinical trials at this time, and it is uncertain whether additional funding will be available when we need it on terms that will be acceptable to us, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As the COVID-19 coronavirus continues to spread around the globe, we have experienced disruptions that impacted our business and clinical trials, including halting the enrollment of new patients in our previous Phase 2b investigator-sponsored clinical trial of SYN-010 and postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. We are actively monitoring the global situation and its potential impact on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the future effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">License and Contractual Agreement Obligations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have entered into several license and collaborative agreements for the right to use research, technology and patents. Some of these license and collaborative agreements may contain milestones. The specific timing of such milestones cannot be predicted and are dependent on future developments as well as regulatory actions which cannot be predicted with certainty (including actions which may never occur). Further, under the terms of certain licensing agreements, we may have the obligation to pay certain milestones contingent upon the achievement of specific levels of sales.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the years ended December&#160;31, 2021 and 2020, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Consulting Fees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160;2017, we engaged a regulatory consultant to assist in our efforts to prepare, file and obtain FDA approval for ribaxamase.&#160;The term of the engagement was on a&#160;monthly basis, provided that either party may terminate the agreement at any time by providing the other party a six-month notice period. We were obligated to pay the consultant a&#160;monthly retainer in addition to the success fee payments of up to an aggregate of $4,500,000 for attainment of certain regulatory milestones. We do not deem the contingent fee is probable at this time.</p><a id="_bdd84293_1f6b_4e11_a7d6_3ee2c72a761b"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 7A.</b><span style="font-size:12pt;">&#160;&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Quantitative and Qualitative Disclosures About Market Risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is a smaller reporting company as defined by Rule&#160;12b-2 of the Exchange Act and is not required to provide the information required under this item.</p><a id="_7c23aabd_cc0d_4201_8f13_3f06c1bd15e1"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 8.</b>&#160;&#160;&#160;&#160;<span style="font-style:italic;font-weight:bold;">Financial Statements and Supplementary Data</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:93.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:93.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:6.41%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:93.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (BDO USA, LLP; Potomac, Maryland; PCAOB ID# <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:AuditorFirmId" id="Narr_JoIwNyBaZEa118QuT_ZqIQ">243</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;width:6.41%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:93.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ConsolidatedBalanceSheets_619126"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">58</p></td></tr><tr><td style="vertical-align:top;width:93.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ConsolidatedStatementsofOperations_77785"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations</span></a></p></td><td style="vertical-align:bottom;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">59</p></td></tr><tr><td style="vertical-align:top;width:93.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ConsolidatedStatementsofDeficitEquity_82"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of (Deficit) Equity</span></a></p></td><td style="vertical-align:bottom;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">60</p></td></tr><tr><td style="vertical-align:top;width:93.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#ConsolidatedStatementsofCashFlows_49132"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:top;width:93.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a href="#a1OrganizationandNatureofOperationsandBa"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4f4b3b8d_e8b6_4d8a_88cf_36eb8f79acb9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Report of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45.35pt;text-indent:-45.35pt;margin:0pt;">Stockholders and Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45.35pt;text-indent:-45.35pt;margin:0pt;">Synthetic Biologics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;">Rockville, Maryland</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Consolidated Financial Statements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Synthetic Biologics, Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations, stockholders&#8217; deficit, and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (i) relates to accounts or disclosures that are material to the consolidated financial statements, and (ii) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Evaluation of Liquidity </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As described in Note 1 to the consolidated financial statements, the Company has a significant accumulated deficit and has experienced significant losses and incurred negative cash flows since inception. &#160;The Company expects to continue incurring losses for the foreseeable future. &#160;Further, the Company has spent, and expects to continue to spend, a substantial amount of funds in connection with implementing its business strategy, including planned product development efforts, clinical trials and research and discovery efforts. The Company is dependent on its ability to raise additional funding from the capital markets in order to continue to fund its operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We identified management&#8217;s evaluation of the Company&#8217;s liquidity as a critical audit matter due to the significant judgments and assumptions used by management in (i) preparing its forecast of cash expenditures to support the Company&#8217;s drug development and clinical trials, including anticipated expenditures related to the acquisition of VCN BioSciences, S.L (&#8220;VCN&#8221;) subsequent to year end as described in Note 9, and (ii) providing complete and accurate disclosures related to the Company&#8217;s liquidity. Auditing these judgments and assumptions involved especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;">The primary procedures we performed to address this critical audit matter included:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Testing the completeness and accuracy of underlying data used in the forecasted cash expenditures by (i) inspecting contractual arrangements with third-party clinical research organizations and suppliers, and (ii) considering current and past expenditures in evaluating the forecasted fixed and variable costs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Assessing the reasonableness of management&#8217;s key assumptions in forecasting cash expenditures by (i) performing a retrospective review of historical forecasts, (ii) comparing information related to the Company&#8217;s ongoing and anticipated clinical trials and drug development pipeline to management&#8217;s assumptions, and (iii) assessing the anticipated cash flows required to fund the payment of the cash portion of the transaction price for the acquisition of VCN and the forecasted expenditures that will be required to fund the development of VCN&#8217;s various drug candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluating the adequacy of management&#8217;s disclosure in the consolidated financial statements regarding the Company&#8217;s liquidity by comparing to other audit evidence obtained to determine whether such information is consistent with or contradictory to the Company&#8217;s liquidity disclosure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:AuditorName" id="Narr_19Q5F0CdYkabZL8g-g1rJw">BDO USA, LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#39;s auditor since 2012.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="dei:AuditorLocation" id="Narr_zZWezzShcEy6PqQiN3Yg0Q">Potomac, Maryland</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:45pt;text-indent:-45pt;margin:0pt 0pt 12pt 0pt;">March 16, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_876ff9ba_8052_4ea3_baca_e6e93a8d7d37"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><a id="ConsolidatedBalanceSheets_619126"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(In thousands except share and par value amounts)</b></p><a id="_ade81df4_990e_457e_9c28_f8e3fe281e79"></a><a id="Tc_8W7pFcBNEEOlQIEgA2WN2Q_1_2"></a><a id="Tc_SwLjxp3U6UuJVFnrJjl5Gw_1_5"></a><a id="Tc_ouOWxgY8ikiZjCVrbOt43g_2_2"></a><a id="Tc_WvZk-kO32UCcyYUSqy7MyQ_2_5"></a><a id="Tc_0VDNW6fNqEShDnEynomyaQ_3_0"></a><a id="Tc_mV2950opSEWKn9riGMyeKw_5_0"></a><a id="Tc_s30bBEpoyUyjsp-JrNUHWA_6_0"></a><a id="Tc_P-ppTBqN1kqrv6dhWwuAWw_6_2"></a><a id="Tc_x6_BhcnL6kKgc2iG-9dBFA_6_5"></a><a id="Tc_Y74B6ovT30KDne7Aha--jQ_7_0"></a><a id="Tc_4-yCkmVQ4kGUFNTWtkOriQ_8_0"></a><a id="Tc_KJ35VTInP0W_kJFgxnedVA_10_0"></a><a id="Tc_4-CpxSyTqUGzqSASViUdJA_12_0"></a><a id="Tc__87EH41r8ECOYxRn1ehCGA_14_0"></a><a id="Tc_ISUcHq09QEGu6LvRYyZK5Q_16_0"></a><a id="Tc_q-uRARWmsUa0eps-LeCaEQ_16_2"></a><a id="Tc_pzuJJvCSEEawKkS0y0KZpQ_16_5"></a><a id="Tc_UjR_vj7apEycaizKGqd90w_18_0"></a><a id="Tc_2HVfu5Y3wky0lou9IZx0bg_20_0"></a><a id="Tc_4pDVOwkyIkuErYsGCNCI3g_21_0"></a><a id="Tc_3AY4lIo6z0eaHSPLs7fccw_21_2"></a><a id="Tc_fHCfHEmoZUO1TBGKBT1gSQ_21_5"></a><a id="Tc_upVMUVqWR02ZC6j4YCUtzQ_22_0"></a><a id="Tc_MrPDO7SIH0G-0fEcSrW7ug_23_0"></a><a id="Tc_APP2wAOtL0SmY1VXnUU3hg_24_0"></a><a id="Tc_NTeJBjftV0Cz7IIIe7cCCA_25_0"></a><a id="Tc_V2uDABHf3UmSYNAXG9ap2w_26_0"></a><a id="Tc_ISWYiyxOTke3WoQOUhZxxg_27_0"></a><a id="Tc_g6mYJMZMOEW_Sykd8qF0LQ_29_0"></a><a id="Tc_thMoUUsjU0KueuyVNp157A_30_0"></a><a id="Tc_4UUAQpy2EEG6TrF1qClgew_31_0"></a><a id="Tc_ucPf2wRrVU2YwoCIdXyHMA_32_0"></a><a id="Tc_b_K5UYX220S8delhiidTUQ_33_0"></a><a id="Narr_vUv14VqWvkygJmS6ANth5Q"></a><a id="Narr_vPUbkM2GlUSf-0WLFDpbhQ"></a><a id="Tc_nr_7peIQtkuvPwvqZEy_mg_34_0"></a><a id="Tc_OwXvjffM7EihfiC_ebKTcg_35_0"></a><a id="Tc_zbbp_MYrdkWEIHePMOlMgg_36_0"></a><a id="Tc_3FwZWv8TfEqdRESQQY3brA_37_0"></a><a id="Tc_S7kLWycZ8Each932zidYdA_37_3"></a><a id="Tc_QmDiPCuNWU2laFKwVQutUQ_38_0"></a><a id="Tc_k2zt0Q5IRkarutd5WVv1Ig_39_0"></a><a id="Tc_-3bRCejI1km5B4l8d9J0CQ_39_2"></a><a id="Tc_5TUJJcs-s02MNrneUcfiCA_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc__lJhleaxWkWD9C7a388QhA_6_3">67,325</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_IhmLzKzyGk6ymQm0B8cGnw_6_6">6,227</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_jC8SFo5dT0WpQImbP5edGQ_7_3">1,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_XaBvtAcTIkuPIRNAwa-ijA_7_6">1,707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Total Current Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_i-H79Uox0kmyqni-Oz3wKg_8_3">68,858</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_P7bnqApJs0K2IdofZLrrbA_8_6">7,934</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Property and equipment, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_QsdCNIHHIU6xp2lazl1I6Q_10_3">101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_LEr9Am4zEkOLgp-o_U5lCQ_10_6">174</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Right of use asset</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_dGQXUPy4V0SSL4X0m7RCqw_12_3">1,383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_APSnGvLvrUGeqPtWH7F6_g_12_6">279</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deposits and other assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:DepositsAndOtherAssetsNoncurrent" scale="3" id="Tc_9KGf_p3uwUa6KtteDJQOWA_14_3">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:DepositsAndOtherAssetsNoncurrent" scale="3" id="Tc_pkMnrIQH906qYnp9LY4gQA_14_6">23</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_yCRlYafJBUW5qBYkapJQ1g_16_3">70,365</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_G6uEe5XAoECARBUVsQ1N6A_16_6">8,410</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current Liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_zhpqeyRcuUmYM3uTr7mhnA_21_3">524</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_uehZkXyusUKD6Dk5AybX7w_21_6">886</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_BVcOBeah1UG4nbXB_Z_viQ_22_3">1,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_opKb27YpqEaMCUB5LEDQTw_22_6">925</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Accrued employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_vOBUzihzaEG-o0QJ7OXBrA_23_3">978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="Tc_FtjAz8YFSke4SvQEXn9iEQ_23_6">868</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_6vbRcbTMNEeLuHhbjd7WQg_24_3">124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_R0YzVY8Xz0m-IQ4O4ypHpw_24_6">287</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 12pt;"><b style="font-weight:bold;">Total Current Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_ARYRAjjj3UuKohUFBcbriQ_25_3">3,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_gQK6IMglgkuMlqV9ndud-w_25_6">2,966</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Lease liability - Long term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_1zXxSlA1k0Okloo_6-7NCg_26_3">1,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_gGPI36vwYku6emEoHe1b_A_26_6">186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc__mAfHYKXWU-rtgsNxZX8dw_27_3">4,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_TalyIMAJFUic1RC4k_jNyg_27_6">3,152</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Commitments and Contingencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_pHpHOTsQ8k6yuHhORq5anA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_ZQSm3RSFNUWe7-1pBlUnCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;">Series&#160;A Preferred Stock, </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_XCPTLxGJiUuiusz_JWd1DA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_-ywaUWrjKkyr1lg8R-sLuA">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> par value; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_fjy_1E7Y_UCLYIFOtXyuBg"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_f6lP6fCkFUSFYIkuxf2_pQ">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;white-space:pre-wrap;">  shares authorized; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_jtd7eQTpTEOYhsxM-FqWUA">0</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="Narr_0LE6d80Fo0G8dvtbJyrGeg">120,000</ix:nonFraction></span><span style="font-size:9pt;"> </span><span style="-sec-ix-hidden:Hidden_Fdq-HoAqqU2n8c5YodGVLg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_f4gZt4BnFEalpG9LgsR3Xw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:zerodash" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_lmGX3NWDHkOZkxzjN9T41Q_30_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="Tc_6Xg4lkPtQU-CgQ2ZBVilSg_30_6">12,798</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217; Equity (Deficit):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;">Series&#160;B Preferred Stock,&#160;</span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Wq3oOh6GyUmroMkarzwyRA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_9weAVK5DfEqtxVEIo5Qw2Q">1,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> par value; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_DpCLsmLUgkSzbYY__xeOlQ"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_tiFisDwvr0-yJPoRN9JrQw">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> shares authorized, </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_oeuykZxbF0CK2rcUDL2mXg">0</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_CuBnlQg7okKJK8ZK77W4JA">3,973</ix:nonFraction></span><span style="font-size:9pt;"> </span><span style="-sec-ix-hidden:Hidden_e1t6MXX3JEGFq5wEFzIGlA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_amWeR7lJNkqz2tqB1vva4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> as of December&#160;31,&#160;2021 and December&#160;31,&#160;2020, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="Tc_hrR9AAa_v0G8k36RSYX_Bw_32_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockValue" scale="3" id="Tc_Qq2tYr0Lr024Em15FSkKFw_32_6">2,477</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Common stock,&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_yLRpncve9kOYqi2beMAUtQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_dzZBRE-8O0K3W43OI0mO6g">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_azRuMz524k-FEF02lHsfAA"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_pztgZwEVqEqReqME3XxS1g">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_BSQPtdY2BUm6ogsZsHyw0Q">132,044,866</ix:nonFraction> issued and <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_YfenoYpdKUa10u2OuzEk2Q">132,042,538</ix:nonFraction> outstanding at December&#160;31,&#160;2021 and <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_75D7cJNjdUSiQenORIVKrw">29,252,253</ix:nonFraction> issued and <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr__adGeaHuVk-ust1iiPFbdQ">29,249,925</ix:nonFraction> outstanding at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_5OH0Y6yHYU6LCKOmMpnBMg_33_3">132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_EYJFCgq1KUat4DDLXoP2Ig_33_6">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_YsYbgkCHOkSErEI3KP0_Fw_34_3">336,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_FF5dpQI_j0KPrc9SOUF5ZA_34_6">240,821</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_GJ0pI0ESCk6EqCGU1HHc0Q_35_3">271,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_sd--Bk3N5UKR1PTenNmLcg_35_6">248,094</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Synthetic Biologics,&#160;Inc. and Subsidiaries Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_DFoibmQQAEqjqWmjAPBgwQ_36_3">65,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_w45LQUfnpUetCqXWOo_eWQ_36_6">4,767</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Non-controlling interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" sign="-" scale="3" id="Tc_L51e-__fPEa-Sny4agcS2A_37_6">2,773</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Stockholders&#8217; Equity (Deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_ygT3wckGP06Klv7fP1hHBA_38_3">65,408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_S5bM82f4ZU2vPgGUbhkvaQ_38_6">7,540</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total Liabilities and Stockholders&#8217; Equity </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_lR6-NJ6uTEyVy0sCOdUt3g_39_3">70,365</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_rkMDINbJJ02xmq2wvmEx_A_39_6">8,410</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2332f881_1f91_4eb0_b241_e71edf137e52"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><a id="ConsolidatedStatementsofOperations_77785"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and per share amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d2005cbc_b87b_4739_a77f_17cd46ad2f85"></a><a id="Tc_2xTACw1TrkGM-8R39WkNsA_1_2"></a><a id="Tc_QK4E9wfL3UGRYafrT_FYFg_2_2"></a><a id="Tc_I5QRT1ySCkqSl9A6A8iV3A_2_5"></a><a id="Tc_4_xU46Xo-kiXsIX4Hwq_8A_3_0"></a><a id="Tc_Too4dgFSaUm0NptnHWYwbQ_4_0"></a><a id="Tc_fMqFGYce50OuhLLH2w0S1A_4_2"></a><a id="Tc_8HVZ9Ye44UmZ7Pj2FEUkpQ_4_5"></a><a id="Tc_3YGxwCSlakWsFNn9lpWJXQ_5_0"></a><a id="Tc_Cu6_sqJr30iLJRZLxebCSw_6_0"></a><a id="Tc_9-ERhWe8akW-1o7XHp0MbA_7_0"></a><a id="Tc_fM_AG5vkVkiq-B8DyOhlSw_8_0"></a><a id="Tc_PxVhW98Kjkm8ACOJPW-9rg_9_0"></a><a id="Tc_NqJE-7Rk-E-L1jSENycfkg_10_0"></a><a id="Tc_7rV2y4N2K0ecprnDkXul1Q_12_0"></a><a id="Tc_Hj1TB3rYuUalnetLwQPgDw_14_0"></a><a id="Tc_KuFscqDwLkSeibNG0BnmUQ_16_0"></a><a id="Tc_JIurT1tX_0WzFrl4WgF_7Q_16_2"></a><a id="Tc_gNMt9igPoEyIIdEGDC1ZRg_16_5"></a><a id="Tc_cxjwmqf-jUOAg8ccIghHCw_18_0"></a><a id="Tc_C3JNf1LZAUSaiuXXau6p0Q_19_0"></a><a id="Tc_dLkYFJg82EmyjuN6ga9KcQ_20_0"></a><a id="Tc_knVjfQ_97km08QBJYP2oGg_21_0"></a><a id="Tc_j5Y741D3pEaqKuKiTQfMPw_22_0"></a><a id="Tc_O-MrYr1_dEa5uilDPfvIvA_22_2"></a><a id="Tc_tPe2OFzgbkigBl2bJNfpjg_22_5"></a><a id="Tc_IoF2gQQ7UUqHerHu93tcPQ_24_0"></a><a id="Tc_wOg1o4PJu02V-eQpHcxrxQ_26_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:25.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the&#160;year ended</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Costs and Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_06AYPakes0mWKLrQQmdwaQ_4_3">6,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_lJZgnQG9R0GLmM3581gTIw_4_6">5,029</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_z04EWOcXX0-FEwYVpiiL1A_5_3">7,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_1is1AROzD0W0zSiH9Rql4A_5_6">5,131</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total Operating Costs and Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_U4XxVEirPk6DIXnXZjdGeQ_6_3">14,274</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_ScoEwhPNIUOkA6N_INBMDw_6_6">10,160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss from Operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_h9bX_EUJV02ou3_1Rh3MrQ_7_3">14,274</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_zDUqNfJ4SU-UVmWnQtajLA_7_6">10,160</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other Income:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_Nm8w2cLbjUCyYegEbTDzWA_9_3">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_wg4Ae5NPIEGXxfw7MQMbRA_9_6">44</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">Total Other Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_R7bY-7-8oU60in0XIiwvvw_10_3">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_jo7YEXL3CEm6kvfCyx5NLA_10_6">44</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_g-BgJuo0AkaALr4kywJZ-g_12_3">14,268</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_YswN2E6o70CRGFD4Klt6bw_12_6">10,116</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Loss Attributable to Non-controlling Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_rRd9vxyjBkeArDvNLaFITw_14_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_5uZGXWDVC0y1BpRwxcWsDw_14_6">73</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Loss Attributable to Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Gmw1maCtgUSR-bV-p3YaBA_16_3">14,267</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_UfQPJpv_xE-AmOyJfDnbEQ_16_6">10,043</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Series&#160;A Preferred Stock Dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_FeVQVpH5ukWOCQOPbGT4pA_18_3">24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_mXNms1UigEOa2pCcc7Y9aA_18_6">254</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Series&#160;B Preferred Stock Dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B8SS6pik5UydvtJcCB9dlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_pbekA9qxU0uUqI5GjBS_8Q_19_3">1,496</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="Tc_LeyfVXPQG0u28s8kco4P3A_19_6">1,380</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effect of Series A Preferred Stock price adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ" decimals="-3" format="ixt:numdotdecimal" name="syn:PreferredStockPriceAdjustment" scale="3" id="Tc_UpBIFBVf8Umv2gVK3Gx4ww_20_3">7,402</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig" decimals="-3" format="ixt:zerodash" name="syn:PreferredStockPriceAdjustment" scale="3" id="Tc_85UiMwtxb0e73pZuPiuRFA_20_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Effect of Warrant exercise price adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:zerodash" name="syn:WarrantExercisePriceAdjustment" scale="3" id="Tc_0_l_-0gHpUGOWOLG0QJC8Q_21_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="syn:WarrantExercisePriceAdjustment" scale="3" id="Tc_tRU-SRkrxUKI1VHikcesHw_21_6">880</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Loss Attributable to Common Stockholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_n7mLT64GIUKCMY6Ssdpedw_22_3">23,189</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_41NGWoKJ5EeWLKYs6GZkug_22_6">12,557</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net Loss Per Share&#160;- Basic and Dilutive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_tNvE2AVdREediPDrorC8RQ;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_w-BbEaIpykuq_3anqftQWw_24_3">0.19</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_7MwD_ebw_UmKjW6bRvU1Yw;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">$</b></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_tmxrERUH3k6ugYGWkkw-0w_24_6">0.66</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Weighted average number of shares outstanding during the period&#160;- basic and dilutive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_C4KwpEaThEO-tywcsFtkXg_26_3">121,875,042</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_VxJ3fhbcoUeXNfyzXkIkrQ_26_6">19,011,362</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e62a9bde_bde6_467e_8bb0_a450d5e897cc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><a id="ConsolidatedStatementsofDeficitEquity_82"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Stockholders (Deficit) Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands, except share and par value amounts)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_70a298f1_0730_481b_b9a0_1d6bcd8aee92"></a><a id="Tc_hNi_ks1pNUyTSSXQY9XcuA_1_2"></a><a id="Tc_Mf1EcCIsHESS7idgzwSM0Q_1_7"></a><a id="Tc_FPksrEVUKkyTJmVYQBIMVQ_2_21"></a><a id="Tc_ab2p4o77CEqe39eB3v4AZQ_3_15"></a><a id="Tc_jcx03lac30uDgFBsL0EwQg_3_18"></a><a id="Tc_5QUe831x3EKBjRRrJZIcEg_3_21"></a><a id="Tc_NVFvxDj0-E2ud5Ca_3HJYw_4_2"></a><a id="Tc_ZiqoHPJoeUiTjFdWxOwIjA_4_4"></a><a id="Tc_OjNY9cN1yU6AGsvlGqvEeQ_4_7"></a><a id="Tc_5KkX5oeD4EOR84SsxmR7Gg_4_9"></a><a id="Tc_lAMER3JCuUuYh3R4fKwJ_g_4_12"></a><a id="Tc_DmeyhYDRA0u4b9uflAfYkw_4_15"></a><a id="Tc_y1usS5eR0UC4igNdHPfsIw_4_18"></a><a id="Tc_EfT4amvIR0Crh0R2sPmENg_4_21"></a><a id="Tc_ir4SIZQuFUeqqEjf-igkLw_6_0"></a><a id="Tc_blSvY9XwtEywnSeivTGkRA_6_4"></a><a id="Tc_blmYWKurlEGcdextPxqa-g_6_9"></a><a id="Tc_DVT48Cu4ZUmFjvGfDQtxow_6_12"></a><a id="Tc_ilA3sohz9UiEuo8BAl1JHg_6_15"></a><a id="Tc_epkLOiyxh0mVKw5icjpuMA_6_18"></a><a id="Tc_CE60cnnioU6o9XpN3XfgyQ_6_21"></a><a id="Tc_q2UO5gyJAEi4EDHpIZrhYQ_8_0"></a><a id="Tc_xOzxbSSSPE6QlMZEACc4HQ_8_2"></a><a id="Tc_2Cgt0yt_LUinNh95f4iVAg_8_7"></a><a id="Tc_Z7HBkfaIjU2J5khECdpIGg_9_0"></a><a id="Tc_KYj-B9sUbUG3-gBFARqU5A_9_7"></a><a id="Tc_jy9QHrjOhUGLohYDekD-Xw_10_0"></a><a id="Tc_WQs_kcI4m0K7ENe3eFJK4g_10_2"></a><a id="Tc_Ksf6P2Ia9E65-IPatWss4A_10_7"></a><a id="Tc_KcYQokjjKE6RUS7UXa47ZQ_11_0"></a><a id="Tc_mAvg6TsZCESV6mxSgzQdIA_11_2"></a><a id="Tc_fGIXpjG_TEOkBFfradQpdg_11_7"></a><a id="Tc_0ERN9-dTrE2_pVcFot6KyQ_12_0"></a><a id="Tc_h2PhukcX5k-0em-sBcAhuw_12_2"></a><a id="Tc_v9u8_nG5D0iLmBGPfZzKwg_12_7"></a><a id="Tc_Zbe5JyBNEEeiffTMOLU_ow_13_0"></a><a id="Tc_oG2FVavdDki8O7vJh-xEEg_14_0"></a><a id="Tc_1wwJEopIv0mTqJ3NiA_HLQ_14_2"></a><a id="Tc_yQKmlbA2IUOGJh3dmV6ICA_14_7"></a><a id="Tc_uuRKfp6KmESy5i8KQgJf_Q_16_0"></a><a id="Tc_axwqBHbmkkm99ZofzhOL9Q_16_4"></a><a id="Tc_8ABPPvOBQ0GH_kE1XqIZjw_16_9"></a><a id="Tc_E1Eyr6e2a0q1jiCGLQIHUw_16_12"></a><a id="Tc_78tk_O43aUyh-6fB9b8fgw_16_15"></a><a id="Tc_cPL_ZE30Uky8-E79RSwMaA_16_18"></a><a id="Tc_lh8HxKJ-9kmO68KcDE1a2Q_16_21"></a><a id="Tc_E-OLHypkqEmDf8DPilPUzQ_18_0"></a><a id="Tc_R_mkXhldP0-Sqtgnt_idPA_18_2"></a><a id="Tc_khC7qFi16UmUhoSxeNtL9Q_18_7"></a><a id="Tc_ZmYK3vBILE64-gLLx_W2Tw_19_0"></a><a id="Tc_hAqiTAL7KU6aww0MEg10AA_19_7"></a><a id="Tc_UEgAvs5hW0eAv5iWwVt6Xw_20_0"></a><a id="Tc_XZKZ-SsU3Uumyl_ycRE_gw_20_2"></a><a id="Tc_Rl4hOav17kKORQmkoKjeTQ_20_7"></a><a id="Tc_cRDVSyPo_0W78p0Vvw_1NA_21_0"></a><a id="Tc_NKulPxOquECeFy_7b93OmQ_21_7"></a><a id="Tc_0WQcQXfKt0OApK7YHTZxHQ_22_0"></a><a id="Tc_7J6Pm-Z5CkSOzZMyzGthlg_22_2"></a><a id="Tc_A2M43WadfkadGZNANnXpQw_22_7"></a><a id="Tc_3fb-MJCYREeHaZpMzu5lKg_23_0"></a><a id="Tc_BFt0TCSYsUie0U77dykIDg_23_7"></a><a id="Tc_8juveFVnhEqGXRvZ10bzfQ_24_0"></a><a id="Tc_tH2om6xEgU-Ihx5SMHhqow_25_0"></a><a id="Tc_PvCduF7ORkm655nUnnjN3A_25_2"></a><a id="Tc_h3NZYlK5F0CAk-FV040T5g_25_7"></a><a id="Tc_aT1jG-vx2UWBt4Zt2JDPMw_26_0"></a><a id="Tc_Ine6yH2FIki47fF5o5VP7g_26_2"></a><a id="Tc_Gd_ZxC4CFkWR4xIhcibHeA_26_7"></a><a id="Tc_c-PqkxnNZEy1PsZp48b9zg_27_0"></a><a id="Tc_aahJQGbHNU6oSZft1TbgRg_27_4"></a><a id="Tc__XXrMSyUp0i66nRdK2MCdg_27_7"></a><a id="Tc_QrOoeqflaEaGJ-BLfreRyg_27_9"></a><a id="Tc_9RkPoNCqo0yT8xBcOt51QA_27_12"></a><a id="Tc_9u017qqdWEm9Ifr6H3Q_LQ_27_15"></a><a id="Tc_alvNDHJxo06ezyepbUE_Ow_27_18"></a><a id="Tc_h-O91Sq7cU63SoLiAzoISQ_27_21"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:11.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series&#160;B Preferred</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Controlling&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">APIC</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Deficit) Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:right;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E9oQZ01YbkmNNdN49AavHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_ZBOydCz3EEqtnfPdGiBCbg_6_2">16,806,430</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E9oQZ01YbkmNNdN49AavHw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_qY_Ki7CigUqgwYIkQ4cOzQ_6_5">17</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YJu4vcU5tUaCOKLeOjoE9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_mFUZONVSD0CThymU_B9Rlw_6_7">7,638</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YJu4vcU5tUaCOKLeOjoE9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_On1k083_LUiIdw_rfxanpA_6_10">4,761</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TY4ik2aZpkKjKDPnPKTE7g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_2F_HwulyfUaRCeQs5ABXcw_6_13">232,580</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w6f6JU4750WKM1AQ8ouQ7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_nTsFGh7hQ0WpJ-S9TysRMA_6_16">235,537</ix:nonFraction>)</b></p></td><td style="vertical-align:middle;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_nK4S9nYjdkezj6o91cTQfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_ZEULZHuOb0WllVa19KBsQQ_6_19">2,878</ix:nonFraction>)</b></p></td><td style="vertical-align:middle;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_Gn6zviUWT0GDWnD9b4pA8w_6_22">1,057</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_2RenfdXGU0yOF3bUzShnmQ_8_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_CySD4yNL30OCg9oWX-e00w_8_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_CD-C81TpyUqLBPbYRf4J0g_8_13">350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_vHknjwVB2UGmyJzeUbDiZA_8_16">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_HR1JWkhSN0CrpqbVstTrUw_8_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_tkYIpVr4eE6gHHspS4OHVw_8_22">350</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock issued under &#8220;at-the-market&#8221; offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g" decimals="0" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingShare" scale="0" id="Tc_8S2DktcuAkOEECdIXO5JpQ_9_2">9,256,535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_EIxEzNWgakenL94vBLKnHQ_9_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_XqSBTT7mf0C4AicEnsJ1Qw_9_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_uOq9-ju5Uk-Rb14E7ip2kw_9_13">3,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_tYZSzDXOvEWOwfYZumkNKA_9_16">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_Uh5SiE__JUKD1ewX52RHXA_9_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_9gDSn1Amk0-sEbmBbq1_Zg_9_22">3,359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series A Preferred Stock Dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_c5JH0TMaykiws9goRfSt9w_10_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_kJZob0k7hkCSrxxN5dwwkQ_10_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_Nue3FctjBE-f9vS-KuOqrw_10_13">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_rqb4hvL2TkevdFKP2tSKRg_10_16">254</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_L1fJqiCXVkuaaHd5TnmRZQ_10_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_G4udq3NbokeouYMfSkgiVw_10_22">254</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of SYN Biomics Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_6bnNvhgGCUSbUf0tbIyeLQ_11_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_Cme4MMa1wk-luGPqK6OWYQ_11_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_ik451BYK30y92PlLz8B38w_11_13">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_q_b35sphDEWW6DDnIID80g_11_16">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_3GYsPDRq5UuCQJ3SxdkR5Q_11_19">178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueOfSynBiomicsStock" scale="3" id="Tc_QO_wGXTztEiI8oXBOMLF8w_11_22">178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Effect of Warrant exercise price adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfWarrantExercisePrice" scale="3" id="Tc_9WhZyHhoIEiuUieJ__9d7w_12_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfWarrantExercisePrice" scale="3" id="Tc_FutQEt_bfkeharrUu5i5_g_12_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw" decimals="-3" format="ixt:numdotdecimal" name="syn:AdjustmentsToEffectOfWarrantExercisePrice" sign="-" scale="3" id="Tc_OcWqZ-eIMkeuh8wPGHKEfQ_12_13">880</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ" decimals="-3" format="ixt:numdotdecimal" name="syn:AdjustmentsToEffectOfWarrantExercisePrice" scale="3" id="Tc_XwxwIYdOqkC9E5ZaBu7AoA_12_16">880</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfWarrantExercisePrice" scale="3" id="Tc_YuvkZMG4uEyxMiOaVRfjsg_12_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfWarrantExercisePrice" scale="3" id="Tc_SnV3NJLbq0yuTfPzs65D5A_12_22">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series&#160;B Preferred Stock to Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g" decimals="0" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" scale="0" id="Tc_cKNAIVOJY025S108xNoFXw_13_2">3,186,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_RdhrwKRyX0Klm4pPqhjF8w_13_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g" decimals="0" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" sign="-" scale="0" id="Tc_3uoMDz-7r0yWd9ogmeKa6Q_13_7">3,665</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_iRcanFz9f0-7ZIFOxlWJBw_13_10">2,284</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_xM1VdfwSLk-wOh1_j1diyQ_13_13">3,661</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_YF4FRR-jy0G1wHeSZV_4TQ_13_16">1,380</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg" decimals="-3" format="ixt:zerodash" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_OrpCDurO4U6AClfstLRGFg_13_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_elkFRZqK206fho5H07WfxQ_13_22">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_3-Of7JKwjU6nLJZBwAMszQ_14_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_sISitfxmn0SI7YKzdoRPjA_14_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_1Ooca4VYvkGVejjKSw4WDQ_14_13">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_FmIXbvKx80KJkJy9DiQKUw_14_16">10,043</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_zoN6FLNEzEiS1C5oQl7dXQ_14_19">73</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_XsxtaqrRwE6Y3u4VHz4QpA_14_22">10,116</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:middle;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BD7rNLuWk0iEFQwVRkploA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_wh4mr11tBESaYvYe8SwxZA_16_2">29,249,925</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BD7rNLuWk0iEFQwVRkploA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_s6RXSLduEEaaf4Cb7IZkLw_16_5">29</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VbneEhxFhkiVk48Qo2CSMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_YXdWQyY2gEO-5dfKcAaeJA_16_7">3,973</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VbneEhxFhkiVk48Qo2CSMg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_tAT_CA70bEKvnsI4FOdXTw_16_10">2,477</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oR9rstllEUaUPKUvptIWbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Uu6WfKqgs0uAYu3CktoQAQ_16_13">240,821</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lizShvTQnU27DK8SmxrMjg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_j6My3TAvJk2BRpXHhMrdwg_16_16">248,094</ix:nonFraction>)</b></p></td><td style="vertical-align:middle;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember__lq54v75EEqpd9AIZOp9HA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_2i9dZm8z5Uy0Un9SmIDqBg_16_19">2,773</ix:nonFraction>)</b></p></td><td style="vertical-align:middle;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:middle;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_3idhAzEEPUGcL7V2T-xmoQ_16_22">7,540</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_OB0MPTkLEka2A57cxa_3gw_18_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_u-bQBODp5EKiUXY9ltJSjQ_18_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_0ninDHf6rU-QeUXX9DAL9g_18_13">416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_VOzmLcgNxUylE4wDBbXyZg_18_16">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA" decimals="-3" format="ixt:zerodash" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_5ntpBl4tA0aqpssyMQbizg_18_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" id="Tc_kHYUmdr31kG_UwzHaKyiYQ_18_22">416</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock issued under &quot;at-the-market&quot; offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ" decimals="0" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingShare" scale="0" id="Tc_E0EhdMTtuEuCmI2HvsGW4w_19_2">78,685,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_vF7b9fLINkqCFfP5XrI-uQ_19_5">79</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_01dIgVrhhEW0U_FN4R488g_19_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_44qgU0ePzky4S1eiTvb2eQ_19_13">65,881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_MYXbcLyyCE-yUcoYDJMPOQ_19_16">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_d9-zXV8XQ06sAhQs80L8Kg_19_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodAtMarketOfferingValue" scale="3" id="Tc_J5lXKKeCNUWecONX97CbcA_19_22">65,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Series&#160;A Preferred Stock Dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_C-KCTCQ8JkOSB2IWWx6yLQ_20_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_71vmzg5WNUuK0aeEE3FT_A_20_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_zTB0IN9GCUat2IK1Mi155Q_20_13">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_WujQ99yWvU6ba6bYgZc50g_20_16">24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA" decimals="-3" format="ixt:zerodash" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_lbVOP_dUq0qo77Xn9lAQOA_20_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStock" scale="3" id="Tc_TdEKcmYqrEikc_FmXr6UAA_20_22">24</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Warrants Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ" decimals="0" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_Wy0LynG1QkmFl2d9Z46KWw_21_2">11,655,747</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc__2UVHUJq3kWkszFshfA7wA_21_5">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_hdWy1F9h60KR5_NIspO1zw_21_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_7AH8yAtsekuYa1lv7h8FQg_21_13">8,030</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_namAuVGFoE6-Itoz797ZPQ_21_16">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA" decimals="-3" format="ixt:zerodash" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_cISsn6e-sk-BJaV_MOwt6w_21_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="syn:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="Tc_UJjrYE6PrUqplYfsD5ndCg_21_22">8,042</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Effect of Series A Preferred Stock price adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_vNNAr2Q09kK1ScQE_bO_DQ_22_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_rupBWmO_GE6UUFitLaUypQ_22_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA" decimals="-3" format="ixt:numdotdecimal" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_6nnRYBI-wUinA2YLPj0K7g_22_13">7,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ" decimals="-3" format="ixt:numdotdecimal" name="syn:AdjustmentsToEffectOfPreferredStockPrice" sign="-" scale="3" id="Tc_OJpw3XmVLUGaKcqfSCycpQ_22_16">7,402</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_LTj8NL8-AUe33VVK2iSdaA_22_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:zerodash" name="syn:AdjustmentsToEffectOfPreferredStockPrice" scale="3" id="Tc_JUSNfiGsr0Sc3s9CPMlbHQ_22_22">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series&#160;A Preferred Stock to Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p4kGNEYs-UaBwLK97CJoow" decimals="0" format="ixt:numdotdecimal" name="syn:Conversionofseriesapreferredstocktocommonstockshares" scale="0" id="Tc_KA3yhfM1C0mWtbwAy3S6pQ_23_2">8,996,768</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p4kGNEYs-UaBwLK97CJoow" decimals="-3" format="ixt:numdotdecimal" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_Vtn1CtZe30u4Cg958gSpPQ_23_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_u3tJQ_TKWUKU4AV_VlfaIA" decimals="-3" format="ixt:zerodash" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_TRFah3AQ4EeUom32aJLKhA_23_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z7S1T7sWPU-5mMUOHtvhAg" decimals="-3" format="ixt:numdotdecimal" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_NiIyAV7C3U6idcQdDjGk2w_23_13">12,813</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_US3t8HW7-0GmoQhdLHyCwQ" decimals="-3" format="ixt:zerodash" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_xRitiwI_E0KdQ3LWi7pvdw_23_16">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_fJelKMiPik68kesEofzomQ" decimals="-3" format="ixt:zerodash" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc__k04QUzBM0CuvduB6yX8EQ_23_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ" decimals="-3" format="ixt:numdotdecimal" name="syn:Conversionofseriesbpreferredstocktocommonstock" scale="3" id="Tc_vvaZvKTAW0aNbyWClE3siQ_23_22">12,822</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series&#160;B Preferred Stock to Common</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3rOlqxEP0ybyVhLBiTYEw" decimals="0" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" scale="0" id="Tc_J5veoq8DSEueh5hN8648qg_24_2">3,454,783</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3rOlqxEP0ybyVhLBiTYEw" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_7Di4isoAiUWuAU4k1_xjUQ_24_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ" decimals="0" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStockShares" sign="-" scale="0" id="Tc_HGnOhsB7FUqTN86pXZ8Rhg_24_7">3,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_bnRJjB--UUmleFsmDjbfjQ_24_10">2,477</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8-WgejdDaEqgy2EWOSkLzA" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_rT1ZrsXpwU-WSCEVRef3DA_24_13">3,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nYSwPr0VKkqWTeFT1i_ttQ" decimals="-3" format="ixt:numdotdecimal" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" sign="-" scale="3" id="Tc_d7QBJpfxhE21EHUc6tuFtQ_24_16">1,497</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_iWZnfq9DoESxxwMr9XQsEw" decimals="-3" format="ixt:zerodash" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_Cq_wMugcc0qSMhU_Vq5M8A_24_19">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B8SS6pik5UydvtJcCB9dlw" decimals="-3" format="ixt:zerodash" name="syn:ConversionOfSeriesBPreferredStockToCommonStock" scale="3" id="Tc_X1NUxdmZ0EupoICKgeQHeQ_24_22">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_maMRHTz0kEOhJsNH6cODow_25_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_RWcXx3l6qESgAnPQemUAPw_25_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA" decimals="-3" format="ixt:zerodash" name="us-gaap:ProfitLoss" scale="3" id="Tc_OjPrWJwiMEO8Eu_KwECyxw_25_13">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_7xOgGm1KXUeKBowRqYZA2g_25_16">14,267</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_swACYSLaIUOgDlOv_L4ULg_25_19">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_tqJf3IeVQUawzyu5gEQChg_25_22">14,268</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Reversal of noncontrolling interest due to return of Syn Biomics shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="Tc_HoWbjdcJj0eQIt6qCkJFfg_26_5">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="Tc_SAdkoXNCR0Ozo59YosOdxg_26_10">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" sign="-" scale="3" id="Tc_r15yegbWmEOcuSQhV1Glug_26_13">2,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="Tc_DCdjHkevZU2Ml57Xh3C5jg_26_16">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="Tc_sfSBgxdvNk2jkbgFkI7LLw_26_19">2,774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="Tc_k0H9GfWxq0y-3i5vP1iLFg_26_22">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:28.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FpJzkt3PvkCZCGFfIrDKyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_2dnbb-oMuEehDqi1bmgW-A_27_2">132,042,538</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FpJzkt3PvkCZCGFfIrDKyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_eAiMPXQUXEOSAniv-07MEg_27_5">132</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_tjgiVhZrI0OhzmtDQzO8PA" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_p16_VnkhPkigjHdFHbm8FA_27_10">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y8DpvdHRXUi1PZn6rztZ4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_j1Xsomao8UipTkAIyklSHg_27_13">336,560</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HesMEARWFkamUpDQQXE38g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_QdLulnBQCkykwHeHFcOqog_27_16">271,284</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember__EXyzsLBqku0E4Q28xmdZQ" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_mqlQXuInZk2P2B96jBYyww_27_19">&#8212;</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_pSF_boR-1ky52c5AS2XP2g_27_22">65,408</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">See accompanying notes to consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_593d5846_6764_422d_80f4_1737d95a1cd1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><a id="ConsolidatedStatementsofCashFlows_49132"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(In thousands)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_97c45f1a_ebda_4061_90bb_e1ac7afcdb0a"></a><a id="Tc_MBBBtmmayEC0ll-Kph0fSw_1_2"></a><a id="Tc_uf6yHXPJn0iHU37XBPjJwQ_2_2"></a><a id="Tc_4W8Qe6tPSkSQ2x7dOLydTA_2_5"></a><a id="Tc_Ka2fDf5m-kGVeLu-DuFVwQ_3_0"></a><a id="Tc_oed6UxmFZE6M3w9pyJIB5Q_4_0"></a><a id="Tc_uTGRRHKqv0eXD0SxZX-QPA_4_2"></a><a id="Tc_-z0ACj8s6ESLE8hhHAz0Ig_4_5"></a><a id="Tc_9gHB3-kRnUinietaWwxGPg_5_0"></a><a id="Tc_Noj-k8PTi0ys-TtvlGKJmg_6_0"></a><a id="Tc_B5EhY5MTWk6zGa81XOPe5w_7_0"></a><a id="Tc_KX0MmF22M02vWLNLGLPyHg_8_0"></a><a id="Tc_aJ9XJe7VnEWdLOIuGQU-bQ_9_0"></a><a id="Tc_TbWLWl96x0eryksY463uHw_10_0"></a><a id="Tc_lmWmNH0HXkqLojOfJpGGDw_11_0"></a><a id="Tc_i3nR3fLj4EmKCB8X2N8LaA_12_0"></a><a id="Tc_7evZyHrfwkys95WaZo4q5A_13_0"></a><a id="Tc_PyNjLJKQhUOMi2_sRX3Qfg_14_0"></a><a id="Tc_hAA-I3GOy0Ci4ZUjGmq48w_15_0"></a><a id="Tc_bCC1PtvfGkW6cIQqjfEhnA_16_0"></a><a id="Tc_ckiYFKcOV0WRCBjvhepv-Q_18_0"></a><a id="Tc_gT0PeZASxkemt1Afn6CTig_19_0"></a><a id="Tc_9bf0Yy-_0ki0liwRSHOokg_20_0"></a><a id="Tc_U66udK8jaUWDX91nCetAIA_22_0"></a><a id="Tc_Aci3cUJaG02si6e7dcmUbw_23_0"></a><a id="Tc_aCcHsPcIJ0SIFxnCz1AGjA_24_0"></a><a id="Tc__9drnHwr80CnDEtlyhX__Q_25_0"></a><a id="Tc_t5oylGUwS06ER40M-TciYw_26_0"></a><a id="Tc_9x2nECiXV0SqhD6TAindyw_27_0"></a><a id="Tc_cas27TYcIU-qQT_HacQIXA_28_0"></a><a id="Tc_MdPyhMBAEkCCyY4CgA-I9Q_28_2"></a><a id="Tc_JPm7dJKTTE6zw0psigGWOw_28_5"></a><a id="Tc_XBBgp1PO6UCQyqsDPRlV0A_30_0"></a><a id="Tc_TLXpvGZSR0yNC9pnxJboFg_31_0"></a><a id="Tc_UkjYs93u-UutmKvfQl8gAQ_31_2"></a><a id="Tc_9CmwlYFyLUuR8vACszvw5g_31_5"></a><a id="Tc_uiYxxCqgJUWM0sp9ns2wpw_32_0"></a><a id="Tc_nACgAL-luEmKLV67TojhTQ_32_2"></a><a id="Tc_DaDM_PernkC4fd_26ABKmg_32_5"></a><a id="Tc_XMGnNvoY9kiIJD8OIoJ65A_33_0"></a><a id="Tc_tx1JyKarYU-CF51p5jIaCg_33_2"></a><a id="Tc_kvWlrNBwa06HxckYytm3XQ_33_5"></a><a id="Tc_MRQ1CJIhXkmEeogXCadP3g_34_0"></a><a id="Tc_tFbLbiEDck6BsIJWPT0A6g_34_2"></a><a id="Tc_rGylyHrOS0mVMptJXP9dJQ_34_5"></a><a id="Tc_u5nv7P2xEESMc0iFvByi0Q_35_0"></a><a id="Tc_mqx2lmaiKECIYeeKFAaEAw_35_2"></a><a id="Tc_XbKUfH6DXE2lli9JcNqVeA_35_5"></a><a id="Tc_TfgV3_vTRkWLZnZaW4VuPQ_36_0"></a><a id="Tc_RGLYFTdBe0SCgHSgJCw_Wg_36_2"></a><a id="Tc_HOU483A9fUuuGbTyDOrglw_36_5"></a><a id="Tc_7lgrJ-xLrUW2kmhNDkLGeQ_37_0"></a><a id="Tc_Oaw6NEoP0UOpZKjNfgltVQ_37_2"></a><a id="Tc_47PUNs1QEkqaGd1sWGl2HQ_37_5"></a><a id="Tc_mePSBIbOZkqhrHug3I1gNA_38_0"></a><a id="Tc_rT1cr92zVUyl2Ra7Oegx3g_38_2"></a><a id="Tc_8LfLO1vOKUG7INOgnKrY8g_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;width:23.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the&#160;year ended</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows From Operating Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_O64SPO78mEuiJcrSNG_YFQ_4_3">14,268</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_08HNJWJWh0Ch6bDrnyHXag_4_6">10,116</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_PuyDBrMSYEWKRuONYdkuLw_6_3">416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_SL1BH7smqUO2YOclz4vyKw_6_6">350</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Subsidiary stock issuances to vendor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:zerodash" name="syn:SubsidiaryStockIssuesToVendor" scale="3" id="Tc_HLk_DjX9Q06AcZmM-QyI1A_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="syn:SubsidiaryStockIssuesToVendor" scale="3" id="Tc_93qu2mWDUkOgfTnpLUMolw_7_6">178</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_ImPqSJGxa0qS0xrp_7v_9g_8_3">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_Ir3Sgz05WUyjigcQGP9ktg_8_6">201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_VDNPQAlRvEG7dt83G1qPfQ_10_3">174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_l9Dwk49XsU2hbc3cm91QZA_10_6">326</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right of use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="syn:IncreaseDecreaseRightOfUseAssets" scale="3" id="Tc_tIghzbwdBUawGtcTvIdyfw_11_3">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="syn:IncreaseDecreaseRightOfUseAssets" scale="3" id="Tc_fZP-pbm3VkePqIZLy3C_gA_11_6">141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_2Ot0osB7QUG4pHOO8OZEUw_12_3">363</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_fTNh_HKkUU2Er8O2Hn11mg_12_6">1,429</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="Tc_d7g-ZTLXoEaOv00jp0k5Ug_13_3">1,004</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_kx0CFw1JdEmxPui-rUCVCw_13_6">851</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accrued employee benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="Tc_ASu_4cXAHEG3r2ft-h3PUA_14_3">110</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" sign="-" scale="3" id="Tc_9BI79pRItkSGH5qAWVIdoQ_14_6">67</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="syn:IncreaseDecreaseLeaseLiability" sign="-" scale="3" id="Tc_8HbsA02QxEyC0gFWIweZJg_15_3">216</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="syn:IncreaseDecreaseLeaseLiability" sign="-" scale="3" id="Tc_X-qpBldapkWxOiDoul6pBg_15_6">249</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Cash Used In Operating Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_GlK7cw9DMUG_auolK5UIWw_16_3">12,890</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_tRxzgh7L8kWMkOQ7KjESaw_16_6">12,168</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows From Investing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_bdoCxBwNpEmM4rI408Oh2w_19_3">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_PTPANZ71UESBzxsPIdnlKw_19_6">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Cash Used In Investing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_ucUVGVL-9EmExN5qX92BYg_20_3">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_SdRu8ywS-ECeXyQbcuO4eg_20_6">9</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash Flows From Financing Activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from &#8220;at-the-market&#8221; stock issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_MyHd35Sx2069t9Ia_49OmA_23_3">65,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_kvGT153hlkmyGAtdCgoyAA_23_6">3,359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock for warrant exercises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_L7Z2MVw-qEOaxcr1NqKp-Q_24_3">8,042</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="Tc_ob58jizmXEOYFh79c1qiOQ_24_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net Cash Provided By Financing Activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_-9xNZD1TYkChHgqrO8eiow_25_3">74,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Q_6H7-3kcU22x5lv_oKg-g_25_6">3,359</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net increase (decrease) in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" id="Tc_Xw4CoDN3FUa9W3oVeoUSHA_26_3">61,098</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="3" id="Tc_IJ4xeWN610WZ4rElRbWa0w_26_6">8,818</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ULTgwvSciE2zeed_GfSU2Q_27_3">6,227</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_MSM3vAeGSEWYU5a_Z3GD-g_27_6">15,045</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents at end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_SWo3pw9uiUuUBSVfbbmbPw_28_3">67,325</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Jn0_CIOhAUSx9ecfH0uSRA_28_6">6,227</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NONCASH FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series&#160;A Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_HL3ptuyk1EuS6UKtefBIvw_31_3">12,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig" decimals="-3" format="ixt:zerodash" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_iG705Wv_C0agCrH9FWsgFw_31_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of Series A Preferred Stock price adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="syn:PreferredStockPriceAdjustment" scale="3" id="Tc_5P84ryEQ3UimjccUPBvcCQ_32_3">7,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="syn:PreferredStockPriceAdjustment" scale="3" id="Tc_oDei177RuEuMKf4Pje6MGQ_32_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Return of SYN Biomics Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="syn:ReturnOfSynBiomicsStock" scale="3" id="Tc_ZKlLAocuiEy-RHwl_tcOQQ_33_3">2,774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="syn:ReturnOfSynBiomicsStock" scale="3" id="Tc_P8KTla6-AUKtjIqtaImgRQ_33_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Series&#160;B Preferred Stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B8SS6pik5UydvtJcCB9dlw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_hSelucVzH0KN7qMCKzTvEQ_34_3">2,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" id="Tc_WW7GHekdZkyvHxLi-I4M-Q_34_6">2,284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deemed dividends for accretion of Series B Preferred Stock discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="syn:DeemedDividendsWithBeneficialConversionFeature" scale="3" id="Tc_M5AL9dSVfEyfgzGBYVQvng_35_3">1,496</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="syn:DeemedDividendsWithBeneficialConversionFeature" scale="3" id="Tc_OU5lJnfWBUqocj_EaSO-xQ_35_6">1,380</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of use assets from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_QpBUvwHPxEq-OjMoe11V5w_36_3">1,270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_HlMUHODK_EOF3hfySixfkw_36_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">In-kind dividends in preferred stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockPaidinkind" scale="3" id="Tc_dXmnToKvwEShypr2da25eg_37_3">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DividendsPreferredStockPaidinkind" scale="3" id="Tc_fuaGMe7vyUSKaQ51PxDvCg_37_6">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Effect of Warrant exercise price adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:zerodash" name="syn:WarrantExercisePriceAdjustment" scale="3" id="Tc_3iG2Zl8aAkCTWinSgx4MZA_38_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="syn:WarrantExercisePriceAdjustment" scale="3" id="Tc_zYKd12AdBki1EeUIMXKW_w_38_6">880</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_961f5651_9b70_4771_ba33_f66eabf9501d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="a1OrganizationandNatureofOperationsandBa"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_VStRXgqK50iOP6zCpuVyhg" continuedAt="Tb_VStRXgqK50iOP6zCpuVyhg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and Nature of Operations and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;) is a diversified clinical-stage company operating in <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_7dQAK-Ay_0GzcvHqS8468g">one</ix:nonFraction> segment currently developing therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company&#8217;s lead clinical development candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) <i style="font-style:italic;">Clostridioides difficile</i> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under Current Good Manufacturing Practice (cGMP) conditions and intended to treat both local GI and systemic diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company was also developing SYN-010 to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). On September 30, 2020, Cedars Sinai Medical Center (CSMC) (the Company&#8217;s SYN-010 clinical development partner) informed the Company that it agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients. Based on the results of a planned interim futility analysis, it was concluded that although SYN-010 was well tolerated, it was unlikely to meet its primary endpoint by the time enrollment is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Structure and Basis of Presentation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company had eight subsidiaries, Pipex Therapeutics,&#160;Inc. (&#8220;Pipex Therapeutics&#8221;), Effective Pharmaceuticals,&#160;Inc. (&#8220;EPI&#8221;), Solovax,&#160;Inc. (&#8220;Solovax&#8221;), CD4 Biosciences,&#160;Inc. (&#8220;CD4&#8221;), Epitope Pharmaceuticals,&#160;Inc. (&#8220;Epitope&#8221;), Healthmine,&#160;Inc. (&#8220;Healthmine&#8221;), Putney Drug Corp. (&#8220;Putney&#8221;) and Synthetic Biomics,&#160;Inc. (&#8220;SYN Biomics&#8221;). Pipex Therapeutics, EPI, Healthmine and Putney are wholly owned, and Solovax, CD4, Epitope and SYN Biomics are majority-owned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For financial reporting purposes, the outstanding common stock of the Company is that of Synthetic Biologics,&#160;Inc. All statements of operations, (deficit) equity and cash flows for each of the entities are presented as consolidated. All subsidiaries were formed under the laws of the State of Delaware on January&#160;8, 2001, except for EPI, which was incorporated in Delaware on December&#160;12, 2000, Epitope which was incorporated in Delaware in January&#160;2002, Putney which was incorporated in Delaware in November&#160;2006, Healthmine which was incorporated in Delaware in December&#160; 2007 and SYN Biomics which was incorporated in Nevada in December&#160;2013.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company has a significant accumulated deficit, and with the exception of the three months ended June&#160;30, 2010 and the three months ended December&#160;31, 2017, the Company has experienced significant losses and incurred negative cash flows since inception. The Company expects to continue incurring losses for the foreseeable future, with the recognition of revenue being contingent on successful phase 3 clinical trials and requisite approvals by the FDA or foreign equivalents. Historically, the Company has financed its operations primarily through public and private sales of its common stock and a private placement of its preferred stock, and it expects to continue to seek to obtain required capital in a similar manner. The Company has spent, and expects to continue to spend, a substantial amount of funds in connection with implementing its business strategy, including planned product development efforts, clinical trials and research and discovery efforts.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_VStRXgqK50iOP6zCpuVyhg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Organization and Nature of Operations and Basis of Presentation&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash and cash equivalents totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_KId_huFtAESLl_Az5514qg">67.3</ix:nonFraction> million as of December 31, 2021, which includes the net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-5" format="ixt:numdotdecimal" name="syn:ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts" scale="6" id="Narr_9PzmUu2YMkC519-eVSspcA">66</ix:nonFraction> million from sales of its Common Stock in &#8220;at-the-market&#8221; (ATM) equity offerings during 2021 and cash proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_eznordvkD02fpKVCnes7Zw">8.0</ix:nonFraction> million through the exercise of a portion of the October 2018 warrants. With these additional sources of liquidity<span style="color:#333333;background:#ffffff;">,</span> the Company believes it will be able to fund its operations through the next twelve months from the issuance date of these financial statements. Management believes its plan, which includes the further development of SYN-020, additional testing of SYN-004 (ribaxamase) and the advancement of VCN-01 will allow the Company to meet its financial obligations, further advance key products, and maintain the Company&#8217;s planned operations for at least one year from the issuance date of these consolidated financial statements. If necessary, the Company may attempt to utilize the ATM or seek to raise additional capital on the open market, neither of which is guaranteed. Use of the ATM is limited by certain restrictions and management&#8217;s plan does not rely on additional capital from either of these sources. If the Company is not able to obtain additional capital (which is not assured at this time), our long-term business plan may not be accomplished and we may be forced to cease certain development activities. More specifically, the completion of any later stage clinical trial will require significant financing or a significant partnership.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_HSA2bovUyUSrJt2bMNj7ug" continuedAt="Tb_HSA2bovUyUSrJt2bMNj7ug_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_EQ9FYC9fBUqr8zJXsxv0jw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All intercompany transactions and accounts have been eliminated in consolidation.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:UseOfEstimates" id="Tb_DJB0Dv9A50-QUifQtf4j6A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants, preferred stock and stock options granted for services or compensation, respectively, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:NoncontrollingInterestPolicyTextBlock" id="Tb_gQW83zzV00-yubVmiszSYA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Non-controlling Interest</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s non-controlling interest represents the minority stockholder&#8217;s ownership interest related to the Company&#8217;s subsidiary, SYN Biomics. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#8217;s common stockholders on the face of the Consolidated Statements of Operations. On September&#160;5, 2018, the Company entered into an agreement with the minority stockholder for an investigator-sponsored Phase 2 clinical study of SYN-010. Prior to this agreement and IRB approval in December&#160;2018, the Company&#8217;s equity interest in SYN Biomics was <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_X7OTRMegzEONug23YJ7vFw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_FZH6Xu_wLECn1-t24SndHw">88.5</ix:nonFraction>% and the non-controlling stockholder&#8217;s interest was <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_X7OTRMegzEONug23YJ7vFw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_Xe0gAHaT-EGtCV1tOogiSQ">11.5</ix:nonFraction>%. In consideration of the support, the Company issued additional shares of stock to the minority stockholder, resulting in the Company&#8217;s equity interest in SYN Biomics being <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_9LSkUvA6w0uBjCFRvatWDw">83.0</ix:nonFraction>% and the non-controlling stockholder&#8217;s interest is <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_12_31_2021_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_cBapFdW9TUCTcjAUH7txKQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_ev3AQrXYxUuIoca9240LXg">17.0</ix:nonFraction>%. During 2021, the minority stockholder returned its shares of SYN Bionics to the Company for no consideration. The Company&#39;s interest in SYN Biomics is now 100%. This is reflected in the Consolidated Statements of Equity (Deficit).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:RisksAndUncertaintiesPolicyTextBlock" id="Tb_PfpOFHl2HEmq2UKsQnpuSQ" continuedAt="Tb_PfpOFHl2HEmq2UKsQnpuSQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. These conditions may not only limit the Company&#8217;s access to capital, but also make it difficult for its customers, its vendors and its ability to accurately forecast and plan future business activities.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HSA2bovUyUSrJt2bMNj7ug_cont1" continuedAt="Tb_HSA2bovUyUSrJt2bMNj7ug_cont2"><ix:continuation id="Tb_PfpOFHl2HEmq2UKsQnpuSQ_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies&#160;&#8211;&#160;(continued)</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_EG8sFimo1kaiI0zI6v2rhg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three&#160;months or less.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_Gatmj9FgZEKd6zWN7o41iw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:EstimatedUsefulLifeOfAssetTableTextBlock" id="Tb_qUk1kbx560KaRyW-RddY0A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Asset Description</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:top;width:48.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Office equipment and furniture</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_06odZ0po2U2Duco7oDcnHg" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_qHqpXrVrjEyKN-nI-sfDqA">3</ix:nonNumeric>&#160;&#8211;&#160;<ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_qOfAb8XKjEiqZKgjiMEWCw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_Z73_PD7TuE2JFiLIBbZV5w">5&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements and fixtures</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lesser of estimated useful life or lease term</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_w0lDfcjsp0G0jZ4Z1qBAyA">87,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_qVVpzotRYkuOtfvQFPiKWg">201,000</ix:nonFraction> for the&#160;years ended December&#160;31, 2021 and 2020, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts with any gain or loss reported in the consolidated statement of operations. Repairs and maintenance are charged to expense as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews property and equipment for impairment to determine if assets are impaired due to obsolescence. As a result of this review, there was no impairment recognized for the&#160;years ended December&#160;31, 2021 and 2020.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_AUh0GONzNkCMwb8DAbZPdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_22nbGBafNU6BBkr18R_rYg" continuedAt="Tb_22nbGBafNU6BBkr18R_rYg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the year ended December 31, 2021 includes the effect of the Series A preferred stock price adjustment of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ" decimals="-5" format="ixt:numdotdecimal" name="syn:PreferredStockPriceAdjustment" scale="6" id="Narr_arf4s6IOQUeDZeycspVmAA">7.4</ix:nonFraction> million, the accretion of the Series B preferred discount of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_XT6XJ5XjDUuV4c_EGi70aw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDiscountOnShares" scale="6" id="Narr_9bwPtVf_WUSTjk2DRYw7Yw">1.5</ix:nonFraction> million on converted shares and Series A preferred stock accrued dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_E07f6QbiCEq3peUEus5GHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDiscountOnShares" scale="6" id="Narr_SZD2Ew56vUWNo__yqBor5g">0.1</ix:nonFraction> million. Net loss attributable to common stockholders for the year ended December 31, 2020 excludes net loss attributable to non-controlling interest of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_syn_SeriesAAndSeriesBPreferredStockMember_fpL3K7hVwEiXTKmMFfDtbQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="Narr_oSnDqyZcCUGJ6v7wipwvEg">0.1</ix:nonFraction> million and includes the accretion of Series B preferred discount of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_wVR9EwKxu0OMQoL-9aHnSw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDiscountOnShares" scale="6" id="Narr_mQDfKDO6WUadxNA9kwUZUw">1.4</ix:nonFraction> million on converted shares, the effect of warrant exercise adjustment of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig" decimals="-5" format="ixt:numdotdecimal" name="syn:WarrantExercisePriceAdjustment" scale="6" id="Narr_qNvTK8W5DkWAkN_bX05NHQ">1.0</ix:nonFraction> million and Series A preferred stock accrued dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig" decimals="-5" format="ixt:numdotdecimal" name="syn:AccretionOfPreferredStockDeemedDividend" scale="6" id="Narr_Pfrt1a_RrECfjO1CIpAGjA">0.3</ix:nonFraction> million. The number of shares of common stock underlying Series A Preferred shares convertible to common stock that were excluded from the computation of the net loss per common share for the year ended December 31, 2020 was <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_dA_PkSgtVU65D66JGjeFgw">678,258</ix:nonFraction>. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that was excluded from the computation of net loss per common share and for the year ended December 31, 2020 was <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_cmKecbbWoU6zrY7-S2cLvA">3,454,783</ix:nonFraction>. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share for the&#160;year ended December&#160;31, 2021 were <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_OptionMember_UcsU_7n8D0Gh9M_a12yMqQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_jbOJ4HYxu06b9uH8dsdVPA">6,255,275</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_CsW_sJTdhUmHG2HCpG3-rQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_oXj7gZahcU2CZvqzhcc-cg">6,344,966</ix:nonFraction>, respectively, and for the&#160;year ended December&#160;31, 2020 were <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_OptionMember_w-qS4dRJ3U6O4DpjgVohSQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_rKZTm5Vknk-kNO7tiglfBg">3,997,418</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_p0e-bc-m1k-aY-9mEgL6FQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_apH6VTF0HkClmU8geujv2A">18,000,713</ix:nonFraction>, respectively, because their effect is anti-dilutive.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HSA2bovUyUSrJt2bMNj7ug_cont2" continuedAt="Tb_HSA2bovUyUSrJt2bMNj7ug_cont3"><ix:continuation id="Tb_22nbGBafNU6BBkr18R_rYg_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies&#160;&#8211;&#160;(continued)</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_PFxraIpTN0inXtqoM0g7Vw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries, stock-based compensation and related employee costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of our product candidates. Research and development expenses include external contract research organization (&#8220;CRO&#8221;) services. The Company makes payments to the CROs based on agreed upon terms and may include payments in advance of study services. The Company reviews and accrues CRO expenses based on services performed and relies on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. At December&#160;31, 2021 and 2020, the Company has accrued CRO expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="6" id="Narr_grIuZEdtOkepha0GXNglGQ">0.7</ix:nonFraction> million, that are included in accrued expenses. The Company has prepaid CRO costs at December&#160;31, 2021 and 2020 of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" id="Narr_Cyc3s9VXMUC1qo92Syh-hQ"><ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" scale="6" id="Narr_6Lx9HEz8sU-VIVPxVikJOw">0.5</ix:nonFraction></ix:nonFraction> million that are included in prepaid expenses.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_Ze8KZGjGNE6_JqRXY6Zsog" continuedAt="Tb_Ze8KZGjGNE6_JqRXY6Zsog_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accounting Standards Codification (&#8220;ASC&#8221;) 820, <i style="font-style:italic;">Fair Value Measurement</i>, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are classified on a three-tier hierarchy as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 inputs: Inputs, other than quoted prices, that are observable either directly or indirectly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The carrying amounts of the Company&#8217;s short-term financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include money market accounts of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_syn_MoneyMarketAccountsMember_RVHGBSefSU2di_Mp-C0IXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_zxBzpmaiP0aSGboLXQyIwA">193,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_syn_MoneyMarketAccountsMember_sKG50uvlI0qAGAuG7zjYtg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Narr_bUxJri87Ak2xBAGCxZFROA">114,000</ix:nonFraction> as of December&#160;31, 2021 and 2020, respectively, that are measured using Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In using this model, the fair value is determined by applying Level 3 inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions. The assumptions used in calculating the estimated fair value of the warrants represent the Company&#8217;s best estimates; however, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different. In 2021 and 2020, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#8217;s current stock price.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HSA2bovUyUSrJt2bMNj7ug_cont3" continuedAt="Tb_HSA2bovUyUSrJt2bMNj7ug_cont4"><ix:continuation id="Tb_Ze8KZGjGNE6_JqRXY6Zsog_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies&#160;&#8211;&#160;(continued)</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:StockBasedPaymentArrangementsPolicyTextBlock" id="Tb_oQd6v96yT0aWW_MS6y8CzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Payment Arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date typically using the Black-Scholes option pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations, depending on the nature of the services provided.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:DerivativesPolicyTextBlock" id="Tb_dzhQ6_sv60eyldIAs9ZeZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Derivative Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The warrants issued in conjunction with the public offering of the Company&#8217;s securities in November&#160;2016 include a provision that if the Company were to enter into a certain transaction, as defined in the warrant agreement, the warrants would be purchased from the holder for cash. The provisions of these warrants preclude equity accounting treatment under ASC 815, <i style="font-style:italic;">Derivatives and Hedging.</i> Accordingly, the Company is required to record the warrants as liabilities at their fair value upon issuance and re-measure the fair value at each period end with the change in fair value recorded in the Consolidated Statement of Operations. When the warrants are exercised or cancelled, they are reclassified to equity. The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In November 2020, all liability-classified warrants expired. In 2019, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#8217;s current stock price.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_7UB2a3YNZEOc138yryhe5w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes deferred tax assets and liabilities based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the&#160;years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management assesses the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex tax laws of multiple jurisdictions. The Company records the related interest expense and penalties, if any, as tax expense in the tax provision. At December&#160;31, 2021 and 2020, the Company did not record any liabilities for uncertain tax positions.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_WgR7M8NWC02JK1xQuhJilQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements and Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Financial Accounting Standards Board (&quot;FASB&quot;) issued Accounting Standards Update (&quot;ASU&quot;) 2020-06, <i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#39;s Own Equity (subtopic 815-40)</i>: <i style="font-style:italic;">Accounting for Convertible Instruments and Contracts in an Entity&#39;s Own Equity</i>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#39;s own equity and improves and amends the related earnings per share guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company is currently assessing the impact of ASU 2020-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2021, the FASB issued Accounting Standards Update 2021-08 that address the accounting for Contract Assets and Liabilities from Contracts with Customers in a business combination (&#8220;ASU 2021-08&#8221;), with an effective date for SYN of January 1,2 2024 (earlier adoption permitted). ASU 2021-08 provides that existing contract assets and liabilities (including deferred costs to obtain and deferred revenue) are measured in a business combination under the measurement and recognition requirements of ASC 606. ASU 2021-08 should generally &#8220;result in an acquirer recognizing and measuring the acquired contract assets and liabilities consistent with how they were recognized and measured in the acquiree&#8217;s financial statements.&#8221; The Company is currently assessing the impact of ASU 2021-08 on its consolidated financial statements.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_HSA2bovUyUSrJt2bMNj7ug_cont4"></ix:continuation><a id="_b138618c_6883_47a8_a539_10fbb797b42e"></a><a id="Tc_xg_w2FfMYk2rGQ3yQVN39Q_1_2"></a><a id="Tc_VPhHDUmxL0OI6_JdUc-YKA_1_5"></a><a id="Tc_CEBAvDzUt0m7Fn5bAe5lCw_2_2"></a><a id="Tc_p1Tc8YPR4EOTUEdAt9hXOw_2_5"></a><a id="Tc_cVEc-8KtCUeT2q07ehf1QA_3_0"></a><a id="Tc_qCTqzR1W-0WQsVD5btZi-Q_3_2"></a><a id="Tc_IRuh_0qL6kaUHiDZUo-eLg_3_5"></a><a id="Tc_RUaVWfMn4kC0PQcm5jV2kA_4_0"></a><a id="Tc_QFPf4ojtCEaNWwxeN5eyrA_5_0"></a><a id="Tc_97mRqoumtE2h6szAPfmY1Q_6_0"></a><a id="Tc_-j33PDRh7UK2JAxIetL8vg_7_0"></a><a id="Tc_aCQDY8kwRE-_tbyt56REcQ_9_0"></a><a id="Tc_scLWQSvl3UuXq6ecvZq1KA_9_2"></a><a id="Tc_Qzwt_S5wgUOh2BndgMHB7A_9_5"></a><a id="_ad02198e_f0f6_4732_9c73_3302a2cdcb11"></a><a id="Tc_RTnJo5D6skKYE-7CLhG_2Q_1_2"></a><a id="Tc_h_VmxMkAFE-pV2yov6d-8w_1_5"></a><a id="Tc_etnwcEfD3EmtxpdstxkO3w_2_2"></a><a id="Tc_4IP9optyaka868JHW_lXvA_2_5"></a><a id="Tc_iv4OAm5ImkmturbpiHSbMg_3_0"></a><a id="Tc_blwGTSPsUEaKw0N6fWB3-A_3_2"></a><a id="Tc_0MLtGXGMP0GeCQN74vILAA_3_5"></a><a id="Tc_qgX5KWxDRUWR3DFj3l-R0A_4_0"></a><a id="Tc_T0ERMBQhHEKC9wp5zMxanw_5_0"></a><a id="Tc_PezM6M8ZYUGp4gkVaPia5w_7_0"></a><a id="Tc_fgoYEA82xkmzzsu5kZKmbQ_9_0"></a><a id="Tc_Ug5tfr--sE2MuxNgMpeypw_9_2"></a><a id="Tc_CFR6E_HxmEKg1mwl0VdYzw_9_5"></a><a id="_459cab98_fb1b_4442_b919_249101b311eb"></a><a id="Tc_LHNQxm8kxUiqJ4msF4gMpg_1_2"></a><a id="Tc_x8jysXBGFEaoZLgFtsEpfg_1_5"></a><a id="Tc_QSNBEtTpokWPmmHoWzkrDA_2_2"></a><a id="Tc_xtfACk8PAkq0nYGgxGYBKw_2_5"></a><a id="Tc_CDDguI9-LE6TpZ_X2I9UQA_3_0"></a><a id="Tc_VsmnEiKcrUuQn8I-kcMEKA_3_2"></a><a id="Tc_hYrf9S_2d0G96-uj-LjYsQ_3_5"></a><a id="Tc_R_zrIbot_k-zsHWc_MryjA_4_0"></a><a id="Tc_a8qd-ZgfpEy5U2s77v9CIg_5_0"></a><a id="Tc_4GpaGYIIqkOra0cC_xcb4g_5_6"></a><a id="Tc_zQK08nmvn0mZtKf8d_BcYA_7_0"></a><a id="Tc_HBodUSIVuUOb4TR4OxKTZQ_7_2"></a><a id="Tc_JeVLSZKMJUWLbV97BIluwg_7_5"></a><a id="_b8f90ec8_bd06_41f0_8d25_d8248aeb8807"></a><a id="Tc_QJWlCQtdRku5N2DrgVR6Cg_1_2"></a><a id="Tc_R_cNNmASZ0aFIvLh6DyNkw_1_5"></a><a id="Tc_NOJxFA4iYEaO_xZkyD8RcQ_2_2"></a><a id="Tc_Tu7RqFQ03kCklLui8eSKkw_2_5"></a><a id="Tc_Y_OCGIrIcUCMkpWmOz8PXA_3_0"></a><a id="Tc_V0p5aZ36VUu99j1i3fmxvA_3_2"></a><a id="Tc_OxHr_hqdfUCM5Qj9DN8t7w_3_5"></a><a id="Tc_2H_4PcFXZk-eRCUGI7Rw3A_4_0"></a><a id="Tc_1M3dQh_naUCNG_UJRZAuDA_6_0"></a><a id="Tc_zUfdnp02SkqxZ8xyeGH7jg_6_2"></a><a id="Tc_u9-z2-hYHk-xuuuXTUpZoQ_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="Tb_G6ZcRg50E0KMvZswRRyHzQ" continuedAt="Tb_G6ZcRg50E0KMvZswRRyHzQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Selected Balance Sheet Information</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="Tb_fBzTslO8HkCDtgMVGVOrTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PREPAID EXPENSES AND OTHER CURRENT ASSETS (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_opw2V_9SjkGxOqNsrph2gg_3_3">803</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidInsurance" scale="3" id="Tc_PixjeSfSxUODTe3R_jZTYw_3_6">639</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid clinical research organizations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidClinicalResearchOrganizationsExpenseCurrent" scale="3" id="Tc_3EdhgHPVJEKtNOXC1dhlhQ_4_3">458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidClinicalResearchOrganizationsExpenseCurrent" scale="3" id="Tc_SfwDN9G0jk69Pl9DiVaRcw_4_6">470</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid consulting, subscriptions and other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidConsultingSubscriptionsAndOtherExpenses" scale="3" id="Tc_hXcb9ZrKwUG9X8f5SG1QtQ_5_3">272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidConsultingSubscriptionsAndOtherExpenses" scale="3" id="Tc_fd13on5GcEazOg11it4YMQ_5_6">90</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock sales receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_QmfqfgqxzkKXp6GIt4nzWg_6_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="Tc_ZhztR82PpEyKL83Zt_N0WQ_6_6">469</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:zerodash" name="syn:PrepaidManufacturingExpense" scale="3" id="Tc_OJPtNEhTzEWrRZF0Cg6LYQ_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:PrepaidManufacturingExpense" scale="3" id="Tc_Gd4GPvcg2UKf1cMv_HvfqA_7_6">39</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_LYSKIATeUEG8xzEOoccqyw_9_3">1,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_IssBv-uZ-Eq_ZgZA02pHJg_9_6">1,707</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prepaid CRO expense is classified as a current asset. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_3C_Nb-FkJ06Jm8ScLtJ88g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROPERTY AND EQUIPMENT (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_ZvDVzBKGkEueIM7aytJo4w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-GUkKl0wJ02hP4zMn3DG6Q_3_3">827</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_ThDy-dV5AU6IEh4MuJpfGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_fTOxBgQOfky0NBUweBC-aw_3_6">813</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_mGRCO12RFEyXuQzUlkC0Ow" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_FKIIKeO6_ESwxfZbXqLOjg_4_3">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_588QHXjz8kSla7aDWmJMXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_qPFdDaOZokSrDxpDy_X-pA_4_6">439</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_IzIuFnR8zEGM4rQkXo15Fw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_RJAOQWb4NEu-pHL9fe9rSA_5_3">11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_xIpjyVqOO0Og8SZMiELCjw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_M0wddhUo_EqUuH68djbHIQ_5_6">11</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_MsK-6VAtCkiOuRpzjrq5cg_6_3">932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_b9EjvBnI30y8Y73QCDRpQw_6_6">1,263</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_5nBkyBErvk-yvJ_ClMaLgA_7_3">831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_CM8C325ZjkW3gUT3BEYtjg_7_6">1,089</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_FSv8QfB7KEq9Hs7t3Cq2EA_9_3">101</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_QKaEnmvxpUSDQnikMHarsg_9_6">174</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:AccruedExpensesTableTextBlock" id="Tb_fWVkO4pVu06uZuHY2gYmZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ACCRUED EXPENSES (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vendor payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:AccruedVendorPayments" scale="3" id="Tc_S-wa4crrBUO5BICeX1VTrw_3_3">1,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:AccruedVendorPayments" scale="3" id="Tc_g2PjpUe2h0WktNsCnDUl-A_3_6">225</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical consulting services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:AccruedClinicalConsultingServices" scale="3" id="Tc_5Q_mLIf2DEu-Wiite35BBQ_4_3">696</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:AccruedClinicalConsultingServices" scale="3" id="Tc_lMHkGNkCFkCpQnTyRiPr8Q_4_6">700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued manufacturing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:AccruedManufacturingCosts" scale="3" id="Tc_ZU4-SHOvD0S5rh5y1TPzLg_5_3">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_TW4RQGlNTkej1PYaUytPWw_7_3">1,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_vghHt2gul0615UTYA6eTUA_7_6">925</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:AccruedEmployeeBenefitsTableTextBlock" id="Tb_sCtakR8mPkiHjVh6YdgUFg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ACCRUED EMPLOYEE BENEFITS (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued bonus expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_V-ZfUQaOokCGHdN_vd9OJQ_3_3">886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="Tc_DbjvLHHoJUiOS-_pvmzlUg_3_6">724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_jnXondMtNU6-f3Fad9jX1Q_4_3">92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_10DGZ7zVk06MfO6eA6wMgA_4_6">144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_NHgdPbMeFEWVeYnAVa6REQ_6_3">978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_UWu5NYpss0uSZyK9M2qnFw_6_6">868</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_G6ZcRg50E0KMvZswRRyHzQ_cont1"></ix:continuation><a id="Tc_wBqW_Cb54kqMgp08-6QDfQ_1_2"></a><a id="Tc_uvZlk50vw0WAUpy-Phcf2w_2_2"></a><a id="Tc_qK8xjUegUUKASNagwNzDgg_2_5"></a><a id="Tc_s3ApFW2r4E671mGtYStW5g_3_0"></a><a id="Tc_xLlgoRWpTUeJnrEx57g3eg_3_2"></a><a id="Tc_a6EzAxAWTk6d6d0AAb3aEw_3_5"></a><a id="Tc_F3jXeBs55ESWYbF_ai9J8A_4_0"></a><a id="Tc_5rtvStPYyEW_Jr83n9W4EQ_4_4"></a><a id="Tc_6258xFGyUEmab2qkDyjg8w_4_7"></a><a id="Tc_s8bEYAzkVkmjnj2NyL_4xw_5_0"></a><a id="Tc_tIF7qL1ZG06yBhG0DEbgpA_5_4"></a><a id="Tc_U5BRX_kajUWvqN4UGXgDxQ_5_7"></a><a id="Tc_Ipz3XCoZ5kaxFDky9-1vAQ_6_0"></a><a id="Tc_Tw8hjfcNqEuboqyTGttxGw_6_4"></a><a id="Tc_OnHXkXQrK0mJYot-psvugA_6_7"></a><a id="Tc_q2IdLhWew0O7QdNgA4QEwA_7_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_OzB6yYT9bUywRdLdEvW50w" continuedAt="Tb_OzB6yYT9bUywRdLdEvW50w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Stock-Based Compensation and Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March&#160;20, 2007, the Company&#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_3_20_2007_us-gaap_PlanNameAxis_syn_StockPlan2007Member_sZjnQm5mlUKRuIz8LR01dg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_IDm6rJu-F0yTyZT-_jAa4Q">71,429</ix:nonFraction> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November&#160;2, 2007. The exercise price of stock options under the 2007 Stock Plan was determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_3_1_2007_To_3_20_2007_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_syn_StockPlan2007Member_6vT1SirORkqYa-QBH8UMpQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_9SoLkpEr30-IawWCqrc9DA">7,143</ix:nonFraction>. Options become exercisable over various periods from the date of grant, and generally expire ten&#160;years after the grant date. As of December&#160;31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockPlan2007Member_auU9NgALU0aCvHRUD6P_0Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_lX6J-lg2sE6m1N0DTgqWqw">5,145</ix:nonFraction> options issued and outstanding under the 2007 Stock Plan. There are no shares available to be issued under this plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_11_2_2010_us-gaap_PlanNameAxis_syn_StockPlan2010Member_Zt_SyFnbm0e4SI86EXshXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_z8zD1toLq0iC_7PRNjSWOA">85,714</ix:nonFraction> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. From time to time the number of shares authorized for options was increased such that <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_9_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_YKWmzXomVU-N4eCGaM8B_w" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="6" id="Narr_a7Wq0USk20y5Cijhapg2nQ">4,000,000</ix:nonFraction> million were authorized as of September 30, 2021. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant and expire between five and ten&#160;years after the grant date. As of December&#160;31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_syn_StockPlan2010Member_4D5WRURlwE63c5hlGLugSw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_ubHsqT6peEiNhdx5e4gR2w">2,450,130</ix:nonFraction> options issued and outstanding under the 2010 Stock Plan. There are no shares available to be issued under this plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 17, 2020, the stockholders approved and adopted the 2020 Stock Incentive Plan (&quot;2020 Stock Plan&quot;) for the issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_9_17_2020_us-gaap_PlanNameAxis_syn_StockPlan2020Member_KiYSEy59102VWky5jzVKvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_GeVdUwhHDEWaRQ7YctY1zQ">4,000,000</ix:nonFraction> shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. As of December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_8UEIx49YJkWPUL6XsZYSRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_6lLfCYhHcEm2e68oJq4ofw">3,800,000</ix:nonFraction> options issued and outstanding under the 2010 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized over the stated vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The assumptions used for the&#160;years ended December&#160;31, 2021 and 2020 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="Tb_-y3eFvN-BkSlzDYtKZ3oCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="2" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" scale="0" id="Tc_ysx-_ETBGkeM-G4dDcuslA_3_3">0.33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="2" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" scale="0" id="Tc_4SbBRzF_WECuyI6aUdDevA_3_6">0.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_u2aU_BmnXEqBscPZUav2-Q_4_3">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_CzZkd7RZj0qQOz3GXn7jjQ_4_6">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_quBpVZgBa02hkHYO17C57A_5_3">92</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_xDorFklgk0KsqpFRDdpLZw_5_6">88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_GZme9a8CdEqKkGKLqw5uyA_6_3">1.12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_nOhfK6XpukOtt2AkSpp4vw_6_6">0.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life of option (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_EFswqIgXIEiI8NToyXtH-Q_7_3"> 4.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_pbYMhcsOUUiEHfclEiQpWw_7_6"> 4.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividends&#160;&#8212;</i>The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OzB6yYT9bUywRdLdEvW50w_cont1" continuedAt="Tb_OzB6yYT9bUywRdLdEvW50w_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation and Warrants&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility</i>&#8212;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The expected volatility assumption is derived from the historical volatility of the Company&#8217;s common stock over a period approximately equal to the expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate</i>&#8212;The assumed risk-free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected life of the option</i>&#8212;The period of time that the options granted are expected to remain unexercised. Options granted during the&#160;year have a maximum term of seven&#160;years. The Company estimates the expected life of the option term based on the weighted average life between the dates that options become fully vested and the maximum life of options granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">immediate vesting,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in full on one-year anniversary date of grant date,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">half vesting immediately and remaining over three&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarterly over three&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">annually over three&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-third immediate vesting and remaining annually over two&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-half immediate vesting and remaining over nine&#160;months,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-quarter immediate vesting and remaining over three&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-quarter immediate vesting and remaining over 33&#160;months,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monthly over one year, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monthly over three&#160;years.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2021 and 2020, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_EmployeesAndDirectorsMember_nY8Xr06tV0aNNWlTT_5fvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Y_UbxepkC02o8bb0P4dwxQ">2,260,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_EmployeesAndDirectorsMember_LECQK4-VqUWq2chzZjdaUA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_oNqgch1AgUeH38hMZ4KqHw">1,540,000</ix:nonFraction> options to employees and directors having an approximate fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_VjXYAcDWp02HBkXd6GYVAg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_sOww47jwpk-IfArdfzIPGQ">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_ombmDTe2AkCAbJcUoj-n9g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_mvPKb3dsRk2kTAA6gjw2jQ">0.4</ix:nonFraction> million based upon the Black-Scholes option pricing model, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees for the&#160;years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_MCFQsLEw-UuxHL58RoxInQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_cfjj2XwhJ0CLySnBl5Iqew">204,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_-3VYIo1Se0a3VB9LflrxFQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_uzKkOATCfEa_2pSSTBobWg">213,000</ix:nonFraction>, respectively. Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to consultants for the&#160;years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_eQmeAnrjzk6zi6wV_bY3hg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_dM6LRrYPa0urcgeN9nbC3w">212,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_thyNdGbiIUKfEg211NQAxQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_BgLB95JHKEKKaM-ZwFc3kw">137,000</ix:nonFraction>, respectively.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9bb2de86_f7ae_48c1_9a98_c43322e2a7d8"></a><a id="Tc_ijs3q5s8B0Gl7xyZrFg6LA_1_4"></a><a id="Tc_5z2JRNI6cE2Z_PqgRDiL-A_1_7"></a><a id="Tc_e8PHxt1f1Eyi_7VCps9EkA_1_9"></a><a id="Tc_k_-dC82srkq9RhwNn8mZlA_2_4"></a><a id="Tc_u4mUFbST0kqTxX1InXgnJg_2_7"></a><a id="Tc_yFJVRV1M60OeqGWNf1H9sw_2_9"></a><a id="Tc_mp2IoILLP0S2IfK9lVWWQg_3_2"></a><a id="Tc_Pv5ieutk7kqSzLjEST0fLg_3_4"></a><a id="Tc_6qqwst0OtECyVmDEcRr4eQ_3_7"></a><a id="Tc_BCmS-7XMekiEvJXo5F7WUg_3_9"></a><a id="Tc_trHeys7zxEef3neo-Re-KQ_4_0"></a><a id="Tc_nNYDvThcmEKi35lZ755xxQ_4_4"></a><a id="Tc_g8Qb_Pkmu0yeFFQo8Ga_zQ_4_7"></a><a id="Tc_Mx2rGjA4OkyE-116QanUlw_4_9"></a><a id="Tc_C5oppFIvy0irq0WHPFN-Eg_6_0"></a><a id="Tc_OFCSMSuDAEqGm1xGPFox9Q_7_0"></a><a id="Tc_WpmRj95TcUGiUFBM7gJtoQ_7_2"></a><a id="Tc_YSk1q5EfTEy_5CPtSZQVNA_7_5"></a><a id="Tc_Pb2VXO8AEkqKPwdmCf_sXQ_8_0"></a><a id="Tc_10jUiliUK0SuqgEOao_O0g_9_0"></a><a id="Tc_blpiKFZGAkKrEUnTbhy94A_10_0"></a><a id="Tc_ssc4UDwx-Eif6Kq2FplhdQ_10_7"></a><a id="Tc_MIIHJlPCUkyCZwPAX1UtUw_12_0"></a><a id="Tc_2LjFBl2LdE6OqYVjj09E6g_13_0"></a><a id="Tc_OsyOhmtpkUuEliY78F1uMA_13_2"></a><a id="Tc_SID5HV2e1kqNU05nCN8G1Q_13_5"></a><a id="Tc_JeZOQDScO0yEEVGFZhG7uA_14_0"></a><a id="Tc_6nOjm-Pu4kiZKKp5SfzxOw_15_0"></a><a id="Tc_gTy0XOlMpU2obep2T-bt0g_15_2"></a><a id="Tc_pA5ojeRsLk2aJopochLwmA_15_5"></a><a id="Tc_bqdK4db2TUu8CL0WkwB3qw_17_0"></a><a id="Tc_sro6H33XJ02llghtzfG4fg_17_4"></a><a id="Tc_j1zat6QUD0-QDdc7hccKxA_17_7"></a><a id="Tc_TwDQGhiaw0avFhq1WMOu4g_17_9"></a><a id="Tc_Z4sAfLtYHkG3fVY-plcnDA_19_0"></a><a id="Tc_5S9nd1z8u0m4bcHVaNSf6Q_19_4"></a><a id="Tc_TZayjZzw80i1eU-9qcKdiw_19_7"></a><a id="Tc_O9GoWrOe0EGifkHI58fa5A_19_9"></a><a id="Tc_aZH0AMi75Ey5iFZ3l6AAGQ_21_0"></a><a id="Tc_4p0MQDm0hk-KixoPt2bJuA_21_4"></a><a id="Tc_57dg9J72P0qsKStQ_45KOA_23_0"></a><a id="Tc_TRhvWQbAtU6FnlEfEesMAA_23_4"></a><a id="Tc_RpuTCw46U0Cqyr-uSv_2yA_25_0"></a><a id="Tc_D4bDSBJ30EC3N-RKmfYzQg_25_4"></a><a id="Tc_e6s-Y5azB0uuyKQUInwlbw_27_0"></a><a id="Tc_P1MTMAf3P0aLTTqIETejrw_27_4"></a><a id="_ced30d78_ad4b_4f7e_8a2c_fd66c635994a"></a><a id="Tc_eDCPvFvWvkmFC0tAlxp77w_1_0"></a><a id="Tc_9x7IIEnIvEyfrzAYQhmJTg_1_10"></a><a id="Tc_0rt4Wb_aRUa9lvSOBiIv5g_2_8"></a><a id="Tc_ALK8xHKdQES5xMQlD-m0LQ_2_15"></a><a id="Tc_YMEgP_IKMUmhZX4mZ0oeAQ_3_5"></a><a id="Tc_-NzLgFiLOEmCObyZG-aAbA_3_8"></a><a id="Tc_upROfP8en0-AvqUvPfK3KA_3_12"></a><a id="Tc_o9A4c-2CPkeZAQRfok3iFw_3_15"></a><a id="Tc_YQHI-rHxLkWnViK1eThqWg_4_5"></a><a id="Tc_q4QfGME_ekOjAFwwKB5owQ_4_8"></a><a id="Tc_SzDv5OghhUmaM4phDy67eQ_4_12"></a><a id="Tc_6uyLO41Eo0WsXpmz14orOw_4_15"></a><a id="Tc_wfcqql_9VE2wUB8ddo6B6A_5_0"></a><a id="Tc_lFFxquKzCUyBeJ7tVIXXZQ_5_5"></a><a id="Tc_HvnFgRVWt0WklS9UDJN3ag_5_8"></a><a id="Tc_nhsuZw8i-kK5gRLWCJ8sJA_5_12"></a><a id="Tc_2GGZo7ahDUOxj7llcA7UEg_5_15"></a><a id="Tc_PuUk0yytz0in9rrVhq0XIQ_6_0"></a><a id="Tc_dpKKOeApfkSeg-YiGUVyvw_6_3"></a><a id="Tc_mRtyVbacYEWCwtCxfy9kaw_6_5"></a><a id="Tc_GQcWj0QyKUu-BqeJrszUww_6_8"></a><a id="Tc_-zQgWe1x90mV3GpRIJuQJw_6_10"></a><a id="Tc_E-YXHHwRRUCtOQjTxCBrJw_6_12"></a><a id="Tc_dAWAEX9lUUyHkCpUGThf_g_6_15"></a><a id="Tc_Pqn3Jde0xEu-_MmZssy40g_7_0"></a><a id="Tc_fJKg6q5We0qtlmY0YPbxeQ_7_1"></a><a id="Tc_q6cOCnEmME2JFji0brpyWA_7_5"></a><a id="Tc_-Y7YGAk85USNF6s-zaiP1w_7_12"></a><a id="Tc_9FDHZ3FGtUe1HJIgfSjUOw_8_1"></a><a id="Tc_unCogWHG3E25oYlB_ocE6w_9_1"></a><ix:continuation id="Tb_OzB6yYT9bUywRdLdEvW50w_cont2" continuedAt="Tb_OzB6yYT9bUywRdLdEvW50w_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation and Warrants&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_ahDpXAPfKkKDqESChoyS-A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of stock option activity for the&#160;years ended December&#160;31, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;Exercise&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;- December&#160;31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZD4aLXU3F02Cocoebc69mg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_oHNQs1KiCkSP_9yBAZYuQw_4_2">2,502,012</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZD4aLXU3F02Cocoebc69mg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ldwP4oNo5UyWLcXEMqJwKA_4_5">3.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TmfP0gKxNEy5KmAuY3LXKg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_69XuosZf3UyKO0DJKZ75Yw">6.51</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZD4aLXU3F02Cocoebc69mg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_JipiAMUuUkm4SC6tVXT_-g_4_10">153,353</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_Fj3wExvBYEKh67Z-Z97d2A_6_2">1,540,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_dxezlVwA1kCT394t3WAfkg_6_5">0.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_zv-Dc9hWTESCGbWbRz-7bQ_8_2">14,944</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_6IeSf0hEG0GcF_lVmIILLQ_8_5">17.57</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_Mc_QKL3CjEa-iJVDe8AFyA_9_2">29,650</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_h6kl8F4LmkSNk-ICf9iePA_9_5">0.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;- December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zVfa8-ihl0GXFzR6eyN9PA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_5IE7lGplb0ija8o78dZhQQ_10_2">3,997,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zVfa8-ihl0GXFzR6eyN9PA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_nWLaDcbB0U2Z4lOfnfXlqw_10_5">2.35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_bERT4HlK3U2ciwl5KQ-DCQ">6.09</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zVfa8-ihl0GXFzR6eyN9PA" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_5xqisTb4p0CrPmfuBtMJCA_10_10">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_GQQ8GbidGEazpTfYeXBlig_12_2">2,260,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_pw8nWhY5DUGlqVt0gPAsTw_12_5">0.33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_6640NelleUKDI-fCATvMyQ_14_2">2,143</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_10hzyPzfuE22J4pHIimV2A_14_5">45.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;-December&#160;31, 2021&#160;- outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_E2nq_Mpr7UuZ4fSz1HFx9g_17_2">6,255,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_YozHlz10cke5cey8EBePQw_17_5">1.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Narr_LXLUIAQY-EmDGEsixmZZlg">5.58</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA" decimals="0" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_-Nz8wISEEEiIll5y61KAKQ_17_10">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;-&#160;&#160;December&#160;31, 2021&#160;- exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_UOyXXa0sQEWJjVQNeLuzVQ_19_2">2,786,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_lrwN7YC3SkCHUhiFdw-Ysw_19_5">3.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Narr_6JyXbOlYPEOHtajyNrF0_g">4.44</ix:nonNumeric> years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA" decimals="0" format="ixt:zerodash" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_g_tPCyG5ik2Ax2415XWIPA_19_10">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grant date fair value of options granted&#160;-&#160;December&#160;31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" scale="0" id="Tc_KCsu1GF5I0aY4tP2pMeSRQ_21_5">501,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average grant date fair value - December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_vsXptH1V5kWfHGr0XbvWQQ_23_5">0.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grant date fair value of options granted&#160;- December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" scale="0" id="Tc_oOoO5cgQYEep--0R7jT6EA_25_5">412,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average grant date fair value&#160;- December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_LdN10xj7K0mT16bR4jdqcg_27_5">0.27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="Tb_ekeerMJojEaW8nL8D5j_Uw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The options outstanding and exercisable at December&#160;31, 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;width:62.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:24.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr__QXyRCpDNUumXYhmaDeQNw">0.00</ix:nonFraction>&#160;&#8211;&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_ReietgNrxEyCeAkUzQLkFg">40.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_E7peh95PLUyujO5n6s3eeg_7_3">6,189,257</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_kbUhLz0-gEGFnZxCUp1XbQ_7_6">0.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_WvvWmsUv0Uaoe2yHQ6yQuw_7_8">6&#160;years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_Q7X4EdRA2UCbsjQH-73Vbg_7_10">2,720,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_uysMCWBGvkWxE-sfPIF0oQ_7_13">1.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_NMS1ZuIwD0quS7AWjHTKew_7_15">4 years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_BDKxrCiyPEemGzKIT-tg0A">41.00</ix:nonFraction>&#160;&#8211;&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_2mfJfAFcWEGEsKomcMH3MA">70.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_FIDD4yEQZEa0yHr2yGmx-w_8_3">6,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_mjl8Qzfmr0K92rns0_-J9g_8_6">52.07</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_GSJrzI_RWk2lGlGoXZ8KeQ_8_8">2&#160;years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_srBzGC9ZgkOiVQ5XhZByJA_8_10">6,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_0BDIl7dE7kKizgWmKuhhPA_8_13">52.07</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_1Pkwg2WP6kWmt17G3-51jg_8_15">2&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_H5XQFVEHj0SokMHSuZCbEA">71.00</ix:nonFraction>&#160;&#8211;&#160;$<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_cDfS6GVcIUez-cDu8Lvp0A">102.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_1O_4pCuXRkSMi5wDsBJNDQ_9_3">59,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_y25Jebn4hESetTL0tZAmjw_9_6">85.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_Z0JWz4QyZk--dmo8NDwS6A_9_8">2 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_WncmHUtmSki7web6Ilqwvg_9_10">59,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_XnojmG17XEWIqP9TSsbrPw_9_13">85.19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Tc_DZq_-dATtkaIaLevNHgW8g_9_15">2&#160;years</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, total unrecognized stock-based compensation expense related to stock options was $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_mn3TepQ9SEqXexXzb82kfQ">771,000</ix:nonFraction>, which is expected to be expensed through February 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FASB&#8217;s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits in 2021 or 2020. Cash received from option exercises under the Company&#8217;s stock-based compensation plans for the&#160;years ended December&#160;31, 2021 and 2020 was <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_1XgdCm0r80qHNt-NhD8z_g"><ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_fZLxkREZHkyFxhHMi4Ak9g">zero</ix:nonFraction></ix:nonFraction>.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OzB6yYT9bUywRdLdEvW50w_cont3" continuedAt="Tb_OzB6yYT9bUywRdLdEvW50w_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation and Warrants&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October&#160;15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_10_15_2018_To_10_15_2018_XRwkhJ_Dmk-8YpsoxAckVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_2L3ihd4lYESQg-7YBNiMCw">18.6</ix:nonFraction> million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_e0SFi2g7CEyrvY0QNpCI5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_YTEbpq32xU68dDmrpIT8dQ">2,520,000</ix:nonFraction> Class&#160;A Units (the &#8220;Class&#160;A Units&#8221;), with each Class&#160;A Unit consisting of one share of common stock, and one <ix:nonNumeric contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_ClassOfWarrantOrRightAxis_syn_OctoberTwoThousandEighteenWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_syn_UnderwrittenPublicOfferingMember_Kff7vF4eSUKF3WYZhsclQg" format="ixt-sec:durwordsen" name="syn:WarrantTerm" id="Narr_gkIciZ7VvkeVQ5mfGBbueg">five-year</ix:nonNumeric> warrant to purchase one share of common stock at an initial exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_10_15_2018_zFSd_b_S1kyXW8-66Kwglw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_ZHuTyDzbsUOqQmZJizCNwA">1.38</ix:nonFraction> per share, which subsequently was reduced to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_10_15_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_h58kDK3e0kC9mHm8SZusWg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_QwV6otMEXU-iCrGppiPTDg">0.69</ix:nonFraction> per share (each a &#8220;Warrant&#8221; and collectively, the &#8220;Warrants&#8221;), with each Class&#160;A Unit to be offered to the public at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M20NXTQpLkugL1IJr-5fEg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_uwBzHXPspEyGojRk3uSSEw">1.15</ix:nonFraction>, and (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_IfsKKTpoWkaVjjV1uYXCvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_BXVQ62H75kSVJ7Jt6OWkgQ">15,723</ix:nonFraction> Class&#160;B Units (the &#8220;Class&#160;B Units&#8221;, and together with the Class&#160;A Units, the &#8220;Units&#8221;), with each Class&#160;B Unit offered to the public at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_s-Pfj2QNzkqM0zSeb9teSw">1,000</ix:nonFraction> per Class&#160;B Unit and consisting of one share of the Company&#8217;s Series&#160;B Convertible Preferred Stock (the &#8220;Series&#160;B Preferred Stock&#8221;), with a stated value of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Narr_aOHwdsbD4kum5UwGbUYGOw">1,000</ix:nonFraction> and convertible into shares of common stock at the stated value divided by a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA" decimals="2" format="ixt:numdotdecimal" name="syn:PreferredStockConversionPricePerShare" scale="0" id="Narr_Vii7w5OLRECSSBhwz4YmcQ">1.15</ix:nonFraction> per share, with all shares of Series&#160;B Preferred Stock convertible into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_PZVzHfhXukyP8arICYeFSQ">13,672,173</ix:nonFraction> shares of common stock, and issued with an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_3Kn9Wj-M-U2EBcPcpa_-tA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_8lWUmtG5xkCcU0yUD3s9gA">13,672,173</ix:nonFraction> Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 16, 2020, the exercise price of the Warrants was reduced from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_11_16_2020_CZ8bHk5Mp0ir4tpe8uIf9A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_HnvnQD8RUU2qsZ7O6XMAfQ">1.38</ix:nonFraction> per Warrant per full share of the Company&#8217;s common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_11_16_2020_CZ8bHk5Mp0ir4tpe8uIf9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_xw46pZjdCEempCcUWPw9WA">0.001</ix:nonFraction> par value per share (the &#8220;Common Stock&#8221;), to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_11_16_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_JKnuxTVzpU26lxfBbgZZXg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_lbajP5BeZkOuNvMawBkf3A">0.69</ix:nonFraction> per Warrant per full share of common stock in accordance with the anti-dilution terms of the Warrant. The reduction was the result of the issuance of shares of common stock by the Company through its &#8220;at the market offering&#8221; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_1_2020_To_12_31_2020_7WfemUuB9kSDPnEwicRDoA" decimals="-5" format="ixt:numdotdecimal" name="syn:WarrantExercisePriceAdjustment" scale="6" id="Narr_8Jdn1XnXT0SzCHnubTbPQw">0.9</ix:nonFraction> million during the year ended December 31, 2020, which reduces the income available to common stockholders. In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the &#8220;Underwriters&#8221;), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the &#8220;Over-allotment Option&#8221;) to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_11_16_2020_To_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_IPq28Mt1gUW_3j_-pwfbiQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_jaGXcOuRv0igUngecr7oGg">2,428,825</ix:nonFraction> shares of common stock and/or additional Warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_AwBR-gCbEkOKHtktUYXQIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_RV5Hp7g-qE-T5j8ztHpkMA">2,428,825</ix:nonFraction> shares of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_AwBR-gCbEkOKHtktUYXQIA" decimals="0" format="ixt:numdotdecimal" name="syn:IssueOfWarrantsToPurchaseCommonStock" scale="0" id="Narr_zc9ayfdCMUiN9XLJklq8ew">1,807,826</ix:nonFraction> shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the Warrants may only be exercised through a cashless exercise. <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_lFLYRnJu9E6DTZmBZSMdfA">No</ix:nonFraction> fractional shares of common stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations. During the year ended December 31, 2021, <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_UcLPi0nU_k-Nrovhui30Ew" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr__jLfWkniGUKmvCqvOm8IDw">11,655,747</ix:nonFraction> warrants were exercised for cash proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" id="Narr_VZb2ZhIP2kCP3sPBWDIruQ">8.0</ix:nonFraction> million. There were <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_12_1_2020_To_12_31_2020_7WfemUuB9kSDPnEwicRDoA" decimals="0" format="ixt-sec:numwordsen" name="syn:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Narr_vH4ibFVnYUOdcGuSYCcPRA">no</ix:nonFraction> warrants exercised during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 18, 2016, the Company completed a public offering of <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MDjl32aA7Eup2n9x0SL85A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_PMrq28eTX0u_v5YuyzPztQ">714,286</ix:nonFraction> shares of common stock in combination with accompanying warrants to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_11_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_cCtXQSarIUqWy1ntHvFVqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_7Ms034dmeEWd7HGw3JQ2cg">1,428,571</ix:nonFraction> shares of the common stock. The stock and warrants were sold in combination, with <ix:nonFraction unitRef="Unit_Standard_item_yMnlz8fE9U-5tR1qkqQKuA" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_qr4fxMiyiEuZKSyigooSJg" decimals="INF" format="ixt-sec:numwordsen" name="syn:NumberOfShareSold" scale="0" id="Narr_Qqs6VbDSLEeV6kIgVl7wMg">two</ix:nonFraction> warrants for each share of common stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase <ix:nonFraction unitRef="Unit_Standard_item_yMnlz8fE9U-5tR1qkqQKuA" contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_MCMoFtcreUerjsPb8Xr3IA" decimals="INF" format="ixt-sec:numwordsen" name="syn:NumberOfSharesPurchase" scale="0" id="Narr_wWv6aFuqnUiDrW_bs-FY1Q">one</ix:nonFraction> share of common stock. The purchase price for each share of common stock and accompanying warrants was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_puysgE2QRkquEuEWCphmDg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Ra0eMw1W6EiloarJ5xfxQQ">35.00</ix:nonFraction>. The shares of common stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_11_18_2016_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_us-gaap_SeriesAMember_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_JdtyyC7Z80SCunUZpuqFNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_J60vI-BzGEaFRuBVTyZtbQ">50.05</ix:nonFraction> and the per share exercise price of the Series B warrants is $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ZxaIHv3whUOoORl_cB5qNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_i7suSosfpkKWl627h7EQpQ">60.20</ix:nonFraction>, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants could be exercised at any time on or after the date of issuance. The Series A warrants were exercisable until the four-year anniversary of the issuance date and expired November 16, 2020. The Series B warrants expired December 31, 2017 and none were exercised prior to expiration. The warrants included a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tO6QgfwYmUKrmumFN_QdXw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_WBJ745ghREG2loX8_m6mvg">15.7</ix:nonFraction> million and changes in estimated fair value were recorded as non-cash income or expense in the Company&#8217;s Statement of Operations at each subsequent period. At December 31, 2019, the fair value of the warrant liability was $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ZNP2PWLgIUK7spcejRs3hQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="6" id="Narr_qXdzunkkDEm433x2xJ4vwQ">100</ix:nonFraction>. The warrants were valued on the date of grant and on each remeasurement period.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1a705381_f51e_4f5b_82a1_cff52fdc63d3"></a><a id="Tc_dKlpRbqMmke2pUKuUQ33gQ_1_2"></a><a id="Tc_Fc9i2HWMCEyyTy5okvJisQ_1_4"></a><a id="Tc_PQLgYwvFTkm_qEwZzCGPDg_2_2"></a><a id="Tc_u9oUb9JYZk-kYTNSv0qk8g_2_4"></a><a id="Tc_PZzSvamXzE6pGIpStVz0YA_3_0"></a><a id="Tc_YbRt2v58DUWUgIdppMYEEA_3_4"></a><a id="Tc_H0kVrZgatk-mA1nhSLNqIg_4_0"></a><a id="Tc_LjF7-B67kkW-SrvFqxPbeQ_4_2"></a><a id="Tc_2baDOh0EJkuuE3ILihU5JQ_4_5"></a><a id="Tc_6KMDy1vbo0KGndFDfSUDCg_5_0"></a><a id="Tc_R-0ohYAzoke2r4FcQoSzBw_5_2"></a><a id="Tc_DYa3ZbAKQUmXHuqtKGHXUg_5_5"></a><a id="Tc_MzRJs3CTcU6TTU-QKgVZcw_6_0"></a><a id="Tc_fqK8-XBQfkqvhWLaGC_ERw_7_0"></a><a id="Tc_Il2AcA4w4EumwNPgEQnnfQ_8_0"></a><a id="Tc_E8uVwQx8zESShWjSv_zlJw_8_2"></a><a id="Tc_BmwxuZ_-1keI79b0hHek4g_8_5"></a><a id="Tc_bkNkGojJKUuty3_3cczfWQ_9_0"></a><a id="Tc_lBp87uohS0WNPdP6EdWuEQ_9_5"></a><a id="Tc_Zj4p4e43k0SZK0WSiiRvMA_10_0"></a><a id="Tc_MHtalBBQYkyAJ6T7HKssng_10_2"></a><a id="Tc_ujNCu9JefEuC7nvcREkEOw_11_0"></a><a id="Tc_vhOmqgYoGUewFY-cIsFg4A_11_4"></a><a id="_d345d53c_a875_4573_bac4_55466a9685d9"></a><a id="Tc_0U9DUotiXEWbi3mW2doBbw_1_7"></a><a id="Tc_VdXOGDQqfEeJTsjC8Q47QA_2_3"></a><a id="Tc_42_MOSZyw0y-WAwHR9DEPA_2_5"></a><a id="Tc_-bWl6AEE10Gss_5xdAah7w_2_7"></a><a id="Tc_qT7gbOlwbkSnOJjZAdFDPg_3_0"></a><a id="Tc_XTAE-1ePcEW5RdstfAp3yw_3_3"></a><a id="Tc_bNF8mWgQjk-eNdMAn-Fk9g_3_5"></a><a id="Tc_G0_tP4Ezl0KtD4hwXs9l9g_3_7"></a><a id="Tc_Xu0PaC6ajk2MHZdFPt6mMw_4_0"></a><a id="Tc_On3OxzahAEWUs0QtZGvsfw_4_7"></a><a id="Tc_ItSVrwwPC0CxvdTJz6fEYA_5_7"></a><a id="Tc_nM0zkUIqgkSX5G-7xkjBvA_6_0"></a><a id="Tc_OP89vzGLwU2VgVf57hn9Zg_6_7"></a><ix:continuation id="Tb_OzB6yYT9bUywRdLdEvW50w_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation and Warrants&#160;&#8211;&#160;(continued)</b></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:ScheduleOfWarrantActivityTableTextBlock" id="Tb_fPhtjdK-802y68LgEDh9OA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of all warrant activity for the Company for the years ended December 31, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_EJ-tdWfqn06pCTbI_UrUfQ_3_2">18,714,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_3ImM-U5nIkCFETfqd_4QrQ_3_5">3.24</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_42ZBNmi9n0y0u57lqsMHLw_6_2">714,286</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_E7GRbNDUUEmfWoiIpM1RbA_6_5">50.05</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_4LqABqzzTU6VBtO5glGdKA_7_2">18,000,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_xdxjRfQncUOu05B408e56Q_7_5">0.69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="INF" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" scale="0" id="Tc_eyNufAgL2UyA6tv3G3XkEw_9_2">11,655,747</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_SBEZ6Pg_WkyfgmWx8TybNQ_10_5">0.69</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_jnZl_Ns4PkKrwJuW70ds3Q_11_2">6,344,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_yoMpj6VAtUGvacX6zR7dEg_11_5">0.69</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 26, 2017, the Company entered into a consulting agreement for advisory services for a period of six months. As compensation for such services, the consultant was paid an upfront payment, is paid a monthly fee and on January 24, 2018 was issued a warrant exercisable for <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_26_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_MzByem4-e0OSJosV2hHEFA" decimals="INF" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" scale="0" id="Narr_jqglhGKfJECKg5_E27l21g">714</ix:nonFraction> shares of the Company&#8217;s common stock on the date of issue. The warrant is equity classified and the fair value of the warrant approximated $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_26_2017_V_Q0QMOYikCPg8S4qD1ovg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="0" id="Narr_faWvjMcoxEqdC1C55Mm9cg">9,000</ix:nonFraction> and was measured using the Black-Scholes option pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A summary of all outstanding and exercisable warrants as of December 31, 2021 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" id="Tb_aIi27KZCE0GMYwq-ygxv_A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_nGWIzttATUuENHWAb_1Gxg" decimals="2" format="ixt:numdotdecimal" name="syn:WarrantsExercisePrice" scale="0" id="Tc_hned9R1FBU2-8uY1XxGymA_4_1">0.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_Qfjmc-RTiEuH6kugXZ51Iw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_0ZLWtkrP6USCA-5zpFpMug_4_3">6,344,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_Qfjmc-RTiEuH6kugXZ51Iw" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" scale="0" id="Tc_wUdp4MkJFECxFYUqTMoDTQ_4_5">6,344,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_nGWIzttATUuENHWAb_1Gxg" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="Narr_F_12Spjzp0WMBbrXBXo9og">0.99</ix:nonNumeric>&#160;years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_mAkr-3jFnkW2bbxcAR8RYQ" decimals="2" format="ixt:numdotdecimal" name="syn:WarrantsExercisePrice" scale="0" id="Tc_L04kz6A_D0S9eJOp016Vjg_5_1">18.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_VMLlPD7ENUWWhTbFeid_mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_xR_s11cCT0uLmvFRMK88ng_5_3">714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_VMLlPD7ENUWWhTbFeid_mw" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" scale="0" id="Tc_wAPDFFXaA0y-NQBVGoRh3A_5_5">714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_mAkr-3jFnkW2bbxcAR8RYQ" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="Narr_KfzLZdWCvEGenlpnNMiWQQ">1.78</ix:nonNumeric>&#160;years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_Y6KWsIfrY0W-AXmu4z1SHg" decimals="2" format="ixt:numdotdecimal" name="syn:WarrantsExercisePrice" scale="0" id="Tc_G28xn7CwFUGxwR3iz9NlpQ_6_1">0.69</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_8CxCH8oNkEm74aCXq-VOTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_F2OqvpWyg0yDikAg-YwkJA_6_3">6,344,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_8CxCH8oNkEm74aCXq-VOTA" decimals="0" format="ixt:numdotdecimal" name="syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" scale="0" id="Tc_ZhbA4spmKUWwgqmEqJ9IwA_6_5">6,344,966</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_Y6KWsIfrY0W-AXmu4z1SHg" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="Narr_FC7fodRG3Uy2RfpAPXCX2w">1.78</ix:nonNumeric> years</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_6nUtADnyVkm5zRYI84HkFQ" continuedAt="Tb_6nUtADnyVkm5zRYI84HkFQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series B Preferred Stock </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_10_15_2018_To_10_15_2018_XRwkhJ_Dmk-8YpsoxAckVw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_9ApwoL6Y40ewsANyMhkp0A">18.6</ix:nonFraction> million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_e0SFi2g7CEyrvY0QNpCI5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ZDCqPVZxzU-NEYNNWvuVWw">2,520,000</ix:nonFraction> Class&#160;A Units, with each Class&#160;A Unit offered to the public at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_s7IXISQsS0a3OcfgiH0M5w">1.15</ix:nonFraction>, and (ii)&#160;<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_IfsKKTpoWkaVjjV1uYXCvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_IrmrsLzDC0KDc8Vw14UnYQ">15,723</ix:nonFraction> Class&#160;B Units, with each Class&#160;B Unit offered to the public at a public offering price of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Narr_XNQQ8Y4AMUCv2x96uOZciQ">1,000</ix:nonFraction> per Class&#160;B Unit and consisting of one share of the Company&#8217;s Series&#160;B Preferred Stock, with a stated value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_c76S7XkJfkCtVN9HcQFm2w">1,000</ix:nonFraction> and convertible into shares of common stock at the stated value divided by a conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA" decimals="2" format="ixt:numdotdecimal" name="syn:PreferredStockConversionPricePerShare" scale="0" id="Narr_LUqjwpu8_UixyIP-awzAgw">1.15</ix:nonFraction> per share, with all shares of Series&#160;B Preferred Stock convertible into an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="Narr_h_QHHL_U6keeI6LRzgPGLg">13,672,173</ix:nonFraction> shares of common stock, and issued with an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_I2ym8-ECqUmzrLIL8pB_FQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_at_aNXw8Lka6DBIg07Gsxw">13,672,173</ix:nonFraction> October&#160;2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series&#160;B Preferred Stock discount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October&#160;10, 2018, the Company granted the Underwriters a 45 day option (the &#8220;Over-allotment Option&#8221;) to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_10_1_2018_To_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_g8yBpnY3o0iFqkOSqvylXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_tUuCUNTda0qWemyb9m4SDQ">2,428,825</ix:nonFraction> shares of common stock and/or additional warrants to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_uAjHlff2ZEySANOAcEoi0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_uIfHZ9KlF0uD6dDH2dR_kQ">2,428,825</ix:nonFraction> shares of common stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_uAjHlff2ZEySANOAcEoi0A" decimals="0" format="ixt:numdotdecimal" name="syn:IssueOfWarrantsToPurchaseCommonStock" scale="0" id="Narr_isoltVok2kCoYQbpc0rlkg">1,807,826</ix:nonFraction> shares of common stock.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6nUtADnyVkm5zRYI84HkFQ_cont1" continuedAt="Tb_6nUtADnyVkm5zRYI84HkFQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Stockholders&#8217; Equity &#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The conversion price of the Series&#160;B Preferred Stock and exercise price of the October&#160;2018 Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the common stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, the exercise price of the Warrants was reduced from $<ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_11_16_2020_To_11_16_2020_84bpVptC1E-TU2cJmJR7uQ" decimals="2" format="ixt:numdotdecimal" name="syn:PreferredStockSharesConverted" scale="0" id="Narr_8wtl7w_n1kGekwItAHF9_w">1.38</ix:nonFraction> per Warrant per full share of common stock to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_11_16_2020_To_11_16_2020_84bpVptC1E-TU2cJmJR7uQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPriceDecrease" scale="0" id="Narr_36OqUkrCGkO0MxCfR4_gfg">0.69</ix:nonFraction> per Warrant per full share of common stock. The reduction was the result of the issuance of shares of common stock by the Company through its &#8220;at the market offering&#8221; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend in accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_11_16_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CBpL-RLdCE6YnRWt9ySuKg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDiscountOnShares" scale="6" id="Narr_fJt-5quDj0m8CqBf_FgVZA">0.9</ix:nonFraction> million, which reduces the income available to common stockholders for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The October&#160;2018 Warrants are immediately exercisable at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B1Z-wDViY0io9Y60hJ5IyQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_OPHNKrM4qUGICwo9lOIn_g">0.69</ix:nonFraction>  per share of common stock (which was <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_3SlaVldlt0uuxM4dd8Zq4g" decimals="2" format="ixt:numdotdecimal" name="syn:PercentageOfIssueOfThePublicOffering" scale="-2" id="Narr_1B5tMBsgJkCwxb9qIufaew">120</ix:nonFraction>% of the public offering price of the Class&#160;A Units) and will expire on <ix:nonNumeric contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_3SlaVldlt0uuxM4dd8Zq4g" format="ixt:datemonthdayyearen" name="syn:InvestmentWarrantsExpirationDate1" id="Narr_xI9uvhHlYEqyMaszkAzX2w">October&#160;15, 2023</ix:nonNumeric>. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October&#160;2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October&#160;2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (&#8220;BCF&#8221;) at the issuance date. Because the Series B Preferred Stock has <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_Cwqe83tdOUusRZp-w4iEKQ">no</ix:nonFraction> stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#8220;deemed dividend&#8221; and impacts earnings per share. During the years ended December 31, 2021 and 2020, <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="INF" format="ixt:numdotdecimal" name="syn:PreferredStockSharesConverted" scale="0" id="Narr_XZzyZudR6Uy3M8ht5kPPwg">3,973</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="INF" format="ixt:numdotdecimal" name="syn:PreferredStockSharesConverted" scale="0" id="Narr_CJp3ByQs8U6YrxwRfR_7qw">3,665</ix:nonFraction> shares, respectively, were converted resulting in the recognition of deemed dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_XT6XJ5XjDUuV4c_EGi70aw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDiscountOnShares" scale="6" id="Narr_tUfDCahkvU-DO48L0kzNpQ">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockRedemptionDiscount" scale="6" id="Narr_2z-44B1B70CI83pKnhX5dg">1.4</ix:nonFraction> million, respectively, for the amortization of the Series B Preferred Stock discount upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series A Preferred Stock </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;11, 2017, the Company entered into a share purchase agreement (the &#8220;Purchase Agreement&#8221;) with an investor (the &#8220;Investor&#8221;), pursuant to which the Company offered and sold in a private placement &#160; <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_5WO4v6359U6n6BT9EUOLpA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_SqMMpJ1I0kCEL9dgFJT9gg">120,000</ix:nonFraction> shares of its Series&#160;A Convertible Preferred Stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-JYGHuWq50WFYfi0Zl8OPg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_0lIyfE6nNkamm3IhzwnmKA">0.001</ix:nonFraction> per share (the &#8220;Series&#160;A Preferred Stock&#8221;) for an aggregate purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_5WO4v6359U6n6BT9EUOLpA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="6" id="Narr_-eFqaO1uK0e1arMK65EpDw">12</ix:nonFraction> million, or $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_5WO4v6359U6n6BT9EUOLpA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" scale="0" id="Narr_Zq-rmADA6kernY_JTLo0Tg">100</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Series&#160;A Preferred Stock ranks senior to the shares of the Company&#8217;s common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series&#160;A Preferred Stock are entitled to a cumulative dividend at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_sv_0fuv8bkWCrP44DfdJ4Q"><ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_qICuPUhDHUiU_z9QXsa8Cg">2.0</ix:nonFraction></ix:nonFraction>%&#160;per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series&#160;A Preferred Stock classifying the Series&#160;A Preferred Stock. The Series&#160;A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Y8P_QWYzfky5T_au5O14bg" decimals="2" format="ixt:numdotdecimal" name="syn:PreferredStockConversionPricePerShare" scale="0" id="Narr_cKo9zDJbXkmXwBqQt6A0FA">0.54</ix:nonFraction> per share which was increased to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPriceIncrease" scale="0" id="Narr_UrFERw4LBE2dwcPhJ63Zbw">18.90</ix:nonFraction> after taking into account the 2018 reverse stock split, subject to certain customary anti-dilution adjustments, and was decreased to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_27_2021_To_1_27_2021_DAGJFo-tVEioslNEUzr8Og" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPriceDecrease" scale="0" id="Narr_koU4Knk8QEGcmOznEBr1-A">1.50</ix:nonFraction> on January 27, 2021, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any conversion of Series&#160;A Preferred Stock may be settled by the Company in shares of common stock only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The holder&#8217;s ability to convert the Series&#160;A Preferred Stock into common stock is subject to<ix:nonNumeric contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g" name="us-gaap:ConvertiblePreferredStockTermsOfConversion" id="Narr_g95RbpFJwEeMr401N9jP9g">(i)&#160;a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii)&#160;if so elected by the Investor, a 4.99% blocker provision that will prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#8217;s common stock or voting power at any time, and (iii)&#160;applicable regulatory restrictions. </ix:nonNumeric></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6nUtADnyVkm5zRYI84HkFQ_cont2" continuedAt="Tb_6nUtADnyVkm5zRYI84HkFQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Stockholders&#8217; Equity &#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series&#160;A Preferred Stock are entitled to a preference on liquidation equal to the greater of (i)&#160;an amount per share equal to the stated value plus any accrued and unpaid dividends on such share of Series&#160;A Preferred Stock (the &#8220;Accreted Value&#8221;), and (ii)&#160;the amount such holders would receive in such liquidation if they converted their shares of Series&#160;A Preferred Stock (based on the Accreted Value and without regard to any conversion limitation) into shares of the common stock immediately prior to any such liquidation, dissolution or winding-up (the greater of (i)&#160;and (ii), is referred to as the &#8220;Liquidation Value&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Except as otherwise required by law, the holders of Series&#160;A Preferred Stock have no voting rights, other than customary protections against adverse amendments and issuance of&#160;<i style="font-style:italic;">pari passu</i>&#160;or senior preferred stock. Upon certain change of control events involving the Company, prior to the filing of the amendment to the Certificate of Designation for the Series A Preferred Stock described below, the Company will be required to repurchase all of the Series&#160;A Preferred Stock at a redemption price equal to the greater of (i)&#160;the Accreted Value and (ii)&#160;the amount that would be payable upon a change of control (as defined in the Certificate of Designation) in respect of common stock issuable upon conversion of such share of Series&#160;A Preferred Stock if all outstanding shares of Series&#160;A Preferred Stock were converted into common stock immediately prior to the change of control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On or at any time after <ix:nonNumeric contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g" name="us-gaap:PreferredStockRedemptionTerms" id="Narr_F03uxURHCkGyF6_57Szz0g">(i)&#160;the VWAP (as defined in the Certificate of Designation) for at least 20 trading&#160;days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6&#160;months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share of Series&#160;A Preferred Stock of $7,875.00, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&#160;A Convertible Preferred Stock or (ii)&#160;the five&#160;year anniversary of the issue date, the Company shall have the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Convertible Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Series&#160;A Preferred Stock was classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company&#8217;s control. Since the effective conversion price of the Series&#160;A Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is BCF at the issuance date. Because the Series&#160;A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#8220;deemed dividend&#8221; and impacts earnings per share. During the&#160;year ended December&#160;31, 2017, the Company recorded a discount of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_2eCFDmHGOUmlUJq481sbrQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDiscountOnShares" scale="6" id="Narr_hHH4I3s710K4LPzF9uE4fQ">6.9</ix:nonFraction> million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_BQ77y5ola0aDzP3L6mwvjg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_gHbpxdtHaEmrGywBykALbQ">2</ix:nonFraction>% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the years ended December 31, 2021 and 2020, the Company accrued dividends of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="Narr_yJgojw0cIE6v1Q383FXlEQ">24,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="0" id="Narr_Fde3pwTvkk6mBSAoecpm4Q">254,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 27, 2021, the Company filed an amendment to the Certificate of Designation for the Series A Preferred Stock to (i) lower the stated Conversion Price through September 30, 2021 and (ii) remove their change in control put. The Amendment to the Certificate of Designation for the Series A Convertible Preferred Stock (the &#8220;Certificate of Amendment&#8221;) that was filed with the Secretary of State of the State of Nevada adjusted the conversion price from $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_9_1_2021_To_9_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_k_-xpTQWD0GCQdXycMKDSg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPriceIncrease" scale="0" id="Narr_c2kP5wlCK0azV5GMjKmz-g">18.90</ix:nonFraction> per share to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw" contextRef="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bg6a5VAYZkmiWar8_qygxA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionPriceDecrease" scale="0" id="Narr__4u9Me0Am0G6zyAl96lgkA">1.50</ix:nonFraction> per share and removed the redemption upon change of control. The Company received notice from the holder of the Series A Preferred Stock that it was increasing the Maximum Percentage as defined in the &#8220;Certificate of Designation&#8221; from <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JT5YJdWctkSrgjj-7sNP_A" decimals="4" format="ixt:numdotdecimal" name="syn:BeneficialOwnershipPercentage" scale="-2" id="Narr_5H1NDCruUk-AbIEsNMw2hw">4.99</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_3_29_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_19H4jFVReE6xfC5K5cBF2g" decimals="4" format="ixt:numdotdecimal" name="syn:BeneficialOwnershipPercentage" scale="-2" id="Narr_c_I4k-ZkQ02jTp5Gz0xoyA">9.99</ix:nonFraction>%, such increase to be effective 61 days from the date thereof. The holder of the Series A Preferred Stock converted all of its shares of Series A Preferred Stock and there are no remaining shares of the Series A Convertible Preferred stock outstanding. During January and February 2021, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_2_28_2021_p7WYQOUTpUi11HMdW1VRjQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_m5QhZbikdEeBVy0Pm8dqsg">8,996,768</ix:nonFraction> shares of its common stock upon the conversion effected on such date by the holder of <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zR9PSAiA3US5NsG8x7-7Ww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Zs4eJ4DwXki9_bUnZdS9Lw">120,000</ix:nonFraction> shares of its Series A Convertible Preferred Stock. The fair value of the consideration issued to the holder to induce conversion was accounted for as a deemed dividend and increased net loss available to common shareholders for purposes of calculating loss per share. The Company estimated the fair value of the inducement consideration of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-5" format="ixt:numdotdecimal" name="syn:EstimatedFairValueOfInducementConsideration" scale="6" id="Narr_hl22SEoVW0GPRUooaeAzjg">7.4</ix:nonFraction> million and as a result recorded a corresponding deemed dividend of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-5" format="ixt:numdotdecimal" name="syn:EstimatedFairValueOfInducementConsideration" scale="6" id="Narr_WRbq2lZGvky-MZ-TMIFeCw">7.4</ix:nonFraction> million during the year ended December 31, 2021.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_6nUtADnyVkm5zRYI84HkFQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Stockholders&#8217; Equity &#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">B. Riley Securities Sales Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets &amp; Co. (now known as B. Riley Securities), which enables the Company to offer and sell shares of the common stock from time to time through B. Riley Securities, Inc. as the Company&#8217;s sales agent. Sales of common stock under the B. Riley Securities Sales Agreement are made in sales deemed to be &#8220;at-the-market&#8221; equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley Securities, Inc. is entitled to receive a commission rate of up to <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_8_5_2016_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_z5Ev0yENHUmoho2bPyB-eQ" decimals="3" format="ixt:numdotdecimal" name="syn:BrokerageCommissionPercentage" scale="-2" id="Narr_ovTm4IAHaUaS1V00g-FCyw">3.0</ix:nonFraction>% of gross sales in connection with the sale of the common stock sold on the Company&#8217;s behalf. For the year ended December 31, 2020, the Company sold through the B. Riley Securities Sales Agreement an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_vVcxs-TyVEOrQ1i7bBXI3A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_nYpUBxVfc0GUF_SOUtUV7w">9.3</ix:nonFraction> million shares of common stock and received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_ISVZPzMHc0Ggvc_ZgMPJ2A" decimals="-5" format="ixt:numdotdecimal" name="syn:ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" scale="6" id="Narr_dvOUVXgp7UK6VzNYebuIQw">3.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 9, 2021, the Company entered into an amended and restated sales agreement with B. Riley Securities, Inc. (&#8220;B. Riley&#8221;) and A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) in order to include AGP as an additional sales agent for the Company&#8217;s &#8220;at the market offering&#8221; program (the &#8220;Amended and Restated Sales Agreement&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the year ended December 31, 2021, the Company sold through the At Market Issuance Sales Agreement and the Amended and Restated Sales Agreement approximately <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_U6tWdREtxkuc90dTPJYBog" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_didrsbaOq0iuGc4TPeOqXQ">78.7</ix:nonFraction> million shares of the Company&#8217;s common stock and received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_U6tWdREtxkuc90dTPJYBog" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_lBKXl4UIwkej6HklIXvx-Q">66.0</ix:nonFraction> million.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:MinorityInterestDisclosureTextBlock" id="Tb_kHmI_Ep5jUeEYPVUDMNImw" continuedAt="Tb_kHmI_Ep5jUeEYPVUDMNImw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Non-controlling Interest</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;5, 2018, the Company entered into an agreement (the &#8216;Stock Purchase Agreement&#8221;) with Cedars-Sinai Medical Center (CSMC) for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#8220;Study&#8221;). The Study will provide further evaluation of the efficacy and safety of SYN-010, the Company&#8217;s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (<i style="font-style:italic;">M. smithii</i>) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In consideration of the support provided by CSMC for the Study, the Company paid $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_9_5_2018_To_9_5_2018_uBFbvYxH-EmzEpTcsw0I4Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Narr_0VqWvAopZEi6fNnj6A10jg">328,000</ix:nonFraction> to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (&#8220;IRB&#8221;) : (i)&#160;issued to CSMC <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_QYEqV_MK-kaCxh0ejQsXbA" decimals="0" format="ixt:numdotdecimal" name="syn:NumberOfCommonStockToBeIssued" scale="0" id="Narr_0HkxZ-GD7UGtAh38CmSq0A">50,000</ix:nonFraction> shares of common stock of the Company; and (ii)&#160;transferred to CSMC an additional <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYTAthCVn0yW8kcGh07aqw" decimals="0" format="ixt:numdotdecimal" name="syn:AdditionalNumberOfCommonStockToBeIssued" scale="0" id="Narr_eT6_dDueYkWq1KuWJpLG3w">2,420,000</ix:nonFraction> shares of common stock of its subsidiary SYN Biomics,&#160;Inc. (&#8220;SYN Biomics&#8221;) owned by the Company, such that after such issuance CSMC owned an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_QYEqV_MK-kaCxh0ejQsXbA" decimals="0" format="ixt:numdotdecimal" name="syn:NumberOfCommonStockToBeHeldByRelatedParty" scale="0" id="Narr_6md9QZ4JQE-vDABouCebew">7,480,000</ix:nonFraction> shares of common stock of SYN Biomics, representing <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_Ub1M_a5LVE-DkomejQsGNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_lZAwdmgDRkyXodK7UGrELg">17</ix:nonFraction>% of the issued and outstanding shares of SYN&#160;Biomics&#8217; common stock.&#160;The services rendered are recorded to research and development expense in proportion with the progress of the study and are based overall on the fair value of the shares ($<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_9_1_2018_To_9_5_2018_BLr1pn9j6UusGha5FDmjVw" decimals="0" format="ixt:numdotdecimal" name="syn:FairValueOfSharesIssued" scale="0" id="Narr_ERLBZo5mEkOpHtyoAvL9Tg">285,000</ix:nonFraction>) as determined at the date of IRB approval. During the years ended December 31, 2021 and 2020, research and development expense recorded related to this transaction approximated $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_U6tWdREtxkuc90dTPJYBog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_ajeZojSlH0GJFL-insIGIw">1,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_XdJgrqbMT0ShQF0kRBhn7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Narr_jOeEV_5gfkab94NVmyJBiQ">225,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Stock Purchase Agreement also provides CSMC with a right, commencing on the six&#160;month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of Common Stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 30, 2020, CSMC Medically Associated Science and Technology Program (MAST) formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment is completed.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_kHmI_Ep5jUeEYPVUDMNImw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Non-controlling Interest &#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed to following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. On September 30, 2020, CSMC (the Company&#8217;s SYN-010 clinical development partner) informed the Company that it discontinued the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients. During 2021, CSMC returned its shares of SYN Biomics to the Company. The Company&#8217;s interest in SYN Biomics is now <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_12_31_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_2hlEGz94m0y871onqyMQIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_sSBD-hkA8UaUvhXZzbvpkA">100</ix:nonFraction>%. &#160;This is reflected in the Consolidated Statements of Equity (Deficit).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s non-controlling interest is accounted for under ASC 810, <i style="font-style:italic;">Consolidation</i> and represents the minority stockholder&#8217;s ownership interest related to the Company&#8217;s subsidiary, SYN Biomics. In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#8217;s common stockholders in the face of the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of December&#160;31, 2020, the accumulated net loss attributable to the non-controlling interest was $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_lfF71se-CkmmyddDrmHIPQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="Narr_ZTznWx2C_kWypBHcIjikaQ">2.8</ix:nonFraction> million and includes $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_DrPimentelsMember_6pUuXCugXk6NelClzj9WWw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="Narr_h5F4DUiXgUqS7FW3z0Pb_Q">73,000</ix:nonFraction> of prior&#160;year losses attributable to minority stockholders including the reversal of Dr.&#160;Pimentel&#8217;s 2015 losses of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ConsolidationItemsAxis_srt_ConsolidationEliminationsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_DrPimentelsMember_0ZR0S_QqJE-CfP4OWtt76g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" id="Narr_fmfI257JDkKT_OnNnUCDQA">505,000</ix:nonFraction> associated with the exchange of his shares of common stock in SYN Biomics for shares of the Company&#8217;s common stock. During 2021, the minority stockholder returned its shares of SYN Biomics to the Company for no consideration. The Company&#8217;s interest in SYN Biomics is now <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_12_31_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_2hlEGz94m0y871onqyMQIQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="Narr_3U_6aQFnx0uIORsnze-JtQ">100</ix:nonFraction>%.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" id="Tb_2SLpeiHpLUKw70bCIgk0pw" continuedAt="Tb_2SLpeiHpLUKw70bCIgk0pw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. License, Collaborative and Employment Agreements and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">License and Collaborative Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As described below, the Company has entered into several license and collaborative agreements for the right to use research, technology and patents. Some of these license and collaborative agreements may contain milestones. The specific timing of such milestones cannot be predicted and is dependent on future developments as well as regulatory actions which cannot be predicted with certainty (including actions which may never occur). Further, under the terms of certain licensing agreements, the Company may have the obligation to pay certain milestones contingent upon the achievement of specific levels of sales. Due to the long-range nature of such commercial milestone amounts, they are neither probable at this time nor predictable and consequently are not included in this disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Washington University School of Medicine in St. Louis Clinical Trial Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 7, 2019, the Company entered into a clinical trial agreement (&#8220;CTA&#8221;) with Washington University School of Medicine in St. Louis (&#8220;Washington University&#8221;) to conduct a Phase 1b/2a single-center, randomized, double-blinded, placebo-controlled clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of oral SYN-004 (ribaxamase) in up to 36 adult allogeneic hematopoietic cell transplant (HCT) recipients (the &#8220;Study&#8221;). Under the terms of the CTA, the Company will serve as the sponsor of the Study and supply SYN-004 (ribaxamase), as well as compensate Washington University for all research services to be provided in connection with the Study which is estimated to cost approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_8_7_2019_To_8_7_2019_us-gaap_TypeOfArrangementAxis_syn_ClinicalTrialAgreementMember_e8nSUVWVOUOzmBeVgBlJ_g" decimals="0" format="ixt:numdotdecimal" name="syn:EstimatedResearchCosts" scale="0" id="Narr_bGo9ezXRN0CiMcL5PB0FgA">3,200,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The CTA continues in effect until completion of all obligations under the CTA. Either party may terminate the CTA prior to completion of its obligations (i) if authorization of the study is withdrawn by the FDA; (ii) if the emergence of any adverse reaction or side effect with SYN-004 (ribaxamase) administered in the Study is of such magnitude or incidence in the opinion of either party to support termination; or (iii) upon a breach of the terms of the CTA if the breaching party fails to cure the breach within 30 days after receipt of notice. The Company has the right to terminate the CTA (i) effective immediately if Washington University fails to perform the study in accordance with the terms of the protocol, the CTA or applicable laws or regulations or if Washington University or the principal investigator become debarred or (ii) upon 14 days written notice and Washington University has the right to terminate the CTA upon 14 days notice if the principal investigator becomes unable to perform or complete the Study and the parties have not, prior to the expiration of such fourteen (14) day period, agreed to an alternative principal investigator.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2SLpeiHpLUKw70bCIgk0pw_cont1" continuedAt="Tb_2SLpeiHpLUKw70bCIgk0pw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">7. License, Collaborative and Employment Agreements and Commitments&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cedars-Sinai Medical Center (&#8220;CSMC&#8221;) Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December&#160;5, 2013, the Company, through its newly formed, majority owned subsidiary, SYN Biomics, entered into a worldwide exclusive License Agreement with CSMC for the development of new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes. As part of the terms of the License Agreement, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_GqTzjk6ZRUmQxuCuv8dWDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_uo7LjZDTWkCuZtCtNgQQyA">9,569</ix:nonFraction> unregistered shares of the Company&#8217;s common stock to CSMC, paid $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_GqTzjk6ZRUmQxuCuv8dWDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="0" id="Narr_WhDbnohkIEqf6Qtfdp5eVw">150,000</ix:nonFraction> for the initial license fee and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9Xpcg3JLq0uiDoVj62uKQg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="0" id="Narr_c7vaVdaR4ESZw7tqKeJhAw">220,000</ix:nonFraction> for patent reimbursement fees. The License Agreement also provides that, commencing on the second anniversary of the License Agreement, SYN Biomics will pay an annual maintenance fee, which payment shall be creditable against annual royalty payments owed under the License Agreement. In addition to royalty payments which are a&#160;percentage of net sales of license and technology products, SYN Biomics is obligated to pay CSMC a&#160;percentage of any non-royalty sublicense revenues, as well as additional consideration upon the achievement of milestones (the first two of which are payable in cash or unregistered shares of Company stock at the Company&#8217;s option).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The License Agreement provided for termination: (i)&#160;automatically if SYN Biomics enters into a liquidating bankruptcy or other specified bankruptcy event or if the performance of any term, covenant, condition or provision of the License Agreement will jeopardize the licensure of CSMC, its participation in certain reimbursement programs, its full accreditation by the Joint Commission of Accreditation of Healthcare Organizations or any similar state organizations, its tax exempt status or is deemed illegal; (ii)&#160;upon 30&#160;days notice from CSMC if SYN Biomics fails to make a payment or use commercially reasonable efforts to exploit the patent rights; (iii)&#160;upon 60&#160;days notice from CSMC if SYN Biomics fails to cure any breach or default of any material obligations under the License Agreement; or (iv)&#160;upon 90&#160;days notice from SYN Biomics if CSMC fails to cure any breach or default of any material obligations under the License Agreement. SYN Biomics also has the right to terminate the License Agreement without cause upon six&#160;months notice to CSMC; however, upon such termination, SYN Biomics is obligated to pay a termination fee with the amount of such fee reduced: (i)&#160;if such termination occurs after an Investigational New Drug submission to the FDA but prior to completion of a Phase 2 clinical trial, (ii)&#160;reduced further if such termination occurs after completion of Phase 2 clinical trial but prior to completion of a Phase 3 clinical trial; and (iii)&#160;reduced to zero if such termination occurs after completion of a Phase 3 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2 clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#8220;Study&#8221;). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company&#8217;s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (<i style="font-style:italic;">M. smithii</i>) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">University of Texas Austin Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December&#160;19, 2012, the Company entered into a License Agreement with University of Texas Austin (&#8220;UT&#8221;) Austin for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related to pertussis antibodies. The License Agreement provides that UT Austin is entitled to payment of past patent expenses, an annual payment of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_1_2012_To_12_19_2012_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_gp7VGPemIUmMsNTJacOkog" decimals="0" format="ixt:numdotdecimal" name="syn:LicenseAgreementAnnualPaymentsDue" scale="0" id="Narr_mHKc7Khi8UO4lDwkCS-lTA">50,000</ix:nonFraction> per&#160;year commencing on the effective date through December&#160;31, 2014, a $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_1_2012_To_12_19_2012_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_gp7VGPemIUmMsNTJacOkog" decimals="0" format="ixt:numdotdecimal" name="syn:LicenseAgreementFinalPaymentDue" scale="0" id="Narr_GywWfTER10aWO0gA6yqSbw">25,000</ix:nonFraction> payment on December&#160;31, 2015 and milestone payments of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_PhaseIClinicalTrialsMember_TUHpBF3yc0CkN3QUWLfWmw" decimals="0" format="ixt:numdotdecimal" name="syn:MilestonePayment" scale="0" id="Narr_bkV_IX-7UUKTxmUnmFRsJg">50,000</ix:nonFraction> upon commencement of Phase 1 clinical trials, $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_PhaseIiiClinicalTrialsMember_lswYHCn0iEGpMO6RGGHoqQ" decimals="0" format="ixt:numdotdecimal" name="syn:MilestonePayment" scale="0" id="Narr_Cj1RgP_or0WaG5AGvGQbKg">100,000</ix:nonFraction> upon commencement of Phase 3 clinical trials, $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_NdaSubmissionInUsMember_iAOhW_VZcEGqi0gmByMIAg" decimals="0" format="ixt:numdotdecimal" name="syn:MilestonePayment" scale="0" id="Narr_9bvy_V7m2kmclEaK8O8kpQ">250,000</ix:nonFraction> upon NDA submission in the U.S., $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_EuropeanMedicinesAgencyApprovalMember_P8LwHIwz0kewI_WCPzgecA" decimals="0" format="ixt:numdotdecimal" name="syn:MilestonePayment" scale="0" id="Narr_sgLWl-jGxEiiilF_RLQXHQ">100,000</ix:nonFraction> upon European Medicines Agency approval and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_RegulatoryApprovalInAsianCountryMember_b29ls9jD-Eq0pdQkSHFuxw" decimals="0" format="ixt:numdotdecimal" name="syn:MilestonePayment" scale="0" id="Narr_9pPGuEXQAUaH6-X8tji4jQ">100,000</ix:nonFraction> upon regulatory approval in an Asian country. In&#160;addition, UT Austin is entitled to a running royalty upon net sales. The License Agreement terminates upon the expiration of the patent rights; provided, however that the License Agreement is subject to early termination by the Company in its discretion and by UT Austin for a breach of the License Agreement by the Company.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2SLpeiHpLUKw70bCIgk0pw_cont2" continuedAt="Tb_2SLpeiHpLUKw70bCIgk0pw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. License, Collaborative and Employment Agreements and Commitments&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the License Agreement, the Company and UT Austin also entered into a Sponsored Research Agreement pursuant to which UT Austin will perform certain research work related to pertussis. The Sponsored Research Agreement may be renewed annually, in the sole discretion of the Company, after the first&#160;year for two additional one&#160;year terms with a fixed fee for the first&#160;year of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_FirstYearMember__Bn5hy98mU6mfmfCN95quw" decimals="0" format="ixt:numdotdecimal" name="syn:ResearchAgreementFixedFee" scale="0" id="Narr_UTPREhKN3USHgtyE36tzvA">303,287</ix:nonFraction>. The Sponsored Research Agreement was renewed for the second and third&#160;years for a fixed fee of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_SecondYearMember_BTboTCNJsUKQRiy6cxkbug" decimals="0" format="ixt:numdotdecimal" name="syn:ResearchAgreementFixedFee" scale="0" id="Narr_C9zXEw2lEkaXv1ubrwxQCQ">316,438</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_ThirdYearMember_pDW3ZJBjLEOCTDy7Fvp73A" decimals="0" format="ixt:numdotdecimal" name="syn:ResearchAgreementFixedFee" scale="0" id="Narr_91iG29b28kuFheksXvT79g">328,758</ix:nonFraction> respectively, all payable in quarterly installments. The Sponsored Research Agreement expires January 17, 2023; provided, however, the Sponsored Research Agreement is subject to early termination upon the written agreement of the parties, a default in the material obligations under the Research Agreement which remain uncured for 60&#160;days after receipt of notice, automatically upon the Company&#8217;s bankruptcy or insolvency and by the Company in its sole discretion at any time after the one&#160;year anniversary of the date of execution thereof upon no less than 90&#160;days&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Prev ABR LLC (&#8220;Prev&#8221;) Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;28, 2012, the Company entered into an agreement (&#8220;Prev Agreement&#8221;) to acquire the C. diff program assets of Prev, including the pre-Investigational New Drug (IND) package, Phase 1 and Phase 2 clinical data, manufacturing process data and all issued and pending U.S. and international patents. Upon execution and closing of the Prev Agreement, the Company paid Prev cash payments of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_11_2_2012_To_11_28_2012_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember__uZ5OPc6pka-czPBvUDXXw" decimals="0" format="ixt:numdotdecimal" name="syn:AdditionalCashPaymentForLicenseAgreement" scale="0" id="Narr_rn3t1wfPc0y7jr6_gZKexg">235,000</ix:nonFraction> and issued <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_11_2_2012_To_11_28_2012_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember__uZ5OPc6pka-czPBvUDXXw" decimals="0" format="ixt:numdotdecimal" name="syn:UnregisteredSharesIssuedToLicenseAgreement" scale="0" id="Narr_U3Lnvixt1kaYlKCwY1-f3w">17,858</ix:nonFraction> unregistered shares of its common stock to Prev. As set forth in the Prev Agreement, Prev may be entitled to receive additional consideration upon the achievement of certain milestones, including: (i)&#160;commencement of an IND; (ii)&#160;commencement of a Phase 1 clinical trial; (iii)&#160;commencement of a Phase 2 clinical trial; (iv)&#160;commencement of a Phase 3 clinical trial; (v)&#160;filing a Biologic License Application (BLA) in the U.S. and for territories outside of the U.S. (as defined in the Prev Agreement); and (vi)&#160;approval of a BLA in the U.S. and for territories outside the U.S. With exception of the first milestone payment, the remaining milestones are payable <ix:nonNumeric contextRef="Duration_11_2_2012_To_11_28_2012_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember__uZ5OPc6pka-czPBvUDXXw" name="syn:AdditionalConsiderationPayable" id="Narr_Ki2cHk2-Q02Ipd99LIFnOA">50% in cash and 50% in our stock</ix:nonNumeric>, however, at Prev&#8217;s option the entire milestone may be payable in shares of the Company&#8217;s stock. As of December&#160;31, 2015, the first three milestones have been met, and at Prev&#8217;s option, Prev elected to receive <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember_OdBA1XZNCkSZ2xDmj4iqwg" decimals="0" format="ixt:numdotdecimal" name="syn:OptionsToBeReceivedCommonStockShares" scale="0" id="Narr_7L8fcFCEE0mg77L22EHS6Q">18,724</ix:nonFraction> shares of the Company&#8217;s common stock. Currently, assets licensed under this agreement are used in the Company&#8217;s &#160;Phase 1b/2a Clinical Study in Allogeneic HCT Recipients. No milestones were achieved or such payments were made during the&#160;years ended December&#160;31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2018, the Company entered into a three-year employment agreement with Steven A. Shallcross, (the &#8220;Employment Agreement&#8221;), to serve as the Chief Executive Officer and to continue to serve as the Chief Financial Officer of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Employment Agreement has a stated term of three&#160;years but may be terminated earlier pursuant to its terms. If Mr.&#160;Shallcross&#8217; employment is terminated for any reason, he or his estate as the case may be, will be entitled to receive the accrued base salary, vacation pay, expense reimbursement and any other entitlements accrued by him to the extent not previously paid (the &#8220;Accrued Obligations&#8221;); provided, however, that if his employment is terminated (i)&#160;by the Company without Cause or by Mr.&#160;Shallcross for Good Reason (as each is defined in the Employment Agreement) then in addition to paying the Accrued Obligations, (a)&#160;the Company will continue to pay his then current base salary and continue to provide benefits at least equal to those that were provided at the time of termination for a period of twelve (12)&#160;months and (b)&#160;he shall have the right to exercise any vested equity awards until the earlier of six (6)&#160;months after termination or the remaining term of the awards; or (ii)&#160;by reason of his death or Disability (as defined in the Employment Agreement), then in addition to paying the Accrued Obligations, Mr.&#160;Shallcross would have the right to exercise any vested options until the earlier of six (6)&#160;months after termination or the remaining term of the awards. In such event, if Mr.&#160;Shallcross commenced employment with another employer and becomes eligible to receive medical or other welfare benefits under another employer-provided plan, the medical and other welfare benefits to be provided by the Company as described herein would terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 30, 2020, the Board of Directors of the Company awarded Steven A. Shallcross (i) a cash bonus equal to <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_12_30_2020_To_12_30_2020_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_5Rwg92J14EiVYGDVwneJ0A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" id="Narr_1H2u0RhvF0SDvV4ibBNlyQ">62</ix:nonFraction>% of his prior base salary and (ii) an option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_12_30_2020_To_12_30_2020_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_5Rwg92J14EiVYGDVwneJ0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_08AEf8mSNkSFoNsChkCFJQ">450,000</ix:nonFraction> shares of the Company&#8217;s common stock. On December 23, 2020, the Board of the Company awarded Steven A. Shallcross (i) a cash bonus equal to <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_12_23_2020_To_12_23_2020_lK-7ce7kgUKMLA_1odurJw" decimals="4" format="ixt:numdotdecimal" name="syn:CostOfLivingAdjustmentsPercentage" scale="-2" id="Narr_n2M29U9JFE2W__j03hBF3w">62.5</ix:nonFraction>% of his prior base salary and (ii) an option to purchase <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_12_23_2020_To_12_23_2020_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_CEW0YNQQwU-z7FPuSvxFMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToEmployees" scale="0" id="Narr_VtNvrHSM6k2me9gqobfmtQ">450,000</ix:nonFraction> shares of the Company&#8217;s common stock.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_5a7469f8_858f_4330_9fb6_14ab9b18a71b"></a><a id="Tc_6oXxa9rrCUeiEs9WrrpN7w_1_0"></a><a id="Tc_68wcAXn8RUu6mb82Anz7Aw_2_0"></a><a id="Tc_3vDvNmWHDEWjBf-iMXDZpg_3_0"></a><a id="Tc_5Kx37pzRGEWYcH4PgbpSzQ_4_0"></a><a id="Tc_asLJhSVW_UCQiCR8xCXSUA_5_0"></a><a id="Tc_NmzkSKJ_V06l7rh7lFOKaQ_6_0"></a><a id="Tc_X9MhDS6S_UiDF-lJnbRpng_7_0"></a><a id="Tc_nOyNMZ3ER0-u-YOujXLe8w_8_0"></a><a id="Tc_Km7pfY3OW0-wEWDozi4sgw_10_0"></a><a id="Tc_FmmikD1ipkaYo16mKB6fSA_12_0"></a><a id="Tc_Cp20PEhy502aazc-uiA4-A_13_0"></a><a id="Tc_UGuBsEYoxEqSSx4hjTgQIA_13_2"></a><ix:continuation id="Tb_2SLpeiHpLUKw70bCIgk0pw_cont3" continuedAt="Tb_2SLpeiHpLUKw70bCIgk0pw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 23, 2021, the Board of Directors of the Company awarded Steven A. Shallcross (i) a cash bonus equal to approximately <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_12_23_2021_To_12_23_2021_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_ob3-lBLKQ0-1m3VgfFdc-g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" id="Narr_Q1ikMjQz2km3G-llybly3Q">62.5</ix:nonFraction>% of his current base salary, and (ii) an option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g" contextRef="Duration_12_23_2021_To_12_23_2021_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_ob3-lBLKQ0-1m3VgfFdc-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_bk65e_O0SkycOOj74vVVeA">650,000</ix:nonFraction> shares of the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. License, Collaborative and Employment Agreements and Commitments&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating Lease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s existing lease as of December 31, 2021 is classified as an operating lease. As of December 31, 2021, the Company has one operating lease for facilities with a remaining term expiring in 2027. During the quarter ended June 30, 2021, the Company renewed its facility lease by entering into a Second Lease Amendment which extends the lease term for 63 months beginning on September 1, 2022 and ending on December 31, 2027 at stated rental rates and including a 3 month rent abatement. The Second Amendment also has options for a Tenant Improvement Allowance and a Second Extension Term. The Second Amendment also gives the Company the right to expand their space by giving notice to the landlord before December 31, 2021. The Company did not give notice to expand the space during 2021. The Second Extension Term is offered at market rates and there is no economic incentive for the lessee, therefore the Company has determined that it is not part of the original lease term. There is an option in this Second Amendment to Lease for the Company to borrow funds for tenant improvements subject to an <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_DyYjOhCiDUSh2oyHw0yOCQ">8.5</ix:nonFraction>% interest rate. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statements of operations, and for the years ended December 31, 2021 and 2020 approximated $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Narr_-vJo21Bs4E-DVEliOe4GtQ">280,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Narr_bYcVILUEIUiGbU_nlT8QoA">209,000</ix:nonFraction>, respectively. For the years ended December 31, 2021 and 2020, operating cash flows used for operating leases approximated $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Narr_bExzAKTYx02-aEc21PlCbQ">321,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Narr_4YKcpwYVfU6Fs5yH0LDAHg">309,000</ix:nonFraction>, respectively, and the right of use assets exchanged for operating the lease obligation was $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeaseAgreementsMember_FPxvWRsyyEuHDdGJz_4XaA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="Narr_1ItfuOVZGkKuD16-05kCPQ">1.3</ix:nonFraction> million. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="0" format="ixt:numdotdecimal" name="syn:NonCashAdditionOfRightOfUseAssets" scale="0" id="Narr_uAA45ZMU0kyeh7Y6QVTb-g">538,000</ix:nonFraction>.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_NKzciBSzIUa3HZlZ9IBH3Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A maturity analysis of our operating leases as of December 31, 2021 is as follows <i style="font-style:italic;">(amounts in thousands of dollars)</i>:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future undiscounted cash flow for the years ending December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_dzc3FxPwdUqdjKLW_lVIbg_2_3">247</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_8Yf1JJACIEK0eNDPk3VyNg_3_3">327</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_vJ4Oy3x7EUqyWdrf0J_eGQ_4_3">337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_gVo2W9mWa0mggrmzI41FFQ_5_3">347</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_w9UhaiRKKEKkIVHUZD3V0w_6_3">357</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:LesseeOperatingLeaseLiabilityPaymentsDueYearSix" scale="3" id="Tc_1IsRWx8Yz02HYOi3C7YpSg_7_3">368</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_Dr8nSqX-aESlnmFU-sJsHA_8_3">1,983</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount factor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_YSytBnBeNkqVwK4QC_kywA_10_3">456</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_YmEvW5Sg1kyNFgYcXmib7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_N8IMM0KUfEuDnQaXN1NSog_11_3">1,527</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_UeUeijSZQEeSIaFersKafA_12_3">124</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability - long term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_p5NIoXPv9ESJV0sm_hPd8w_13_3">1,403</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Consulting Fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160;2017, the Company engaged a regulatory consultant to assist in the Company&#8217;s efforts to prepare, file and obtain FDA approval for ribaxamase.&#160;The term of the engagement is on a&#160;monthly basis, provided that either party may terminate the agreement at any time by providing the other party a six-month notice period. The Company was obligated to pay the consultant a&#160;monthly retainer in addition to success fee payments of up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_11_1_2017_To_11_30_2017_9RYWQN6O80iVs8ielspjNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="0" id="Narr_8PkglPO6k0WwvQj9nNPOYQ">4,500,000</ix:nonFraction> for attainment of certain regulatory milestones. The achievement of the milestones is not probable at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of COVID-19 and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_2SLpeiHpLUKw70bCIgk0pw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. License, Collaborative and Employment Agreements and Commitments&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As COVID-19 continued to spread around the globe, the Company experienced disruptions that impacted its business and clinical trials, including the postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company&#8217;s business, the clinical development of SYN-004 (ribaxamase) and SYN-020, the business of the Company&#8217;s suppliers and other commercial partners, the Company&#8217;s corporate development objectives and the value of and market for the Company&#8217;s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, especially in light of the new variants, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company&#39;s business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.</p></ix:continuation><a id="Tc_kMGrqrG1o0qWTgYs7l80Fw_1_2"></a><a id="Tc_isBEpoOsEUOijZz7sNRs4A_1_5"></a><a id="Tc_YhophIkMn0ClUwC015T0qA_2_0"></a><a id="Tc_ppkkFebd8E6mLpx8jDwbYg_2_2"></a><a id="Tc_nvJBwbYa0UOlFIMhAt_5wg_2_5"></a><a id="Tc_0wv3qR4-skmtcvaU3-AAxQ_3_0"></a><a id="Tc_v_gznzk0VkGr7AwjNOcEMg_4_0"></a><a id="Tc_xxhstGVJO0e9MfpRih8ZiA_5_0"></a><a id="Tc_vFynctw8Yk64_htfZELVHQ_6_0"></a><a id="Tc_GLscauvhoUKl5SbSIrRB9g_7_0"></a><a id="Tc_qb2HOnowdU-SFguCIkMEaQ_8_0"></a><a id="Tc_dlzJP8XOakad3tHeiwsRnw_9_0"></a><a id="Tc_HhloJ1yYBUeayKTW0Slu4A_10_2"></a><a id="Tc_mgFrRrxZhkG1RuwJhyBqRw_10_5"></a><a id="_b3acec6f_c703_4469_a41a_7b6c2d04b49c"></a><a id="Tc_vbHvaHUNyEiYp8UqTzWxjg_1_2"></a><a id="Tc_hQOdaAEv40O6XGX795gG1A_1_5"></a><a id="Tc_DX7bjmsbnU2NnGju8PA3Uw_2_0"></a><a id="Tc_SHhzRV_VJkeoebRTk-6GHA_3_0"></a><a id="Tc_HvWWe_ZfeUWTcee5E96uyw_3_2"></a><a id="Tc_6ueJdt2nUkyQF-yf43pigg_3_5"></a><a id="Tc_M-xs1jdoBkKhVmOVTrgY2A_4_0"></a><a id="Tc_KS9s6JH4H0OE6j_r3JUrjQ_5_0"></a><a id="Tc_5tabZzMJBEG0K67x__gQoQ_6_0"></a><a id="Tc_ikxEjFr2okiBqhpZRTzCzg_7_0"></a><a id="Tc_kcZYuBkWLUukZ88GOlQCxw_8_0"></a><a id="Tc_bRcb6eArJUK9k7g08Z37fQ_9_0"></a><a id="Tc_TjTQqqrQyUSIh8x27nGveQ_10_0"></a><a id="Tc_NTCbrPRkCESiePfGiW5Xyw_11_0"></a><a id="Tc_mJq-fGRYik6DdEPVw8RIfw_12_0"></a><a id="Tc_NKTqad4ZikmP6cuzU2OxEg_12_2"></a><a id="Tc_rddIXpN4G0CsNRpgmG9Gbw_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_CuX8Zf18uEWJH9h09Q9gDg" continuedAt="Tb_CuX8Zf18uEWJH9h09Q9gDg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There was <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_DfwEYxp2nEqQ33YtHnd6Ug"><ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Narr_9EBopNpysUiB4b9cbKgSSg">no</ix:nonFraction></ix:nonFraction> income tax expense for the&#160;years ended December 31, 2021 and 2020 due to the Company&#8217;s net losses. <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Group_cqBW5xslPUu9Z5TA5xAREg" continuedAt="Group_cqBW5xslPUu9Z5TA5xAREg_2" escape="true">The Company&#8217;s tax expense differs from the &#8220;expected&#8221; tax expense for the years ended December 31, 2021 and 2020. For 2021, the &#8220;expected&#8221; tax expense is computed by applying the Federal corporate statutory tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_ppvkWxwF4027bvy1U_yy0Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_8ljnfKO4202UIOLIt9HZ0w">21</ix:nonFraction>% and a net, after Federal benefit state tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Narr_NBL9QdcCrkuO_ve77CmrNw">6.46</ix:nonFraction>% (state blended rate was <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Narr_B7W9qoo--0OyIdbApwy5HQ">8.18</ix:nonFraction>%) to loss before taxes. For 2020, the &#8220;expected&#8221; tax expense is computed by applying the Federal corporate statutory tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_MRPkLh7Yjk6pd-zFujqF_A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_-umAEsxtvkiEqepTB8TOdA">21</ix:nonFraction>% and a net, after Federal benefit state tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Narr_yTjPWSXwCU2MbB_e9Rpftw">6.45</ix:nonFraction>% (state blended rate was <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Narr_su-UiP1cVEapNWSBYEMuYQ">8.17</ix:nonFraction>.%) to loss before taxes. These results are as follows <i style="font-style:italic;">(in thousands):</i></ix:nonNumeric></p><ix:continuation id="Group_cqBW5xslPUu9Z5TA5xAREg_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">2020</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Computed &#8220;expected&#8221; tax-benefit - Federal</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" sign="-" scale="3" id="Tc_s0EUhWWhE0GG-VpgRfYQSQ_2_3">3,045</ix:nonFraction>)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" sign="-" scale="3" id="Tc_6Jsl3zvA5kS1oFzqDzStPA_2_6">2,124</ix:nonFraction>)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Computed &#8220;expected&#8221; tax-benefit - State</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" sign="-" scale="3" id="Tc_RQ9yb6YjekOj5NVaKrm-SQ_3_3">931</ix:nonFraction>)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" sign="-" scale="3" id="Tc_8i-ofmYK0Ui_Q2UDI_Wxfw_3_6">616</ix:nonFraction>)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Adjustment of &#8220;expected&#8221; tax-benefit to actual</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:zerodash" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" scale="3" id="Tc_cgwRO1OrVk-s1_sfnykOnw_4_3">&#8212;</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" scale="3" id="Tc_IHa4q0zQLkil_TNqo5HA2g_4_6">&#8212;</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Meals, entertainment and other</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="Tc_jonvvkE2GUmu6Kbfgploow_5_3">&#8212;</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" scale="3" id="Tc_dG4RAPMU3UOZeKFIRS544w_5_6">&#8212;</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Non-deductible stock-based compensation</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="Tc_yle8ppMnMEGg61g8frtvrw_6_3">32</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="Tc_U0Y-mB8EqkKOOXUYTw_0jQ_6_6">32</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">State Tax Rate Adjustment</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="Tc_B0g90sISQEqgGAVhLYUaJA_7_3">932</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" sign="-" scale="3" id="Tc_XMBxcShJP0Gq7rk8fJ7M1w_7_6">1,221</ix:nonFraction>)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Federal and state NOL Adjustment</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="Tc_6f31Fdj4jEqkoLwbnp2veQ_8_3">&#8212;</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="Tc_r7L60W8pz0i_mWx986kKWA_8_6">&#8212;</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Change in valuation allowance</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="3" id="Tc_OalBjmr1g0q-oR9YQExFZQ_9_3">3,012</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" sign="-" scale="3" id="Tc_C26nJ4pxJUyDmd-a7PZJ-g_9_6">3,929</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_OP7i8ojufkabOVE-TaCbMQ_10_3">&#8212;</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_tDPVFEV9_kK7HEXyhSbZ4g_10_6">&#8212;</ix:nonFraction></i></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_ouhXX79kkE-LE9XtMaX3Cw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effects of temporary differences that gave rise to significant portions of deferred tax assets at December&#160;31, 2021 and 2020 are as follows (<i style="font-style:italic;">in thousands</i>):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for services</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsStocksIssuedForServices" scale="3" id="Tc_z6vv2ehULEmv9e5GnVcWKw_3_3">1,504</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsStocksIssuedForServices" scale="3" id="Tc_4SCzhL24ek-ceKm0un2hdg_3_6">1,428</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Accrued compensation</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="Tc_GuTZ7JDJnUakt9HUGryxxg_4_3">27</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="3" id="Tc_rRBqVxZfwUCd0kavtiz1hQ_4_6">42</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for acquisition of program</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" scale="3" id="Tc_WqanQaU7EEu1zjmPr6J4bg_5_3">1,462</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" scale="3" id="Tc_T2r_bi9gRUyoaKFrEyT5kw_5_6">1,436</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for license agreement</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsStockIssuedForlicenseAgreement" scale="3" id="Tc_SPs16QTtYEW3aGMP_Hg4Wg_6_3">1,363</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsStockIssuedForlicenseAgreement" scale="3" id="Tc_UsM9QZNxk06Ka9pMmqTjuA_6_6">1,574</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for milestone payment</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsStockIssuedForMilestonePayment" scale="3" id="Tc_VcWGpXWNwUWIdwNTkjYzzw_7_3">236</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsStockIssuedForMilestonePayment" scale="3" id="Tc_V6ztuCY6I0WZeoCojqMRsg_7_6">262</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Amortizable License Fee</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee" scale="3" id="Tc_3eAypMYyYkuST74NtQ-fCQ_8_3">4</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="syn:DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee" scale="3" id="Tc_xQ7EQevqb0SaO9issJNJ7g_8_6">5</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Net operating loss carry-forward</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_cFLYQw7_I0mOMJEHqDztPQ_9_3">16,884</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_y0Lda3aBFkaBwoC8xruXFA_9_6">12,540</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Total gross deferred tax assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_sDb6lQm-l0Ccm_eo0QSOCg_10_3">21,480</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_8MI9v2SQTUeENdeWlUmGlA_10_6">17,287</ix:nonFraction></i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Less: valuation allowance</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_0YRVb7LHOEGMY2rh8ZAslA_11_3">21,480</ix:nonFraction>)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_T09pUeAoL02cXhfFiZXcLg_11_6">17,287</ix:nonFraction>)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Total net deferred tax assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_sUZgGBIXaUaKG4qHW5lZwQ_12_3">&#8212;</ix:nonFraction></i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> <ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_fc_vUAtof0eUdMN4jwMSsg_12_6">&#8212;</ix:nonFraction></i></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_CuX8Zf18uEWJH9h09Q9gDg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Income Taxes&#160;&#8211;&#160;(continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2021, the Company has a gross Federal net operating loss carry-forward of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_UK3e-jtmmUmh8BzgvIYmHA">58.3</ix:nonFraction> million available to offset future taxable income. The Company&#8217;s pre-2018 net operating losses expire on various dates through <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="syn:OperatingLossCarryforwardsExpireDate" id="Narr_hPCsfpK0Ekeyz7Gov9KAmQ">2037</ix:nonNumeric>. In addition, it was determined that the utilization of gross Federal net operating losses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_HRovq6U78E-v3Zs9fQPjlA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_bfw97HOcY0Gaipo-2xl0tA">198.8</ix:nonFraction> million was limited by $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_HRovq6U78E-v3Zs9fQPjlA" decimals="-5" format="ixt:numdotdecimal" name="syn:OperatingLossCarryforwardsLimitationOnUse" scale="6" id="Narr_TJ0fHFAdj0itWq09xNc6-w">155.6</ix:nonFraction> million. due to change of control ownership changes that occurred under Section 382 of the Internal Revenue Code. State NOL&#8217;s are also limited by Section 382 of the Internal Revenue Code and were limited accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2020, the Company completed an Internal Revenue Code Section 382 analysis of its historical net operating loss carry-forward amount. As a result, the prior year net operating loss carry-forward of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2020Member_FiWLkKZ3vEKpx7yg9MiRzw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_mUDguuKeJke_l9MofX9Rrw">188.6</ix:nonFraction> million was limited by $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2020_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_XDETk7h4EEaL0z0ltMNi8Q" decimals="-5" format="ixt:numdotdecimal" name="syn:OperatingLossCarryforwardsLimitationOnUse" scale="6" id="Narr_xSa-a6n8n0GlQsZjFfVm3A">155.6</ix:nonFraction> million. The decrease in the prior year net operating loss is attributable to change of control ownership shifts which were determined for the years 2013 and 2018 which caused the reduction in the value of the historical net operating loss carry-forward amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An updated section 382 analysis was performed in 2021 to identify if any additional ownership shifts occurred in the current year. It was determined that an ownership shift occurred on January 20, 2021. The result of the updated 2021 analysis produced an IRC 382 limit due to the 2021 ownership shift. However, all previously limited net operating losses remain available for use in future periods. The Company&#8217;s pre-2018 net operating losses expire on various dates through <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_gGcNUhXIPkSw2CheAQJBxw" name="syn:OperatingLossCarryforwardsExpireDate" id="Narr_au3j3td2M06o2hY8aH9kfg">2037</ix:nonNumeric> while the net operating loss carry-forward originating in the 2018 year and later carry-forward indefinitely and are subject to additional limitations based on taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 20109-12, &#8220;Income Taxes Topic 740-Simplifying the Accounting for Income Taxes&#8221; (&#8220;ASU 2019-12&#8221;), which intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application of Topic 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein, and early adoption is permitted. The Company adopted ASU 2019-12 in the current period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The valuation allowance at December 31, 2021 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="Narr_Uo3sHObH20CWlylQUkXBZw">21.5</ix:nonFraction> million. The net change in valuation allowance during the year ended December 31, 2021, was an increase of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="Narr_RAs4JavyfE-SkYbHstVWzw">4.2</ix:nonFraction> million primarily due to increases in gross federal and state deferred tax assets in 2021. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2021.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_zGvqaL-Nq0-0Z4UlRUWzDA" continuedAt="Tb_zGvqaL-Nq0-0Z4UlRUWzDA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 3, 2022, the Company entered into a <ix:nonNumeric contextRef="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGuOmgQVFUWelRGFisfwCQ" format="ixt-sec:durwordsen" name="us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" id="Narr_ZlreESq4_EiwjcbsyEGypw">three-year</ix:nonNumeric> employment agreement with Steven A. Shallcross (the &#8220;Employment Agreement&#8221;), who has served as the Company&#8217;s Chief Executive Officer since December 6, 2018 and as the Company&#8217;s Chief Financial Officer since June 1, 2015, to continue to serve as the Chief Executive Officer and Chief Financial Officer of the Company. The Employment Agreement replaced the prior employment agreement with the Company that Mr. Shallcross entered into on December 6, 2018, as amended December 5, 2019. Pursuant to the Employment Agreement, Mr. Shallcross is entitled to an annual base salary of $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGuOmgQVFUWelRGFisfwCQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" scale="0" id="Narr_MOtJK6dggUOQmJSB8hIo7A">585,000</ix:nonFraction> and an annual cash performance bonus of up to fifty percent (<ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="Duration_1_3_2022_To_1_3_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6rAbrvfSCUWGUsBaubIWMQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" scale="-2" id="Narr_a4QuB8QAwUm9ukcWdkrmJA">50</ix:nonFraction>%) of his annual base salary as well as discretionary annual equity awards pursuant to the Company&#8217;s incentive plans. The annual bonus will be based upon the assessment of the Board of Mr. Shallcross&#8217;s performance. The Employment Agreement also includes confidentiality obligations and inventions assignments by Mr. Shallcross and non-solicitation and non-competition provisions.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;min-height:14.4pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Synthetic Biologics,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Consolidated Financial Statements</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zGvqaL-Nq0-0Z4UlRUWzDA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 10, 2022, the Company completed the acquisition of all the outstanding shares of VCN (the &#8220;VCN Shares&#8221;) from the shareholders of VCN. VCN is a private, clinical-stage biopharmaceutical company developing new oncolytic adenoviruses for the treatment of cancer. VCN&#8217;s lead product candidate, VCN-01, is being studied in clinical trials for pancreatic cancer and retinoblastoma. VCN-01 is designed to be administered systemically, intratumorally or intravitreally, either as a monotherapy or in combination with standard of care, to treat a wide variety of cancer indications. VCN-01 is designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment, Degrading the tumor stroma has been shown to improve access to the tumor by the virus and additional therapies such as chemo- and immuno-therapies. Importantly, degrading the stroma exposes tumor antigens, turning &#8220;cold&#8221; tumors &#8220;hot&#8221; and enabling a sustained anti-tumor immune response. VCN has the rights to four exclusive patents for proprietary technologies, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional patents pending. As consideration for the purchase of the VCN Shares, the Comany paid $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_3_10_2022_To_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nY9W9p5hLEOy0btQJThIaA" decimals="0" format="ixt:numdotdecimal" name="syn:ConsiderationPurchasePaid" scale="0" id="Narr_mifqZP2VD0G7tq0dgQ7Q1w">4,700,000</ix:nonFraction> to Grifols Innovation and New Technologies Limited  the owner of approximately <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_BusinessAcquisitionAxis_syn_GrifolsInnovationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4zfGfEAdcUanM58rCqi1Pg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="Narr_p4e21E8LfUiVnKZ40kkEmA">86</ix:nonFraction>% of the equity of VCN, and issued to the remaining sellers and certain key employees and consultants of VCN the closing Shares, representing <ix:nonFraction unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_BusinessAcquisitionAxis_syn_NewTechnologiesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WiHLxploBU2xe-zdv1Ih8Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="Narr_SH-2BgG14EetFKSqVqpyog">19.99</ix:nonFraction>% of the outstanding shares of the Company&#8217;s common stock on December 14, 2021, the date of the Purchase Agreement. In addition to the consideration described above, under the terms of the Purchase Agreement, the Company assumed up to $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_3_10_2022_To_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nY9W9p5hLEOy0btQJThIaA" decimals="0" format="ixt:numdotdecimal" name="syn:CashPaymentsExistingLiabilities" scale="0" id="Narr_FQnzPXaDi0C8wna-DaPGZg">2,400,000</ix:nonFraction> of existing liabilities of VCN and has agreed to make cash payments to Grifols upon the achievement of certain clinical and commercialization milestones, as described below. In connection with the Acquisition, prior to the closing the Company loaned VCN $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="Duration_3_10_2022_To_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nY9W9p5hLEOy0btQJThIaA" decimals="0" format="ixt:numdotdecimal" name="syn:ClosingFinanceCosts" scale="0" id="Narr_2IKKL4wj-0KLOa2N565smA">425,000</ix:nonFraction> to help finance the costs of certain of VCN&#8217;s research and development activities and, at the Closing, VCN and Grifols entered into a sublease agreement for the sublease by VCN of the laboratory and office space currently occupied by it as well as a transitional services agreement. As a Purchase Agreement post-Closing covenant, Synthetic has agreed to commit to fund VCN&#8217;s research and development programs, including but not limited to VCN01 PDAC phase 2 trial, VCN01 RB pivotal trial and necessary G&amp;A within a budgetary plan of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6abns4wbvk2nLNMGsIo3mg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="Narr_V7hwrwzwSUqjed3jMP-1Dw">27.8</ix:nonFraction> million.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Milestone Payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ" decimals="-6" format="ixt:numdotdecimal" name="syn:BusinessCombinationMilestonePaymentsSafeToProceed" scale="6" id="Narr_fsN348dMQUW9Kw6XzYEqhg">3</ix:nonFraction>MM upon VCN-01 US IND Safe to Proceed pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;, or other first indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg" decimals="-4" format="ixt:numdotdecimal" name="syn:BusinessCombinationMilestonePaymentsSafeToProceed" scale="6" id="Narr_u2no04GC2E-W8YD-mAVY8Q">2.75</ix:nonFraction>MM upon VCN-01 US IND Safe to Proceed &#8211; retinoblastoma (&#8220;RB&#8221;, or other second indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ" decimals="-4" format="ixt:numdotdecimal" name="syn:BusinessCombinationMilestonePaymentsFirstPatientDosed" scale="6" id="Narr_OPo0bnshsEW_pIfqZDkuuQ">3.25</ix:nonFraction>MM upon VCN-01 US first patient dosed&#8211; PDAC (or other first indication) after receipt of VCN-01 US IND Safe to Proceed for PDAC being informed</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg" decimals="-4" format="ixt:numdotdecimal" name="syn:BusinessCombinationMilestonePaymentsFirstPatientDosed" scale="6" id="Narr_40osaQonhEGu0BAUBV8coQ">3.25</ix:nonFraction>MM upon VCN-01 US first patient dosed &#8211; RB (or other second indication) after receipt of VCN-01 US IND Safe to Proceed for RB being informed</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ" decimals="-6" format="ixt:numdotdecimal" name="syn:BusinessCombinationMilestonePayments" scale="6" id="Narr_rgIuScbStEe6PJjgcRBWgw">6</ix:nonFraction>MM upon VCN-01 US Phase 2 trial meets the primary endpoint or if a Phase 2 trial is not conducted and only a Phase 3 trial is conducted then upon a Phase 3 being initiated &#8211; PDAC (or other first indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg" decimals="-6" format="ixt:numdotdecimal" name="syn:BusinessCombinationMilestonePayments" scale="6" id="Narr_W8WlqiU3m0qYeFgXvu381Q">8</ix:nonFraction>MM upon VCN-01 Pivotal Trial meeting the primary endpoint or upon BLA Submission &#8211; RB (or other second indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6abns4wbvk2nLNMGsIo3mg" decimals="-6" format="ixt:numdotdecimal" name="syn:BusinessCombinationMilestonePayments" scale="6" id="Narr_cuQmV0Jep0ecLdj3L2cfjA">12</ix:nonFraction>MM upon VCN-01 US Phase 3 trial meeting the primary endpoint or upon BLA Submission &#8211; PDAC (or other first indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ" decimals="-6" format="ixt:numdotdecimal" name="syn:BusinessCombinationMilestonePaymentsBlaApproval" scale="6" id="Narr_4_9Ct-Kb_0q1oBGysLv9Yg">16</ix:nonFraction>MM upon VCN-01 BLA Approval &#8211; PDAC (or other first indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$<ix:nonFraction unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q" contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg" decimals="-6" format="ixt:numdotdecimal" name="syn:BusinessCombinationMilestonePaymentsBlaApproval" scale="6" id="Narr_8QeBAThZH0Cyd9hWXMlTBA">16</ix:nonFraction>MM upon VCN-01 BLA Approval &#8211; RB (or other second indication)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e3137fbd_7177_4eec_97ba_9c3fbef35de6"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.</b><span style="font-size:12pt;">&#160;&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_b2069897_0f97_4c39_bc6c_33681f923f39"></a><a id="Item9AControlsandProcedures_509870"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9A.</b><span style="font-size:12pt;">&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Controls and Procedures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Evaluation of Disclosure Controls and Procedures</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has adopted and maintains disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in the reports filed under the Exchange Act, such as this Annual Report on Form&#160;10-K, is collected, recorded, processed, summarized and reported within the time periods specified under the rules&#160;of the SEC. The Company&#8217;s disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As required under Exchange Act Rule&#160;13a-15, the Company&#8217;s management, including the Chief Executive Officer who also serves as its Chief Financial Officer, after evaluating the effectiveness of disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) as of the end of the period covered by this Annual Report on Form&#160;10-K, has concluded that based on such evaluation, the Company&#8217;s disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules&#160;and forms, and that such information is accumulated and communicated to the Company&#8217;s management, including the Company&#8217;s Chief Executive Officer who is also its Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule&#160;13a-15. Internal control over financial reporting is defined in Rule&#160;13a-15(f)&#160;and 15(d)-15(f)&#160;under the Exchange Act as a process designed to provide reasonable assurance to the Company&#8217;s management and Board of Directors regarding the preparation and fair presentation of published financial statements. Management conducted an assessment of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2021 based on the framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated Framework (2013). Based on the assessment, management concluded that, as of December&#160;31, 2021, the Company&#8217;s internal control over financial reporting was effective at a reasonable assurance level based on those criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s management, including its Chief Executive Officer who is also its Chief Financial Officer, does not expect that the Company&#8217;s disclosure controls and procedures and its internal control processes will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of error or fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Changes in Internal Control Over Financial Reporting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company made changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) to assess the limitation of the net operating loss carry-forward and its tax impact through an Internal Revenue Code Section 382 analysis during our fiscal quarter ended December 31, 2021. There has been no other change in our internal control over financial reporting during our fiscal quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_85463822_f1bc_4d77_a8ed_b8b70fc74e55"></a><a id="Item9BOtherInformation_266663"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9B.</b><span style="font-size:12pt;">&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Other Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_f7a4ae4f_762c_4a50_aca4_a59d23c55228"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9C.</b>&#160;&#160;&#160;<span style="font-style:italic;font-weight:bold;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not Applicable</p><a id="_9eaaff15_7a5e_4186_a231_8468c5932112"></a><a id="PARTIII_87758"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;III</b></p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 10.&#160;&#160;&#160;</b><span style="font-style:italic;font-weight:bold;">Directors, Executive Officers and Corporate Governance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Below is certain information regarding our directors and executive officers.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:57.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Age</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven A. Shallcross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, Chief Financial Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:35.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey J. Kraws</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 57</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman</p></td></tr><tr><td style="vertical-align:bottom;width:35.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Monahan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 75</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:35.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey Wolf, J.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 58</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:57.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Steven A. Shallcross.</span> &#160;&#160;Mr. Shallcross has been a member of our Board of Directors since December 6, 2018 and currently serves as our Chief Executive Officer, a position he was appointed to on December 6, 2018, and our Chief Financial Officer. Mr. Shallcross was appointed as our Interim Chief Executive Officer on December 5, 2017 and has served as our Chief Financial Officer, Treasurer and Secretary since joining us in June 2015. Mr. Shallcross brings to our company operational, financial and international biotech industry experience, as well as an established track record at leading the financial development and strategy for several publicly traded biotech companies. From May 2013 through May 2015, Mr. Shallcross served as Executive Vice President and Chief Financial Officer of Nuo Therapeutics, Inc. (formerly Cytomedix, Inc.). In January 2016, Nuo Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and on April 25, 2016, the Bankruptcy Court entered an order granting approval of Nuo&#8217;s plan of reorganization. From July 2012 to May 2013, Mr. Shallcross held the offices of Executive Vice President, Chief Financial Officer and Treasurer of Empire Petroleum Partners, LLC, a motor fuel distribution company. From July 2011 to March 2012, Mr. Shallcross was Acting Chief Financial Officer of Senseonics, a privately-held medical device company located in Germantown, MD. From January 2009 to March 2011, he served as Executive Vice President and Chief Financial Officer of Innocoll AG (formerly privately held Innocoll Holdings, Inc.), a global, commercial-stage biopharmaceutical company specializing in the development and commercialization of collagen-based products. He also served for four years as the Chief Financial Officer and Treasurer of Vanda Pharmaceuticals, Inc., leading the company through its successful IPO and follow-on offering and previously served as the Senior Vice President and Chief Financial Officer of Middlebrook Pharmaceuticals, Inc. (formerly Advancis Pharmaceutical Corporation). In addition, Mr. Shallcross also served as the Chief Financial Officer of Bering Truck Corporation. Since June 2019, Mr. Shallcross has served on the board of directors of Elys Game Technology, Corp. (Nasdaq:ELYS), an international, vertically integrated commercial-stage company engaged in various aspects of the leisure gaming industry and since April 2021, he has served on the board of directors of TwinVee Powercats, Co., a designer, manufacturer and marketer of recreational and commercial power catamaran boats. He holds an MBA from the University of Chicago&#8217;s Booth School of Business, a Bachelor of Science degree in Accounting from the University of Illinois, Chicago, and is a Certified Public Accountant in the State of Illinois.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr. Shallcross brings to the Board significant strategic, business and financial experience related to the business and financial issues facing biotechnology companies. Mr. Shallcross has a broad understanding of the financial markets, financial statements as well as generally accepted accounting principles. Through his services as our Chief Executive Officer and Chief Financial Officer, he has developed extensive knowledge of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jeffrey J. Kraws.</span> &#160;&#160;Mr. Kraws has been a member of the Company&#8217;s Board of Directors since January of 2006, and was appointed independent, non-executive Chairman of the Board in May 2012. Since 2003, Mr. Kraws has served as Chief Executive Officer and co-founder of Crystal Research Associates and CRA Advisors, and since February 2012, he has served as partner and co-founder of TopHat Capital, LLC. Since November 9, 2021, Mr. Kraws has served as the Chief Executive Officer of GridIron Bionutrients, Inc. From August 2016 through January 2021, Mr. Kraws served as the Co-President of Ra Medical Systems Inc. (NYSE: RMED), a medical device company. Mr. Kraws is a partner at Grannus Securities Pty Ltd. (an Australian based private equity fund) since November 2015. Mr. Kraws is a partner of PDK Healthcare Innovations LLC. He also consults and assists in management of private companies through his private practice. Mr. Kraws has received some of the most prestigious awards in the industry. Among other awards, he was given a &#8220;5-Star Rating&#8221; in 2001 by Zacks and was ranked the number one analyst among all pharmaceutical analysts for stock performance in 2001 by Starmine.com. Prior to founding Crystal Research Associates, Mr. Kraws served as co-president of The Investor Relations Group (IRG), a firm representing primarily under-followed, small-capitalization companies. Previously, Mr. Kraws served as a managing director of healthcare research for Ryan Beck &amp; Co. and as director of research/senior pharmaceutical analyst and managing director at Gruntal &amp; Co., LLC (prior to its merger with Ryan Beck &amp; Company). Mr. Kraws served as managing director of the healthcare research group and senior pharmaceutical analyst at First Union Securities (formerly EVEREN Securities); as senior U.S. pharmaceutical analyst for the Swedish-Swiss conglomerate Asea Brown Boveri; and as managing director and president of the Brokerage/Investment Banking operation of ABB Aros Securities, Inc. He also served as senior pharmaceutical analyst at Nationsbanc Montgomery Securities, BT Alex Brown &amp; Sons, and Buckingham Research. Mr. Kraws also has industry experience, having been responsible for competitive analysis within the treasury group at Bristol-Myers-Squibb Company. During 2006 through February of 2007, Mr. Kraws served as our Vice President of Business Development, on a part-time basis. Since December 2013, Mr. Kraws serves on the board of directors of Avivagen Inc. (TSX:VIV) and from 2013 until 2020 served on the board of directors of Saleen Automotive, Inc. (OTC Pink: SLNN). He holds an M.B.A. from Cornell University and a B.S. degree from State University of New York&#160;&#8212;&#160;Buffalo. Mr. Kraws brings a strong business background to us, having worked as a pharmaceutical analyst for over 22 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr. Kraws brings to the Board significant strategic, business and financial experience related to the business and financial issues facing pharmaceutical companies. Mr. Kraws has a broad understanding of the operational, financial and strategic issues facing pharmaceutical companies. His healthcare experience, executive and leadership experience further qualify him as a member of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">John Monahan.</span> &#160;&#160;Dr. Monahan has been a member of the Company&#39;s Board of Directors since November 11, 2020. Dr. Monahan has served on the board of directors of Heat Biologics, Inc. (Nasdaq: HTBX), a biopharmaceutical company primarily engaged in the development of immune therapies and vaccines, since November 2009, and from August 2016 until May 2021 also served on the board of directors of the biotech company Anixa Biosciences, Inc. (formerly known as ITUS Corporation) (Nasdaq: ANIX), a biotechnology company focused on using the body&#39;s immune system to diagnose, treat and prevent cancer. He is also a board member of Cellix Ltd. (Ireland) and has served on a number of other public and private boards over the years. Dr. Monahan co-founded Avigen Inc. (Nasdaq: AVGN) in 1992, a company which has become a leader in its sector for the development of novel pharmaceutical products for the treatment of serious human diseases. Over a 12-year period as Chief Executive Officer of Avigen he raised over $235 million in several private and public financings including its initial public offering. From 1989-1992, he was Vice President of Research &amp; Development at Somatix Therapy Corp., Alameda, CA and from 1985-1989 he was Director of Molecular &amp; Cell Biology at Triton Biosciences Inc., Alameda, CA. Prior to that from 1982-1985, he was Research Group Chief, Department of Molecular Genetics, Hoffmann-LaRoche, Inc. Nutley, NJ, and from 1975 to 1977 he was an Instructor at Baylor College of Medicine, Houston TX. Dr. Monahan served as a scientific advisory consultant to the Company from 2015 to November 10, 2020 and from 2010 through 2015 he was the Company&#39;s Senior Executive Vice President of Research &amp; Development. Dr. Monahan was also a Scientific Advisory Board member of Agilis Biotherapeutics (recently merged into PTC Therapeutics), from 2014 to 2019. Dr. Monahan received his Ph.D. in Biochemistry from McMaster University, Canada and his B.Sc. from University College Dublin, Ireland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Dr. Monahan brings to our Board of Directors significant knowledge of and experience in the pharmaceutical and medical industries. He has extensive business, managerial, executive and leadership experience that further qualify him to serve as a member of the Board and a valuable understanding of biochemistry and our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jeffrey Wolf, J.D.</span> &#160;&#160;Mr. Wolf, who has been a member of the Company&#8217;s Board of Directors since 2006, has substantial experience in creating, financing, nurturing and growing new ventures based upon breakthrough research and technology. In August 2008, Mr. Wolf founded Heat Biologics, Inc. (NASDAQ: HTBX), a publicly traded company engaged in research and development of drugs focused on combating cancer and other diseases. Since April 2010, Mr. Wolf has served as the Chief Executive Officer and Chairman of the Board of Heat Biologics, Inc. Prior to founding Heat Biologics, Inc., from June 1997 to March 2011, Mr. Wolf has served as managing director at Seed-One Ventures, LLC a venture firm focused on launching and growing exceptional healthcare companies from the ground up. Since founding Seed-One, Mr. Wolf has founded and run several medical companies. Mr. Wolf&#8217;s start-ups include Avigen, a San Francisco-based gene therapy company where he was a co-founder and director; TyRx Pharma, a Princeton-based company focused on the development of bio-compatible polymers where he was a co-founder and Chairman; Elusys Therapeutics, a New Jersey company focused on the development of novel technology to remove blood-borne pathogens where he was a cofounder, Chairman and Chief Executive Officer; and GenerationOne, a Miami-based company focused on mobile-based collaborative care, where he was the founder, Chairman and Chief Executive Officer. Mr. Wolf received his M.B.A. from Stanford Business School, his J.D. from New York University School of Law and his B.A. from the University of Chicago, where he graduated with honors in Economics. Mr. Wolf serves as a director of several Seed-One portfolio companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr. Wolf has extensive knowledge of the industry and in particular research and development. His legal and business background provide him with a broad understanding of the legal, operational, financial and strategic issues facing our company. Having served as a board member on other public company boards, Mr. Wolf has an extensive understanding of the operational, financial and strategic issues facing public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Directors&#8217; Term of Office</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Directors will hold office until the next annual meeting of stockholders and the election and qualification of their successors. Officers are elected annually by our Board of Directors and serve at the discretion of the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Committee</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Audit Committee is comprised of Mr. Wolf (Chairman), Mr. Kraws and Dr. Monahan. The Audit Committee is responsible for recommending our independent public accounting firm and reviewing management&#8217;s actions in matters relating to audit functions. The Committee reviews with our independent public accountants the scope and results of the audit engagement and the system of internal controls and procedures. The Committee also reviews the effectiveness of procedures intended to prevent violations of laws. The Committee also reviews, prior to publication, our reports on Form 10-K and Form 10-Q. Our Board has determined that all audit committee members are independent under applicable SEC regulations and NYSE American rules. Our Board of Directors has determined that each of Mr. Wolf and Mr. Kraws qualify as &#8220;audit committee financial experts&#8221; as that term is used in Section 407 of Regulation S-K. Our Audit Committee charter is located on our website <i style="font-style:italic;">www.syntheticbiologics.com</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation Committee</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Compensation Committee consists of Mr. Kraws (Chairman), Dr. Monahan and Mr. Wolf. This committee performs several functions, including reviewing all forms of compensation provided to our executive officers, directors, consultants and employees, including stock compensation. Our Board has determined that all compensation committee members are independent under applicable SEC regulations and NYSE American rules. Our Compensation Committee charter is located on our website <i style="font-style:italic;">www.syntheticbiologics.com</i>.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Nominations Committee</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Nominations Committee consists of Dr. Monahan (Chairman), Mr. Kraws and Mr. Wolf. This committee performs several functions, including identifying qualified individuals to become members of the Board and recommending appointments to the Board and appointment of executive officers. The committee seeks individuals who have an inquisitive and objective perspective, practical wisdom and mature judgment, and the talent and expertise to understand and provide sound and prudent guidance with respect to our activities, operations and interests. Candidates must also be individuals who have the highest personal and professional integrity, who have demonstrated exceptional ability and judgment, and who are likely to be the most effective, in conjunction with the other members of the Board, in collectively serving the long-term interests of stockholders. Our Board has determined that all nominations committee members are independent under applicable SEC regulations and NYSE American rules. Our Nominations Committee charter is located on our website <i style="font-style:italic;">www.syntheticbiologics.com</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Delinquent Section&#160;16(a)&#160;Reports</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Section&#160;16(a)&#160;of the Exchange Act requires our executive officers, directors and persons who beneficially own more than 10&#160;percent of a registered class of the Synthetic Biologics&#8217; equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock. Such officers, directors and persons are required by SEC regulation to furnish us with copies of all Section&#160;16(a)&#160;forms that they file with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Based solely on a review of the copies of such forms that were received by us, or written representations from certain reporting persons that no Forms 5 were required for those persons, we are not aware of any failures to file reports or report transactions in a timely manner during the&#160;year ended December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Code of Ethics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have long maintained a Code of Conduct which is applicable to all of our directors, officers and employees. In addition, we have adopted a Code of Ethics for Financial Management which applies to our Chief Executive Officer, Chief Financial Officer, Treasurer and Controller. Each of these codes is posted on our website at <i style="font-style:italic;">www.syntheticbiologics.com</i>.</p><a id="_c1927ae6_0909_4e81_a515_a32f27dff0df"></a><a id="Item11ExecutiveCompensation_150315"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 11.</b><span style="font-size:12pt;">&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Executive Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are a &#8220;smaller reporting company&#8221; and the following compensation disclosure is intended to comply with the requirements applicable to smaller reporting companies. Although the rules&#160;allow us to provide less detail about our executive compensation program, the Compensation Committee is committed to providing the information necessary to help stockholders understand its executive compensation-related decisions. Accordingly, this section includes supplemental narratives that describe the 2021 executive compensation program for our Named Executive Officer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes all compensation awarded to, earned by or paid to Steven A. Shallcross, our Named Executive Officer, during the fiscal&#160;years presented below.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">All&#160;Other</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name and Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Position</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Salary&#160;($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Bonus&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards&#160;($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">($)</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total&#160;($)</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Shallcross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 584,775</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 365,625</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 144,216</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,508</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,124,124</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 565,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 350,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 120,257</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,992</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,062,249</span></p></td></tr><tr><td style="vertical-align:bottom;width:33.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">and Chief Financial Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr. Shallcross was appointed as our Chief Executive Officer on December 6, 2018. Mr. Shallcross&#39; annual salary was $550,000 commencing December 6, 2018 and increased to $565,000 and $584,775 on December 5, 2019 and December 30, 2020, respectively.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Amount reflects the grant date fair value of the Named Executive Officer&#8217;s stock options, calculated in accordance with FASB ASC Topic 718. For a discussion of the assumptions used in calculating these values, see Note 5 to our consolidated financial statements. In December 2020 and December 2021, Mr. Shallcross was issued an option to purchase 450,000 and 650,000 shares of common stock, respectively; the awards vest monthly over 36 months.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The all other compensation column is comprised of vacation accrual paid, and the portion of medical, dental and vision premiums paid by us on behalf of our Named Executive Officers. These benefits are offered to all Synthetic Biologics&#8217; employees who work at least 17.5 hours per week.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This bonus was earned in 2021 and paid in 2022.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Narrative Disclosure to Summary Compensation Table</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview of Our Compensation Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">A. Philosophy and Objectives</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Compensation Committee seeks to attract and retain executive talent by offering competitive base salaries, bonuses and long-term incentives. The Compensation Committee&#8217;s philosophy is to provide a compensation package that attracts and retains superior executive talent and delivers higher rewards for superior performance and consequences for underperformance. It is also the Compensation Committee&#8217;s practice to provide a balanced mix of cash and equity-based compensation that aligns both the short and long-term interests of our executives with that of our stockholders. Our executive compensation program is based on the following philosophies and objectives:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Compensation Should Align with Stockholders&#8217; Interests</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212; The Compensation Committee believes that executives&#8217; interests should be aligned with those of the stockholders. Executives are granted stock options so that their total compensation is tied directly to the same value realized by our stockholders. Executive bonuses are tied directly to the value that we gain from an executive&#8217;s contribution to our success as a whole.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Compensation is Competitive &#8212;</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Compensation Committee seeks to provide a total compensation package that attracts, motivates and retains the executive talent that we need in order to maximize its return to stockholders. To accomplish this objective, executive compensation is reviewed annually to ensure that compensation levels are competitive and reasonable given our level of performance and other comparable companies with which we compete for talent.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Compensation Motivates and Rewards the Achievement of Goals</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212; Our executive compensation program is designed to appropriately reward both individual and collective performance that meets and exceeds our annual, long-term and strategic goals. To accomplish this objective, a substantial percentage of total compensation is variable, &#8220;at risk&#8221;, both through annual incentive compensation and the granting of long-term incentive awards.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">B. Oversight of Executive Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Role of the Compensation Committee</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of its charter, the Compensation Committee is responsible for the review of all aspects of our executive compensation program and makes decisions regarding the compensation of the Named Executive Officers. Our sole Named Executive Officer for the year ended December 31, 2021 was Steven Shallcross, our Chief Executive Officer who also serves as our Chief Financial Officer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Compensation Committee&#8217;s responsibilities include but are not limited to the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Establishing on an annual basis the performance goals and objectives for purposes of determining the compensation of our Chief Executive Officer and other senior executive officers.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluating the Chief Executive Officer&#8217;s performance at least annually in light of those goals and objectives, and based upon these evaluations setting the compensation level for those officers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing the competitive position of, and making recommendations to, the Board of Directors with respect to the cash-based and equity-based compensation plans and our programs relating to compensation and benefits.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Overseeing administration of our stock option plan and incentive compensation plans, making recommendations to the Board of Directors regarding the granting of options and incentives and otherwise assisting the Board of Directors in administering awards under these plans.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Reviewing the financial performance and operations of our major benefit plans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additional information regarding the Compensation Committee&#8217;s responsibilities is set forth in its charter, which is posted on our website at <i style="font-style:italic;">www.syntheticbiologics.com</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Role of the Chief Executive Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Chief Executive Officer makes recommendations to the Compensation Committee regarding the compensation of our other Named Executive Officers, if any. The Chief Executive Officer does not participate in any discussions or processes concerning his own compensation and participates in a non-voting capacity in discussions or processes concerning the compensation of our other members of management. In addition to our Chief Executive Officer, as well as members of our management and consultants also attend Compensation Committee meetings from time to time and may take part in discussions of executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">C. Program Design</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Compensation Committee uses a simple and straightforward approach in compensating our Named Executive Officers in which base salary, annual incentives and stock options are the principal components. In addition, executive officers generally participate in the same benefit programs as other full-time employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our executive compensation program is designed to provide executives with a reasonable level of fixed compensation through base salary and benefits, and an opportunity to earn incentive compensation through the annual and long-term incentive programs based on a mix of individual and corporate performance, individual performance and the value of our stock. We do not currently have formal policies for allocating compensation among base salary, performance-based bonus and equity awards. Instead our Compensation Committee uses its judgment to establish a total direct compensation opportunity for each Named Executive Officer that is a mix of current, short-term and long-term incentive compensation and cash and non-cash compensation that it believes appropriate to achieve the goals of our executive compensation program and corporate objectives. Our target pay mix places a significant emphasis on performance based variable compensation. The incentive plans are designed to pay well when performance meets or exceeds expectations and pay little or no incentive if performance is below expectations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In designing and implementing our executive compensation program, our Compensation Committee considers our company&#8217;s operating and financial objectives, including our risk profile, and the effect that its executive compensation decisions will have on encouraging our executive officers to take an appropriate level of business risk consistent with our overall goal of enhancing long-term stockholder value. In particular, the Compensation Committee considers those business risks identified in our risk factors and the known trends and uncertainties identified in our management discussion and analysis and considers how our executive compensation program serves to achieve our operating and financial objectives while at the same time mitigating any incentives for our executive officers to engage in excessive risk-taking to achieve short-term results that may not be sustainable in the long-term.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Target compensation comprises base salary and performance based variable compensation, including targeted cash bonus amounts and equity-based compensation. As an executive&#8217;s level of responsibility increases, the Compensation Committee generally targets a greater portion of the executive&#8217;s compensation to be contingent upon performance in the form of variable compensation. For example, historically our Named Executive Officers have a higher&#160;percentage of compensation at risk (and thus greater upside and downside potential) relative to our other employees. The Compensation Committee believes this is appropriate because our Named Executive Officers have the greatest influence on our performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2021, the salary for our Chief Executive Officer who also serves as our Chief Financial Officer was 52% of his target compensation package and performance based variable compensation comprised 45% of his target compensation. Of the performance based variable compensation 28% was equity-based compensation and 72% was his target cash bonus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">D. Compensation Review Process</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Compensation Committee annually reviews compensation for our Named Executive Officers. The Compensation Committee considers the executive&#8217;s role and responsibilities, corporate and individual performance, and industry-wide compensation practices and trends for other companies of similar size. This approach is used to set base salaries, bonuses, stock option award levels and the mix of compensation elements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We strive to attract and retain the most highly qualified executive officers in an extremely competitive market. Our Compensation Committee believes that it is important when making its compensation decisions to be informed as to the competitive market for executive talent, including the current practices of comparable public companies with which we compete for such talent. Consequently, our Compensation Committee primarily reviewed a report from Meridian Compensation Partners, LLC that had been provided to the Compensation Committee. With respect to its analysis of the compensation of the Chief Executive Officer, the Compensation Committee took into account that our Chief Executive Officer also serves as our Chief Financial Officer, which is not typical for most companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">While the Compensation Committee does take into consideration the data it reviewed, the Committee does not attempt to benchmark our executive compensation against any specific level, range, or&#160;percentile of compensation paid at any other companies, does not apply any specific measures of internal or external pay equity in reaching its conclusions, and does not employ tally sheets, wealth accumulation, or similar tools in its analysis. Rather, the Compensation Committee reviews compensation data from the survey and report mentioned above, as reference points in making executive compensation decisions especially in light of the fact that our Chief Executive Officer is also performing the role of Chief Financial Officer. The Compensation Committee&#8217;s general aim is for our compensation to remain competitive with the market, falling above or below the median of the market data as appropriate based on corporate and individual executive performance, and other factors deemed to be appropriate. Competitive market positioning is only one of several factors, as described below, that the Compensation Committee considers in making compensation decisions, and therefore individual Named Executive Officer compensation may fall at varying levels as compared to the market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Compensation Committee values the opinion of our stockholders. At our 2019 Annual Meeting of Stockholders approximately 59% of the votes that were cast (excluding broker non-votes) were cast in favor of our say-on-pay proposal adopting a resolution approving the compensation paid to our Named Executive Officers as disclosed in our proxy statement for our 2019 Annual Meeting of Stockholders. In addition, at our 2019 Annual Meeting of Stockholders approximately the greatest number of votes were cast in favor of a three (3)&#160;year frequency for holding an advisory vote on executive compensation. Our Compensation Committee decided not to make any significant changes to the executive compensation policies; however, our Compensation Committee continues to monitor and evaluate our compensation program in light of our stockholders&#8217; views and our transforming business needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">E. Components of Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We provide four compensation components to Named Executive Officers:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">base salary;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">bonuses based on the achievement of specified goals and objectives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">long-term incentives; and </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">benefits</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Base Salaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We provide our Named Executive Officers a base salary commensurate with their position, responsibilities and experience. In setting the base salary, the Compensation Committee considers the scope and accountability associated with each Named Executive Officer&#8217;s position and such factors as performance and experience of each Named Executive Officer. We design base pay to provide the essential reward for an employee&#8217;s work that is required to be competitive in attracting talent. Once base pay levels are initially determined, increases in base pay may be provided to recognize an employee&#8217;s specific performance achievements or expansion of responsibilities. The base salaries are targeted to be competitive with other similar biotechnology companies. Base salaries for the Named Executive Officers are set by their respective employment contracts and are reviewed annually by the Compensation Committee. Based on the analysis of the peer group and other comparative research performed by the Committee, the Committee was able to compare the base salary for the Chief Executive Officer who also serves as our Chief Financial Officer, including base salary, long-term incentives and bonuses. Upon the appointment of Mr. Shallcross to serve as our Chief Executive Officer in December 2018 and in light of the fact that he also serves as our Chief Financial Officer, it was determined that his overall compensation levels were not competitive with the peer group and therefore his annual base salary was increased to $550,000, which was the same annual base salary as that of our prior Chief Executive Officer. Mr. Shallcross&#8217; employment agreement, dated December 6, 2018, was amended on December 5, 2019 to reflect a 3% merit adjustment to Mr. Shallcross&#8217; base salary, increasing his annual base salary to $565,000 and further amended on December 31, 2020 to reflect a 3.5% merit adjustment to Mr. Shallcross&#8217; base salary, increasing his annual base salary to $584,775. Pursuant to his current employment agreement, which was entered into on January 3, 2022, after expiration of the prior agreement, Mr. Shallcross&#8217; base salary is $585,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2020 and current base salary for our Chief Executive Officer who also serves as our Chief Financial Officer is:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Named Executive Officer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Base&#160;Salary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Base&#160;Salary</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven A. Shallcross, Chief Executive Officer and Chief Financial Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 565,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 584,775</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Bonuses</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Compensation Committee also makes recommendations to the full Board of Directors for determining bonuses. The Compensation Committee also used information from the report and analysis discussed above in determining bonus as well as its own research of peer company compensation. For the year ended December 31, 2021, the Compensation Committee approved a $365,000 cash bonus and an option grant to purchase 650,000 shares of our common stock for Mr. Shallcross.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The employment agreement with Mr. Shallcross that was in effect during 2021 provided that he was eligible for a bonus of up to seventy five percent (75%) of his base salary (a &#8220;Target Bonus&#8221;) in cash or equity and Mr. Shallcross received a cash bonuses with a value equal to approximately eighty-three (83%) of his Target Bonus. The bonuses are to be rewarded in the discretion of the Compensation Committee and the Board of Directors, based on a review of achievements for the year. The Compensation Committee believes that the granting of a bonus is appropriate to motivate the Named Executive Officers. The Compensation Committee focuses on individual performance, which enables the Compensation Committee to differentiate among executives and emphasize the link between personal performance and compensation. Although the Compensation Committee does not use any fixed formula in determining bonuses, it does link bonuses to objectives the Compensation Committee deems important such as financings, reduction in burn rate and achievement of clinical milestones.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Long-Term Incentives</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Compensation Committee believes that a substantial portion of the Named Executive Officer&#8217;s compensation should be awarded in equity-based compensation since equity-based compensation is directly linked to the interests of stockholders. The Compensation Committee has elected to grant stock options to the Named Executive Officers and other key employees as the primary long-term incentive vehicle. In making this determination, the Compensation Committee considered a number of factors including: the accounting impact, potential value of stock option grants versus other equity instruments and cash incentives, and the alignment of equity participants with stockholders. The Compensation Committee determined to grant stock options to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enhance the link between the creation of stockholder value and executive compensation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide an opportunity for equity ownership;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">act as a retention tool; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide competitive levels of total compensation.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mr.&#160;Shallcross&#8217; 2020 and 2021 bonuses included a grant of options exercisable for 450,000 and 650,000 shares of common stock, respectively. The stock options granted vest in equal&#160;monthly installments over a three-year term and are subject to the recipient&#8217;s continued employment, therefore acting as a significant retention incentive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Compensation Committee reviews the performance, potential burn rates and dilution levels to create an option pool that may be awarded to employee participants. Grants to the Named Executive Officers are determined by the Compensation Committee after reviewing market data, including the reports and analysis discussed above and after considering each executive&#8217;s performance, role and responsibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Compensation Committee does not seek to time equity grants to take advantage of information, either positive or negative, about our company that has not been publicly disclosed. Option grants are effective on the date the award determination is made by the Compensation Committee and the exercise price of options is the closing market price of our common stock on the business day of the grant or, if the grant is made on a weekend or holiday, on the prior business day.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Benefits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Named Executive Officers are eligible to participate in our standard medical, dental, vision, disability insurance, life insurance plans and other health and welfare plans provided to other full-time employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of our Named Executive Officers are entitled to participate in our 401(k)&#160;contributory defined contribution plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Pension Benefits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not currently provide pension arrangements or post-retirement health coverage for our employees, although we may consider such benefits in the future.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Retirement Benefits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Each of our Named Executive Officers are eligible to participate in our 401(k)&#160;contributory defined contribution plan. Pursuant to our 401(k)&#160;plan, all eligible employees, including our Named Executive Officers, are provided with a means of saving for their retirement. We currently match all participating employee contributions up to maximum of 4&#160;percent of compensation which vest immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Nonqualified Deferred Compensation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We do not provide any nonqualified deferred compensation plans to our employees, although we may consider such benefits in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Conclusion</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Attracting and retaining talented and motivated management and key employees is essential to creating long-term stockholder value. Offering a competitive, performance-based compensation program with a substantial equity component helps to achieve this objective by aligning the interests of the executive officers and other key employees with those of stockholders. We believe that our compensation program met these objectives and that our 2021 compensation program was appropriate in light of the challenges we and our employees face.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risk Analysis of Our Compensation Program</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Compensation Committee has reviewed our compensation policies as generally applicable to our employees and believes that our policies do not encourage excessive or inappropriate risk taking and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on us. As part of its assessment, the Compensation Committee considered, among other factors, the allocation of compensation among base salary and short- and long-term compensation, and our approach to establishing company-wide and individual financial, operational and other performance goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Outstanding Equity Awards at Fiscal&#160;Year End</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The table below reflects all outstanding equity awards made to each of the Named Executive Officers that are outstanding at December 31, 2021. We currently grant stock-based awards pursuant to our 2020 Stock Incentive Plan (the &#8220;2020 Stock Plan&#8221;) and have outstanding awards under our 2001 Stock Incentive Plan (the &#8220;2001 Stock Plan&#8221;), 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) and 2010 Stock Incentive Plan (the &#8220;2010 Stock Plan&#8221;).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Underlying</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unexercised </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unexercised</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b>&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant&#160;Date</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unexercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price&#160;($)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Shallcross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/23/21</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 650,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/23/28</p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/30/20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 300,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.42</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/30/27</p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/06/19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 300,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 150,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.42</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/04/26</p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/20/18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 200,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.69</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/06/25</p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/20/17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,716</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/20/24</p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/30/16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,286</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 28.00</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11/30/23</p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/04/15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,858</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 96.60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12/04/22</p></td></tr><tr><td style="vertical-align:bottom;width:21.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">06/01/15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,715</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 75.60</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">06/01/25</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Shallcross Options will vest pro rata, on a&#160;monthly basis, over 36&#160;months.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Employment Agreements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Steven A. Shallcross, Chief Executive Officer, Chief Financial Officer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 3, 2022, we entered into a three-year employment agreement with Mr. Shallcross (the &#8220;2022 Shallcross Employment Agreement&#8221;), to serve as the Chief Executive Officer and to continue to serve as our Chief Financial Officer. Mr. Shallcross has served as our Chief Financial Officer since June 1, 2015, initially pursuant to the terms of a two year employment agreement that we entered with him on April 28, 2015 (the &#8220;Initial Shallcross Employment Agreement&#8221;) and then pursuant an employment agreement we entered into with him on December 6, 2018, which replaced the Initial Shallcross Agreement (the &#8220;Amended Shallcross Employment Agreement&#8221;) Mr. Shallcross was appointed as a director of the Company. Mr. Shallcross does not receive additional compensation for service as our director. The material terms of the 2022 Shallcross Employment Agreement and Amended Shallcross Agreement are set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Amended Shallcross Employment Agreement, as amended, Mr.&#160;Shallcross is entitled to an annual base salary of $584,775 and an annual performance bonus of up to seventy five&#160;percent (75%) of his annual base salary. The annual bonus will be based upon the assessment of the Board of Mr.&#160;Shallcross&#8217;s performance. The Amended Shallcross Employment Agreement also includes confidentiality obligations and inventions assignments by Mr.&#160;Shallcross and non-solicitation and non-competition provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Amended Shallcross Employment Agreement has a stated term of three&#160;years but may be terminated earlier pursuant to its terms. If Mr.&#160;Shallcross&#8217;s employment is terminated for any reason, he or his estate as the case may be, will be entitled to receive the accrued base salary, vacation pay, expense reimbursement and any other entitlements accrued by him to the extent not previously paid (the &#8220;Accrued Obligations&#8221;); provided, however, that if his employment is terminated (i)&#160;by us without Cause or by Mr.&#160;Shallcross for Good Reason (as each is defined in the Shallcross Employment Agreement) then in addition to paying the Accrued Obligations, (a)&#160;we will continue to pay his then current base salary and continue to provide benefits at least equal to those that were provided at the time of termination for a period of twelve (12)&#160;months and (b)&#160;he shall have the right to exercise any vested equity awards until the earlier of six (6)&#160;months after termination or the remaining term of the awards; or (ii)&#160;by reason of his death or Disability (as defined in the Shallcross Employment Agreement), then in addition to paying the Accrued Obligations, Mr.&#160;Shallcross would have the right to exercise any vested options until the earlier of six (6)&#160;months after termination or the remaining term of the awards. In such event, if Mr.&#160;Shallcross commenced employment with another employer and becomes eligible to receive medical or other welfare benefits under another employer-provided plan, the medical and other welfare benefits to be provided by us as described herein would terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Amended Shallcross Employment Agreement provides that upon the closing of a &#8220;Change in Control&#8221; (as defined in the Shallcross Employment Agreement), all unvested options shall immediately vest and the time period that Mr.&#160;Shallcross will have to exercise all vested stock options and other awards that Mr.&#160;Shallcross may have will be equal to the shorter of: (i)&#160;six (6)&#160;months after termination, or (ii)&#160;the remaining term of the award(s). If within one (1)&#160;year after the occurrence of a Change in Control, Mr.&#160;Shallcross terminates his employment for &#8220;Good Reason&#8221; or we terminate Mr.&#160;Shallcross&#8217;s employment for any reason other than death, disability or Cause, Mr.&#160;Shallcross will be entitled to receive: (i)&#160;the portion of his base salary for periods prior to the effective date of termination accrued but unpaid (if any); (ii)&#160;all unreimbursed expenses (if any); (iii)&#160;an aggregate amount (the &#8220;Change in Control Severance Amount&#8221;) equal to two (2)&#160;times the sum of his base salary plus an amount equal to the bonus that would be payable if the &#8220;target&#8221; level performance were achieved under the Company&#8217;s annual bonus plan (if any) in respect of the fiscal&#160;year during which the termination occurs (or the prior fiscal&#160;year if bonus levels have not yet been established for the&#160;year of termination); and (iv)&#160;the payment or provision of any other benefits. If within two (2)&#160;years after the occurrence of a Change in Control, Mr.&#160;Shallcross terminates his employment for &#8220;Good Reason&#8221; or we terminate Mr.&#160;Shallcross&#8217;s employment for any reason other than death, disability or Cause, Mr.&#160;Shallcross will be entitled to also receive for the period of two (2)&#160;consecutive&#160;years commencing on the date of such termination of his employment, medical, dental, life and disability insurance coverage for him and the members of his family that are not less favorable to him than the group medical, dental, life and disability insurance coverage carried by us for him.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Change in Control Severance Amount is to be paid in a lump sum if the Change in Control event constitutes a &#8220;change in the ownership&#8221; or a &#8220;change in the effective control&#8221; of the Company or a &#8220;change in the ownership of a substantial portion of a corporation&#8217;s assets&#8221; (each within the meaning of Section&#160;409A of the Internal Revenue Code (&#8220;Rule&#160;409A&#8221;)), or in 48 substantially equal payments, if the Change in Control event does not so comply with Section&#160;409A.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 3, 2022, we entered into a three-year employment agreement with Steven A. Shallcross (the &#8220;2022 Employment Agreement&#8221;), The 2022 Employment Agreement replaced the prior employment agreement with the us that Mr. Shallcross entered into on December 6, 2018, as amended December 5, 2019 (the &#8220;Amended Employment Agreement&#8217;). The material terms of the Employment Agreement are set forth below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the 2022 Employment Agreement, Mr. Shallcross is entitled to an annual base salary of $585,000 and an annual cash performance bonus of up to fifty percent (50%) of his annual base salary as well as discretionary annual equity awards pursuant to the Company&#8217;s incentive plans. The annual bonus will be based upon the assessment of the Board of Mr. Shallcross&#8217;s performance. The 2022 Employment Agreement also includes confidentiality obligations and inventions assignments by Mr. Shallcross and non-solicitation and non-competition provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2022 Employment Agreement has a stated term of three years but may be terminated earlier pursuant to its terms. If Mr. Shallcross&#8217;s employment is terminated for any reason, he or his estate as the case may be, will be entitled to receive the unpaid base salary through the date of termination and accrued vacation, any unpaid annual bonus earned with respect to any calendar year ending on or preceding the date of termination, expense reimbursement and any other entitlements accrued by him to the extent not previously paid (the &#8220;Accrued Obligations&#8221;); provided, however, that if his employment is terminated (i) by the us without Cause or by Mr. Shallcross for Good Reason (as each is defined in the Employment Agreement) then, subject to him executing a general release in form acceptable to the us that becomes effective, in addition to paying the Accrued Obligations, (a) we will continue to pay his then current base salary and if the Executive timely elects continued coverage under COBRA, the Company will continue to provide benefits at least equal to those that were provided at the time of termination for a period of twelve (12) months and (b) all unvested equity awards will vest and he shall have the right to exercise any such vested equity awards until the earlier of eighteen (18) months after termination or the remaining term of the awards; or (ii) by reason of his death or Disability (as defined in the Employment Agreement), then in addition to paying the Accrued Obligations, Mr. Shallcross or his estate would have the right to exercise any vested options until the earlier of six (6) months after termination or the remaining term of the awards. In such event, if Mr. Shallcross commenced employment with another employer and becomes eligible to receive medical or other welfare benefits under another employer-provided plan, the medical and other welfare benefits to be provided by the Company as described herein would terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2022 Employment Agreement provides that upon the closing of a &#8220;Change in Control&#8221; (as defined in the 2022 Employment Agreement), all unvested options shall immediately vest and the time period that Mr. Shallcross will have to exercise all vested stock options and other awards that Mr. Shallcross may have will be equal to the shorter of: (i) eighteen (18) months after termination, or (ii) the remaining term of the award(s). If within one (1) year after the occurrence of a Change in Control, Mr. Shallcross terminates his employment for &#8220;Good Reason&#8221; or the Company terminates Mr. Shallcross&#8217;s employment for any reason other than death, disability or Cause, Mr. Shallcross will be entitled to receive: (i) the portion of his base salary for periods prior to the effective date of termination accrued but unpaid (if any); (ii) all unreimbursed expenses (if any); (iii) an aggregate amount (the &#8220;Change in Control Severance Amount&#8221;) equal to two (2) times the sum of his base salary plus an amount equal to the bonus that would be payable if the &#8220;target&#8221; level performance were achieved under the Company&#8217;s annual bonus plan (if any) in respect of the fiscal year during which the termination occurs (or the prior fiscal year if bonus levels have not yet been established for the year of termination) subject to him executing a general release in form acceptable to the Company that becomes effective. If within two (2) years after the occurrence of a Change in Control, Mr. Shallcross terminates his employment for &#8220;Good Reason&#8221; or the Company terminates Mr. Shallcross&#8217;s employment for any reason other than death, disability or Cause, Mr. Shallcross will be entitled to also receive for the period of two (2) consecutive years commencing on the date of such termination of his employment, medical, dental, life and disability insurance coverage for him and the members of his family that are not less favorable to him than the group medical, dental, life and disability insurance coverage carried by the Company for him subject to him executing a general release in form acceptable to the Company that becomes effective. The Change in Control Severance Amount is to be paid in a lump sum if the Change in Control event constitutes a &#8220;change in the ownership&#8221; or a &#8220;change in the effective control&#8221; of the Company or a &#8220;change in the ownership of a substantial portion of a corporation&#8217;s assets&#8221; (each within the meaning of Section 409A of the Internal Revenue Code (&#8220;Rule 409A&#8221;)), or in 48 substantially equal payments, if the Change in Control event does not so comply with Section 409A.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation of Directors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth information for the fiscal&#160;year ended December&#160;31, 2021 regarding the compensation of our directors who at December&#160;31, 2021 were not also our Named Executive Officers.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fees&#160;Earned&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid&#160;in&#160;Cash</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey J. Kraws<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 176,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,374</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 220,624</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Monahan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 66,250</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,374</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 110,624</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey Wolf</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 73,750</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 44,374</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 118,124</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.75pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The amounts in the &#8220;Option Awards&#8221; column reflect the dollar amounts of the grant date fair value for the financial statement reporting purposes for stock options for the fiscal&#160;year ended December&#160;31, 2021 in accordance with ASC 718. The fair value of the options was determined using the Black-Scholes model. For a discussion of the assumptions used in computing this valuation, see &#8220;Management&#8217;s Discussion and Analysis of Financial Conditions and Results of Operations&#8221; and Note&#160;5 of the Notes&#160;to Consolidated Financial Statements in our Annual Report on Form&#160;10-K for the fiscal&#160;year ended December&#160;31, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As of December&#160;31, 2021, the following are the outstanding aggregate number of option awards held by each of our directors who were not also Named Executive Officers:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:78.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:78.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Option</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Awards</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(#)</b></p></td></tr><tr><td style="vertical-align:bottom;width:78.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey J. Kraws</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 697,324</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Monahan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 375,215</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:78.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey Wolf</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 697,324</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During 2021, each non-employee member of the Board of Directors received an annual cash retainer of $43,000, our independent, non-executive Chairman of the Board of Directors receives an annual cash retainer of $150,000, all non-employee directors receive an annual cash fee of $7,500, $5,000 and $3,750 for service on the Audit, Compensation and Nominations Committees, respectively, and the Chairman of the Audit, Compensation and Nominations Committees receive an additional annual cash fee of $15,000, $10,000 and $7,500, respectively. In addition, each non-employee member of the Board of Directors was issued an option exercisable for 200,000 shares of our common stock, for a term of seven years, vesting monthly over one year of the date of grant. In setting 2021 and 2020 compensation for directors, the Compensation Committee relied on a report form Meridian Compensation Partners, LLC. Based on an analysis of director compensation set forth in the report, our financial performance, general market conditions and the interests of stockholders, it was determined that the annual cash retainer for serving on the board and the committee retainers would remain for 2022 the same as they were in 2021 and 2020.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Mr. Kraws was appointed as our independent, non-executive Chairman of the Board of Directors in May 2012. Pursuant to his agreement Mr. Kraws receives an annual retainer of $150,000 for serving as our Chairman.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Dr. Monahan was appointed as a director on November 11, 2020.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Compensation Committee Interlocks</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the last fiscal&#160;year ended December&#160;31, 2021, none of our executive officers served on the Board of Directors or Compensation Committee of any other entity whose officers served either on our Board of Directors or Compensation Committee.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fc0b4fac_0f93_456f_acda_7461c6eb0fb5"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 12.</b><span style="font-size:12pt;">&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth information, as of March 16, 2022, or as otherwise set forth below, with respect to the beneficial ownership of our common stock (i)&#160;all persons known to us to be the beneficial owners of more than 5% of the outstanding shares of our common stock; (ii)&#160;each of our directors and our named executive officers named in the Summary Compensation Table; and (iii)&#160;all of our directors and our executive officer as a group.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:29.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares&#160;Owned&#160;</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Percentages</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Name and Address of Beneficial Ownership (2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Owned</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of&#160;Shares&#160;</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(3)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey J. Kraws <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(4)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 487,192</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven Shallcross <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(5)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 993,397</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey Wolf <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(6)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 480,656</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John Monahan <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(7)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 237,019</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">All current officers and directors as a group (4 persons)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,198,264</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1.37</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 43.2pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:43.2pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">represents less than 1% of our common stock</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The address for each officer and directors is 9605 Medical Center, Suite&#160;270, Rockville, Maryland 20850.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Beneficial ownership is determined in accordance with SEC rules&#160;and generally includes voting or investment power with respect to securities. Except as indicated in the footnotes to the table, to the knowledge of the Company, the persons named in the table have sole voting and investment power with respect to all shares of common stock, options and/or warrants shown as beneficially owned by them, subject to community property laws, where applicable. Pursuant to the rules&#160;of the SEC, the number of shares of our common stock deemed outstanding includes shares issuable pursuant to options held by the respective person or group that are currently exercisable or may be exercised within 60&#160;days of March 16, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As of March 16, 2022, the Company had 158,37,840 shares of common stock outstanding.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 480,656 shares issuable upon exercise of options held by Mr.&#160;Kraws that are exercisable within the 60-day period following March&#160;16, 2022. Does not include an additional 216,668 shares issuable upon exercise of options held by Mr.&#160;Kraws that are not exercisable within the 60-day period following March 16, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 893,397 shares issuable upon exercise of options held by Mr. Shallcross that are exercisable within the 60-day period following March 16, 2022. Does not include an additional 955,278 shares issuable upon exercise of options held by Mr. Shallcross that are not exercisable within the 60-day period following March 16, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 480,656 shares issuable upon exercise of options held by Mr. Wolf that are exercisable within the 60-day period following March 16, 2022. Does not include an additional 216,668 shares issuable upon exercise of options held by Mr. Wolf that are not exercisable within the 60-day period following March 16, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18.7pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Includes 237,019 shares issuable upon exercise of options held by Dr. Monahan that are exercisable within the 60-day period following March 16, 2022. Does not include an additional 136,196 shares issuable upon exercise of options held by Dr. Monahan that are not exercisable within the 60-day period following March 16, 2022.</span></td></tr></table><div style="margin-top:8pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Equity Compensation Plan Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth information about the securities authorized for issuance under our equity compensation plans for the fiscal&#160;year ended December&#160;31, 2021.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Available&#160;for&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">to&#160;be&#160;Issued&#160;Upon&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-Average</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Future&#160;Issuance&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;of&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;Price&#160;of</b>&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Under&#160;Equity&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Compensation</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Plan Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Plans</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity compensation plans approved by stockholders:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2001 Stock Incentive Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2007 Stock Incentive Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,145</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 69.52</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2010 Stock Incentive Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,450,130</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3.39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">2020 Stock Incentive Plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,800,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 0.36</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 200,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity compensation plans not approved by stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">N/A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">.</p></td></tr><tr><td style="vertical-align:bottom;width:43.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,255,275</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 200,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_00526059_5005_4b4c_8959_e5780498fd77"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 13.</b><span style="font-size:12pt;">&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Certain Relationships and Related Transactions, and Director Independence</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to our charter, our Audit Committee shall review on an on-going basis for potential conflicts of interest, and approve if appropriate, all our &#8220;Related Party Transactions&#8221; as required by Section&#160;120 of the NYSE American Company Guide. For purposes of the Audit Committee Charter, &#8220;Related Party Transactions&#8221; shall mean those transactions required to be disclosed pursuant to SEC Regulation S-K, Item&#160;404.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Board of Directors undertook a review of the independence of the members of the Board of Directors and considered whether any director has a material relationship with our company that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning their background, employment and affiliations, including family relationships, the Board of Directors has determined that Mr. Kraws, Dr. Monahan and Mr. Wolf are independent directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Except as disclosed under &#8220;Executive Compensation,&#8221; there were no related party transactions during the two&#160;year&#8217;s ended December&#160;31, 2021 or the current&#160;year.</p><a id="_c40abb93_944a_4d2f_a227_7044db808c42"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 14.&#160;&#160;&#160;</b><span style="font-style:italic;font-weight:bold;">Principal Accountant Fees and Services</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Independent Registered Public Accounting Firm Fees and Services</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table sets forth the aggregate fees including expenses billed to us for the&#160;years ended December&#160;31, 2021 and 2020 by BDO USA,&#160;LLP.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Audit Fees and Expenses (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 344,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 282,000</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 344,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 282,000</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Audit fees and expenses were for professional services rendered for the audit and reviews of the consolidated financial statements of the Company, professional services rendered for issuance of consents and assistance with review of documents filed with the SEC.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Audit Committee Pre-Approval Policy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Audit Committee has adopted procedures for pre-approving all audit and non-audit services provided by the independent registered public accounting firm, including the fees and terms of such services. These procedures include reviewing detailed back-up documentation for audit and permitted non-audit services. The documentation includes a description of, and a budgeted amount for, particular categories of non-audit services that are recurring in nature and therefore anticipated at the time that the budget is submitted. Audit Committee approval is required to exceed the pre-approved amount for a particular category of non-audit services and to engage the independent registered public accounting firm for any non-audit services not included in those pre-approved amounts. For both types of pre-approval, the Audit Committee considers whether such services are consistent with the rules&#160;on auditor independence promulgated by the SEC and the Public Company Accounting Oversight Board (PCAOB). The Audit Committee also considers whether the independent registered public accounting firm is best positioned to provide the most effective and efficient service, based on such reasons as the auditor&#8217;s familiarity with our business, people, culture, accounting systems, risk profile, and whether the services enhance our ability to manage or control risks and improve audit quality. The Audit Committee may form and delegate pre-approval authority to subcommittees consisting of one or more members of the Audit Committee, and such subcommittees must report any pre-approval decisions to the Audit Committee at its next scheduled meeting. All of the services provided by the independent registered public accounting firm were pre-approved by the Audit Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9280e014_186d_41a7_9342_5dc88b903d33"></a><a id="PARTIV_978496"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART&#160;IV</b></p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 15.</b>&#160;&#160;&#160;<span style="font-style:italic;font-weight:bold;">Exhibits and Financial Statement Schedules</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The following financial statements are included in this Annual Report on Form&#160;10-K for the fiscal&#160;years ended December&#160;31, 2021 and 2020.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Independent Registered Public Accounting Firm</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December&#160;31, 2021 and 2020</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consolidated Statements of Operations for the&#160;years ended December&#160;31, 2021 and 2020</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consolidated Statements of (Deficit) Equity for the&#160;years ended December&#160;31, 2021 and 2020</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;years ended December&#160;31, 2021 and 2020</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">All financial statement schedules have been omitted as the required information is either inapplicable or included in the Consolidated Financial Statements or related notes.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">(a)(3)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Exhibits</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EXHIBIT INDEX</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following exhibits are either filed as part of this report or are incorporated herein by reference:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465921016924/tm216028d1_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated At Market Issuance Sales Agreement by and among Synthetic Biologics, Inc., B. Riley Securities, Inc. and A.G.P./Alliance Global Partners, dated February 9, 2021 (Incorporated by reference to Exhibit 1.1 of the Registrant&#8217;s Current Report on Form 8-K filed February 10, 2021), File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1.2</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465921060274/tm2114499d2_ex1-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated May 3, 2021, to the Amended and Restated At Market Issuance Sales Agreement by and among Synthetic Biologics, Inc., B. Riley Securities, Inc. and A.G.P./Alliance Global Partners, dated February 9, 2021 ((Incorporated by reference to Exhibit 1.1 of the Registrant&#8217;s Current Report on Form 8-K filed May 3, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465921149412/tm2135322d2_ex2-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Share Purchase Agreement by and among Synthetic Biologics, Inc., VCN Biosciences, S.L. and the shareholders of VCN Biosciences, S.L. dated December 14, 2021(Incorporated by reference to Exhibit 2.1 of the Registrant&#8217;s Current Report on Form 8-K filed December 14, 2021, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2.2</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465922032661/tm228957d1_ex2-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment, dated March 9, 2022, to the Share Purchase Agreement, by and among Synthetic Biologics, Inc., VCN Biosciences, S.L. and the shareholders of VCN Biosciences, S.L., dated December 14, 2021 (Incorporated by reference to Exhibit 2.1 of the Registrant&#8217;s Current Report on Form 8-K filed March 11, 2022, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certificate of Incorporation, as amended&#160;(Incorporated by reference to (i) <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000089016308000665/s11-8824_ex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed October 16, 2008, File No. 001-12584,</span></a>&#160;&#160;(ii) <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000095012401502861/c64437ex3-1.txt"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibit 3.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2001 filed August 14, 2001, File No. 001-12584;</span></a> and (iii) <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/0000921895-98-000694-index.html"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibits 3.1</span></a>, <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/0000921895-98-000694-index.html"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.1</span></a> and <a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/0000921895-98-000694-index.html"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">4.2</span></a> of the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 1998 filed August 14, 1998, File No. 001-12584.)</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex31.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Merger (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed October 19, 2009, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Merger filed with the Secretary of State of Delaware (Incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K filed October 19, 2009, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000089016309000007/s22-9415_ex33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Articles of Incorporation filed with the Nevada Secretary of State (Incorporated by reference to Exhibit 3.3 of the Registrant&#8217;s Current Report on Form 8-K filed October 19, 2009, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420411060729/v238878_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws Adopted and Effective October 31, 2011 (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed November 2, 2011, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420412009508/v302955_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed February 16, 2012, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420415031962/v411020_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed May 18, 2015, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420417047316/v474831_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed September 8, 2017, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.9</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420417047548/v474946_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designations for Series A Preferred Stock to Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed September 12, 2017, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.10</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418043710/tv500716_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Change Pursuant to NRS 78. 209 (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed August 13, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.11</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418050928/tv503400_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed September 26, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.12</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420417047548/v474946_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designations for Series B Preferred Stock to Certificate of Incorporation (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K filed October 15, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.13</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418053807/tv504760_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to Certificate of Designations for Series B Preferred Stock to Certificate of Incorporation (Incorporated by reference to Exhibit 3.2 of the Registrant&#8217;s Current Report on Form 8-K filed October 15, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.14</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465921009794/tm214840d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Certificate of Designation for the Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 of the Registrant&#8217;s Current Report on Form 8-K/A filed on February 1, 2021 File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420413038075/v348628_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Stock Certificate (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-3 filed on July 3, 2013, File No. 333-189794.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418026171/tv492231_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant issued December 26, 2017 to InSite Communications (Incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Current Report on Form 10-Q filed May 5, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.3</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418053807/tv504760_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant Agency Agreement, dated October 15, 2018, by and between Synthetic Biologics, Inc. and Corporate Stock Transfer, Inc. (including the form of warrant certificate) (Incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Current Report on Form 8-K filed October 15, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4.4</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex4d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Securities of Synthetic Biologics, Inc.</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.1*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000089016308000028/s11-8078_ex42.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2007 Stock Incentive Plan (Incorporated by reference to Exhibit 4.2 of the Registrant&#8217;s Registration Statement on Form S-8 filed January 18, 2008, File No. 333-148764.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.2*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000095015209000057/k47262exv10w1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Director/Officer Indemnification Agreement (Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed January 6, 2009, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.3*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420410063805/v204023_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2010 Stock Incentive Plan (Incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Registration Statement on Form S-8 filed November 29, 2010, File No. 333-170858.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex10d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Asset Purchase Agreement dated November 8, 2012 between Synthetic Biologics, Inc. and Prev ABR LLC</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.5+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420412069077/v330545_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Patent License Agreement dated December 19, 2012 between Synthetic Biologics, Inc. and The University of Texas at Austin (Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed December 21, 2012, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420412069077/v330545_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sponsored Research Agreement dated December 19, 2012 between Synthetic Biologics, Inc. and The University of Texas at Austin (Incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Current Report on Form 8-K filed December 21, 2012, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.7*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420413062332/v360550_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2010 Stock Incentive Plan (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-8 filed on November 15, 2013, File No. 333-192355.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.8+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420413066566/v362603_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive License Agreement between Synthetic Biologics, Inc., Synthetic Biomics, Inc. and Cedars-Sinai Medical Center dated December 5, 2013 (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2013, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420413066566/v362603_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Stock Purchase Agreement between Synthetic Biologics, Inc., Synthetic Biomics, Inc. and Cedars-Sinai Medical Center dated December 5, 2013(Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2013, File No. 001-12584.)</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420413066566/v362603_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Stock Purchase Agreement between Synthetic Biologics, Inc., Synthetic Biomics, Inc. and Cedars-Sinai Medical Center dated December 5, 2013 (Incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2013, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.11*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420415022349/v406688_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2010 Stock Incentive Plan. (Incorporated by reference to Exhibit B to the Definitive Proxy Statement filed on April 13, 2015, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.12*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420415047653/v414477_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Synthetic Biologics, Inc. 2010 Stock Incentive Plan, as amended and restated on May 15, 2015. (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-8 filed on August 10, 2015, File No. 333-206268.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.13</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420419034736/tv525023_def14a.htm#a_033"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to the License Agreement between Synthetic Biologics, Inc., Synthetic Biomics, Inc. and Cedar-Sinai Medical Center, dated September 4, 2015. (Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 filed November 5, 2015, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.14*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420415070350/v426642_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement. (Incorporated by reference to Exhibit 10.2 of the Registrant&#8217;s Current Report on Form 8-K filed December 10, 2015, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.15*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420416122164/v448017_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Synthetic Biologics, Inc. 2010 Stock Incentive Plan, as amended and restated on May 31, 2016. (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-8 filed on August 31, 2016, File No. 333-206268.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.16*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465920090343/tm2026181-1_def14a.htm#z_001"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated 2010 Stock Incentive Plan (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-8 filed on September 8, 2017, File No. 333-220401.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.17</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420417047548/v474946_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Share Purchase Agreement dated as of September 11, 2017 between Synthetic Biologics, Inc. and MSD Credit Opportunity Master Fund, L.P. (Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed September 12, 2017, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.18</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420417047548/v474946_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement dated as of September 11, 2017 between Synthetic Biologics, Inc. and MSD Credit Opportunity Master Fund, L.P. (Incorporated by reference to Exhibit 4.1 of the Registrant&#8217;s Current Report on Form 8-K filed on September 12, 2017, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418010286/tv485536_ex10-53.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Exclusive License Agreement entered into February 16, 2017 between Synthetic Biologics, Inc. and Cedars-Sinai Medical Center. (Incorporated by reference to Exhibit 10.53 of the Registrant&#8217;s Annual Report on Form 10-K filed on February 22, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418010286/tv485536_ex10-54.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment dated August 22, 2017 to Sponsored Research Agreement dated December 19, 2012 between Synthetic Biologics, Inc. and The University of Texas at Austin (Incorporated by reference to Exhibit 10.54 of the Registrant&#8217;s Annual Report on Form 10-K filed on February 22, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418048214/tv502397_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Stock Purchase Agreement entered into as of September 5, 2018 by and among Synthetic Biologics, Inc., Synthetic Biomics, Inc., and Cedars-Sinai Medical Center(Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed on September 6, 2018, File No. 001-12584.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.22*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420418063398/tv508585_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement between Synthetic Biologics, Inc. and Steven A. Shallcross dated as of December 6, 2018 (Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed on December 6, 2018), File No. 001-12584.</span></a> </p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.23*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420419034736/tv525023_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Synthetic Biologics, Inc. 2010 Stock Incentive Plan, as amended (incorporated by reference to Appendix A to the Definitive Proxy Statement filed with the Securities and Exchange Commission on July 15, 2019, File No. 001-12584)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.24+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000114420419038566/tv526986_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Clinical Trial Agreement between Washington University School of Medicine in St. Louis and Synthetic Biologics, Inc. dated August 7, 2019  (Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed on August 8, 2019, File No. 001-12584)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.25</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">*</p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465919070212/tm1923941d6_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Employment Agreement with Steven A. Shallcross dated December 5, 2019 (Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed on December 5, 2019, File No. 001-12584)</span></a><span style="white-space:pre-wrap;">  </span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.26*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465920090343/tm2026181-1_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Synthetic Biologics, Inc. 2020 Stock Incentive Plan (Incorporated by reference to Appendix A to the Registrant&#8217;s Definitive Proxy Statement on Schedule 14A filed on August 4, 2020, File No. 001-12584)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.27*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465920119032/tm2034204d1_ex4-11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Incentive Stock Option Grant Agreement (Incorporated by reference to Exhibit 4.11 to the Registration Statement on Form S-8 filed on October 28, 2020, File No. 333-249712)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.28*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465920119032/tm2034204d1_ex4-12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Nonqualified Stock Option Grant Agreement (Incorporated by reference to Exhibit 4.12 to the Registration Statement on Form S-8 filed on October 28, 2020, File No. 333-249712)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.29*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465920119032/tm2034204d1_ex4-13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Award Agreement (Incorporated by reference to Exhibit 4.13 to the Registration Statement on Form S-8 filed on October 28, 2020, File No. 333-249712)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.30</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465920123646/tm2029564d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Termination of Exclusive License Agreement, effective November 9, 2020, by and among Cedars- Sinai Medical Center, Synthetic Biologics, Inc. and Synthetic Biomics, Inc. (Incorporated by Reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed on November 10, 2020 File No. 001-12584)</span></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.31*</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/894158/000110465922000998/tm221380d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement with Steven Shallcross dated January 3, 2022 (Incorporated by reference to Exhibit 10.1 of the Registrant&#8217;s Current Report on Form 8-K filed on January 4, 2022, File No. 001-12584)</span></a><span style="white-space:pre-wrap;">  </span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.32+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex10d32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Contract to Grant Marketing License for Catalan Institute of Oncology Patent Ownership Application to VCN Biosciences S.L. </span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.33+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex10d33.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement between Bellvitge Biomedical Research Institute Foundation (Idibell) and VCN Biosciences S.L. dated May 4, 2016</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.34+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex10d34.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Technology Transfer Agreement between Bellvitge Biomedical Research Institute and VCN Biosciences S.L. dated August 31, 2010 </span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10.35+</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex10d35.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration Agreement to Conduct a Clinical Trial and Grant Operating License Agreement between Hospital Sant Joan Dee Deu and VCN Biosciences, S.L dated February 15, 2016</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries </span><sup style="font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Independent Registered Public Accounting Firm (BDO USA, LLP) </span><sup style="font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Steven A. Shallcross, Chief Executive Officer, pursuant to Rule 13a-14(a)/15d-14(a) </span><sup style="font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Steven A. Shallcross, Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) </span><sup style="font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Steven A. Shallcross, Chief Executive Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 </span><sup style="font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="syn-20211231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Steven A. Shallcross, Chief Financial Officer pursuant to Section 1350 of the Sarbanes-Oxley Act of 2002 </span><sup style="font-family:'Times New Roman','Times','serif';font-size:6pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></a></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">Inline XBRL Instance Document </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">Inline XBRL Taxonomy Extension Schema Document </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">Inline XBRL Taxonomy Extension Label Linkbase Document </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document </span><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:top;width:8.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (formatted in XBRL in Exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">(1)</b></span><b style="font-weight:bold;">Filed herewith.</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">*</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Management contract or compensatory plan or arrangement required to be identified pursuant to Item&#160;15(a)(3)&#160;of this report.</b></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Company the submitted certain portions of these agreements in accordance &#160;with Item 601 (b)(10) of Regulation S-K. the Company agrees to furnish unredacted copies of these exhibits to the SEC upon request.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f147374b_c338_41d1_80a8_c0767f41d6f8"></a><a id="Item16Form10KSummary_42441"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 16.</b><span style="font-size:12pt;">&#160;&#160;&#160;</span><span style="font-style:italic;font-weight:bold;">Form 10-K Summary</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9eda0077_53d4_4399_8455_93dd1592a445"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">SYNTHETIC BIOLOGICS,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Chief Executive Officer, Chief Financial Officer&#160;and Director</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Date: March 16, 2022</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">POWER OF ATTORNEY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven A. Shallcross, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 16, 2022</p></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By&#160;:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, Chief Financial Officer and Director</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 16, 2022</p></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By&#160;:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jeffrey J. Kraws</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey J. Kraws</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 16, 2022</p></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John J. Monahan</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John J. Monahan</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 16, 2022</p></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:44.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Jeffrey Wolf</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Jeffrey Wolf</p></td></tr><tr><td style="vertical-align:top;width:49.91%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:5.13%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>syn-20211231xex4d4.htm
<DESCRIPTION>EX-4.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:41:57 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;4.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DESCRIPTION OF SECURITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REGISTERED PURSUANT TO SECTION&#160;12 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Synthetic Biologics,&#160;Inc. (the &#8220;Registrant,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221;) has one class of securities registered under Section&#160;12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), which is our common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">General</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following description of the Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the Registrant&#8217;s Articles of Incorporation, as amended (the &#8220;Articles of Incorporation&#8221;), and Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), each of which are incorporated by reference as an exhibit to our Annual Report on Form&#160;10-K. We encourage you to read our Articles of Incorporation, our Bylaws and the applicable provisions of Nevada Revised Statute (the &#8220;NRS&#8221;), for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Description of Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Authorized Shares of Common Stock</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We currently have authorized 200,000,000 million shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Voting Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The holders of the Common Stock are entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the shares of the Common Stock entitled to vote in any election of directors can elect all of the directors standing for election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Dividend Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of Common Stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Liquidation Rights</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the event of our liquidation, dissolution or winding up, holders of the Common Stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any then outstanding shares of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Other Rights and Preferences</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The holders of the Common Stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to the Common Stock. The rights, preferences and privileges of the holders of the Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Fully Paid and Nonassessable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All of our outstanding shares of Common Stock are fully paid and nonassessable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The transfer agent and registrar for the Common Stock is Equiniti Trust Company (f/k/a Corporate Stock Transfer,&#160;Inc.). The transfer agent&#8217;s address is 3200 Cherry Creek South Drive, Suite&#160;430, Denver, Colorado 80209.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Listing on the NYSE American</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Common Stock is listed on the NYSE American under the symbol &#8220;SYN.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Stockholder Registration Rights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the terms of the registration rights agreement that we entered into with Intrexon and an affiliated entity, we were required to file a registration statement with respect to securities issued and are required to maintain the effectiveness of such registration statement. The failure to do so could result in the payment of damages by us. The registration statement was declared effective on April&#160;29, 2013.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Certain Provisions of our Articles of Incorporation and Bylaws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our Articles of Incorporation and Bylaws contain certain provisions that may have anti-takeover effects, making it more difficult for or preventing a third party from acquiring control of the Registrant or changing our board of directors and management. According to our Articles of Incorporation and Bylaws, the holders of the Common Stock do not have cumulative voting rights in the election of our directors. The lack of cumulative voting makes it more difficult for other stockholders to replace our board of directors or for a third party to obtain control of our company by replacing its board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Authorized but Unissued Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our authorized but unissued shares of Common Stock will be available for future issuance without stockholder approval. We may use additional shares of Common Stock for a variety of purposes, including future public offerings to raise additional capital, to fund acquisitions and as employee compensation. The existence of authorized but unissued shares of Common Stock could render more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Nevada Law</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Business Combinations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The &#8220;business combination&#8221; provisions of Sections 78.411 to 78.444, inclusive, of the NRS generally prohibit a Nevada corporation with at least 200 stockholders from engaging in various &#8220;combination&#8221; transactions with any interested stockholder for a period of two years after the date of the transaction in which the person became an interested stockholder, unless the transaction is approved by the board of directors prior to the date the interested stockholder obtained such status or the combination is approved by the board of directors and thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held by disinterested stockholders, and extends beyond the expiration of the two-year period, unless:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the combination was approved by the board of directors prior to the person becoming an interested stockholder or the transaction by which the person first became an interested stockholder was approved by the board of directors before the person became an interested stockholder or the combination is later approved by a majority of the voting power held by disinterested stockholders; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a) the highest price per share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of Common Stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever is higher, or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A &#8220;combination&#8221; is generally defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction or a series of transactions, with an &#8220;interested stockholder&#8221; having: (a)&#160;an aggregate market value equal to 5% or more of the aggregate market value of the assets of the corporation, (b)&#160;an aggregate market value equal to 5% or more of the aggregate market value of all outstanding shares of the corporation, (c)&#160;10% or more of the earning power or net income of the corporation, and (d)&#160;certain other transactions with an interested stockholder or an affiliate or associate of an interested stockholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In general, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or within two years, did own) 10% or more of a corporation&#8217;s voting stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire our company even though such a transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Control Share Acquisitions</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The &#8220;control share&#8221; provisions of Sections 78.378 to 78.3793, inclusive, of the NRS apply to &#8220;issuing corporations&#8221; that are Nevada corporations with at least 200 stockholders, including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly in Nevada. The control share statute prohibits an acquirer, under certain circumstances, from voting its shares of a target corporation&#8217;s stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&#8217;s disinterested stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less than a majority, and a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above thresholds, those shares in an offer or acquisition and acquired within 90 days thereof become &#8220;control shares&#8221; and such control shares are deprived of the right to vote until disinterested stockholders restore the right. These provisions also provide that if control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all voting power, all other stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled to demand payment for the fair value of their shares in accordance with statutory procedures established for dissenters&#8217; rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A corporation may elect to not be governed by, or &#8220;opt out&#8221; of, the control share provisions by making an election in its articles of incorporation or bylaws, provided that the opt-out election must be in place on the 10th day following the date an acquiring person has acquired a controlling interest, that is, crossing any of the three thresholds described above. We have not opted out of the control share statutes, and will be subject to these statutes if we are an &#8220;issuing corporation&#8221; as defined in such statutes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The effect of the Nevada control share statutes is that the acquiring person, and those acting in association with the acquiring person, will obtain only such voting rights in the control shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable, could have the effect of discouraging takeovers of our company.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>3
<FILENAME>syn-20211231xex10d4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:42:02 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ASSET PURCHASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This Asset Purchase Agreement (the &#8220;Agreement&#8221;) is made and entered into as of the 8</font><sup style="font-size:8.25pt;vertical-align:top;">th </sup><font style="font-size:11pt;">day of November, 2012 by and between SYNTHETIC BIOLOGICS, INC, a Nevada corporation having its principal place of business at 617 Detroit Street, Ann Arbor, Michigan 48104 (&#8220;Synthetic&#8221; or &#8220;Buyer&#8221;), and PREV ABR LLC, a Maryland limited liability company having its principal place of business at 7272 Wisconsin Avenue, Suite 300, Bethesda, Maryland 20814 (&#8220;Seller&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">W I T N E S S E T H</b><b style="font-size:11pt;font-weight:bold;">:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">WHEREAS, Seller owns and desires to sell and assign to Buyer certain assets and related intellectual property (collectively, the &#8220;Assets&#8221;) as specifically defined in Section 1.1 of this Agreement &#160;and Buyer desires to purchase and acquire such Assets from Seller and, thereafter, to use, market, license, sublicense, develop, maintain, collect and otherwise deal with the Assets without restriction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">NOW, THEREFORE, in consideration of the respective representations and warranties hereinafter set forth and of the mutual covenants and agreements contained herein, the parties hereto agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE I</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">DEFINITIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">As used herein, the following terms shall have the following meanings:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:32.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">1.1 &#160;</font></font><font style="font-size:11pt;">&#8220;</font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Assets</u><font style="font-size:11pt;">&#8221; shall mean the Seller&#8217;s CDAD program including </font><font style="font-size:11pt;">any and all of the following assets of the Seller, including any and all rights and benefits constituting and relating to the Seller&#39;s &#946;-lactamase technology and all other biomedical or pharmaceutical technologies of the Seller and all &#946;-lactamase products detained and/or developed with the aforementioned technologies, including without limitation the lead P1A, P2A and P3A-based products in preclinical and clinical phases </font><font style="font-size:11pt;">(the &#8220;Program&#8221;)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 3.6pt;"><font style="font-size:11pt;">and all tangible and intangible intellectual property and know how exclusively related thereto including the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><font style="font-size:11pt;">all methods &#160;and data sets , and all technical documentation pertaining to the Program, including any specifications, flow charts, diagrams, lab results and any and all notes, all inventor notebook pages specific to the Program, plans and other documentation describing problems, future directions or other matters exclusively related to the Program;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 0pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><font style="font-size:11pt;">(i) all patents, patent rights, copyrights, trademarks, trademark rights, tradenames, tradename rights and patent, copyright or trademark applications exclusively respecting the Program and related intellectual property; (ii) all reissues, reexaminations, extensions, continuations, continuations-in-part, continuing prosecution applications, requests for continuing examinations, divisions and registrations of any item in any of the foregoing categories; (iii) foreign counterparts of any of the foregoing; (iv) all patent and patent applications claiming any right of priority to or through the patent applications of the patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto; (v) all rights to apply in all countries of the world for patents certificates of invention, utility models, industrial design protections, design patent protections, or other governmental grants or issuances of any type related to any item in any of the foregoing categories (i) through (v), including, without limitation, under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperation Treaty, or any other convention, treaty, agreement, or understanding; (vi) all invention, invention disclosures and discoveries described in any of the patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto that are included in any claim in such patents, and/or are subject matter capable of being reduced to a patent claim in a reissue or reexamination proceeding brought on any of the patents; (vii) all causes of action (whether known or unknown, or whether currently pending, filed or otherwise) and other enforcement rights under, or on account of, any of the patents and/or rights (as described on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;">); (viii) all rights to collect royalties and other payments</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 3.6pt;"><font style="font-size:11pt;">under or on account of the patents or any item in any categories (i) through (vii); (ix) all ideas, know-how, trade secrets, inventions, invention disclosures, discoveries, technology, designs and any other proprietary rights which Seller owns, in each case with respect to any of the above, pertaining exclusively to the Program (collectively, &#8220;Proprietary Rights&#8221;); and (x) a list of upcoming filings, all US Patent and Trademark Office and other patentability assessments;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) </font></font><font style="font-size:11pt;">all cGMP and non-cGMP material and master call banks of P1A, P2A and P3A and all other tangible assets related thereto;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">any and all U.S. and international investigational new drug applications (IND) and pre-INDs of Seller;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">information and know-how related to research, development, manufacture and/or business (commercial/marketing), used or held for use in connection with the Program;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">any and all health and regulatory registrations, approvals and/or applications and related documentation for the Program;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:11pt;">any and all drugs, formulations and user devices, applications, and safety data;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h)</font></font><font style="font-size:11pt;">all other information, documentation and goodwill relating to the Program;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><font style="font-size:11pt;">all regulatory files (paper and electronic) or so-called regulatory files and records of communications and filings with any and all regulatory authorities in both paper and electronic form; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:68.4pt;margin:0pt 0pt 12pt 3.6pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(j)</font></font><font style="font-size:11pt;">the Assets shall be maintained by the Seller&#8217;s office and warehouse located at Wisconsin Avenue, Bethesda, MD and working and mater cell banks, cGMP and non-cGMP drug substance and drug product wherever located pending the Closing or until earlier relocated by operation of this Agreement. The Seller shall cooperate with and allow the Buyer to remove the Assets during normal business hours during such period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">1.2 &#160; </font></font><font style="font-size:11pt;">&#8220;Buyer&#8221; shall refer to Synthetic Biologics, Inc., however Synthetic Biologics, Inc shall have the right, in its sole discretion, to determine that the Assets shall be acquired by one of its wholly owned subsidiaries and in such case Buyer shall refer to such wholly owned subsidiary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE II</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">SALE AND PURCHASE OF ASSETS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Sale and Purchase</u><font style="font-size:11pt;">. &#160;Subject to the terms and conditions contained herein, Seller hereby sells, transfers, assigns, conveys and delivers to Buyer, and Buyer hereby purchases and accepts from Seller, all of Seller&#39;s right, title and</font><font style="font-size:11pt;"> interest in and to the Assets, free and clear of any liens, pledges, security interests, claims or encumbrances of any kind, other than liens for taxes not yet due and payable. &#160;Upon the Closing, Buyer shall have the sole responsibility and authority to prosecute any pending patent application included in the Assets or related thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Limitation on Assumption</u><font style="font-size:11pt;">. &#160;Except for the Assumed Liabilities (as defined in Section 2.3 below), Buyer shall not assume, pay or discharge or in any respect be liable for any liability, obligation, commitment or expense of Seller arising in connection with the Assets or otherwise. &#160;The liabilities for which Buyer shall not be liable include, without limitation, any liability (actual or contingent), loss, commitment, obligation or expense of Seller:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) </font></font><font style="font-size:11pt;">incident to, or arising out of, the negotiation and preparation of, or performance under this Agreement by Seller, including, without limitation, costs incurred in connection with the assignment of the Assets;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><font style="font-size:11pt;">incident to, or arising out of, any claims, actions, suits, proceedings, liabilities, fines, penalties, deficiencies or judgments existing on the date hereof or arising at any time thereafter as a result of or in connection with the conduct of the business of Seller, including, without limitation, the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">ownership or use of the Assets by Seller and Seller&#8217;s conduct of its business up to and including the Closing Date;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) </font></font><font style="font-size:11pt;">incident to, or arising out of, any tax liabilities (or penalties or interest thereon), domestic or foreign (including any which may arise as a result of the sale of the Assets as contemplated by this Agreement), of Seller on account of this Agreement or the operations of Seller up to and including the Closing Date; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d) </font></font><font style="font-size:11pt;">incident to or arising out of any liability incurred prior to the date hereof with respect to the patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto, including annuity, maintenance, extension, legal and other similar fees.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.3</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Assumption of Liabilities; Limitation on Seller&#39;s Liability</u><font style="font-size:11pt;">. &#160;Buyer (or Synthetic and Buyer jointly and severally, if Buyer is a wholly owned subsidiary of Synthetic) shall assume, be responsible for and pay, perform and discharge when due all liabilities, obligations, commitments or expenses arising after the Closing from the ownership, possession and/or use of the Assets by Buyer, its affiliates, successors or assigns (collectively, the &#8220;Assumed Liabilities&#8221;). &#160;In addition, Buyer (or &#160;Synthetic and Buyer jointly and severally, if Buyer is a wholly owned subsidiary of Synthetic ) shall &#160;assume, be responsible for and pay, perform and discharge when due the following liabilities, obligations, commitments or expenses arising after the execution of this Agreement and prior to the Closing; provided, however that neither the Buyer &#160;nor any affiliate, parent &#160;or subsidiary thereof shall have no such obligation if this Agreement is terminated prior to Closing:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) </font></font><font style="font-size:11pt;">incident to, or arising out of, any claims, actions, suits, proceedings, liabilities, fines, penalties, deficiencies or judgments as a result of Buyer&#8217;s conduct of its business or Buyer&#8217;s ownership and use of the Assets after the execution of this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><font style="font-size:11pt;">incident to, or arising out of, any tax liabilities (or penalties or interest thereon), domestic or foreign, of Buyer or the operations of Buyer or Buyer&#8217;s ownership and use of the Assets after</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">the Closing, specifically excluding any tax liabilities associated with the transactions contemplated by this Agreement; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">incident to or arising out of any liability incurred after the date hereof &#160;with respect to the patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto, including annuity, maintenance, extension, legal and other similar fees with respect to the filings in the jurisdictions set forth on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">To the extent Buyer is (or &#160;Synthetic and Buyer are, if Buyer is a wholly owned subsidiary of Synthetic) responsible for any such costs or expenses pursuant to this Section 2.3 and the expenses are advanced by the Seller between execution of this Agreement and Closing, at the Closing, Buyer (or &#160;Synthetic and Buyer, if Buyer is a wholly owned subsidiary of Synthetic ) and shall reimburse Seller for such costs and expenses, with such reimbursement being a condition to Seller&#8217;s obligation to close. &#160;If Buyer does not close the transaction contemplated herein or the transaction is terminated, neither Buyer nor any affiliate, parent or subsidiary thereof shall have any obligation to Seller under this Section 2.3 and its only obligation to Seller shall be under Article XII of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.4 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Consideration</u><font style="font-size:11pt;">. &#160;The consideration payable by Buyer (or Synthetic and Buyer, if Buyer is a wholly owned subsidiary of Synthetic) for the Assets to be sold to Buyer as provided herein shall be as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><font style="font-size:11pt;">A cash payment payable by wire transfer of immediately available funds to an account designated by Seller in writing in the amount of Two Hundred Thirty Five Thousand Dollars ($235,000) payable as follows: (i) One Hundred Thousand Dollars ($100,000) payable on the date of the execution of this Agreement; and (ii) One Hundred Thirty Five Thousand Dollars ($135,000) payable on the Closing Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">On the Closing Date, Six Hundred Twenty Five Thousand (625,000) shares of Synthetic&#8217;s common stock (the &#8220;Shares&#8221;), of which Two Hundred Fifty Thousand (250,000) Shares shall be issued to Seller and Three Hundred Seventy Five Thousand (375,000) shares shall be held in escrow</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">by Gracin &amp; Marlow, LLP, as escrow agent, for a period of 180 days in accordance with the terms of the Escrow Agreement annexed hereto as </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit C</u><font style="font-size:11pt;"> (the &#8220;Escrow Agreement&#8221;); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) </font></font><font style="font-size:11pt;">The fees set forth on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit D</u><font style="font-size:11pt;"> annexed hereto upon the attainment of the milestones set forth on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit D</u><font style="font-size:11pt;">. &#160;Buyer and Seller shall promptly make such payments upon reaching such milestones.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2.5 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Allocation of the Purchase Price</u><font style="font-size:11pt;">. &#160;For tax purposes, the parties agree that all of the consideration for the Assets shall be allocated to the purchase of the Program and the other Assets in accordance with Section 1060 of the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder (and any similar provision of domestic or foreign law, as appropriate) as set forth on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit E</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">ARTICLE III</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">CLOSING; CONDITIONS TO CLOSING; DELIVERIES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Closing</u><font style="font-size:11pt;">. &#160;The closing of this transaction (the &#8220;Closing&#8221;) shall be held on the date which is five days after all conditions to Closing set forth in Section 3.2 have been met, unless this Agreement has been earlier terminated in accordance with the provisions of Article XI (the &#8220;Closing Date&#8221;) at such time and place upon which the parties shall agree.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conditions to Buyer&#8217;s Obligation</u><font style="font-size:11pt;">. Buyer&#8217;s obligation hereunder to purchase and pay for the Assets is subject to the satisfaction, on or before the Closing, of the following conditions, any of which may be waived, in whole or in part, by Buyer in its sole discretion:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Warranties Correct; Performance</u><font style="font-size:11pt;">. &#160;The representations and warranties of Seller contained in this Agreement (including the Exhibits hereto) shall be true, complete and accurate in all material respects (except that such representations and warranties which are qualified as to materiality shall be accurate and complete in all respects) as of the date hereof and the Closing Date, and Seller shall have delivered to Buyer a certificate, dated as of the date hereof and the Closing Date, to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">such effect signed by its President. &#160;Seller shall have duly and properly performed, complied with and observed in all material respects each of its covenants, agreements and obligations contained in this Agreement to be performed, complied with and observed on or before the Closing Date, and Seller shall have delivered to Buyer a certificate, dated the Closing Date, to such effect signed by its Managing Member.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Purchase Permitted by Applicable Laws</u><font style="font-size:11pt;">. &#160;The purchase of and payment for the Assets to be purchased by Buyer hereunder shall not be prohibited by any applicable law or governmental regulation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Proceedings; Receipt of Documents</u><font style="font-size:11pt;">. &#160;All corporate and other proceedings taken or required to be taken by Seller in connection with the transactions contemplated hereby and all documents incident thereto shall have been taken and shall be reasonably satisfactory in form and substance to Buyer, and Buyer shall have received all such information and such counterpart originals or certified or other copies of such documents as Buyer may reasonably request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">(d)  </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Delivery of Documents</u><font style="font-size:11pt;white-space:pre-wrap;">.  Seller shall have delivered, or caused to be delivered, to Buyer the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(i) </font><font style="display:inline-block;width:22.87pt;"></font><font style="font-size:11pt;">on the date hereof and the Closing Date, a certificate of the Managing Member of Seller, certifying resolutions of the Managing Member of Seller authorizing the transactions contemplated herein and the incumbency of the Managing Member of Seller executing any document or instrument delivered in connection with such transactions;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(ii) </font><font style="display:inline-block;width:19.81pt;"></font><font style="font-size:11pt;">on the date hereof and the Closing Date, a limited liability company good standing certificate of Seller from the jurisdiction in which Seller is organized dated as of a recent date;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iii)</font><font style="display:inline-block;width:19.5pt;"></font><font style="font-size:11pt;">on the Closing Date documentation evidencing the assignment of all patents from the inventors of the Program to Seller and the related filing with the US Patent and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">Trademark Office and all files and documents reasonably necessary to establish Seller&#8217;s ownership of the Assets;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iv) </font><font style="display:inline-block;width:17.37pt;"></font><font style="font-size:11pt;">on the Closing Date documentation evidencing the payment of all patent prosecution fees owed on such date and all annuity, maintenance, extension and the like fees on the patents that comprise the Assets through the date of Closing;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(v) </font><font style="display:inline-block;width:20.42pt;"></font><font style="font-size:11pt;">on the Closing Date a duly executed Assignment and Bill of Sale with respect to the Assets, in substantially the form of </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit F</u><font style="font-size:11pt;"> annexed hereto and with respect to all of the Patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto an executed and notarized Patent Assignment in the form of </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit H</u><font style="font-size:11pt;"> annexed hereto for filing by the Buyer with the United States Patent and Trademark Office;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(vi)</font><font style="display:inline-block;width:20.12pt;"></font><font style="font-size:11pt;">on the Closing Date, evidence of ownership of the Patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;">;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(vii)</font><font style="display:inline-block;width:17.06pt;"></font><font style="font-size:11pt;">on the Closing Date a duly executed copy of the Escrow Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(viii) </font><font style="display:inline-block;width:11.26pt;"></font><font style="font-size:11pt;">on the Closing Date transfer of possession of any tangible property related to the Program which is in Seller&#8217;s possession or readily available to Seller; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(ix) </font><font style="display:inline-block;width:17.37pt;"></font><font style="font-size:11pt;">all other consents, agreements, schedules, documents and exhibits required by this Agreement to be delivered by Seller at or before the Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e) &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Adverse Decision</u><font style="font-size:11pt;">. &#160;There shall be no action, suit, investigation or proceeding pending or threatened by or before any court, arbitrator or administrative or governmental body which seeks to restrain, enjoin, prevent the consummation of or otherwise affect the transactions contemplated by this Agreement or questions the validity or legality of any such transactions or seeks to recover damages or to obtain other relief in connection with any such transactions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f) &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Approvals and Consents</u><font style="font-size:11pt;">. &#160;Seller shall have duly obtained all authorizations, consents, rulings, approvals, licenses, franchises, permits and certificates, or exemptions therefrom, by or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">of all governmental authorities and non-governmental administrative or regulatory agencies having jurisdiction over the parties hereto, this Agreement, the Assets or the transactions contemplated hereby, including, without limitation, all third parties pursuant to existing agreements or instruments by which Seller may be bound, which are required for the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby, at no material cost or other material adverse consequence to Buyer, and all thereof shall be in full force and effect at the time of Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Employees and Consultants</u><font style="font-size:11pt;">. &#160;Seller shall have delivered to Buyer agreements signed by each of its employees, if any, and consultants involved in any manner with development efforts related to the Program (i) waiving any and all rights to, and conveying to Seller, any and all right, title and interest in, all proprietary products, patents, copyrights, trademarks (or applications in respect of any thereof) and any and all other intellectual property comprising any part of the Assets or developed or conceived by such employee or consultant while so employed; and (ii) agreeing that each such employee or consultant will not disclose any confidential information and documents related to the Assets in perpetuity, except as may be permitted under such agreements for exclusions typically taken for information already released to the public and other similar exclusions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Due Diligence</u><font style="font-size:11pt;">. Buyer shall have completed the due diligence on the Assets and the Seller, the completion of and the satisfactoriness of the scientific and financial due diligence in the sole discretion of the Buyer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Audit</u><font style="font-size:11pt;">.</font><font style="display:inline-block;width:8.19pt;"></font><font style="font-size:11pt;">If Buyer shall deem it necessary, Seller shall have permitted a PCAOB registered independent accounting firm retained by Buyer, at Buyer&#8217;s expense, to review the books and records of Seller and such firm shall have either completed an audit of Buyer&#8217;s books and records or concluded that Buyer&#8217;s books and records are auditable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.3 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conditions to the Obligation of Seller</u><font style="font-size:11pt;">. &#160;The obligation of Seller to consummate the transactions contemplated hereby is subject to the fulfillment of the following conditions on or prior to the Closing Date, any of which may be waived, in whole or in part, by Seller in its sole discretion:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Representations and Warranties Correct; Performance</u><font style="font-size:11pt;">. &#160;The representations and warranties of Buyer in this Agreement shall be true, complete and accurate in all material respects (except that such representations and warranties which are qualified as to materiality shall be accurate and complete in all respects) when made and on and as of the date hereof and the Closing Date and Buyer shall have delivered to Seller a certificate, dated the date hereof and the Closing Date, certifying to such matters and signed by its President. &#160;Buyer shall have duly and properly performed, complied with and observed in all material respects each of its covenants, agreements and obligations contained in this Agreement to be performed, complied with and observed on or before the Closing Date. &#160;Buyer shall have delivered to Seller a certificate, dated the Closing Date, certifying to such matters and signed by its President.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Purchase Permitted by Applicable Laws</u><font style="font-size:11pt;">. &#160;The purchase of and payment for the Assets shall not be prohibited by any applicable law or governmental regulation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Adverse Decision</u><font style="font-size:11pt;">. There shall be no action, suit, investigation or proceeding pending or threatened by or before any court, arbitrator or administrative or governmental body which seeks to restrain, enjoin or prevent the consummation of or otherwise affect the transactions contemplated by this Agreement or questions the validity or legality of any such transactions or seeks to recover damages or to obtain other relief in connection with any such transactions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Delivery of Documents</u><font style="font-size:11pt;">. &#160;Buyer shall have delivered, or caused to be delivered, to Seller the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(i) </font><font style="display:inline-block;width:22.87pt;"></font><font style="font-size:11pt;">on the date hereof and the Closing Date, a certificate of an appropriate officer of Buyer (or a certificate of both Synthetic and Buyer, if Buyer is a wholly owned</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">subsidiary of Synthetic), certifying resolutions of the Board of Directors of Buyer authorizing the transactions contemplated herein and the incumbency of officers of Buyer executing any document or instrument delivered in connection with such transactions;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(ii) </font><font style="display:inline-block;width:19.81pt;"></font><font style="font-size:11pt;">on the date hereof evidence that Buyer has been duly incorporated in Nevada and on the Closing Date, a corporate good standing certificate of Buyer from the jurisdiction in which Buyer is incorporated dated as of a recent date;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iii)</font><font style="display:inline-block;width:19.5pt;"></font><font style="font-size:11pt;">the cash consideration set forth in Section 2.4(a) on the dates specified therein;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iv)</font><font style="display:inline-block;width:20.12pt;"></font><font style="font-size:11pt;">on the Closing Date, certificates evidencing the Shares, of which Three Hundred Seventy Five Thousand (375,000) shall be delivered to the escrow agent in accordance with the terms of the Escrow Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(v)</font><font style="display:inline-block;width:23.17pt;"></font><font style="font-size:11pt;">on the Closing Date a duly executed copy of the Escrow Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(vi)</font><font style="display:inline-block;width:20.12pt;"></font><font style="font-size:11pt;">on the Closing Date documentation evidencing approval of the NYSE MKT, LLC of the issuance of the Shares;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(vii)</font><font style="display:inline-block;width:17.06pt;"></font><font style="font-size:11pt;">on the Closing Date payment of any audit fees incurred by Buyer from a PCAOB registered and certified accounting firm retained by Buyer in connection with this transaction;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(viii) </font><font style="display:inline-block;width:11.26pt;"></font><font style="font-size:11pt;">all other consents, agreements, schedules, documents and exhibits required by this Agreement to be delivered by Buyer at or before the Closing; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(ix)</font><font style="display:inline-block;width:20.12pt;"></font><font style="font-size:11pt;white-space:pre-wrap;">reimbursement of costs and expenses for which Buyer (or Buyer and Synthetic, if Buyer is a wholly owned subsidiary of Synthetic)  are responsible under Section 2.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE IV</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">SELLER&#8217;S REPRESENTATIONS AND WARRANTIES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Seller represents and warrants to, and agrees with, Buyer as follows as of the date hereof:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Organization and Good Standing</u><font style="font-size:11pt;">. &#160;Seller is a limited liability company duly organized, validly existing and in good standing under the laws of the State of Maryland.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Limited Liability Company Authority</u><font style="font-size:11pt;">. &#160;Seller has full authority to execute and to perform this Agreement in accordance with its terms; the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby does not and will not result in a breach, violation or default or give rise to an event which, with the giving of notice or after the passage of time, or both, would result in a breach, violation or default of (i) any of the terms or provisions of Seller&#39;s Articles of Organization or Operating Agreement; or (ii) of any indenture, agreement, judgment, decree or other instrument or restriction to which Seller is a party or by which Seller or any of the Assets may be bound or affected, except in the case of clause (ii) where such breach, violation or default would not have a material adverse effect on the assets or the Program (&#8220;Material Adverse Effect&#8221;); the execution and delivery of this Agreement has been and, as of the Closing Date, the consummation of the transactions contemplated hereby will have been, duly authorized by all requisite limited liability company action on the part of Seller and, as of the date hereof, no further authorization or approval, whether of the stockholders or directors of Seller or governmental bodies or otherwise will be necessary in order to enable Seller to enter into and perform the same; and, assuming the due authorization, execution and delivery of this Agreement by Buyer, this Agreement constitutes a valid and binding obligation of Seller enforceable against Seller in accordance with its terms, subject to applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent transfer and other similar laws affecting creditors&#8217; rights generally</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">from time to time in effect and to general principles of equity (including concepts of materiality, reasonableness, good faith and fair dealing) regardless of whether considered in a proceeding in equity or at law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">4.3  </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Title to Assets</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><font style="font-size:11pt;">Seller has good and marketable title to all of the Assets, including, without limitation, the Program and the Proprietary Rights;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">None of such Assets, or the use thereof is subject to any easements or restrictions or to any mortgages, liens, pledges, charges, security interests, encumbrances or encroachments, or to any rights of others of any kind of nature whatsoever. &#160;There are no agreements or arrangements between Seller and any third person which have any effect upon Seller&#39;s title to or other rights respecting the Assets;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">Seller has made available to Buyer all files owned or controlled by Seller relating to the ownership, prosecution or issuance of the Proprietary Rights being assigned other than those files retained by its patent and/or trademark counsel, in which case Seller has made its counsel available to Buyer; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">Seller is unaware of any divisional, continuation, continuation in part, reissue or re-examination applications, or any patents issued therefrom, that rely on the patents set forth on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.4 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Intellectual Property</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Seller owns all right, title and interest by assignment and possesses a valid and enforceable right to use, all of the Proprietary Rights used in the Program, and no claim to the contrary by any other person to the rights of Seller with respect to the foregoing is pending or, to Seller&#8217;s knowledge, threatened and Seller does not have any reason to believe that Seller will not be able to properly record</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">the assignment of the patents and patent applications that are included in the Assets with the appropriate U.S. and international patent offices in the name of Buyer at Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">There is no unauthorized use, disclosure, infringement or misappropriation of Seller&#8217;s Proprietary Rights by any third party, other than any such unauthorized use, disclosure, infringement or misappropriation that would not have a Material Adverse Effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> attached hereto lists all patents and patent applications and all registered trademarks, service marks and copyrights included as part of the Assets (&#8220;Registered Proprietary Rights&#8221;). &#160;Except as set forth on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;">, Seller owns exclusively all such Registered Proprietary Rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">Seller has no present or known future obligation or requirement to compensate any person with respect to the Assets, whether by the payment of royalties or not, or whether by reason of the ownership, use, license, lease, sale or any commercial use or any disposition whatsoever of the Program or the Proprietary Rights;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">None of the present or former employees of Seller own directly or indirectly, or has any other right or interest in, in whole or in part, the Program, or the Proprietary Rights;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(f)</font></font><font style="font-size:11pt;">Seller has not granted any rights or interest in the Assets to any third party;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g) </font></font><font style="font-size:11pt;">All issued patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto are subsisting and in full force and effect. Neither the execution of this Agreement nor the assignment of the patents and patent rights listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto will result in any loss or impairment of the right, title and interest in and to such patents. &#160;None of the patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto is currently involved in any reexamination reissue, interference, opposition or similar proceeding, and no such proceedings are pending or threatened;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(h) &#160; </font></font><font style="font-size:11pt;">All licenses necessary for the present conduct of Seller&#39;s business related to the Program and its making, using, licensing and selling of the Program and products related thereto have been obtained and are listed in </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(i) &#160;</font></font><font style="font-size:11pt;">To the best knowledge of Seller, the pending patent applications listed in Exhibit B are currently pending at the United States Patent and Trademark Office and International PTO and all required filings relating thereto have been made.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.5 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Compliance With Law</u><font style="font-size:11pt;">. &#160;Seller is not in violation in any material respect of any laws, governmental orders, rules or regulations to which the Assets or Seller&#39;s business related to the Assets are subject.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.6 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Agreements</u><font style="font-size:11pt;">. &#160;There are no material contracts, instruments, commitments or agreements relating to the Assets, whether oral or written, including any license or sublicense agreements, presently in effect to which Seller is a party or to which Seller or any of its properties is subject, including, without limitation, the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><font style="font-size:11pt;">any plan or contract or arrangement, oral or written, relating to the Assets providing for employment or consulting services, bonuses, royalties, commissions, pensions, stock purchase or stock option or other stock rights, deferred compensation, retirement or severance payments, profit sharing, or the like;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) &#160;</font></font><font style="font-size:11pt;">any instrument or arrangement relating to the Assets evidencing or relating in any way to (i) indebtedness for borrowed money by way of direct loan, purchase money obligation, conditional sale, lease purchase arrangement, guarantee or otherwise; (ii) liens, encumbrances or security interests (other than liens for taxes not yet due and payable); (iii) guaranties or indemnification; or (iv) investments in any person;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) </font></font><font style="font-size:11pt;">any contract relating to the Assets containing provisions limiting the freedom of Seller to engage in any business or compete in any line of business or in any geographic area or with any person;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d) </font></font><font style="font-size:11pt;">any license, sublicense, lease or sublease agreement relating to the Assets, whether as licensor, sublicensor, licensee, sublicensee, lessor, sublessor, lessee, sublessee or otherwise, or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">any agreements relating to the Assets with dealers, vendors, customers, suppliers, sales representatives, any governmental entity, fund or university, or any agents, marketing representatives, brokers or distributors; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">any joint venture contract or arrangement or other agreement relating to the Assets involving a sharing of profits or expenses, or any joint or other technology development, cooperation or exchange contract or arrangement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.7 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Litigation</u><font style="font-size:11pt;">. &#160;There are no actions, suits, proceedings or investigations (including any purportedly on behalf of Seller) relating to the Assets pending or, to the knowledge of Seller, threatened against or affecting the Assets or Seller&#39;s business related to the Assets whether at law or in equity or admiralty or before or by any governmental department, commission, board, agency, court or instrumentality, domestic or foreign; including any patent enforcement actions or any other intellectual property prosecution actions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.8</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Liabilities.</u><font style="font-size:11pt;"> &#160;As of the Closing Date, there will be no outstanding liabilities with respect to the Assets, other than liens for taxes not yet due and payable, and all intellectual property prosecution fees owed through the date hereof, if any have been paid in full. &#160;As of the Closing Date, all filing, maintenance and annuity, extensions and like fees required to be paid or accrued as of the date hereto with respect to all of the issued patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto will have been paid by Seller (for the avoidance of doubt, such timely payment includes payment of any maintenance fees for which the fee is payable even if the surcharge date or final deadline for such fee would be in the future). With respect to the jurisdictions set forth on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;">, the anticipated filing, maintenance and annuity, extensions and like fees required that will be required to be paid with respect to all of the issued patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto within the next thirty (30) days is accurate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.9 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Brokers</u><font style="font-size:11pt;">. &#160;There has been no broker or finder involved in any manner in the negotiations leading up to the execution of this Agreement or the consummation of any transactions contemplated</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">hereby and Seller agrees to indemnify Buyer against and hold Buyer harmless from any claim made by any party for a broker&#39;s or finder&#39;s fee or other similar payment based upon any agreements, arrangements or understanding made by Seller.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.10 </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Accredited Investor.</u><font style="font-size:11pt;"> &#160;The Seller is acquiring the Shares for its own account for investment only and not with a view towards the public sale or distribution thereof and not with a view to or for sale in connection with any distribution thereof. The Seller was not formed for the purpose of investing in the Shares. &#160;Each member of the Seller is (i) an &#8220;accredited investor&#8221; as that term is defined in Rule 501 of the General Rules and Regulations under the Securities Act by reason of Rule 501(a)(3); (ii) experienced in making investments of the kind described in this Agreement and the related documents; (iii) able, by reason of the business and financial experience of its officers and professional advisors (who are not affiliated with or compensated in any way by the Buyer or any of its affiliates or selling agents), to protect its own interests in connection with the transactions described in this Agreement, and the related documents, and (iv) able to afford the entire loss of its investment in the Shares. &#160;The Seller understands that the Shares are being offered and issued to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Buyer is relying upon the truth and accuracy of, and the Seller&#8217;s compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Seller set forth herein in order to determine the availability of such exemptions and the eligibility of the Seller to acquire the Shares;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.11 </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">SEC Filings</u><font style="font-size:11pt;">.</font><font style="display:inline-block;width:15.76pt;"></font><font style="font-size:11pt;">The Seller and its advisors, if any, have been furnished with all materials relating to the business, finances and operations of the Buyer and materials relating to the offer and sale of the Shares which have been requested by the Seller. &#160;The Seller and its advisors, if any, have been afforded the opportunity to ask questions of the Buyer and have received complete and satisfactory answers to any such inquiries. &#160;Without limiting the generality of the foregoing, the Seller has also had the opportunity to obtain and to review the Buyer&#8217;s Annual Report on Form 10-K/A for the year ended</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">December 31, 2011, its Quarterly Report on Form 10-Q for each of the quarters ended March 31, 2012 and June 30, 2012 filed with the Securities and Exchange Commission (the &#8220;SEC Documents&#8221;). &#160;Neither the Buyer nor any other person on its behalf has made any representations to the Seller except as contained in the Buyer&#8217;s SEC Documents or in this Agreement and in making the decision to purchase the Shares, the Seller has not relied on any representation or information other than those which Seller has independently investigated and verified.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.12</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Risks.</u><font style="font-size:11pt;"> The Seller understands that its investment in the Shares involves a high degree of risk and that Seller can bear the economic risk of the purchase of the Shares, including total loss of his investment. Seller has adequate means of providing for current needs and has no need for liquidity in the investment. &#160;Reference is made to the factors discussed in the &#8220;Risk Factor&#8221; section of Buyer&#8217;s SEC documents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.13</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Grants</u><font style="font-size:11pt;">. The Seller has no knowledge that any pending NIH grants or any other grants that it has shall be terminated or are subject to termination or non-fulfillment either prior to or as a result of this Agreement. &#160;Seller shall provide all reasonable cooperation to assist Buyer in finalizing any NIH pending grants associated with the Program.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.14</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exclusive Representations and Warranties</u><font style="font-size:11pt;">. &#160;Other than the representations and warranties set forth in this Agreement (including the Exhibits hereto), Seller is not making any other representation or warranty, express or implied, with respect to the Assets or the Program.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE V</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">REPRESENTATIONS AND WARRANTIES OF BUYER</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Buyer (or Synthetic and Buyer jointly and severally, if Buyer is a wholly owned subsidiary of Synthetic) represents and warrants to, and agrees with, Seller as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Organization and Good Standing</u><font style="font-size:11pt;">. &#160;It is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Corporate Authority</u><font style="font-size:11pt;">. &#160;It has full authority to execute and to perform this Agreement in accordance with its terms; the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby does not and will not result in a breach, violation or default or give rise to an event which, with the giving of notice or after the passage of time, or both, would result in a breach, violation or default of any of the terms or provisions of its Certificate of Incorporation, By-Laws or of any indenture, agreement, judgment, decree or other instrument or restriction to which it is a party or by which it may be bound or affected; the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all requisite corporate action on the part of it and no further authorization or approval, whether of its stockholders or directors or governmental bodies or otherwise, is necessary in order to enable it to enter into and perform the same (other than NYSE MKT approval); and this Agreement constitutes a valid and binding obligation enforceable against it in accordance with its terms.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.3 </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Capitalization</u><font style="font-size:11pt;">. Synthetic has provided to Seller a schedule that sets forth its authorized and issued capital stock, options, warrants and convertible securities. &#160;Other than as set forth on such schedule, Synthetic does not have outstanding any options to purchase, or any rights or warrants to subscribe for, or any securities or obligations convertible into or any contracts or commitments to issue or sell common stock or any such warrants, convertible securities or obligations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.4 </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Validity of Shares</u><font style="font-size:11pt;">. &#160;The Shares have been duly authorized and upon receipt of the approval of the NYSE MKT LLC, will be validly issued (including, without limitation, in compliance with applicable federal and state securities laws) and when issued as provided herein will be fully paid and non-assessable. &#160;Such Shares are free and clear of all mortgages, pledges, liens, security interests, encumbrances, conditional sales agreements, charges, claims and restrictions of any kind and nature</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">whatsoever, and the Seller will obtain good and valid title to such Shares free and clear of all mortgages, pledges, liens, security interests, encumbrances, conditional sales agreements, charges, claims and restrictions of any kind and nature whatsoever.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.5</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">SEC Documents</u><font style="font-size:11pt;">. Notwithstanding the foregoing, it represents and warrants that each of the SEC Documents presents fairly Synthetic&#8217;s financial condition as of the date of such filing and there has been no material adverse change in its financial condition from the date of the SEC Documents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5.5 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Brokers</u><font style="font-size:11pt;">. &#160;There has been no broker or finder involved in any manner in the negotiations leading up to the execution of this Agreement or the consummation of any transactions contemplated hereby and Buyer agrees to indemnify Seller against and hold Seller harmless from any claim made by any party for a broker&#39;s or finder&#39;s fee or other similar payment based upon any agreements, arrangements or understanding made by Buyer.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE VI</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">COVENANTS OF SELLER</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.1 </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Delivery of Assets</u><font style="font-size:11pt;">. &#160;Simultaneously herewith, Seller shall deliver to Buyer all materials and other information Seller has which comprise or exclusively relate to the Assets, including all existing, proposed or expired agreements exclusively respecting the Program and all regulatory filings related to the Assets.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Further Assurances</u><font style="font-size:11pt;">. &#160;Seller agrees that, at any time after the date hereof, upon the request of Buyer, it will do, execute, acknowledge and deliver, or will cause to be done, executed, acknowledged and delivered, all such further acknowledgments, deeds, assignments, bills of sale, transfers, conveyances, instruments, consents and assurances as may reasonably be required for the better assigning, transferring, granting, conveying, assuring and confirming to Buyer, its successors and assigns, the Assets to be transferred to Buyer as provided herein. &#160;Seller agrees to cause its officers, managing member and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">management to reasonably cooperate with Buyer and Buyer&#8217;s representatives and agents to make themselves available to the extent reasonably necessary to complete the transfer of the Assets and the filing of any assignments with the United States Patent and Trademark Office and any foreign similar office. &#160;In the event that a party hereto becomes aware of any existing patent or pending patent application that is covered by the definition of Proprietary Rights but which is not currently listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto, such patent or patent application shall automatically be covered by the definition of Proprietary Rights and shall be deemed to constitute a Proprietary Right of Buyer. &#160;Seller, at no cost or expense to Seller, shall take all action reasonably requested by Buyer to effectuate the assignment to Buyer of any grants or pending grants and to effectuate the obtainment and possession of any tangible material related to the Program.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.3 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Information Rights</u><font style="font-size:11pt;">. &#160;Buyer shall provide Seller with any rights to non-public financial information, financial statements, inspection rights, and other information rights specifically provided to any other common shareholders.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.4</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Conduct of the Business Pending the Closing</u><font style="font-size:11pt;">. &#160; From and after the date hereof until the Closing Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a)</font></font><font style="font-size:11pt;">Seller shall carry on its business relating to the Assets and the Program in the ordinary course consistent with past practice, including, without limitation, the prosecution of any pending patent applications, and the payment of any maintenance fees upon the earliest date due on any patents, included in the Assets or related thereto, shall preserve its ownership in the Assets, and shall not engage in any transaction or activity relating to the Assets, enter into any agreement, or make any commitment relating to the Assets;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><font style="font-size:11pt;">Seller shall preserve and keep intact its business organization relating to the Assets;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">Except as permitted by this Agreement, without the prior written consent of Buyer, Seller will not:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(i) </font><font style="display:inline-block;width:22.87pt;"></font><font style="font-size:11pt;">permit or allow any of the Assets to be subjected to any mortgages, liens, pledges, charges, security interests, encumbrances or encroachments, or to any rights of others of any kind of nature whatsoever;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(ii) </font><font style="display:inline-block;width:19.81pt;"></font><font style="font-size:11pt;">take any actions to modify, terminate or amend any of the documents comprising the Assets;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iii) </font><font style="display:inline-block;width:16.75pt;"></font><font style="font-size:11pt;">engage in the sale, license, assignment, transfer, conveyance, lease, mortgage, pledge or other disposition of the Assets;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iv) </font><font style="display:inline-block;width:17.37pt;"></font><font style="font-size:11pt;">incur any liability relating to the Assets other than the fees set forth in Section 2.3 which Seller has agreed to pay and Buyer has (or Synthetic and Buyer, if Buyer is a wholly owned subsidiary of Synthetic have) agreed to reimburse; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">(v) </font><font style="display:inline-block;width:20.42pt;"></font><font style="font-size:11pt;">agree, whether in writing or otherwise, to do any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d) &#160;</font></font><font style="font-size:11pt;">Seller shall not do any act or omit to do any act, which will cause a breach of any contract or commitment of Seller or which would cause the breach of any representation, warranty or covenant made hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE VII</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">CONDUCT OF BUSINESS OF BUYER PENDING FILING OF AN IND</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Between the Closing Date and the filing of an IND:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Regular Course of Business</u><font style="font-size:11pt;">. &#160;Buyer shall carry on its business relating to the Assets and the Program in the ordinary course consistent with past practice, including, without limitation, the prosecution of any pending patent applications, and the payment of any maintenance fees upon the earliest date due on any patents, included in the Assets or related thereto, shall preserve its ownership in</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">the Assets, and shall not engage in any transaction or activity relating to the Assets, enter into any sale, license, pledge or encumbrance of the Assets. &#160;To the extent that Buyer deems it advisable to sublicense ex-U.S. rights prior to the filing on an IND to further the development of Assets in international regulatory jurisdictions wherein any such sublicense will be subject to the terms of this Agreement, Seller agrees to not unreasonably withhold consent for such sublicense without consideration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Organization</u><font style="font-size:11pt;">. &#160;Buyer shall preserve and keep intact its business organization relating to the Assets and shall use reasonable efforts to continue to make all payments and filings necessary to maintain all patent filings in jurisdictions in which Seller currently has made filings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.3 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Certain Changes</u><font style="font-size:11pt;">. &#160;Except as permitted by this Agreement, without the prior written consent of Seller, Buyer will not:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) </font></font><font style="font-size:11pt;">permit or allow any of the Assets to be subjected to any mortgages, liens, pledges, charges, security interests, encumbrances or encroachments, or to any rights of others of any kind of nature whatsoever;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><font style="font-size:11pt;">take any actions to modify, terminate or amend any of the documents comprising the Assets;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) </font></font><font style="font-size:11pt;">engage in the sale, license, assignment, transfer, conveyance, lease, mortgage, pledge or other disposition of the Assets;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d) </font></font><font style="font-size:11pt;">incur any liability relating to the Assets; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e) </font></font><font style="font-size:11pt;">agree, whether in writing or otherwise, to do any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.4 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Default</u><font style="font-size:11pt;">. &#160;Buyer shall not do any act or omit to do any act, which will cause a breach of any contract or commitment of Buyer or which would cause the breach of any representation, warranty or covenant made hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE VIII</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">SURVIVAL; INDEMNIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Survival of Representations and Warranties</u><font style="font-size:11pt;">. &#160;The representations and warranties set forth in Article IV shall survive the Closing Date. &#160;All covenants and agreements that by their terms apply, or that are to be performed in whole or in part at or after the Closing, shall survive from and after the Closing Date for the period provided in such covenant or agreement, if any, or otherwise until fully performed. The provisions of this Section 8.1 shall survive the termination of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Seller Indemnity Against Claims</u><font style="font-size:11pt;">. &#160;Seller hereby agrees to indemnify and hold Buyer harmless from and against any and all liabilities, losses, damages, claims, costs and reasonable expenses of any nature, including attorney fees and costs (&#8220;Loss&#8221;) to the extent such Loss arises from or in connection with the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><font style="font-size:11pt;">any material breach by Seller of any representation or warranty contained in this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) &#160;</font></font><font style="font-size:11pt;">any material breach by Seller of any of its covenants contained in this Agreement; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) &#160;</font></font><font style="font-size:11pt;">any excluded liability.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The indemnity granted by Seller in this paragraph shall not apply with respect to any Loss arising out of any breach by Buyer of its representations, warranties and agreements set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.3 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Buyer Indemnity Against Claims</u><font style="font-size:11pt;">. &#160;Buyer hereby agrees to indemnify and hold Seller harmless from and against any and all Losses to the extent such Losses arise from or in connection with the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><font style="font-size:11pt;">any material breach by Buyer of any representation or warranty contained in this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) &#160;</font></font><font style="font-size:11pt;">any material breach by Buyer of any of its covenants contained in this Agreement; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) &#160;</font></font><font style="font-size:11pt;">any Assumed Liability.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The indemnity granted by Buyer in this paragraph shall not apply with respect to any Loss arising out of any breach by Seller of its representations, warranties and agreements set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.4 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notice of Claim, Assumption of Defense and Settlement of Claims.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:76.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><font style="font-size:11pt;">A party seeking indemnification (an &#8220;Indemnified Party&#8221;) under this Article VIII shall promptly give notice (an &#8220;Indemnification Notice&#8221;) in accordance with Section 13.1 hereof to the indemnifying party (the &#8220;Indemnifying Party&#8221;) after the Indemnified Party shall have knowledge of any demands, claims, actions or causes of action (singly, a &#8220;Claim&#8221; and hereinafter referred to collectively, as &#8220;Claims&#8221;) which might give rise to a Claim by the Indemnified Party against the Indemnifying Party, stating the nature and basis of said Claim and the amount thereof, to the extent known. &#160;A failure to give notice hereunder shall not relieve the Indemnifying Party from any obligation hereunder except to the extent such failure to give notice shall materially and adversely affect the Indemnifying Party&#8217;s ability to defend the Claim. &#160;After the delivery of an Indemnification Notice certifying that the Indemnified Party has incurred or had asserted against it any Losses for which indemnity may be sought in accordance with the terms of this Article VIII, the Indemnified Party shall deliver to the Indemnifying Party all information and documentation reasonably requested by the Indemnifying Party with respect to such Loss.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:76.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) &#160;</font></font><font style="font-size:11pt;">With respect to any third party Claims made subsequent to the Closing Date, the following procedures shall be observed:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(i) &#160;</font><font style="display:inline-block;width:20.12pt;"></font><font style="font-size:11pt;">Promptly after delivery of an Indemnification Notice in respect of a Claim, the Indemnifying Party may elect, by written notice to the Indemnified Party, to undertake the defense thereof with counsel reasonably satisfactory to the Indemnified Party and at the sole cost and expense of the Indemnifying Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(ii) &#160;</font><font style="display:inline-block;width:17.06pt;"></font><font style="font-size:11pt;">Failure by the Indemnifying Party to notify the Indemnified Party of its election to defend any such action within twenty (20) days after notice thereof shall have been given, shall be deemed a waiver by the Indemnifying Party of its right to defend and settle such</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">action. &#160;If the Indemnifying Party assumes the defense of any such Claim, its obligations hereunder as to such Claim shall be limited to taking all steps reasonably necessary in the defense or settlement of such Claim and to holding the Indemnified Party harmless from and against any and all Losses awarded in any such proceeding or arising out of any settlement approved by the Indemnifying Party or any judgment in connection with such Claim.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iii)</font><font style="display:inline-block;width:19.5pt;"></font><font style="font-size:11pt;">The Indemnifying Party shall not, in the defense of any such Claim, consent to the entry of any judgment (except with the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed) or enter into any settlement (except with the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed ) which does not include as an unconditional term thereof the giving by the claimant or the plaintiff to the Indemnified Party of a complete release from all liability in respect of such Claim.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(iv)</font><font style="display:inline-block;width:20.12pt;"></font><font style="font-size:11pt;">If &#160;the Indemnifying Party does not assume the defense of a Claim, the Indemnified Party shall diligently defend such claim, and the Indemnifying Party shall promptly reimburse the Indemnified Party for all reasonable expenses, legal or otherwise, incurred by the Indemnified Party in connection with the defense against and settlement of such Claim, net of any tax benefits realized by Buyer arising from such expenses, as and when the same shall be incurred by the Indemnified Party; provided, however, that the Indemnified Party provides an undertaking to repay such expenses to the Indemnifying Party if it is ultimately and finally determined by a court of competent jurisdiction and all rights of appeal have lapsed that such Indemnified Party is not entitled to indemnification under this Article VIII or under applicable law or otherwise. &#160;The Indemnified Party shall not admit any liability with respect to, or settle, compromise or discharge, such third party Claim without the Indemnifying Party&#8217;s prior written consent, which will not be unreasonably withheld or delayed. In the event the Indemnified Party assumes the defense of the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">Claim, the Indemnified Party will keep the Indemnifying Party reasonably informed of the progress of any such defense, compromise or settlement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(v)</font><font style="display:inline-block;width:23.17pt;"></font><font style="font-size:11pt;">The Indemnifying Party shall reimburse the Indemnified Party for all Losses actually incurred by the Indemnified Party as ultimately and finally determined by a court of competent jurisdiction, net of any tax benefits realized by Buyer arising from such Losses.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:76.5pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:31.5pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c)</font></font><font style="font-size:11pt;">With respect to any Claims other than third party Claims made subsequent to the Closing Date, the following procedures shall be observed:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:11pt;">(i) &#160;</font><font style="display:inline-block;width:20.12pt;"></font><font style="font-size:11pt;">The Indemnifying Party shall have thirty (30) days following receipt of any Indemnification Notice pursuant hereto to (A) agree to the amount or method of determination of Losses set forth in the Indemnification Notice to pay such amount to the Indemnified Party in immediately available funds, or (B) provide the Indemnified Party with notice that they disagree with the amount or method of determination of Losses set forth in the Indemnification Notice, and the parties shall thereafter attempt to resolve the disagreement by negotiation in good faith; provided that if the parties are unable to reach agreement within sixty (60) days of such notice, the dispute shall be submitted for final adjudication to the applicable court sitting in the State of Michigan in accordance with Section 13.3. &#160;The Indemnifying Party shall reimburse the Indemnified Party for all Losses actually incurred by the Indemnified Party as ultimately and finally determined by a court of competent jurisdiction, net of any tax benefits realized by Buyer arising from such Losses.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.5 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Limitations; Exclusive Remedy; Effect of Knowledge of Breach</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) </font></font><font style="font-size:11pt;">Buyer and Seller acknowledge and agree that the indemnification provided in this Article&#160;VIII shall not be the sole remedy for Losses related to or arising at law, under any statute or in equity, or otherwise out of this Agreement or the transactions contemplated hereby (other than claims of or causes of action arising from a finding of actual fraud or willful misconduct); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><font style="font-size:11pt;">Without limiting the effect of any other limitation contained in this Article VIII, no representation or warranty of Seller, on the one hand, or Buyer, on the other hand, shall be deemed to be or to have been breached if the other party establishes by documentary evidence that the counterparty had knowledge, on or prior to the date of this Agreement of the breach of such representation or warranty, or of any facts or circumstances rendering such representation or warranty inaccurate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.6 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Right to Set Off</u><font style="font-size:11pt;">. Notwithstanding anything to the contrary set forth in this Agreement or any Exhibit hereto, with respect to any amounts due and payable to Buyer under this Article VIII, Buyer shall have the right to set off the amount of such Loss against any amounts due to Seller hereunder or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE IX</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">CONFIDENTIALITY AND NON-COMPETITION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Confidentiality</u><font style="font-size:11pt;">. &#160;From after the Closing Date and for a period of five (5) years thereafter or earlier termination of this Agreement, Seller shall retain in strictest confidence, and shall not use for its benefit or for the benefit of others all confidential information comprising or related to the Assets, including, without limitation, the technology, know-how, trade secrets, transferred hereby to Buyer, product development techniques or plans, or technical processes, designs and design projects exclusively respecting the Program; </font><i style="font-size:11pt;font-style:italic;">provided, however</i><font style="font-size:11pt;">, that Seller may use or disclose any such confidential information to fulfill any of its obligations hereunder. &#160;Notwithstanding the foregoing, Seller shall not be prohibited from using or disclosing any such confidential information which: (i) enters the public domain or is publicly available, provided that such public knowledge was not the result of any breach of this Agreement attributable to the Seller, or (ii) is required to be disclosed by such Seller pursuant to applicable law or court order, in which case, the Seller shall give written notice to Buyer prior to such disclosure so that Buyer may seek a protective order or other appropriate remedy, and the Seller will</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">reasonably cooperate with Buyer in any proceeding to obtain a protective order or other remedy. From after the execution of this Agreement until the Closing Date or earlier termination of this Agreement, each party shall retain in strictest confidence, and shall not use for its benefit or for the benefit of others all confidential information comprising or related to the Assets other than in order to fulfill its obligations under this Agreement, including, without limitation, the technology, know-how, trade secrets, transferred hereby to Buyer, product development techniques or plans, or technical processes, designs and design projects exclusively respecting the Program.&#160; </font><font style="font-size:11pt;">Notwithstanding the foregoing, neither party shall be prohibited from using or disclosing any such confidential information which: (i) enters the public domain or is publicly available, provided that such public knowledge was not the result of any breach of this Agreement attributable to the receiving party; or (ii) is required to be disclosed by the receiving party pursuant to applicable law, rule or regulation applicable to such party or court order, in which case, the receiving party shall give written notice to the disclosing party prior to such disclosure so that the disclosing party may seek a protective order or other appropriate remedy, and the receiving party will reasonably cooperate with the disclosing party in any proceeding to obtain a protective order or other remedy.&#160; The Buyer&#8217;s obligations under the third sentence of this Section 9.1 shall continue for a period of five (5) years after execution of this Agreement if this Agreement is terminated prior to Closing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">9.2  </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Non-Competition</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><font style="font-size:11pt;">For a period ending on the earlier of termination of this Agreement or five (5) years from and after the Closing Date, Seller shall not, directly or indirectly engage in a business or enterprise (either as proprietor, partner, employee, agent, consultant, or controlling stockholder) in the development or marketing of any program or intellectual property focused on Clostridium Difficile Associated Diarrhea (CDAD) (a &#8220;competing business&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) &#160;</font></font><font style="font-size:11pt;">The provisions of this Section 9.2 shall not prevent Seller from directly or indirectly investing its assets in securities of any corporation, or otherwise acquiring an equity interest in</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">any enterprise, equity securities of which are publicly owned and traded, provided that such investments or interests shall not result in (i) Seller directly or indirectly owning beneficially, in the aggregate, five percent (5%) or more of the equity securities of any enterprise engaged in a competing business or (ii) Seller being able to control or actively participate in the policy decisions of such competing business.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) &#160;</font></font><font style="font-size:11pt;">It is the desire and intent of the parties that the provisions of this Section 9.2 shall be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. &#160;If any particular provision or portion of this Section 9.2 shall be adjudicated to be invalid or unenforceable in any jurisdiction, this Section 9.2 shall be deemed amended to delete therefrom such provision or portion adjudicated to be invalid or unenforceable, such amendment to apply only with respect to the operation of this paragraph in the particular jurisdiction in which such adjudication is made. &#160;If there is a breach or threatened breach of the provisions of this Section 9.2, Buyer shall be entitled to an injunction restraining the Seller from such breach without the obligation of posting a bond. &#160;Nothing herein shall be construed as prohibiting Buyer from pursuing any other remedies for such breach or threatened breach.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d) &#160;</font></font><font style="font-size:11pt;">Seller declares that the foregoing territorial and time limitations are reasonable and properly required for the adequate protection of the business of Buyer. &#160;In the event any such territorial or time limitation is deemed to be unreasonable by a court of competent jurisdiction, Seller agrees to the reduction of either said territorial or time limitation to such area or period which said court shall have deemed reasonable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e) &#160;</font></font><font style="font-size:11pt;">The existence of any claim or cause of action by Seller against Buyer or any subsidiary other than under this Agreement shall not constitute a defense to the enforcement by Buyer or any subsidiary of the foregoing restrictive covenants, but such claim or cause of action shall be litigated separately.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f) &#160;</font></font><font style="font-size:11pt;">The undertakings and covenants of Seller contained in this Section 9.2 are an integral part of the transactions set forth in this Agreement and the consideration paid by Buyer pursuant to this Agreement shall be consideration not only for the Assets but also for such undertakings and covenants.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE X</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">SPECIAL COVENANTS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">10.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Cooperation</u><font style="font-size:11pt;">. &#160;The parties shall cooperate with each other fully with respect to actions reasonably required or requested to be undertaken with respect to tax audits, administrative actions or proceedings, litigation and any other matters that may occur after the date hereof, and each party shall maintain and make available to the other party upon reasonable request all corporate, tax and other records required or requested in connection with such matters. Seller shall also reasonably assist Buyer, at no cost to Seller, in asserting claims under the assigned patents including obtaining from the inventors prompt production of documents and facts, giving of testimony, execution of petitions and other assistance necessary for filing patent applications, infringement and enforcement or other actions or proceedings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">10.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Publicity</u><font style="font-size:11pt;">. &#160;Each party hereto agrees that it shall not disclose any of the terms and conditions of this Agreement or the transactions contemplated hereby and that no publicity release or announcement concerning this Agreement or the transactions contemplated hereby shall be issued, in each case without the advance written approval of the other party; provided, however that each party shall be entitled to disclose the terms and conditions of this Agreement and the transactions contemplated hereby if it is required to be disclosed by it pursuant to applicable law, rule or regulation or court order. Notwithstanding the foregoing, each party may disclose the terms of this Agreement to their accountants</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">and attorneys solely for use in connection with the preparation of tax returns or in complying with the terms of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE XI</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">CLAWBACK RIGHTS/UNWIND</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Rights of the Seller To Force An Unwind</u><font style="font-size:11pt;">. &#160;If on or prior to the date that is (i) thirty (30) months after the date of the execution of this Agreement, the Buyer has not initiated toxicology studies in a non-rodent model, or (ii) thirty-six (36) months of the date of execution of this Agreement, the Buyer has not filed an IND under the Program and such failure to file &#160;is not related to and &#160;not due to any action or inaction of the Seller or a breach of the representations or warranties or covenants of the Seller contained in this Agreement, then, as an exclusive remedy, Seller may elect, in its sole discretion, to have the Assets reverted back to Seller and Buyer shall no longer have any right, title or interest in the Assets. &#160;Notwithstanding the foregoing, Buyer shall have the right to extend the foregoing thirty (30) &#160;and thirty-six (36) month periods by an additional twelve (12) months by advancing to Seller the first milestone payment of One Hundred Thousand Dollars ($100,000 on or before (a) thirty (30) months of the date of execution of this Agreement if Buyer has not initiated toxicology studies in a non-rodent model under the Program, or (b) thirty-six (36) months of the date of execution of this Agreement if Buyer has not filed an IND under the Program, time being of the essence. &#160;In addition, if a change of control of Buyer (or Buyer or Synthetic, if Buyer is a wholly owned subsidiary of Synthetic) shall occur and thereafter Buyer fails to use reasonable efforts to pursue development of the Program, then, as an exclusive remedy, Seller may elect, in its sole discretion, to have the Assets reverted back to Seller and Buyer shall no longer have any right, title or interest in the Assets. For purposes of this Section 11.1 a change in control shall mean (a) any person (excluding current beneficial owners of five percent (5%) or more of Synthetic&#8217;s outstanding common stock) becomes the beneficial owner (as term is defined in the Securities Exchange Act of 1934)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">directly or indirectly, of securities representing more than fifty percent (50%) of the total voting power of Buyer&#8217;s (or Buyer&#8217;s or Synthetic&#8217;s, if Buyer is a wholly owned subsidiary of Synthetic) shares; or (b) within a twelve (12) month period, there is a change in the composition of the Board of Directors as a result of which fewer than a majority of the then directors are Incumbent Directors.&#160;&#160;Incumbent Directors shall mean directors who are either directors of the Seller at least twelve (12) months prior to such change in composition or are elected by the Board of Directors with the affirmative vote of a majority of the Incumbent Directors at the time of election. At any time after the thirty (30) month or thirty-six (36) month periods in this Section 11.1, Seller may request from Buyer documentation that Buyer has initiated toxicology studies in a non-rodent model under the Program or that Buyer has filed an IND under the Program. Within fifteen (15) days after such a request from Seller, Buyer shall provide such documentation to Seller. &#160;If pursuant to this Section 11.1 the Assets revert to Seller, then Section 9.1 shall apply to the Confidential Information obtained by Buyer from Seller (exclusive of any improvements or enhancements made to the Assets by Buyer) as though Buyer was the Seller and Seller was the Buyer for purposes of Section 9.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Procedure upon Unwind</u><font style="font-size:11pt;">. &#160;In the event of an unwind pursuant to Section 11.1 hereof, written notice thereof shall forthwith be given to the other parties hereto and the Buyer shall immediately execute and deliver to Buyer, a Bill of Sale and Assignment, in substantially the same form as annexed hereto as </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit F</u><font style="font-size:11pt;"> (other than to reflect Buyer as the assignor and Seller as the assignee), and a Recordable Patent Assignment, in substantially the form annexed hereto as </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit H</u><font style="font-size:11pt;"> (other than to reflect Buyer as the assignor and Seller as the assignee), assigning all of Buyer&#8217;s right, title and interest in the Assets and intellectual property originally conveyed hereunder, to Seller, and from and after the date of delivery of the written notice, Buyer&#8217;s interest in the such assets and intellectual property rights shall terminate. &#160;Such assignment shall be in at least all of the jurisdictions set forth on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;">. If the transactions contemplated by this Agreement is unwound Buyer will redeliver to Seller all documents,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">work papers and other material of the Seller relating to the transactions contemplated hereby that the Seller has delivered to the Buyer whether so obtained before or after the execution hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE XII</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">TERMINATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">12.1 </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Right To Terminate</u><font style="font-size:11pt;white-space:pre-wrap;">.  This Agreement may be terminated at any time prior to the Closing:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a) </font></font><font style="font-size:11pt;">by mutual written agreement of Seller and Buyer;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><font style="font-size:11pt;">by the Seller if the Closing shall not have been consummated on or before the thirtieth day after the execution of this Agreement; </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided</u><font style="font-size:11pt;">, </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">however</u><font style="font-size:11pt;">, that the right to terminate this Agreement under this Section 12.1(b) shall not be available to the Seller if the failure to fulfill any obligation under this Agreement by Seller has been the cause of, or resulted in, the failure of the Closing to occur on or before such date; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(c) </font></font><font style="font-size:11pt;">by the Buyer at any time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The party desiring to terminate this Agreement pursuant to Section 12.1 shall give notice of such termination to the other party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">12.2 </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Effect of Termination</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;">(a) </font></font><font style="font-size:11pt;white-space:pre-wrap;">If this Agreement is terminated as permitted by Section 12.1(c), such termination shall be without liability of either party to the other party to this Agreement except that Buyer shall be entitled to the prompt reimbursement by Seller of one half (Fifty Thousand Dollars) of the cash  payment made to Seller under Section 2.4 of this Agreement and any fees paid by Buyer pursuant to Section 2.3 of this Agreement; </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">provided further</u><font style="font-size:11pt;"> that if such termination shall result from the failure of Seller to fulfill its obligations under this Agreement then Buyer shall be entitled to the prompt reimbursement by Seller of the entire One Hundred Thousand Dollars ($100,000) paid to Seller under Section 2.4 of this Agreement in addition to reimbursement of any fees paid by Buyer pursuant to Section 2.3 of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">ARTICLE XIII</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">GENERAL PROVISIONS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.1 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notices</u><font style="font-size:11pt;">. &#160;All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given or made as follows: &#160;(i) if sent by registered or certified mail in the United States return receipt requested, upon receipt; (ii) if sent by nationally recognized overnight air courier, one (1) business day after mailing; (iii) if sent by facsimile transmission or electronic mail, with a copy mailed on the same day in the manner provided in clauses (i) or (ii) of this Section 13.1, when transmitted and receipt is confirmed; and (iv) if otherwise actually personally delivered, when delivered, in each case if addressed:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">(a)  </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">in the case of Synthetic or Buyer to:</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">Synthetic Biologics, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">617 Detroit Avenue, Suite 100</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">Ann Arbor, Michigan 48104</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">Facsimile: (734) 332-7878</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;white-space:pre-wrap;">Attention:  Jeffrey L. Riley</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">Email Address: jriley@syntheticbiologics.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">with a copy (which shall not constitute notice) to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">Gracin &amp; Marlow, LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">405 Lexington Avenue, 26thFloor</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">New York, New York 10174</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;white-space:pre-wrap;">Attention:  Leslie Marlow, Esq.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">Facsimile: (212) 208-4657</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">Email Address: lmarlow@gracinmarlow.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:left;white-space:pre-wrap;">(b)  </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">in the case of Seller to:</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">Prev ABR LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">7272 Wisconsin Avenue, Suite 300</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;">Bethesda, Maryland 20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">Attention: R Michael Floyd</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">Facsimile: (301) 986 4811</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">Email Address:mfloyd@lsmgrp.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">or to such other address or to such other person as Buyer or Seller shall have last designated by written notice given as herein provided.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.2 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Modification</u><font style="font-size:11pt;">. &#160;This Agreement and the Exhibits and Schedules annexed hereto contain the entire agreement between the parties hereto and there are no agreements, warranties or representations with respect to the subject matter hereof which are not set forth herein. &#160;All prior negotiations, agreements and understandings are superseded hereby. &#160;This Agreement may not be modified or amended except by an instrument in writing duly signed by or on behalf of the parties hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.3 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Governing Law</u><font style="font-size:11pt;">. &#160;This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Michigan applicable to agreements made and to be performed entirely within the State. &#160;Seller hereby irrevocably consents to the jurisdiction of any Michigan State or Federal court located in Michigan over any action or proceeding arising out of any dispute between Seller and Buyer, and irrevocably agrees, in this regard, not to commence any action or proceeding arising out of any dispute between Seller and Buyer in any other jurisdiction. &#160;Seller further irrevocably consents to the service of process in any such action or proceeding by the mailing of a copy of such process to it at the address set forth above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.4 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Binding Effect; Assignment</u><font style="font-size:11pt;">. &#160;This Agreement shall be binding upon the parties and inure to the benefit of the successors and assigns of the respective parties hereto. &#160;Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other party; provided, however, that Buyer may assign its rights and obligations under this Agreement, without the prior written consent of the other party, to an affiliate or to a successor of the relevant portion of the assigning party&#8217;s business by reason of merger, sale of all or substantially all of its assets or any similar transaction, provided that such successor agrees in writing to be bound by this Agreement. &#160;Any permitted assignee shall assume all obligations of its assignor under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.5 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts</u><font style="font-size:11pt;">. &#160;This Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.6 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Paragraph Headings</u><font style="font-size:11pt;">. &#160;The paragraph headings in this Agreement are for convenience of reference only and shall not be deemed to alter or affect any provision hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.7 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Transaction Expenses</u><font style="font-size:11pt;">. &#160;Notwithstanding anything else in this Agreement to the contrary, the parties hereto shall each be responsible for the payment of (and shall indemnify and hold the other party or parties hereto harmless against) any and all of its own expenses, including without limitation the fees and expenses of counsel, accountants and other advisers, arising out of or relating directly or indirectly to the transactions contemplated by this Agreement, whether or not such transactions are consummated in whole or in part.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.8 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Waiver</u><font style="font-size:11pt;">. &#160;The waiver of one breach or default hereunder shall not constitute the waiver of any other or subsequent breach or default.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.9 &#160;</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Agency</u><font style="font-size:11pt;">. &#160;This Agreement shall not constitute either party the legal representative or agent of the other, nor shall either party have the right or authority to assume, create, or incur any liability or any obligation of any kind, express or implied, against or in the name of or on behalf of the other party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.10</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Knowledge</u><font style="font-size:11pt;">.</font><font style="display:inline-block;width:18.54pt;"></font><font style="font-size:11pt;">For purpose of this Agreement, knowledge shall mean Seller&#8217;s actual knowledge, after reasonable investigation, and the actual knowledge of any employee or member of Seller.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-size:11pt;">, the parties hereto have duly executed this Agreement the day and date first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SYNTHETIC BIOLOGICS, INC</b><font style="font-size:11pt;">.</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Jeff Riley</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Jeff Riley</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">CEO</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">PREV ABR LLC</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ R. Michael Floyd</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:top;width:44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">R. Michael Floyd</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:top;width:44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Managing Member</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">INTENTIONALLY OMITTED.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">PATENTS AND JURISDICTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:86.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MODIFIED BETA-LACTAMASES AND METHODS AND USES RELATED THERETO (P3A)</p></td></tr><tr style="height:12pt;"><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Country</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Filing</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Application No.</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Status</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Patent No. </p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expiry Date</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">24-May-2010</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FI-20105572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Lapsed</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PCT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">17-May-2011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PCT FI2011/050450</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WO partly positive</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">May-31</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:86.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">MODIFIED BETA-LACTAMASES AND METHODS FOR ITS PREPARATION (P2A)</p></td></tr><tr style="height:12pt;"><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Country</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Filing</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Application No.</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Status</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Patent No. </p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expiry Date</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">FI</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21-Jun-2006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">20065431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FI 119190</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21-Jun-26</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">PCT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21-Jun-2007</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PCT/FI2007/050372</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">WO positive</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21 Jun 2026 FI</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">National filings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">21-Dec-2008</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:86.42%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NON-SPORULATING BACILLUS SUBTILIS, ITS MANUFACTURE AND USE (HOST PATENT)</p></td></tr><tr style="height:12pt;"><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Country</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date of Filing</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Application No.</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Status</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Patent No.</p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Expiry Date</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">FI</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6-Nov-2001</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">20012143</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">FI 112666</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11-Jun-21</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3-May-2004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">02774801.1-2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11-May-22</p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:13.57%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">US</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5-May-2004</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10/494,411</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.32%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">US 2005/0158843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.01%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1-Oct-24</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:40%;"><tr style="height:14.4pt;"><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:72.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Patents Costs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:14.4pt;"><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:72.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">HOST Patent</p></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">600</p></td></tr><tr style="height:14.4pt;"><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:72.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Response to Host Action </p></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3,900</p></td></tr><tr style="height:14.4pt;"><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:72.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Response to EPO </p></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,800</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:14.4pt;"><td colspan="3" style="vertical-align:middle;white-space:nowrap;width:100%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">National Phase of PCT P3A:</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Aus</p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3,250</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Canada</p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3,250</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">India</p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3,250</p></td></tr><tr style="height:14.4pt;"><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:72.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">South Africa</p></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3,250</p></td></tr><tr style="height:14.4pt;"><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:72.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Euro PCT (EP)</p></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5,700</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Brazil</p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,000</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">China</p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,250</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Japan</p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5,800</p></td></tr><tr style="height:14.4pt;"><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:72.17%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">South Korea</p></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,650</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Russia</p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,400</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:middle;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">USA</p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4,250</p></td></tr><tr style="height:14.4pt;"><td style="vertical-align:top;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;white-space:nowrap;width:27.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:15pt;"><td style="vertical-align:top;white-space:nowrap;width:65.74%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 7.2pt;">Total</p></td><td style="vertical-align:top;white-space:nowrap;width:6.43%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:middle;white-space:nowrap;width:27.82%;border-bottom:2.25pt double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">52,350</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ESCROW AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">ESCROW AGREEMENT, dated November ___, 2012, by and between by and between SYNTHETIC BIOLOGICS, INC, a Nevada corporation having its principal place of business at 617 Detroit Street, Suite 100, Ann Arbor, Michigan 48104 (the &#8220;Pledgee&#8221;), PREV ABR LLC, a Maryland limited liability company having its principal place of business at 7272 Wisconsin Avenue, Suite 300, Bethesda, Maryland 20814 (the &#8220;Pledgor&#8221;) and Gracin &amp; Marlow, LLP, attorneys at law, a New York limited liability partnership with an address at 405 Lexington Avenue, 26</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Floor, New York, New York 10174, as escrow agent (the &#8220;Escrow Agent&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.1pt;margin:0pt;"><font style="font-size:11pt;">WHEREAS, Pledgor is a party to an Asset Purchase Agreement, dated the date hereof (the &#8220;Asset Purchase Agreement&#8221;), pursuant to which Pledgor is receiving shares of common stock of Pledgee;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.1pt;margin:0pt;"><font style="font-size:11pt;">WHEREAS, the Pledgor wishes to pledge Three Hundred Seventy Five Thousand (375,000) shares of the common stock of Pledgee (the &#8220;Shares&#8221;) to be held in escrow and released to the parties in accordance with the terms hereof (the Shares are hereinafter referred to as the &#8220;Escrowed Items&#8221;);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.1pt;margin:0pt 0pt 12.6pt 0pt;"><font style="font-size:11pt;">WHEREAS, the Pledgee and Pledgor wish for the Escrowed Items to be deposited with the Escrow Agent pursuant to the terms of this Escrow Agreement; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.1pt;margin:0pt 0pt 12.6pt 0pt;"><font style="font-size:11pt;">WHEREAS, the Escrow Agent is willing to act as escrow agent pursuant to the terms of this Escrow Agreement with respect to the Escrowed Items;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36.1pt;margin:0pt 0pt 12.6pt 0pt;"><font style="font-size:11pt;">NOW THEREFORE, in consideration of the premises and the covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12.6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">1. </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Establishment of Escrow Account</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11.44pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Deposit into Escrow</u><font style="font-size:11pt;">. The Pledgor hereby instructs the Pledgee to deposit the Escrowed Items with the Escrow Agent on the date hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Acceptance</u><font style="font-size:11pt;">. Upon receipt of the Escrowed Items, the Escrow Agent agrees to hold the Escrowed Items in accordance with the terms and conditions of this Escrow Agreement (the &#8220;Escrow&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:49.5pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10.94pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10.94pt;margin-top:0pt;text-align:justify;"><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Release from Escrow</u><font style="font-size:11pt;">. &#160;Upon receipt of joint written instructions executed by the Pledgor, and Pledgee, the Escrow Agent shall deliver and release the number of shares of common stock being held as part of the Escrowed Items designated in such joint written instructions in the amounts and to each person or entity specified in the joint written instructions. If joint written instructions for all of the Escrowed Items are not provided to the Escrow Agent prior to the six (6) month year anniversary of execution of this Agreement and the Escrow Agent has not received a copy of any notice of a Claim from Pledgee under Section 8.2 of the Asset Purchase Agreement, the Escrow Agent shall deliver any remaining Escrowed Items to Pledgor. &#160;If at any time Pledgee and/or Pledgor objects to a distributionrequested by the other, then the Escrow Agent will not release the Escrowed Items but will continue to hold the Escrowed Items until directed to cause the delivery of the Escrowed Items either: (i) by joint written notice to the Escrow Agent by the Pledgor and Pledgee (which may be signed in counterparts); (ii) a final order of the applicable arbitrator or court unless such order is appealed and execution on such order is stayed, in</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 67.5pt;"><font style="font-size:11pt;">which case a final order of the court considering such appeal or such motion is vacated; or (iii) otherwise required by laws or court order..</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">3.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Termination of this Escrow Agreement</u><font style="font-size:11pt;">. This Escrow Agreement shall terminate when the Escrowed Items shall have been distributed as above provided subject to the provisions of Section 4 which shall survive any such termination.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">4.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Rights and Duties of Escrow Agent</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Duties Limited</u><font style="font-size:11pt;">. The Escrow Agent undertakes to perform only such duties as are expressly set forth herein, which duties, as hereinabove set forth in Sections 1, 2 and 3 hereof, shall terminate upon the release of the Escrowed Items as contemplated above. The parties hereto acknowledge that the duties to be performed by the Escrow Agent hereunder are of a ministerial nature only, and that the Escrow Agent shall not be liable for any error, omission or action taken by it unless such error, omission or action was the result of the Escrow Agent&#39;s gross negligence or willful default.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Reliance</u><font style="font-size:11pt;">. The Escrow Agent may rely upon, and shall be protected in acting or refraining from acting upon, any written notice, instruction or request furnished to it hereunder and believed by it to be genuine and to have been signed or presented by the Pledgee and Pledgor, provided that any modification of this Escrow Agreement shall be required to be signed by the Pledgee, Pledgor and the Escrow Agent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Good Faith</u><font style="font-size:11pt;">. The Pledgee and Pledgor shall jointly indemnify the Escrow Agent and hold it harmless from and against any loss, liability or expense incurred without gross negligence or bad faith on its part, arising out of or in connection with the Escrow Agreement, including the costs and expenses of defending itself against any such claim or liability. The Escrow Agent may consult with counsel of its own choice, and shall have full and complete authorization and no liability for any action taken or suffered by it hereunder in good faith and in accordance with the opinion of such counsel.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Disputes</u><font style="font-size:11pt;">. It is understood and agreed that should any dispute arise, the Escrow Agent is authorized and directed to retain the Escrowed Items or deposit them with a court of competent jurisdiction, until the dispute shall have been settled either by mutual written agreement of the parties concerned or a by a final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but the Escrow Agent shall be under no duty whatsoever to institute or defend any such proceedings. In addition, the Escrow Agent is acting, and may continue to act, as counsel to the Pledgee in connection with the subject transaction, including in connection with any dispute as to the proper application of the Escrowed Items, whether or not the Escrowed Items are being held by the Escrow Agent or have been delivered to a successor escrow agent or a court of competent jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">5. </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Resignation; Successor Escrow Agent</u><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) </font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Resignation</u><font style="font-size:11pt;">. The Escrow Agent may resign at any time by giving five days&#39; notice of such resignation to the Pledgee and Pledgor. Thereafter, such original Escrow Agent shall have no further obligation hereunder except to hold the Escrowed Items. In such event, the original Escrow Agent shall refrain from taking any action until it shall receive joint written instructions from the Pledgee and Pledgor designating a successor escrow agent. Upon receipt of such instructions, the Escrow Agent shall promptly deliver the Escrowed Items to such successor escrow agent and shall thereafter have no further obligations hereunder. &#160;Notwithstanding the foregoing, the Escrow Agent in its sole discretion may at any time after its resignation deposit the Escrowed Items with a court of competent jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b)</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Successor Escrow Agent</u><font style="font-size:11pt;">. The Pledgee and Pledgor together shall have the right to terminate the appointment of the Escrow Agent hereunder by giving notice in writing of such termination to the Escrow Agent, specifying the date upon which such termination shall take effect. In the event of such termination, the Pledgee and Pledgor agree that they will jointly appoint a successor escrow agent at or before the time such notice becomes effective, and the Escrow Agent hereby agrees that it shall turn over and deliver the Escrowed Items to such successor escrow agent. Upon delivery of the Escrowed Items, the Escrow Agent shall be discharged of any further duties under this Escrow Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11.8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">6.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Fees and Expenses of the Escrow Agent</u><font style="font-size:11pt;">. The Pledgee and Pledgor agree, jointly and severally, to (i) pay the Escrow Agent Two Thousand Five Hundred Dollars ($2,500) upon execution of this Escrow Agreement; and (ii) reimburse the Escrow Agent for all necessary expenses, disbursements and advances (including reasonable attorneys&#39; fees) incurred or made by it in connection with carrying out its duties hereunder. The liability of the Pledgee and Pledgor under this Section 6 shall be joint and several.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11.8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">7.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Waivers and Modifications</u><font style="font-size:11pt;">. This Escrow Agreement may be amended, modified, extended, superseded or canceled, and any of the terms, covenants, representations, warranties or conditions hereof may be waived, only by a written instrument executed by all of the parties hereto. The failure of any party at any time or times to require performance of any provision hereof shall in no manner affect the right of such party at a later time to enforce the same. No waiver by any party of the breach of any term, covenant, representation or warranty contained in this Escrow Agreement as a condition to such party&#39;s obligation hereunder shall release or affect any liability resulting from such breach, and no waiver of any nature, whether by conduct or otherwise, in anyone or more instances, shall be deemed to be construed as a further or continuing waiver of any such condition or breach, a waiver of any other condition or a waiver of any breach of any other condition, term, covenant, representation or warranty of this Escrow Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11.8pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">8.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Notices</u><font style="font-size:11pt;">. Any notice, demand or other communication required or permitted to be given pursuant to this Escrow Agreement shall have been sufficiently given for all purposes (a) if delivered personally to the party or to an executive officer of the party to whom such notice, demand or other communication is directed on the date of such personal delivery; or (b) if sent by registered or certified mail, postage prepaid, addressed to the party to whom such notice, demand or other communication is directed at its address set forth below on the fifth business day after the date on which it was deposited in a regularly maintained receptacle for the deposit of United States mail; or (c) if sent by facsimile transmission, or electronic mail, with a copy mailed on the same day by first class mail, postage prepaid.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">If to the Pledgee:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">Synthetic Biologics, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">617 Detroit Street<br>Ann Arbor, Michigan, 48104</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">Facsimile: 734-332-7878</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">Email:jriley@synethticbiologics.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">Attention: Jeffrey Riley</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">If to Pledgor:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Prev ABR LLC</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">7272 Wisconsin Avenue</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Bethesda, Maryland 20814</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Facsimile: (301) 986 4811</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Email Address:mfloyd@lsmgrp.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Attention: R Michael Floyd</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">If to the Escrow Agent:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Gracin &amp; Marlow, LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">405 Lexington Avenue, 26</font><sup style="font-size:8.25pt;vertical-align:top;">th</sup><font style="font-size:11pt;"> Floor</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">New York, New York 10174</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">Facsimile: (212) 208-4657</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Attention:  Leslie Marlow</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11.35pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">9.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">No Assignment</u><font style="font-size:11pt;">. This Escrow Agreement shall be binding upon the successors and permitted assigns of the parties hereof. No assignment of any rights or delegation of any obligations provided for herein may be made by any party hereto without the express written consent of all other parties hereto, except for the provisions of Section 5 respecting successor escrow agents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11.35pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">10.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Entire Agreement</u><font style="font-size:11pt;">. This Escrow Agreement contains the entire agreement among the parties hereto with respect to the subject matter hereof, and there are no representations, warranties, understandings or agreements other than those expressly set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11.35pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">11.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Further Assurances</u><font style="font-size:11pt;">. If at any time any party hereto shall consider or be advised that any further agreements, assurances or other documents are reasonably necessary or desirable to carry out the provisions hereof and the transactions contemplated hereby, the parties hereto shall execute and deliver any and all such agreements or other documents, and do all things necessary or appropriate to carry out fully the provisions hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11.35pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">12.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Governing Law</u><font style="font-size:11pt;">. The validity of this Escrow Agreement and the rights, obligations and relations of the parties hereunder shall be construed and determined under and in accordance with the laws of the State of New York without giving effect to the conflict of laws rules of such State. ALL PARTIES HEREBY SUBMIT TO THE JURISDICTION OF THE STATE OF NEW YORK IN CONNECTION WITH ANY LEGAL PROCEEDINGS COMMENCED IN CONNECTION WITH THIS ESCROW AGREEMENT.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 11.35pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">13.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Counterparts</u><font style="font-size:11pt;">. This Escrow Agreement may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">14.</font></font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Section Headings</u><font style="font-size:11pt;">. The section headings contained in this Escrow Agreement are inserted for purposes of convenience of reference only and shall not affect the meaning or interpretation hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">IN WITNESS WHEREOF, the parties have executed this Escrow Agreement as of the date first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93%;"><tr style="height:10.35pt;"><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SYNTHETIC BIOLOGICS, INC.</b></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:48.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">PREV ABR LLC</b></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:48.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;">Title:</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">ESCROW AGENT:</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">GRACIN &amp; MARLOW, LLP</b></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:48.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;white-space:pre-wrap;">Name:  Leslie Marlow</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:52.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title: Partner</font></p></td><td style="vertical-align:top;width:47.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">MILESTONE PAYMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">EACH OF THE FOLLOWING PAYMENTS OR STOCK ISSUANCES SHALL BE DUE AND PAYABLE OR ISSUED, AS THE CASE MAY BE, WITHIN 5 BUSINESS DAYS AFTER ACHIEVING THE RESPECTIVE MILESTONE AND AFTER RECEIPT OF NECESSARY REGULATORY APPROVALS</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Filing of an IND: USD $100,000 in cash</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Initiation of Phase 1 (first subject dosed): USD $250,000 50% of which will be paid in cash and the remaining 50% to be paid in the stock equivalent. At Seller&#8217;s option, the full milestone may be paid in stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Commencement of Phase 2 (first subject dosed): USD $1,000,000 50% of which will be paid in cash and the remaining 50% to be paid in the stock equivalent. At Seller&#8217;s option, the full milestone may be paid in stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Commencement of Phase 3 (first patient dosed): USD $2,000,000 50% of which will be paid in cash and the remaining 50% to be paid in the stock equivalent. At Seller&#8217;s option, the full milestone may be paid in stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">BLA Filing: USD $3,000,000 50% of which will be paid in cash and the remaining 50% to be paid in the stock equivalent. At Seller&#8217;s option, the full milestone may be paid in stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Filing BLA in any other territory: USD $1,000,000 50% of which will be paid in cash and the remaining 50% to be paid in the stock equivalent. At Seller&#8217;s option, the full milestone may be paid in stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">BLA Approval: USD $5,000,000 50% of which will be paid in cash and the remaining 50% to be paid in the stock equivalent. At Seller&#8217;s option, the full milestone may be paid in stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">BLA Approval in any other territory: USD $2,000,000 50% of which will be paid in cash and the remaining 50% to be paid in the stock equivalent. At Seller&#8217;s option, the full milestone may be paid in stock.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Any and all payments in stock contemplated in this Agreement shall be subject to prior approval of the NYSE MKT LLC or any other exchange on which Synthetic&#8217;s securities shall be listed. If such exchange approval is not received, such payment shall be made in each case based upon the average of the opening and closing prices of Synthetic&#8217;s stock on the date such milestone is achieved (or in the event the milestone is achieved on a date in which the stock market is closed on the next business date for such market). &#160;Seller acknowledges that its right to be paid in stock is subject to a limitation such that the aggregate maximum number of shares of Synthetic&#8217;s stock that may be issued in accordance with the terms of this Agreement, including but not limited to all issuances set forth on this Exhibit D and the 625,000 shares to be issued in accordance with Section 2.4(b) of this Agreement, shall not exceed 19.99% of Synthetic&#8217;s outstanding number of shares of common stock on the date of execution of this Agreement; provided, however, that &#160;Synthetic shall have the right, in its sole discretion, to obtain shareholder approval to issue shares of stock in excess of the 19.99% cap in accordance with all applicable exchange</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 5pt 0pt;"><font style="font-size:11pt;">requirements and if such shareholder approval is obtained then Synthetic shall have the right, in its sole discretion, to make such payments in shares of its common stock. For purposes of the Asset Purchase Agreement all of the countries located in Europe shall be one territory, Korea, Japan and India shall be one territory, South America including Brazil shall be one territory and The United States and Canada shall be one territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT E</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">SECTION 2.5</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">I.R.C. SECTION 1060 ALLOCATION</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">For tax purposes, the Seller and Buyer shall allocate the purchase price as follows:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">80% to the patents and patent applications relating to the CDAD program;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">10% to the preclinical package for P1A, P2A and P3A</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">10% for the master cell banks or P1A, P2A, and P3A</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 5pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT F</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ASSIGNMENT AND BILL OF SALE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">KNOW ALL MEN BY THESE PRESENTS</b><font style="font-size:11pt;">, that Synthetic Biologics, Inc., a Nevada corporation having its principal place of business at 617 Detroit Avenue, Suite 100, Ann Arbor, Michigan 48104 (&#8220;Buyer&#8221;), for and in consideration of the receipt of the consideration set forth in the Asset Purchase Agreement executed on the date hereof between the Buyer and PREV ABR LLC, a Maryland limited liability company, having its principal place of business at 7201 Wisconsin Avenue, Bethesda, Maryland 20814 (&#8220;PrevAb&#8221;) and other good and valuable consideration in full payment for the assets hereinafter specified, the receipt and sufficiency of which is hereby acknowledged, has granted, bargained, sold and by these presents does grant, bargain, sell, convey and deliver to Buyer, and its successors and assigns, the following assets:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">PrevAb&#8217;s CDAD program including </font><font style="font-size:11pt;">any and all of the following assets of PrevAb, including any and all rights and benefits constituting and relating to PrevAb&#39;s &#946;-lactamase technology and all other biomedical or pharmaceutical technologies of PrevAb and all &#946;-lactamase products detained and/or developed with the aforementioned technologies, including without limitation the lead P1A, P2A and P3A-based products in preclinical and clinical phases </font><font style="font-size:11pt;"> (the &#8220;Program&#8221;) and all tangible and intangible intellectual property and know how exclusively related thereto including the following:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(a) &#160;</font></font><font style="font-size:11pt;">all methods &#160;and data sets, and all technical documentation pertaining to the Program, including any specifications, flow charts, diagrams, lab results and any and all notes, all inventor notebook pages specific to the Program, plans and other documentation describing problems, future directions or other matters exclusively related to the Program;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(b) </font></font><font style="font-size:11pt;">(i) all patents, patent rights, copyrights, trademarks, trademark rights, tradenames, tradename rights and patent, copyright or trademark applications exclusively respecting the Program and related intellectual property; (ii) all reissues, reexaminations, extensions, continuations, continuations-in-part, continuing prosecution applications, requests for continuing examinations, divisions and registrations of any item in any of the foregoing categories; (iii) foreign counterparts of any of the foregoing; (iv) all patent and patent applications claiming any right of priority to or through the patent applications of the patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto; (v) all rights to apply in all countries of the world for patents certificates of invention, utility models, industrial design protections, design patent protections, or other governmental grants or issuances of any type related to any item in any of the foregoing categories (i) through (v), including, without limitation, under the Paris Convention for the Protection of Industrial Property, the International Patent Cooperation Treaty, or any other convention, treaty, agreement, or understanding; (vi) all invention, invention disclosures and discoveries described in any of the patents listed on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;"> hereto that are included in any claim in such patents, and/or are subject matter capable of being reduced to a patent claim in a reissue or reexamination proceeding brought on any of the patents; (vii) all causes of action (whether known or unknown, or whether currently pending, filed or otherwise) and other enforcement rights under, or on account of, any of the patents and/or rights (as described on </font><u style="font-size:11pt;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</u><font style="font-size:11pt;">); (viii) all rights to collect royalties and other payments under or on account of the patents or any item in any categories (i) through (vii); (ix) all ideas, know-how, trade secrets, inventions, invention disclosures, discoveries, technology, designs and any other proprietary rights which Seller owns, in each case with respect to any of the above, pertaining exclusively to the Program (collectively, &#8220;Proprietary Rights&#8221;); and (x) a list of upcoming filings, all US Patent and Trademark Office and other patentability assessments;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(c) </font></font><font style="font-size:11pt;">all cGMP and non-cGMP material and master call banks of P1A, P2A and P3A and all other tangible assets related thereto;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(d)</font></font><font style="font-size:11pt;">any and all U.S. and international investigational new drug applications (IND) and pre-INDs of Seller;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(e)</font></font><font style="font-size:11pt;">all grants and other non-dilutive funding sources associated with the CDAD Program if legally assignable or transferable by Seller to Buyer;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(f)</font></font><font style="font-size:11pt;">all scientific consulting agreements with the members of PrevAb&#8217;s scientific advisory board;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(g)</font></font><font style="font-size:11pt;">information and know-how related to research, development, manufacture and/or business (commercial/marketing), used or held for use in connection with the Program;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(k)</font></font><font style="font-size:11pt;">any and all health and regulatory registrations, approvals and/or applications and related documentation for the Program;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(l)</font></font><font style="font-size:11pt;">any and all drugs, formulations and user devices, applications, and safety data; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(m)</font></font><font style="font-size:11pt;">all other information, documentation and goodwill relating to the Program; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">(n)</font></font><font style="font-size:11pt;">all regulatory files (paper and electronic) or so-called regulatory files and records of communications and filings with any and all regulatory authorities in both paper and electronic form.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TO HAVE AND TO HOLD </b><font style="font-size:11pt;">the said assets unto Buyer, its successors and assigns, to and for its own use, forever.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">1. &#160;</font></font><font style="font-size:11pt;">PrevAb warrants to Buyer its successors and assigns, that at the time of delivery of this Bill of Sale to Buyer, PrevAb has good and valid title to said assets to the same extent assigned to it by PrevAb and good and lawful right to grant, bargain, sell, convey and deliver said assets as aforesaid and that the title to said assets are as of the date of delivery of said assets to Buyer, free and clear of all claims, liens, pledges, security interests and other encumbrances of any nature whatsoever(&#8220;Liens&#8221;). &#160;PrevAb further warrants that upon delivery of this Bill of Sale to Buyer, Buyer shall have good and valid legal title to the assets described in this Bill of Sale, free and clear of all claims, liens, pledges, security interests and other encumbrances of any nature whatsoever. The foregoing is subject to any Liens that were unknown to PrevAb but were in effect at the time of the sale of the Assets to Buyer by PrevAb.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">2. &#160;</font></font><font style="font-size:11pt;">PrevAb agrees to execute and deliver to Buyer &#160;such other documents and instruments of sale, conveyance, transfer and assignment, satisfactory in form and substance to Buyer, as may be reasonably requested by Buyer in order to effect PrevAb&#8217;s assignment of assets hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">IN WITNESS WHEREOF</b><font style="font-size:11pt;">, the parties hereto have caused these presents to be executed as of the ___ day of November, 2012.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.9%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">PREVABR LLC</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:45.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SYNTHETIC BIOLOGICS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By:</font></p></td><td style="vertical-align:top;width:45.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Name;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Title:</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Intentionally Omitted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Exhibit B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Title</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:85.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">MODIFIED BETA-LACTAMASES AND METHODS AND USES RELATED THERETO (P3A)</font></p></td></tr><tr style="height:12pt;"><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Country</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Date of Filing</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Application No.</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Status</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Patent No. </font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Expiry Date</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">EP</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">24-May-2010</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">FI-20105572</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Lapsed</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PCT</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">17-May-2011</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">PCT FI2011/050450</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">WO partly positive</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">May-31</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Title</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:85.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">MODIFIED BETA-LACTAMASES AND METHODS FOR ITS PREPARATION (P2A)</font></p></td></tr><tr style="height:12pt;"><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Country</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Date of Filing</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Application No.</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Status</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Patent No. </font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Expiry Date</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FI</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">21-Jun-2006</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">20065431</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Granted</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">FI 119190</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">21-Jun-26</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PCT</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">21-Jun-2007</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">PCT/FI2007/050372</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">WO positive</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">21 Jun 2026 FI</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">National filings</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">21-Dec-2008</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:85.37%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">NON-SPORULATING BACILLUS SUBTILIS, ITS MANUFACTURE AND USE (HOST PATENT)</font></p></td></tr><tr style="height:12pt;"><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Country</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Date of Filing</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Application No.</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Status</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Patent No.</font></p></td><td style="background-color:#bfbfbf;vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Expiry Date</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FI</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">6-Nov-2001</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">20012143</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Granted</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">FI 112666</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">11-Jun-21</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">EP</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">3-May-2004</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">02774801.1-2</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">pending</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">11-May-22</font></p></td></tr><tr style="height:12pt;"><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">US</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">5-May-2004</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.25%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">10/494,411</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.67%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Granted</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.02%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">US 2005/0158843</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.83%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;">1-Oct-24</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT G</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">INTENTIONALLY OMITTED.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">EXHIBIT H</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">ASSIGNMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">PREV ABR LLC</b><font style="font-size:11pt;"> with offices at </font><b style="font-size:11pt;font-weight:bold;">7272 Wisconsin Avenue</b><font style="font-size:11pt;">, </font><b style="font-size:11pt;font-weight:bold;">Suite 300</b><font style="font-size:11pt;">, </font><b style="font-size:11pt;font-weight:bold;">Bethesda</b><font style="font-size:11pt;">, </font><b style="font-size:11pt;font-weight:bold;">Maryland 20814</b><font style="font-size:11pt;">, the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, confirm that we have freely assigned, and do hereby freely assign, and transfer to </font><b style="font-size:11pt;font-weight:bold;">SYNTHETIC BIOLOGICS</b><font style="font-size:11pt;">, </font><b style="font-size:11pt;font-weight:bold;">INC.</b><font style="font-size:11pt;">, a corporation, with offices at </font><b style="font-size:11pt;font-weight:bold;">617 Detroit Street</b><font style="font-size:11pt;">, </font><b style="font-size:11pt;font-weight:bold;">Ann Arbor</b><font style="font-size:11pt;">, </font><b style="font-size:11pt;font-weight:bold;">Michigan 48104</b><font style="font-size:11pt;">, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEES: &#160;(1)&#160;our entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the applications listed in &#8220;</font><b style="font-size:11pt;font-weight:bold;">Schedule A</b><font style="font-size:11pt;">&#8221;, including any subsequently filed applications, which claim priority to, and benefit of, the applications listed on </font><font style="font-size:11pt;font-style:italic;font-weight:bold;">&#8220;</font><b style="font-size:11pt;font-weight:bold;">Schedule A</b><font style="font-size:11pt;">&#8221;, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefore; (2)&#160;the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in my name as the ASSIGNEE, or its designee&#39;s election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3)&#160;the entire right, title and interest in and to any Letters Patent which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4)&#160;the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEES of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">We agree, at any time, upon the request of the ASSIGNEES, to execute and to deliver to the ASSIGNEES any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">We further agree at any time to execute and to deliver upon request of the ASSIGNEES such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEES under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">We hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">We further covenant that ASSIGNEES will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEES or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><th style="font-weight:normal;text-align:left;vertical-align:top;width:4.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Date: </font></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:45.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Signature of:</font></p></th></tr><tr><th colspan="2" style="font-weight:normal;text-align:left;vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">On Behalf of: </font><b style="font-size:11pt;font-weight:bold;">PREV ABR LLC</b></p></th></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:216pt;text-indent:-216pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:6.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">State of</font></p></td><td colspan="2" style="vertical-align:top;width:43.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">County of</font></p></td><td style="vertical-align:top;width:40.84%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">On this ______ day of ________________, 20__, before me, the undersigned notary public, personally appeared</font><b style="font-size:11pt;font-weight:bold;"> ________________________</b><font style="font-size:11pt;"> proved to me through satisfactory evidence of identification, which was a </font><b style="font-size:11pt;font-weight:bold;">__________________</b><font style="font-size:11pt;">, to be the person whose name is signed on this document and who swore or affirmed to me that the contents of this document are truthful and accurate to the best of his/her knowledge and belief.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Notary Public</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:20%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">My commission expires</font></p></td><td style="vertical-align:top;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Schedule A</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:13.2pt;"><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Country</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Date of Filing</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Application No.</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Status</b><font style="font-size:11pt;"> </font></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Patent No.</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Expiry Date</b></p></td></tr><tr style="height:12.95pt;"><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:4.5pt;"><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.7pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">EP</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">24-May-2010</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FI20105572</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Lapsed</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12.7pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PCT</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">17-May-2011</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PCT FI2011/050450</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">WO partly positive</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">May-31</font></p></div></div></td></tr><tr style="height:12.75pt;"><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Country</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Date of Filing</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Application No.</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Status</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Patent No.</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Expiry Date</b></p></td></tr><tr style="height:12.7pt;"><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:4.25pt;"><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FI</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">21-June-2006</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">20065431</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Granted</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FI119190</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">21-June-26</font></p></div></div></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PCT</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">21-Jun-2007</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PCT/FI2007/050372</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">WO positive</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">21 Jun 2026 FI</font></p></div></div></td></tr><tr style="height:12.7pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">National filings</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">21-Dec-2008</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.7pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12.75pt;"><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Country</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Date of Filing</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Application No.</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Status</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Patent No.</b></p></td><td rowspan="3" style="background-color:#bfbfbf;vertical-align:top;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Expiry Date</b></p></td></tr><tr style="height:12.95pt;"><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:4.25pt;"><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FI</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">28-Nov-2006</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">20065757</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Granted</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FI119678</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">28-Dec-26</font></p></div></div></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PCT</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">21-Nov-2007</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">PCT7FI2007/05062</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">WO positive</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">28 Dec 2028 FI</font></p></div></div></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">National Filings</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">28-May-2009</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:12.7pt;"><td rowspan="4" style="background-color:#bfbfbf;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Country</b></p></td><td rowspan="4" style="background-color:#bfbfbf;vertical-align:top;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Date of Filing</b></p></td><td rowspan="4" style="background-color:#bfbfbf;vertical-align:top;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Application No.</b></p></td><td rowspan="4" style="background-color:#bfbfbf;vertical-align:top;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Status</b></p></td><td rowspan="4" style="background-color:#bfbfbf;vertical-align:top;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Patent No.</b></p></td><td rowspan="4" style="background-color:#bfbfbf;vertical-align:top;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Expiry Date</b></p></td></tr><tr style="height:12.75pt;"><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.7pt;"><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:4.25pt;"><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:top;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="background-color:#bfbfbf;display:none;vertical-align:bottom;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FI</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">6-Nov-2001</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">20012143</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Granted</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">FI112666</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">11-June-21</font></p></div></div></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">EP</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">3-May-2004</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">02774801.1-2</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Pending</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">11-May-22</font></p></div></div></td></tr><tr style="height:12.75pt;"><td style="vertical-align:middle;width:14.76%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">US</font></p></div></div></td><td style="vertical-align:middle;width:15.78%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">5-May-2004</font></p></div></div></td><td style="vertical-align:middle;width:18.91%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">10/494,411</font></p></div></div></td><td style="vertical-align:middle;width:18.98%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">Granted</font></p></div></div></td><td style="vertical-align:middle;width:15.73%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">US2005/0158843</font></p></div></div></td><td style="vertical-align:middle;width:15.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><div style="height:12.75pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;">1-Oct-24</font></p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>4
<FILENAME>syn-20211231xex10d32.htm
<DESCRIPTION>EX-10.32
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:42:08 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 10.32</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CONTRACT TO GRANT A MARKETING LICENSE FOR CATALAN INSTITUTE OF ONCOLOGY PATENT OWNERSHIP APPLICATION WO2008110579 (International application number PCT/EP2008/052960) TO VCN BIOSCIENCES S.L.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">L&#8217;Hospitalet on May&#160;16,&#160;2009</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">BY AND BETWEEN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">L&#8217;Hospitalet on May&#160;16,&#160;2009 BY AND BETWEEN Of the first part, Joaquim Esperalba Iglesias, General Director of the Catalan Institute of Oncology, of legal age, having as his professional address at Av. Gran Via 199-203, 08907, Hospitalet, Barcelona and holder of DNI (</font><i style="font-size:11pt;font-style:italic;">Documento Nacional de Identidad</i><font style="font-size:11pt;"> [National Identity Document]) number [***], and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Of the second part, Mr Manel Cascallo Piqueras, Sole Director of VCN BIOSCIENCES S.L., of legal age, a company having its registered office at Pg. Circumvallaci&#243; 54 of Gelida (08790), and holder of provisional CIF (</font><i style="font-size:11pt;font-style:italic;">C&#243;digo de Identificaci&#243;n Fiscal</i><font style="font-size:11pt;"> [Tax Identity Code]) number B65109605.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">HEREBY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">The first party, acting on behalf of and in legal representation of the Catalan Institute of Oncology, a public company, (hereinafter ICO), in accordance with its Bylaws, the same which were published by means of the Resolution of the Ministry of Health and Social Security of March&#160;7,&#160;1995 (DOGC (</font><i style="font-size:11pt;font-style:italic;">Diari Oficial de la Generalitat de Catalunya</i><font style="font-size:11pt;"> [Official Gazette of the Autonomous Government of Catalonia]) No. 2029, of 03/24/1995 and by virtue of the powers delegated under the agreement of the Board of Directors of said public company of May&#160;17,&#160;2006, the same which was recorded in a public deed with notarial office registry number 1018, authorized by Notary Public Mr. Carlos Masi&#224; Mart&#237;, Notary of the Illustrious Notary Public Association of Catalonia, issued on May&#160;18,&#160;2006, and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">The second party, acting in the capacity of Sole Director of VCN Biosciences S.L., a company incorporated on May&#160;11,&#160;2009 before the Notary Public Mr. Fernando Morales Limia in l&#8217;Hospitalet de Llobregat, notary office registry 711, pending registration in the Company Register (hereinafter, VCN)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">REPRESENTATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">ICO is a public company that conducts healthcare, teaching and biotechnological research activities in oncology.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">The same is the holder of Patent Application </font><b style="font-size:11pt;font-weight:bold;">WO2008110579 (International application number PCT/EP2008/052960), </b><font style="font-size:11pt;">invented by Manel Cascallo Piqueras, Alena Gros Vidal and Ramon Alemany Bonastre, investigators of the ICO Translational Research Laboratory.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">VCN is interested in acquiring a license for the worldwide marketing and exploitation rights for an indefinite period of time in respect of the aforementioned industrial property.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;">Wherefore, the parties do agree to and establish the following</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CLAUSES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ONE.- PURPOSE OF THE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">The purpose of this agreement is to regulate the licensing of the marketing and exploitation rights of the patent application and corresponding PCT number </font><b style="font-size:11pt;font-weight:bold;">P200700665</b><font style="font-size:11pt;">, the same which is the property of the ICO, with priority date 14/03/2007, entitled </font><font style="font-size:11pt;font-style:italic;font-weight:bold;">&#8220;ADENOVIRUS WITH MUTATIONS IN THE AREA OF ENDOPLASMIC RETENTION OF PROTEIN E3-19K AND THEIR USE IN THE TREATMENT OF CANCER&#8221; </font><font style="font-size:11pt;">to VCN, for its marketing and exploitation, for an indefinite period and for the purpose of granting an exclusive, indefinite worldwide supply sublicense to the Dutch company called ORCA Therapeutics B.V., the aforementioned without prejudice to the provisions of Clause Sixteen.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">This agreement does not include any additional knowledge as to the content of the patent application. In the event that VCN or its sublicensees are interested in these, they will be subject to a transfer advisory agreement in which the corresponding conditions will be regulated.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TWO.- ASSIGNMENT OF LICENSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">VCN, in accordance with the foregoing, automatically receives a manufacturing and marketing license for the purpose of the aforementioned patent, limited to the place, time and purpose indicated in this agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">THREE.- DURATION OF THE AGREEMENT AND EXTENSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">The validity period of the license will be unlimited with the only applicable limit being that of the patent&#8217;s own validity, counted from the date of the signing of this agreement and without prejudice to the provisions of Clause Sixteen.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">FOUR.- AMOUNT AND TERMS OF PAYMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">As consideration for the license of the exploitation rights, VCN will pay ICO a royalty of [***]% of the net value of the income from the concession of the sublicense by VCN to ORCA. A copy of the agreement that will be signed between ORCA and VCN (and that will not differ substantially from the final one) which regulates the economic conditions between both companies and of which ICO will receive [***]% on lump sums plus net invoicing for royalties, is attached hereto as an annex.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Royalties will be settled quarterly and 30 days after the invoice date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">These amounts must be increased with the corresponding VAT, and will be paid into the account with the following </font>IBAN: [***]<font style="font-size:11pt;">on behalf of the Catalan Institute of Oncology; upon the submission of an invoice addressed to Mr. Manel Cascallo Piqueras in VCN&#8217;s name.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">FIVE.- PATENT MAINTENANCE EXPENSES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">During the term of this agreement, VCN will be responsible for the expenses derived from the payment of the annuities to keep the patent in force in any of the geographical areas where it is in force.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SIX.- OWNERSHIP OF PATENT RIGHTS IN OTHER COUNTRIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">If, at VCN&#8217;s request, the parties agree to register this patent in any foreign country, it will be registered in the name of ICO, with this agreement being automatically extended for the exploitation of the patent in said country. The procedures in this regard will be carried out by VCN, the same which will be responsible for the corresponding registration and maintenance expenses.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Should VCN not be interested in this regard, ICO may carry out said registration, being free to license the patent to third parties in the countries covering said registration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SEVEN.- USE OF THE PATENTS ASSIGNED BY ICO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">ICO reserves the right to use the techniques, Know-how and inventions assigned to VCN in this agreement, exclusively for the purposes of its own research.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">EIGHT.- OBLIGATION TO EXPLOIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">VCN and its sublicensees undertake to use all diligent and commercially reasonable efforts for the exploitation of the patent. Otherwise, ICO may proceed to recover the license.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Pursuant to Title IX Chapter I and II of Law 11/1986, of March&#160;20, on Invention Patents and Utility Models, the holder of a patent has the obligation to exploit it sufficiently.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">If, due to negligence or lack of action of the licensee or their sublicensee to obtain the different clinical phases and authorizations necessary for its marketing, or in case of insufficient, geographical and/or quantitative, exploitation, ICO reserves the right to recover at any time and in their entirely, its industrial property rights licensed under the present agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">NINE.- ASSIGNMENT OF RIGHTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">VCN may assign to ORCA the rights derived from this agreement, without prior consent from ICO and in respect of the conditions of the annex to this agreement (Agreement with ORCA).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">VCN and/or ORCA will provide a copy to ICO of the documentation relating to any other sublicense of VCN or ORCA to third parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TEN.- RESPONSIBILITY FOR EXPLOITATION RISKS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">VCN assumes all the risks derived from the industrial development of the aforementioned industrial property, both in relation to the products, reliability, clinical trials, etc., as well as in relation to the production systems.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">ELEVEN.- TAX RESPONSIBILITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">VCN will be responsible for all tax payments that may arise from the manufacture and commercial exploitation of the purpose, or object, of the patent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">TWELVE.- GUARANTEES TO CUSTOMERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">VCN will be responsible for providing the given guarantees to customers in respect of the manufactured object. ICO assumes no liability to third parties and will be held completely harmless from litigation arising from the clinical phase as well as from the commercial manufacturing of the invention that is the purpose of the assignment.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">THIRTEEN.- OBLIGATIONS OF VCN TOWARDS ICO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">VCN has the following obligations vis-a-vis ICO:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">To submit a plan and budget to ICO for the development of the patent, or, if relevant, the general terms that will be negotiated in the case of sublicensing with third parties.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;text-align:justify;">To send annual written reports, in specifying the following:</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">-</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">advances in research, clinical trials, FDA or EMEA approvals</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">-</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">timely information on the status of patent processing,</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">-</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">development actions, marketing actions and development costs</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">-</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">sales volumes of the products subject to this agreement and their invoicing date, from the immediately preceding semester.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">-</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">the accounting records pertaining to the patents affecting this agreement and facilitate access, every two years, to such records, to ICO or to the person or party appointed by the latter to verify compliance with the agreed commitments.</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">-</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">any other information of interest to ICO</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 54pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">ICO may require that VCN conduct and participate in the conduct of an audit of its ORCA licensee. To this end, VCN shall promptly inform ICO of its intention to conduct an audit of ORCA or its sublicensees with reasonable advance notice.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">VCN undertakes to defend the interests of ICO as an option for conducting additional preclinical research and development related to the marketing of the industrial property that is the purpose of this agreement.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">FOURTEEN.- CANCELLATION DUE TO COMMERCIAL UNFEASIBILITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">If, upon completion of the development of the patent that is the purpose of this Agreement, the two parties believe that it is not feasible to commercially exploit the products obtained, they will negotiate the cancellation thereof by mutual agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">However, if VCN decides not to maintain the patent, it will notify ICO at least 90 days in advance so that ICO has the option to recover its patent rights.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">FIFTEEN.- TERMINATION OF THE CONTRACT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">A breach of any of the obligations set out and contracted in the present agreement, by either of the parties, authorizes the other party to terminate the same. In such case, all manufacture and commercial exploitation by VCN will be automatically cancelled, with the latter being obliged to pay the royalty corresponding to the current semester.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SIXTEEN.- PUBLIC DEED</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">This document will be recorded in a public deed at the request of any of the contracting parties, at their expense, or when required by applicable legislation.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SEVENTEEN.- JURISDICTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">VCN and ICO undertake to resolve any disagreement that may arise in the development of this agreement in an amicable manner.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">In the event of conflict, both parties agree to submit to the Courts of Barcelona, waiving their respective jurisdiction which may differ therefrom.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">In witness whereof, the parties do hereby sign this document in two identical copies at the place and on the date indicated herein above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/</font><b style="font-size:11pt;font-weight:bold;"> JOAQUIM ESPERALBA IGLESIAS</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">&#160;&#160;&#160;&#160;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">/s/ MANEL CASCALLO PIQUERAS</b></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><b style="font-size:11pt;font-weight:bold;">JOAQUIM ESPERALBA IGLESIAS</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><b style="font-size:11pt;font-weight:bold;">MANEL CASCALLO PIQUERAS</b></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:11pt;">DIRECTOR GENERAL</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="font-size:11pt;">SOLE DIRECTOR</font></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><b style="font-size:11pt;font-weight:bold;">CATALAN INSTITUTE OF ONCOLOGY</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><b style="font-size:11pt;font-weight:bold;">VCN BIOSCIENCES S.L.</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>5
<FILENAME>syn-20211231xex10d33.htm
<DESCRIPTION>EX-10.33
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:42:12 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.33</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In Barcelona, on March&#160;4,&#160;2016 (the &#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;),</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BY AND BETWEEN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Of the first part,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(1)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">FUNDACI&#211; INSTITUT D&#8217;INVESTIGACI&#211; BIOM&#200;DICA DE BELLVITGE [BELLVITGE BIOMEDICAL RESEARCH INSTITUTE FOUNDATION] (IDIBELL)</b>, a Catalan foundation duly incorporated and registered in the <i style="font-style:italic;">Registry of Foundations</i> of <i style="font-style:italic;">the Office of the General Director of Law and Legal Entities</i> of the <i style="font-style:italic;">Department of Justice</i> of the <i style="font-style:italic;">Autonomous Government of Catalonia</i> under number 459, having its address at Hospital Duran i Reynals 3&#170; planta, Gran Via de l&#39;Hospitalet, 199-203, 08908 L&#39;Hospitalet de Llobregat (Barcelona), and holding current CIF (C&#243;digo de Identificaci&#243;n Fiscal [Tax Identification Code]) number G58863317 (&#8220;<b style="font-weight:bold;">IDIBELL</b>&#8221;). IDIBELL is represented herein by <b style="font-weight:bold;">Dr Jaume Revent&#242;s i Puigjaner</b>, whose personal details are not recorded due to of his professional position, as Director, by virtue of the appointment agreed by the IDIBELL Board of Trustees, in the meeting celebrated of March 18, 2014.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Of the second part,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">(2)</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">VCN BIOSCIENCES, S.L.</b>, a company duly incorporated under the laws of Spain, having its legally registered office at Avenida de la Generalitat 152, 08174, Sant Cugat del Vall&#233;s (Barcelona), and holder of Tax Identification Number B-65,109,605<b style="font-weight:bold;"> </b>(&#8220;<b style="font-weight:bold;">VCN</b>&#8221;). VCN is represented herein by <b style="font-weight:bold;">Mr. Manel Cascallo Piqueras</b>, of legal age, of Spanish nationality, whose legal address for the present purposes is located at Avenida de la Generalitat 152, 08174, Sant Cugat del Vall&#233;s (Barcelona), and with DNI (Documento Nacional de Identidad [National Identity Document]) number [***], the same which is legally valid, acting in his capacity as legal representative, in accordance with the sufficient power of attorney that he has produced and put away.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">IDIBELL and VCN will hereinafter be referred to collectively as the &#8220;<b style="font-weight:bold;">Parties</b>&#8221;, whilst each one of them, individually, shall be referred to as a &#8220;<b style="font-weight:bold;">Party</b>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Parties, recognizing that they each have the necessary legal capacity to be bound by and enter into legal contracts do agree to execute the present license agreement (the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;) wherefore and to that end do make the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REPRESENTATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">I.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">IDIBELL is a foundation whose general principles of activity are the promotion, development, management and dissemination of biomedical research as well as training in the field of health sciences and the promotion of the transfer of technology gathered from its research activities.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">II.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Whereas the INSTITUT CATAL&#192; D&#8217;ONCOLOGIA [CATALAN INSTITUTE OF ONCOLOGY] (hereinafter, &#8220;<b style="font-weight:bold;">ICO</b>&#8221;) is a public company dedicated to cancer-related activity and whose purpose is to reduce the impact of cancer in Catalonia, and, within the framework of said activity, develops actions for cancer prevention, care, training and research.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">III.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">On October&#160;2,&#160;2007, IDIBELL and the ICO signed a &#8220;<i style="font-style:italic;">Framework Collaboration Agreement&#8221; </i>(the &#8220;<b style="font-weight:bold;">Framework Agreement</b>&#8221;) [***].</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">IV.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Wherefore, as a result of their research activities, IDIBELL and ICO have obtained a series of scientific results and knowledge based on which certain scientific technology and knowledge has been derived, the same which is subject to protection by means of the patent application for which IDIBELL and ICO are both equal joint holders, by virtue of the provisions of the <i style="font-style:italic;">Framework Agreement</i> referred to in representation III herein above.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">1/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">V.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">IDIBELL and ICO do freely wish and desire to grant VCN, who wishes to accept the same, a License for the use and exploitation of the Patent in the Territory (as these terms are defined herein below), all in respect of the terms and conditions described in this Agreement and its Annexes (the &#8220;<b style="font-weight:bold;">License</b>&#8221;). For clarification purposes, the License to be granted includes the Licensee&#39;s right to sublicense the use and exploitation thereof to any third party, with the sole requirement that the Licensee communicate this in advance in writing to the Licensor for information purposes, except in the cases provided for in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause Two, Section 2</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Following from the above, the Parties do hereby sign this Agreement, the same which will be governed by the following</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COVENANTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">First. </b><b style="font-weight:bold;">Definitions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">For the purposes of this Agreement, the following words shall have the meaning set forth in this Clause, unless they may clearly be understood otherwise as a result of the given context and, if not included below, the meaning set forth elsewhere in the Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:28.1pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93%;"><tr style="height:1pt;"><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Consideration</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means each and all of the fees, <i style="font-style:italic;">royalties</i> and/or payments stipulated in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 3.1</u>;</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Fiscal Year</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means the calendar year, that is, from January&#160;1 to December&#160;31;</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Effective Date</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means the date set out in the heading of this Agreement;</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Grifols Group</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means Grifols, S.A. and all of its subsidiaries and/or entities controlled, either directly or indirectly, by it;</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Sublicensing Income</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means the amount of income actually collected by Licensee from any third party derived from the License (full or partial), or from any other form of exploitation thereof granted further to this Agreement, that, by way of example but not limited thereto, has been received in the form of an upfront payment, milestone payments and/or royalties and provided that the Patent enjoys protection in the different countries that constitute the Territory to which the License refers. For clarification purposes, &#8220;Sublicensing Income&#8221; expressly excludes: [***]</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Licensor</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means, jointly, IDIBELL and ICO;</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Licensee</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means VCN;</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Parties</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means, as the case may be, the Licensor and/or Licensee; and &#8220;<b style="font-weight:bold;">Party</b>&#8221;;</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Patent</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means the entire family of patents whose priority application is European patent application EP 14 38 2162.7, submitted under the title &#8220;<i style="font-style:italic;">Adenovirus comprising an albumin-binding molety</i>&#8221;, along with all of the information and experimental data, in any format, documents, programs, products, equipment, tests, evaluations, prototypes, samples, formulas, specifications, processes, know-how, technical descriptions, data, industrial secrets, developments, methods and/or practices related to the research that has given rise to the</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">2/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:28.1pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93%;"><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Patent, subject or not to protection in the Territory (as defined below), and that can be employed to register, defend and maintain the Patent, where applicable, vis-a-vis the different assessment agencies. For clarification purposes, &#8220;Patent&#8221; expressly includes, but is not limited to, any property right derived from the Patent, such as Supplementary Protection Certificates or equivalents, divisional or equivalent patents and/or continuations in part or the equivalent, provided they do not involve, nor have new inventive activity or novelty, these which shall not be included in the definition. A copy of European patent application EP 14 38 2162.7 is attached hereto as Annex I. The concept of Patent expressly excludes any pre-existing rights, or those that are generated during the term of the Agreement, that are owned by VCN and that could be incorporated into the same;</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Resulting Product</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">refers to any product that incorporates the Licensed Patent, solely or jointly with other patents and/or intellectual and/or industrial property rights (including know how);</p></td></tr><tr><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:5.6pt;"><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Territory</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means the whole world; and</p></td></tr><tr style="height:5.6pt;"><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:5.6pt;"><td style="vertical-align:top;width:27.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<b style="font-weight:bold;">Net Sales</b>&#8221;</p></td><td style="vertical-align:top;width:72.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means the value of Licensee&#39;s income from sales of the Resulting Product in the Territory, minus any discounts and compensations, and free of credits or liens and indirect taxes, &#160;provided that the marketing of the Resulting Product in the corresponding countries of the Territory is indeed protected by the Patent. Sales to distributors shall be understood to be included within the concept of Net Sales (excluding the possibility of considering as Sublicensing Income all sublicenses granted to said distributors and/or final users/clients as necessary for the marketing and/or use of the Resulting Product in the Territory). [***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">When the given context so requires, words expressed in singular shall include the plural and vice versa whilst words expressed in one gender shall include all genders.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The headings of the clauses are included for reference purposes and do not affect the interpretation of this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Second. </b><b style="font-weight:bold;">Granting of the license. Scope and exclusions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">By virtue of this Agreement, and subject to the terms and conditions thereof, Licensor hereby grants the Licensee, the latter who accepts the same, an exclusive, sublicensable and non-transferable license, for the Patent and on all experimental information and data, in any format, documents, programs, products, equipment, tests, evaluations, prototypes, samples, formulas, specifications, processes, know-how, technical descriptions, data related to industrial secrets, developments, methods and/or practices related to the research that has given rise to the Patent, subject or not to protection as intellectual or industrial property rights (with the exception of moral rights), and that may be used for the registration of the Patent in the Territory for its use and exploitation (including any forms of economic exploitation rights that may fall upon it) as well as for its defence and maintenance, where applicable, in the Territory (the &#8220;<b style="font-weight:bold;">License</b>&#8221;). For said purposes, the Licensor warrants that all Licensor investigators and employees have subscribed to as many documents as necessary to duly recognize ownership of all intellectual and industrial property rights (excluding moral rights) in favour of the Licensor. For these purposes, the Licensee may request a copy of these documents at any time from Licensor.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">3/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***] Notwithstanding the foregoing, the Licensee shall inform the Licensor of any sublicensing agreements. In any and all cases, any and all sublicenses must be granted under terms compatible with this License and in strict observance of the rights granted in favour of Licensee. .[***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The License expressly includes, but is not limited to, all rights over the Patent that, in accordance with any of the modalities admitted by applicable laws, are susceptible to exploitation and/or marketing existing at the time that the present Agreement is signed, or included in the form of improvements or developments incorporated into the Patent during the execution thereof. For this purpose, the Licensor undertakes to make available to the Licensee all documentation and technical knowledge necessary for the use and exploitation of the Patent.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensor shall maintain a right of use over the Patent limited to its research and/or teaching activities. If, as a result of such research and/or teaching activities, the Licensor obtains results or knowledge capable of developing, optimizing, improving or adapting the Patent, the following regime shall apply:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.4.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensor shall automatically grant a license in favour of the Licensee, with a scope identical to that one provided for in this Agreement and which is included in the remuneration provided for in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 3,</u> regarding the developments, optimizations, improvements or adaptations of the Patent that they do duly hold or that may have been obtained, based on knowledge (including, but not limited to, the commercial experience obtained from the marketing of the Resulting Product and its use by its end clients) and/or technology (including any pre-existing intellectual and industrial property rights or rights generated during the execution of the Agreement) owned by VCN.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.4.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensee shall have a pre-emptive right to the exploitation and/or marketing of the developments, optimizations, improvements or adaptations of the Patent that are not based on knowledge (including, but not limited to, commercial experience obtained from the marketing of the Resulting Product and use thereof by its end clients) and/or technology (including any pre-existing intellectual and industrial property rights or rights generated during the execution of the Agreement) owned by VCN.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In compliance with the provisions of the <u style="text-decoration:underline;text-decoration-color:#000000;">foregoing Clause</u>, the Licensor undertakes to: (a) grant any public or private documents that are reasonably required by the Licensee for this purpose and, if necessary; and (b) require such issuance from its internal work staff. The Licensee shall be responsible for all expenses related to the granting of the public documents referred to in Section (a) herein above.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensor undertakes not to establish any kind of property right of guarantee over the Patent that could affect the scope and conditions of the License, unless they have previously informed the Licensee thereof, and obtained the latters express and written authorization, for which the Licensor must provide as much documentation as necessary for an adequate assessment by the Licensee of said authorization. The Licensee shall not be obligated, as a result of any rights conferred under the License, to authorize the Licensor to establish property rights in respect of the Patent. A refusal by the Licensee shall not, in any case, imply grounds for termination of this Agreement nor shall it generate additional compensation in favour of the Licensor.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensee grants the Licensor a non-exclusive, not sublicensable, not transferable license, limited to the territory of the country of Spain, during the term of the Agreement and exclusively for the purposes of research and improvement of the Patent, on the intellectual property rights (except for moral rights) and the pre-existing industrial rights that could be used in conjunction with the Patent and, where applicable, those that could have been generated in the course of the execution of the Agreement and that are owned by VCN.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">4/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Third. </b><b style="font-weight:bold;">Consideration</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In consideration for the License, the Licensee shall pay the Licensor:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.1.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the following fixed amounts:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:56.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***] ([***]) euros, payable upon the signing of this Agreement, as an upfront payment), advance or up-front fee; plus</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 42.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:56.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***] ([***]) euros, payable twenty-five (25) days following the date of concession of the Patent, in a minimum of three (3) European jurisdictions, as consideration for the fulfilment of objectives, milestone payments; plus</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 42.55pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:56.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***] ([***]) euros, payable twenty-five (25) days following the date of concession of an American patent (US) derived from the Patent, as consideration for the fulfilment of objectives or <i style="font-style:italic;">milestones</i>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.1.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">a fee or royalty<i style="font-style:italic;">, </i>equivalent to [***] percent ([***]%) of the annual Net Sales figure, payable in accordance with the provisions of <u style="text-decoration:underline;text-decoration-color:#000000;">Clauses 3.2 and 3.3</u>; plus</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.1.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">a fee or royalty, equivalent to the percentages that were applicable in accordance with the provisions of <u style="text-decoration:underline;text-decoration-color:#000000;">Annex II</u> of the annual Sublicensing Income figure (the &#8220;<b style="font-weight:bold;">Royalties for Sublicensing Income&#8221;</b>), payable in accordance with the provisions of <u style="text-decoration:underline;text-decoration-color:#000000;">Clauses 3.2 and 3.3</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><u style="text-decoration:underline;text-decoration-color:#000000;">Invoicing</u>: Within three (3) months of the end of each Fiscal Year, the Licensee shall submit a written report to the Licensor including (i) total Net Sales; and (ii) total Sublicensing Income for the Fiscal Year. Upon receipt of the report and in accordance with the information indicated therein, the Licensor shall issue the corresponding invoice to the Licensee.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><u style="text-decoration:underline;text-decoration-color:#000000;">Payment</u>: All payments must be made by bank transfer to the bank account indicated on the corresponding invoice, within sixty (60) days following the date of the invoice, the same which will stipulate the VAT amount applicable at that time. Any failure to pay due amounts within the term will entitle the Licensor to claim the payment of default interest equal to the legal interest applicable at any time, which will accrue from the date on which the payment should have been made until the date of actual payment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***].</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Audits:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.5.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensee shall maintain orderly and up-to-date accounting records at all times, and shall retain all Licensee&#39;s supporting documents, receipts and invoices for the past four (4) years. This obligation shall remain applicable throughout the term of the Agreement in addition to for the four (4) years following termination thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.5.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Licensor shall have the right to conduct an audit once a year for the sole purpose of calculating, checking and verifying the Sublicensing Income and Net Sales figures provided by the Licensor. The Licensor shall be obliged to communicate in writing to Licensee their intent to conduct the audit, must indicate the date on which it will be executed as well as the persons or entity responsible for its conduct, with a minimum notice of seven (7) business days.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.5.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that the results of the review or audit are justifiably divergent from the figures provided by the Licensee, the remuneration received by the Licensor, in accordance with the concepts set forth in this Agreement, shall be regularized accordingly.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">5/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.5.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.5.5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***].</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.5.6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***].</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">For all relevant purposes, the Licensor expressly represents and warrants to the Licensee that any amounts payable pursuant to this Clause are the sole amounts payable by the Licensee in consideration for the License, releasing this party from liability, and holding them harmless for all purposes, for any claim to economic rights that may correspond to either the ICO and, where applicable, the Investigator or any third party as a result of the License and/or the exploitation and/or marketing of the Patent.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Fourth. </b><b style="font-weight:bold;">Right of reversal</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">As of the third year from the Date of Effect, the Licensor shall have the right to revoke the License, reversing the Patent in its favour and without the Licensee being entitled to receive any indemnification or compensation whatsoever, in the event that the Licensee:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.1.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">During a continuous period of two (2) year(s), abandons its research or development activities of the Patent, or activities aimed at the exploitation of Resulting Products;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.1.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensee has undertaken no marketing whatsoever at any time during the term of this Agreement; or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.1.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Will use the Patent for purposes other than those provided for in the License granted under the present Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In order to exercise the right of reversal, a written communication by the Licensor, of their intent to exercise the aforementioned right shall be sufficient. Said written communication must substantiate the existence of any of the cases indicated in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 4.1</u> and shall grant the Licensee the period established in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 6.2.4</u> for the correction thereof. In the event that such circumstance is not remedied by the Licensee within the aforementioned period, the Licensor shall have the right to revoke the License and the Licensee shall return or deliver to the Licensor the Patent covered by the License at the time of the initial Agreement or that was generated directly by the Licensor during the course thereof, and which remains covered by the License. The Licensee&#39;s obligation to incorporate or deliver to the Licensor any intellectual and industrial property rights that may have generated under this Agreement and of which they are the legal owner, is expressly excluded.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Likewise, the Licensor shall return and deliver to the Licensee any elements subject to intellectual and industrial property rights owned by the Licensee and which have been licensed to the Licensor, the same who shall not hold any right once the License has been revoked or the Agreement has been terminated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Fifth. </b><b style="font-weight:bold;">Liability and indemnity regime. Ethical business conduct</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties shall be responsible for ensuring strict compliance with all regulations applicable to the activities that are carried out under this Agreement, expressly agreeing to be mutually indemnify each other and to compensate each other financially in the case of any damage or harm suffered in the event of any claims of any nature being filed against them.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the fulfilment of their obligations under this Agreement, the Parties, including their workers and representatives, shall carry out their activity in accordance with ethical commercial principles and in accordance with all laws applicable in Spain, in particular, with</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">6/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">the anti-corruption rules issued by Spain (Criminal Code) and by the European Union, the OECD and the Council of Europe, applicable to the aforementioned activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The License described in this Agreement is granted without warranties of any kind, express or implicit, including, but not limited to, a warranty of marketability, patentability and/or adequacy for a certain purpose, except for those warranties expressly covered by this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Sixth. </b><b style="font-weight:bold;">Duration and early termination</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This Agreement will enter into force on the Effective Date, and will be valid and remain effective indefinitely, provided that any of the property rights derived from the Patent is in force in any of the countries in the Territory.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.1pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">6.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">This Agreement may be prematurely terminated given any of the following circumstances:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.2.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">By mutual agreement of the Parties; and/or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.2.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">By the Licensor, in the event of at least two successive breaches, or three alternate breaches calculated annually, of the obligation of the Licensee to pay the Consideration; and/or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.2.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">By the Licensee, at their discretion, in the cases set forth in <u style="text-decoration:underline;text-decoration-color:#000000;">Clauses 7.3.2</u> and <u style="text-decoration:underline;text-decoration-color:#000000;">7.3.3</u> or due to the absence of protection of the Patent in any of the countries in the Territory; and/or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.2.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Due to some breach of any of the obligations, by one of the Parties (the &#8220;<b style="font-weight:bold;">Non-Compliant Party</b>&#8221;), if, once required to do so by the Compliant Party by means of a written communication (the &#8220;<b style="font-weight:bold;">Termination Communication</b>&#8221;), the Non-Compliant Party has still not proceeded to remedy the breach within thirty (30) calendar days following receipt of the Termination Communication (the &#8220;<b style="font-weight:bold;">Termination due to Non-Compliance</b>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Upon termination of the Contract:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.3.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">if the Parties have any obligation pending compliance by virtue thereof, they shall be obliged to comply with it without this involving, in any case or under any circumstances, an extension thereof, and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.3.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the Parties shall return any documentation, information and/or material that belongs to the other Party and that has been delivered to them as a result of the execution of this Agreement, including, but not limited to, the Confidential Information, and will undertake to refrain from making use of such documentation, information and/or material as of that moment.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.3.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The rights and obligations set forth in the First, Fifth, Sixth (only 6.3.4), Seventh, Eighth and Eleventh covenants shall remain in force after the termination or expiration of this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.3.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The sublicenses granted to final recipients of the Resulting Products shall remain in force, regardless of the cause of termination and without these involving obligations towards the Licensor by VCN.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Seventh. </b><b style="font-weight:bold;">Property Rights: Registration, maintenance and defence. Liability and indemnities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Registration and extension</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.1.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Licensee shall have the exclusive power to request the extension or registration, anywhere in the Territory, and before any authority, of any inventions that are</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">7/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 61.2pt;">protected or protectable by the Patent, including provisional patents, new patents or any other forms of protection of industrial and/or intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.1.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensor undertakes not to request, in any way, either by itself or acting through a third party, for an extension or registration of the inventions protected by the Patent in any jurisdiction, without prejudice to the provisions set out in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 7.2.2</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Maintenance</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.2.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensee shall have the obligation to retain and maintain the rights protected by the Patent anywhere in the Territory and before any authority.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.2.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that, with respect to a/any particular jurisdiction/s, the Licensee decides not to maintain the rights protected by the Patent, the may request their maintenance from the Licensee, with the Licensor assuming all costs and expenses related to such maintenance. It shall only be understood that the Licensee declines to maintain a particular jurisdiction when they state such in writing. In this latter case, the Licensor shall be able to assume, in its own name and for its own benefit, the maintenance of the Patent, bearing the costs and expenses for such maintenance, excluding such jurisdiction from the Territory and not generating in its favour any fees, royalties or any consideration for the License.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.2.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensor may request the registration of the License if it is advisable or necessary in accordance with applicable regulations, in which case it shall bear the corresponding costs and expenses.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Defence</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.3.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licensee shall have the exclusive power to assume, at its sole discretion, in any part of the Territory and before any authority, the defence and protection of the rights protected by the Patent:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:56.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">in the event of a violation or alleged violation of the rights protected by the Patent by any third party; and/or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:56.7pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">when a third party has filed an action for an alleged violation of patent rights with a priority date.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.3.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In cases of infringement, violation or alleged infringement of the rights protected by the Patent by any third party (the &#8220;<b style="font-weight:bold;">Third Party Violation</b>&#8221;), the following rules shall apply [***].</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.3.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In cases in which a third party files an action for infringement, violation or alleged infringement or violation of its priority rights (the &#8220;<b style="font-weight:bold;">Third Party Claim</b>&#8221;), the following rules shall apply: [***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.3.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***].</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Eighth. </b><b style="font-weight:bold;">Confidentiality and Protection of Personal Data</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In compliance with the provisions of Organic Law 15/1999, of December&#160;13, on Personal Data Protection and its implementing regulations, by means of this stipulation, VCN hereby informs the signatories of this Agreement that the personal data they provide by virtue hereof, or that they may subsequently provide, shall be incorporated into a file under their responsibility, the purpose of which is to maintain, comply with, develop, control and execute the provisions of this Agreement. On the other hand, in those cases in which if necessary, IDIBELL undertakes to obtain due consent and inform the staff and/or third-party investigators whose data will be transferred to VCN in connection with the execution of this Agreement, in respect of the terms required by the applicable regulations, as well as in order to comply with any other obligation necessary for such transfer.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">8/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">In the event that the signatories wish to exercise their rights of access, rectification, cancellation, and (sic) in those cases where possible, objection, before VCN, they may communicate their wish to the addresses contained in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause Ten</u>, attaching a photocopy of the legal document duly proving their identity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The existence and content of this Agreement as well as all information exchanged between the Parties in execution thereof, especially any information relating to the Patent, shall be considered confidential information (the &#8220;<b style="font-weight:bold;">Confidential </b>Information&#8221;) throughout the term hereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Party receiving the Confidential Information:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.3.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Shall not disclose such Confidential Information to third parties except as required by the competent authorities;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.3.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Shall limit access to the Confidential Information to those employees who, under an obligation of confidentiality, are required to have access to such information for the purposes inherent to the fulfilment of this Agreement;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.3.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Shall use the Confidential Information received solely and exclusively to fulfil the purposes established in this Agreement; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.3.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">At the end of this Agreement, must return the Confidential Information received without keeping a copy or summary thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This Clause shall not apply to:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.4.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Information that is currently, or were to become public knowledge without the intervention of the receiving Party;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.4.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Information that the receiving Party may demonstrate, through sufficient documentation, was already known to it before being provided by the disclosing Party;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.4.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Information received from a third party not subject to a confidentiality obligation with respect to the disclosing Party; and/or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:25.2pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.4.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Information that needs to be disclosed under the law or in respect of a court order, however, in such case, the disclosing Party must be notified of such request with sufficient advance notice so that it may request assistance to prevent or limit such disclosure, and provided that any disclosure extends solely and exclusively to what is necessary, the disclosure being subject to prior consultation, which shall be sent to the Disclosing Party in order to establish the time and extent of such disclosure.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Ninth. </b><b style="font-weight:bold;">Force Majeure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">In the event that the Parties cannot comply with the terms of this Agreement due to an eventuality beyond their reasonable control, including actions taken by government agencies or bodies, war, hostilities between nations, disturbances, upset, strike, lockout, acts of sabotage, shortage of supplies or energy, natural phenomena such as: typhoons, floods, fires, hurricanes, earthquakes, tsunamis or any other cause of a similar type over which the Parties have no control, and when there is no negligence involved, none of the Parties will be responsible for any delay or lack of compliance, provided that any of the aforementioned conditions prevented them from fulfilling their obligations. When such breach extends for a period of more than three (3) consecutive months, either Party may immediately terminate this Agreement, notifying the other Party of such. In such case, the affected Party must communicate this in writing to the other Parties, detailing the reasons</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">9/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">for force majeure, and must make every effort to overcome or resolve those obstacles that would prevent it with complying with the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Tenth. </b><b style="font-weight:bold;">Miscellaneous</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that any clause of this Agreement is declared void, illegal or unenforceable by a competent judge or authority in any jurisdiction, such clause shall be deemed not to be part of this Agreement, and shall not affect the enforceability of the remainder of this Agreement, nor the validity, legality or enforceability of such clause in any other jurisdiction.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any notification, approval, consent, request, demand or other communication relating to this Agreement that must be issued by either Party shall be made in writing and shall be signed by the Party issuing it or on its behalf and, unless delivered in person to the other Party, shall be submitted or sent by <i style="font-style:italic;">burofax</i> (certified fax), fax, certified mail or email with acknowledgment of receipt, addressed to the following addresses:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">Fundaci&#243; Institut d&#8217;Investigaci&#243; Biom&#232;dica de Bellvitge (IDIBELL)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">Hospital Duran i Reynals, 3a planta</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">Gran Via de l&#8217;Hospitalet, 199-203</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">L&#8217;Hospitalet de Llobregat (08908) Barcelona</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">e-mail: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">To the attention of {***}</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">VCN BIOSCIENCES, S.L.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">Avenida de la Generalitat, 152</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">Sant Cugat del Vall&#233;s (08174) Barcelona</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">Fax: +34&#160;93&#160;571&#160;2359</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">e-mail: [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">To the attention of [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Neither party may assign, subrogate or delegate, in whole or in part, to a third party, the rights and obligations contained in this Agreement, unless expressly authorized to do so in writing by the other Party. The foregoing provision shall not be construed as limiting the rights conferred in this Agreement in relation to the License and its extension.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any public announcement or disclosure relating to this Agreement or its vicissitudes must have been expressly agreed between the Parties, including the terms of such announcement or disclosure and the means in which they will be made public.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties each act exclusively as independent contractors as established in this Agreement. Neither Party is empowered, nor has any right or legal authority, express or implied, to create or assume any obligation of any kind in the name and on behalf of the other Party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties acknowledge and agree that any other agreements and/or contracts, written and/or verbal, executed between them and related to the purpose of this Agreement will be replaced by the same for any and all purposes from the time of entry into force.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any failure or delay in the exercise of any right or in the requirement of compliance with any obligations arising from this Agreement shall not constitute a waiver of such right or requirement of compliance with the obligation, nor waiver of any other rights or requirements for compliance with obligations.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.9.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any modification of this Agreement must be made in writing and signed by duly authorized representatives of both Parties.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">10/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><b style="font-weight:bold;">Eleventh. </b><b style="font-weight:bold;">Applicable law and conflict resolution</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">11.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties agree that this Agreement shall be governed by the agreements contained herein and, failing that, Spanish legislation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">11.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties agree that in the event of any litigation, discrepancy, issue or claim resulting from the execution or interpretation of this Agreement, the Parties shall submit to the exclusive jurisdiction of the courts of the city of Barcelona.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Parties do hereby sign this Agreement, in two exact copies having one and the same effect, at the place and on the date indicated in the heading of these presents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BELLVITGE BIOMEDICAL RESEARCH INSTITUTE FOUNDATION (IDIBELL)</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">VCN BIOSCIENCES, S.L.</b></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ </b>Jaume Revent&#242;s i Puigjaner</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ </b>Manel Cascall&#243; Piqueras</p></td></tr><tr><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signed: Jaume Revent&#242;s i Puigjaner</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signed: Manel Cascall&#243; Piqueras</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position: Director</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position: General Director</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CATALAN INSTITUTE OF ONCOLOGY</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approved by</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dr. Candela Calle Rodr&#237;guez</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signed: Dr. Candela Calle Rodr&#237;guez</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position: General Director</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">11/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ANNEX I: COPY OF THE PATENT APPLICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">12/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ANNEX II: SUBLICENSING INCOME FEES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:42.55pt;"><td style="vertical-align:middle;width:50%;border-bottom:1px dotted #000000;border-left:1px dotted #000000;border-right:1px dotted #000000;border-top:1px dotted #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Sublicensing Income</font></p></td><td style="vertical-align:middle;width:50%;border-bottom:1px dotted #000000;border-left:1px dotted #000000;border-right:1px dotted #000000;border-top:1px dotted #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-style:italic;font-weight:bold;">Royalty for Sublicensing Income</font></p></td></tr><tr style="height:42.55pt;"><td style="vertical-align:middle;width:50%;border-bottom:1px dotted #000000;border-left:1px dotted #000000;border-right:1px dotted #000000;border-top:1px dotted #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Sublicensing Income obtained within a term of 3 years following the Effective Date</p></td><td style="vertical-align:middle;width:50%;border-bottom:1px dotted #000000;border-left:1px dotted #000000;border-right:1px dotted #000000;border-top:1px dotted #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Royalty of [***] of the Sublicensing Income</p></td></tr><tr style="height:42.55pt;"><td style="vertical-align:middle;width:50%;border-bottom:1px dotted #000000;border-left:1px dotted #000000;border-right:1px dotted #000000;border-top:1px dotted #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Sublicensing Income obtained within a term of 3-7 years following the Effective Date</p></td><td style="vertical-align:middle;width:50%;border-bottom:1px dotted #000000;border-left:1px dotted #000000;border-right:1px dotted #000000;border-top:1px dotted #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="white-space:pre-wrap;">Royalty of  [***] of the Sublicensing Income</font></p></td></tr><tr style="height:42.55pt;"><td style="vertical-align:middle;width:50%;border-bottom:1px dotted #000000;border-left:1px dotted #000000;border-right:1px dotted #000000;border-top:1px dotted #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;">Sublicensing Income obtained within a term of 7 years following the Effective Date</p></td><td style="vertical-align:middle;width:50%;border-bottom:1px dotted #000000;border-left:1px dotted #000000;border-right:1px dotted #000000;border-top:1px dotted #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 14.4pt;"><font style="white-space:pre-wrap;">Royalty of  [***] of the Sublicensing Income</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">***</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BELLVITGE BIOMEDICAL RESEARCH INSTITUTE FOUNDATION (IDIBELL)</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">VCN BIOSCIENCES, S.L.</b></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">/s/ </b>Jaume Revent&#242;s i Puigjaner</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ </b>Manel Cascall&#243; Piqueras</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signed: Jaume Revent&#242;s i Puigjaner</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Signed: Manel Cascall&#243; Piqueras</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position: Director</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position: General Director</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CATALAN INSTITUTE OF ONCOLOGY</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dr. Candela Calle Rodr&#237;guez</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approved by</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="white-space:pre-wrap;">Signed: Dr.  Candela Calle Rodr&#237;guez</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position: General Director</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">13/13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>6
<FILENAME>syn-20211231xex10d34.htm
<DESCRIPTION>EX-10.34
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:42:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.34</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TECHNOLOGY TRANSFER AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="syn-20211231xex10d34001.jpg" alt="Graphic" style="display:inline-block;height:72.95pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:224.65pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="syn-20211231xex10d34002.jpg" alt="Graphic" style="display:inline-block;height:72.95pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:114.25pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TECHNOLOGY TRANSFER AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Hospitalet de Llobregat, on 31 August 2010</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APPEARING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As party of the first part,<b style="font-weight:bold;"> Mr Emili&#224; Pola</b>, of legal age, holder of National ID No.&#160;46.042.576-A, on behalf and in representation of the <b style="font-weight:bold;">BELLVITGE BIOMEDICAL RESEARCH INSTITUTE </b>(hereinafter &#8220;<b style="font-weight:bold;">IDIBELL</b>&#8221;), with headquarters at L&#8217;Hospitalet de Llobregat (Barcelona), IDIBELL Duran i Reynals, 3a planta, Gran Via de l&#39;Hospitalet, 199, 08907, and with Tax ID Code (Codi d&#8217;Identificaci&#243; Fiscal, CIF) G-58863317. Mr Emili&#224; Pola[***] is acting as Director of IDIBELL, by virtue of the power of attorney granted on 16 September 2008 before the Notary Public of L&#8217;Hospitalet de Llobregat, Mr Jorge Farres Reig, under number 1991 of his notarial records.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Dr Manel M. Cascall&#243; Piqueras</b>, of legal age, married, with registered address at [***], holder of National ID No.&#160;[***], on his own behalf and representation and on behalf of and in representation of <b style="font-weight:bold;">VCN BIOSCIENCES, S.L.</b>, a company with registered address in Gelida at Passeig Circumval laci&#243;, No.&#160;54, holder of CIF B65109605, incorporated through a public deed notarised on 11 May 2009, before the Notary Public of L&#8217;Hospitalet de Llobregat, Mr Fernando Morales Limia, under number 711 of his notarial records. Acting as Director of the Company, as contained in the articles of incorporation (hereinafter the &#8220;<b style="font-weight:bold;">Company</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Hereinafter, the Company and IDIBELL shall be jointly referred to as the &#8220;<b style="font-weight:bold;">Parties</b>&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Parties, in their respective representation, sign this Technology Transfer Agreement (hereinafter referred to as the &#8220;<b style="font-weight:bold;">Agreement</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WHEREAS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">I.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">IDIBELL is a private research foundation owned, among others, by the Autonomous Government of Catalonia, the University of Barcelona and Bellvitge University Hospital, which aims to promote, develop, manage and disseminate</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 2 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">biomedical research and training in the field of health sciences, primarily on the Bellvitge campus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">II.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Whereas IDIBELL wishes to encourage the transfer of technology and scientific knowledge derived from research activities conducted in its environment to society.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">III.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Whereas the Company is dedicated to developing oncolytic adenoviruses for tumour therapies, as well as the marketing, development, utilisation or production of biotechnology agents for the prevention, diagnosis and treatment of cancer.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">IV.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Whereas on 2 October 2007, IDIBELL entered into, with the Catalan Oncology Institute (hereinafter &#8220;<b style="font-weight:bold;">ICO</b>&#8221;, its acronym in Catalan) the &#8220;<i style="font-style:italic;">Framework Collaboration Agreement between the Catalan Oncology Institute and the Bellvitge Biomedical Research Institute</i>&#8221; (hereinafter the &#8220;<b style="font-weight:bold;">Framework Agreement</b>&#8221;), [***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">V.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Whereas, within the scope of its research activities in the Framework Agreement, IDIBELL and ICO have obtained a series of scientific results and knowledge that has led to certain scientific technology and knowledge that has been protected by the Patent application of which IDIBELL and ICO are co-holders, by virtue of the provisions of the Framework Agreement and which is identified under Appendix 1 to this Agreement (hereinafter the &#8220;<b style="font-weight:bold;">Patent</b>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">VI.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***].</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">VII.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">That the Company is interested in obtaining an exclusive licence for the use and utilisation of the technology referred to in Recital V above, for the purposes of carrying out its own activities. Likewise, IDIBELL, in compliance with its purposes and the scope of the ICO management mandate, is interested in granting the above-mentioned licence to the Company under the terms and conditions set forth in this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">VIII.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Now therefore, the Parties, by virtue of the powers of representation they hold, mutually acknowledge their sufficient legal capacity to execute this Agreement, and for such purpose, proceed to sign it in accordance with the following</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 3 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CLAUSES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">1.</b></font><b style="font-weight:bold;">AIM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The aim of this Agreement is to define the terms and conditions under which IDIBELL grants to the Company, which accepts it, a licence to exclusively use and utilise the research results obtained by IDIBELL and ICO covered by the Framework Agreement, as well as any intellectual and/or industrial property rights thereto (including the Patent), as described in Appendix 1, attached hereto (hereinafter the &#8220;<b style="font-weight:bold;">Technology</b>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">IDIBELL shall make technical knowledge available to the Company relating to the Patent which is essential for its proper utilisation. The afore-mentioned information shall be subject to clauses 12 and 13 hereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Accordingly, the aim of this Agreement is to govern certain aspects of the relationship between the Parties, within the framework of this technology transfer procedure on behalf of the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.</b></font><b style="font-weight:bold;">NATURE AND EXTENSION OF THE LICENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This licence (hereinafter the &#8220;<b style="font-weight:bold;">Licence</b>&#8221;) is granted on an exclusive basis throughout the entire world, with the only limitations set forth herein.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This Agreement is established for the effective term of the Patent. However, in the event that an intellectual property or industrial property right is requested to be licenced to the Company under this Agreement and this Agreement expires after the one described in the preceding section, the Agreement shall remain in force with regard to the respective protective title until its respective expiration date.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licence is non-transferable, except with prior written approval from IDIBELL, which shall, in any case, be made at market price, in terms consistent with this Licence and in strict observance of the rights granted on behalf of IDIBELL and ICO, which must be sufficiently safeguarded in all cases.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licence is sub-licensable to third parties, notwithstanding the Company&#8217;s right to require prior written approval from IDIBELL. In all cases, any sublicense</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 4 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">must be granted under terms consistent with this Licence and in strict observance of the rights granted on behalf of IDIBELL and ICO, which must be sufficiently safeguarded in all cases. For such purposes, the Company shall forward to IDIBELL the sublicense agreement or the Licence transmission agreement for the latter to provide, if applicable, its authorisation. Notwithstanding the foregoing, IDIBELL may report, with the respective approval of ICO, the modification of the sublicense authorisation regime in this Agreement, for which only prior written approval will be required, under the assumptions that sublicense is granted i) below market conditions; or ii) on behalf of an entity linked to the Company, without prejudice to the Company forwarding a copy to IDIBELL of any sublicense agreement, once entered into.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that Patent is finally not granted, for any reason, this Licence shall likewise be deemed as having been granted, with regard to the scientific and technological knowledge that the Technology provides to IDIBELL and ICO, with the Company retaining the exclusive right to market and utilise the knowledge described in Recital V.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.6.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties agree that the Company will submit a Patent development plan and budget within three (3) months of signing the Agreement. This obligation shall be a termination condition hereof, whereby in the event of a breach, this Licence shall cease to have legal effects and the technology shall be revert to IDIBELL and ICO without the Company having any right to obtain financial compensation.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.7.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties agree that the Company shall make its best efforts to advance in the development of the Technology licenced to the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.8.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Likewise, without prejudice to the obligation established in clause 3.3.4, the Company shall submit reports every year (in December) to IDIBELL describing the following:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(i)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the status of the Patent application;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(ii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">technological development efforts and the costs derived therefrom;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(iii)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">efforts to market the Technology; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(iv)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">an itemized list of income generated by marketing the Technology.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt 0pt 0pt 28.34pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 5 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">3.</b></font><b style="font-weight:bold;">LICENCE PRICE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.1pt;">In consideration for the granting of the Licence, the Company shall pay IDIBELL the compensation established below, without prejudice to, for the purposes of respecting the Framework Agreement, the income obtained by IDIBELL hereunder, which shall be equally distributed to IDIBELL and ICO as co-holders in equal shares of the rights to utilise the Technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Variable compensation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.65pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">3.1.1.</i></font><i style="font-style:italic;">Royalties</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">The Company shall pay IDIBELL royalties (hereinafter the &#8220;<b style="font-weight:bold;">Royalties</b>&#8221;), at an amount equal to [***] percent ([***]%) of the income that the Company has actually collected from the utilisation of products derived from the Technology, prior to applying the relevant Value-added Tax, if any (hereinafter the &#8220;<b style="font-weight:bold;">Invoicing</b>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">Notwithstanding the provisions of the preceding paragraph, and without prejudice to clause 2.4, the Company shall pay Royalties to IDIBELL at an amount equal to [***] percent ([***]%) of the income that the Company has actually received related to (i) the sublicenses of the Technology which, if any, it grants on behalf of third parties; (ii) advance payments or payments made for goals that were met and/or services associated with the Technology; or (iii) any other income arising from the utilisation of the Technology except for those described in the preceding paragraph. For the purposes hereof, income described in this paragraph under these items shall be deemed to be included under the item of Invoicing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.65pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">3.1.2.</i></font><i style="font-style:italic;">Form of payment of Royalties</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;">The Company shall notify IDIBELL of the yearly Invoicing that can generate within 3 (three) months of end of each calendar year in which the variable compensation established in this clause can be generated, as established in clause 3.2.1, as well as the total amount of the variable compensation that, if applicable, it has earned, with the Company then proceeding to pay the aforementioned Royalties, plus the respective Value-added Tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 6 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:43.65pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">3.1.3.</i></font><i style="font-style:italic;">Review and Verification</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;">Every year, the Company shall provide IDIBELL with all accounting information required to verify the accuracy and veracity of the respective Invoicing figures submitted by the Company and, at the least, the annual accounts (including the balance sheet, profit &amp; loss statement, and annual report and financial statements) and the audited invoicing data, in the event that the Company audits its annual accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;">In this regard, the Company shall at all times keep an orderly and up-to-date accounting of the utilisation of the Technology, retaining in all cases all documents, vouchers and invoices from the Company corresponding, at all times, to the past four (4) years. This obligation shall apply throughout the entire term of the Agreement and for four (4) years after its termination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;">In addition, and in any case, IDIBELL shall be entitled, once per year, to carry out a verification with an auditor appointed by IDIBELL for the exclusive purposes of calculating, checking and verifying the Invoicing figures submitted by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;">In the event that the auditor&#8217;s results do not match the figures submitted by the Company, the compensation received by IDIBELL shall be adjusted accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 27pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">[***] additionally, in the event that the total annual difference between the results of the verification and the figures submitted by the Company exceeds [***] percent ([***]%), the Company shall pay IDIBELL, as a penalty, a quantity equal to [***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">4.</b></font><b style="font-weight:bold;">CONTINUATION OF RESEARCH ACTIVITIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">IDIBELL and ICO shall, in all cases, retain the right to use the Technology to carry out any teaching, health care or research (non-marketing) activities in connection with the Technology, with the results obtained being their property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">5.</b></font><b style="font-weight:bold;">PROTECTION OF LICENCED TECHNOLOGY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Company may choose to request a new industrial property title on the licenced Technology (including technology that, on the date this Agreement is signed, has</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 7 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">not yet been protected), in whole or in part, domestically and/or internationally (including extensions thereto or to the Patent), listing IDIBELL and ICO as titleholders in equal parts of the respective protective title, with the Company assuming the costs and arrangement of obtaining and maintaining the respective protective title. In this case, the Licence shall also be understood to be granted in connection with this request and the protective title, under the same terms as those set forth herein for the Licence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that IDIBELL is the Party interested in applying for a new industrial property title on the Technology, in whole or in part, domestically and/or internationally (including all international extensions of the Patent), it shall notify the Company which, if interested in protecting it, shall have a three (3) month period to apply for the respective protective title under the terms described in the preceding paragraph. In the event that the Company is not interested in the protective title or extension or has not commenced the above procedure within three (3) months, IDIBELL may request, in its name (and/or in the name of ICO) a new industrial property title on the licenced Technology domestically and/or internationally (and/or extend the Patent internationally), as the case may be, assuming the costs and arrangements for its granting and maintenance. In this scenario, IDIBELL may revoke the Licence on the new requested protective title or international extension corresponding to the territorial scope of protection requested, by express written notification to the Company.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that the Company intends to cease taking responsibility over the Patent (or any extensions thereto), it must notify IDIBELL of this in writing within ninety (90) days, so that it can properly exercise its rights to the respective protective title. In this regard, the Company shall provide IDIBELL with all documentation relating to the protective title, agreeing to sign, if applicable, any necessary official documents so that IDIBELL may exercise its rights.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Company shall request that this Licence be registered before the public agency at which this Patent was requested or, if applicable, before the public agency at which new protective titles are requested, if possible in accordance with applicable regulations, with the right to reversion described herein being expressly included. The Company shall bear the respective costs and expenses.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that the reversion mentioned in the preceding paragraph is effective, the Company shall cooperate for the purposes of updating the registration, as applicable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 8 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">6.</b></font><b style="font-weight:bold;">DEFENCE OF THE LICENCED TECHNOLOGY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Company shall be responsible for the defending the intellectual and/or industrial property rights relating to the Technology in the event of a breach by a third party and shall take the initiative to defend those rights. This shall also apply to the proper maintenance and management of any protective title obtained.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Notwithstanding the foregoing, IDIBELL may assume direction of the defence of the rights to the Technology at any time, in the event of inaction, possible lack of diligence by the Company, or if deemed desirable.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that either Party becomes aware of a third party&#8217;s breach of the intellectual property and/or industrial property rights relating to the Technology, it shall immediately notify the other Party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Expenses incurred by either Party for defending the rights to the Technology shall be assumed, in all cases, by the Company. [***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">7.</b></font><b style="font-weight:bold;">FUTURE TECHNOLOGY AND INNOVATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties agree that if the Gene and Viral Therapy Group of the Catalan Oncology Institute obtains new knowledge derived from the licenced Technology resulting in a change or improvement, then IDIBELL, if interested in commercially utilising it, shall notify the Company, who shall have a priority right to obtain a right to employ and utilise it, which must be exercised within three (3) months of the offer by IDIBELL. If this term expires and the Company has not exercised its priority right to the new knowledge, IDIBELL may freely utilise this knowledge, without prejudice to the rights granted herein. The priority right described above will be subject to strict compliance with applicable asset-related regulations.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that the changes or improvements in the Licenced Technology are developed under a research and development agreement between IDIBELL and the Company, that agreement shall define the ownership of the intellectual and industrial property rights and the rights to utilise them.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 9 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">8.</b></font><b style="font-weight:bold;">RIGHT OF REVERSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">IDIBELL shall have the right to fully or partially revoke the Licence, as applicable, thus reverting the right to the Technology to IDIBELL and ICO, with the Company having no right to receive any indemnity or compensation, in the event that the Company:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">ceases business activities for a continuous period of one (1) year, ceases to employ and/or utilise the Technology or part thereof subject to Licence. Notwithstanding the foregoing, the right of reversion shall not apply in the event that the Company continues to employ or utilise the results of the research and development activity, whether conducted directly or by third parties, over the Licenced Technology.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">uses the Technology in violation of the foundational principles of IDIBELL or ICO, as described in their Bylaws.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.35pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">decides to stop maintaining the Patent or any extension thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Company undertakes to provide IDIBELL with written notification of any of these circumstances one (1) month in advance, so that the Company may exercise the right of reversion established in this clause.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In order to execute the right of reversion, it shall be sufficient for IDIBELL to provide notification of the execution of such aforementioned right, which could be justified by any of the circumstances described in section 8.1 above, and all documentation associated with the Technology shall be released to it.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">9.</b></font><b style="font-weight:bold;">HARMLESSNESS OF IDIBELL AND ICO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">9.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Licence described herein is granted without warranties of any kind, express or implied, including, without limitation, a warranty of marketability, patentability and/or fitness for a particular purpose, or non-infringement of any patent or other third-party intellectual and industrial property rights.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 10 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">9.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Company, as the party exercising the rights to utilise the Technology, shall hold IDIBELL and ICO fully harmless from any incidental or consequential damages, liabilities, claims, obligations, judgments, sentences and expenses of any kind in which it may incur as a result of third-party claims in connection with the Company&#8217;s utilisation of the Licenced Technology.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">9.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">If an industrial property right to the Technology is not granted over the Technology, this shall not be grounds for termination hereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">10.</b></font><b style="font-weight:bold;">BREACH</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event of a breach of the obligations, undertakings, provisions, terms, conditions, clauses or covenants established herein, the Party or Parties injured by the breach may choose to enforce the Agreement or to terminate it, with compensation for damages due in both cases.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">10.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In no event shall termination hereof exempt the Company from its obligation to pay any outstanding amounts hereunder.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">11.</b></font><b style="font-weight:bold;">CONFIDENTIALITY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">11.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties agree that the information directly or indirectly related to the non-public know-how comprising the Licenced Technology is secret and confidential in nature. The Parties agree not to disclose this information and to maintain it under strict confidentiality and secrecy, expressly prohibiting the disclosure of any information and knowledge related to the Licence granted, and to subsequent developments thereof, such as technical procedures, templates, drawings, know-how, etc.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">11.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The aforementioned restrictions on disclosure and use shall not apply to information already in the public domain or entering the public domain by a means other than breach hereof, or that must be disclosed by express mandate of law, an order issued by a competent authority, a decree, regulation or other legal rule, in which case the other Party must be notified before such disclosure.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 11 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">11.3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Without prejudice to this confidentiality obligation, in the event that any Party is interested in the total or partial dissemination or publication of any confidential information relating to the Technology and which would comprise an industrial secret, in order to publish it in articles, conferences, lectures or acts of similar nature, in scientific journals, publications or seminars, then the other Party&#8217;s written permission shall be required, which must grant or deny it within thirty (30) days of receipt of such notification. Failure to respond, in one sense or another, shall be interpreted as tacit consent.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">11.4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The provisions of this clause shall remain in full force and shall bind the Parties regardless of the termination hereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">12.</b></font><b style="font-weight:bold;">PERSONAL DATA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">12.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">For automated or non-automated processing of the personal data of any of the Parties for any purpose, and for the transfer of data to third-party companies or persons, the Party undertaking the data processing or transfer must obtain prior express consent from the affected Party under the terms established in the Organic Law on Data Protection.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">12.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">For the dissemination by any of the Parties or by any information means related to the other Party, either to establish links allowing access to one of the other Party&#8217;s web pages, the Party intending to disseminate or embed the link shall obtain prior express consent from the affected Party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">13.</b></font><b style="font-weight:bold;">PRESERVATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">13.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">If any provision hereof is declared null or void, either in whole or in part, such nullity or voiding will only affect the provision or portion thereof which is null or void, with the remainder hereof remaining in effect, with the affected provision or part thereof being regarded as not having been written.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">13.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">For such purposes, the Agreement shall only cease to be valid as regards that null or void provision. No other part or provision of this Agreement shall be voided, invalidated, damaged or affected by such nullity or voiding. In this case, the Parties shall negotiate, in good faith, a new clause that is valid, effective and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 12 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;">enforceable for the purposes of substituting the one that is not, in terms as similar as possible to the original.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 28.35pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">14.</b></font><b style="font-weight:bold;">ASSIGNMENT OF CONTRACTUAL POSITION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">14.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Company may not assign its contractual position herein to any third party, except with prior written consent from IDIBELL.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">14.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">IDIBELL may, at any time, assign its contractual position herein and/or management of the rights to the Technology to an entity in its group. In this scenario, the assignee of IDIBELL&#8217;s contractual position and/or management of the rights to the Technology shall fully assume the rights and obligations incumbent on IDIBELL hereunder.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">15.</b></font><b style="font-weight:bold;">NOTICES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All notices, approvals, consents, requests, demands or other communications that must be given to any of the Parties in writing may be delivered personally or by sending a certified letter with acknowledgement of receipt to the addresses listed in the heading hereof.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">16.</b></font><b style="font-weight:bold;">TAXES AND COSTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Parties agree that each of them shall assume and pay its own costs and expenses (including those of a tax nature) incurred as a result of the provisions herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:28.35pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">17.</b></font><b style="font-weight:bold;">GOVERNING LAW AND JURISDICTION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">17.1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties agree that to resolve any dispute arising as a result of the interpretation, execution and performance hereof, the courts of the city of L&#39;Hospitalet de Llobregat shall hold jurisdiction.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">17.2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This Agreement shall be governed by and construed in accordance with the laws of the Spanish State.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:28.35pt;text-align:justify;text-indent:-28.35pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 13 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">IN WITNESS WHEREOF</b>, the Parties sign this Agreement, issued in two (2) identical counterparts to a single effect, at the location and on the date stated in the heading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ </b><b style="font-weight:bold;">Emili&#224; Pola</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ Dr Manel M. Cascall&#243; Piqueras</b></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BIOMEDICAL RESEARCH INSTITUTE OF BELLVITGE</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">VCN BIOSCIENCES, S.L.</b></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Emili&#224; Pola</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Dr Manel M. Cascall&#243; Piqueras</b></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Administrator</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 14 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 11pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">APPENDIX 1 - LICENCED TECHNOLOGY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Technology licenced by IDIBELL to the Company consists of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9642;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Spanish Patent No. P200901201, under the title &#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:justify;">Oncolytic adenoviruses for treating cancer</i><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">&#8221;, filed on 6 May 2009.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">The invention is related to an oncolytic adenovirus that comprises a sequence encoding a hyaluronidase enzyme inserted in its genome. This adenovirus spreads more efficiently in the tumour mass and therefore the oncolytic effect is increased. Injecting the oncolytic adenovirus of the invention endovenously, 10-fold tumour volume regressions are obtained. Therefore the oncolytic adenovirus of the present invention is useful for the treatment of a cancer or a pre-malignant state of cancer.</i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:14pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Technology Transfer Agreement</i></p></td><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Page 15 of 15</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>7
<FILENAME>syn-20211231xex10d35.htm
<DESCRIPTION>EX-10.35
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:42:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 10.35</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">``</p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">COLLABORATION AGREEMENT TO CONDUCT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CLINICAL TRIAL AND GRANT AN OPERATING LICENSE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BY AND BETWEEN</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">VCN BIOSCIENCES, S.L.</b>, a company duly incorporated under the laws of Spain, having its registered office at Pol&#237;gon Can Sant Joan, Av. de la Generalitat, n&#186; 152-158, 08174-Sant Cugat del Vall&#232;s (Barcelona) (&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">VCN</u>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">HOSPITAL SANT JOAN DE D&#201;U [SANT JOAN DE D&#201;U HOSPITAL]</b>, an entity duly incorporated under the laws of Spain, with registered office at Passeig Sant Joan de D&#233;u, no 2, 08950-Esplugues de Llobregat (Barcelona) (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Hospital</u>&#8221;); and <b style="font-weight:bold;">FUNDACI&#211; SANT JOAN DE D&#201;U [SANT JOAN DE D&#201;U FOUNDATION]</b>, an entity duly incorporated under the laws of Spain, having its registered office at Santa Rosa 39-57 08950-Esplugues de Llobregat (Barcelona) (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Foundation</u>&#8221; together with the Hospital which shall be referred to as the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Institution</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REPRESENTATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">I.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Institution plans to conduct the clinical trial titled &#8220;A Phase I, single-centre, open label dose-escalation study to evaluate the safety and activity of the oncolytic adenovirus VCN-01 in patients with refractory retinoblastoma (Phase I)&#8221; (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Trial</u>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">II.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Institution is interested in VCN collaborating in preparing and executing the Trial, including, but not limited to, the conduct of experiments necessary to obtain the approval thereof, collaborating in writing the documentation to be submitted to the relevant regulatory agencies, etc., as well as the provision of the adenovirus &#8220;VCN-01&#8221; developed and owned by VCN (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Product</u>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">III.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties (as defined herein below) wish to regulate their rights and obligations during and after the execution of the Trial.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">IV.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Accordingly, the Parties, recognizing that they each have sufficient legal capacity to be bound by the terms of the same, sign this Agreement (as per the term(s) defined herein below), which will be governed in accordance with the following</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CLAUSES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">1</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Definitions</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">For the purposes of this Agreement, the following words shall have the meaning set forth in this Clause, unless they may clearly be understood otherwise as a result of the given context and, if not included below, the meaning set forth elsewhere in the Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93%;"><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Agreement</u>&#8221;</p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means this Collaboration Agreement to Conduct a Clinical Trial and Grant an Operating License, along with each and every one of the annexes attached or that may come to be attached hereto;</p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Monitoring Committee</u>&#8221;</p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">has the meaning established in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 4.1</u>;</p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Effective Date</u>&#8221;</p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means 15/02/2016, which is the date on which this Agreement enters into force and takes full effect;</p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Grifols Group</u>&#8221;</p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means any company controlled, directly or indirectly, by Grifols, S.A.;</p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">License</u>&#8221;</p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">has the meaning established in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 6.1</u>;</p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Parties</u>&#8221;</p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means, jointly, VCN and the Institution, whilst &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Party</u>&#8221; refers to any/either of the Parties;</p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Patents</u>&#8221; </p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means any patent application or patent that may be generated or resulting from the Results;</p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Protocol</u>&#8221;</p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">means the Trial protocol, a summary thereof which is attached hereto as <u style="text-decoration:underline;text-decoration-color:#000000;">Annex I</u> to this Agreement; and</p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:31.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Results</u>&#8221;</p></td><td style="vertical-align:top;width:68.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">which shall be taken to mean all data, both pre-clinical and clinical, reports, partial or final, and any and all other information that may result from the conduct of the Trial, including all data, reports and/or documents resulting from the Trial and that have been generated or obtained by the Institution prior to this Agreement being signed;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 5pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">When a given context so requires, words expressed in singular shall include the plural form and vice versa whilst words expressed in one gender shall include all genders.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The headings of the Clauses are included for reference purposes and shall not affect the interpretation of this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">2</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Purpose</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The purpose of this Agreement is to regulate the terms and conditions that will govern the preparation and execution of the Trial in respect of the terms set out herein below.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Furthermore, the purpose hereof is to regulate the rights of each of the Parties to the Results of the Trial.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">3</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Conduct of the Trial</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Institution guarantees that the Trial (i) conforms to the provisions established in the Protocol and no amendment thereto shall be valid without the prior written consent of both Parties and (ii) shall be carried out in strict compliance with the rules applicable to this type of clinical trial.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">VCN shall provide the Hospital, when the latter so requests in writing and at no cost to the Hospital, the quantities of the Product that the Hospital needs to conduct the Trial, in the manner and within the periods agreed by and between the Parties at any given time.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">VCN guarantees that the manufacture and supply of the Products will be carried out in accordance with the regulations applicable to this type of product, including but not limited to the Good Manufacturing Practices (GMP) in force at all times.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In addition, VCN undertakes to perform, at its own expense, all additional studies that are necessary to include the Product in the Trial.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Attached as <u style="text-decoration:underline;text-decoration-color:#000000;">Annex II</u> to this Agreement is a detail of the different obligations that each of the Parties assumes for the preparation and execution of the Trial.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">4</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Monitoring Committee</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Hospital shall conduct the Trial in accordance with the directives indicated by the Trial Monitoring Committee, the same which the Parties shall establish within a maximum period of thirty (30) days counted from the Effective Date (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Monitoring Committee</u>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Each of the Parties shall appoint two (2) representatives who shall form part of the Monitoring Committee. Any change of representative must be notified in writing by one Party to the other within a reasonable term. One (1) VCN representative will be appointed chair of the Monitoring Committee at the first meeting that is held.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Monitoring Committee must meet, at the least, every sixty (60) days to analyse the development of the Trial. In this regard, the Institution&#39;s representatives undertake to deliver reports on the development of the Trial to VCN&#39;s representatives for analysis by VCN. Likewise, once the Trial is completed, the Institution&#39;s representatives will deliver to VCN&#39;s representatives a final report of the Trial in order to analyse the Results thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Notwithstanding the provisions of the preceding Clause, either Party may request in writing from the other the holding of additional meeting in the event that such is duly justified.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.5</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Meetings may be held in person, by videoconference or by telephone conference, as agreed on each occasion. The Chairman of the Monitoring Committee will be responsible for writing and issuing minutes of all meetings of the Monitoring Committee, which must be signed by all of its representatives.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.6</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Each member of the Monitoring Committee shall have one (1) vote on all matters dealt with within the Monitoring Committee. The decisions of the Monitoring Committee shall be approved by a majority of votes of its representatives. In the event of a tie, the Chair of the Monitoring Committee will have a casting vote.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">5</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Trial Results</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">All Trial Results, both positive and negative, as well as any intellectual and/or industrial property right(s) (including any Patent) resulting from the conduct of the Trial shall be the property of [***].</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">No Party may publish the Results, whether positive or negative, without the prior written consent of the other Party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><u style="text-decoration:underline;text-decoration-color:#000000;">Negative Results</u>. If the Monitoring Committee deems that the Trial Results are negative, the following terms and conditions shall apply. To determine whether the Trial Results are positive or negative, the Monitoring Committee will follow the criteria established in <u style="text-decoration:underline;text-decoration-color:#000000;">Annex III</u> attached to this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Institution may continue with the development of the Product for the treatment of retinoblastoma, at its expense and with the prior written approval from VCN, and, if it is interested in granting an operating license over the Results to a third party, it must obtain prior written approval from VCN; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">each of the Parties shall assume the costs and expenses incurred by each in the course of the execution of the Trial.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><u style="text-decoration:underline;text-decoration-color:#000000;">Positive Results</u>.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.4.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">If the Monitoring Committee deems that the Trial Results are positive and VCN is interested in continuing with the execution of the following development phases of the Product for the treatment of retinoblastoma, the following terms and conditions will apply:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the Parties undertake to apply their best efforts to negotiate and, where appropriate, sign an agreement to collaborate in the development and execution of the following phases of the development of the Product for the treatment of retinoblastoma;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Institution at this time grants VCN, who does accept, a license to use the Results under the terms and conditions set out in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 6.1</u>;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">VCN undertakes to pay the Foundation the amount of five hundred thousand Euros (&#8364;500,000). The payment of said amount may be corrected as provided for in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 5.4.3</u> (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Compensation</u>&#8221;);</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In addition to the payment of the Compensation, VCN undertakes to pay the Foundation three hundred twenty thousand Euros (&#8364;320,000). VCN will make said payment once the pivotal study, to be carried out by VCN, has been completed, following from the Results and which allow the same to obtain the marketing authorization of the product or products following from the Results. It is agreed that in any and all cases, said payment must be made within a maximum period of four (4) years from the date on which Institution has delivered the final report of the Trial to VCN; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(e)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the Parties undertake to apply their best efforts to negotiate and, where appropriate, sign a Product supply agreement in order that the Hospital can use it for compassionate use in the treatment of retinoblastoma.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21.25pt;text-align:justify;text-indent:-21.25pt;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.4.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that the Monitoring Committee deems that the Trial Results are positive but VCN is not interested in continuing with the execution of the following phases of the Trial, the following terms and conditions will apply:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Institution may continue with the development of the Product for the treatment of retinoblastoma, at its cost and with the prior written approval of VCN, and, if it is interested in granting a license to use the Results to a third party, it must obtain the prior written approval of VCN;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">VCN undertakes to pay the Foundation the Compensation, in application of the provisions of <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 5.4.3</u> ; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the Parties do undertake to apply their best efforts to negotiate and, where appropriate, sign a Product supply agreement in order that the Hospital can use the same for compassionate use in the treatment of retinoblastoma.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.4.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Institution expressly acknowledges and agrees that the Compensation, as referred to in <u style="text-decoration:underline;text-decoration-color:#000000;">Clauses 5.4.1 (c) and 5.4.2 (b),</u> shall be reduced based on (i) the public and/or private economic aid that third parties may grant to Institution for the conduct of the Trial; and/or (ii) any advance payments that VCN wishes to make before the end of the Trial (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Final Compensation</u>&#8221;).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;">As an example, if a public or private entity grants the Institution financial assistance for a value of [***], VCN will be obliged to pay the Foundation only [***] in respect of the Final Compensation, in accordance with the provisions of <u style="text-decoration:underline;text-decoration-color:#000000;">Clauses 5.4.1 (c) and 5.4.2 (b)</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;">VCN will pay said Final Compensation to the Foundation once the Institution has delivered the final report of the Trial to VCN, upon receipt of the corresponding invoice issued by the Foundation, in which all applicable taxes will be duly itemized. VCN shall make said payment by bank transfer to the following account held by the Foundation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 78pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:28.35pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">-</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">[***]</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.4.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Foundation and the Hospital shall agree in good faith as to the distribution between both institutions of the amounts indicated in <u style="text-decoration:underline;text-decoration-color:#000000;">Clauses 5.4.1 (c), 5.4.1 (d) and 5.4.2 (b).</u></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">6</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">License for the Results and Patents</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In the event that the Monitoring Committee deems that the Trial Results are positive and VCN is interested in continuing with the execution of the following phases of Product development, in accordance with the provisions in <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 5.4.1 (b)</u> and as consideration for the amount to be paid by VCN to the Foundation under the terms of <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 5.4.1 (d)</u>, the Institution does hereby grant to VCN, who accepts the same, an exclusive, worldwide and indefinite license to use and exploit the Trial Results and their possible Patents exclusively for the treatment of retinoblastoma (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">License</u>&#8221;). The License grants VCN the right to sublicense the use and exploitation of the Trial Results and the Patents to any company of the Grifols Group or to a third party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">All costs related to the operation of the License shall be borne by VCN.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">6.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Institution shall assist VCN in everything that VCN reasonably requests for the proper exploitation of the License.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">7</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Patent Processing, Management and Defence</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Institution expressly authorizes VCN to assume, at its sole discretion, the processing, management and maintenance of the Patents of this Agreement at the national and/or international level. The Institution shall provide VCN with all documentation necessary for the processing, management and maintenance of the Patents and shall collaborate with VCN in any procedure necessary for the performance of such activities.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;">For clarification purposes, the authorization granted by virtue of this Clause and within the parameters established herein, enables VCN to make decisions, freely and unilaterally, regarding the content, protection, maintenance and extension of the Patents including but not limited to, modifying their claims, description, presentation mode and/or countries to which the effects thereof may or may not be extended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Likewise, the Institution expressly authorizes VCN to assume, at its sole discretion, anywhere in the world and before any authority, the defence and protection of the Patents (i) in the event of a violation or alleged violation thereof by any third party, and/or (ii) when an action has been filed against any or all of the Patents for a presumed violation of a patent with a date preceding the same. &#160; All expenses and costs associated with such defence and protection shall be borne exclusively by VCN, with any payment received as indemnity and/or compensation being received by the same, in its sole favour.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Should VCN decide not to assume the management of the defence of any or all of the Patents in any event, they must communicate this reliably and with sufficient advance notice to the Institution, who may assume the management of the defence of the Patents, in which case this Party will assume the expenses they may incur and any indemnity and/or compensation payment received will be received by them, in their sole favour.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">7.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The authorizations granted in the preceding Clauses are understood to be granted to both VCN and any company part of the Grifols Group.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">8</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Confidentiality</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This Agreement, its Annex(es), as well as all information exchanged between the Parties relating to this Agreement and the relationships resulting therefrom shall be considered confidential information (the &#8220;<u style="text-decoration:underline;text-decoration-color:#000000;">Confidential Information</u>&#8221;) in accordance with this Agreement.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In particular, the Parties undertake to:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">not disclose said Confidential Information to third parties except as may be required by the competent authorities;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">to limit access to the Confidential Information to those employees who, subject to an obligation of confidentiality, need to have access to such information for the purposes inherent to the fulfilment of this Agreement;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">to use the Confidential Information that is received solely and exclusively to fulfil the purposes established in this Agreement; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18.55pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">at the end of this Agreement, said persons must return the Confidential Information without keeping any copy or summary thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:127.6pt;text-align:justify;text-indent:-127.6pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This Clause shall not apply to:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">information that is currently or becomes public knowledge without the intervention of the receiving Party;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">information that the receiving Party may demonstrate, through sufficient documentation, was already known to it before being provided by the disclosing</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;">Party;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">information received from a third party not subject to a confidentiality obligation with respect to the disclosing Party; and/or</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 56.7pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:35.45pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:21.25pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">information that needs to be disclosed under the law or further to a court order, but, in this case, the disclosing Party must be notified of such request with sufficient advance notice so that it may request assistance to prevent or limit such disclosure, and this provided that any disclosure extends solely and exclusively to what is necessary, with the disclosure being subject to prior consultation, sent to the Disclosing Party for the purposes of setting the time/period and extent of such disclosure. Any disclosure made under this <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 8.3 (d)</u> shall be subject to prior consultation with the disclosing Party to set the effective date of disclosure and the period/scope thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">8.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This Clause shall be in force following the termination of this Agreement for any reason.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">9</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Compensation</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;">Each Party undertakes to hold each other harmless for any claims, penalties, damages and/or losses that may arise from non-compliance or defective compliance with their respective obligations in accordance with the provisions of this Agreement and any applicable legal regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">10</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Term</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;">This Agreement will enter into force on the Effective Date and will be valid until (i) all obligations arising from the execution of the Trial have been fulfilled, or (ii) if it is terminated early in accordance with the provisions of <u style="text-decoration:underline;text-decoration-color:#000000;">Clause 11</u>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">11</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Termination</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">11.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Without prejudice to any cause of termination established in the Law, this Agreement may be terminated by either of the Parties, by prior notification, in the event of a serious breach by a Party, of any of their contractual and/or legal obligations, or, in the case of any other type of breach, when the breaching Party has been asked in writing to remedy it yet has not been remedied the situation within thirty (30) days from the date on which the written request was sent, this without prejudice to any claims and indemnities that the complying Party may be entitled to request.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">11.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Upon termination of the Agreement, in the event that the Parties are subject to any obligation further to compliance with the same, they shall be obliged to comply with the same, without such involving, in any case or circumstances, an extension thereof.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">12</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Force Majeure</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 34.2pt;">In the event that the Parties cannot comply with the terms of this Agreement due to an eventuality beyond their reasonable control, including actions taken by government agencies or bodies, war, hostilities between nations, disturbances, upset, strike, lockout, acts of sabotage, shortage of supplies or energy, natural phenomena such as: typhoons, floods, fires, hurricanes, earthquakes, tsunamis or any other cause of a similar type over which the Parties have no control, and when there is no negligence involved, neither of the Parties will be responsible for any delay or lack of compliance, provided that the conditions mentioned herein above prevent them from fulfilling their obligations. When a breach extends for a period of more than three (3) consecutive months, either Party may immediately terminate this Agreement, notifying the other Parties. In this case, the affected Party must communicate this in writing to the other Parties, detailing the reasons of the force majeure, and must make every effort to overcome or resolve those obstacles preventing it from compliance with the Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 34.2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">13</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Notifications</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;">Any agreement, notification and/or notice established in this Agreement must be made in writing and sent to the following contact persons at the following addresses:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:92.91%;"><tr><td colspan="2" style="background-color:#d9d9d9;vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">For VCN[***]</b></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;">Contact person:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fax:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Email:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:70.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="background-color:#d9d9d9;vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">For the Hospital &#160; &#160;[***]</b></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;">Contact person:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fax:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Email:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:70.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="background-color:#d9d9d9;vertical-align:top;width:100%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">For the Foundation</b></p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt;margin:0pt;">Contact person:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Address:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="padding-left:36pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:70.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Telephone:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Fax:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Email:</p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">[***]</p></td></tr><tr><td style="vertical-align:top;width:29.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.3pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">14</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Governing Law and Jurisdiction</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">14.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties agree that this Agreement is commercial in nature and shall be governed by the terms and conditions included herein and set out under the laws of Spain.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">14.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">In order to settle any litigation that were to arise from this Agreement, the Parties submit to arbitration by law by the <i style="font-style:italic;">Barcelona Arbitral Tribunal</i>, which will be responsible for appointing one (1) arbitrator, expert in the subject matter of this Agreement, and, to the arbitration conducted in accordance with the rules of this Tribunal, undertaking to fully comply with the arbitration decision that will be considered final, non-appealable and binding.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">15</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-weight:bold;">Miscellaneous</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:35.45pt;text-align:justify;text-indent:-35.45pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">15.1</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties act exclusively as independent contractors, as established in this Agreement. Neither Party is empowered, nor has any right or legal authority, express or implied, to create or assume any obligation of any kind in the name and on behalf of any of the other Parties.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">15.2</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">This Agreement, together with its Annex(es), constitute the full and entire agreement by and between VCN and the Institution regarding the purpose thereof, and entirely replaces and supersedes any negotiation, agreement or prior commitment, verbal or written, between VCN and the Institution, this agreement which may not be changed or modified in any way, except in writing and duly signed by the authorized representatives of each Party.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.4pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">15.3</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any failure or delay in the exercise of any right or in the requirement of compliance with any obligations arising from this Agreement shall not constitute a waiver of such right or requirement of compliance with the obligation, nor the waiver of any other rights or requirements for compliance with obligations.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 35.45pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:35.45pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">15.4</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The Parties expressly acknowledge and accept that <u style="text-decoration:underline;text-decoration-color:#000000;">Clauses 5, 6, 7, 8, 9, 12, 13, 14 and 15</u> shall survive the termination of this Agreement for any reason.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In witness whereof, the Parties do sign all pages of the present Agreement, the same which is being drawn up in two identical copies with one and the same effect, at the place and on the date indicated in the heading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/&#8230; Manel Cascall&#243; Piqueras</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/&#8230; Manel del Castillo</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">VCN</b></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">THE HOSPITAL</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Manel Cascall&#243; Piqueras</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Manel del Castillo</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position: General Director</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position: Managing Director</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Place: Sant Cugat del Vall&#232;s (Barcelona)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Location: Esplugues de Llobregat</p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Emili Bargall&#243;</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">THE FOUNDATION</b></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Emili Bargall&#243;</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Position: Director</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Location: Esplugues de Llobregat</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:4.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">11</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><img src="syn-20211231xex10d35003.jpg" alt="Graphic" style="display:inline-block;height:63.35pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:89.75pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><img src="syn-20211231xex10d35004.jpg" alt="Graphic" style="display:inline-block;height:47.05pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:72.95pt;"></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Annex I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Protocol Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:24pt 0pt 0pt 0pt;">12</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Annex II:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Obligations of the Parties related to Trial preparation and execution</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">[***]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Annex III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="text-decoration:underline;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Criteria to determine whether the results of the Trial are positive or negative*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">[***]</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>8
<FILENAME>syn-20211231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:42:21 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SYNTHETIC BIOLOGICS,&#160;INC. SUBSIDIARIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table lists all of the subsidiaries of Synthetic Biologics,&#160;Inc. and the jurisdiction of incorporation of each subsidiary. Each subsidiary does business under its corporate name indicated in the table.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:30.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:32.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Subsidiary Name</b></p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ownership</b></p></td><td style="vertical-align:bottom;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:32.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction of Incorporation</b></p></td></tr><tr><td style="vertical-align:top;width:33.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Pipex Therapeutics,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Wholly owned</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.41%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:33.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Effective Pharmaceuticals,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Wholly owned</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:33.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Solovax,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Majority-owned</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:33.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CD4 Biosciences,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Majority-owned</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:33.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Epitope Pharmaceuticals,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Majority-owned</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:33.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Healthmine,&#160;Inc.</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Wholly owned</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:33.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Putney Drug Corp.</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Wholly owned</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:33.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Synthetic Biomics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">VCN Biosciences, S.L.</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Wholly-owned</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Wholly-owned</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Nevada</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Spain</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>syn-20211231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:42:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Synthetic Biologics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Rockville, MD</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form&#160;S-3 (Nos. 333-180562, 333-188219, 333-156973, 333-206267, 333-207327, 333-203323 , 333-226500, 333-224728, 333-255726 and 333-260449), the Registration Statement on Form&#160;S-1 (Nos. 333-227400) and Form&#160;S-8 (Nos. 333-192355, 333-170858, 333-148764, 333-206268, 333-213388, 333-220401, 333-227668,&#160;333-233959 and 333-249712) of Synthetic Biologics,&#160;Inc. of our report dated March 4, 2021 relating to the consolidated financial statements, which appears in this Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ BDO USA, LLP</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Potomac, Maryland</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;16, 2022</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>syn-20211231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:42:26 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibits 31.1 and 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO RULE 13a-14 OR RULE 15d-14 OF THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO SECTION&#160;302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I, Steven A. Shallcross, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">I have reviewed this Annual Report on Form 10-K of Synthetic Biologics, Inc.;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-size:1pt;visibility:hidden;">&#8203;</font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 16, 2022</p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.15%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer, Principal Financial<br>Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>syn-20211231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 3/16/2022 08:42:29 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibits 32.1 and 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO 18 U.S.C. SECTION&#160;1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to 18 U.S.C. &#167;1350, as created by Section&#160;906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Synthetic Biologics,&#160;Inc. (the &#8220;Registrant&#8221;) hereby certifies, to such officer&#8217;s knowledge, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the accompanying Annual Report on Form 10-K of the Registrant for the year ended December 31, 2021 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">(2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br><font style="font-size:1pt;visibility:hidden;">&#8203;</font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March&#160;16, 2022</p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:45.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:bottom;width:45.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:40%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven A. Shallcross</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer, Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:4.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer, Principal Financial<br>Officer and Principal Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>syn-20211231x10k001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syn-20211231x10k001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $/ KD# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#UZ&+1M/\
M#5O?7UK;+$D"-(YA!/('MZFJG]N>$O\ GWB_\ S_ /$U%XF_Y)?+_P!>L7\U
MKSZ'4+N.%$6=@H& * /1O[<\)?\ /O%_X!G_ .)H_MSPE_S[Q?\ @&?_ (FO
M/?[2O/\ GNU']I7O_/=ORH ]"_MSPE_S[Q?^ 9_^)H_MSPE_S[Q?^ 9_^)K@
M&O=212SM,H'=DP*C_M.\_P"?AJ /0_[<\)?\^\7_ (!G_P")H_MSPE_S[Q?^
M 9_^)KSXZA?A%<RN$;[K$<'Z4W^T[S_GX:@#T/\ MSPE_P ^\7_@&?\ XFC^
MW/"7_/O%_P" 9_\ B:\^2_OY&VQRR.W7"KDTW^T[S_GX:@#T/^W/"7_/O%_X
M!G_XFC^W/"7_ #[Q?^ 9_P#B:\\_M.\_Y^&H_M.\_P">[4 >A_VYX2_Y]XO_
M  #/_P 31_;GA+_GWB_\ S_\37GO]I7G_/=J0ZG>X/[]NE 'J.ES^'-9>=+&
MWMI'@QYBFW"E<].H]JFU*/0M)M/M-[:6T<6X)GR >3T' KA_A$S/=>(&8DL9
M8R2>_#5T/Q)_Y%,_]?$7\Z '_P!N>$O^?>+_ , S_P#$T?VYX2_Y]XO_  #/
M_P 37G:ZC>*@ G; &!2_VG>?\]VH ]#_ +<\)?\ /O%_X!G_ .)H_MSPE_S[
MQ?\ @&?_ (FO/CJ%^%#F60*>C%>#3?[3O/\ GX:@#T/^W/"7_/O%_P" 9_\
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MJ<=0OU17,KA&^ZQ'!^AH ]!_MSPE_P ^\7_@&?\ XFC^W/"7_/O%_P" 9_\
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MG_@,?_B:\\;4KZ,X=MI]&3%.2_U&0 H&8,< K'G)]* /0?[5\)?W;3_P&/\
M\31_:OA+^[:?^ Q_^)KSO^U+PG D&>F-HI7U*^C<H[;6'560 B@#T/\ M7PE
M_=M/_ 8__$T?VKX2_NVG_@,?_B:\Z_M6[_YZ+_WR*/[5N_\ GH/^^10!Z+_:
MOA+^[:?^ Q_^)H_M7PE_=M/_  &/_P 37G7]JW?_ #T7_OD4?VK=_P#/1?\
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M=0W=ZI(&2?*(ZCT(I]QJEM*;T6FK1VS-?)*LA)&Z,* >@Y^E<+YTG_/G=?\
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M_P"_1H\Z3_GSNO\ OT: )J1ONGZ5%YTG_/G=?]^C099""/LEU_WZ- &9H_\
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MZ?+Y4XFC3=M!X)YZU\I54I8EJ.]SZZBXQPJ<EI8SO^%2^&?2[_[_ '_UJ/\
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M&?2[_P"_W_UJXW_A.]:_Z#S_ /@,G^%'_"=ZU_T'G_\  9/\*/J&,_G7WO\
MR#^T,'_(_N7^9V7_  J7PSZ7?_?[_P"M1_PJ7PSZ7?\ W^_^M7&_\)WK7_0>
M?_P&3_"C_A.]:_Z#S_\ @,G^%'U#&?SK[W_D']H8/^1_<O\ ,[+_ (5+X9]+
MO_O]_P#6H_X5+X9]+O\ [_?_ %JXW_A.]:_Z#S_^ R?X4?\ "=ZU_P!!Y_\
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M,G^%/ZAC/YU][_R#^T,'_(_N7^9V7_"I?#/I=_\ ?[_ZU'_"I?#/I=_]_O\
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MR,,#D>M #G^XWTKR"O7W^XWTKR"@#J?%_P#R2:X_Z](OYK7BR_='TKVGQ?\
M\DFN/^O2+^:UXLOW1]*]_*/X<O4^>SG^)'T%HH )S@$XZX%'UXKUSQ@HHHS0
M 444$$8R",],B@ HHS10 44 %B H))X '>G,CH 71ESTW#&:!C:0]#2TAZ&@
M1Z+\$>FO?]=8OY-72?%?_D2)/^OB+^=<W\$>FO?]=8OY-72?%?\ Y$B3_KXB
M_G7R[_WSYGU<?]R_[=/%^U%':BOJ#Y05 I=0[;5) +8S@>M=0W@BZ%RT(NXS
MYEPD-JQ7 G#+N+#T %<M6E+K^J3)8*UX^+#_ (]B."G^/XUE451VY'8VI.DD
M_:*YHV7AFTU2[N;>QU=7-O$SLTD)0;@< =>A]:KZAX6U&QO5MDADF(CC:5@A
M B9OX6^E03>(=2G$P:2)!-&8Y/*A5-P)R>@ZY[U7O]5OM3NA=7=PSS!53>..
M%Z=.]1&-;FU>G]>AI*5!QT3O_7J;-UX26VN+>,:I&4>[-G-(T1'ER\< =QSU
MK#U&S.GZE=61?>8)#&6QC..]7I?$VJSSV\TLT;O;OYB9A7!?^\1CEO<U1O[Z
M?4KV2[N2AFD.7*(%!/K@=ZJDJJ?ON_\ 7H35=%KW%;^O4K4445L<YT7PP_Y*
M5'_UZR?TKVS7_P#D7M1_Z]I/_037B?PP_P"2E1_]>LG]*]LU_P#Y%[4?^O:3
M_P!!-?,8[_>6?5X#_=4>">%M".NI,@F>/[/ )2(XO,9^0, 9'/-7YO!FI?:K
MV.T:&XBM7V&7>$#-MW%0#W ZBL+2M1N]/M9!:S&+SXA'(0.2N0>#VY%:;>)]
M6<3B2:)UG(:16A4@MC&[&.&QWKWVJ_->+5CYY2H<MIIW+EUX1EMO,5;I)W%O
M%,!&1P7. &YX^M02>$-6CE",+?;B0O*)ALCV'#;CVQD?G5<^)-4*!3.G$:1;
MO+7<54Y4$XYP:<OB?5E?<+E2"TC,IC4JQ?[P(Q@@X'%)+$+JAMX9O9EQ?!M^
MUI*=\2WJ3^4L#. )!LW JW?([4A\(7DUU#;V4B2R26R3E9#L.6S\H]>E5E\5
MZROG'[2I:5MY9HE)4[=OR\?+QQQ2V_BS6;4@Q72\*BC=$K8"YV]1UY/-*V)[
MH?-ANS)[+P=J-R]B9WAMH;M]B.S@D=><?A4#^%M1$4LL9@EC0OLVRC=*J'#,
MH[@4Q?$^KQP10QW*QI'()1LC4$L.A/'-(?$NJF"6$3HJ2%ONQ*"H;[P4X^4'
MN!3MB+[HF^&M:S+3>"]87C%L6R1M$ZYW!=VW'KCG%4;C0;^UTF/4W6,VKL%)
M5\E2>@(J7_A)]7\WS/M*[S)YN?+'WMFS/_?/%,O/$6IW^GBQN9U>W&WCRU!.
MWID@9.*<57NKV%+ZO9VN/BT:+[)I<MQ=-&^H2E454W;$!QN//<]JT?\ A#7F
MN[BWLKT3R6UXMK,#'M*@_P ?7[HP?RK*76I%L;"$1*9["1F@F;!&T\[2IX.#
MR*>GB75H[^\O8KD1SWB;)V2, ./ICK[TI1KOX7W_ #_R*C+#KXEV_+_,T$\(
MB:VEGAOXQ&D,LRR2@*L@1MO'/ ^M9-]IJVNGV%]#*9(;M&^\,%'4X9?_ *_O
M3K?7M1M8(X(IE\J.%H%1HU8%&.2#D<\U'>ZE]JL;&SCA\J"T0@#=DN['+,?\
M*J*JJ7O.Z_37_@$S=%Q]U6?ZZ?\ !*-%%%;G,%%%% !1110 4444 %3:=J5[
MH>HQZCILWE3IU!^ZX[JP[BH"0HR3@5J^$_"=[XVORJ%H-)B;$]SC[_\ LK[_
M ,JY\54IPIOVFQTX6G4G47L]SV;P=XHMO%EC)?0(T<B;8YXST5_8]Q72UFZ3
MIMIH\0L+"!8;:%%"(H_4^IK2KY.33;Y=CZ^*:2YMPHHHJ2@HHHH **** "BB
MB@ HHHH @?\ X_8O]TU/5=_^/V+_ '35B@ HHHH **** "BBB@ HHHH *H:W
M:S7V@ZC:6^/.GM98H\G'S,I Y^IJ_5;45E?2[M(-WG-"X3:<'=M.,?C0!Y18
M^"_&%AHTQTF.'1Y3;V\$EK#<Y,Y0_O) PX1B.!W/<UNVVB>.?M.G+)JSBW:%
M7NWDD!=)4W;5 '!#93=_N^]97AOPWXVT?3;"0WUQ%+>SPI=0A_.,$8SOD)D)
M&X\9V\4[45^(][;ZK!FZB"?,C0")"2LPVB$@Y8&/).[OQ0 VS\*^.IQ:OJ=V
MLMU;7OGI)-*'6-MA&]<<[<D?*?RJ&73?B!;6-I;33:A,T]U@I#>#>N(6W,TN
MW"H7P0.W2M*6Z^(XU"[%G SQB)_)%RD2Q[=HV'(.?-SG(/RTK77C\W.FBVBO
M'@94WFYA@5BV_P#>>=M/RJ%SMV\D]: &MX8\:R;EDU+9)*T1GN;641L^VWVG
MM_ST%4H/^$YC\;Z/:WAU&6(?9S/+"<6RH%/F!^,,Q..<UHSV6KZ=\(OLUPES
M'.D@^TJ&+2"$RY;!'/W?TJM?Z3XDE\122V"7S;[FW?3;R*YVVL%H -Z.F>21
MGJISD<T 3W_P^U#4O%VN:Q)+%%'(0UHJ >9*?(*;6?/RID\KCGK6OX+T+6]!
ML[NSU"5KBT^S0_9XI)@VU]A$B@]ESC%<='H7BW['?K:6VJ07)BO1<O-=96X+
M/F 1#<<$#O@8KJ_!>F:S;PZJ)8KRSL)H8UM+>]F\R1)=F)&SN8A2W;/Y4 8^
MF:!KMII>LVW]C?V=-K-U'%LM9E>&WAP0S #H=N<GN2/2M/4/"=W)XZT2]T_3
M8;>TTXJ)+GS5'FQA,8V@;LCH!G;7.P:/XPFTL031ZQ;-9Z8;222*=6>:4S!M
MR M\PV@Y)(.#@5>TFWU>T?PO#=6TUOJ0U"7Y!*[[K3;\S."S;<_+\I)P>E '
MJ3_<;Z5Y!7K[_<;Z5Y!0!U/B_P#Y)-<?]>D7\UKQ9?NCZ5[3XO\ ^237'_7I
M%_-:\R\+P6<\EYY\<$MVEONLX;AML<DF>AY /';->[E<^2C*7F>#FL.>M"/D
M:?AK6-/LM#FM;RY6$,[.3$&$WW<#D JP]C4NH:UHMS;/<>79RW"V$<4$;0$%
M9 ?FSVZ=*FET;P]-=%YV6*4+;K/!:S@(DKDA\$YX P>.E4V\.:2D,7^E&16G
M:.:Z$Z!;8!L#*=6R.<BNB])RYM;LYOWT8\BLTBPMWX1W6>Z*#RQ(AVB)MRKM
M.\2'^++8QBH9+WPQ<685X+:"9H8V+Q0ME9 YW#'IMQQ5B71M%TX7I!1F-E*?
M)EF21EVN KJPZ%AD@=:F@\/Z!87T<4A-V;RTEN+=990@5"!L!)'WR<TN:GO>
M7_#%<M1Z6C_PYA>*)=$EFLFT?RLA6%P8D*J3GY3@@=JWM4U_1+J2<75W]NLY
MW@\JW2,@VX4#><D#&?0=:J'1-+N$5]WFSQV<3+:1SQQ%B2=Q+8P=OYFJWAJS
MTC4(KFUO_)@>TG%R)7;F2(9W1Y[]!^=4_9N";O[OWZD+VBFTK>]]VAL6D7A[
M5-4E2PM+%I!$-C;',0&_DLI PVWOR*SKR?P[#J,5JB6J1"]E\^7R2^V,8V8]
M1UZ4UK/1[W31?2A8@MM/<+;P.L9R'PJYQGIZYIR^&=':V2X%TWE2+;E LZ%L
ML3Y@P?3CK4KEB_>;[?H6^>2]U+N7;?4/"=MJXNK<VT<B^2P=H7,8P?GVC'#>
M^,54EU?09(VED6*XF6*4HLR,R[VER./]W-9^J:-IUGXHL;&"=6M)FC\P^:'*
M@GD$X&#[5HQ6UK)>:WY=A8MJ4-TL4%I<$(BP@X) ) )Z?G3Y::2E=O;_ "$I
M5&W&R6K_ ,S1M++P[<VM_=6MO:_9$:=FDG4YQM^0(3TP>QKS@'Y/?%=_%I_A
M>XO[^)7@2#3YQ<9W\3Q[?FC![X88'L:YZY2"Z\(M??9HX)4OVCB9%QO1AG;[
M[:TH3Y6]];;^9GB(<R6VE]O(ZCX(]->_ZZQ?R:O0/%7AY?$^B-IKW+6X,BOO
M5=QX/I7G_P $>FO?]=8OY-7=>,]?G\->'VU&WBCED$J)MDSC!.,\5X-52>)?
M)O<]ZBXK"KGVL<=_PIM/^@]/_P!^!_C1_P *;3_H/3_]^!_C35^)>K,H8)I>
M#SSO_P :7_A96K_W-+_-O\:[_J^8=_Q1Y_UC+^WX,7_A3:?]!Z?_ +\#_&C_
M (4VG_0>G_[\#_&D_P"%E:O_ '-+_-O\:/\ A96K_P!S2_S;_&CZOF'?\4'U
MC+^WX,7_ (4VG_0>G_[\#_&C_A3:?]!Z?_OP/\:3_A96K_W-+_-O\:/^%E:O
M_<TO\V_QH^KYAW_%!]8R_M^#%_X4VG_0>G_[\#_&C_A3:?\ 0>G_ ._ _P :
M3_A96K_W-+_-O\:/^%E:O_<TO\V_QH^KYAW_ !0?6,O[?@Q?^%-I_P!!Z?\
M[\#_ !H_X4VG_0>G_P"_ _QI/^%E:O\ W-+_ #;_ !H_X65J_P#<TO\ -O\
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MI?YM_C1_PLK5_P"YI?YM_C1]7S#O^*#ZQE_;\&+_ ,*;3_H/3_\ ?@?XT?\
M"FT_Z#T__?@?XTG_  LK5_[FE_FW^-'_  LK5_[FE_FW^-'U?,._XH/K&7]O
MP8H^#%M(RBXUNXDAW NBQ!2P[C.>*])L+"UTNQBLK*!(;>)=J(@P *\QE^*>
MIV@266UL)X]PW)"6#$=\9->CZ+K5CK^FQW]A,)(GZCNA[@CL:XL73Q$+>V.[
M!U<-._L2RG_'Y-_NK_6IZ@3_ (_)?]U?ZU/7$=P4444 %%%% !1110 4444
M%%%% %>3_C]A_P!UJL57D_X_8?\ =:K% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1CG-%% "/]QOI7D%>OO]QOI7D% '4^+_\ DDUQ
M_P!>D7\UKQ91E1]*]I\7_P#))KC_ *](OYK7BR_='TKW\H_AR]3Y[.?XD?0,
M#THP/2EHKUSQA,#TJ6>XFNG#W$KRL%"@N<X Z#Z5'10.XF!Z4N***!!BDP/2
MEHH !QTXJ2XN)KN8S7$K2RD %W.2<>]1T4>8[O8,"I)+B>2WC@>5VABSY:$\
M+GK@5'2'H:+ F>B_!'IKW_76+^35TGQ7_P"1(D_Z^(OYUS?P1Z:]_P!=8OY-
M72?%?_D2)/\ KXB_G7R[_P!\^9]5'_<O^W3Q>BCM17U!\H*B[Y%3(&X@9/05
MM-X3U83SP>4ADBG2# ;[[L,C;ZC'/TK$(R*Z"7QCJ<@TO:(D?3CN1@.93C;E
M_7CBLJGM-.2QM2]E9^TN1P^%+^YN)8+2>SN9(HVD<0S;L8ZCZUGWVEW6GW45
MM,@,LL:2*J\\-T!]ZOCQ&8&NFL=/M[-KF,H[1LQ();=N&3Z]J-2\5ZIJ-\]U
MYWD-(J+(D7"N5[D5$77YM4K&DE0Y=&[BS^$]2M[BW@8VS--*8,K,,)(.JL>Q
MYK)O+62QO9K2;'FPN4?!R,BMJY\62W5Q;RR:?;!8KC[4Z*S 2S<?,>>.G05E
M:I??VGJ4]Z8$@:9M[(A)&X]3S54G5O[Z)JJC;]VRI1116QSG1?##_DI4?_7K
M)_2O;-?_ .1>U'_KVD_]!->)_##_ )*5'_UZR?TKVS7_ /D7M1_Z]I/_ $$U
M\QCO]Y9]7@/]U1\\Z/I5WJ=I,UI'YAMH1*ZC[Q&0.!W/-:Q\'ZN$N&$49-NL
M;R(&^8!P"./QYK+T75KC2[&Y2W !N[<0L^2&09!R"._%;/\ PFFHB7S42-)=
M\+[\DD^6NW!]<CK7O2]O?W+6_P"&_P""?/15"WOWO_P__ (9?"6HP0SS3/;1
M1PR-%N:3AV R0./YXJ)_#5^GD1EK?[5-L*6@E'FX;H2*NKXTNXY;V:.S@6:[
M9V<[W*_,,<IG:<=LBJS^)YWN+>]^QVPU*#8!>#=N(7@97..G!I)XCJE_7Z%-
M8;HW_7ZE#4M,?3'"/<VL[9*L+>3?M8=0:O1^%[N34#8?:+5+E+<7#J[D;%QG
M!XZ@<U2U'4(KZ42PZ?;VC[B[&(L=[$Y[DX'M6M)XE@CUV;5K>S$TES;B.6.8
MD!&*[6VD'D$#]:J3J\JMO9_>1%4>9WVNON*0\-WY".K0&)K5KL2A_E\L'!Y]
M<\8JG?Z=+IXMF=DDBN81-%(F<,I_J#UJXOB*[3PW)HB)&+=W+!_XE4G.S/IF
MF:GJ<4\.F6]GYBQV,.U9'&&9R<D^PSTIQ=7F][;]!25'E]W?]2C<6D]J(C/&
M4$T8D3/=3W_2K_\ PC]VME#<RRVL)G4/##)+B21<XR!3=5U_4-8AMXKN9F2%
M H7.=Q&?F/OS4KZ^9[.UBN;"VGGM4$<-PQ8,J@Y (!P?K3;JV6FO425&[UTZ
M%J7P7J<5S% TUF3)/]GW"7A9<9VGCKBL*ZMS:W4MNSH[1,5+1G*DCTK9D\67
MUQX@CU:Y43>5)YD5LSMY<;8[5CW4XN;R:X6)8A*Y?8I)"Y^M%+VM_P!YV_$=
M7V-OW??\"&BBBMCG"BBB@ HHHH **** "BBB@ K0T#Q!?^%M2%Y8G=$QQ/;D
M_+(/Z'WK/)Q5K0=!U'Q?JGV#3@8X$/\ I%T1\L8]!ZGVKGQ3I*F_:['3A8U7
M47LMSWKP[KUCXCMVO["4,A50Z'[T;?W6'K6W6'X;\/V'AJU.G:?$$C55+N?O
M2-W9CW-;E?)RM=\NQ]?&]ES;A1114E!1110 4444 %%%% !1110!!)_Q^0_[
MK5/4$G_'Y#_NM4] !1110 4444 %%%% !1110 4444 %%%% !7/^-QJ1\&:H
M-(\_[?Y)\G[/GS,Y_AQWKH#TXKRVV\5:[:VNHWEQ->SZO%(ZR:6]F5@MX_,V
MK(&"Y8!?FX)SS0!!_:'C73;"Y?2;;4Y-.DG46[7\)GN4Q&,C82&V-)D9/(%/
MO]7\>7L][:SZ1((?LT3JL$3!5DRNX;\@L>OW3BI_^$]\520020:+;X$:L[/'
M*!,#,8PR#J 1AL'G%1W7Q'\06\]G:_V7;->.LA:W$<I:<K,$Q'C[N0<Y;B@"
M2_\ $?CG3(=1NY+:,VRI<-'YEMM$ 24*C$Y^;*$L!QG%='\/=>O/$?AZ:^NY
MO/ NY(X9O)\KS(U(PVWMWKE8_&?B6PFM;*32WNX[F]G5I[I&P5\\JL8P, A>
M<G.14 \>^+-+TTI)IL%S<+?RP,QMGC2%5Y1& [L.C#CZT >NT5%:RM/:0S/'
MY;R1JS)G[I(SBI: $?[C?2O(*]??[C?2O(* .I\7_P#))KC_ *](OYK7BR_=
M'TKVGQ?_ ,DFN/\ KTB_FM>++]T?2O?RC^'+U/GLY_B1]!:***]<\8**** "
MBBB@ HHHH **** "D/0TM(>AH ]%^"/37O\ KK%_)J[OQGX?G\3>'FTZWF2&
M0RH^]P2.#[5PGP1Z:]_UUB_DU>@>*O$(\,:(VHFW\\"18]F[;]XXSG!KY2KS
M?67R;W/KJ/+]57/M;4\X_P"%0ZU_T%K3_OAO\*/^%1:U_P!!:T_[X;_"MT?$
MVY90PT5"#R#]K'_Q-+_PLNZ_Z B?^!8_^)KOY<Q[?BO\SS^;+>_X/_(P?^%1
M:U_T%K3_ +X;_"C_ (5%K7_06M/^^&_PK>_X67=?] 1/_ L?_$T?\++NO^@(
MG_@6/_B:.7,>WY?YAS9;W_!_Y&#_ ,*BUK_H+6G_ 'PW^%'_  J+6O\ H+6G
M_?#?X5O?\++NO^@(G_@6/_B:/^%EW7_0$3_P+'_Q-'+F/;\O\PYLM[_@_P#(
MP?\ A46M?]!:T_[X;_"C_A46M?\ 06M/^^&_PK>_X67=?] 1/_ L?_$T?\++
MNO\ H")_X%C_ .)HY<Q[?E_F'-EO?\'_ )&#_P *BUK_ *"UI_WPW^%'_"HM
M:_Z"UI_WPW^%;W_"R[K_ * B?^!8_P#B:/\ A9=U_P! 1/\ P+'_ ,31RYCV
M_+_,.;+>_P"#_P B+P?\-[_P[XG35[F_@F586C*(I!.<<_I7?ZE:M>Z9=6J,
M%::)D!/09&*Y'P_\0_[;\2IHKZ<()6B:4NL^\ #MT]Z["_NOL.GW%ULW^3&T
MFW.,X&<5YN(]JJO[SXCU,/[)TOW7PGD:?!_6415&JVF ,?<;_"G?\*BUK_H+
M6G_?#?X5LV_Q3FN8$FBT5"K#/-T!_P"RU+_PLNZ_Z B?^!8_^)KTN7,.WY?Y
MGF<V6]_P?^1@_P#"HM:_Z"UI_P!\-_A1_P *BUK_ *"UI_WPW^%;W_"R[K_H
M")_X%C_XFC_A9=U_T!$_\"Q_\31RYCV_+_,7-EO?\'_D8/\ PJ+6O^@M:?\
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MJBC[PXY<'B@!+7XC:W-/H<4FDPE;Z<Q2R1!WXW !E7L,$Y))QBO3J3 '84M
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M_P *Z\7_ /0.@_\  A?\:/\ A77B_P#Z!T'_ ($+_C7I?_"R= ];O_OP:/\
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MI+^]9E@0@,57)YKC=67M?:=;G:J4?9>SZ6L>)_\ "N?%W_0.@_\  A?\:/\
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M&:E'A'QVMI:6Z64"&T9F@F6X42(&Z@'/2N\_X63H'K=_]^#1_P +)T#UN_\
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MAONGZ52=Q,]1^!W.C:P3U^V?^RBND^*'_(A7WU3^=<W\#?\ D#:Q_P!?@_\
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M K8X;&#\V,]JED\6W=BD$$UKF:&$2.%E!$JF/<,DC@YJ=F\*/=2VLD,C?:5
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MJZE6*"*W1G=N@&!5'_A.O#7_ $%8O^^6_P *N,FMB9)/<\:_X0;Q9_T!)/\
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M)XU_P@WBS_H"2?\ ?Q:/^$&\6?\ 0$D_[^+7LO\ PG7AK_H*Q?\ ?+?X4?\
M"=>&O^@K%_WRW^%'//L'+$\:_P"$&\6?] 23_OXM'_"#>+/^@))_W\6O9?\
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M!VFZGI&CV]EJ][]KO$B&6Q]P=DS_ !8]:Z.N4Z HHHH **** "BBB@ HHHH
M**** ()?^/N#_@7\JY/Q1XZ;P[JRV(L?/W(&#;L=>U=9+_Q]0?\  OY5Y]\0
MHEL]9M;^6S2YAG00_.<!&#9!SVK?#QC*=I*YQX^=2%'FINQ;U/Q_?Z1%!)=Z
M.@69=R[9LX/H?>NDCUTGP_::JT&5F"LR \JIZGWP.:\FGNHPY7^SX)6F8(D:
MRAPI/]T8KU6.&32M!TRU,88($CED*;O+&.6Q]>/QK2O3C"*LM3GP->I5J2O*
MZ7]=D._X22 *SM$?+$_E[@<_)_?/H.10?$ 5R)('0*WSD@G8O8G'4'U&15,7
M<C7,R*B+&8<AWM\%SD]1W%,:[N%2)&LXXI%D5) (?EY4DLI]#_\ 6KEL>E<T
M4\0137?V2./;*SE4+G"LN,AOQ[?0TCZ\4N&@-N2RS>46!^7[N>M45O)Y+BYB
MDM(I% ,=ON@X<@_*,^@SW_"K6G7HN+R-9K=(@T:ML\K!$N<'F@9,^N;88)?)
M)CDC21V7YA'D9Y YIHUUVM6G6%-JR^7@L1GG&>E9IO;J)8-MC%L,DNXK#T <
M -CV&3[U*;FYCN'06T4D!?*ND0#2<9W$=P#Z46%<O3:S+ ]PK6X80,%8H2V,
MC.<=<?2M>.198DD4Y5@"#7,"XOWC1Y8X/WL+3 ^1DY4<9J=M7OHXE_=[E,!_
M>"(\2[=P&/3'%%AW.BHJ"SN!<VL<F<DJ-W&.<<TMW-+!:2RP6[7$JKE858*7
M/ID\"D,Q/&7B<^$M&BU$6;78>YC@,:MM(#'EAP<X SBN6G^+D"Z%J>IP:6SB
MWO%MK2.281FY!7=OY'R_*"<>U78O'/A_6M&L[_7K)[&W>X\RS6X_>,S1GF3"
M9P%/4GBH=6UGP''/J%U]EM[W4+<27!B,;;976,9VLPV%MA'3/% #[SXEF"ZE
MEM],6XTN"VMKF:X%QA]DQPI5,?-@]>16CXI\;/X<U.SMO[/#6TZ;VO)Y&CB7
MD +N"MAN<_-@>]8$4_P^LYH[J^TZVM)+:0PP !Y0!'@\@# V[AUZ5O3S^"?$
MGB=+&9K:\U2)>$(;# 8;']UL9!QSB@!EE\1].N!+]JLKRTVW$\"%U!$GE LQ
M!!]%-5[GXF63:E86VFVD]U',ZBXE*8$0*%PH]7P.E9MQ<^#KS4YK:X\-R-87
M&IM:M?' C:\P00%W;AGD9Q@FK.G)HMSXBE%OX0DAU?3988B2ZD1HP(63*DKD
M+V/- '5Z#XGT[Q()GTUI)(X50M(5PN67=M!]0.H[5LUP7AG4+;0;'5M'TW0K
MT7.GRFXFBDFBS)YK%MV\':.!T." !76:#K,'B#0[35;>.6.&Y3>J2KAA]: -
M!_N-]*\@KU]_N-]*\@H [/7XY)OAA<1Q(SNUB@55&2>E>%I8:BJ '3;S@?\
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MPIF<NV/3)JW10 C_ '&^E>05Z^_W&^E>04 =EXB_Y)=<_P#7BO\ 2O%X+T+
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MKP\6DKW.#%X%8F2;=K'SUYT?H_\ WP:/.CSG#_\ ?!KZ%_MOPYZP_P#@.?\
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MIY?]CQ_F/GOST]'_ .^#2>='Z/\ ]\&OH7^V_#GK#_X#G_XFC^V_#GK#_P"
MY_\ B:/[7E_*']CQ_F/GKSH_1_\ O@T>?&.S_P#?!KZ%_MOPYZP_^ Y_^)H_
MMOPYZP_^ Y_^)H_M>7\H?V/'^8^>O.C]'_[X-'GH.S_]\&OH7^V_#GK#_P"
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;@KT=O%&CE2/M9Z?\\V_PKS+[5#_?_0T ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>syn-20211231x10k002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syn-20211231x10k002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $/ I4# 2(  A$! Q$!_\0
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M_:=[_P _#4JZC?,P59I&)[ 9- 'H7]N^$?\ GWA_\ 6_^)H_MWPC_P ^\/\
MX M_\37GS7^H)C?+*N>FY<9IO]I7I.!.U 'H?]N^$?\ GWA_\ 6_^)H_MWPC
M_P ^\/\ X M_\37GK:A?HY1YI%8'!5A@C\*3^T[W_GX:@#T/^W?"/_/O#_X
MM_\ $T?V[X1_Y]X?_ %O_B:\].H7ZHKF60*V=K$<''7!I/[3O?\ GX:@#T/^
MW?"/_/O#_P" +?\ Q-']N^$?^?>'_P  6_\ B:\\_M.]_P"?AJ/[3O?^?AJ
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MXV],].GO3/[3O?\ GX:@#T/^W?"/_/O#_P" +?\ Q-(=>\( $F"$ <DFQ/\
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M[MG_ . I_P#B:\V_M6\_YZC_ +Y%+_:MY_ST'_? H ](_M;PC_=L_P#P%/\
M\31_:WA'^[9_^ I_^)KS;^U;S_GJ/^^!3_[0U#Y?O?,<+^Z^\?;CF@#T;^UO
M"/\ =L__  %/_P 31_:WA'^[9_\ @*?_ (FO-VU.]5BK/A@<$% "#1_:MY_S
MT'_? H ](_M;PC_=L_\ P%/_ ,31_:WA'^[9_P#@*?\ XFO-_P"U;S_GH/\
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M+&$F!9XR #Y;4 >M>(O^19U7_KSF_P#0#7BD'^I3Z5[7XA!;PUJJJ"2;.4
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MZ#&K_P#@0?\ &C_A*[[_ *#&K_\ @0?\:/['J?S+\0_MFG_*_P #WNBO!/\
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M/^$\UK_H/O\ ^ D?_P 31]0QG\Z^]_Y!_:&#_D?W+_,['_A4OACTO/\ O_\
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M:V^H8S^=?>_\C#^T,'_(_N7^9V/_  J7PQZ7G_?_ /\ K4?\*E\,>EY_W_\
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M?^RT4>._^8?_ -M/_9:* *GCK_DDY_ZY6O\ Z&E>-CH*]D\=?\DG/_7*U_\
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MY:4Q^:6#X4, !Q4>I-X]O'GM(H;R2PGLG0>=' C,I@?)<J<K-YNP +\N.?7
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M:WTM- ,VFW,:VB_VM<0GRN#]D15_>C#9 R_KVJZB@_>U[?<12=1>[IW^_P#
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MUC+NWX,=_P *:3_H8)__  ''_P 51_PII/\ H8)__ <?_%4W_A96K_W-(_\
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MO_<TC_Q__P"*H^KYAW_%!]8R[M^#&P_!Y)8@_P#;\XSG_EW'K_O5)_PII/\
MH8)__ <?_%5%'\1]6CC"!-)P/]__ .*I_P#PLK5_[FD?^/\ _P 51]7S#O\
MB@^L9=V_!CO^%-)_T,$__@./_BJ/^%-)_P!#!/\ ^ X_^*IO_"RM7_N:1_X_
M_P#%4?\ "RM7_N:1_P"/_P#Q5'U?,._XH/K&7=OP8[_A32?]#!/_ . X_P#B
MJ/\ A32?]#!/_P" X_\ BJ;_ ,+*U?\ N:1_X_\ _%4?\+*U?^YI'_C_ /\
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M3ZS.P$DG40J0?D3^I[_2O&S25%JS^(]O*8UD[KX3O:***\(]\**** "BBB@
MHHHH **** "H+;_EM_UU-3U!;?\ +;_KJ: )Z*** "BBB@ HHHH **** "BB
MB@ HHHH *Y;QZ-0.@V_]GC4#_I]O]H_L\L)O(WCS-NWYONYZ5T\I=8G,:AG"
MDJI.,GL*\KL_&&N66@1WLEU=W>IR/&FH0WNG.D&FN0Y.!&@9AE0@&6ZAB>>0
M"2VU/Q_8?V=;Q6-U/;/.YB-U#YDKPFXPJSN&'EE83NW'.3@'G(J%=8\>W"/=
M3:3.;FV>\,!%JZ(<6[&,!-V2-^T?,#DG@]ZLS>//%[ R1:!;P Q_ZF>.8NC_
M &/[0<D<$;@8^QR1W&*JZI\0?$%X=9L+"R5&BM)B/L\4AGMF%HLRR%L;3\[;
M-OWLXXH A\2^-?&'AO3W%Z\43":X6"Y^PY-P1%&\2"/?P"[NI89^X.*];@9W
MMXVD&'* L,=\<UY7JOC;Q6PUJSM=)2";3X?,MY9;=Y)#L9/WFW&&#*S$8Z8[
M]MS0O&>M:EXR&D7&F0I9>5N%P$D0R#RU82KNXV,20 >1CDD\4 =Y1110!QWC
MO_F'_P#;3_V6BCQW_P P_P#[:?\ LM% %3QU_P DG/\ URM?_0TKQL=!7LGC
MK_DDY_ZY6O\ Z&E>-CH*^@RC^%+U/G,Y_BQ]!:***]8\@**** "BBB@ HHHH
M **** "MWX=_\E/TS_KE-_Z+-85;OP[_ .2GZ9_URF_]%FN/,/\ =Y';E_\
MO,3W;5[-]1T:^L8V5'N+>2)6;H"RD9/YUY2/A!K*C U:RP.GR-_A7K&IWO\
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MSG&<=J]<TN_35-(LM0C1D2Z@2=4;JH90P!_.@"W145S(8;:60=40M^0K@_\
MA*_%9CTUTT_1G^WXVJMX^8@4WY?Y../3G-)LN%-SV/0:*\WN/&GBVWUR/2SH
MVFL9%1TN%NV\IE9P@(.W/4C/'%=1X?U;4KZ]O+74H[)7@2-T>SE,B.K9[D#G
MBA.Y<Z,HJ[:^]'04444S$**** "BBB@ J.*WA@:5HH8XVE??(44 NV ,GU.
M!GV%244 %%%% !1110!QWCO_ )A__;3_ -EHH\=_\P__ +:?^RT4 5/'7_))
MS_URM?\ T-*\;'05[)XZ_P"23G_KE:_^AI7C8Z"OH,H_A2]3YS.?XL?06BBB
MO6/("BBB@ HHHH **** "BBB@ K=^'?_ "4_3/\ KE-_Z+-85;OP[_Y*?IG_
M %RF_P#19KCS#_=Y';E_^\Q/;?$__(IZQ_UXS?\ H!KYRB_U2_2OHWQ/_P B
MGK'_ %XS?^@&OG*+_5+]*X<GVD=^=;P^8_/O2@$D 'DG'6DHZBO:/#-)M U9
M9IH392^;#,L#H""1(W*J.><CGBGR>'-7C6=C:%E@C\V4QR*X5,D$\$]"#^5:
MK>-[@-I,B6B"6R;?.Q;_ (^6"",$^AV<?C5:Q\1VVCBY_LFQEA\[RSF:<2?=
M?<0?E&5(.W%<O/B+?"OZ^?S.ODP]_B?]?+Y&1)IM[%J?]FO _P!LWA/)!R2Q
MQ@<?45;/AS6!=M:_89#*L1F.UE*[!GYMP.,<$=>HJ]+XNG_X2(ZI!:0)']H6
M<1,BEA@ ;?,QNQQ4EOXHL[?4;69=.G^S6EK);01"X&[Y]VXLVWG[QQP*;G7M
MI'I^/W_UW$H8>^LGO^'W?UV.8SGO1GWI6V;V\L,$S\H8Y(';)I*Z3E&R_P"J
M;Z5[)\'O^2?P_P#7S-_Z&:\:E_U3?2O9?@]_R3^'_KYF_P#0S7D9O\$?4]K)
MOCEZ&!\8O^0KHW_7&7^:U0ET>PEL-->ZM8[91ILUS,ULX5Y)4^ZI))ZK@]._
MX5?^,7_(6T;_ *XR_P UK+C\'6EY:67V"X=YIFB2:5V $+N"<-'M##IP<G-&
M%DEAH-NVXL5%O$S2C?8+KPWHT":E*-0E*6!RRF12T@>-3%MP.3O)#>P[5;;P
MAHPO[:!+V[DC=6/FJZ%9<*"&4]0,DYX.*SHO!$LIB==0A%O,L/DR&%\LTK,J
M@KU7E3DFHO\ A#)?LHD-];++M1WC96PBM*8L[NAPP_*NCF6WM7]QAR/?V2^\
MU_[%T>*VMQ"B.\;7L<MQYZ2*2BDH"".2<#! '0^V&-X.T[R+5XYYG62:./S6
MN$5)@83(2O!VG(Q@Y-4V\!S"[,37T0BS$B2^2Q$CR,54#&?E^4_-TI\F@:EJ
M*VEE>:T&"V[W/DN"5AC0E"0>A.5Q]*GF7V:GY^I7*W\5/\O)%R;PUH<<,UH)
M6#"]MP;MIEW0Q.@)R.A )Q]<>AJC?>'])LK:ZN))+D/%;I)]D^T1EU8RE,%@
M,$$8; &<4EMX-A1+F6ZO8YHQ%<M;_9P2)#&@;<6Q@#)'!Z\UC06-JGAR34IU
MD>1KM;>)$;:  NYR>.N, ?6KAKM-O;^OP_K4SGIO!+?^OQ,SGUHS[UVDGA"R
MNM6O-*TY[I;N%+>6,3.I#H^W>> /NAP?P-8]WING-I^J7%@\Q%C>+&KR,")8
MFR >G!RN?H?:MXXB$MO+\=CGEAIQW\_PW,//O1GWHHK<YQCINPRL5=3N5E."
MI'0@^M>O^ /'_P#:X31]8D"ZFHQ%*>!<@?\ L_MWZBO())%B0NYP!7;?#OP+
M-KEU#K^K(\6GQ,'M(.5,[ Y#GT4=O7Z=?,S-473O/?H>KE<JRJ6AMU/;****
M^</I0HHHH **** "BBB@ J"X^]!_UT'\C4]07'WH/^NH_D: )Z*** "BBB@
MHHHH **** "BBB@ J"WZS?\ 70_R%3U!;\&?_KH?Y"@">OBKQ_\ \E%\2?\
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M<^+_ /H&P?\ @2G^-'_"N?%__0-@_P# E/\ &O2O^%DZ!_T^?^ [4?\ "R=
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MO_Z!L'_@2G^-'_"N?%__ $#8/_ E/\:]*_X63H'_ $^?^ [4?\+)T#_I\_\
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M1M!CBVG[9G)/_'LWJ:D_X63H'_3Y_P" [5R5IU:LN:9V4:=.C'E@=?17(?\
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M]/?I6[KFNZ)=R1-;:9'<[7E/[R'[.$1B-D?[LC=MP>3ZU9?Q;8FQ:W%LK?\
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M+0F23W/&O^$&\6_] .3_ +^+_C1_P@WBW_H!R?\ ?Q?\:]E_X3KPS_T%X?\
MOEO\*/\ A.O#/_07A_[Y;_"KYY]B>6)XU_P@WBW_ * <G_?Q?\:/^$%\6_\
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M_OEO\*/^$Z\,_P#07A_[Y;_"CGGV#EB>-?\ "#>+?^@')_W\7_&C_A!O%O\
MT Y/^_B_XU[+_P )UX9_Z"\/_?+?X4?\)UX9_P"@O#_WRW^%'//L'+$\:_X0
M;Q;_ - .3_OXO^-'_"#>+?\ H!R?]_%_QKV7_A.O#/\ T%X?^^6_PH_X3KPS
M_P!!>'_OEO\ "CGGV#EB>,/X#\6.A7^Q)!D?\]%_QKU_X<Z5>Z+X&L-/U" P
MW432[T)!QF5B.GL0:L?\)UX9_P"@O#_WRW^%;&GZC9ZK9)>6,Z3V[E@LB="0
M2#^1!%1*4GN5%);'"?%/0-6UPZ2=+LFN?(\[S-K ;<[,=?H?RKSW_A!O%O\
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MY;_"C_A.O#/_ $%X?^^6_P *.>?8.6)XU_P@WBW_ * <G_?Q?\:/^$&\6_\
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MZYZDUKT4 84?@WP_%J%M?IID0N[5%2&;<VY54Y SGD9]:W:** ..\=_\P_\
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MS;4KN1K?3;MU,%DPY8_\]>?N\<#'7OT%8U8K<U@WL>KT445B:!1110 4444
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MW&D.L5G#+)&9)622Z"1&0F(%-C#@@_/N&"<<5!H>H^!(-5L[U+>UM-8O0"A
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M^@;>_P#?DT?8=0_Z!M[_ -^37TM_:5C_ ,_MO_W]7_&C^TK'_G]M_P#OZO\
MC1SR[!RQ[GS3]AU#_H&WO_?DT?8=0_Z!M[_WY-?2W]I6/_/[;_\ ?U?\:/[2
ML?\ G]M_^_J_XT<\NP<L>Y\T_8=0_P"@;>_]^31]AU#_ *!M[_WY-?2W]I6/
M_/[;_P#?U?\ &C^TK'_G]M_^_J_XT<\NP<L>Y\T_8=0_Z!M[_P!^31]AU#_H
M&WO_ 'Y-?2W]I6/_ #^V_P#W]7_&C^TK'_G]M_\ OZO^-'/+L'+'N?-/V'4/
M^@;>_P#?DUU'PPT^^A^(<5Q-97$4/V25=\D94 _+Q7MW]I6/_/[;_P#?U?\
M&GQ7EK.^R*YAD;KM1P32E*35FAI13T9!K"EM$OU4$DV\@  R3\IKYKCT_440
M*=-O,CTA-?4!(4$D@ <DFJ_]HV/_ #^V_P#W]7_&IA)K9#DD]SYI^PZA_P!
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M&#R:C.L>(/M%M/\ V9,'MTF2,"U; $N=^>>?O'%?0]%'M/(.0^>AK6OA O\
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MN_VR6^O'I6)X2DUD^+K9/#@S>#_7%O\ 5"/OYG^S^N<8YQ7G8VC"M!U-FO\
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MO+^4/['C_,?/7GQC^]_WP:ZCX7?-\2(G .TVDHR01_=KUW^W?#?_ #TA_P#
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M[,;YGPT]PP^>9O4^@]!V_.G1^(] B),=PB9Z[8&&?_':D_X2G1?^?S_R$_\
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M1C/:G_\ "4Z+_P _G_D)_P#"C_A*=%_Y_/\ R$_^%%A778LV%^;B5XI9(3(
M"%C5AQWZBM"L;_A*-$#%OM8R>I\I_P#"E_X2G1?^?S_R$_\ A3$S8K"ETR\L
M-9GU+35BF6Y $\$C;3D=U;!_(U+_ ,)3HO\ S^?^0G_PH_X2G1?^?S_R$_\
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53[[[%]FN-^S?N^1AC.WU'M10!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>syn-20211231xex10d34002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syn-20211231xex10d34002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "8 .X# 2(  A$! Q$!_\0
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M<RKJ7,W<]ZO?#/A?Q; ;B)86D8<3VK ,/KC^M<%K?PLU2P#RZ;*M[".=GW9
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M444 %%%%(#Z%\%:Q_;?A6SN&.9D7RI?]Y>/\#6!\5=9^Q:#%IL38EO&^<?[
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M^C?XUY[JF@ZKHKE=0LI81V<C*G\>E987,L-B?@EKV>Y=;"5J/Q(SJ**!DD
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M;K_OPW^%']FW_P#SXW7_ 'X;_"BBCZY/L@]C$/[-O_\ GQNO^_#?X4?V;?\
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4_P#GQNO^_#?X444?7)]D'L8G_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>syn-20211231xex10d34001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syn-20211231xex10d34001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "8 =0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "D)"@EB !U)J"^OK;3K22ZNY5BB09+,:\(\;
M?%.^UN633]$8P68.UIAU:HG-1W-Z-"=5Z;'?^-OB?8>'(C;V)6[OCP$4Y JO
MX.^+&GZXR6>I 6EZ3@ ]#7@R1A'+EF>0]78Y)I)HRX#H=LR'*.."#7-[:5[G
MIK!4N7E?WGV$"" 0<@]Z*\_^&/B^+6?#\-I>W*_VA#\A5CR1VKT"NJ,E)71Y
M%2FZ<G%A34<.2!U%.IBQA6)'>J('T444 %%%% !1110 444 @]#0 4444 %%
M&><=Z* "BF[U_O#\Z4,K=&!^AH 6BD) ZD#ZTF]/[R_G0 ZBC.1F@$'H<T %
M%!( R3BF[T_O+^= #J* 01D'(HR,XSS0 4444 %%)O7^\/SH#*V<$''H: %H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9--'!
M&9)75$'5F.!0 ^HKBZ@M(C+<2I$@_B8XK@?%'Q9TC15>&R;[7=#@!>1FO'-=
M\6^(/%UZL#22;Y#A+>+I^-8SK):+4[*.#G/66B/HZP\4Z/J=^UE:7L<DZ_P@
M]:N:GJ=KI%A+>WD@CAC&22:\T^&_PY?PONUW59#]KV9" _='O7)?$;QC)XCN
M6L(7*VL;8*@_>I.JXQN]RHX6,ZO+!^ZMV9WC3QS=^+KQDB=H].0X1 <;O>N6
M "@*!@"I JQH H  Z5&3DURW;=V>LHQBN6.P445/!$'D7/(/6ANPTKC;%I[?
M6[&2UE:*=I  5/O7UE9[_L,'F'+^6NX^^*\ ^&WA1/$7B9[Z7(M+(Y7_ &C7
MT*H"J%'0# KIPZ=KGEYA-.2BN@M%%%=!YP4444 %%%% !1110 C?<;Z5P?@/
M4;R]U[7HKF=I(XI (U/\-=X_W&^E>=?#K_D8_$7_ %U% &E\4+[4;'P?(^EW
M+6]V\BHKCWJM\-/%<^M:*;#4B5U6T&V0-U<?WJD^*G'A6/\ Z^4K#\0V,WA]
M=*\8::A'E0A+U%Z-'CK0!>^%NL:AJ\NM/?W+3&*Z9$W=@#TJY\4M7O=+T"VC
MLK@VS75RD+3#J@)ZU@_!*Y6]M-7NXQA)[EI%'L37H?B/0;'Q%I,EC?\ $9Y5
M^Z'U% '"+\.[@@ >.KS)_P!H?XUW/AS1'T+31;2WTM[)G)FEZFO.KWX36UG8
MS7,?BK4-\2EURX[?C77_  YU.YU/PI&]U(9)(G,6\]6 [T 5_&?A2_U43:A;
M^(+NR6")G6&,?*2!FN-^&V@ZKXCL(M9O?$=V?+E(, ^ZP![UZWK'_($O_P#K
MVD_]!-<)\%?^1+;_ *[-_,T >BL-D+ =EXKAOA;J-YJ.D:A)>3M,Z7DBJ6[
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M'J.*F^*/B35/#GA:&YTK'VF215 /?/:LCXL?\C%X3_Z^C_2KGQ7.-(T4]?\
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M* &KN$8W$%L<D>M<1X*UB]U'Q1XEM;F3=%:SJL0]!7<'H:\X^'G_ ".?B_\
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MV*/*/"UZ=10!QN@_#VPTW2TM[YS=W.XL\P.-Q-%=E10 4444 %! ((/0T44
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MN[8S74^!_$D_B/2))+J(1W-N_E2@=S7(Q^*/B -(0#PQ;>7Y PWF'IMZU?\
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MWY^+OA@'M"W\S7INH_\ (-N?^N;?RH \FM?B/XRU03SZ;H:SVR2M&KA>N*]
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MHHH " 1@C(J"&SMH'9XH(T9N254 FBB@">BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>syn-20211231xex10d35004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syn-20211231xex10d35004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !B )@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#EZ]*^#O\
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MTC1OAWYDFIZY%]JNE5&5L*  3T7D]^IKBM;^)NN:INCM&73[<\8A.7(]W/\
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DI?\ "C^S[+_GSM_^_2_X444 ']GV7_/G;_\ ?I?\**** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>syn-20211231xex10d35003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 syn-20211231xex10d35003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "$ +L# 2(  A$! Q$!_\0
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M-<O\2?\ DF_B#_KS>@#E_!/AC3M,T[3/&=SJ4D CTT))&V!$J#G-5;M&U/Q
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MI$FAE&Y)%.01[5SG_"5'5]*U>6PTV>:SMUDB6X# "4@$-@=>#Q57P)=W-O\
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MM!I]]-=^%+H6%^R6$[FZ>Z),@=DP2,]5S3K3P=?WWP[U_1)U\BYO+ZXEA).
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5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>syn-20211231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/16/2022 8:41:32 PM-->
<!--Modified on: 3/16/2022 8:41:32 PM-->
<xsd:schema xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" targetNamespace="http://www.syntheticbiologics.com/20211231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:syn="http://www.syntheticbiologics.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations" id="StatementConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>40301 - Disclosure - Selected Balance Sheet Information - Schedule of PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails">
        <link:definition>40302 - Disclosure - Selected Balance Sheet Information - Schedule of PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails">
        <link:definition>40303 - Disclosure - Selected Balance Sheet Information - Schedule of ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" id="DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails">
        <link:definition>40304 - Disclosure - Selected Balance Sheet Information - Schedule of ACCRUED EMPLOYEE BENEFITS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails" id="DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails">
        <link:definition>40701 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Maturity analysis of operating leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>40801 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsDetails">
        <link:definition>40802 - Disclosure - Income Taxes - Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" id="StatementConsolidatedStatementsOfStockholdersDeficitEquity">
        <link:definition>00300 - Statement - Consolidated Statements of Stockholders (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails" id="DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - Organization, Nature of Operations and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails" id="DisclosureStockBasedCompensationAndWarrantsDetails">
        <link:definition>40401 - Disclosure - Stock-Based Compensation and Warrants - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails" id="DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails">
        <link:definition>40402 - Disclosure - Stock-Based Compensation and Warrants - Summary of stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails" id="DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails">
        <link:definition>40403 - Disclosure - Stock-Based Compensation and Warrants - Options outstanding and exercisable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails" id="DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails">
        <link:definition>40404 - Disclosure - Stock-Based Compensation and Warrants - Stock incentive plan and other information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails" id="DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails">
        <link:definition>40405 - Disclosure - Stock-Based Compensation and Warrants - Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails" id="DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails">
        <link:definition>40406 - Disclosure - Stock-Based Compensation and Warrants - Summary of all warrant activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" id="DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails">
        <link:definition>40407 - Disclosure - Stock-Based Compensation and Warrants - Summary of all outstanding and exercisable warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails" id="DisclosureStockholdersEquityDetails">
        <link:definition>40501 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" id="DisclosureNonControllingInterestDetails">
        <link:definition>40601 - Disclosure - Non-controlling Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails" id="DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails">
        <link:definition>40702 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>40803 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40901 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation" id="DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation" id="DisclosureSelectedBalanceSheetInformation">
        <link:definition>10301 - Disclosure - Selected Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrants" id="DisclosureStockBasedCompensationAndWarrants">
        <link:definition>10401 - Disclosure - Stock-Based Compensation and Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>10501 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest" id="DisclosureNonControllingInterest">
        <link:definition>10601 - Disclosure - Non-controlling Interest</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitments" id="DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitments">
        <link:definition>10701 - Disclosure - License, Collaborative and Employment Agreements and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10801 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10901 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables" id="DisclosureSelectedBalanceSheetInformationTables">
        <link:definition>30303 - Disclosure - Selected Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables" id="DisclosureStockBasedCompensationAndWarrantsTables">
        <link:definition>30403 - Disclosure - Stock-Based Compensation and Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables" id="DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables">
        <link:definition>30703 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30803 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="syn-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element name="DepositsAndOtherAssetsNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syn_DepositsAndOtherAssetsNoncurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <xsd:element name="ConversionOfSeriesBPreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_ConversionOfSeriesBPreferredStockToCommonStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodValueOfSynBiomicsStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="ConversionOfSeriesBPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" substitutionGroup="xbrli:item" />
  <xsd:element id="syn_IncreaseDecreaseLeaseLiability" name="IncreaseDecreaseLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_IncreaseDecreaseRightOfUseAssets" name="IncreaseDecreaseRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_DeemedDividendsWithBeneficialConversionFeature" name="DeemedDividendsWithBeneficialConversionFeature" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="StockWarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_StockWarrantsAbstract" substitutionGroup="xbrli:item" />
  <xsd:element id="syn_AccruedExpensesTableTextBlock" name="AccruedExpensesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_AccruedEmployeeBenefitsTableTextBlock" name="AccruedEmployeeBenefitsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" name="ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" name="PrepaidClinicalResearchOrganizationsExpenseCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="syn_PrepaidConsultingSubscriptionsAndOtherExpenses" name="PrepaidConsultingSubscriptionsAndOtherExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="ComputersAndOfficeEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_ComputersAndOfficeEquipmentMember" substitutionGroup="xbrli:item" />
  <xsd:element name="AccruedManufacturingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syn_AccruedManufacturingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="syn_AccruedClinicalConsultingServices" name="AccruedClinicalConsultingServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="syn_AccruedVendorPayments" name="AccruedVendorPayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="StockPlan2007Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_StockPlan2007Member" substitutionGroup="xbrli:item" />
  <xsd:element name="StockPlan2010Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_StockPlan2010Member" substitutionGroup="xbrli:item" />
  <xsd:element name="GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" substitutionGroup="xbrli:item" />
  <xsd:element name="StockWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_StockWarrantsMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePrice1820Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_ExercisePrice1820Member" substitutionGroup="xbrli:item" />
  <xsd:element name="WarrantsExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_WarrantsExercisePrice" substitutionGroup="xbrli:item" />
  <xsd:element id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element name="OctoberTwoThousandEighteenWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_OctoberTwoThousandEighteenWarrantsMember" substitutionGroup="xbrli:item" />
  <xsd:element name="UnderwrittenPublicOfferingMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="syn_UnderwrittenPublicOfferingMember" substitutionGroup="xbrli:item" />
  <xsd:element id="syn_WarrantTerm" name="WarrantTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_PreferredStockConversionPricePerShare" name="PreferredStockConversionPricePerShare" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="syn_NumberOfCommonStockToBeIssued" name="NumberOfCommonStockToBeIssued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="syn_AdditionalNumberOfCommonStockToBeIssued" name="AdditionalNumberOfCommonStockToBeIssued" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="syn_NumberOfCommonStockToBeHeldByRelatedParty" name="NumberOfCommonStockToBeHeldByRelatedParty" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="syn_FairValueOfSharesIssued" name="FairValueOfSharesIssued" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="BrokerageCommissionPercentage" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="syn_BrokerageCommissionPercentage" substitutionGroup="xbrli:item" />
  <xsd:element id="syn_IssueOfWarrantsToPurchaseCommonStock" name="IssueOfWarrantsToPurchaseCommonStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element name="InvestmentWarrantsExpirationDate1" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_InvestmentWarrantsExpirationDate1" substitutionGroup="xbrli:item" />
  <xsd:element id="syn_PreferredStockSharesConverted" name="PreferredStockSharesConverted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfIssueOfThePublicOffering" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="syn_PercentageOfIssueOfThePublicOffering" substitutionGroup="xbrli:item" />
  <xsd:element id="syn_StockIssuedDuringPeriodAtMarketOfferingValue" name="StockIssuedDuringPeriodAtMarketOfferingValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="syn_StockIssuedDuringPeriodAtMarketOfferingShare" name="StockIssuedDuringPeriodAtMarketOfferingShare" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_BalanceSheetInformationAbstract" name="BalanceSheetInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts" name="ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_PrepaidManufacturingExpense" name="PrepaidManufacturingExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="syn_ClinicalTrialAgreementMember" name="ClinicalTrialAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_EstimatedResearchCosts" name="EstimatedResearchCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_SubsidiaryStockIssuesToVendor" name="SubsidiaryStockIssuesToVendor" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" name="DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" name="LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_NoncontrollingInterestPolicyTextBlock" name="NoncontrollingInterestPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_StockBasedPaymentArrangementsPolicyTextBlock" name="StockBasedPaymentArrangementsPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_EstimatedUsefulLifeOfAssetTableTextBlock" name="EstimatedUsefulLifeOfAssetTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_SYNBiomicsMember" name="SYNBiomicsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_MoneyMarketAccountsMember" name="MoneyMarketAccountsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_SeriesAAndSeriesBPreferredStockMember" name="SeriesAAndSeriesBPreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_RangeOfExercisePrice0004000Member" name="RangeOfExercisePrice0004000Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_RangeOfExercisePrice41007000Member" name="RangeOfExercisePrice41007000Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_RangeOfExercisePrice710010200Member" name="RangeOfExercisePrice710010200Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_SeriesWarrantsMember" name="SeriesWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" name="ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_DrPimentelsMember" name="DrPimentelsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" name="LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_QuarterlyInstallmentsPaymentPeriodAxis" name="QuarterlyInstallmentsPaymentPeriodAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_QuarterlyInstallmentsPaymentPeriodDomain" name="QuarterlyInstallmentsPaymentPeriodDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_FirstYearMember" name="FirstYearMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_SecondYearMember" name="SecondYearMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_ThirdYearMember" name="ThirdYearMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_PhaseIClinicalTrialsMember" name="PhaseIClinicalTrialsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_PhaseIiiClinicalTrialsMember" name="PhaseIiiClinicalTrialsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_NdaSubmissionInUsMember" name="NdaSubmissionInUsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_EuropeanMedicinesAgencyApprovalMember" name="EuropeanMedicinesAgencyApprovalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_RegulatoryApprovalInAsianCountryMember" name="RegulatoryApprovalInAsianCountryMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_PrevAbrLlcMember" name="PrevAbrLlcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_StevenAShallcrossMember" name="StevenAShallcrossMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" name="LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_ResearchAgreementFixedFee" name="ResearchAgreementFixedFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="syn_MilestonePayment" name="MilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_AdditionalCashPaymentForLicenseAgreement" name="AdditionalCashPaymentForLicenseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_UnregisteredSharesIssuedToLicenseAgreement" name="UnregisteredSharesIssuedToLicenseAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_AdditionalConsiderationPayable" name="AdditionalConsiderationPayable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_OptionsToBeReceivedCommonStockShares" name="OptionsToBeReceivedCommonStockShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_DeferredTaxAssetsStocksIssuedForServices" name="DeferredTaxAssetsStocksIssuedForServices" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" name="DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement" name="DeferredTaxAssetsStockIssuedForlicenseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="syn_DeferredTaxAssetsStockIssuedForMilestonePayment" name="DeferredTaxAssetsStockIssuedForMilestonePayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee" name="DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="syn_IncomeTaxesTable" name="IncomeTaxesTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_IncomeTaxLineItems" name="IncomeTaxLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_OperatingLossCarryforwardsExpireDate" name="OperatingLossCarryforwardsExpireDate" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_SyntheticBiomicsIncMember" name="SyntheticBiomicsIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_CedarssinaiMedicalCenterMember" name="CedarssinaiMedicalCenterMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_LicenseAgreementAnnualPaymentsDue" name="LicenseAgreementAnnualPaymentsDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="syn_LicenseAgreementFinalPaymentDue" name="LicenseAgreementFinalPaymentDue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember" name="ShareBasedPaymentArrangementEmployeeAndConsultantMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_CostOfLivingAdjustmentsPercentage" name="CostOfLivingAdjustmentsPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_NonCashAdditionOfRightOfUseAssets" name="NonCashAdditionOfRightOfUseAssets" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_ConsultantMember" name="ConsultantMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_AccretionOfPreferredStockDeemedDividend" name="AccretionOfPreferredStockDeemedDividend" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_FbrCapitalMarketsCoMember" name="FbrCapitalMarketsCoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_StockPlan2020Member" name="StockPlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_OperatingLossCarryforwardsLimitationOnUse" name="OperatingLossCarryforwardsLimitationOnUse" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="syn_BeneficialOwnershipPercentage" name="BeneficialOwnershipPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="syn_WarrantExercisePriceAdjustment" name="WarrantExercisePriceAdjustment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_ExercisePrice0.69Member" name="ExercisePrice0.69Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="syn_Conversionofseriesapreferredstocktocommonstockshares" name="Conversionofseriesapreferredstocktocommonstockshares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_Conversionofseriesbpreferredstocktocommonstock" name="Conversionofseriesbpreferredstocktocommonstock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="syn_PreferredStockPriceAdjustment" name="PreferredStockPriceAdjustment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="syn_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_AdjustmentsToEffectOfPreferredStockPrice" name="AdjustmentsToEffectOfPreferredStockPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="syn_EstimatedFairValueOfInducementConsideration" name="EstimatedFairValueOfInducementConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="syn_NumberOfSharesPurchase" name="NumberOfSharesPurchase" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="syn_NumberOfShareSold" name="NumberOfShareSold" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ExercisePrice0.69TwoMember" id="syn_ExercisePrice0.69TwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Dr.SlimanMember" id="syn_Dr.SlimanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReturnOfSynBiomicsStock" id="syn_ReturnOfSynBiomicsStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" id="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdjustmentsToEffectOfWarrantExercisePrice" id="syn_AdjustmentsToEffectOfWarrantExercisePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConsiderationPurchasePaid" id="syn_ConsiderationPurchasePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NewTechnologiesMember" id="syn_NewTechnologiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="VcnPrivateMember" id="syn_VcnPrivateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CashPaymentsExistingLiabilities" id="syn_CashPaymentsExistingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ClosingFinanceCosts" id="syn_ClosingFinanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BusinessCombinationMilestonePayments" id="syn_BusinessCombinationMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherFirstIndicationMember" id="syn_OtherFirstIndicationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherSecondIndicationMember" id="syn_OtherSecondIndicationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BusinessCombinationMilestonePaymentsSafeToProceed" id="syn_BusinessCombinationMilestonePaymentsSafeToProceed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessCombinationMilestonePaymentsFirstPatientDosed" id="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="BusinessCombinationMilestonePaymentsBlaApproval" id="syn_BusinessCombinationMilestonePaymentsBlaApproval" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrifolsInnovationMember" id="syn_GrifolsInnovationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>syn-20211231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/16/2022 8:41:32 PM-->
<!--Modified on: 3/16/2022 8:41:32 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" />
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637830600909778727" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637830600909778727" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637830600909778727" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637830600909778727" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637830600909778727" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637830600909778727" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637830600909778727" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637830600909778727" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637830600909788728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637830600909788728" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637830600909788728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637830600909788728" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_637830600909788728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="syn_DepositsAndOtherAssetsNoncurrent_637830600909788728" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637830600909788728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_637830600909788728" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637830600909788728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637830600909788728" xlink:to="us-gaap_LiabilitiesCurrent_637830600909788728" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637830600909788728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637830600909788728" xlink:to="us-gaap_AccountsPayableCurrent_637830600909788728" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637830600909788728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637830600909788728" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637830600909788728" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637830600909788728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637830600909788728" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637830600909788728" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637830600909788728" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637830600909788728" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637830600909788728" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637830600909798731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637830600909788728" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637830600909798731" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637830600909798731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637830600909798731" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637830600909798731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637830600909798731" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637830600909798731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637830600909798731" xlink:to="us-gaap_StockholdersEquity_637830600909798731" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637830600909798731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637830600909798731" xlink:to="us-gaap_PreferredStockValue_637830600909798731" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637830600909798731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637830600909798731" xlink:to="us-gaap_CommonStockValue_637830600909798731" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637830600909798731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637830600909798731" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637830600909798731" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637830600909798731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637830600909798731" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637830600909798731" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest_637830600909808737" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637830600909798731" xlink:to="us-gaap_MinorityInterest_637830600909808737" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637830600909808737" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_637830600909808737" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637830600909808737" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637830600909808737" xlink:to="us-gaap_ProfitLoss_637830600909808737" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637830600909808737" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss_637830600909808737" xlink:to="us-gaap_OperatingIncomeLoss_637830600909808737" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637830600909808737" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637830600909808737" xlink:to="us-gaap_OperatingExpenses_637830600909808737" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637830600909808737" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637830600909808737" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637830600909808737" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637830600909808737" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_637830600909808737" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637830600909808737" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637830600909808737" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss_637830600909808737" xlink:to="us-gaap_NonoperatingIncomeExpense_637830600909808737" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637830600909808737" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637830600909808737" xlink:to="us-gaap_InvestmentIncomeInterest_637830600909808737" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600909818732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637830600909808737" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600909818732" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment_637830600909818732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="syn_WarrantExercisePriceAdjustment_637830600909818732" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_637830600909818732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_637830600909818732" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment_637830600909818732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="syn_PreferredStockPriceAdjustment_637830600909818732" order="4" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637830600909818732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="us-gaap_ProfitLoss_637830600909818732" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637830600909818732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="us-gaap_ShareBasedCompensation_637830600909818732" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637830600909818732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637830600909818732" order="3" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SubsidiaryStockIssuesToVendor" xlink:label="syn_SubsidiaryStockIssuesToVendor_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="syn_SubsidiaryStockIssuesToVendor_637830600909828731" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637830600909828731" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncreaseDecreaseRightOfUseAssets" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="syn_IncreaseDecreaseRightOfUseAssets_637830600909828731" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637830600909828731" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637830600909828731" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637830600909828731" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncreaseDecreaseLeaseLiability" xlink:label="syn_IncreaseDecreaseLeaseLiability_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600909818732" xlink:to="syn_IncreaseDecreaseLeaseLiability_637830600909828731" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637830600909828731" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637830600909828731" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637830600909828731" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637830600909828731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637830600909828731" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637830600909838730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637830600909828731" xlink:to="us-gaap_ProceedsFromWarrantExercises_637830600909838730" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637830600909838730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637830600909828731" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637830600909838730" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Selected Balance Sheet Information - Schedule of  PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_637830600909838730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_637830600909838730" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637830600909838730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_637830600909838730" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrepaidConsultingSubscriptionsAndOtherExpenses" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_637830600909838730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_637830600909838730" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrepaidManufacturingExpense" xlink:label="syn_PrepaidManufacturingExpense_637830600909838730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="syn_PrepaidManufacturingExpense_637830600909838730" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637830600909838730" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_637830600909838730" order="5" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information - Schedule of  PROPERTY AND EQUIPMENT (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637830600909848734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637830600909848734" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637830600909848734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637830600909848734" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Selected Balance Sheet Information - Schedule of  ACCRUED EXPENSES  (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedClinicalConsultingServices" xlink:label="syn_AccruedClinicalConsultingServices_637830600909848734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="syn_AccruedClinicalConsultingServices_637830600909848734" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedVendorPayments" xlink:label="syn_AccruedVendorPayments_637830600909848734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="syn_AccruedVendorPayments_637830600909848734" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedManufacturingCosts" xlink:label="syn_AccruedManufacturingCosts_637830600909848734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="syn_AccruedManufacturingCosts_637830600909848734" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information - Schedule of  ACCRUED EMPLOYEE BENEFITS  (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637830600909848734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_637830600909848734" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_637830600909848734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedVacationCurrent_637830600909848734" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Maturity analysis of operating leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637830600909858734" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637830600909858734" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637830600909858734" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637830600909858734" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637830600909858734" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:label="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_637830600909858734" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_637830600909858734" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637830600909858734" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_637830600909858734" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_637830600909858734" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_637830600909858734" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_637830600909868731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_637830600909868731" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637830600909868731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637830600909868731" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637830600909868731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637830600909868731" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637830600909868731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637830600909868731" order="8" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes - Deferred Tax Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637054396826100280" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637830600909868731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637054396826100280" xlink:to="us-gaap_DeferredTaxAssetsGross_637830600909868731" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStocksIssuedForServices" xlink:label="syn_DeferredTaxAssetsStocksIssuedForServices_637830600909868731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637830600909868731" xlink:to="syn_DeferredTaxAssetsStocksIssuedForServices_637830600909868731" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_637830600909868731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637830600909868731" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_637830600909868731" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:label="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_637830600909868731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637830600909868731" xlink:to="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_637830600909868731" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStockIssuedForlicenseAgreement" xlink:label="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement_637830600909868731" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637830600909868731" xlink:to="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement_637830600909868731" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStockIssuedForMilestonePayment" xlink:label="syn_DeferredTaxAssetsStockIssuedForMilestonePayment_637830600909878732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637830600909868731" xlink:to="syn_DeferredTaxAssetsStockIssuedForMilestonePayment_637830600909878732" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee" xlink:label="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee_637830600909878732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637830600909868731" xlink:to="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee_637830600909878732" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637830600909878732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637830600909868731" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637830600909878732" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637830600909878732" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet_637054396826100280" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637830600909878732" order="2" use="optional" weight="-1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>syn-20211231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/16/2022 8:41:32 PM-->
<!--Modified on: 3/16/2022 8:41:32 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedStatementsOfStockholdersDeficitEquity" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureNonControllingInterestDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.syntheticbiologics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="syn-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract" xlink:title="us-gaap_LiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_1" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OperatingLeaseLiabilityCurrent_1" order="3" priority="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_1" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesAbstract To us-gaap_OperatingLeaseLiabilityNoncurrent_1" order="4" priority="0" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:title="us-gaap_DerivativeInstrumentRiskAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1" xlink:title="us-gaap_DerivativeContractTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_1" xlink:to="us-gaap_DerivativeContractTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DerivativeInstrumentRiskAxis_1 To us-gaap_DerivativeContractTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_1" xlink:title="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_1" xlink:title="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_1" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_1 To us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_1" xlink:title="us-gaap_BusinessAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_1" xlink:title="us-gaap_BusinessAcquisitionAcquireeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BusinessAcquisitionAxis_1" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BusinessAcquisitionAxis_1 To us-gaap_BusinessAcquisitionAcquireeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodAxis_1" xlink:title="syn_QuarterlyInstallmentsPaymentPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodDomain_1" xlink:title="syn_QuarterlyInstallmentsPaymentPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodAxis_1" xlink:to="syn_QuarterlyInstallmentsPaymentPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:syn_QuarterlyInstallmentsPaymentPeriodAxis_1 To syn_QuarterlyInstallmentsPaymentPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis_1" xlink:title="us-gaap_RestructuringCostAndReserveAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestructuringCostAndReserveAxis_1" xlink:to="us-gaap_TypeOfRestructuringDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestructuringCostAndReserveAxis_1 To us-gaap_TypeOfRestructuringDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_PreferredStockPriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_WarrantExercisePriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders (Deficit) Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingValue" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingShare" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdjustmentsToEffectOfWarrantExercisePrice" xlink:label="syn_AdjustmentsToEffectOfWarrantExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_AdjustmentsToEffectOfWarrantExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStock" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStockShares" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdjustmentsToEffectOfPreferredStockPrice" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_AdjustmentsToEffectOfPreferredStockPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_Conversionofseriesbpreferredstocktocommonstock" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_Conversionofseriesbpreferredstocktocommonstock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_Conversionofseriesapreferredstocktocommonstockshares" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_Conversionofseriesapreferredstocktocommonstockshares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SubsidiaryStockIssuesToVendor" xlink:label="syn_SubsidiaryStockIssuesToVendor" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="syn_SubsidiaryStockIssuesToVendor" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncreaseDecreaseRightOfUseAssets" xlink:label="syn_IncreaseDecreaseRightOfUseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="syn_IncreaseDecreaseRightOfUseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncreaseDecreaseLeaseLiability" xlink:label="syn_IncreaseDecreaseLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="syn_IncreaseDecreaseLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="syn_PreferredStockPriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ReturnOfSynBiomicsStock" xlink:label="syn_ReturnOfSynBiomicsStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="syn_ReturnOfSynBiomicsStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeemedDividendsWithBeneficialConversionFeature" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="syn_DeemedDividendsWithBeneficialConversionFeature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockPaidinkind" xlink:label="us-gaap_DividendsPreferredStockPaidinkind" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_DividendsPreferredStockPaidinkind" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="syn_WarrantExercisePriceAdjustment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="syn_SummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="syn_SYNBiomicsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_MoneyMarketAccountsMember" xlink:label="syn_MoneyMarketAccountsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="syn_MoneyMarketAccountsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_OptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesAAndSeriesBPreferredStockMember" xlink:label="syn_SeriesAAndSeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="syn_SeriesAAndSeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="syn_SummaryOfSignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="syn_SummaryOfSignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="syn_WarrantExercisePriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="syn_AccretionOfPreferredStockDeemedDividend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PreferredStockDiscountOnShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockSharesConverted" xlink:label="syn_PreferredStockSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="syn_PreferredStockSharesConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="syn_PreferredStockPriceAdjustment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information - Schedule of  PROPERTY AND EQUIPMENT (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ComputersAndOfficeEquipmentMember" xlink:label="syn_ComputersAndOfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="syn_ComputersAndOfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Stock-Based Compensation and Warrants - Summary of stock option activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Stock-Based Compensation and Warrants - Options outstanding and exercisable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RangeOfExercisePrice0004000Member" xlink:label="syn_RangeOfExercisePrice0004000Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="syn_RangeOfExercisePrice0004000Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RangeOfExercisePrice41007000Member" xlink:label="syn_RangeOfExercisePrice41007000Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="syn_RangeOfExercisePrice41007000Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RangeOfExercisePrice710010200Member" xlink:label="syn_RangeOfExercisePrice710010200Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="syn_RangeOfExercisePrice710010200Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Stock-Based Compensation and Warrants - Stock incentive plan and other information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPlan2007Member" xlink:label="syn_StockPlan2007Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="syn_StockPlan2007Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPlan2010Member" xlink:label="syn_StockPlan2010Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="syn_StockPlan2010Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPlan2020Member" xlink:label="syn_StockPlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="syn_StockPlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockWarrantsMember" xlink:label="syn_StockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="syn_StockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember" xlink:label="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EmployeesAndDirectorsMember" xlink:label="syn_EmployeesAndDirectorsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_EmployeesAndDirectorsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConsultantMember" xlink:label="syn_ConsultantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_ConsultantMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesBWarrantsMember" xlink:label="syn_SeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="syn_SeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Stock-Based Compensation and Warrants - Stock Warrants (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockWarrantsMember" xlink:label="syn_StockWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="syn_StockWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OctoberTwoThousandEighteenWarrantsMember" xlink:label="syn_OctoberTwoThousandEighteenWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="syn_OctoberTwoThousandEighteenWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesWarrantsMember" xlink:label="syn_SeriesWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="syn_SeriesWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesBWarrantsMember" xlink:label="syn_SeriesBWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="syn_SeriesBWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_UnderwrittenPublicOfferingMember" xlink:label="syn_UnderwrittenPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="syn_UnderwrittenPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_SeriesAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ClassOfTreasuryStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantTerm" xlink:label="syn_WarrantTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_WarrantTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_PreferredStockConversionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_WarrantExercisePriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_PercentageOfIssueOfThePublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfShareSold" xlink:label="syn_NumberOfShareSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_NumberOfShareSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfSharesPurchase" xlink:label="syn_NumberOfSharesPurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="syn_NumberOfSharesPurchase" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Stock-Based Compensation and Warrants - Summary of all outstanding and exercisable warrants (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ExercisePrice0.69Member" xlink:label="syn_ExercisePrice0.69Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="syn_ExercisePrice0.69Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ExercisePrice1820Member" xlink:label="syn_ExercisePrice1820Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="syn_ExercisePrice1820Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ExercisePrice0.69TwoMember" xlink:label="syn_ExercisePrice0.69TwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="syn_ExercisePrice0.69TwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantsExercisePrice" xlink:label="syn_WarrantsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="syn_WarrantsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassAMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassBMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FbrCapitalMarketsCoMember" xlink:label="syn_FbrCapitalMarketsCoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="syn_FbrCapitalMarketsCoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPurchaseAgreementMember" xlink:label="syn_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="syn_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_PreferredStockConversionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_WarrantExercisePriceAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_PercentageOfIssueOfThePublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDiscountOnShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceIncrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BeneficialOwnershipPercentage" xlink:label="syn_BeneficialOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_BeneficialOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EstimatedFairValueOfInducementConsideration" xlink:label="syn_EstimatedFairValueOfInducementConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_EstimatedFairValueOfInducementConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_AccretionOfPreferredStockDeemedDividend" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="us-gaap_PreferredStockRedemptionTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockRedemptionTerms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BrokerageCommissionPercentage" xlink:label="syn_BrokerageCommissionPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_BrokerageCommissionPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockRedemptionDiscount" xlink:label="us-gaap_PreferredStockRedemptionDiscount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockRedemptionDiscount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockSharesConverted" xlink:label="syn_PreferredStockSharesConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_PreferredStockSharesConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_InvestmentWarrantsExpirationDate1" xlink:label="syn_InvestmentWarrantsExpirationDate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_InvestmentWarrantsExpirationDate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:label="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Non-controlling Interest (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="us-gaap_MinorityInterestTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DrPimentelsMember" xlink:label="syn_DrPimentelsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_DrPimentelsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_CedarssinaiMedicalCenterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_MinorityInterestTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="syn_SYNBiomicsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SyntheticBiomicsIncMember" xlink:label="syn_SyntheticBiomicsIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_OwnershipDomain" xlink:to="syn_SyntheticBiomicsIncMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_MinorityInterestTable" xlink:to="srt_ConsolidationItemsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationEliminationsMember" xlink:label="srt_ConsolidationEliminationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationEliminationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPurchaseAgreementMember" xlink:label="syn_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="syn_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="us-gaap_MinorityInterestLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="syn_NumberOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FairValueOfSharesIssued" xlink:label="syn_FairValueOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="syn_FairValueOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails" xlink:type="extended" xlink:title="40702 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:to="syn_QuarterlyInstallmentsPaymentPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:to="syn_QuarterlyInstallmentsPaymentPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FirstYearMember" xlink:label="syn_FirstYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:to="syn_FirstYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SecondYearMember" xlink:label="syn_SecondYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:to="syn_SecondYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ThirdYearMember" xlink:label="syn_ThirdYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:to="syn_ThirdYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PhaseIClinicalTrialsMember" xlink:label="syn_PhaseIClinicalTrialsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="syn_PhaseIClinicalTrialsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PhaseIiiClinicalTrialsMember" xlink:label="syn_PhaseIiiClinicalTrialsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="syn_PhaseIiiClinicalTrialsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NdaSubmissionInUsMember" xlink:label="syn_NdaSubmissionInUsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="syn_NdaSubmissionInUsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EuropeanMedicinesAgencyApprovalMember" xlink:label="syn_EuropeanMedicinesAgencyApprovalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="syn_EuropeanMedicinesAgencyApprovalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RegulatoryApprovalInAsianCountryMember" xlink:label="syn_RegulatoryApprovalInAsianCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="syn_RegulatoryApprovalInAsianCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPurchaseAgreementMember" xlink:label="syn_StockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="syn_StockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ClinicalTrialAgreementMember" xlink:label="syn_ClinicalTrialAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="syn_ClinicalTrialAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrevAbrLlcMember" xlink:label="syn_PrevAbrLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="syn_PrevAbrLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StevenAShallcrossMember" xlink:label="syn_StevenAShallcrossMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="syn_StevenAShallcrossMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_Dr.SlimanMember" xlink:label="syn_Dr.SlimanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="syn_Dr.SlimanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_CedarssinaiMedicalCenterMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="syn_SYNBiomicsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseAgreementAnnualPaymentsDue" xlink:label="syn_LicenseAgreementAnnualPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_LicenseAgreementAnnualPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseAgreementFinalPaymentDue" xlink:label="syn_LicenseAgreementFinalPaymentDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_LicenseAgreementFinalPaymentDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ResearchAgreementFixedFee" xlink:label="syn_ResearchAgreementFixedFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_ResearchAgreementFixedFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_MilestonePayment" xlink:label="syn_MilestonePayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_MilestonePayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalCashPaymentForLicenseAgreement" xlink:label="syn_AdditionalCashPaymentForLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_AdditionalCashPaymentForLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_UnregisteredSharesIssuedToLicenseAgreement" xlink:label="syn_UnregisteredSharesIssuedToLicenseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_UnregisteredSharesIssuedToLicenseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalConsiderationPayable" xlink:label="syn_AdditionalConsiderationPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_AdditionalConsiderationPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_PaymentsForFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OptionsToBeReceivedCommonStockShares" xlink:label="syn_OptionsToBeReceivedCommonStockShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_OptionsToBeReceivedCommonStockShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CostOfLivingAdjustmentsPercentage" xlink:label="syn_CostOfLivingAdjustmentsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_CostOfLivingAdjustmentsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_NumberOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FairValueOfSharesIssued" xlink:label="syn_FairValueOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_FairValueOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NonCashAdditionOfRightOfUseAssets" xlink:label="syn_NonCashAdditionOfRightOfUseAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_NonCashAdditionOfRightOfUseAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EstimatedResearchCosts" xlink:label="syn_EstimatedResearchCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_EstimatedResearchCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToEmployees" xlink:label="us-gaap_PaymentsToEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="us-gaap_PaymentsToEmployees" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncomeTaxesTable" xlink:label="syn_IncomeTaxesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="syn_IncomeTaxesTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="syn_IncomeTaxesTable" xlink:to="us-gaap_TaxPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2018Member" xlink:label="us-gaap_TaxYear2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2020Member" xlink:label="us-gaap_TaxYear2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxYear2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncomeTaxLineItems" xlink:label="syn_IncomeTaxLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="syn_IncomeTaxLineItems" xlink:to="syn_IncomeTaxesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="syn_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="syn_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="syn_IncomeTaxLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="syn_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="syn_IncomeTaxLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="syn_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OperatingLossCarryforwardsLimitationOnUse" xlink:label="syn_OperatingLossCarryforwardsLimitationOnUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="syn_IncomeTaxLineItems" xlink:to="syn_OperatingLossCarryforwardsLimitationOnUse" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OperatingLossCarryforwardsExpireDate" xlink:label="syn_OperatingLossCarryforwardsExpireDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="syn_IncomeTaxLineItems" xlink:to="syn_OperatingLossCarryforwardsExpireDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="syn_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Subsequent Events (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StevenAShallcrossMember" xlink:label="syn_StevenAShallcrossMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="syn_StevenAShallcrossMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_VcnPrivateMember" xlink:label="syn_VcnPrivateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="syn_VcnPrivateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OtherFirstIndicationMember" xlink:label="syn_OtherFirstIndicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_OtherFirstIndicationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OtherSecondIndicationMember" xlink:label="syn_OtherSecondIndicationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="syn_OtherSecondIndicationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_BusinessAcquisitionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_GrifolsInnovationMember" xlink:label="syn_GrifolsInnovationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="syn_GrifolsInnovationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NewTechnologiesMember" xlink:label="syn_NewTechnologiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="syn_NewTechnologiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConsiderationPurchasePaid" xlink:label="syn_ConsiderationPurchasePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="syn_ConsiderationPurchasePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CashPaymentsExistingLiabilities" xlink:label="syn_CashPaymentsExistingLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="syn_CashPaymentsExistingLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ClosingFinanceCosts" xlink:label="syn_ClosingFinanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="syn_ClosingFinanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePaymentsSafeToProceed" xlink:label="syn_BusinessCombinationMilestonePaymentsSafeToProceed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="syn_BusinessCombinationMilestonePaymentsSafeToProceed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePaymentsFirstPatientDosed" xlink:label="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePayments" xlink:label="syn_BusinessCombinationMilestonePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="syn_BusinessCombinationMilestonePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePaymentsBlaApproval" xlink:label="syn_BusinessCombinationMilestonePaymentsBlaApproval" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="syn_BusinessCombinationMilestonePaymentsBlaApproval" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>syn-20211231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/16/2022 8:41:32 PM-->
<!--Modified on: 3/16/2022 8:41:32 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Consolidated Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Accrued employee benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="syn_DepositsAndOtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DepositsAndOtherAssetsNoncurrent" xlink:to="syn_DepositsAndOtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Deposits and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Accrued employee benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease Liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability - long term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Series A Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity (Deficit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series B Preferred Stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at September 30, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, Shares Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Costs and Expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total Operating Costs and Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other Income :</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total Other Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Non-controlling interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net Loss Attributable to Non-controlling Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Preferred stock accrued dividends</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PreferredStockPriceAdjustment" xlink:to="syn_PreferredStockPriceAdjustment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PreferredStockPriceAdjustment_lbl" xml:lang="en-US">The amount represents the effect of preferred stock price adjustment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PreferredStockPriceAdjustment_lbl" xml:lang="en-US">Preferred Stock Price Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="syn_PreferredStockPriceAdjustment_lbl" xml:lang="en-US">Effect of Series A Preferred Stock Price adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PreferredStockPriceAdjustment_lbl" xml:lang="en-US">Preferred stock price adjustment</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_WarrantExercisePriceAdjustment" xlink:to="syn_WarrantExercisePriceAdjustment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_WarrantExercisePriceAdjustment_lbl" xml:lang="en-US">The amount represents the effect of warrant exercise price adjustment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_WarrantExercisePriceAdjustment_lbl" xml:lang="en-US">Warrant Exercise Price Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="syn_WarrantExercisePriceAdjustment_lbl" xml:lang="en-US">Effect of Warrant exercise price adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_WarrantExercisePriceAdjustment_lbl" xml:lang="en-US">Effect of Warrant exercise price adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Loss Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net Loss Per Share - Basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net Loss Per Share - Dilutive</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares outstanding during the period - basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares outstanding during the period - dilutive</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Consolidated Statements of Stockholders (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">APIC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non-Controlling InterestAccumulated Non-Controlling Stockholders'</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingValue" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodAtMarketOfferingValue" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period at the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue_lbl" xml:lang="en-US">Stock Issued During Period At Market Offering Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue_lbl" xml:lang="en-US">Stock issued under "at-the-market" offering</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingShare" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodAtMarketOfferingShare" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare_lbl" xml:lang="en-US">Number of new stock issued during the period at the market offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare_lbl" xml:lang="en-US">Stock Issued During Period At Market Offering Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare_lbl" xml:lang="en-US">Stock issued under "at-the-market" offering (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Dividends, Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Series A Preferred Stock Dividends</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" xlink:to="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_lbl" xml:lang="en-US">Represents the value of new stock of syn biomics stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_lbl" xml:lang="en-US">Stock Issued During Period Value Of Syn Biomics Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_lbl" xml:lang="en-US">Issuance of SYN Biomics Stock</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdjustmentsToEffectOfWarrantExercisePrice" xlink:label="syn_AdjustmentsToEffectOfWarrantExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AdjustmentsToEffectOfWarrantExercisePrice" xlink:to="syn_AdjustmentsToEffectOfWarrantExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AdjustmentsToEffectOfWarrantExercisePrice_lbl" xml:lang="en-US">The amount changes in effect of warrant exercise price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AdjustmentsToEffectOfWarrantExercisePrice_lbl" xml:lang="en-US">Adjustments To Effect Of Warrant Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="syn_AdjustmentsToEffectOfWarrantExercisePrice_lbl" xml:lang="en-US">Effect of Warrant exercise price adjustment</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStock" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ConversionOfSeriesBPreferredStockToCommonStock" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock_lbl" xml:lang="en-US">Represents conversion of preferred stock to common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of Series B Preferred Stock to Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of Series B Preferred Stock to Common</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStockShares" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ConversionOfSeriesBPreferredStockToCommonStockShares" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_lbl" xml:lang="en-US">Number of conversion of series B preferred stock to common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_lbl" xml:lang="en-US">Conversion of Series B Preferred Stock to Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_lbl" xml:lang="en-US">Conversion of Series B Preferred Stock to Common (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_lbl" xml:lang="en-US">Reversal of noncontrolling interest due to return of Syn Biomics shares</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="syn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Warrants Exercised</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Warrants Exercised (In shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Warrants Exercised</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdjustmentsToEffectOfPreferredStockPrice" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AdjustmentsToEffectOfPreferredStockPrice" xlink:to="syn_AdjustmentsToEffectOfPreferredStockPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice_lbl" xml:lang="en-US">The amount of adjustment to effect of preferred stock price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice_lbl" xml:lang="en-US">Adjustments To Effect Of Preferred Stock Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice_lbl" xml:lang="en-US">Effect of Series A Preferred Stock price adjustment</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_Conversionofseriesbpreferredstocktocommonstock" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_Conversionofseriesbpreferredstocktocommonstock" xlink:to="syn_Conversionofseriesbpreferredstocktocommonstock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock_lbl" xml:lang="en-US">Conversion Of Series B Preferred Stock To Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock_lbl" xml:lang="en-US">ConversionOfSeriesBPreferredStockToCommonStock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock_lbl" xml:lang="en-US">Conversion of Series A Preferred Stock to Common</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_Conversionofseriesapreferredstocktocommonstockshares" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_Conversionofseriesapreferredstocktocommonstockshares" xlink:to="syn_Conversionofseriesapreferredstocktocommonstockshares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares_lbl" xml:lang="en-US">Conversion of preferred shares to common</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares_lbl" xml:lang="en-US">ConversionOfSeriesAPreferredStockToCommonStockShares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares_lbl" xml:lang="en-US">Conversion of Series A Preferred Stock to Common (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SubsidiaryStockIssuesToVendor" xlink:label="syn_SubsidiaryStockIssuesToVendor" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SubsidiaryStockIssuesToVendor" xlink:to="syn_SubsidiaryStockIssuesToVendor_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_SubsidiaryStockIssuesToVendor_lbl" xml:lang="en-US">Value of subsidiary stock issued in lieu of cash for services contributed to the entity. Value of the subsidiary stock issued includes, but is not limited to, services contributed by vendors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SubsidiaryStockIssuesToVendor_lbl" xml:lang="en-US">Subsidiary Stock Issues To Vendor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_SubsidiaryStockIssuesToVendor_lbl" xml:lang="en-US">Subsidiary stock issuances to vendor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncreaseDecreaseRightOfUseAssets" xlink:label="syn_IncreaseDecreaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_IncreaseDecreaseRightOfUseAssets" xlink:to="syn_IncreaseDecreaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US">An amount of increase decrease in lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US">Increase decrease Right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_lbl" xml:lang="en-US">Right of use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xml:lang="en-US">Accrued employee benefits</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncreaseDecreaseLeaseLiability" xlink:label="syn_IncreaseDecreaseLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_IncreaseDecreaseLeaseLiability" xlink:to="syn_IncreaseDecreaseLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_IncreaseDecreaseLeaseLiability_lbl" xml:lang="en-US">An amount of Increase decrease right of use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_IncreaseDecreaseLeaseLiability_lbl" xml:lang="en-US">Increase decrease lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_IncreaseDecreaseLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Used in Operating Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Used in Investing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from "at the market" stock issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from issuance of common stock for warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Cash proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by Financing Activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">NONCASH FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion of Stock</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ReturnOfSynBiomicsStock" xlink:label="syn_ReturnOfSynBiomicsStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ReturnOfSynBiomicsStock" xlink:to="syn_ReturnOfSynBiomicsStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ReturnOfSynBiomicsStock_lbl" xml:lang="en-US">Return of SYN Biomics Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ReturnOfSynBiomicsStock_lbl" xml:lang="en-US">Return of SYN Biomics Stock</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeemedDividendsWithBeneficialConversionFeature" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DeemedDividendsWithBeneficialConversionFeature" xlink:to="syn_DeemedDividendsWithBeneficialConversionFeature_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature_lbl" xml:lang="en-US">Amount of Deemed Dividends With Beneficial Conversion Feature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature_lbl" xml:lang="en-US">Deemed dividends for beneficial conversion features</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature_lbl" xml:lang="en-US">Deemed dividends for accretion of Series B Preferred Stock discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets from operating lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockPaidinkind" xlink:label="us-gaap_DividendsPreferredStockPaidinkind" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockPaidinkind" xlink:to="us-gaap_DividendsPreferredStockPaidinkind_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockPaidinkind_lbl" xml:lang="en-US">Dividends, Preferred Stock, Paid-in-kind</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DividendsPreferredStockPaidinkind_lbl" xml:lang="en-US">In-kind dividends paid in preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Nature of Operations and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Nature of Operations and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_BalanceSheetInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BalanceSheetInformationAbstract_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BalanceSheetInformationAbstract_lbl" xml:lang="en-US">Selected Balance Sheet Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xml:lang="en-US">Selected Balance Sheet Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Stock-Based Compensation and Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation and Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US">Non-controlling Interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_lbl" xml:lang="en-US">Non-controlling Interest</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:label="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:to="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_lbl" xml:lang="en-US">License, Collaborative and Employment Agreements and Commitments</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" xlink:to="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock_lbl" xml:lang="en-US">The entire disclosure of license, collaborative and employment agreement and commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock_lbl" xml:lang="en-US">License Collaborative And Employment Agreements And Commitments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock_lbl" xml:lang="en-US">License, Collaborative and Employment Agreements and Commitments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NoncontrollingInterestPolicyTextBlock" xlink:label="syn_NoncontrollingInterestPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NoncontrollingInterestPolicyTextBlock" xlink:to="syn_NoncontrollingInterestPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy noncontrolling interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Noncontrolling Interest [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Non-controlling Interest</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RisksAndUncertaintiesPolicyTextBlock" xlink:label="syn_RisksAndUncertaintiesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_RisksAndUncertaintiesPolicyTextBlock" xlink:to="syn_RisksAndUncertaintiesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy regarding risk and uncertainties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_RisksAndUncertaintiesPolicyTextBlock_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockBasedPaymentArrangementsPolicyTextBlock" xlink:label="syn_StockBasedPaymentArrangementsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockBasedPaymentArrangementsPolicyTextBlock" xlink:to="syn_StockBasedPaymentArrangementsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockBasedPaymentArrangementsPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy regarding stock based payment arrangements for various stocks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockBasedPaymentArrangementsPolicyTextBlock_lbl" xml:lang="en-US">Stock Based Payment Arrangements [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_StockBasedPaymentArrangementsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Payment Arrangements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements and Developments</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EstimatedUsefulLifeOfAssetTableTextBlock" xlink:label="syn_EstimatedUsefulLifeOfAssetTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_EstimatedUsefulLifeOfAssetTableTextBlock" xlink:to="syn_EstimatedUsefulLifeOfAssetTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_EstimatedUsefulLifeOfAssetTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of estimated useful life of assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_EstimatedUsefulLifeOfAssetTableTextBlock_lbl" xml:lang="en-US">Estimated Useful Life Of Asset [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_EstimatedUsefulLifeOfAssetTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment, net</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedExpensesTableTextBlock" xlink:label="syn_AccruedExpensesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccruedExpensesTableTextBlock" xlink:to="syn_AccruedExpensesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccruedExpensesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of accrued expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccruedExpensesTableTextBlock_lbl" xml:lang="en-US">Accrued Expenses [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccruedExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedEmployeeBenefitsTableTextBlock" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccruedEmployeeBenefitsTableTextBlock" xlink:to="syn_AccruedEmployeeBenefitsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of information related to accrued employee benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock_lbl" xml:lang="en-US">Accrued Employee Benefits [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued employee benefits</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used for awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of options outstanding and exercisable</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ScheduleOfWarrantActivityTableTextBlock" xlink:to="syn_ScheduleOfWarrantActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of warrant activity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Schedule Of Warrant Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">Summary of all warrant activity</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:to="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure relates to warrant outstanding and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule Of Warrant Outstanding and Exercisable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_lbl" xml:lang="en-US">Summary of all outstanding and exercisable warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturity analysis of operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts" xlink:label="syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts" xlink:to="syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance of ATM offering, net of issuance cost during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds From Issuance ATM Offering, Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from issuance ATM offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office Equipment And Furniture</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="syn_SummaryOfSignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="syn_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SYNBiomicsMember" xlink:to="syn_SYNBiomicsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_SYNBiomicsMember_lbl" xml:lang="en-US">S Y N Biomics</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SYNBiomicsMember_lbl" xml:lang="en-US">SYN Biomics [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_MoneyMarketAccountsMember" xlink:label="syn_MoneyMarketAccountsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_MoneyMarketAccountsMember" xlink:to="syn_MoneyMarketAccountsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_MoneyMarketAccountsMember_lbl" xml:lang="en-US">Money Market Accounts [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesAAndSeriesBPreferredStockMember" xlink:label="syn_SeriesAAndSeriesBPreferredStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SeriesAAndSeriesBPreferredStockMember" xlink:to="syn_SeriesAAndSeriesBPreferredStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_SeriesAAndSeriesBPreferredStockMember_lbl" xml:lang="en-US">Series A And Series B Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SeriesAAndSeriesBPreferredStockMember_lbl" xml:lang="en-US">Series A and Series B Preferred Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="syn_SummaryOfSignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="syn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Equity interest by parent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid Expense</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccretionOfPreferredStockDeemedDividend" xlink:to="syn_AccretionOfPreferredStockDeemedDividend_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccretionOfPreferredStockDeemedDividend_lbl" xml:lang="en-US">This element represents the amount of accretion of the Series B preferred stock deemed dividend.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccretionOfPreferredStockDeemedDividend_lbl" xml:lang="en-US">Accretion of Preferred Stock Deemed Dividend</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccretionOfPreferredStockDeemedDividend_lbl" xml:lang="en-US">Accretion of Preferred Stock Deemed Dividend</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDiscountOnShares" xlink:to="us-gaap_PreferredStockDiscountOnShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDiscountOnShares_lbl" xml:lang="en-US">Preferred Stock, Discount on Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDiscountOnShares_lbl" xml:lang="en-US">Accretion of preferred discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDiscountOnShares_lbl" xml:lang="en-US">Preferred Stock Redemption Discount</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockSharesConverted" xlink:label="syn_PreferredStockSharesConverted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PreferredStockSharesConverted" xlink:to="syn_PreferredStockSharesConverted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PreferredStockSharesConverted_lbl" xml:lang="en-US">The no of shares converted into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PreferredStockSharesConverted_lbl" xml:lang="en-US">Preferred Stock Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PreferredStockSharesConverted_lbl" xml:lang="en-US">Preferred Stock Shares Converted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" xlink:to="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_lbl" xml:lang="en-US">Sum of the amount paid in advance for clinical research organization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_lbl" xml:lang="en-US">Prepaid Clinical Research Organizations Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_lbl" xml:lang="en-US">Prepaid clinical research organizations</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrepaidConsultingSubscriptionsAndOtherExpenses" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PrepaidConsultingSubscriptionsAndOtherExpenses" xlink:to="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_lbl" xml:lang="en-US">Sum of the amount paid in advance for consulting, subscriptions and other expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_lbl" xml:lang="en-US">Prepaid Consulting Subscriptions And Other Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_lbl" xml:lang="en-US">Prepaid consulting, subscriptions and other expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Other Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Stock sales receivable</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrepaidManufacturingExpense" xlink:label="syn_PrepaidManufacturingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PrepaidManufacturingExpense" xlink:to="syn_PrepaidManufacturingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PrepaidManufacturingExpense_lbl" xml:lang="en-US">Amount of Prepaid Manufacturing Expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PrepaidManufacturingExpense_lbl" xml:lang="en-US">Prepaid Manufacturing Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PrepaidManufacturingExpense_lbl" xml:lang="en-US">Prepaid manufacturing expenses</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ComputersAndOfficeEquipmentMember" xlink:label="syn_ComputersAndOfficeEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ComputersAndOfficeEquipmentMember" xlink:to="syn_ComputersAndOfficeEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ComputersAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computers and office equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ComputersAndOfficeEquipmentMember_lbl" xml:lang="en-US">Computers and office equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross, Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedVendorPayments" xlink:label="syn_AccruedVendorPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccruedVendorPayments" xlink:to="syn_AccruedVendorPayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccruedVendorPayments_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccruedVendorPayments_lbl" xml:lang="en-US">Accrued Vendor Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccruedVendorPayments_lbl" xml:lang="en-US">Accrued vendor payments</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedClinicalConsultingServices" xlink:label="syn_AccruedClinicalConsultingServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccruedClinicalConsultingServices" xlink:to="syn_AccruedClinicalConsultingServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccruedClinicalConsultingServices_lbl" xml:lang="en-US">The carrying value of accrued clinical consulting services payable as on balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccruedClinicalConsultingServices_lbl" xml:lang="en-US">Accrued Clinical Consulting Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccruedClinicalConsultingServices_lbl" xml:lang="en-US">Accrued clinical consulting services</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedManufacturingCosts" xlink:label="syn_AccruedManufacturingCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AccruedManufacturingCosts" xlink:to="syn_AccruedManufacturingCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AccruedManufacturingCosts_lbl" xml:lang="en-US">The manufacturing costs incurred in the production of goods for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AccruedManufacturingCosts_lbl" xml:lang="en-US">Accrued manufacturing costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AccruedManufacturingCosts_lbl" xml:lang="en-US">Accrued manufacturing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued Bonuses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Accrued bonus expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued vacation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xml:lang="en-US">Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_lbl" xml:lang="en-US">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk -free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options, Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Options, Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options, Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options, Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Balance Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life, Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Ending Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Exercise price of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RangeOfExercisePrice0004000Member" xlink:label="syn_RangeOfExercisePrice0004000Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_RangeOfExercisePrice0004000Member" xlink:to="syn_RangeOfExercisePrice0004000Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_RangeOfExercisePrice0004000Member_lbl" xml:lang="en-US">Range of Exercise Price 0.00-40.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RangeOfExercisePrice41007000Member" xlink:label="syn_RangeOfExercisePrice41007000Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_RangeOfExercisePrice41007000Member" xlink:to="syn_RangeOfExercisePrice41007000Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_RangeOfExercisePrice41007000Member_lbl" xml:lang="en-US">Range of Exercise Price 41.00-70.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RangeOfExercisePrice710010200Member" xlink:label="syn_RangeOfExercisePrice710010200Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_RangeOfExercisePrice710010200Member" xlink:to="syn_RangeOfExercisePrice710010200Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_RangeOfExercisePrice710010200Member_lbl" xml:lang="en-US">Range Of Exercise Price 71.09-102.00 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Options Outstanding, Range of Exercise Price Lower</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Options Outstanding, Range of Exercise Price Upper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options Outstanding, Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Outstanding, Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Options Exercisable, Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options Exercisable, Weighted Average Remaining Contractual Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPlan2007Member" xlink:label="syn_StockPlan2007Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockPlan2007Member" xlink:to="syn_StockPlan2007Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockPlan2007Member_lbl" xml:lang="en-US">2007 Stock Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPlan2010Member" xlink:label="syn_StockPlan2010Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockPlan2010Member" xlink:to="syn_StockPlan2010Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockPlan2010Member_lbl" xml:lang="en-US">2010 Stock Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPlan2020Member" xlink:label="syn_StockPlan2020Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockPlan2020Member" xlink:to="syn_StockPlan2020Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockPlan2020Member_lbl" xml:lang="en-US">Represents information pertaining to 2020 Stock Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockPlan2020Member_lbl" xml:lang="en-US">2020 Stock Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockWarrantsMember" xlink:label="syn_StockWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockWarrantsMember" xlink:to="syn_StockWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockWarrantsMember_lbl" xml:lang="en-US">Stock Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember" xlink:label="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember" xlink:to="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember_lbl" xml:lang="en-US">Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee or employer-consultant relationships based on law of pertinent jurisdiction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember_lbl" xml:lang="en-US">Employees and consultants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EmployeesAndDirectorsMember" xlink:label="syn_EmployeesAndDirectorsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_EmployeesAndDirectorsMember" xlink:to="syn_EmployeesAndDirectorsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">n/a.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_EmployeesAndDirectorsMember_lbl" xml:lang="en-US">Employees And Directors [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConsultantMember" xlink:label="syn_ConsultantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ConsultantMember" xlink:to="syn_ConsultantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ConsultantMember_lbl" xml:lang="en-US">n/a.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ConsultantMember_lbl" xml:lang="en-US">Consultant [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:to="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">General and Administrative Expenses and Research and Development Expense [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesBWarrantsMember" xlink:label="syn_SeriesBWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SeriesBWarrantsMember" xlink:to="syn_SeriesBWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US">Employees [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per warrant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockWarrantsAbstract" xlink:label="syn_StockWarrantsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockWarrantsAbstract" xlink:to="syn_StockWarrantsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockWarrantsAbstract_lbl" xml:lang="en-US">Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfTreasuryStockTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfTreasuryStockTable_lbl" xml:lang="en-US">Class of Treasury Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_UnderwrittenPublicOfferingMember" xlink:label="syn_UnderwrittenPublicOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_UnderwrittenPublicOfferingMember" xlink:to="syn_UnderwrittenPublicOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_UnderwrittenPublicOfferingMember_lbl" xml:lang="en-US">Underwritten Public Offering [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_lbl" xml:lang="en-US">Auction Market Preferred Securities, Stock Series [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_lbl" xml:lang="en-US">Auction Market Preferred Securities, Stock Series, Title [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAMember" xlink:to="us-gaap_SeriesAMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAMember_lbl" xml:lang="en-US">Series A [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OctoberTwoThousandEighteenWarrantsMember" xlink:label="syn_OctoberTwoThousandEighteenWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_OctoberTwoThousandEighteenWarrantsMember" xlink:to="syn_OctoberTwoThousandEighteenWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_OctoberTwoThousandEighteenWarrantsMember_lbl" xml:lang="en-US">October 2018 Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesWarrantsMember" xlink:label="syn_SeriesWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SeriesWarrantsMember" xlink:to="syn_SeriesWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SeriesWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassBMember" xlink:to="us-gaap_CommonClassBMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassBMember_lbl" xml:lang="en-US">Common Class B [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xml:lang="en-US">Equity, Class of Treasury Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from "at the market" stock issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantTerm" xlink:label="syn_WarrantTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_WarrantTerm" xlink:to="syn_WarrantTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_WarrantTerm_lbl" xml:lang="en-US">Represents the warrant term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_WarrantTerm_lbl" xml:lang="en-US">Warrant Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_WarrantTerm_lbl" xml:lang="en-US">Warrant Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PreferredStockConversionPricePerShare" xlink:to="syn_PreferredStockConversionPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">Preferred Stock Conversion Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PreferredStockConversionPricePerShare_lbl" xml:lang="en-US">Preferred Stock Conversion Price Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_IssueOfWarrantsToPurchaseCommonStock" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">It represent additional of warrant to purchase of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Issue of warrants to purchase common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock_lbl" xml:lang="en-US">Issue of warrants to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PercentageOfIssueOfThePublicOffering" xlink:to="syn_PercentageOfIssueOfThePublicOffering_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_PercentageOfIssueOfThePublicOffering_lbl" xml:lang="en-US">Percentage of issue of public offering price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PercentageOfIssueOfThePublicOffering_lbl" xml:lang="en-US">Percentage of issue of the public offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_PercentageOfIssueOfThePublicOffering_lbl" xml:lang="en-US">Percentage of issue of the public offering</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" xml:lang="en-US">The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_lbl" xml:lang="en-US">Warrants Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds From Warrants Exercised</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfShareSold" xlink:label="syn_NumberOfShareSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NumberOfShareSold" xlink:to="syn_NumberOfShareSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NumberOfShareSold_lbl" xml:lang="en-US">Represents the information pertaining to Number of Share sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NumberOfShareSold_lbl" xml:lang="en-US">Number of Share sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NumberOfShareSold_lbl" xml:lang="en-US">Number of Share sold</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfSharesPurchase" xlink:label="syn_NumberOfSharesPurchase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NumberOfSharesPurchase" xlink:to="syn_NumberOfSharesPurchase_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NumberOfSharesPurchase_lbl" xml:lang="en-US">Represents the shares purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NumberOfSharesPurchase_lbl" xml:lang="en-US">Number of Shares purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NumberOfSharesPurchase_lbl" xml:lang="en-US">Number of Shares purchase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Warrants, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of Warrants, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_lbl" xml:lang="en-US">Number of share warrants exercised during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_lbl" xml:lang="en-US">Number of Warrants, Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of Warrants, Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ExercisePrice0.69Member" xlink:label="syn_ExercisePrice0.69Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ExercisePrice0.69Member" xlink:to="syn_ExercisePrice0.69Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ExercisePrice0.69Member_lbl" xml:lang="en-US">It represents information about  exercise price of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ExercisePrice0.69Member_lbl" xml:lang="en-US">Exercise Price 0.69 [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ExercisePrice1820Member" xlink:label="syn_ExercisePrice1820Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ExercisePrice1820Member" xlink:to="syn_ExercisePrice1820Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ExercisePrice1820Member_lbl" xml:lang="en-US">Exercise Price 18.20 [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ExercisePrice0.69TwoMember" xlink:label="syn_ExercisePrice0.69TwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ExercisePrice0.69TwoMember" xlink:to="syn_ExercisePrice0.69TwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ExercisePrice0.69TwoMember_lbl" xml:lang="en-US">It represents information about  exercise price of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ExercisePrice0.69TwoMember_lbl" xml:lang="en-US">Exercise Price 0.69 Two [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantsExercisePrice" xlink:label="syn_WarrantsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_WarrantsExercisePrice" xlink:to="syn_WarrantsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_WarrantsExercisePrice_lbl" xml:lang="en-US">Exercise price of the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_WarrantsExercisePrice_lbl" xml:lang="en-US">Warrants Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_WarrantsExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Warrants Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Common and Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FbrCapitalMarketsCoMember" xlink:label="syn_FbrCapitalMarketsCoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_FbrCapitalMarketsCoMember" xlink:to="syn_FbrCapitalMarketsCoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_FbrCapitalMarketsCoMember_lbl" xml:lang="en-US">FbrCapitalMarketsCoMember</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_FbrCapitalMarketsCoMember_lbl" xml:lang="en-US">Fbr Capital Markets Co [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPurchaseAgreementMember" xlink:label="syn_StockPurchaseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StockPurchaseAgreementMember" xlink:to="syn_StockPurchaseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_StockPurchaseAgreementMember_lbl" xml:lang="en-US">na</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received Per Transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceIncrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price, Increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price, Increase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease_lbl" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price, Decrease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BeneficialOwnershipPercentage" xlink:label="syn_BeneficialOwnershipPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BeneficialOwnershipPercentage" xlink:to="syn_BeneficialOwnershipPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BeneficialOwnershipPercentage_lbl" xml:lang="en-US">Percentage of beneficial ownership.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BeneficialOwnershipPercentage_lbl" xml:lang="en-US">Beneficial Ownership Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_BeneficialOwnershipPercentage_lbl" xml:lang="en-US">Maximum percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Common stock issued upon conversion</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EstimatedFairValueOfInducementConsideration" xlink:label="syn_EstimatedFairValueOfInducementConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_EstimatedFairValueOfInducementConsideration" xlink:to="syn_EstimatedFairValueOfInducementConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_EstimatedFairValueOfInducementConsideration_lbl" xml:lang="en-US">Amount of Estimated Fair Value of Inducement Consideration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_EstimatedFairValueOfInducementConsideration_lbl" xml:lang="en-US">Estimated Fair Value of Inducement Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_EstimatedFairValueOfInducementConsideration_lbl" xml:lang="en-US">Estimated fair value of inducement consideration</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="us-gaap_PreferredStockRedemptionTerms" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionTerms" xlink:to="us-gaap_PreferredStockRedemptionTerms_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionTerms_lbl" xml:lang="en-US">Preferred Stock, Redemption Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionTerms_lbl" xml:lang="en-US">Preferred Stock, Redemption Terms</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BrokerageCommissionPercentage" xlink:label="syn_BrokerageCommissionPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BrokerageCommissionPercentage" xlink:to="syn_BrokerageCommissionPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BrokerageCommissionPercentage_lbl" xml:lang="en-US">Represent that percentage of commission revenue from buying and selling securities on behalf of customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BrokerageCommissionPercentage_lbl" xml:lang="en-US">Brokerage Commission percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_BrokerageCommissionPercentage_lbl" xml:lang="en-US">Brokerage Commission percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockRedemptionDiscount" xlink:label="us-gaap_PreferredStockRedemptionDiscount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionDiscount" xlink:to="us-gaap_PreferredStockRedemptionDiscount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionDiscount_lbl" xml:lang="en-US">Preferred Stock Redemption Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionDiscount_lbl" xml:lang="en-US">Preferred Stock Redemption Discount</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_InvestmentWarrantsExpirationDate1" xlink:label="syn_InvestmentWarrantsExpirationDate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_InvestmentWarrantsExpirationDate1" xlink:to="syn_InvestmentWarrantsExpirationDate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_InvestmentWarrantsExpirationDate1_lbl" xml:lang="en-US">Expiration date of warrants held.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_InvestmentWarrantsExpirationDate1_lbl" xml:lang="en-US">Investment Warrants Expiration Date1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_InvestmentWarrantsExpirationDate1_lbl" xml:lang="en-US">Investment Warrants Expiration Date1</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:label="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:to="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_lbl" xml:lang="en-US">The cash inflow from the additional capital contribution for exclusive channel collaboration agreement to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock For Exclusive Channel Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock for Exclusive Channel Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="us-gaap_MinorityInterestTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestTable" xlink:to="us-gaap_MinorityInterestTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestTable_lbl" xml:lang="en-US">Noncontrolling Interest [Table]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DrPimentelsMember" xlink:label="syn_DrPimentelsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DrPimentelsMember" xlink:to="syn_DrPimentelsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DrPimentelsMember_lbl" xml:lang="en-US">Dr. Pimentels [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_CedarssinaiMedicalCenterMember" xlink:to="syn_CedarssinaiMedicalCenterMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_CedarssinaiMedicalCenterMember_lbl" xml:lang="en-US">This member stands for Cedarssinai Medical Center.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_CedarssinaiMedicalCenterMember_lbl" xml:lang="en-US">Cedarssinai Medical Center [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SyntheticBiomicsIncMember" xlink:label="syn_SyntheticBiomicsIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SyntheticBiomicsIncMember" xlink:to="syn_SyntheticBiomicsIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_SyntheticBiomicsIncMember_lbl" xml:lang="en-US">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SyntheticBiomicsIncMember_lbl" xml:lang="en-US">Synthetic Biomics Inc [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US">Consolidation Items [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationItemsDomain_lbl" xml:lang="en-US">Consolidation Items [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationEliminationsMember" xlink:label="srt_ConsolidationEliminationsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationEliminationsMember" xlink:to="srt_ConsolidationEliminationsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidationEliminationsMember_lbl" xml:lang="en-US">Consolidation, Eliminations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="us-gaap_MinorityInterestLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xml:lang="en-US">Noncontrolling Interest [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xml:lang="en-US">Noncontrolling Interest</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NumberOfCommonStockToBeIssued" xlink:to="syn_NumberOfCommonStockToBeIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">The number of common stock to be issued under stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">Number Of Common Stock To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">Number Of Common Stock To Be Issued</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AdditionalNumberOfCommonStockToBeIssued" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">The additional number of common stock to be issued under stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">Additional Number Of Common Stock To Be Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_lbl" xml:lang="en-US">Additional Number Of Common Stock To Be Issued</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_lbl" xml:lang="en-US">The additional number of common stock to be held by the related party under stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_lbl" xml:lang="en-US">Number Of Common Stock To Be Held By Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_lbl" xml:lang="en-US">Number Of Common Stock To Be Held By Related Party</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FairValueOfSharesIssued" xlink:label="syn_FairValueOfSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_FairValueOfSharesIssued" xlink:to="syn_FairValueOfSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_FairValueOfSharesIssued_lbl" xml:lang="en-US">Amount represents the fair value of shares issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_FairValueOfSharesIssued_lbl" xml:lang="en-US">Fair Value Of Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_FairValueOfSharesIssued_lbl" xml:lang="en-US">Fair Value Of Shares Issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:label="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Six</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Discount factor</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US">Operating Lease, Liability, Statement of Financial Position [Extensible List]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:to="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_lbl" xml:lang="en-US">License, Collaborative and Employment Agreements and Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:to="syn_QuarterlyInstallmentsPaymentPeriodAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodAxis_lbl" xml:lang="en-US">Quarterly Installments Payment Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:to="syn_QuarterlyInstallmentsPaymentPeriodDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodDomain_lbl" xml:lang="en-US">Quarterly Installments Payment Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FirstYearMember" xlink:label="syn_FirstYearMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_FirstYearMember" xlink:to="syn_FirstYearMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_FirstYearMember_lbl" xml:lang="en-US">First Year [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SecondYearMember" xlink:label="syn_SecondYearMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_SecondYearMember" xlink:to="syn_SecondYearMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_SecondYearMember_lbl" xml:lang="en-US">Second Year [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ThirdYearMember" xlink:label="syn_ThirdYearMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ThirdYearMember" xlink:to="syn_ThirdYearMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ThirdYearMember_lbl" xml:lang="en-US">Third Year [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PhaseIClinicalTrialsMember" xlink:label="syn_PhaseIClinicalTrialsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PhaseIClinicalTrialsMember" xlink:to="syn_PhaseIClinicalTrialsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PhaseIClinicalTrialsMember_lbl" xml:lang="en-US">Phase I Clinical Trials [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PhaseIiiClinicalTrialsMember" xlink:label="syn_PhaseIiiClinicalTrialsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PhaseIiiClinicalTrialsMember" xlink:to="syn_PhaseIiiClinicalTrialsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PhaseIiiClinicalTrialsMember_lbl" xml:lang="en-US">Phase III Clinical Trials [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NdaSubmissionInUsMember" xlink:label="syn_NdaSubmissionInUsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NdaSubmissionInUsMember" xlink:to="syn_NdaSubmissionInUsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NdaSubmissionInUsMember_lbl" xml:lang="en-US">NDA Submission In US [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EuropeanMedicinesAgencyApprovalMember" xlink:label="syn_EuropeanMedicinesAgencyApprovalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_EuropeanMedicinesAgencyApprovalMember" xlink:to="syn_EuropeanMedicinesAgencyApprovalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_EuropeanMedicinesAgencyApprovalMember_lbl" xml:lang="en-US">European Medicines Agency Approval [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RegulatoryApprovalInAsianCountryMember" xlink:label="syn_RegulatoryApprovalInAsianCountryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_RegulatoryApprovalInAsianCountryMember" xlink:to="syn_RegulatoryApprovalInAsianCountryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_RegulatoryApprovalInAsianCountryMember_lbl" xml:lang="en-US">Regulatory Approval In Asian Country [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ClinicalTrialAgreementMember" xlink:label="syn_ClinicalTrialAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ClinicalTrialAgreementMember" xlink:to="syn_ClinicalTrialAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ClinicalTrialAgreementMember_lbl" xml:lang="en-US">Represents the information pertaining to clinical trial agreement ("CTA").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ClinicalTrialAgreementMember_lbl" xml:lang="en-US">Clinical Trial Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrevAbrLlcMember" xlink:label="syn_PrevAbrLlcMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_PrevAbrLlcMember" xlink:to="syn_PrevAbrLlcMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_PrevAbrLlcMember_lbl" xml:lang="en-US">Prev Abr Llc [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StevenAShallcrossMember" xlink:label="syn_StevenAShallcrossMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_StevenAShallcrossMember" xlink:to="syn_StevenAShallcrossMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_StevenAShallcrossMember_lbl" xml:lang="en-US">Steven A. Shallcross</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_Dr.SlimanMember" xlink:label="syn_Dr.SlimanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_Dr.SlimanMember" xlink:to="syn_Dr.SlimanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_Dr.SlimanMember_lbl" xml:lang="en-US">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_Dr.SlimanMember_lbl" xml:lang="en-US">Dr. Sliman [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xml:lang="en-US">Licensing Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xml:lang="en-US">Operating Lease [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:to="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_lbl" xml:lang="en-US">License, Collaborative and Employment Agreements and Commitments [Line Items]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseAgreementAnnualPaymentsDue" xlink:label="syn_LicenseAgreementAnnualPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_LicenseAgreementAnnualPaymentsDue" xlink:to="syn_LicenseAgreementAnnualPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_LicenseAgreementAnnualPaymentsDue_lbl" xml:lang="en-US">Amount of annual payments due under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_LicenseAgreementAnnualPaymentsDue_lbl" xml:lang="en-US">License Agreement Annual Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_LicenseAgreementAnnualPaymentsDue_lbl" xml:lang="en-US">Annual payments due under license agreement</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseAgreementFinalPaymentDue" xlink:label="syn_LicenseAgreementFinalPaymentDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_LicenseAgreementFinalPaymentDue" xlink:to="syn_LicenseAgreementFinalPaymentDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_LicenseAgreementFinalPaymentDue_lbl" xml:lang="en-US">Amount of the final payment due under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_LicenseAgreementFinalPaymentDue_lbl" xml:lang="en-US">License Agreement Final Payment Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_LicenseAgreementFinalPaymentDue_lbl" xml:lang="en-US">Final payment due under license agreement</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ResearchAgreementFixedFee" xlink:label="syn_ResearchAgreementFixedFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ResearchAgreementFixedFee" xlink:to="syn_ResearchAgreementFixedFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ResearchAgreementFixedFee_lbl" xml:lang="en-US">The amount of research and development costs incurred for a fixed-price, all payable in quarterly installments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ResearchAgreementFixedFee_lbl" xml:lang="en-US">Research Agreement Fixed Fee</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_MilestonePayment" xlink:label="syn_MilestonePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_MilestonePayment" xlink:to="syn_MilestonePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_MilestonePayment_lbl" xml:lang="en-US">A milestone payment is an authority payment made to a contractor which is linked to the contractor delivering a service or commodity such that, should the agreement be terminated at the point of payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_MilestonePayment_lbl" xml:lang="en-US">Milestone Payment</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalCashPaymentForLicenseAgreement" xlink:label="syn_AdditionalCashPaymentForLicenseAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AdditionalCashPaymentForLicenseAgreement" xlink:to="syn_AdditionalCashPaymentForLicenseAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AdditionalCashPaymentForLicenseAgreement_lbl" xml:lang="en-US">The amount of additional cash payment for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AdditionalCashPaymentForLicenseAgreement_lbl" xml:lang="en-US">Additional Cash Payment For License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_AdditionalCashPaymentForLicenseAgreement_lbl" xml:lang="en-US">Additional Cash Payment for License Agreement</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_UnregisteredSharesIssuedToLicenseAgreement" xlink:label="syn_UnregisteredSharesIssuedToLicenseAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_UnregisteredSharesIssuedToLicenseAgreement" xlink:to="syn_UnregisteredSharesIssuedToLicenseAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_UnregisteredSharesIssuedToLicenseAgreement_lbl" xml:lang="en-US">The number of shares issued during the period for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_UnregisteredSharesIssuedToLicenseAgreement_lbl" xml:lang="en-US">Unregistered Shares Issued To License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_UnregisteredSharesIssuedToLicenseAgreement_lbl" xml:lang="en-US">Unregistered Shares Issued to License Agreement</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalConsiderationPayable" xlink:label="syn_AdditionalConsiderationPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_AdditionalConsiderationPayable" xlink:to="syn_AdditionalConsiderationPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_AdditionalConsiderationPayable_lbl" xml:lang="en-US">Description related to additional consideration payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_AdditionalConsiderationPayable_lbl" xml:lang="en-US">Additional Consideration Payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payments for Other Fees</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OptionsToBeReceivedCommonStockShares" xlink:label="syn_OptionsToBeReceivedCommonStockShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_OptionsToBeReceivedCommonStockShares" xlink:to="syn_OptionsToBeReceivedCommonStockShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_OptionsToBeReceivedCommonStockShares_lbl" xml:lang="en-US">It Represents options to be received common stock shares reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_OptionsToBeReceivedCommonStockShares_lbl" xml:lang="en-US">Options To Be Received Common Stock Shares</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CostOfLivingAdjustmentsPercentage" xlink:label="syn_CostOfLivingAdjustmentsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_CostOfLivingAdjustmentsPercentage" xlink:to="syn_CostOfLivingAdjustmentsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_CostOfLivingAdjustmentsPercentage_lbl" xml:lang="en-US">Represents the information pertaining to cost of living adjustments percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_CostOfLivingAdjustmentsPercentage_lbl" xml:lang="en-US">Cost of Living Adjustments Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_lbl" xml:lang="en-US">Annual base salary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US">Annual cash performance bonus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NonCashAdditionOfRightOfUseAssets" xlink:label="syn_NonCashAdditionOfRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NonCashAdditionOfRightOfUseAssets" xlink:to="syn_NonCashAdditionOfRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NonCashAdditionOfRightOfUseAssets_lbl" xml:lang="en-US">The amount of non cash addition to right of use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NonCashAdditionOfRightOfUseAssets_lbl" xml:lang="en-US">Non Cash Addition of Right of Use Assets</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EstimatedResearchCosts" xlink:label="syn_EstimatedResearchCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_EstimatedResearchCosts" xlink:to="syn_EstimatedResearchCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_EstimatedResearchCosts_lbl" xml:lang="en-US">Amount of estimated research services cost provided.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_EstimatedResearchCosts_lbl" xml:lang="en-US">Estimated Research Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToEmployees" xlink:label="us-gaap_PaymentsToEmployees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToEmployees" xlink:to="us-gaap_PaymentsToEmployees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToEmployees_lbl" xml:lang="en-US">Payments to Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsToEmployees_lbl" xml:lang="en-US">Annual Base Salary</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Computed "expected" tax-benefit - Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Computed "expected" tax-benefit - State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xml:lang="en-US">Adjustment of "expected" tax-benefit to actual</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_lbl" xml:lang="en-US">Meals, entertainment and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Non-deductible stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal and state net operating loss adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStocksIssuedForServices" xlink:label="syn_DeferredTaxAssetsStocksIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DeferredTaxAssetsStocksIssuedForServices" xlink:to="syn_DeferredTaxAssetsStocksIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_DeferredTaxAssetsStocksIssuedForServices_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stocks issued for services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DeferredTaxAssetsStocksIssuedForServices_lbl" xml:lang="en-US">Deferred Tax Assets Stocks Issued For Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_DeferredTaxAssetsStocksIssuedForServices_lbl" xml:lang="en-US">Stock issued for services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xml:lang="en-US">Accrued compensation</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:label="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:to="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stock issued for acquisition of program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_lbl" xml:lang="en-US">Deferred Tax Assets Stock Issued For Acquisition Of Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_lbl" xml:lang="en-US">Stock issued for acquisition of program</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStockIssuedForlicenseAgreement" xlink:label="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement" xlink:to="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stock issued for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement_lbl" xml:lang="en-US">Deferred Tax Assets Stock Issued Forlicense Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement_lbl" xml:lang="en-US">Stock issued for license agreement</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStockIssuedForMilestonePayment" xlink:label="syn_DeferredTaxAssetsStockIssuedForMilestonePayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DeferredTaxAssetsStockIssuedForMilestonePayment" xlink:to="syn_DeferredTaxAssetsStockIssuedForMilestonePayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_DeferredTaxAssetsStockIssuedForMilestonePayment_lbl" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Stock Issued For Milestone Payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DeferredTaxAssetsStockIssuedForMilestonePayment_lbl" xml:lang="en-US">Deferred Tax Assets Stock Issued For Milestone Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_DeferredTaxAssetsStockIssuedForMilestonePayment_lbl" xml:lang="en-US">Stock issued for milestone payment</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee" xlink:label="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee" xlink:to="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee_lbl" xml:lang="en-US">Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from amortizable license fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Amortizable License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee_lbl" xml:lang="en-US">Amortizable license fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry-forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Total net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncomeTaxesTable" xlink:label="syn_IncomeTaxesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_IncomeTaxesTable" xlink:to="syn_IncomeTaxesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_IncomeTaxesTable_lbl" xml:lang="en-US">Income Taxes [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario, Plan [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2018Member" xlink:label="us-gaap_TaxYear2018Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2018Member" xlink:to="us-gaap_TaxYear2018Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxYear2018Member_lbl" xml:lang="en-US">Tax Year 2018 [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2020Member" xlink:label="us-gaap_TaxYear2020Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxYear2020Member" xlink:to="us-gaap_TaxYear2020Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxYear2020Member_lbl" xml:lang="en-US">Tax Year 2020 [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncomeTaxLineItems" xlink:label="syn_IncomeTaxLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_IncomeTaxLineItems" xlink:to="syn_IncomeTaxLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_IncomeTaxLineItems_lbl" xml:lang="en-US">Income Tax [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OperatingLossCarryforwardsLimitationOnUse" xlink:label="syn_OperatingLossCarryforwardsLimitationOnUse" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_OperatingLossCarryforwardsLimitationOnUse" xlink:to="syn_OperatingLossCarryforwardsLimitationOnUse_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_OperatingLossCarryforwardsLimitationOnUse_lbl" xml:lang="en-US">Amount of limitations on the use of all operating loss carryforwards available to reduce future taxable income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_OperatingLossCarryforwardsLimitationOnUse_lbl" xml:lang="en-US">Operating Loss Carryforwards Limitation On Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="syn_OperatingLossCarryforwardsLimitationOnUse_lbl" xml:lang="en-US">Limitation on Operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OperatingLossCarryforwardsExpireDate" xlink:label="syn_OperatingLossCarryforwardsExpireDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_OperatingLossCarryforwardsExpireDate" xlink:to="syn_OperatingLossCarryforwardsExpireDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_OperatingLossCarryforwardsExpireDate_lbl" xml:lang="en-US">The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_OperatingLossCarryforwardsExpireDate_lbl" xml:lang="en-US">Operating Loss Carryforwards Expire Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_VcnPrivateMember" xlink:label="syn_VcnPrivateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_VcnPrivateMember" xlink:to="syn_VcnPrivateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_VcnPrivateMember_lbl" xml:lang="en-US">VCN Private</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_VcnPrivateMember_lbl" xml:lang="en-US">VCN Private [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OtherFirstIndicationMember" xlink:label="syn_OtherFirstIndicationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_OtherFirstIndicationMember" xlink:to="syn_OtherFirstIndicationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_OtherFirstIndicationMember_lbl" xml:lang="en-US">Other First Indication.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_OtherFirstIndicationMember_lbl" xml:lang="en-US">Other First Indication [Member]</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OtherSecondIndicationMember" xlink:label="syn_OtherSecondIndicationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_OtherSecondIndicationMember" xlink:to="syn_OtherSecondIndicationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_OtherSecondIndicationMember_lbl" xml:lang="en-US">Other second indication.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_OtherSecondIndicationMember_lbl" xml:lang="en-US">Other Second Indication</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_GrifolsInnovationMember" xlink:label="syn_GrifolsInnovationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_GrifolsInnovationMember" xlink:to="syn_GrifolsInnovationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_GrifolsInnovationMember_lbl" xml:lang="en-US">Grifols Innovation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_GrifolsInnovationMember_lbl" xml:lang="en-US">Grifols Innovation</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NewTechnologiesMember" xlink:label="syn_NewTechnologiesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_NewTechnologiesMember" xlink:to="syn_NewTechnologiesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_NewTechnologiesMember_lbl" xml:lang="en-US">New Technologies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_NewTechnologiesMember_lbl" xml:lang="en-US">New technologies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Maximum Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_lbl" xml:lang="en-US">Employment agreement term</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConsiderationPurchasePaid" xlink:label="syn_ConsiderationPurchasePaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ConsiderationPurchasePaid" xlink:to="syn_ConsiderationPurchasePaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ConsiderationPurchasePaid_lbl" xml:lang="en-US">Amount of consideration for the purchase paid.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ConsiderationPurchasePaid_lbl" xml:lang="en-US">Consideration Purchase Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ConsiderationPurchasePaid_lbl" xml:lang="en-US">Consideration purchase paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_lbl" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CashPaymentsExistingLiabilities" xlink:label="syn_CashPaymentsExistingLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_CashPaymentsExistingLiabilities" xlink:to="syn_CashPaymentsExistingLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_CashPaymentsExistingLiabilities_lbl" xml:lang="en-US">Amount of cash payments existing liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_CashPaymentsExistingLiabilities_lbl" xml:lang="en-US">Cash Payments Existing Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_CashPaymentsExistingLiabilities_lbl" xml:lang="en-US">Existing liabilities</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ClosingFinanceCosts" xlink:label="syn_ClosingFinanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_ClosingFinanceCosts" xlink:to="syn_ClosingFinanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_ClosingFinanceCosts_lbl" xml:lang="en-US">Amount of finance the costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_ClosingFinanceCosts_lbl" xml:lang="en-US">Closing Finance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_ClosingFinanceCosts_lbl" xml:lang="en-US">Finance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xml:lang="en-US">Budgetary plan</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePaymentsSafeToProceed" xlink:label="syn_BusinessCombinationMilestonePaymentsSafeToProceed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BusinessCombinationMilestonePaymentsSafeToProceed" xlink:to="syn_BusinessCombinationMilestonePaymentsSafeToProceed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BusinessCombinationMilestonePaymentsSafeToProceed_lbl" xml:lang="en-US">Amount of business combination milestone payments safe to proceed .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BusinessCombinationMilestonePaymentsSafeToProceed_lbl" xml:lang="en-US">Business Combination Milestone Payments Safe to Proceed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_BusinessCombinationMilestonePaymentsSafeToProceed_lbl" xml:lang="en-US">Milestone payments safe to proceed</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePaymentsFirstPatientDosed" xlink:label="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed" xlink:to="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed_lbl" xml:lang="en-US">Amount of business combination milestone payments first patient dosed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed_lbl" xml:lang="en-US">Business Combination Milestone Payments First Patient Dosed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed_lbl" xml:lang="en-US">Milestone payments first patient dosed</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePayments" xlink:label="syn_BusinessCombinationMilestonePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BusinessCombinationMilestonePayments" xlink:to="syn_BusinessCombinationMilestonePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BusinessCombinationMilestonePayments_lbl" xml:lang="en-US">Amount of business combination milestone payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BusinessCombinationMilestonePayments_lbl" xml:lang="en-US">Business Combination Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_BusinessCombinationMilestonePayments_lbl" xml:lang="en-US">Milestone payments</label>
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePaymentsBlaApproval" xlink:label="syn_BusinessCombinationMilestonePaymentsBlaApproval" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="syn_BusinessCombinationMilestonePaymentsBlaApproval" xlink:to="syn_BusinessCombinationMilestonePaymentsBlaApproval_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="syn_BusinessCombinationMilestonePaymentsBlaApproval_lbl" xml:lang="en-US">Amount of business combination milestone payments BLA approval .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="syn_BusinessCombinationMilestonePaymentsBlaApproval_lbl" xml:lang="en-US">Business Combination Milestone Payments BLA Approval</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="syn_BusinessCombinationMilestonePaymentsBlaApproval_lbl" xml:lang="en-US">Milestone payments BLA approval</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>syn-20211231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8042.36810 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/16/2022 8:41:32 PM-->
<!--Modified on: 3/16/2022 8:41:32 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedStatementsOfOperations" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedStatementsOfStockholdersDeficitEquity" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation" roleURI="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformation" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrants" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrants" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockholdersEquity" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureNonControllingInterest" roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitments" roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitments" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureIncomeTaxes" roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://www.syntheticbiologics.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationTables" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsTables" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables" roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureStockholdersEquityDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureNonControllingInterestDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="syn-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637830600910878744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637830600910878744" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637830600910878744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637830600910878744" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637830600910878744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_637830600910878744" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637830600910878744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637830600910878744" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637830600910888744" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637830600910888744" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637830600910888744" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637830600910888744" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637830600910888744" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637830600910888744" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry_637830600910888744" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637830600910888744" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637830600910888744" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637830600910888744" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637830600910888744" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637830600910888744" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637830600910888744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637830600910888744" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637830600910898742" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637830600910898742" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637830600910898742" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637830600910898742" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637830600910898742" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637830600910898742" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637830600910898742" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637830600910898742" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637830600910898742" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637830600910898742" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637830600910898742" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637830600910908743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637830600910908743" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637830600910908743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637830600910908743" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637830600910908743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_637830600910908743" order="30" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637830600910908743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_637830600910908743" order="31" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_637830600910908743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_637830600910908743" order="32" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637830600910908743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_637830600910908743" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637830600910908743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_637830600910908743" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637830600910908743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_637830600910908743" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_637830600910918743" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_AssetsAbstract_637830600910918743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637830600910918743" xlink:to="us-gaap_AssetsCurrentAbstract_637830600910918743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637830600910918743" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637830600910918743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637830600910918743" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637830600910918743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637830600910918743" xlink:to="us-gaap_AssetsCurrent_637830600910918743" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637830600910918743" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637830600910918743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637830600910918743" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637830600910918743" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DepositsAndOtherAssetsNoncurrent" xlink:label="syn_DepositsAndOtherAssetsNoncurrent_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637830600910918743" xlink:to="syn_DepositsAndOtherAssetsNoncurrent_637830600910918743" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637830600910918743" xlink:to="us-gaap_Assets_637830600910918743" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637830600910918743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637830600910918743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637830600910918743" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637830600910928751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637830600910928751" xlink:to="us-gaap_AccountsPayableCurrent_637830600910928751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637830600910928751" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637830600910928751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637830600910928751" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_637830600910928751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637830600910928751" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637830600910928751" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637830600910928751" xlink:to="us-gaap_LiabilitiesCurrent_637830600910928751" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637830600910918743" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637830600910928751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637830600910918743" xlink:to="us-gaap_Liabilities_637830600910928751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637830600910918743" xlink:to="us-gaap_CommitmentsAndContingencies_637830600910928751" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637830600910918743" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637830600910928751" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637830600910928751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637830600910918743" xlink:to="us-gaap_StockholdersEquityAbstract_637830600910928751" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_637830600910938746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637830600910928751" xlink:to="us-gaap_PreferredStockValue_637830600910938746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637830600910938746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637830600910928751" xlink:to="us-gaap_CommonStockValue_637830600910938746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_637830600910938746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637830600910928751" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_637830600910938746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637830600910938746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637830600910928751" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637830600910938746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637830600910938746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637830600910928751" xlink:to="us-gaap_StockholdersEquity_637830600910938746" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest_637830600910938746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637830600910928751" xlink:to="us-gaap_MinorityInterest_637830600910938746" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637830600910938746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637830600910928751" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637830600910938746" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637830600910938746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637830600910918743" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637830600910938746" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Consolidated Balance Sheets (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637830600910948747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637830600910948747" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued_637830600910948747" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637830600910948747" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637830600910948747" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_637830600910948747" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_637830600910948747" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_637830600910948747" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637830600910948747" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_637830600910948747" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_637830600910948747" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637830600910948747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_637830600910948747" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - Consolidated Statements of Operations">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_177" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_177" xlink:to="us-gaap_StatementTable_637830600910958747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600910958747" xlink:to="us-gaap_StatementEquityComponentsAxis_637830600910958747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637830600910958747" xlink:to="us-gaap_EquityComponentDomain_637830600910958747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637830600910958747" xlink:to="us-gaap_PreferredStockMember_637830600910958747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600910958747" xlink:to="us-gaap_StatementClassOfStockAxis_637830600910958747" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637830600910958747" xlink:to="us-gaap_ClassOfStockDomain_637830600910958747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600910958747" xlink:to="us-gaap_SeriesAPreferredStockMember_637830600910958747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600910958747" xlink:to="us-gaap_SeriesBPreferredStockMember_637830600910958747" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600910958747" xlink:to="us-gaap_StatementLineItems_637830600910958747" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_OperatingExpensesAbstract_637830600910958747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637830600910958747" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637830600910958747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637830600910958747" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637830600910958747" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637830600910958747" xlink:to="us-gaap_OperatingExpenses_637830600910958747" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_OperatingIncomeLoss_637830600910958747" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_637830600910958747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_637830600910958747" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637830600910958747" xlink:to="us-gaap_InvestmentIncomeInterest_637830600910968746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_637830600910958747" xlink:to="us-gaap_NonoperatingIncomeExpense_637830600910968746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_ProfitLoss_637830600910968746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600910968746" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_NetIncomeLoss_637830600910968746" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_637830600910968746" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="syn_PreferredStockPriceAdjustment_637830600910968746" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="syn_WarrantExercisePriceAdjustment_637830600910968746" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637830600910968746" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637830600910968746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_EarningsPerShareBasic_637830600910968746" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_EarningsPerShareDiluted_637830600910978745" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637830600910978745" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910958747" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637830600910978745" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" xlink:type="extended" xlink:title="00300 - Statement - Consolidated Statements of Stockholders (Deficit) Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_345" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_345" xlink:to="us-gaap_StatementTable_637830600910978745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600910978745" xlink:to="us-gaap_StatementEquityComponentsAxis_637830600910978745" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637830600910978745" xlink:to="us-gaap_CommonStockMember_637830600910978745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637830600910978745" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637830600910978745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637830600910978745" xlink:to="us-gaap_RetainedEarningsMember_637830600910978745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637830600910978745" xlink:to="us-gaap_NoncontrollingInterestMember_637830600910978745" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637830600910978745" xlink:to="us-gaap_PreferredStockMember_637830600910978745" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637830600910978745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637830600910978745" xlink:to="us-gaap_EquityComponentDomain_637830600910978745" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600910978745" xlink:to="us-gaap_StatementClassOfStockAxis_637830600910988746" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637830600910988746" xlink:to="us-gaap_SeriesBPreferredStockMember_637830600910988746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637830600910988746" xlink:to="us-gaap_SeriesAPreferredStockMember_637830600910988746" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637830600910988746" xlink:to="us-gaap_ClassOfStockDomain_637830600910988746" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600910978745" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637830600910988746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637830600910988746" xlink:to="us-gaap_PrivatePlacementMember_637830600910988746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637830600910988746" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637830600910988746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600910978745" xlink:to="us-gaap_StatementLineItems_637830600910988746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_637830600910988746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingValue" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingValue_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingValue_637830600910988746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodAtMarketOfferingShare" xlink:label="syn_StockIssuedDuringPeriodAtMarketOfferingShare_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_StockIssuedDuringPeriodAtMarketOfferingShare_637830600910988746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock_637830600910988746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_DividendsPreferredStock_637830600910988746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodValueOfSynBiomicsStock" xlink:label="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_637830600910998747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_StockIssuedDuringPeriodValueOfSynBiomicsStock_637830600910998747" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdjustmentsToEffectOfWarrantExercisePrice" xlink:label="syn_AdjustmentsToEffectOfWarrantExercisePrice_637830600910998747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_AdjustmentsToEffectOfWarrantExercisePrice_637830600910998747" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStock" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStock_637830600910998747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStock_637830600910998747" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConversionOfSeriesBPreferredStockToCommonStockShares" xlink:label="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_637830600910998747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_ConversionOfSeriesBPreferredStockToCommonStockShares_637830600910998747" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637830600910998747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_ProfitLoss_637830600910998747" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_637830600910998747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_637830600910998747" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodValueWarrantsExercised_637830600910998747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_StockIssuedDuringPeriodValueWarrantsExercised_637830600910998747" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_637830600910998747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised_637830600910998747" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdjustmentsToEffectOfPreferredStockPrice" xlink:label="syn_AdjustmentsToEffectOfPreferredStockPrice_637830600910998747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_AdjustmentsToEffectOfPreferredStockPrice_637830600910998747" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_Conversionofseriesbpreferredstocktocommonstock" xlink:label="syn_Conversionofseriesbpreferredstocktocommonstock_637830600911008747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_Conversionofseriesbpreferredstocktocommonstock_637830600911008747" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_Conversionofseriesapreferredstocktocommonstockshares" xlink:label="syn_Conversionofseriesapreferredstocktocommonstockshares_637830600911008747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="syn_Conversionofseriesapreferredstocktocommonstockshares_637830600911008747" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911008747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911008747" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600911008747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600911008747" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637830600911008747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_637830600911008747" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6378306009110087471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6378306009110087471" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637830600911008747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_SharesOutstanding_637830600911008747" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6378306009110087471" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600910988746" xlink:to="us-gaap_SharesOutstanding_6378306009110087471" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_732" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_732" xlink:to="us-gaap_StatementTable_637830600911018747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600911018747" xlink:to="us-gaap_StatementClassOfStockAxis_637830600911018747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637830600911018747" xlink:to="us-gaap_ClassOfStockDomain_637830600911018747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911018747" xlink:to="us-gaap_SeriesAPreferredStockMember_637830600911018747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911018747" xlink:to="us-gaap_SeriesBPreferredStockMember_637830600911018747" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600911018747" xlink:to="us-gaap_StatementEquityComponentsAxis_637830600911018747" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637830600911018747" xlink:to="us-gaap_EquityComponentDomain_637830600911018747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637830600911018747" xlink:to="us-gaap_PreferredStockMember_637830600911018747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600911018747" xlink:to="us-gaap_StatementLineItems_637830600911018747" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911018747" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637830600911018747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637830600911018747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637830600911018747" xlink:to="us-gaap_ProfitLoss_637830600911018747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637830600911018747" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637830600911028748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637830600911028748" xlink:to="us-gaap_ShareBasedCompensation_637830600911028748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SubsidiaryStockIssuesToVendor" xlink:label="syn_SubsidiaryStockIssuesToVendor_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637830600911028748" xlink:to="syn_SubsidiaryStockIssuesToVendor_637830600911028748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637830600911028748" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637830600911028748" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637830600911028748" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637830600911028748" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637830600911028748" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637830600911028748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncreaseDecreaseRightOfUseAssets" xlink:label="syn_IncreaseDecreaseRightOfUseAssets_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637830600911028748" xlink:to="syn_IncreaseDecreaseRightOfUseAssets_637830600911028748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637830600911028748" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637830600911028748" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637830600911028748" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_637830600911028748" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637830600911028748" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_637830600911028748" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncreaseDecreaseLeaseLiability" xlink:label="syn_IncreaseDecreaseLeaseLiability_637830600911028748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637830600911028748" xlink:to="syn_IncreaseDecreaseLeaseLiability_637830600911028748" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637830600911018747" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637830600911038749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911018747" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637830600911038749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637830600911038749" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637830600911038749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637830600911038749" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637830600911038749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911018747" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637830600911038749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637830600911038749" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637830600911038749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637830600911038749" xlink:to="us-gaap_ProceedsFromWarrantExercises_637830600911038749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637830600911038749" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637830600911038749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911018747" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_637830600911038749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637830600911038749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911018747" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637830600911038749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637830600911048746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911018747" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637830600911048746" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637830600911048746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911018747" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637830600911048746" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1_637830600911048746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637830600911048746" xlink:to="us-gaap_ConversionOfStockAmountConverted1_637830600911048746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment_637830600911048746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637830600911048746" xlink:to="syn_PreferredStockPriceAdjustment_637830600911048746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ReturnOfSynBiomicsStock" xlink:label="syn_ReturnOfSynBiomicsStock_637830600911048746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637830600911048746" xlink:to="syn_ReturnOfSynBiomicsStock_637830600911048746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeemedDividendsWithBeneficialConversionFeature" xlink:label="syn_DeemedDividendsWithBeneficialConversionFeature_637830600911048746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637830600911048746" xlink:to="syn_DeemedDividendsWithBeneficialConversionFeature_637830600911048746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637830600911048746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637830600911048746" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637830600911048746" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPreferredStockPaidinkind" xlink:label="us-gaap_DividendsPreferredStockPaidinkind_637830600911058748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637830600911048746" xlink:to="us-gaap_DividendsPreferredStockPaidinkind_637830600911058748" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment_637830600911058748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_637830600911048746" xlink:to="syn_WarrantExercisePriceAdjustment_637830600911058748" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_769" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637830600911058748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_769" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637830600911058748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637054396822175987" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637830600911058748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822175987" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637830600911058748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation" xlink:type="extended" xlink:title="10301 - Disclosure - Selected Balance Sheet Information">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637830600911058748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_637830600911058748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrants" xlink:type="extended" xlink:title="10401 - Disclosure - Stock-Based Compensation and Warrants">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637830600911068747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637830600911068747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="10501 - Disclosure - Stockholders' Equity">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637830600911068747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637830600911068747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest" xlink:type="extended" xlink:title="10601 - Disclosure - Non-controlling Interest">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_17" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock" xlink:label="us-gaap_MinorityInterestDisclosureTextBlock_637830600911068747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_17" xlink:to="us-gaap_MinorityInterestDisclosureTextBlock_637830600911068747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitments" xlink:type="extended" xlink:title="10701 - Disclosure - License, Collaborative and Employment Agreements and Commitments">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:label="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_637054396822175987" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock_637830600911068747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_637054396822175987" xlink:to="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock_637830600911068747" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10801 - Disclosure - Income taxes">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637830600911078749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10901 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637830600911078749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637054396822185948" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637830600911078749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_UseOfEstimates_637830600911078749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NoncontrollingInterestPolicyTextBlock" xlink:label="syn_NoncontrollingInterestPolicyTextBlock_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="syn_NoncontrollingInterestPolicyTextBlock_637830600911078749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RisksAndUncertaintiesPolicyTextBlock" xlink:label="syn_RisksAndUncertaintiesPolicyTextBlock_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="syn_RisksAndUncertaintiesPolicyTextBlock_637830600911078749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637830600911078749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637830600911078749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637830600911078749" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637830600911078749" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637830600911078749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637830600911078749" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_637830600911088749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_637830600911088749" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockBasedPaymentArrangementsPolicyTextBlock" xlink:label="syn_StockBasedPaymentArrangementsPolicyTextBlock_637830600911088749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="syn_StockBasedPaymentArrangementsPolicyTextBlock_637830600911088749" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_637830600911088749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_DerivativesPolicyTextBlock_637830600911088749" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637830600911088749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637830600911088749" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637830600911088749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822185948" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637830600911088749" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637054396822195946" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EstimatedUsefulLifeOfAssetTableTextBlock" xlink:label="syn_EstimatedUsefulLifeOfAssetTableTextBlock_637830600911088749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822195946" xlink:to="syn_EstimatedUsefulLifeOfAssetTableTextBlock_637830600911088749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables" xlink:type="extended" xlink:title="30303 - Disclosure - Selected Balance Sheet Information (Tables)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_637830600911088749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_637830600911088749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637830600911088749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637830600911088749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedExpensesTableTextBlock" xlink:label="syn_AccruedExpensesTableTextBlock_637830600911098749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_AccruedExpensesTableTextBlock_637830600911098749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedEmployeeBenefitsTableTextBlock" xlink:label="syn_AccruedEmployeeBenefitsTableTextBlock_637830600911098749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_AccruedEmployeeBenefitsTableTextBlock_637830600911098749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Stock-Based Compensation and Warrants (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_637830600911098749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_637830600911098749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637830600911098749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637830600911098749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_637830600911098749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_637830600911098749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ScheduleOfWarrantActivityTableTextBlock" xlink:label="syn_ScheduleOfWarrantActivityTableTextBlock_637830600911098749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="syn_ScheduleOfWarrantActivityTableTextBlock_637830600911098749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock" xlink:label="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_637830600911098749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock_637830600911098749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables" xlink:type="extended" xlink:title="30703 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Tables)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:label="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637830600911098749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_637830600911098749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30803 - Disclosure - Income Taxes (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637054396822205897" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396822205897" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637830600911108749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396822205897" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637830600911108749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Organization, Nature of Operations and Basis of Presentation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_324082" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_324082" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637830600911108749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts" xlink:label="syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_324082" xlink:to="syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts_637830600911108749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_324082" xlink:to="us-gaap_ProceedsFromWarrantExercises_637830600911108749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_324082" xlink:to="us-gaap_NumberOfOperatingSegments_637830600911108749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637054396822225862" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822225862" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637830600911108749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637830600911108749" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637830600911108749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637830600911108749" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637830600911108749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637830600911108749" xlink:to="us-gaap_OfficeEquipmentMember_637830600911108749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637830600911108749" xlink:to="srt_RangeAxis_637830600911108749" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637830600911108749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637830600911108749" xlink:to="srt_RangeMember_637830600911108749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637830600911108749" xlink:to="srt_MinimumMember_637830600911118749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637830600911108749" xlink:to="srt_MaximumMember_637830600911118749" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637830600911108749" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637830600911118749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637830600911118749" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637830600911118749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637054396822235811" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SummaryOfSignificantAccountingPoliciesTable" xlink:label="syn_SummaryOfSignificantAccountingPoliciesTable_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637054396822235811" xlink:to="syn_SummaryOfSignificantAccountingPoliciesTable_637830600911118749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable_637830600911118749" xlink:to="srt_OwnershipAxis_637830600911118749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637830600911118749" xlink:to="srt_OwnershipDomain_637830600911118749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637830600911118749" xlink:to="syn_SYNBiomicsMember_637830600911118749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable_637830600911118749" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637830600911118749" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_637830600911118749" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637830600911118749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_MoneyMarketAccountsMember" xlink:label="syn_MoneyMarketAccountsMember_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_637830600911118749" xlink:to="syn_MoneyMarketAccountsMember_637830600911118749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable_637830600911118749" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_637830600911118749" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_637830600911118749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis_637830600911118749" xlink:to="us-gaap_DerivativeContractTypeDomain_637830600911118749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain_637830600911118749" xlink:to="us-gaap_OptionMember_637830600911128749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable_637830600911118749" xlink:to="us-gaap_FinancialInstrumentAxis_637830600911128749" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_637830600911128749" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637830600911128749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_637830600911128749" xlink:to="us-gaap_WarrantMember_637830600911128749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable_637830600911118749" xlink:to="us-gaap_StatementClassOfStockAxis_637830600911128749" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637830600911128749" xlink:to="us-gaap_ClassOfStockDomain_637830600911128749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesAAndSeriesBPreferredStockMember" xlink:label="syn_SeriesAAndSeriesBPreferredStockMember_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911128749" xlink:to="syn_SeriesAAndSeriesBPreferredStockMember_637830600911128749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911128749" xlink:to="us-gaap_SeriesBPreferredStockMember_637830600911128749" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911128749" xlink:to="us-gaap_SeriesAPreferredStockMember_637830600911128749" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesTable_637830600911118749" xlink:to="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637830600911128749" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637830600911128749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637830600911128749" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637830600911138749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637830600911138749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_637830600911138749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_637830600911138749" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_637830600911138749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_637830600911138749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_637830600911138749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_637830600911138749" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_637830600911138749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_637830600911138749" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_637830600911138749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_637830600911138749" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment_637830600911138749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="syn_WarrantExercisePriceAdjustment_637830600911138749" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend_637830600911138749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="syn_AccretionOfPreferredStockDeemedDividend_637830600911138749" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600911138749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600911138749" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637830600911148748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637830600911148748" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares_637830600911148748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_PreferredStockDiscountOnShares_637830600911148748" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockSharesConverted" xlink:label="syn_PreferredStockSharesConverted_637830600911148748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="syn_PreferredStockSharesConverted_637830600911148748" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637830600911148748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637830600911148748" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637830600911148748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637830600911148748" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockPriceAdjustment" xlink:label="syn_PreferredStockPriceAdjustment_637830600911148748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_SummaryOfSignificantAccountingPoliciesLineItems_637830600911128749" xlink:to="syn_PreferredStockPriceAdjustment_637830600911148748" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Selected Balance Sheet Information - Schedule of  PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_637830600911148748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_PrepaidInsurance_637830600911148748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrepaidClinicalResearchOrganizationsExpenseCurrent" xlink:label="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_PrepaidClinicalResearchOrganizationsExpenseCurrent_637830600911158762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrepaidConsultingSubscriptionsAndOtherExpenses" xlink:label="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_PrepaidConsultingSubscriptionsAndOtherExpenses_637830600911158762" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="us-gaap_OtherReceivablesNetCurrent_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent_637830600911158762" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrepaidManufacturingExpense" xlink:label="syn_PrepaidManufacturingExpense_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_PrepaidManufacturingExpense_637830600911158762" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637830600911158762" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Selected Balance Sheet Information - Schedule of  PROPERTY AND EQUIPMENT (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637830600911158762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637830600911158762" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637830600911158762" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637830600911158762" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637830600911158762" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ComputersAndOfficeEquipmentMember" xlink:label="syn_ComputersAndOfficeEquipmentMember_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637830600911158762" xlink:to="syn_ComputersAndOfficeEquipmentMember_637830600911158762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637830600911158762" xlink:to="us-gaap_LeaseholdImprovementsMember_637830600911158762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637830600911158762" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_637830600911158762" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637830600911158762" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637830600911158762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637830600911158762" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637830600911158762" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637830600911158762" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637830600911158762" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637830600911158762" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637830600911158762" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637830600911168760" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Selected Balance Sheet Information - Schedule of  ACCRUED EXPENSES  (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedVendorPayments" xlink:label="syn_AccruedVendorPayments_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_AccruedVendorPayments_637830600911168760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedClinicalConsultingServices" xlink:label="syn_AccruedClinicalConsultingServices_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_AccruedClinicalConsultingServices_637830600911168760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccruedManufacturingCosts" xlink:label="syn_AccruedManufacturingCosts_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="syn_AccruedManufacturingCosts_637830600911168760" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent_637830600911168760" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Selected Balance Sheet Information - Schedule of  ACCRUED EMPLOYEE BENEFITS  (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BalanceSheetInformationAbstract" xlink:label="syn_BalanceSheetInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_AccruedBonusesCurrent_637830600911168760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_AccruedVacationCurrent_637830600911168760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_BalanceSheetInformationAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637830600911168760" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Stock-Based Compensation and Warrants - (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_246" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_246" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice_637830600911168760" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637830600911168760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_246" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637830600911168760" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_246" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_637830600911178750" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_246" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_637830600911178750" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_246" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637830600911178750" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Stock-Based Compensation and Warrants - Summary of stock option activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_261" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_261" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911178750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911178750" xlink:to="us-gaap_AwardTypeAxis_637830600911178750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637830600911178750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_637830600911178750" xlink:to="us-gaap_EmployeeStockOptionMember_637830600911178750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637830600911178750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637830600911178750" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637830600911178750" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_637830600911178750" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637830600911178750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637830600911178750" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637830600911188749" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637830600911188749" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637830600911188749" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637830600911188749" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_637830600911188749" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_637830600911188749" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378306009111887491" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6378306009111887491" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637830600911188749" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637830600911188749" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637830600911188749" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637830600911188749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_637830600911188749" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637830600911198761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637830600911198761" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637830600911198761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637830600911198761" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_637830600911198761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_637830600911198761" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637830600911198761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911178750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637830600911198761" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Stock-Based Compensation and Warrants - Options outstanding and exercisable (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637054396822474758" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911198761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637054396822474758" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911198761" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637830600911198761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911198761" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637830600911198761" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911198761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637830600911198761" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911198761" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RangeOfExercisePrice0004000Member" xlink:label="syn_RangeOfExercisePrice0004000Member_637830600911198761" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911198761" xlink:to="syn_RangeOfExercisePrice0004000Member_637830600911198761" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RangeOfExercisePrice41007000Member" xlink:label="syn_RangeOfExercisePrice41007000Member_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911198761" xlink:to="syn_RangeOfExercisePrice41007000Member_637830600911238745" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RangeOfExercisePrice710010200Member" xlink:label="syn_RangeOfExercisePrice710010200Member_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911198761" xlink:to="syn_RangeOfExercisePrice710010200Member_637830600911238745" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911198761" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_637830600911238745" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_637830600911238745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_637830600911238745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_637830600911238745" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_637830600911238745" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_637830600911238745" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_637830600911238745" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_637830600911238745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911238745" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_637830600911238745" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails" xlink:type="extended" xlink:title="40404 - Disclosure - Stock-Based Compensation and Warrants - Stock incentive plan and other information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_393" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_393" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" xlink:to="us-gaap_PlanNameAxis_637830600911248746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637830600911248746" xlink:to="us-gaap_PlanNameDomain_637830600911248746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPlan2007Member" xlink:label="syn_StockPlan2007Member_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637830600911248746" xlink:to="syn_StockPlan2007Member_637830600911248746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPlan2010Member" xlink:label="syn_StockPlan2010Member_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637830600911248746" xlink:to="syn_StockPlan2010Member_637830600911248746" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPlan2020Member" xlink:label="syn_StockPlan2020Member_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637830600911248746" xlink:to="syn_StockPlan2020Member_637830600911248746" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockWarrantsMember" xlink:label="syn_StockWarrantsMember_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637830600911248746" xlink:to="syn_StockWarrantsMember_637830600911248746" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" xlink:to="us-gaap_GranteeStatusAxis_637830600911248746" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637830600911248746" xlink:to="us-gaap_GranteeStatusDomain_637830600911248746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember" xlink:label="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637830600911248746" xlink:to="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember_637830600911248746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember_637830600911248746" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637830600911248746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911248746" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637830600911248746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911248746" xlink:to="us-gaap_RelatedPartyDomain_637830600911248746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EmployeesAndDirectorsMember" xlink:label="syn_EmployeesAndDirectorsMember_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637830600911248746" xlink:to="syn_EmployeesAndDirectorsMember_637830600911258747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConsultantMember" xlink:label="syn_ConsultantMember_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637830600911248746" xlink:to="syn_ConsultantMember_637830600911258747" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" xlink:to="us-gaap_IncomeStatementLocationAxis_637830600911258747" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637830600911258747" xlink:to="us-gaap_IncomeStatementLocationDomain_637830600911258747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember" xlink:label="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637830600911258747" xlink:to="syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_637830600911258747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" xlink:to="srt_RangeAxis_637830600911258747" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637830600911258747" xlink:to="srt_RangeMember_637830600911258747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637830600911258747" xlink:to="srt_MaximumMember_637830600911258747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637830600911258747" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637830600911258747" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637830600911258747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesBWarrantsMember" xlink:label="syn_SeriesBWarrantsMember_637830600911258747" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637830600911258747" xlink:to="syn_SeriesBWarrantsMember_637830600911258747" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637830600911268744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637830600911268744" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911268744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637830600911268744" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911268744" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_637830600911268744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911268744" xlink:to="us-gaap_EmployeeStockMember_637830600911268744" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637830600911268744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911268744" xlink:to="us-gaap_IPOMember_637830600911268744" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637830600911268744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" xlink:to="srt_TitleOfIndividualAxis_637830600911268744" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911268744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637830600911268744" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911268744" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_637830600911268744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911268744" xlink:to="srt_DirectorMember_637830600911268744" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911248746" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637830600911268744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637830600911268744" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637830600911278745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637830600911278745" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637830600911278745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_637830600911278745" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637830600911278745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637830600911278745" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637830600911278745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637830600911278745" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637830600911278745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637830600911278745" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911278745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911278745" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637830600911278745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637830600911278745" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637830600911278745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_SharesIssuedPricePerShare_637830600911278745" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637830600911288746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637830600911288746" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_637830600911288746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911268744" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_637830600911288746" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails" xlink:type="extended" xlink:title="40405 - Disclosure - Stock-Based Compensation and Warrants - Stock Warrants (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockWarrantsAbstract" xlink:label="loc_syn_StockWarrantsAbstract_410066" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable_637830600911288746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_syn_StockWarrantsAbstract_410066" xlink:to="us-gaap_ClassOfTreasuryStockTable_637830600911288746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637830600911288746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637830600911288746" xlink:to="us-gaap_StatementEquityComponentsAxis_637830600911288746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637830600911288746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637830600911288746" xlink:to="us-gaap_EquityComponentDomain_637830600911288746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_637830600911288746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain_637830600911288746" xlink:to="us-gaap_WarrantMember_637830600911288746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637830600911288746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637830600911288746" xlink:to="us-gaap_PlanNameAxis_637830600911288746" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637830600911288746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637830600911288746" xlink:to="us-gaap_PlanNameDomain_637830600911288746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockWarrantsMember" xlink:label="syn_StockWarrantsMember_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637830600911288746" xlink:to="syn_StockWarrantsMember_637830600911298750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637830600911288746" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637830600911298750" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637830600911298750" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911298750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911298750" xlink:to="us-gaap_IPOMember_637830600911298750" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911298750" xlink:to="us-gaap_OverAllotmentOptionMember_637830600911298750" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_UnderwrittenPublicOfferingMember" xlink:label="syn_UnderwrittenPublicOfferingMember_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911298750" xlink:to="syn_UnderwrittenPublicOfferingMember_637830600911298750" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637830600911288746" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_637830600911298750" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain" xlink:label="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_637830600911298750" xlink:to="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_637830600911298750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAMember" xlink:label="us-gaap_SeriesAMember_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain_637830600911298750" xlink:to="us-gaap_SeriesAMember_637830600911298750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637830600911288746" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637830600911298750" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637830600911298750" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637830600911298750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OctoberTwoThousandEighteenWarrantsMember" xlink:label="syn_OctoberTwoThousandEighteenWarrantsMember_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637830600911298750" xlink:to="syn_OctoberTwoThousandEighteenWarrantsMember_637830600911298750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesWarrantsMember" xlink:label="syn_SeriesWarrantsMember_637830600911298750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637830600911298750" xlink:to="syn_SeriesWarrantsMember_637830600911298750" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SeriesBWarrantsMember" xlink:label="syn_SeriesBWarrantsMember_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637830600911298750" xlink:to="syn_SeriesBWarrantsMember_637830600911308746" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637830600911288746" xlink:to="us-gaap_StatementClassOfStockAxis_637830600911308746" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637830600911308746" xlink:to="us-gaap_ClassOfStockDomain_637830600911308746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911308746" xlink:to="us-gaap_SeriesBPreferredStockMember_637830600911308746" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911308746" xlink:to="us-gaap_CommonClassAMember_637830600911308746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911308746" xlink:to="us-gaap_CommonClassBMember_637830600911308746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637830600911288746" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637830600911308746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911308746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantTerm" xlink:label="syn_WarrantTerm_637830600911308746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="syn_WarrantTerm_637830600911308746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637830600911318745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637830600911318745" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637830600911318745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_SharesIssuedPricePerShare_637830600911318745" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637830600911318745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637830600911318745" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637830600911318745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637830600911318745" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare_637830600911318745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="syn_PreferredStockConversionPricePerShare_637830600911318745" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637830600911318745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637830600911318745" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment_637830600911318745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="syn_WarrantExercisePriceAdjustment_637830600911318745" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637830600911318745" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637830600911318745" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock_637830600911328749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock_637830600911328749" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering_637830600911328749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="syn_PercentageOfIssueOfThePublicOffering_637830600911328749" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637830600911328749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637830600911328749" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_637830600911328749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_ProceedsFromWarrantExercises_637830600911328749" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_637830600911328749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_637830600911328749" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_637830600911328749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_637830600911328749" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637830600911328749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637830600911328749" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_637830600911338756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_637830600911338756" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="syn_StockIssuedDuringPeriodSharesWarrantsExercised_637830600911338756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="syn_StockIssuedDuringPeriodSharesWarrantsExercised_637830600911338756" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfShareSold" xlink:label="syn_NumberOfShareSold_637830600911338756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="syn_NumberOfShareSold_637830600911338756" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfSharesPurchase" xlink:label="syn_NumberOfSharesPurchase_637830600911338756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637830600911308746" xlink:to="syn_NumberOfSharesPurchase_637830600911338756" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails" xlink:type="extended" xlink:title="40406 - Disclosure - Stock-Based Compensation and Warrants  - Summary of all warrant activity (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockWarrantsAbstract" xlink:label="syn_StockWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637830600911338756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637830600911338756" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_637830600911338756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod_637830600911338756" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_637830600911348750" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_637830600911348750" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_637830600911348750" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_637830600911348750" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378306009113487501" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6378306009113487501" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails" xlink:type="extended" xlink:title="40407 - Disclosure - Stock-Based Compensation and Warrants - Summary of all outstanding and exercisable warrants (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockWarrantsAbstract" xlink:label="syn_StockWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_StockWarrantsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911348750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911348750" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637830600911348750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_637830600911348750" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911348750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ExercisePrice0.69Member" xlink:label="syn_ExercisePrice0.69Member_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911348750" xlink:to="syn_ExercisePrice0.69Member_637830600911348750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ExercisePrice1820Member" xlink:label="syn_ExercisePrice1820Member_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911348750" xlink:to="syn_ExercisePrice1820Member_637830600911348750" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ExercisePrice0.69TwoMember" xlink:label="syn_ExercisePrice0.69TwoMember_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_637830600911348750" xlink:to="syn_ExercisePrice0.69TwoMember_637830600911348750" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637830600911348750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911348750" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantsExercisePrice" xlink:label="syn_WarrantsExercisePrice_637830600911348750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911348750" xlink:to="syn_WarrantsExercisePrice_637830600911348750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911348750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_637830600911358750" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber" xlink:label="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911348750" xlink:to="syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber_637830600911358750" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637830600911348750" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_637830600911358750" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Stockholders' Equity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable_637830600911358750" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600911358750" xlink:to="us-gaap_StatementClassOfStockAxis_637830600911358750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637830600911358750" xlink:to="us-gaap_ClassOfStockDomain_637830600911358750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911358750" xlink:to="us-gaap_SeriesAPreferredStockMember_637830600911358750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911358750" xlink:to="us-gaap_SeriesBPreferredStockMember_637830600911358750" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911358750" xlink:to="us-gaap_CommonClassAMember_637830600911358750" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonClassBMember" xlink:label="us-gaap_CommonClassBMember_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637830600911358750" xlink:to="us-gaap_CommonClassBMember_637830600911358750" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600911358750" xlink:to="dei_LegalEntityAxis_637830600911358750" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637830600911358750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637830600911358750" xlink:to="dei_EntityDomain_637830600911358750" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FbrCapitalMarketsCoMember" xlink:label="syn_FbrCapitalMarketsCoMember_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637830600911358750" xlink:to="syn_FbrCapitalMarketsCoMember_637830600911368749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600911358750" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637830600911368749" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637830600911368749" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911368749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911368749" xlink:to="us-gaap_OverAllotmentOptionMember_637830600911368749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637830600911368749" xlink:to="us-gaap_PrivatePlacementMember_637830600911368749" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600911358750" xlink:to="us-gaap_TypeOfArrangementAxis_637830600911368749" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637830600911368749" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911368749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPurchaseAgreementMember" xlink:label="syn_StockPurchaseAgreementMember_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911368749" xlink:to="syn_StockPurchaseAgreementMember_637830600911368749" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637830600911358750" xlink:to="us-gaap_StatementLineItems_637830600911368749" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_637830600911368749" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911368749" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637830600911368749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_SharesIssuedPricePerShare_637830600911368749" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637830600911378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_637830600911378752" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_637830600911378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_637830600911378752" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockConversionPricePerShare" xlink:label="syn_PreferredStockConversionPricePerShare_637830600911378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_PreferredStockConversionPricePerShare_637830600911378752" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637830600911378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_637830600911378752" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637830600911378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637830600911378752" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IssueOfWarrantsToPurchaseCommonStock" xlink:label="syn_IssueOfWarrantsToPurchaseCommonStock_637830600911378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_IssueOfWarrantsToPurchaseCommonStock_637830600911378752" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637830600911378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637830600911378752" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_WarrantExercisePriceAdjustment" xlink:label="syn_WarrantExercisePriceAdjustment_637830600911378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_WarrantExercisePriceAdjustment_637830600911378752" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PercentageOfIssueOfThePublicOffering" xlink:label="syn_PercentageOfIssueOfThePublicOffering_637830600911378752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_PercentageOfIssueOfThePublicOffering_637830600911378752" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDiscountOnShares" xlink:label="us-gaap_PreferredStockDiscountOnShares_637830600911388749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_PreferredStockDiscountOnShares_637830600911388749" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637830600911388749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_637830600911388749" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_637830600911388749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_637830600911388749" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_637830600911388749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_PreferredStockDividendRatePercentage_637830600911388749" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceIncrease_637830600911388749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceIncrease_637830600911388749" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionPriceDecrease" xlink:label="us-gaap_PreferredStockConvertibleConversionPriceDecrease_637830600911388749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_PreferredStockConvertibleConversionPriceDecrease_637830600911388749" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_637830600911388749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_637830600911388749" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_637830600911388749" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_637830600911388749" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BeneficialOwnershipPercentage" xlink:label="syn_BeneficialOwnershipPercentage_637830600911398750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_BeneficialOwnershipPercentage_637830600911398750" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637830600911398750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637830600911398750" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_637830600911398750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_PreferredStockSharesOutstanding_637830600911398750" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EstimatedFairValueOfInducementConsideration" xlink:label="syn_EstimatedFairValueOfInducementConsideration_637830600911398750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_EstimatedFairValueOfInducementConsideration_637830600911398750" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AccretionOfPreferredStockDeemedDividend" xlink:label="syn_AccretionOfPreferredStockDeemedDividend_637830600911398750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_AccretionOfPreferredStockDeemedDividend_637830600911398750" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="us-gaap_PreferredStockRedemptionTerms_637830600911398750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_PreferredStockRedemptionTerms_637830600911398750" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BrokerageCommissionPercentage" xlink:label="syn_BrokerageCommissionPercentage_637830600911398750" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_BrokerageCommissionPercentage_637830600911398750" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637830600911408751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637830600911408751" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637830600911408751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_637830600911408751" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockRedemptionDiscount" xlink:label="us-gaap_PreferredStockRedemptionDiscount_637830600911408751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_PreferredStockRedemptionDiscount_637830600911408751" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PreferredStockSharesConverted" xlink:label="syn_PreferredStockSharesConverted_637830600911408751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_PreferredStockSharesConverted_637830600911408751" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_InvestmentWarrantsExpirationDate1" xlink:label="syn_InvestmentWarrantsExpirationDate1_637830600911408751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_InvestmentWarrantsExpirationDate1_637830600911408751" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637830600911408751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637830600911408751" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement" xlink:label="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_637830600911418754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637830600911368749" xlink:to="syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement_637830600911418754" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Non-controlling Interest (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="us-gaap_NoncontrollingInterestAbstract_637458043501911141" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="us-gaap_MinorityInterestTable_637830600911418754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncontrollingInterestAbstract_637458043501911141" xlink:to="us-gaap_MinorityInterestTable_637830600911418754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911418754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable_637830600911418754" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911418754" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637830600911418754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911418754" xlink:to="us-gaap_RelatedPartyDomain_637830600911418754" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DrPimentelsMember" xlink:label="syn_DrPimentelsMember_637830600911418754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637830600911418754" xlink:to="syn_DrPimentelsMember_637830600911418754" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember_637830600911418754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637830600911418754" xlink:to="syn_CedarssinaiMedicalCenterMember_637830600911418754" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637830600911418754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable_637830600911418754" xlink:to="srt_OwnershipAxis_637830600911418754" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637830600911418754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637830600911418754" xlink:to="srt_OwnershipDomain_637830600911418754" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637830600911418754" xlink:to="syn_SYNBiomicsMember_637830600911428752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SyntheticBiomicsIncMember" xlink:label="syn_SyntheticBiomicsIncMember_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637830600911418754" xlink:to="syn_SyntheticBiomicsIncMember_637830600911428752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable_637830600911418754" xlink:to="srt_ConsolidationItemsAxis_637830600911428752" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis_637830600911428752" xlink:to="srt_ConsolidationItemsDomain_637830600911428752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationEliminationsMember" xlink:label="srt_ConsolidationEliminationsMember_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain_637830600911428752" xlink:to="srt_ConsolidationEliminationsMember_637830600911428752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable_637830600911418754" xlink:to="us-gaap_TypeOfArrangementAxis_637830600911428752" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637830600911428752" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911428752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPurchaseAgreementMember" xlink:label="syn_StockPurchaseAgreementMember_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911428752" xlink:to="syn_StockPurchaseAgreementMember_637830600911428752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="us-gaap_MinorityInterestLineItems_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestTable_637830600911418754" xlink:to="us-gaap_MinorityInterestLineItems_637830600911428752" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_637830600911428752" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_637830600911428752" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="syn_NumberOfCommonStockToBeIssued_637830600911428752" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_637830600911428752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued_637830600911428752" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_637830600911438753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty_637830600911438753" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637830600911438753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637830600911438753" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637830600911438753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637830600911438753" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FairValueOfSharesIssued" xlink:label="syn_FairValueOfSharesIssued_637830600911438753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="syn_FairValueOfSharesIssued_637830600911438753" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637830600911438753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_637830600911438753" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600911438753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_637830600911438753" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637830600911438753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MinorityInterestLineItems_637830600911428752" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637830600911438753" order="11" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Maturity analysis of operating leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_637830600911448753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_637830600911448753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_637830600911448753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_637830600911448753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_637830600911448753" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:label="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_637830600911448753" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_637830600911448753" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_637830600911448753" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_OperatingLeaseLiability_637830600911448753" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637830600911448753" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637830600911448753" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637830600911448753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_409462" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_637830600911448753" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails" xlink:type="extended" xlink:title="40702 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract" xlink:label="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_637054396824344909" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract_637054396824344909" xlink:to="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_QuarterlyInstallmentsPaymentPeriodAxis" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodAxis_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" xlink:to="syn_QuarterlyInstallmentsPaymentPeriodAxis_637830600911458753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_QuarterlyInstallmentsPaymentPeriodDomain" xlink:label="syn_QuarterlyInstallmentsPaymentPeriodDomain_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodAxis_637830600911458753" xlink:to="syn_QuarterlyInstallmentsPaymentPeriodDomain_637830600911458753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FirstYearMember" xlink:label="syn_FirstYearMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodDomain_637830600911458753" xlink:to="syn_FirstYearMember_637830600911458753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SecondYearMember" xlink:label="syn_SecondYearMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodDomain_637830600911458753" xlink:to="syn_SecondYearMember_637830600911458753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ThirdYearMember" xlink:label="syn_ThirdYearMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_QuarterlyInstallmentsPaymentPeriodDomain_637830600911458753" xlink:to="syn_ThirdYearMember_637830600911458753" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" xlink:to="us-gaap_TypeOfArrangementAxis_637830600911458753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637830600911458753" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911458753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PhaseIClinicalTrialsMember" xlink:label="syn_PhaseIClinicalTrialsMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911458753" xlink:to="syn_PhaseIClinicalTrialsMember_637830600911458753" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PhaseIiiClinicalTrialsMember" xlink:label="syn_PhaseIiiClinicalTrialsMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911458753" xlink:to="syn_PhaseIiiClinicalTrialsMember_637830600911458753" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NdaSubmissionInUsMember" xlink:label="syn_NdaSubmissionInUsMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911458753" xlink:to="syn_NdaSubmissionInUsMember_637830600911458753" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EuropeanMedicinesAgencyApprovalMember" xlink:label="syn_EuropeanMedicinesAgencyApprovalMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911458753" xlink:to="syn_EuropeanMedicinesAgencyApprovalMember_637830600911458753" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_RegulatoryApprovalInAsianCountryMember" xlink:label="syn_RegulatoryApprovalInAsianCountryMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911458753" xlink:to="syn_RegulatoryApprovalInAsianCountryMember_637830600911458753" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StockPurchaseAgreementMember" xlink:label="syn_StockPurchaseAgreementMember_637830600911458753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911458753" xlink:to="syn_StockPurchaseAgreementMember_637830600911458753" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ClinicalTrialAgreementMember" xlink:label="syn_ClinicalTrialAgreementMember_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637830600911458753" xlink:to="syn_ClinicalTrialAgreementMember_637830600911468755" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" xlink:to="us-gaap_BusinessAcquisitionAxis_637830600911468755" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637830600911468755" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637830600911468755" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_PrevAbrLlcMember" xlink:label="syn_PrevAbrLlcMember_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637830600911468755" xlink:to="syn_PrevAbrLlcMember_637830600911468755" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" xlink:to="srt_TitleOfIndividualAxis_637830600911468755" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637830600911468755" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911468755" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StevenAShallcrossMember" xlink:label="syn_StevenAShallcrossMember_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911468755" xlink:to="syn_StevenAShallcrossMember_637830600911468755" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_Dr.SlimanMember" xlink:label="syn_Dr.SlimanMember_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911468755" xlink:to="syn_Dr.SlimanMember_637830600911468755" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_637830600911468755" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_637830600911468755" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637830600911468755" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="us-gaap_LicensingAgreementsMember_637830600911468755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637830600911468755" xlink:to="us-gaap_LicensingAgreementsMember_637830600911468755" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_637830600911478752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_637830600911468755" xlink:to="us-gaap_PatentsMember_637830600911478752" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637830600911478752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637830600911478752" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637830600911478752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_637830600911478752" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637830600911478752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:label="us-gaap_LeaseAgreementsMember_637830600911478752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_637830600911478752" xlink:to="us-gaap_LeaseAgreementsMember_637830600911478752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911478752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911478752" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637830600911478752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911478752" xlink:to="us-gaap_RelatedPartyDomain_637830600911478752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CedarssinaiMedicalCenterMember" xlink:label="syn_CedarssinaiMedicalCenterMember_637830600911478752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637830600911478752" xlink:to="syn_CedarssinaiMedicalCenterMember_637830600911478752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637830600911478752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" xlink:to="srt_OwnershipAxis_637830600911478752" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637830600911478752" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637830600911478752" xlink:to="srt_OwnershipDomain_637830600911478752" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_SYNBiomicsMember" xlink:label="syn_SYNBiomicsMember_637830600911488754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637830600911478752" xlink:to="syn_SYNBiomicsMember_637830600911488754" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems" xlink:label="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable_637830600911458753" xlink:to="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseAgreementAnnualPaymentsDue" xlink:label="syn_LicenseAgreementAnnualPaymentsDue_637830600911488754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_LicenseAgreementAnnualPaymentsDue_637830600911488754" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_LicenseAgreementFinalPaymentDue" xlink:label="syn_LicenseAgreementFinalPaymentDue_637830600911488754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_LicenseAgreementFinalPaymentDue_637830600911488754" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ResearchAgreementFixedFee" xlink:label="syn_ResearchAgreementFixedFee_637830600911488754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_ResearchAgreementFixedFee_637830600911488754" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_MilestonePayment" xlink:label="syn_MilestonePayment_637830600911488754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_MilestonePayment_637830600911488754" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637830600911488754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_SharesIssuedPricePerShare_637830600911488754" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalCashPaymentForLicenseAgreement" xlink:label="syn_AdditionalCashPaymentForLicenseAgreement_637830600911488754" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_AdditionalCashPaymentForLicenseAgreement_637830600911488754" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_UnregisteredSharesIssuedToLicenseAgreement" xlink:label="syn_UnregisteredSharesIssuedToLicenseAgreement_637830600911498751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_UnregisteredSharesIssuedToLicenseAgreement_637830600911498751" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalConsiderationPayable" xlink:label="syn_AdditionalConsiderationPayable_637830600911498751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_AdditionalConsiderationPayable_637830600911498751" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees_637830600911498751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_PaymentsForFees_637830600911498751" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911498751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637830600911498751" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OptionsToBeReceivedCommonStockShares" xlink:label="syn_OptionsToBeReceivedCommonStockShares_637830600911498751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_OptionsToBeReceivedCommonStockShares_637830600911498751" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637830600911498751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637830600911498751" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CostOfLivingAdjustmentsPercentage" xlink:label="syn_CostOfLivingAdjustmentsPercentage_637830600911508756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_CostOfLivingAdjustmentsPercentage_637830600911508756" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1_637830600911508756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_ConversionOfStockSharesConverted1_637830600911508756" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_637830600911508756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_637830600911508756" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_637830600911508756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_637830600911508756" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637830600911508756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637830600911508756" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeIssued" xlink:label="syn_NumberOfCommonStockToBeIssued_637830600911508756" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_NumberOfCommonStockToBeIssued_637830600911508756" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_AdditionalNumberOfCommonStockToBeIssued" xlink:label="syn_AdditionalNumberOfCommonStockToBeIssued_637830600911518753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_AdditionalNumberOfCommonStockToBeIssued_637830600911518753" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NumberOfCommonStockToBeHeldByRelatedParty" xlink:label="syn_NumberOfCommonStockToBeHeldByRelatedParty_637830600911518753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_NumberOfCommonStockToBeHeldByRelatedParty_637830600911518753" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_FairValueOfSharesIssued" xlink:label="syn_FairValueOfSharesIssued_637830600911518753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_FairValueOfSharesIssued_637830600911518753" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_637830600911518753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_OperatingLeaseCost_637830600911518753" order="22" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_637830600911528759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_OperatingLeasePayments_637830600911528759" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NonCashAdditionOfRightOfUseAssets" xlink:label="syn_NonCashAdditionOfRightOfUseAssets_637830600911528759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_NonCashAdditionOfRightOfUseAssets_637830600911528759" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_EstimatedResearchCosts" xlink:label="syn_EstimatedResearchCosts_637830600911528759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="syn_EstimatedResearchCosts_637830600911528759" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637830600911528759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637830600911528759" order="26" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637830600911528759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637830600911528759" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToEmployees" xlink:label="us-gaap_PaymentsToEmployees_637830600911528759" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems_637830600911488754" xlink:to="us-gaap_PaymentsToEmployees_637830600911528759" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_637830600911538755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_637830600911538755" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637830600911538755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637830600911538755" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_637830600911538755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_637830600911538755" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_637830600911538755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_637830600911538755" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_637830600911538755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_637830600911538755" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637830600911538755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637830600911538755" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637830600911538755" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637830600911538755" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637830600911548748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637830600911548748" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637830600911548748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826070373" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637830600911548748" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="40802 - Disclosure - Income Taxes - Deferred Tax Assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637054396826090364" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826090364" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStocksIssuedForServices" xlink:label="syn_DeferredTaxAssetsStocksIssuedForServices_637830600911548748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="syn_DeferredTaxAssetsStocksIssuedForServices_637830600911548748" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_637830600911548748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_637830600911548748" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram" xlink:label="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_637830600911548748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram_637830600911548748" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStockIssuedForlicenseAgreement" xlink:label="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement_637830600911548748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="syn_DeferredTaxAssetsStockIssuedForlicenseAgreement_637830600911548748" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsStockIssuedForMilestonePayment" xlink:label="syn_DeferredTaxAssetsStockIssuedForMilestonePayment_637830600911548748" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="syn_DeferredTaxAssetsStockIssuedForMilestonePayment_637830600911548748" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee" xlink:label="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee_637830600911558757" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637830600911558757" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="us-gaap_DeferredTaxAssetsGross_637830600911558757" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637830600911558757" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637830600911548748" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_637830600911558757" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="40803 - Disclosure - Income Taxes - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637054396826110262" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncomeTaxesTable" xlink:label="syn_IncomeTaxesTable_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637054396826110262" xlink:to="syn_IncomeTaxesTable_637830600911558757" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxesTable_637830600911558757" xlink:to="srt_StatementScenarioAxis_637830600911558757" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637830600911558757" xlink:to="srt_ScenarioUnspecifiedDomain_637830600911558757" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637830600911558757" xlink:to="us-gaap_ScenarioPlanMember_637830600911558757" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_637830600911558757" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxesTable_637830600911558757" xlink:to="us-gaap_TaxPeriodAxis_637830600911558757" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis_637830600911558757" xlink:to="us-gaap_TaxPeriodDomain_637830600911568751" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2018Member" xlink:label="us-gaap_TaxYear2018Member_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_637830600911568751" xlink:to="us-gaap_TaxYear2018Member_637830600911568751" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxYear2020Member" xlink:label="us-gaap_TaxYear2020Member_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_637830600911568751" xlink:to="us-gaap_TaxYear2020Member_637830600911568751" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_IncomeTaxLineItems" xlink:label="syn_IncomeTaxLineItems_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxesTable_637830600911558757" xlink:to="syn_IncomeTaxLineItems_637830600911568751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxLineItems_637830600911568751" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637830600911568751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxLineItems_637830600911568751" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_637830600911568751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxLineItems_637830600911568751" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_637830600911568751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxLineItems_637830600911568751" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637830600911568751" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxLineItems_637830600911568751" xlink:to="us-gaap_DeferredTaxAssetsNet_637830600911568751" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxLineItems_637830600911568751" xlink:to="us-gaap_OperatingLossCarryforwards_637830600911568751" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OperatingLossCarryforwardsLimitationOnUse" xlink:label="syn_OperatingLossCarryforwardsLimitationOnUse_637830600911568751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxLineItems_637830600911568751" xlink:to="syn_OperatingLossCarryforwardsLimitationOnUse_637830600911568751" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OperatingLossCarryforwardsExpireDate" xlink:label="syn_OperatingLossCarryforwardsExpireDate_637830600911578743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxLineItems_637830600911568751" xlink:to="syn_OperatingLossCarryforwardsExpireDate_637830600911578743" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637830600911578743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="syn_IncomeTaxLineItems_637830600911568751" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637830600911578743" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Subsequent Events (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637830600911578743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_637830600911578743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637830600911578743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637830600911578743" xlink:to="us-gaap_SubsequentEventTypeAxis_637830600911578743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637830600911578743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637830600911578743" xlink:to="us-gaap_SubsequentEventTypeDomain_637830600911578743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637830600911578743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637830600911578743" xlink:to="us-gaap_SubsequentEventMember_637830600911578743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_637830600911578743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637830600911578743" xlink:to="srt_TitleOfIndividualAxis_637830600911578743" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911578743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_637830600911578743" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911578743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_StevenAShallcrossMember" xlink:label="syn_StevenAShallcrossMember_637830600911578743" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911578743" xlink:to="syn_StevenAShallcrossMember_637830600911578743" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_VcnPrivateMember" xlink:label="syn_VcnPrivateMember_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_637830600911578743" xlink:to="syn_VcnPrivateMember_637830600911588746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637830600911578743" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911588746" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637830600911588746" xlink:to="us-gaap_RelatedPartyDomain_637830600911588746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OtherFirstIndicationMember" xlink:label="syn_OtherFirstIndicationMember_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637830600911588746" xlink:to="syn_OtherFirstIndicationMember_637830600911588746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_OtherSecondIndicationMember" xlink:label="syn_OtherSecondIndicationMember_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637830600911588746" xlink:to="syn_OtherSecondIndicationMember_637830600911588746" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637830600911578743" xlink:to="srt_RangeAxis_637830600911588746" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637830600911588746" xlink:to="srt_RangeMember_637830600911588746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637830600911588746" xlink:to="srt_MaximumMember_637830600911588746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637830600911578743" xlink:to="us-gaap_BusinessAcquisitionAxis_637830600911588746" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis_637830600911588746" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_637830600911588746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_GrifolsInnovationMember" xlink:label="syn_GrifolsInnovationMember_637830600911588746" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637830600911588746" xlink:to="syn_GrifolsInnovationMember_637830600911588746" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_NewTechnologiesMember" xlink:label="syn_NewTechnologiesMember_637830600911598741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain_637830600911588746" xlink:to="syn_NewTechnologiesMember_637830600911598741" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637830600911598741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637830600911578743" xlink:to="us-gaap_SubsequentEventLineItems_637830600911598741" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_637830600911598741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1_637830600911598741" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_637830600911598741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_637830600911598741" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_637830600911598741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage_637830600911598741" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ConsiderationPurchasePaid" xlink:label="syn_ConsiderationPurchasePaid_637830600911598741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="syn_ConsiderationPurchasePaid_637830600911598741" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_637830600911598741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_637830600911598741" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_CashPaymentsExistingLiabilities" xlink:label="syn_CashPaymentsExistingLiabilities_637830600911598741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="syn_CashPaymentsExistingLiabilities_637830600911598741" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_ClosingFinanceCosts" xlink:label="syn_ClosingFinanceCosts_637830600911608741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="syn_ClosingFinanceCosts_637830600911608741" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_637830600911608741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_637830600911608741" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePaymentsSafeToProceed" xlink:label="syn_BusinessCombinationMilestonePaymentsSafeToProceed_637830600911608741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="syn_BusinessCombinationMilestonePaymentsSafeToProceed_637830600911608741" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePaymentsFirstPatientDosed" xlink:label="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed_637830600911608741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="syn_BusinessCombinationMilestonePaymentsFirstPatientDosed_637830600911608741" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePayments" xlink:label="syn_BusinessCombinationMilestonePayments_637830600911608741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="syn_BusinessCombinationMilestonePayments_637830600911608741" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="syn-20211231.xsd#syn_BusinessCombinationMilestonePaymentsBlaApproval" xlink:label="syn_BusinessCombinationMilestonePaymentsBlaApproval_637830600911608741" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637830600911598741" xlink:to="syn_BusinessCombinationMilestonePaymentsBlaApproval_637830600911608741" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441624248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 16, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Synthetic Biologics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3808303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9605 Medical Center Drive, Ste. 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-4364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SYN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,437,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000894158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Potomac, Maryland<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453442685608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 67,325<span></span>
</td>
<td class="nump">$ 6,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,533<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">68,858<span></span>
</td>
<td class="nump">7,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">1,383<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DepositsAndOtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">70,365<span></span>
</td>
<td class="nump">8,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">524<span></span>
</td>
<td class="nump">886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,928<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued employee benefits</a></td>
<td class="nump">978<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">3,554<span></span>
</td>
<td class="nump">2,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability - long term</a></td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">4,957<span></span>
</td>
<td class="nump">3,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Series A Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity (Deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series B Preferred Stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at September 30, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">336,560<span></span>
</td>
<td class="nump">240,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(271,284)<span></span>
</td>
<td class="num">(248,094)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)</a></td>
<td class="nump">65,408<span></span>
</td>
<td class="num">(4,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,773)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Stockholders' Equity (Deficit)</a></td>
<td class="nump">65,408<span></span>
</td>
<td class="num">(7,540)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 70,365<span></span>
</td>
<td class="nump">$ 8,410<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DepositsAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DepositsAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441579896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary Equity, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Temporary Equity, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Temporary Equity, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, Shares Authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, Shares Issued</a></td>
<td class="nump">132,044,866<span></span>
</td>
<td class="nump">29,252,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, Shares Outstanding</a></td>
<td class="nump">132,042,538<span></span>
</td>
<td class="nump">29,249,925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441865400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Costs and Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 6,474<span></span>
</td>
<td class="nump">$ 5,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,800<span></span>
</td>
<td class="nump">5,131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Costs and Expenses</a></td>
<td class="nump">14,274<span></span>
</td>
<td class="nump">10,160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(14,274)<span></span>
</td>
<td class="num">(10,160)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="num">(14,268)<span></span>
</td>
<td class="num">(10,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss Attributable to Non-controlling Interest</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries</a></td>
<td class="num">(14,267)<span></span>
</td>
<td class="num">(10,043)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockPriceAdjustment', window );">Effect of Series A Preferred Stock Price adjustment</a></td>
<td class="num">(7,402)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(880)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss Attributable to Common Stockholders</a></td>
<td class="num">$ (23,189)<span></span>
</td>
<td class="num">$ (12,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss Per Share - Basic</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss Per Share - Dilutive</a></td>
<td class="num">$ (0.19)<span></span>
</td>
<td class="num">$ (0.66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding during the period - basic</a></td>
<td class="nump">121,875,042<span></span>
</td>
<td class="nump">19,011,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding during the period - dilutive</a></td>
<td class="nump">121,875,042<span></span>
</td>
<td class="nump">19,011,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred Stock Dividends, Income Statement Impact</a></td>
<td class="num">$ (24)<span></span>
</td>
<td class="num">$ (254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockPriceAdjustment', window );">Effect of Series A Preferred Stock Price adjustment</a></td>
<td class="num">(7,402)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred Stock Dividends, Income Statement Impact</a></td>
<td class="num">(1,496)<span></span>
</td>
<td class="num">(1,380)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockPriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of preferred stock price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockPriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of warrant exercise price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453436980872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders (Deficit) Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Common Stock </div>
<div>Series B Preferred</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>APIC </div>
<div>Series B Preferred</div>
</th>
<th class="th">
<div>APIC </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>APIC</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series B Preferred</div>
</th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Non-Controlling InterestAccumulated Non-Controlling Stockholders' </div>
<div>Series B Preferred</div>
</th>
<th class="th">
<div>Non-Controlling InterestAccumulated Non-Controlling Stockholders' </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Non-Controlling InterestAccumulated Non-Controlling Stockholders'</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series B Preferred</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Series B Preferred</div></th>
<th class="th"><div>Series A Preferred Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodAtMarketOfferingValue', window );">Stock issued under "at-the-market" offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodAtMarketOfferingShare', window );">Stock issued under "at-the-market" offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,256,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Series A Preferred Stock Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueOfSynBiomicsStock', window );">Issuance of SYN Biomics Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdjustmentsToEffectOfWarrantExercisePrice', window );">Effect of Warrant exercise price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStock', window );">Conversion of Series B Preferred Stock to Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (2,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStockShares', window );">Conversion of Series B Preferred Stock to Common (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,186,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,665)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,116)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248,094)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,773)<span></span>
</td>
<td class="nump">2,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(235,537)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,878)<span></span>
</td>
<td class="nump">$ 4,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,057)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,249,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,806,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodAtMarketOfferingValue', window );">Stock issued under "at-the-market" offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodAtMarketOfferingShare', window );">Stock issued under "at-the-market" offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,685,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Series A Preferred Stock Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStock', window );">Conversion of Series B Preferred Stock to Common</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,497)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,477)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConversionOfSeriesBPreferredStockToCommonStockShares', window );">Conversion of Series B Preferred Stock to Common (in shares)</a></td>
<td class="nump">3,454,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,268)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Reversal of noncontrolling interest due to return of Syn Biomics shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,774)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,774<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants Exercised (In shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,655,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdjustmentsToEffectOfPreferredStockPrice', window );">Effect of Series A Preferred Stock price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,402)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_Conversionofseriesbpreferredstocktocommonstock', window );">Conversion of Series A Preferred Stock to Common</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_Conversionofseriesapreferredstocktocommonstockshares', window );">Conversion of Series A Preferred Stock to Common (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,996,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(271,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,408<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (248,094)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,773)<span></span>
</td>
<td class="nump">$ 2,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,540)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,042,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,249,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdjustmentsToEffectOfPreferredStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of adjustment to effect of preferred stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AdjustmentsToEffectOfPreferredStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdjustmentsToEffectOfWarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount changes in effect of warrant exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AdjustmentsToEffectOfWarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ConversionOfSeriesBPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents conversion of preferred stock to common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ConversionOfSeriesBPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ConversionOfSeriesBPreferredStockToCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of conversion of series B preferred stock to common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ConversionOfSeriesBPreferredStockToCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_Conversionofseriesapreferredstocktocommonstockshares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred shares to common</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_Conversionofseriesapreferredstocktocommonstockshares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_Conversionofseriesbpreferredstocktocommonstock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion Of Series B Preferred Stock To Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_Conversionofseriesbpreferredstocktocommonstock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodAtMarketOfferingShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period at the market offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodAtMarketOfferingShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodAtMarketOfferingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period at the market offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodAtMarketOfferingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueOfSynBiomicsStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of new stock of syn biomics stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodValueOfSynBiomicsStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453440019928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (14,268,000)<span></span>
</td>
<td class="num">$ (10,116,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">416,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SubsidiaryStockIssuesToVendor', window );">Subsidiary stock issuances to vendor</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">178,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="nump">201,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">174,000<span></span>
</td>
<td class="num">(326,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseRightOfUseAssets', window );">Right of use asset</a></td>
<td class="nump">166,000<span></span>
</td>
<td class="nump">141,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(363,000)<span></span>
</td>
<td class="num">(1,429,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,004,000<span></span>
</td>
<td class="num">(851,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued employee benefits</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncreaseDecreaseLeaseLiability', window );">Lease liability</a></td>
<td class="num">(216,000)<span></span>
</td>
<td class="num">(249,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(12,890,000)<span></span>
</td>
<td class="num">(12,168,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(14,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used in Investing Activities</a></td>
<td class="num">(14,000)<span></span>
</td>
<td class="num">(9,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from "at the market" stock issuance</a></td>
<td class="nump">65,960,000<span></span>
</td>
<td class="nump">3,359,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from issuance of common stock for warrant exercises</a></td>
<td class="nump">8,042,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">74,002,000<span></span>
</td>
<td class="nump">3,359,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">61,098,000<span></span>
</td>
<td class="num">(8,818,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">6,227,000<span></span>
</td>
<td class="nump">15,045,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">67,325,000<span></span>
</td>
<td class="nump">6,227,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockPriceAdjustment', window );">Preferred stock price adjustment</a></td>
<td class="nump">7,402,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ReturnOfSynBiomicsStock', window );">Return of SYN Biomics Stock</a></td>
<td class="nump">2,774,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeemedDividendsWithBeneficialConversionFeature', window );">Deemed dividends for accretion of Series B Preferred Stock discount</a></td>
<td class="nump">1,496,000<span></span>
</td>
<td class="nump">1,380,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets from operating lease</a></td>
<td class="nump">1,270,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockPaidinkind', window );">In-kind dividends paid in preferred stock</a></td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">254,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Stock</a></td>
<td class="nump">12,822,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockPriceAdjustment', window );">Preferred stock price adjustment</a></td>
<td class="nump">7,402,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of Stock</a></td>
<td class="nump">2,477,000<span></span>
</td>
<td class="nump">2,284,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeemedDividendsWithBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Deemed Dividends With Beneficial Conversion Feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DeemedDividendsWithBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An amount of Increase decrease right of use assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_IncreaseDecreaseLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncreaseDecreaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An amount of increase decrease in lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_IncreaseDecreaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockPriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of preferred stock price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockPriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ReturnOfSynBiomicsStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Return of SYN Biomics Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ReturnOfSynBiomicsStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_SubsidiaryStockIssuesToVendor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of subsidiary stock issued in lieu of cash for services contributed to the entity. Value of the subsidiary stock issued includes, but is not limited to, services contributed by vendors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_SubsidiaryStockIssuesToVendor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of warrant exercise price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockPaidinkind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockPaidinkind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439858152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Nature of Operations and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Nature of Operations and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Nature of Operations and Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Organization and Nature of Operations and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Synthetic Biologics, Inc. (the &#8220;Company&#8221; or &#8220;Synthetic Biologics&#8221;) is a diversified clinical-stage company operating in one segment currently developing therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company&#8217;s lead clinical development candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) <i style="font-style:italic;">Clostridioides difficile</i> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under Current Good Manufacturing Practice (cGMP) conditions and intended to treat both local GI and systemic diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company was also developing SYN-010 to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). On September 30, 2020, Cedars Sinai Medical Center (CSMC) (the Company&#8217;s SYN-010 clinical development partner) informed the Company that it agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients. Based on the results of a planned interim futility analysis, it was concluded that although SYN-010 was well tolerated, it was unlikely to meet its primary endpoint by the time enrollment is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate Structure and Basis of Presentation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company had eight subsidiaries, Pipex Therapeutics,&#160;Inc. (&#8220;Pipex Therapeutics&#8221;), Effective Pharmaceuticals,&#160;Inc. (&#8220;EPI&#8221;), Solovax,&#160;Inc. (&#8220;Solovax&#8221;), CD4 Biosciences,&#160;Inc. (&#8220;CD4&#8221;), Epitope Pharmaceuticals,&#160;Inc. (&#8220;Epitope&#8221;), Healthmine,&#160;Inc. (&#8220;Healthmine&#8221;), Putney Drug Corp. (&#8220;Putney&#8221;) and Synthetic Biomics,&#160;Inc. (&#8220;SYN Biomics&#8221;). Pipex Therapeutics, EPI, Healthmine and Putney are wholly owned, and Solovax, CD4, Epitope and SYN Biomics are majority-owned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For financial reporting purposes, the outstanding common stock of the Company is that of Synthetic Biologics,&#160;Inc. All statements of operations, (deficit) equity and cash flows for each of the entities are presented as consolidated. All subsidiaries were formed under the laws of the State of Delaware on January&#160;8, 2001, except for EPI, which was incorporated in Delaware on December&#160;12, 2000, Epitope which was incorporated in Delaware in January&#160;2002, Putney which was incorporated in Delaware in November&#160;2006, Healthmine which was incorporated in Delaware in December&#160; 2007 and SYN Biomics which was incorporated in Nevada in December&#160;2013.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company has a significant accumulated deficit, and with the exception of the three months ended June&#160;30, 2010 and the three months ended December&#160;31, 2017, the Company has experienced significant losses and incurred negative cash flows since inception. The Company expects to continue incurring losses for the foreseeable future, with the recognition of revenue being contingent on successful phase 3 clinical trials and requisite approvals by the FDA or foreign equivalents. Historically, the Company has financed its operations primarily through public and private sales of its common stock and a private placement of its preferred stock, and it expects to continue to seek to obtain required capital in a similar manner. The Company has spent, and expects to continue to spend, a substantial amount of funds in connection with implementing its business strategy, including planned product development efforts, clinical trials and research and discovery efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Organization and Nature of Operations and Basis of Presentation&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cash and cash equivalents totaled approximately $67.3 million as of December 31, 2021, which includes the net proceeds of approximately $66 million from sales of its Common Stock in &#8220;at-the-market&#8221; (ATM) equity offerings during 2021 and cash proceeds of approximately $8.0 million through the exercise of a portion of the October 2018 warrants. With these additional sources of liquidity<span style="color:#333333;background:#ffffff;">,</span> the Company believes it will be able to fund its operations through the next twelve months from the issuance date of these financial statements. Management believes its plan, which includes the further development of SYN-020, additional testing of SYN-004 (ribaxamase) and the advancement of VCN-01 will allow the Company to meet its financial obligations, further advance key products, and maintain the Company&#8217;s planned operations for at least one year from the issuance date of these consolidated financial statements. If necessary, the Company may attempt to utilize the ATM or seek to raise additional capital on the open market, neither of which is guaranteed. Use of the ATM is limited by certain restrictions and management&#8217;s plan does not rely on additional capital from either of these sources. If the Company is not able to obtain additional capital (which is not assured at this time), our long-term business plan may not be accomplished and we may be forced to cease certain development activities. More specifically, the completion of any later stage clinical trial will require significant financing or a significant partnership.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453444699256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All intercompany transactions and accounts have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants, preferred stock and stock options granted for services or compensation, respectively, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Non-controlling Interest</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s non-controlling interest represents the minority stockholder&#8217;s ownership interest related to the Company&#8217;s subsidiary, SYN Biomics. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#8217;s common stockholders on the face of the Consolidated Statements of Operations. On September&#160;5, 2018, the Company entered into an agreement with the minority stockholder for an investigator-sponsored Phase 2 clinical study of SYN-010. Prior to this agreement and IRB approval in December&#160;2018, the Company&#8217;s equity interest in SYN Biomics was 88.5% and the non-controlling stockholder&#8217;s interest was 11.5%. In consideration of the support, the Company issued additional shares of stock to the minority stockholder, resulting in the Company&#8217;s equity interest in SYN Biomics being 83.0% and the non-controlling stockholder&#8217;s interest is 17.0%. During 2021, the minority stockholder returned its shares of SYN Bionics to the Company for no consideration. The Company's interest in SYN Biomics is now 100%. This is reflected in the Consolidated Statements of Equity (Deficit).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. These conditions may not only limit the Company&#8217;s access to capital, but also make it difficult for its customers, its vendors and its ability to accurately forecast and plan future business activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three&#160;months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Asset Description</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:top;width:48.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Office equipment and furniture</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3&#160;&#8211;&#160;5&#160;years</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements and fixtures</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lesser of estimated useful life or lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense was approximately $87,000 and $201,000 for the&#160;years ended December&#160;31, 2021 and 2020, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts with any gain or loss reported in the consolidated statement of operations. Repairs and maintenance are charged to expense as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews property and equipment for impairment to determine if assets are impaired due to obsolescence. As a result of this review, there was no impairment recognized for the&#160;years ended December&#160;31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the year ended December 31, 2021 includes the effect of the Series A preferred stock price adjustment of $7.4 million, the accretion of the Series B preferred discount of $1.5 million on converted shares and Series A preferred stock accrued dividends of $0.1 million. Net loss attributable to common stockholders for the year ended December 31, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $1.4 million on converted shares, the effect of warrant exercise adjustment of $1.0 million and Series A preferred stock accrued dividends of $0.3 million. The number of shares of common stock underlying Series A Preferred shares convertible to common stock that were excluded from the computation of the net loss per common share for the year ended December 31, 2020 was 678,258. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that was excluded from the computation of net loss per common share and for the year ended December 31, 2020 was 3,454,783. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share for the&#160;year ended December&#160;31, 2021 were 6,255,275 and 6,344,966, respectively, and for the&#160;year ended December&#160;31, 2020 were 3,997,418 and 18,000,713, respectively, because their effect is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries, stock-based compensation and related employee costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of our product candidates. Research and development expenses include external contract research organization (&#8220;CRO&#8221;) services. The Company makes payments to the CROs based on agreed upon terms and may include payments in advance of study services. The Company reviews and accrues CRO expenses based on services performed and relies on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. At December&#160;31, 2021 and 2020, the Company has accrued CRO expenses of $0.7 million, that are included in accrued expenses. The Company has prepaid CRO costs at December&#160;31, 2021 and 2020 of $0.5 million that are included in prepaid expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accounting Standards Codification (&#8220;ASC&#8221;) 820, <i style="font-style:italic;">Fair Value Measurement</i>, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are classified on a three-tier hierarchy as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 inputs: Inputs, other than quoted prices, that are observable either directly or indirectly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The carrying amounts of the Company&#8217;s short-term financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include money market accounts of $193,000 and $114,000 as of December&#160;31, 2021 and 2020, respectively, that are measured using Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In using this model, the fair value is determined by applying Level 3 inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions. The assumptions used in calculating the estimated fair value of the warrants represent the Company&#8217;s best estimates; however, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different. In 2021 and 2020, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#8217;s current stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2. Summary of Significant Accounting Policies&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Payment Arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date typically using the Black-Scholes option pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations, depending on the nature of the services provided.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Derivative Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The warrants issued in conjunction with the public offering of the Company&#8217;s securities in November&#160;2016 include a provision that if the Company were to enter into a certain transaction, as defined in the warrant agreement, the warrants would be purchased from the holder for cash. The provisions of these warrants preclude equity accounting treatment under ASC 815, <i style="font-style:italic;">Derivatives and Hedging.</i> Accordingly, the Company is required to record the warrants as liabilities at their fair value upon issuance and re-measure the fair value at each period end with the change in fair value recorded in the Consolidated Statement of Operations. When the warrants are exercised or cancelled, they are reclassified to equity. The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In November 2020, all liability-classified warrants expired. In 2019, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#8217;s current stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes deferred tax assets and liabilities based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the&#160;years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management assesses the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex tax laws of multiple jurisdictions. The Company records the related interest expense and penalties, if any, as tax expense in the tax provision. At December&#160;31, 2021 and 2020, the Company did not record any liabilities for uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements and Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, <i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (subtopic 815-40)</i>: <i style="font-style:italic;">Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</i>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity's own equity and improves and amends the related earnings per share guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company is currently assessing the impact of ASU 2020-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2021, the FASB issued Accounting Standards Update 2021-08 that address the accounting for Contract Assets and Liabilities from Contracts with Customers in a business combination (&#8220;ASU 2021-08&#8221;), with an effective date for SYN of January 1,2 2024 (earlier adoption permitted). ASU 2021-08 provides that existing contract assets and liabilities (including deferred costs to obtain and deferred revenue) are measured in a business combination under the measurement and recognition requirements of ASC 606. ASU 2021-08 should generally &#8220;result in an acquirer recognizing and measuring the acquired contract assets and liabilities consistent with how they were recognized and measured in the acquiree&#8217;s financial statements.&#8221; The Company is currently assessing the impact of ASU 2021-08 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439842952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Selected Balance Sheet Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. Selected Balance Sheet Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PREPAID EXPENSES AND OTHER CURRENT ASSETS (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid clinical research organizations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 470</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid consulting, subscriptions and other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock sales receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 469</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,707</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Prepaid CRO expense is classified as a current asset. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROPERTY AND EQUIPMENT (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 439</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,263</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,089)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 174</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ACCRUED EXPENSES (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vendor payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical consulting services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued manufacturing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 925</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ACCRUED EMPLOYEE BENEFITS (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued bonus expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 724</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 868</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439909672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation and Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation and Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. Stock-Based Compensation and Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March&#160;20, 2007, the Company&#8217;s Board of Directors approved the 2007 Stock Incentive Plan (the &#8220;2007 Stock Plan&#8221;) for the issuance of up to 71,429 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November&#160;2, 2007. The exercise price of stock options under the 2007 Stock Plan was determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 7,143. Options become exercisable over various periods from the date of grant, and generally expire ten&#160;years after the grant date. As of December&#160;31, 2021, there were 5,145 options issued and outstanding under the 2007 Stock Plan. There are no shares available to be issued under this plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#8220;2010 Stock Plan&#8221;) for the issuance of up to 85,714 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. From time to time the number of shares authorized for options was increased such that 4,000,000 million were authorized as of September 30, 2021. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company&#8217;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant and expire between five and ten&#160;years after the grant date. As of December&#160;31, 2021, there were 2,450,130 options issued and outstanding under the 2010 Stock Plan. There are no shares available to be issued under this plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 17, 2020, the stockholders approved and adopted the 2020 Stock Incentive Plan ("2020 Stock Plan") for the issuance of up to 4,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. As of December 31, 2021, there were 3,800,000 options issued and outstanding under the 2010 Stock Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of an employee&#8217;s termination, the Company will cease to recognize compensation expense for that employee. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized over the stated vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The assumptions used for the&#160;years ended December&#160;31, 2021 and 2020 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life of option (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected dividends&#160;&#8212;</i>The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation and Warrants&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected volatility</i>&#8212;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The expected volatility assumption is derived from the historical volatility of the Company&#8217;s common stock over a period approximately equal to the expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-free interest rate</i>&#8212;The assumed risk-free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected life of the option</i>&#8212;The period of time that the options granted are expected to remain unexercised. Options granted during the&#160;year have a maximum term of seven&#160;years. The Company estimates the expected life of the option term based on the weighted average life between the dates that options become fully vested and the maximum life of options granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">immediate vesting,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in full on one-year anniversary date of grant date,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">half vesting immediately and remaining over three&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">quarterly over three&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">annually over three&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-third immediate vesting and remaining annually over two&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-half immediate vesting and remaining over nine&#160;months,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-quarter immediate vesting and remaining over three&#160;years,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one-quarter immediate vesting and remaining over 33&#160;months,</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monthly over one year, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monthly over three&#160;years.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the&#160;years ended December&#160;31, 2021 and 2020, the Company granted 2,260,000 and 1,540,000 options to employees and directors having an approximate fair value of $0.5 million and $0.4 million based upon the Black-Scholes option pricing model, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees for the&#160;years ended December&#160;31, 2021 and 2020 was $204,000 and $213,000, respectively. Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to consultants for the&#160;years ended December&#160;31, 2021 and 2020 was $212,000 and $137,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation and Warrants&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of stock option activity for the&#160;years ended December&#160;31, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;Exercise&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;- December&#160;31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,502,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.51 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,353</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,540,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,944)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;- December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,997,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.09 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,260,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,143)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;-December&#160;31, 2021&#160;- outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,255,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.58 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;-&#160;&#160;December&#160;31, 2021&#160;- exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,786,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.44 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grant date fair value of options granted&#160;-&#160;December&#160;31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 501,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average grant date fair value - December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grant date fair value of options granted&#160;- December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 412,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average grant date fair value&#160;- December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The options outstanding and exercisable at December&#160;31, 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;width:62.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:24.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00&#160;&#8211;&#160;$40.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,189,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,720,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41.00&#160;&#8211;&#160;$70.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2&#160;years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">71.00&#160;&#8211;&#160;$102.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2&#160;years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, total unrecognized stock-based compensation expense related to stock options was $771,000, which is expected to be expensed through February 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The FASB&#8217;s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits in 2021 or 2020. Cash received from option exercises under the Company&#8217;s stock-based compensation plans for the&#160;years ended December&#160;31, 2021 and 2020 was zero.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation and Warrants&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October&#160;15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i)&#160;2,520,000 Class&#160;A Units (the &#8220;Class&#160;A Units&#8221;), with each Class&#160;A Unit consisting of one share of common stock, and one five-year warrant to purchase one share of common stock at an initial exercise price of $1.38 per share, which subsequently was reduced to $0.69 per share (each a &#8220;Warrant&#8221; and collectively, the &#8220;Warrants&#8221;), with each Class&#160;A Unit to be offered to the public at a public offering price of $1.15, and (ii)&#160;15,723 Class&#160;B Units (the &#8220;Class&#160;B Units&#8221;, and together with the Class&#160;A Units, the &#8220;Units&#8221;), with each Class&#160;B Unit offered to the public at a public offering price of $1,000 per Class&#160;B Unit and consisting of one share of the Company&#8217;s Series&#160;B Convertible Preferred Stock (the &#8220;Series&#160;B Preferred Stock&#8221;), with a stated value of $1,000 and convertible into shares of common stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series&#160;B Preferred Stock convertible into an aggregate of 13,672,173 shares of common stock, and issued with an aggregate of 13,672,173 Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of the Company&#8217;s common stock, $0.001 par value per share (the &#8220;Common Stock&#8221;), to $0.69 per Warrant per full share of common stock in accordance with the anti-dilution terms of the Warrant. The reduction was the result of the issuance of shares of common stock by the Company through its &#8220;at the market offering&#8221; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend of $0.9 million during the year ended December 31, 2020, which reduces the income available to common stockholders. In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the &#8220;Underwriters&#8221;), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the &#8220;Over-allotment Option&#8221;) to purchase up to an additional 2,428,825 shares of common stock and/or additional Warrants to purchase an additional 2,428,825 shares of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the Warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations. During the year ended December 31, 2021, 11,655,747 warrants were exercised for cash proceeds of $8.0 million. There were no warrants exercised during the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 18, 2016, the Company completed a public offering of 714,286 shares of common stock in combination with accompanying warrants to purchase an aggregate of 1,428,571 shares of the common stock. The stock and warrants were sold in combination, with two warrants for each share of common stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase one share of common stock. The purchase price for each share of common stock and accompanying warrants was $35.00. The shares of common stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants is $50.05 and the per share exercise price of the Series B warrants is $60.20, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants could be exercised at any time on or after the date of issuance. The Series A warrants were exercisable until the four-year anniversary of the issuance date and expired November 16, 2020. The Series B warrants expired December 31, 2017 and none were exercised prior to expiration. The warrants included a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $15.7 million and changes in estimated fair value were recorded as non-cash income or expense in the Company&#8217;s Statement of Operations at each subsequent period. At December 31, 2019, the fair value of the warrant liability was $100. The warrants were valued on the date of grant and on each remeasurement period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">4. Stock-Based Compensation and Warrants&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of all warrant activity for the Company for the years ended December 31, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,714,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.24</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (714,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50.05</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,000,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,655,747)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 26, 2017, the Company entered into a consulting agreement for advisory services for a period of six months. As compensation for such services, the consultant was paid an upfront payment, is paid a monthly fee and on January 24, 2018 was issued a warrant exercisable for 714 shares of the Company&#8217;s common stock on the date of issue. The warrant is equity classified and the fair value of the warrant approximated $9,000 and was measured using the Black-Scholes option pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A summary of all outstanding and exercisable warrants as of December 31, 2021 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.99&#160;years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.78&#160;years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.78 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453440822264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series B Preferred Stock </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October&#160;15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i)&#160;2,520,000 Class&#160;A Units, with each Class&#160;A Unit offered to the public at a public offering price of $1.15, and (ii)&#160;15,723 Class&#160;B Units, with each Class&#160;B Unit offered to the public at a public offering price of $1,000 per Class&#160;B Unit and consisting of one share of the Company&#8217;s Series&#160;B Preferred Stock, with a stated value of $1,000 and convertible into shares of common stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series&#160;B Preferred Stock convertible into an aggregate of 13,672,173 shares of common stock, and issued with an aggregate of 13,672,173 October&#160;2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series&#160;B Preferred Stock discount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October&#160;10, 2018, the Company granted the Underwriters a 45 day option (the &#8220;Over-allotment Option&#8221;) to purchase up to an additional 2,428,825 shares of common stock and/or additional warrants to purchase an additional 2,428,825 shares of common stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Stockholders&#8217; Equity &#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The conversion price of the Series&#160;B Preferred Stock and exercise price of the October&#160;2018 Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the common stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of common stock to $0.69 per Warrant per full share of common stock. The reduction was the result of the issuance of shares of common stock by the Company through its &#8220;at the market offering&#8221; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend in accumulated deficit of $0.9 million, which reduces the income available to common stockholders for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The October&#160;2018 Warrants are immediately exercisable at a price of $0.69  per share of common stock (which was 120% of the public offering price of the Class&#160;A Units) and will expire on October&#160;15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October&#160;2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October&#160;2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (&#8220;BCF&#8221;) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#8220;deemed dividend&#8221; and impacts earnings per share. During the years ended December 31, 2021 and 2020, 3,973 and 3,665 shares, respectively, were converted resulting in the recognition of deemed dividends of $1.5 million and $1.4 million, respectively, for the amortization of the Series B Preferred Stock discount upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series A Preferred Stock </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;11, 2017, the Company entered into a share purchase agreement (the &#8220;Purchase Agreement&#8221;) with an investor (the &#8220;Investor&#8221;), pursuant to which the Company offered and sold in a private placement &#160; 120,000 shares of its Series&#160;A Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series&#160;A Preferred Stock&#8221;) for an aggregate purchase price of $12 million, or $100 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Series&#160;A Preferred Stock ranks senior to the shares of the Company&#8217;s common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series&#160;A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0%&#160;per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series&#160;A Preferred Stock classifying the Series&#160;A Preferred Stock. The Series&#160;A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $0.54 per share which was increased to $18.90 after taking into account the 2018 reverse stock split, subject to certain customary anti-dilution adjustments, and was decreased to $1.50 on January 27, 2021, as described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Any conversion of Series&#160;A Preferred Stock may be settled by the Company in shares of common stock only.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The holder&#8217;s ability to convert the Series&#160;A Preferred Stock into common stock is subject to(i)&#160;a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii)&#160;if so elected by the Investor, a 4.99% blocker provision that will prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#8217;s common stock or voting power at any time, and (iii)&#160;applicable regulatory restrictions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Stockholders&#8217; Equity &#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series&#160;A Preferred Stock are entitled to a preference on liquidation equal to the greater of (i)&#160;an amount per share equal to the stated value plus any accrued and unpaid dividends on such share of Series&#160;A Preferred Stock (the &#8220;Accreted Value&#8221;), and (ii)&#160;the amount such holders would receive in such liquidation if they converted their shares of Series&#160;A Preferred Stock (based on the Accreted Value and without regard to any conversion limitation) into shares of the common stock immediately prior to any such liquidation, dissolution or winding-up (the greater of (i)&#160;and (ii), is referred to as the &#8220;Liquidation Value&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Except as otherwise required by law, the holders of Series&#160;A Preferred Stock have no voting rights, other than customary protections against adverse amendments and issuance of&#160;<i style="font-style:italic;">pari passu</i>&#160;or senior preferred stock. Upon certain change of control events involving the Company, prior to the filing of the amendment to the Certificate of Designation for the Series A Preferred Stock described below, the Company will be required to repurchase all of the Series&#160;A Preferred Stock at a redemption price equal to the greater of (i)&#160;the Accreted Value and (ii)&#160;the amount that would be payable upon a change of control (as defined in the Certificate of Designation) in respect of common stock issuable upon conversion of such share of Series&#160;A Preferred Stock if all outstanding shares of Series&#160;A Preferred Stock were converted into common stock immediately prior to the change of control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On or at any time after (i)&#160;the VWAP (as defined in the Certificate of Designation) for at least 20 trading&#160;days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6&#160;months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share of Series&#160;A Preferred Stock of $7,875.00, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&#160;A Convertible Preferred Stock or (ii)&#160;the five&#160;year anniversary of the issue date, the Company shall have the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Convertible Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Series&#160;A Preferred Stock was classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company&#8217;s control. Since the effective conversion price of the Series&#160;A Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is BCF at the issuance date. Because the Series&#160;A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#8220;deemed dividend&#8221; and impacts earnings per share. During the&#160;year ended December&#160;31, 2017, the Company recorded a discount of $6.9 million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of 2% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the years ended December 31, 2021 and 2020, the Company accrued dividends of $24,000 and $254,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 27, 2021, the Company filed an amendment to the Certificate of Designation for the Series A Preferred Stock to (i) lower the stated Conversion Price through September 30, 2021 and (ii) remove their change in control put. The Amendment to the Certificate of Designation for the Series A Convertible Preferred Stock (the &#8220;Certificate of Amendment&#8221;) that was filed with the Secretary of State of the State of Nevada adjusted the conversion price from $18.90 per share to $1.50 per share and removed the redemption upon change of control. The Company received notice from the holder of the Series A Preferred Stock that it was increasing the Maximum Percentage as defined in the &#8220;Certificate of Designation&#8221; from 4.99% to 9.99%, such increase to be effective 61 days from the date thereof. The holder of the Series A Preferred Stock converted all of its shares of Series A Preferred Stock and there are no remaining shares of the Series A Convertible Preferred stock outstanding. During January and February 2021, the Company issued 8,996,768 shares of its common stock upon the conversion effected on such date by the holder of 120,000 shares of its Series A Convertible Preferred Stock. The fair value of the consideration issued to the holder to induce conversion was accounted for as a deemed dividend and increased net loss available to common shareholders for purposes of calculating loss per share. The Company estimated the fair value of the inducement consideration of $7.4 million and as a result recorded a corresponding deemed dividend of $7.4 million during the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">5. Stockholders&#8217; Equity &#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">B. Riley Securities Sales Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets &amp; Co. (now known as B. Riley Securities), which enables the Company to offer and sell shares of the common stock from time to time through B. Riley Securities, Inc. as the Company&#8217;s sales agent. Sales of common stock under the B. Riley Securities Sales Agreement are made in sales deemed to be &#8220;at-the-market&#8221; equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley Securities, Inc. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of the common stock sold on the Company&#8217;s behalf. For the year ended December 31, 2020, the Company sold through the B. Riley Securities Sales Agreement an aggregate of 9.3 million shares of common stock and received net proceeds of approximately $3.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 9, 2021, the Company entered into an amended and restated sales agreement with B. Riley Securities, Inc. (&#8220;B. Riley&#8221;) and A.G.P./Alliance Global Partners (&#8220;AGP&#8221;) in order to include AGP as an additional sales agent for the Company&#8217;s &#8220;at the market offering&#8221; program (the &#8220;Amended and Restated Sales Agreement&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the year ended December 31, 2021, the Company sold through the At Market Issuance Sales Agreement and the Amended and Restated Sales Agreement approximately 78.7 million shares of the Company&#8217;s common stock and received net proceeds of approximately $66.0 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439770856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interest<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Non-controlling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">Non-controlling Interest</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Non-controlling Interest</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;5, 2018, the Company entered into an agreement (the &#8216;Stock Purchase Agreement&#8221;) with Cedars-Sinai Medical Center (CSMC) for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#8220;Study&#8221;). The Study will provide further evaluation of the efficacy and safety of SYN-010, the Company&#8217;s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (<i style="font-style:italic;">M. smithii</i>) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In consideration of the support provided by CSMC for the Study, the Company paid $328,000 to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (&#8220;IRB&#8221;) : (i)&#160;issued to CSMC 50,000 shares of common stock of the Company; and (ii)&#160;transferred to CSMC an additional 2,420,000 shares of common stock of its subsidiary SYN Biomics,&#160;Inc. (&#8220;SYN Biomics&#8221;) owned by the Company, such that after such issuance CSMC owned an aggregate of 7,480,000 shares of common stock of SYN Biomics, representing 17% of the issued and outstanding shares of SYN&#160;Biomics&#8217; common stock.&#160;The services rendered are recorded to research and development expense in proportion with the progress of the study and are based overall on the fair value of the shares ($285,000) as determined at the date of IRB approval. During the years ended December 31, 2021 and 2020, research and development expense recorded related to this transaction approximated $1,000 and $225,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Stock Purchase Agreement also provides CSMC with a right, commencing on the six&#160;month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of Common Stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 30, 2020, CSMC Medically Associated Science and Technology Program (MAST) formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">6. Non-controlling Interest &#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed to following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. On September 30, 2020, CSMC (the Company&#8217;s SYN-010 clinical development partner) informed the Company that it discontinued the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients. During 2021, CSMC returned its shares of SYN Biomics to the Company. The Company&#8217;s interest in SYN Biomics is now 100%. &#160;This is reflected in the Consolidated Statements of Equity (Deficit).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s non-controlling interest is accounted for under ASC 810, <i style="font-style:italic;">Consolidation</i> and represents the minority stockholder&#8217;s ownership interest related to the Company&#8217;s subsidiary, SYN Biomics. In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#8217;s common stockholders in the face of the Consolidated Statements of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of December&#160;31, 2020, the accumulated net loss attributable to the non-controlling interest was $2.8 million and includes $73,000 of prior&#160;year losses attributable to minority stockholders including the reversal of Dr.&#160;Pimentel&#8217;s 2015 losses of $505,000 associated with the exchange of his shares of common stock in SYN Biomics for shares of the Company&#8217;s common stock. During 2021, the minority stockholder returned its shares of SYN Biomics to the Company for no consideration. The Company&#8217;s interest in SYN Biomics is now 100%.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439819096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaborative and Employment Agreements and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract', window );"><strong>License, Collaborative and Employment Agreements and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock', window );">License, Collaborative and Employment Agreements and Commitments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. License, Collaborative and Employment Agreements and Commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">License and Collaborative Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As described below, the Company has entered into several license and collaborative agreements for the right to use research, technology and patents. Some of these license and collaborative agreements may contain milestones. The specific timing of such milestones cannot be predicted and is dependent on future developments as well as regulatory actions which cannot be predicted with certainty (including actions which may never occur). Further, under the terms of certain licensing agreements, the Company may have the obligation to pay certain milestones contingent upon the achievement of specific levels of sales. Due to the long-range nature of such commercial milestone amounts, they are neither probable at this time nor predictable and consequently are not included in this disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Washington University School of Medicine in St. Louis Clinical Trial Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 7, 2019, the Company entered into a clinical trial agreement (&#8220;CTA&#8221;) with Washington University School of Medicine in St. Louis (&#8220;Washington University&#8221;) to conduct a Phase 1b/2a single-center, randomized, double-blinded, placebo-controlled clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of oral SYN-004 (ribaxamase) in up to 36 adult allogeneic hematopoietic cell transplant (HCT) recipients (the &#8220;Study&#8221;). Under the terms of the CTA, the Company will serve as the sponsor of the Study and supply SYN-004 (ribaxamase), as well as compensate Washington University for all research services to be provided in connection with the Study which is estimated to cost approximately $3,200,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The CTA continues in effect until completion of all obligations under the CTA. Either party may terminate the CTA prior to completion of its obligations (i) if authorization of the study is withdrawn by the FDA; (ii) if the emergence of any adverse reaction or side effect with SYN-004 (ribaxamase) administered in the Study is of such magnitude or incidence in the opinion of either party to support termination; or (iii) upon a breach of the terms of the CTA if the breaching party fails to cure the breach within 30 days after receipt of notice. The Company has the right to terminate the CTA (i) effective immediately if Washington University fails to perform the study in accordance with the terms of the protocol, the CTA or applicable laws or regulations or if Washington University or the principal investigator become debarred or (ii) upon 14 days written notice and Washington University has the right to terminate the CTA upon 14 days notice if the principal investigator becomes unable to perform or complete the Study and the parties have not, prior to the expiration of such fourteen (14) day period, agreed to an alternative principal investigator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">7. License, Collaborative and Employment Agreements and Commitments&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cedars-Sinai Medical Center (&#8220;CSMC&#8221;) Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December&#160;5, 2013, the Company, through its newly formed, majority owned subsidiary, SYN Biomics, entered into a worldwide exclusive License Agreement with CSMC for the development of new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes. As part of the terms of the License Agreement, the Company issued 9,569 unregistered shares of the Company&#8217;s common stock to CSMC, paid $150,000 for the initial license fee and $220,000 for patent reimbursement fees. The License Agreement also provides that, commencing on the second anniversary of the License Agreement, SYN Biomics will pay an annual maintenance fee, which payment shall be creditable against annual royalty payments owed under the License Agreement. In addition to royalty payments which are a&#160;percentage of net sales of license and technology products, SYN Biomics is obligated to pay CSMC a&#160;percentage of any non-royalty sublicense revenues, as well as additional consideration upon the achievement of milestones (the first two of which are payable in cash or unregistered shares of Company stock at the Company&#8217;s option).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The License Agreement provided for termination: (i)&#160;automatically if SYN Biomics enters into a liquidating bankruptcy or other specified bankruptcy event or if the performance of any term, covenant, condition or provision of the License Agreement will jeopardize the licensure of CSMC, its participation in certain reimbursement programs, its full accreditation by the Joint Commission of Accreditation of Healthcare Organizations or any similar state organizations, its tax exempt status or is deemed illegal; (ii)&#160;upon 30&#160;days notice from CSMC if SYN Biomics fails to make a payment or use commercially reasonable efforts to exploit the patent rights; (iii)&#160;upon 60&#160;days notice from CSMC if SYN Biomics fails to cure any breach or default of any material obligations under the License Agreement; or (iv)&#160;upon 90&#160;days notice from SYN Biomics if CSMC fails to cure any breach or default of any material obligations under the License Agreement. SYN Biomics also has the right to terminate the License Agreement without cause upon six&#160;months notice to CSMC; however, upon such termination, SYN Biomics is obligated to pay a termination fee with the amount of such fee reduced: (i)&#160;if such termination occurs after an Investigational New Drug submission to the FDA but prior to completion of a Phase 2 clinical trial, (ii)&#160;reduced further if such termination occurs after completion of Phase 2 clinical trial but prior to completion of a Phase 3 clinical trial; and (iii)&#160;reduced to zero if such termination occurs after completion of a Phase 3 clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September&#160;5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2 clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#8220;Study&#8221;). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company&#8217;s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (<i style="font-style:italic;">M. smithii</i>) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">University of Texas Austin Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December&#160;19, 2012, the Company entered into a License Agreement with University of Texas Austin (&#8220;UT&#8221;) Austin for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related to pertussis antibodies. The License Agreement provides that UT Austin is entitled to payment of past patent expenses, an annual payment of $50,000 per&#160;year commencing on the effective date through December&#160;31, 2014, a $25,000 payment on December&#160;31, 2015 and milestone payments of $50,000 upon commencement of Phase 1 clinical trials, $100,000 upon commencement of Phase 3 clinical trials, $250,000 upon NDA submission in the U.S., $100,000 upon European Medicines Agency approval and $100,000 upon regulatory approval in an Asian country. In&#160;addition, UT Austin is entitled to a running royalty upon net sales. The License Agreement terminates upon the expiration of the patent rights; provided, however that the License Agreement is subject to early termination by the Company in its discretion and by UT Austin for a breach of the License Agreement by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. License, Collaborative and Employment Agreements and Commitments&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the License Agreement, the Company and UT Austin also entered into a Sponsored Research Agreement pursuant to which UT Austin will perform certain research work related to pertussis. The Sponsored Research Agreement may be renewed annually, in the sole discretion of the Company, after the first&#160;year for two additional one&#160;year terms with a fixed fee for the first&#160;year of $303,287. The Sponsored Research Agreement was renewed for the second and third&#160;years for a fixed fee of $316,438 and $328,758 respectively, all payable in quarterly installments. The Sponsored Research Agreement expires January 17, 2023; provided, however, the Sponsored Research Agreement is subject to early termination upon the written agreement of the parties, a default in the material obligations under the Research Agreement which remain uncured for 60&#160;days after receipt of notice, automatically upon the Company&#8217;s bankruptcy or insolvency and by the Company in its sole discretion at any time after the one&#160;year anniversary of the date of execution thereof upon no less than 90&#160;days&#8217; notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Prev ABR LLC (&#8220;Prev&#8221;) Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November&#160;28, 2012, the Company entered into an agreement (&#8220;Prev Agreement&#8221;) to acquire the C. diff program assets of Prev, including the pre-Investigational New Drug (IND) package, Phase 1 and Phase 2 clinical data, manufacturing process data and all issued and pending U.S. and international patents. Upon execution and closing of the Prev Agreement, the Company paid Prev cash payments of $235,000 and issued 17,858 unregistered shares of its common stock to Prev. As set forth in the Prev Agreement, Prev may be entitled to receive additional consideration upon the achievement of certain milestones, including: (i)&#160;commencement of an IND; (ii)&#160;commencement of a Phase 1 clinical trial; (iii)&#160;commencement of a Phase 2 clinical trial; (iv)&#160;commencement of a Phase 3 clinical trial; (v)&#160;filing a Biologic License Application (BLA) in the U.S. and for territories outside of the U.S. (as defined in the Prev Agreement); and (vi)&#160;approval of a BLA in the U.S. and for territories outside the U.S. With exception of the first milestone payment, the remaining milestones are payable 50% in cash and 50% in our stock, however, at Prev&#8217;s option the entire milestone may be payable in shares of the Company&#8217;s stock. As of December&#160;31, 2015, the first three milestones have been met, and at Prev&#8217;s option, Prev elected to receive 18,724 shares of the Company&#8217;s common stock. Currently, assets licensed under this agreement are used in the Company&#8217;s &#160;Phase 1b/2a Clinical Study in Allogeneic HCT Recipients. No milestones were achieved or such payments were made during the&#160;years ended December&#160;31, 2021 and 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December&#160;6, 2018, the Company entered into a three-year employment agreement with Steven A. Shallcross, (the &#8220;Employment Agreement&#8221;), to serve as the Chief Executive Officer and to continue to serve as the Chief Financial Officer of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Employment Agreement has a stated term of three&#160;years but may be terminated earlier pursuant to its terms. If Mr.&#160;Shallcross&#8217; employment is terminated for any reason, he or his estate as the case may be, will be entitled to receive the accrued base salary, vacation pay, expense reimbursement and any other entitlements accrued by him to the extent not previously paid (the &#8220;Accrued Obligations&#8221;); provided, however, that if his employment is terminated (i)&#160;by the Company without Cause or by Mr.&#160;Shallcross for Good Reason (as each is defined in the Employment Agreement) then in addition to paying the Accrued Obligations, (a)&#160;the Company will continue to pay his then current base salary and continue to provide benefits at least equal to those that were provided at the time of termination for a period of twelve (12)&#160;months and (b)&#160;he shall have the right to exercise any vested equity awards until the earlier of six (6)&#160;months after termination or the remaining term of the awards; or (ii)&#160;by reason of his death or Disability (as defined in the Employment Agreement), then in addition to paying the Accrued Obligations, Mr.&#160;Shallcross would have the right to exercise any vested options until the earlier of six (6)&#160;months after termination or the remaining term of the awards. In such event, if Mr.&#160;Shallcross commenced employment with another employer and becomes eligible to receive medical or other welfare benefits under another employer-provided plan, the medical and other welfare benefits to be provided by the Company as described herein would terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 30, 2020, the Board of Directors of the Company awarded Steven A. Shallcross (i) a cash bonus equal to 62% of his prior base salary and (ii) an option to purchase 450,000 shares of the Company&#8217;s common stock. On December 23, 2020, the Board of the Company awarded Steven A. Shallcross (i) a cash bonus equal to 62.5% of his prior base salary and (ii) an option to purchase 450,000 shares of the Company&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 23, 2021, the Board of Directors of the Company awarded Steven A. Shallcross (i) a cash bonus equal to approximately 62.5% of his current base salary, and (ii) an option to purchase 650,000 shares of the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. License, Collaborative and Employment Agreements and Commitments&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Operating Lease</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s existing lease as of December 31, 2021 is classified as an operating lease. As of December 31, 2021, the Company has one operating lease for facilities with a remaining term expiring in 2027. During the quarter ended June 30, 2021, the Company renewed its facility lease by entering into a Second Lease Amendment which extends the lease term for 63 months beginning on September 1, 2022 and ending on December 31, 2027 at stated rental rates and including a 3 month rent abatement. The Second Amendment also has options for a Tenant Improvement Allowance and a Second Extension Term. The Second Amendment also gives the Company the right to expand their space by giving notice to the landlord before December 31, 2021. The Company did not give notice to expand the space during 2021. The Second Extension Term is offered at market rates and there is no economic incentive for the lessee, therefore the Company has determined that it is not part of the original lease term. There is an option in this Second Amendment to Lease for the Company to borrow funds for tenant improvements subject to an 8.5% interest rate. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statements of operations, and for the years ended December 31, 2021 and 2020 approximated $280,000 and $209,000, respectively. For the years ended December 31, 2021 and 2020, operating cash flows used for operating leases approximated $321,000 and $309,000, respectively, and the right of use assets exchanged for operating the lease obligation was $1.3 million. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $538,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A maturity analysis of our operating leases as of December 31, 2021 is as follows <i style="font-style:italic;">(amounts in thousands of dollars)</i>:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future undiscounted cash flow for the years ending December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 337</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 347</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 357</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 368</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,983</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount factor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (456)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_YmEvW5Sg1kyNFgYcXmib7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,527</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (124)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability - long term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,403</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Consulting Fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November&#160;2017, the Company engaged a regulatory consultant to assist in the Company&#8217;s efforts to prepare, file and obtain FDA approval for ribaxamase.&#160;The term of the engagement is on a&#160;monthly basis, provided that either party may terminate the agreement at any time by providing the other party a six-month notice period. The Company was obligated to pay the consultant a&#160;monthly retainer in addition to success fee payments of up to an aggregate of $4,500,000 for attainment of certain regulatory milestones. The achievement of the milestones is not probable at this time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 30, 2020, the World Health Organization (&#8220;WHO&#8221;) announced a global health emergency because of COVID-19 and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">7. License, Collaborative and Employment Agreements and Commitments&#160;&#8211;&#160;(continued)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As COVID-19 continued to spread around the globe, the Company experienced disruptions that impacted its business and clinical trials, including the postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company&#8217;s business, the clinical development of SYN-004 (ribaxamase) and SYN-020, the business of the Company&#8217;s suppliers and other commercial partners, the Company&#8217;s corporate development objectives and the value of and market for the Company&#8217;s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, especially in light of the new variants, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of license, collaborative and employment agreement and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439879560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">There was no income tax expense for the&#160;years ended December 31, 2021 and 2020 due to the Company&#8217;s net losses. The Company&#8217;s tax expense differs from the &#8220;expected&#8221; tax expense for the years ended December 31, 2021 and 2020. For 2021, the &#8220;expected&#8221; tax expense is computed by applying the Federal corporate statutory tax rate of 21% and a net, after Federal benefit state tax rate of 6.46% (state blended rate was 8.18%) to loss before taxes. For 2020, the &#8220;expected&#8221; tax expense is computed by applying the Federal corporate statutory tax rate of 21% and a net, after Federal benefit state tax rate of 6.45% (state blended rate was 8.17.%) to loss before taxes. These results are as follows <i style="font-style:italic;">(in thousands):</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">2020</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Computed &#8220;expected&#8221; tax-benefit - Federal</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (3,045)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (2,124)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Computed &#8220;expected&#8221; tax-benefit - State</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (931)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (616)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Adjustment of &#8220;expected&#8221; tax-benefit to actual</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Meals, entertainment and other</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Non-deductible stock-based compensation</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 32</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 32</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">State Tax Rate Adjustment</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 932</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (1,221)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Federal and state NOL Adjustment</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Change in valuation allowance</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 3,012</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 3,929</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effects of temporary differences that gave rise to significant portions of deferred tax assets at December&#160;31, 2021 and 2020 are as follows (<i style="font-style:italic;">in thousands</i>):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for services</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,504</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,428</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Accrued compensation</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 27</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 42</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for acquisition of program</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,462</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,436</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for license agreement</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,363</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,574</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for milestone payment</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 236</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 262</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Amortizable License Fee</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 4</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 5</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Net operating loss carry-forward</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 16,884</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 12,540</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Total gross deferred tax assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 21,480</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 17,287</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Less: valuation allowance</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (21,480)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (17,287)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Total net deferred tax assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Income Taxes&#160;&#8211;&#160;(continued)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At December 31, 2021, the Company has a gross Federal net operating loss carry-forward of approximately $58.3 million available to offset future taxable income. The Company&#8217;s pre-2018 net operating losses expire on various dates through 2037. In addition, it was determined that the utilization of gross Federal net operating losses of approximately $198.8 million was limited by $155.6 million. due to change of control ownership changes that occurred under Section 382 of the Internal Revenue Code. State NOL&#8217;s are also limited by Section 382 of the Internal Revenue Code and were limited accordingly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In 2020, the Company completed an Internal Revenue Code Section 382 analysis of its historical net operating loss carry-forward amount. As a result, the prior year net operating loss carry-forward of $188.6 million was limited by $155.6 million. The decrease in the prior year net operating loss is attributable to change of control ownership shifts which were determined for the years 2013 and 2018 which caused the reduction in the value of the historical net operating loss carry-forward amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An updated section 382 analysis was performed in 2021 to identify if any additional ownership shifts occurred in the current year. It was determined that an ownership shift occurred on January 20, 2021. The result of the updated 2021 analysis produced an IRC 382 limit due to the 2021 ownership shift. However, all previously limited net operating losses remain available for use in future periods. The Company&#8217;s pre-2018 net operating losses expire on various dates through 2037 while the net operating loss carry-forward originating in the 2018 year and later carry-forward indefinitely and are subject to additional limitations based on taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In December 2019, the FASB issued ASU 20109-12, &#8220;Income Taxes Topic 740-Simplifying the Accounting for Income Taxes&#8221; (&#8220;ASU 2019-12&#8221;), which intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application of Topic 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein, and early adoption is permitted. The Company adopted ASU 2019-12 in the current period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The valuation allowance at December 31, 2021 was approximately $21.5 million. The net change in valuation allowance during the year ended December 31, 2021, was an increase of approximately $4.2 million primarily due to increases in gross federal and state deferred tax assets in 2021. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439827144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Subsequent Events</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On January 3, 2022, the Company entered into a three-year employment agreement with Steven A. Shallcross (the &#8220;Employment Agreement&#8221;), who has served as the Company&#8217;s Chief Executive Officer since December 6, 2018 and as the Company&#8217;s Chief Financial Officer since June 1, 2015, to continue to serve as the Chief Executive Officer and Chief Financial Officer of the Company. The Employment Agreement replaced the prior employment agreement with the Company that Mr. Shallcross entered into on December 6, 2018, as amended December 5, 2019. Pursuant to the Employment Agreement, Mr. Shallcross is entitled to an annual base salary of $585,000 and an annual cash performance bonus of up to fifty percent (50%) of his annual base salary as well as discretionary annual equity awards pursuant to the Company&#8217;s incentive plans. The annual bonus will be based upon the assessment of the Board of Mr. Shallcross&#8217;s performance. The Employment Agreement also includes confidentiality obligations and inventions assignments by Mr. Shallcross and non-solicitation and non-competition provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 10, 2022, the Company completed the acquisition of all the outstanding shares of VCN (the &#8220;VCN Shares&#8221;) from the shareholders of VCN. VCN is a private, clinical-stage biopharmaceutical company developing new oncolytic adenoviruses for the treatment of cancer. VCN&#8217;s lead product candidate, VCN-01, is being studied in clinical trials for pancreatic cancer and retinoblastoma. VCN-01 is designed to be administered systemically, intratumorally or intravitreally, either as a monotherapy or in combination with standard of care, to treat a wide variety of cancer indications. VCN-01 is designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment, Degrading the tumor stroma has been shown to improve access to the tumor by the virus and additional therapies such as chemo- and immuno-therapies. Importantly, degrading the stroma exposes tumor antigens, turning &#8220;cold&#8221; tumors &#8220;hot&#8221; and enabling a sustained anti-tumor immune response. VCN has the rights to four exclusive patents for proprietary technologies, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional patents pending. As consideration for the purchase of the VCN Shares, the Comany paid $4,700,000 to Grifols Innovation and New Technologies Limited  the owner of approximately 86% of the equity of VCN, and issued to the remaining sellers and certain key employees and consultants of VCN the closing Shares, representing 19.99% of the outstanding shares of the Company&#8217;s common stock on December 14, 2021, the date of the Purchase Agreement. In addition to the consideration described above, under the terms of the Purchase Agreement, the Company assumed up to $2,400,000 of existing liabilities of VCN and has agreed to make cash payments to Grifols upon the achievement of certain clinical and commercialization milestones, as described below. In connection with the Acquisition, prior to the closing the Company loaned VCN $425,000 to help finance the costs of certain of VCN&#8217;s research and development activities and, at the Closing, VCN and Grifols entered into a sublease agreement for the sublease by VCN of the laboratory and office space currently occupied by it as well as a transitional services agreement. As a Purchase Agreement post-Closing covenant, Synthetic has agreed to commit to fund VCN&#8217;s research and development programs, including but not limited to VCN01 PDAC phase 2 trial, VCN01 RB pivotal trial and necessary G&amp;A within a budgetary plan of approximately $27.8 million.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Milestone Payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$3MM upon VCN-01 US IND Safe to Proceed pancreatic ductal adenocarcinoma (&#8220;PDAC&#8221;, or other first indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$2.75MM upon VCN-01 US IND Safe to Proceed &#8211; retinoblastoma (&#8220;RB&#8221;, or other second indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$3.25MM upon VCN-01 US first patient dosed&#8211; PDAC (or other first indication) after receipt of VCN-01 US IND Safe to Proceed for PDAC being informed</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$3.25MM upon VCN-01 US first patient dosed &#8211; RB (or other second indication) after receipt of VCN-01 US IND Safe to Proceed for RB being informed</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$6MM upon VCN-01 US Phase 2 trial meets the primary endpoint or if a Phase 2 trial is not conducted and only a Phase 3 trial is conducted then upon a Phase 3 being initiated &#8211; PDAC (or other first indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$8MM upon VCN-01 Pivotal Trial meeting the primary endpoint or upon BLA Submission &#8211; RB (or other second indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$12MM upon VCN-01 US Phase 3 trial meeting the primary endpoint or upon BLA Submission &#8211; PDAC (or other first indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$16MM upon VCN-01 BLA Approval &#8211; PDAC (or other first indication)</p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;">US$16MM upon VCN-01 BLA Approval &#8211; RB (or other second indication)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441516792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All intercompany transactions and accounts have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants, preferred stock and stock options granted for services or compensation, respectively, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NoncontrollingInterestPolicyTextBlock', window );">Non-controlling Interest</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Non-controlling Interest</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s non-controlling interest represents the minority stockholder&#8217;s ownership interest related to the Company&#8217;s subsidiary, SYN Biomics. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#8217;s common stockholders on the face of the Consolidated Statements of Operations. On September&#160;5, 2018, the Company entered into an agreement with the minority stockholder for an investigator-sponsored Phase 2 clinical study of SYN-010. Prior to this agreement and IRB approval in December&#160;2018, the Company&#8217;s equity interest in SYN Biomics was 88.5% and the non-controlling stockholder&#8217;s interest was 11.5%. In consideration of the support, the Company issued additional shares of stock to the minority stockholder, resulting in the Company&#8217;s equity interest in SYN Biomics being 83.0% and the non-controlling stockholder&#8217;s interest is 17.0%. During 2021, the minority stockholder returned its shares of SYN Bionics to the Company for no consideration. The Company's interest in SYN Biomics is now 100%. This is reflected in the Consolidated Statements of Equity (Deficit).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. These conditions may not only limit the Company&#8217;s access to capital, but also make it difficult for its customers, its vendors and its ability to accurately forecast and plan future business activities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three&#160;months or less.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Asset Description</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:top;width:48.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Office equipment and furniture</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3&#160;&#8211;&#160;5&#160;years</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements and fixtures</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lesser of estimated useful life or lease term</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense was approximately $87,000 and $201,000 for the&#160;years ended December&#160;31, 2021 and 2020, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts with any gain or loss reported in the consolidated statement of operations. Repairs and maintenance are charged to expense as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews property and equipment for impairment to determine if assets are impaired due to obsolescence. As a result of this review, there was no impairment recognized for the&#160;years ended December&#160;31, 2021 and 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the year ended December 31, 2021 includes the effect of the Series A preferred stock price adjustment of $7.4 million, the accretion of the Series B preferred discount of $1.5 million on converted shares and Series A preferred stock accrued dividends of $0.1 million. Net loss attributable to common stockholders for the year ended December 31, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $1.4 million on converted shares, the effect of warrant exercise adjustment of $1.0 million and Series A preferred stock accrued dividends of $0.3 million. The number of shares of common stock underlying Series A Preferred shares convertible to common stock that were excluded from the computation of the net loss per common share for the year ended December 31, 2020 was 678,258. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that was excluded from the computation of net loss per common share and for the year ended December 31, 2020 was 3,454,783. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share for the&#160;year ended December&#160;31, 2021 were 6,255,275 and 6,344,966, respectively, and for the&#160;year ended December&#160;31, 2020 were 3,997,418 and 18,000,713, respectively, because their effect is anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company expenses research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries, stock-based compensation and related employee costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of our product candidates. Research and development expenses include external contract research organization (&#8220;CRO&#8221;) services. The Company makes payments to the CROs based on agreed upon terms and may include payments in advance of study services. The Company reviews and accrues CRO expenses based on services performed and relies on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. At December&#160;31, 2021 and 2020, the Company has accrued CRO expenses of $0.7 million, that are included in accrued expenses. The Company has prepaid CRO costs at December&#160;31, 2021 and 2020 of $0.5 million that are included in prepaid expenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Accounting Standards Codification (&#8220;ASC&#8221;) 820, <i style="font-style:italic;">Fair Value Measurement</i>, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are classified on a three-tier hierarchy as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2 inputs: Inputs, other than quoted prices, that are observable either directly or indirectly; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The carrying amounts of the Company&#8217;s short-term financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents include money market accounts of $193,000 and $114,000 as of December&#160;31, 2021 and 2020, respectively, that are measured using Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In using this model, the fair value is determined by applying Level 3 inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions. The assumptions used in calculating the estimated fair value of the warrants represent the Company&#8217;s best estimates; however, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different. In 2021 and 2020, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#8217;s current stock price.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockBasedPaymentArrangementsPolicyTextBlock', window );">Stock-Based Payment Arrangements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stock-Based Payment Arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#8217; grant date typically using the Black-Scholes option pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations, depending on the nature of the services provided.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Derivative Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The warrants issued in conjunction with the public offering of the Company&#8217;s securities in November&#160;2016 include a provision that if the Company were to enter into a certain transaction, as defined in the warrant agreement, the warrants would be purchased from the holder for cash. The provisions of these warrants preclude equity accounting treatment under ASC 815, <i style="font-style:italic;">Derivatives and Hedging.</i> Accordingly, the Company is required to record the warrants as liabilities at their fair value upon issuance and re-measure the fair value at each period end with the change in fair value recorded in the Consolidated Statement of Operations. When the warrants are exercised or cancelled, they are reclassified to equity. The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In November 2020, all liability-classified warrants expired. In 2019, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#8217;s current stock price.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes deferred tax assets and liabilities based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the&#160;years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Management assesses the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex tax laws of multiple jurisdictions. The Company records the related interest expense and penalties, if any, as tax expense in the tax provision. At December&#160;31, 2021 and 2020, the Company did not record any liabilities for uncertain tax positions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements and Developments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements and Developments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, <i style="font-style:italic;">Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (subtopic 815-40)</i>: <i style="font-style:italic;">Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</i>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity's own equity and improves and amends the related earnings per share guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company is currently assessing the impact of ASU 2020-06 on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In October 2021, the FASB issued Accounting Standards Update 2021-08 that address the accounting for Contract Assets and Liabilities from Contracts with Customers in a business combination (&#8220;ASU 2021-08&#8221;), with an effective date for SYN of January 1,2 2024 (earlier adoption permitted). ASU 2021-08 provides that existing contract assets and liabilities (including deferred costs to obtain and deferred revenue) are measured in a business combination under the measurement and recognition requirements of ASC 606. ASU 2021-08 should generally &#8220;result in an acquirer recognizing and measuring the acquired contract assets and liabilities consistent with how they were recognized and measured in the acquiree&#8217;s financial statements.&#8221; The Company is currently assessing the impact of ASU 2021-08 on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding risk and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockBasedPaymentArrangementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding stock based payment arrangements for various stocks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockBasedPaymentArrangementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439827144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EstimatedUsefulLifeOfAssetTableTextBlock', window );">Schedule of Estimated Useful Life</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Asset Description</b></p></td><td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated Useful Life</b></p></td></tr><tr><td style="vertical-align:top;width:48.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Office equipment and furniture</p></td><td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3&#160;&#8211;&#160;5&#160;years</p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Leasehold improvements and fixtures</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Lesser of estimated useful life or lease term</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EstimatedUsefulLifeOfAssetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of estimated useful life of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_EstimatedUsefulLifeOfAssetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453440016408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PREPAID EXPENSES AND OTHER CURRENT ASSETS (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 803</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 639</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid clinical research organizations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 470</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid consulting, subscriptions and other expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 90</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock sales receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 469</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid manufacturing expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,707</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROPERTY AND EQUIPMENT (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computers and office equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 827</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 813</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 94</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 439</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,263</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (831)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,089)</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 101</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 174</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedExpensesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ACCRUED EXPENSES (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vendor payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 225</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical consulting services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 696</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 700</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued manufacturing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,928</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 925</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedEmployeeBenefitsTableTextBlock', window );">Schedule of accrued employee benefits</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ACCRUED EMPLOYEE BENEFITS (in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued bonus expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 724</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued vacation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 868</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedEmployeeBenefitsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to accrued employee benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccruedEmployeeBenefitsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccruedExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441363928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation and Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of assumptions used for awards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividends</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected life of option (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of stock option activity for the&#160;years ended December&#160;31, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted&#160;Average&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average&#160;Exercise&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Intrinsic&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;- December&#160;31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,502,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.51 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153,353</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,540,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,944)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.57</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29,650)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;- December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,997,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6.09 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,260,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,143)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 45.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;-December&#160;31, 2021&#160;- outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,255,275</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.58 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance&#160;-&#160;&#160;December&#160;31, 2021&#160;- exercisable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,786,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4.44 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grant date fair value of options granted&#160;-&#160;December&#160;31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 501,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average grant date fair value - December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Grant date fair value of options granted&#160;- December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 412,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average grant date fair value&#160;- December&#160;31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.27</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of options outstanding and exercisable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The options outstanding and exercisable at December&#160;31, 2021 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;width:62.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:24.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.00&#160;&#8211;&#160;$40.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,189,257</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,720,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4 years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">41.00&#160;&#8211;&#160;$70.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2&#160;years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52.07</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2&#160;years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">71.00&#160;&#8211;&#160;$102.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85.19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2&#160;years</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantActivityTableTextBlock', window );">Summary of all warrant activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A summary of all warrant activity for the Company for the years ended December 31, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,714,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.24</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (714,286)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50.05</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,000,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,655,747)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock', window );">Summary of all outstanding and exercisable warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted&#160;Average</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Warrants</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.99&#160;years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.78&#160;years</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.69</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,344,966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.78 years</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrant activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure relates to warrant outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439895000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaborative and Employment Agreements and Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract', window );"><strong>License, Collaborative and Employment Agreements and Commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity analysis of operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A maturity analysis of our operating leases as of December 31, 2021 is as follows <i style="font-style:italic;">(amounts in thousands of dollars)</i>:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Future undiscounted cash flow for the years ending December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 247</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 327</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 337</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 347</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 357</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 368</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,983</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Discount factor</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (456)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_YmEvW5Sg1kyNFgYcXmib7A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liability</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,527</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability - current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (124)</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability - long term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,403</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453439101336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text">The Company&#8217;s tax expense differs from the &#8220;expected&#8221; tax expense for the years ended December 31, 2021 and 2020. For 2021, the &#8220;expected&#8221; tax expense is computed by applying the Federal corporate statutory tax rate of 21% and a net, after Federal benefit state tax rate of 6.46% (state blended rate was 8.18%) to loss before taxes. For 2020, the &#8220;expected&#8221; tax expense is computed by applying the Federal corporate statutory tax rate of 21% and a net, after Federal benefit state tax rate of 6.45% (state blended rate was 8.17.%) to loss before taxes. These results are as follows <i style="font-style:italic;">(in thousands):</i><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> </i><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">2021</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">2020</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Computed &#8220;expected&#8221; tax-benefit - Federal</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (3,045)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (2,124)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Computed &#8220;expected&#8221; tax-benefit - State</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (931)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (616)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Adjustment of &#8220;expected&#8221; tax-benefit to actual</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Meals, entertainment and other</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Non-deductible stock-based compensation</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 32</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 32</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">State Tax Rate Adjustment</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 932</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (1,221)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Federal and state NOL Adjustment</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Change in valuation allowance</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 3,012</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 3,929</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The effects of temporary differences that gave rise to significant portions of deferred tax assets at December&#160;31, 2021 and 2020 are as follows (<i style="font-style:italic;">in thousands</i>):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for services</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,504</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,428</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Accrued compensation</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 27</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 42</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for acquisition of program</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,462</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,436</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for license agreement</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,363</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 1,574</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Stock issued for milestone payment</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 236</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 262</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Amortizable License Fee</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 4</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 5</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Net operating loss carry-forward</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 16,884</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 12,540</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Total gross deferred tax assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 21,480</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> 17,287</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Less: valuation allowance</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (21,480)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">&#160;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;"> (17,287)</i></p></td></tr><tr><td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Total net deferred tax assets</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">$</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><i style="font-style:italic;"> &#8212;</i></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453440736920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Nature of Operations and Basis of Presentation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Nature of Operations and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 67,325,000<span></span>
</td>
<td class="nump">$ 6,227,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts', window );">Proceeds from issuance ATM offering, net of issuance costs</a></td>
<td class="nump">66,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from exercise of warrants</a></td>
<td class="nump">$ 8,042,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of ATM offering, net of issuance cost during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453436903464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and equipment (Details) - Office Equipment And Furniture<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453433689336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="nump">$ 201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,227,000<span></span>
</td>
<td class="nump">$ 67,325,000<span></span>
</td>
<td class="nump">6,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss Attributable to Non-controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="num">$ (73,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockSharesConverted', window );">Preferred Stock Shares Converted</a></td>
<td class="nump">1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">279,000<span></span>
</td>
<td class="nump">$ 1,383,000<span></span>
</td>
<td class="nump">$ 279,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
<td class="nump">124,000<span></span>
</td>
<td class="nump">287,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockPriceAdjustment', window );">Preferred stock price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,402,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=syn_SeriesAAndSeriesBPreferredStockMember', window );">Series A and Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss Attributable to Non-controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,454,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,496,000<span></span>
</td>
<td class="nump">$ 1,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDiscountOnShares', window );">Accretion of preferred discount</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">678,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">$ 254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccretionOfPreferredStockDeemedDividend', window );">Accretion of Preferred Stock Deemed Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDiscountOnShares', window );">Accretion of preferred discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockPriceAdjustment', window );">Preferred stock price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,402,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,344,966<span></span>
</td>
<td class="nump">18,000,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,255,275<span></span>
</td>
<td class="nump">3,997,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=syn_MoneyMarketAccountsMember', window );">Money Market Accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,000,000<span></span>
</td>
<td class="nump">$ 193,000,000<span></span>
</td>
<td class="nump">$ 114,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=syn_SYNBiomicsMember', window );">SYN Biomics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling Interest, Ownership Percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss Attributable to Non-controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccretionOfPreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of accretion of the Series B preferred stock deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccretionOfPreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockPriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of preferred stock price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockPriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The no of shares converted into common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of warrant exercise price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187103-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=syn_SeriesAAndSeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=syn_SeriesAAndSeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=syn_MoneyMarketAccountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=syn_MoneyMarketAccountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syn_SYNBiomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syn_SYNBiomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453436920904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information - Schedule of PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 803<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PrepaidClinicalResearchOrganizationsExpenseCurrent', window );">Prepaid clinical research organizations</a></td>
<td class="nump">458<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PrepaidConsultingSubscriptionsAndOtherExpenses', window );">Prepaid consulting, subscriptions and other expenses</a></td>
<td class="nump">272<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Stock sales receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PrepaidManufacturingExpense', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 1,533<span></span>
</td>
<td class="nump">$ 1,707<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PrepaidClinicalResearchOrganizationsExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the amount paid in advance for clinical research organization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PrepaidClinicalResearchOrganizationsExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PrepaidConsultingSubscriptionsAndOtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the amount paid in advance for consulting, subscriptions and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PrepaidConsultingSubscriptionsAndOtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PrepaidManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Prepaid Manufacturing Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PrepaidManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441738888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information - Schedule of PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">$ 932<span></span>
</td>
<td class="nump">$ 1,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(831)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">174<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputersAndOfficeEquipmentMember', window );">Computers and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross, Total</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputersAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=syn_ComputersAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441583720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information - Schedule of ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedVendorPayments', window );">Accrued vendor payments</a></td>
<td class="nump">$ 1,028<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedClinicalConsultingServices', window );">Accrued clinical consulting services</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccruedManufacturingCosts', window );">Accrued manufacturing costs</a></td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,928<span></span>
</td>
<td class="nump">$ 925<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedClinicalConsultingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value of accrued clinical consulting services payable as on balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccruedClinicalConsultingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The manufacturing costs incurred in the production of goods for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccruedManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccruedVendorPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccruedVendorPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453443822104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Selected Balance Sheet Information - Schedule of ACCRUED EMPLOYEE BENEFITS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BalanceSheetInformationAbstract', window );"><strong>Selected Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonus expense</a></td>
<td class="nump">$ 886<span></span>
</td>
<td class="nump">$ 724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued vacation expense</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 978<span></span>
</td>
<td class="nump">$ 868<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453440064632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Warrants - (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation and Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk -free interest rate</a></td>
<td class="nump">1.12%<span></span>
</td>
<td class="nump">0.31%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441804664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Warrants - Summary of stock option activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Beginning Balance</a></td>
<td class="nump">3,997,418<span></span>
</td>
<td class="nump">2,502,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted</a></td>
<td class="nump">2,260,000<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired</a></td>
<td class="num">(2,143)<span></span>
</td>
<td class="num">(14,944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options, Ending Balance</a></td>
<td class="nump">6,255,275<span></span>
</td>
<td class="nump">3,997,418<span></span>
</td>
<td class="nump">2,502,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable</a></td>
<td class="nump">2,786,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">0.33<span></span>
</td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="nump">45.15<span></span>
</td>
<td class="nump">17.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">1.61<span></span>
</td>
<td class="nump">$ 2.35<span></span>
</td>
<td class="nump">$ 3.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life, Balance Outstanding</a></td>
<td class="text">5 years 6 months 29 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life, Exercisable</a></td>
<td class="text">4 years 5 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 153,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value of options granted</a></td>
<td class="nump">$ 501,000<span></span>
</td>
<td class="nump">$ 412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Exercise price of options granted</a></td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453442702232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Warrants - Options outstanding and exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_RangeOfExercisePrice0004000Member', window );">Range of Exercise Price 0.00-40.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding, Range of Exercise Price Lower</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper</a></td>
<td class="nump">$ 40.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Options | shares</a></td>
<td class="nump">6,189,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Options | shares</a></td>
<td class="nump">2,720,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_RangeOfExercisePrice41007000Member', window );">Range of Exercise Price 41.00-70.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding, Range of Exercise Price Lower</a></td>
<td class="nump">$ 41.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper</a></td>
<td class="nump">$ 70.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Options | shares</a></td>
<td class="nump">6,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 52.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Options | shares</a></td>
<td class="nump">6,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 52.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_RangeOfExercisePrice710010200Member', window );">Range Of Exercise Price 71.09-102.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Options Outstanding, Range of Exercise Price Lower</a></td>
<td class="nump">$ 71.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Options Outstanding, Range of Exercise Price Upper</a></td>
<td class="nump">$ 102.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding, Options | shares</a></td>
<td class="nump">59,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 85.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding, Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable, Options | shares</a></td>
<td class="nump">59,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 85.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Options Exercisable, Weighted Average Remaining Contractual Life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_RangeOfExercisePrice0004000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_RangeOfExercisePrice0004000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_RangeOfExercisePrice41007000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_RangeOfExercisePrice41007000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_RangeOfExercisePrice710010200Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_RangeOfExercisePrice710010200Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453437420520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Warrants - Stock incentive plan and other information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 18, 2016</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 20, 2007</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Sep. 17, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 15, 2018</div></th>
<th class="th"><div>Dec. 26, 2017</div></th>
<th class="th"><div>Nov. 08, 2016</div></th>
<th class="th"><div>Nov. 02, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants Not Settleable in Cash, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants Not Settleable in Cash, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesBWarrantsMember', window );">Series B Warrants [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant</a></td>
<td class="nump">$ 60.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember', window );">General and Administrative Expenses and Research and Development Expense [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="nump">$ 213,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeesAndDirectorsMember', window );">Employees And Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,260,000<span></span>
</td>
<td class="nump">1,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_ConsultantMember', window );">Consultant [Member] | General and Administrative Expenses and Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 212,000<span></span>
</td>
<td class="nump">$ 137,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employees | General and Administrative Expenses and Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2007Member', window );">2007 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,429<span></span>
</td>
<td class="nump">5,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2007Member', window );">2007 Stock Plan [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member', window );">2010 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member', window );">2010 Stock Plan [Member] | Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,450,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockPlan2020Member', window );">2020 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_ConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_ConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockPlan2007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockPlan2007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockPlan2010Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockPlan2010Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockPlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockPlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453432407368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Warrants - Stock Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 15, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 10, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 18, 2016 </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 26, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 08, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from "at the market" stock issuance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,042,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants Not Settleable in Cash, Fair Value Disclosure | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,960,000<span></span>
</td>
<td class="nump">$ 3,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds From Warrants Exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockConversionPricePerShare', window );">Preferred Stock Conversion Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PercentageOfIssueOfThePublicOffering', window );">Percentage of issue of the public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfShareSold', window );">Number of Share sold | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfSharesPurchase', window );">Number of Shares purchase | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,428,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants Not Settleable in Cash, Fair Value Disclosure | $</a></td>
<td class="nump">$ 15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssueOfWarrantsToPurchaseCommonStock', window );">Issue of warrants to purchase common stock</a></td>
<td class="nump">1,807,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssueOfWarrantsToPurchaseCommonStock', window );">Issue of warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,807,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=syn_UnderwrittenPublicOfferingMember', window );">Underwritten Public Offering [Member] | October 2018 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantTerm', window );">Warrant Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=syn_StockWarrantsMember', window );">Stock Warrants [Member] | IPO [Member] | Series A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,655,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssueOfWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent additional of warrant to purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_IssueOfWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfShareSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Number of Share sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfShareSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfSharesPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the shares purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfSharesPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PercentageOfIssueOfThePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issue of public offering price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PercentageOfIssueOfThePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of warrant exercise price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the warrant term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syn_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=syn_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=syn_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=syn_OctoberTwoThousandEighteenWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=syn_OctoberTwoThousandEighteenWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=syn_StockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=syn_StockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis=us-gaap_SeriesAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441368552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Warrants - Summary of all warrant activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_StockWarrantsAbstract', window );"><strong>Stock Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Beginning Balance</a></td>
<td class="nump">18,000,713<span></span>
</td>
<td class="nump">18,714,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod', window );">Number of Warrants, Exercised</a></td>
<td class="num">(11,655,747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(714,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Ending Balance</a></td>
<td class="nump">6,344,966<span></span>
</td>
<td class="nump">18,000,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">0.69<span></span>
</td>
<td class="nump">50.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_StockWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_StockWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441767320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation and Warrants - Summary of all outstanding and exercisable warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice0.69Member', window );">Exercise Price 0.69 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
<td class="nump">6,344,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
<td class="nump">6,344,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">11 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice1820Member', window );">Exercise Price 18.20 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 18.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice0.69TwoMember', window );">Exercise Price 0.69 Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantsExercisePrice', window );">Weighted Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Warrants Outstanding</a></td>
<td class="nump">6,344,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber', window );">Warrants Exercisable</a></td>
<td class="nump">6,344,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price of the warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice0.69Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice0.69Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice1820Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice1820Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice0.69TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=syn_ExercisePrice0.69TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453432040440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 27, 2021</div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Oct. 15, 2018</div></th>
<th class="th"><div>Oct. 10, 2018</div></th>
<th class="th"><div>Sep. 11, 2017</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 29, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 05, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.38<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPriceDecrease', window );">Preferred Stock, Convertible, Conversion Price, Decrease</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Common stock issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,996,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EstimatedFairValueOfInducementConsideration', window );">Estimated fair value of inducement consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,960,000<span></span>
</td>
<td class="nump">$ 3,359,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockSharesConverted', window );">Preferred Stock Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,973<span></span>
</td>
<td class="nump">3,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssueOfWarrantsToPurchaseCommonStock', window );">Issue of warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,807,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=syn_FbrCapitalMarketsCoMember', window );">Fbr Capital Markets Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BrokerageCommissionPercentage', window );">Brokerage Commission percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement', window );">Proceeds from Issuance of Common Stock for Exclusive Channel Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockConversionPricePerShare', window );">Preferred Stock Conversion Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_WarrantExercisePriceAdjustment', window );">Effect of Warrant exercise price adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDiscountOnShares', window );">Preferred Stock Redemption Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPriceIncrease', window );">Preferred Stock, Convertible, Conversion Price, Increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.90<span></span>
</td>
<td class="nump">$ 18.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPriceDecrease', window );">Preferred Stock, Convertible, Conversion Price, Decrease</a></td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible Preferred Stock, Terms of Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)&#160;a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii)&#160;if so elected by the Investor, a 4.99% blocker provision that will prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#8217;s common stock or voting power at any time, and (iii)&#160;applicable regulatory restrictions. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BeneficialOwnershipPercentage', window );">Maximum percentage</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AccretionOfPreferredStockDeemedDividend', window );">Accretion of Preferred Stock Deemed Dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionTerms', window );">Preferred Stock, Redemption Terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i)&#160;the VWAP (as defined in the Certificate of Designation) for at least 20 trading&#160;days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6&#160;months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share of Series&#160;A Preferred Stock of $7,875.00, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&#160;A Convertible Preferred Stock or (ii)&#160;the five&#160;year anniversary of the issue date, the Company shall have the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Convertible Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from Issuance of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Sale of Stock, Consideration Received Per Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PreferredStockConversionPricePerShare', window );">Preferred Stock Conversion Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,672,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_PercentageOfIssueOfThePublicOffering', window );">Percentage of issue of the public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDiscountOnShares', window );">Preferred Stock Redemption Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock accrued dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,496,000<span></span>
</td>
<td class="nump">1,380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionDiscount', window );">Preferred Stock Redemption Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_InvestmentWarrantsExpirationDate1', window );">Investment Warrants Expiration Date1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 15,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IssueOfWarrantsToPurchaseCommonStock', window );">Issue of warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,807,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AccretionOfPreferredStockDeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of accretion of the Series B preferred stock deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AccretionOfPreferredStockDeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BeneficialOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of beneficial ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BeneficialOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BrokerageCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent that percentage of commission revenue from buying and selling securities on behalf of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BrokerageCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EstimatedFairValueOfInducementConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Estimated Fair Value of Inducement Consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_EstimatedFairValueOfInducementConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_InvestmentWarrantsExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of warrants held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_InvestmentWarrantsExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IssueOfWarrantsToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represent additional of warrant to purchase of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_IssueOfWarrantsToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PercentageOfIssueOfThePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issue of public offering price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PercentageOfIssueOfThePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_PreferredStockSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The no of shares converted into common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_PreferredStockSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution for exclusive channel collaboration agreement to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_WarrantExercisePriceAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents the effect of warrant exercise price adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_WarrantExercisePriceAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.4-07)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187103-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The excess of (1) the carrying amount of the preferred stock in the registrant's balance sheet over (2) the fair value of the consideration transferred to the holders of the preferred stock, during the accounting period, which will be added to net earnings to arrive at net earnings available to common shareholders in the calculation of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=122038299&amp;loc=d3e42851-122695<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=syn_FbrCapitalMarketsCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=syn_FbrCapitalMarketsCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453437368104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Non-controlling Interest (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 05, 2018</div></th>
<th class="th"><div>Sep. 05, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related Party Transaction, Expenses from Transactions with Related Party</a></td>
<td class="nump">$ 328,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="nump">$ 5,131,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_FairValueOfSharesIssued', window );">Fair Value Of Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Income (Loss) Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(73,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=syn_SYNBiomicsMember', window );">SYN Biomics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity Method Investment, Ownership Percentage</a></td>
<td class="nump">88.50%<span></span>
</td>
<td class="nump">88.50%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Equity interest by parent</a></td>
<td class="nump">11.50%<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Income (Loss) Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=syn_SyntheticBiomicsIncMember', window );">Synthetic Biomics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Equity interest by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_DrPimentelsMember', window );">Dr. Pimentels [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Income (Loss) Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_DrPimentelsMember', window );">Dr. Pimentels [Member] | Consolidation, Eliminations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Income (Loss) Attributable to Noncontrolling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 505,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfCommonStockToBeIssued', window );">Number Of Common Stock To Be Issued</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfCommonStockToBeHeldByRelatedParty', window );">Number Of Common Stock To Be Held By Related Party</a></td>
<td class="nump">7,480,000<span></span>
</td>
<td class="nump">7,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member] | SYN Biomics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalNumberOfCommonStockToBeIssued', window );">Additional Number Of Common Stock To Be Issued</a></td>
<td class="nump">2,420,000<span></span>
</td>
<td class="nump">2,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member] | Synthetic Biomics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdditionalNumberOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional number of common stock to be issued under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AdditionalNumberOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_FairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the fair value of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_FairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfCommonStockToBeHeldByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional number of common stock to be held by the related party under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfCommonStockToBeHeldByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock to be issued under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syn_SYNBiomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syn_SYNBiomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syn_SyntheticBiomicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syn_SyntheticBiomicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_DrPimentelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_DrPimentelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441808984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>License, Collaborative and Employment Agreements and Commitments - Maturity analysis of operating leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix', window );">2027</a></td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Discount factor</a></td>
<td class="num">(456)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - current</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">$ (287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability - long term</a></td>
<td class="nump">$ 1,403<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Lease liability - current, Lease liability - long term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453431590296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaborative and Employment Agreements and Commitments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 23, 2021</div></th>
<th class="th"><div>Dec. 30, 2020</div></th>
<th class="th"><div>Dec. 23, 2020</div></th>
<th class="th"><div>Aug. 07, 2019</div></th>
<th class="th"><div>Sep. 05, 2018</div></th>
<th class="th"><div>Dec. 05, 2013</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Dec. 19, 2012</div></th>
<th class="th"><div>Dec. 19, 2012</div></th>
<th class="th"><div>Nov. 28, 2012</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_CostOfLivingAdjustmentsPercentage', window );">Cost of Living Adjustments Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_FairValueOfSharesIssued', window );">Fair Value Of Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000<span></span>
</td>
<td class="nump">$ 209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">321,000<span></span>
</td>
<td class="nump">309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NonCashAdditionOfRightOfUseAssets', window );">Non Cash Addition of Right of Use Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="nump">5,131,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfCommonStockToBeIssued', window );">Number Of Common Stock To Be Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_NumberOfCommonStockToBeHeldByRelatedParty', window );">Number Of Common Stock To Be Held By Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember', window );">Cedarssinai Medical Center [Member] | SYN Biomics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalNumberOfCommonStockToBeIssued', window );">Additional Number Of Common Stock To Be Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">Operating Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseAgreementAnnualPaymentsDue', window );">Annual payments due under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseAgreementFinalPaymentDue', window );">Final payment due under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=syn_StevenAShallcrossMember', window );">Steven A. Shallcross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=syn_Dr.SlimanMember', window );">Dr. Sliman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage</a></td>
<td class="nump">62.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="nump">650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToEmployees', window );">Annual Base Salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=syn_PrevAbrLlcMember', window );">Prev Abr Llc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalCashPaymentForLicenseAgreement', window );">Additional Cash Payment for License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 235,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_UnregisteredSharesIssuedToLicenseAgreement', window );">Unregistered Shares Issued to License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_AdditionalConsiderationPayable', window );">Additional Consideration Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">50% in cash and 50% in our stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OptionsToBeReceivedCommonStockShares', window );">Options To Be Received Common Stock Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syn_PhaseIClinicalTrialsMember', window );">Phase I Clinical Trials [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syn_PhaseIiiClinicalTrialsMember', window );">Phase III Clinical Trials [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syn_NdaSubmissionInUsMember', window );">NDA Submission In US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syn_EuropeanMedicinesAgencyApprovalMember', window );">European Medicines Agency Approval [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syn_RegulatoryApprovalInAsianCountryMember', window );">Regulatory Approval In Asian Country [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=syn_ClinicalTrialAgreementMember', window );">Clinical Trial Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_EstimatedResearchCosts', window );">Estimated Research Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_FirstYearMember', window );">First Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ResearchAgreementFixedFee', window );">Research Agreement Fixed Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,287<span></span>
</td>
<td class="nump">303,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_SecondYearMember', window );">Second Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ResearchAgreementFixedFee', window );">Research Agreement Fixed Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,438<span></span>
</td>
<td class="nump">316,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_ThirdYearMember', window );">Third Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems', window );"><strong>License, Collaborative and Employment Agreements and Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ResearchAgreementFixedFee', window );">Research Agreement Fixed Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328,758<span></span>
</td>
<td class="nump">$ 328,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdditionalCashPaymentForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional cash payment for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AdditionalCashPaymentForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdditionalConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description related to additional consideration payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AdditionalConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_AdditionalNumberOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional number of common stock to be issued under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_AdditionalNumberOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_CostOfLivingAdjustmentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to cost of living adjustments percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_CostOfLivingAdjustmentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_EstimatedResearchCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated research services cost provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_EstimatedResearchCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_FairValueOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount represents the fair value of shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_FairValueOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LicenseAgreementAnnualPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of annual payments due under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_LicenseAgreementAnnualPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LicenseAgreementFinalPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the final payment due under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_LicenseAgreementFinalPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A milestone payment is an authority payment made to a contractor which is linked to the contractor delivering a service or commodity such that, should the agreement be terminated at the point of payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NonCashAdditionOfRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non cash addition to right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NonCashAdditionOfRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfCommonStockToBeHeldByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional number of common stock to be held by the related party under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfCommonStockToBeHeldByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_NumberOfCommonStockToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of common stock to be issued under stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_NumberOfCommonStockToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_OptionsToBeReceivedCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It Represents options to be received common stock shares reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_OptionsToBeReceivedCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ResearchAgreementFixedFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of research and development costs incurred for a fixed-price, all payable in quarterly installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ResearchAgreementFixedFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_UnregisteredSharesIssuedToLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_UnregisteredSharesIssuedToLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to employees, including wages and salaries, during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_CedarssinaiMedicalCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=syn_SYNBiomicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=syn_SYNBiomicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=syn_StevenAShallcrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=syn_StevenAShallcrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=syn_Dr.SlimanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=syn_Dr.SlimanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=syn_PrevAbrLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=syn_PrevAbrLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syn_PhaseIClinicalTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syn_PhaseIClinicalTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syn_PhaseIiiClinicalTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syn_PhaseIiiClinicalTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syn_NdaSubmissionInUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syn_NdaSubmissionInUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syn_EuropeanMedicinesAgencyApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syn_EuropeanMedicinesAgencyApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syn_RegulatoryApprovalInAsianCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syn_RegulatoryApprovalInAsianCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syn_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=syn_ClinicalTrialAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=syn_ClinicalTrialAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_FirstYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_FirstYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_SecondYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_SecondYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_ThirdYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_QuarterlyInstallmentsPaymentPeriodAxis=syn_ThirdYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453440951960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Computed "expected" tax-benefit - Federal</a></td>
<td class="num">$ (3,045)<span></span>
</td>
<td class="num">$ (2,124)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Computed "expected" tax-benefit - State</a></td>
<td class="num">(931)<span></span>
</td>
<td class="num">(616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Adjustment of "expected" tax-benefit to actual</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals, entertainment and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Non-deductible stock-based compensation</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax rate adjustment</a></td>
<td class="nump">932<span></span>
</td>
<td class="num">(1,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal and state net operating loss adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="nump">3,012<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28511-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123452999&amp;loc=d3e28446-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453442689832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeferredTaxAssetsStocksIssuedForServices', window );">Stock issued for services</a></td>
<td class="nump">$ 1,504<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued compensation</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram', window );">Stock issued for acquisition of program</a></td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeferredTaxAssetsStockIssuedForlicenseAgreement', window );">Stock issued for license agreement</a></td>
<td class="nump">1,363<span></span>
</td>
<td class="nump">1,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeferredTaxAssetsStockIssuedForMilestonePayment', window );">Stock issued for milestone payment</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee', window );">Amortizable license fee</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry-forward</a></td>
<td class="nump">16,884<span></span>
</td>
<td class="nump">12,540<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">21,480<span></span>
</td>
<td class="nump">17,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(21,480)<span></span>
</td>
<td class="num">(17,287)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stock issued for acquisition of program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeferredTaxAssetsStockIssuedForMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Stock Issued For Milestone Payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DeferredTaxAssetsStockIssuedForMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeferredTaxAssetsStockIssuedForlicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stock issued for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DeferredTaxAssetsStockIssuedForlicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeferredTaxAssetsStocksIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stocks issued for services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DeferredTaxAssetsStocksIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from amortizable license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453441746008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</a></td>
<td class="nump">6.46%<span></span>
</td>
<td class="nump">6.45%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</a></td>
<td class="nump">8.18%<span></span>
</td>
<td class="nump">8.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="nump">$ 21,480<span></span>
</td>
<td class="nump">$ 17,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Tax Assets, Net of Valuation Allowance</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">$ 58,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OperatingLossCarryforwardsExpireDate', window );">Operating Loss Carryforwards Expire Date</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2018Member', window );">Tax Year 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="nump">198,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OperatingLossCarryforwardsLimitationOnUse', window );">Limitation on Operating loss carryforwards</a></td>
<td class="nump">$ 155,600<span></span>
</td>
<td class="nump">155,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_OperatingLossCarryforwardsExpireDate', window );">Operating Loss Carryforwards Expire Date</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2020Member', window );">Tax Year 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_OperatingLossCarryforwardsExpireDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_OperatingLossCarryforwardsExpireDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_OperatingLossCarryforwardsLimitationOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_OperatingLossCarryforwardsLimitationOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140453432286856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Jan. 03, 2022</div></th>
<th class="th"><div>Dec. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=syn_StevenAShallcrossMember', window );">Steven A. Shallcross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Annual cash performance bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Steven A. Shallcross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1', window );">Employment agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Annual base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Steven A. Shallcross | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage', window );">Annual cash performance bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | VCN Private [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ConsiderationPurchasePaid', window );">Consideration purchase paid</a></td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_CashPaymentsExistingLiabilities', window );">Existing liabilities</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_ClosingFinanceCosts', window );">Finance costs</a></td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Budgetary plan</a></td>
<td class="nump">27,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BusinessCombinationMilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | VCN Private [Member] | Grifols Innovation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | VCN Private [Member] | New technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business Acquisition, Percentage of Voting Interests Acquired</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | VCN Private [Member] | Other First Indication [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BusinessCombinationMilestonePaymentsSafeToProceed', window );">Milestone payments safe to proceed</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BusinessCombinationMilestonePaymentsFirstPatientDosed', window );">Milestone payments first patient dosed</a></td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BusinessCombinationMilestonePayments', window );">Milestone payments</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BusinessCombinationMilestonePaymentsBlaApproval', window );">Milestone payments BLA approval</a></td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | VCN Private [Member] | Other Second Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BusinessCombinationMilestonePaymentsSafeToProceed', window );">Milestone payments safe to proceed</a></td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BusinessCombinationMilestonePaymentsFirstPatientDosed', window );">Milestone payments first patient dosed</a></td>
<td class="nump">3,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BusinessCombinationMilestonePayments', window );">Milestone payments</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_syn_BusinessCombinationMilestonePaymentsBlaApproval', window );">Milestone payments BLA approval</a></td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BusinessCombinationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of business combination milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BusinessCombinationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BusinessCombinationMilestonePaymentsBlaApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of business combination milestone payments BLA approval .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BusinessCombinationMilestonePaymentsBlaApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BusinessCombinationMilestonePaymentsFirstPatientDosed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of business combination milestone payments first patient dosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BusinessCombinationMilestonePaymentsFirstPatientDosed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_BusinessCombinationMilestonePaymentsSafeToProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of business combination milestone payments safe to proceed .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_BusinessCombinationMilestonePaymentsSafeToProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_CashPaymentsExistingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments existing liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_CashPaymentsExistingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ClosingFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of finance the costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ClosingFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_syn_ConsiderationPurchasePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration for the purchase paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">syn_ConsiderationPurchasePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>syn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6409875&amp;loc=d3e20015-108363<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6409961&amp;loc=d3e20487-108367<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=syn_StevenAShallcrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=syn_StevenAShallcrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=syn_VcnPrivateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=syn_VcnPrivateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=syn_GrifolsInnovationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=syn_GrifolsInnovationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=syn_NewTechnologiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=syn_NewTechnologiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_OtherFirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_OtherFirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_OtherSecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=syn_OtherSecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>syn-20211231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:syn="http://www.syntheticbiologics.com/20211231"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="syn-20211231.xsd" xlink:type="simple"/>
    <context id="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tO6QgfwYmUKrmumFN_QdXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ZNP2PWLgIUK7spcejRs3hQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_26_2017_V_Q0QMOYikCPg8S4qD1ovg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2017-12-26</instant>
        </period>
    </context>
    <context id="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zR9PSAiA3US5NsG8x7-7Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_vVcxs-TyVEOrQ1i7bBXI3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:FbrCapitalMarketsCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_IPq28Mt1gUW_3j_-pwfbiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_IfsKKTpoWkaVjjV1uYXCvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_e0SFi2g7CEyrvY0QNpCI5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_g8yBpnY3o0iFqkOSqvylXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-10</endDate>
        </period>
    </context>
    <context id="Duration_11_18_2016_To_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MDjl32aA7Eup2n9x0SL85A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-18</startDate>
            <endDate>2016-11-18</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_tjgiVhZrI0OhzmtDQzO8PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HesMEARWFkamUpDQQXE38g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember__EXyzsLBqku0E4Q28xmdZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y8DpvdHRXUi1PZn6rztZ4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lizShvTQnU27DK8SmxrMjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember__lq54v75EEqpd9AIZOp9HA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oR9rstllEUaUPKUvptIWbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w6f6JU4750WKM1AQ8ouQ7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_nK4S9nYjdkezj6o91cTQfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TY4ik2aZpkKjKDPnPKTE7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FpJzkt3PvkCZCGFfIrDKyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VbneEhxFhkiVk48Qo2CSMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BD7rNLuWk0iEFQwVRkploA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YJu4vcU5tUaCOKLeOjoE9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E9oQZ01YbkmNNdN49AavHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M20NXTQpLkugL1IJr-5fEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_puysgE2QRkquEuEWCphmDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-18</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice710010200Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice41007000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice0004000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice710010200Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice41007000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:RangeOfExercisePrice0004000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TmfP0gKxNEy5KmAuY3LXKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_syn_StockPlan2010Member_4D5WRURlwE63c5hlGLugSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_8UEIx49YJkWPUL6XsZYSRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockPlan2007Member_auU9NgALU0aCvHRUD6P_0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_17_2020_us-gaap_PlanNameAxis_syn_StockPlan2020Member_KiYSEy59102VWky5jzVKvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-17</instant>
        </period>
    </context>
    <context id="As_Of_11_2_2010_us-gaap_PlanNameAxis_syn_StockPlan2010Member_Zt_SyFnbm0e4SI86EXshXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-11-02</instant>
        </period>
    </context>
    <context id="As_Of_3_20_2007_us-gaap_PlanNameAxis_syn_StockPlan2007Member_sZjnQm5mlUKRuIz8LR01dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-03-20</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zVfa8-ihl0GXFzR6eyN9PA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZD4aLXU3F02Cocoebc69mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_EmployeesAndDirectorsMember_nY8Xr06tV0aNNWlTT_5fvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_EmployeesAndDirectorsMember_LECQK4-VqUWq2chzZjdaUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:EmployeesAndDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2007_To_3_20_2007_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_syn_StockPlan2007Member_6vT1SirORkqYa-QBH8UMpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2007Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-03-01</startDate>
            <endDate>2007-03-20</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_YKWmzXomVU-N4eCGaM8B_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockPlan2010Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_XdJgrqbMT0ShQF0kRBhn7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_9_5_2018_To_9_5_2018_uBFbvYxH-EmzEpTcsw0I4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2018-09-05</startDate>
            <endDate>2018-09-05</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_06odZ0po2U2Duco7oDcnHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_qOfAb8XKjEiqZKgjiMEWCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_mGRCO12RFEyXuQzUlkC0Ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_IzIuFnR8zEGM4rQkXo15Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_ZvDVzBKGkEueIM7aytJo4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputersAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_588QHXjz8kSla7aDWmJMXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_xIpjyVqOO0Og8SZMiELCjw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_ThDy-dV5AU6IEh4MuJpfGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">syn:ComputersAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_XRwkhJ_Dmk-8YpsoxAckVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_5WO4v6359U6n6BT9EUOLpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-11</startDate>
            <endDate>2017-09-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_U6tWdREtxkuc90dTPJYBog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-JYGHuWq50WFYfi0Zl8OPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-11</instant>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_BQ77y5ola0aDzP3L6mwvjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_XT6XJ5XjDUuV4c_EGi70aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_E07f6QbiCEq3peUEus5GHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_wVR9EwKxu0OMQoL-9aHnSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_16_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CBpL-RLdCE6YnRWt9ySuKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_2eCFDmHGOUmlUJq481sbrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_9_1_2021_To_9_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_k_-xpTQWD0GCQdXycMKDSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bg6a5VAYZkmiWar8_qygxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-27</startDate>
            <endDate>2021-01-27</endDate>
        </period>
    </context>
    <context id="Duration_1_27_2021_To_1_27_2021_DAGJFo-tVEioslNEUzr8Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2021-01-27</startDate>
            <endDate>2021-01-27</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2020_To_12_23_2020_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_CEW0YNQQwU-z7FPuSvxFMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:Dr.SlimanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2017_To_11_30_2017_9RYWQN6O80iVs8ielspjNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9Xpcg3JLq0uiDoVj62uKQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-02</startDate>
            <endDate>2013-12-05</endDate>
        </period>
    </context>
    <context id="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_GqTzjk6ZRUmQxuCuv8dWDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-12-02</startDate>
            <endDate>2013-12-05</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2020Member_FiWLkKZ3vEKpx7yg9MiRzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeaseAgreementsMember_FPxvWRsyyEuHDdGJz_4XaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_syn_SeriesAAndSeriesBPreferredStockMember_fpL3K7hVwEiXTKmMFfDtbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">syn:SeriesAAndSeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ConsolidationItemsAxis_srt_ConsolidationEliminationsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_DrPimentelsMember_0ZR0S_QqJE-CfP4OWtt76g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:DrPimentelsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_lfF71se-CkmmyddDrmHIPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_DrPimentelsMember_6pUuXCugXk6NelClzj9WWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:DrPimentelsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_cBapFdW9TUCTcjAUH7txKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_Ub1M_a5LVE-DkomejQsGNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SyntheticBiomicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_2hlEGz94m0y871onqyMQIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_X7OTRMegzEONug23YJ7vFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_ppvkWxwF4027bvy1U_yy0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_MRPkLh7Yjk6pd-zFujqF_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGuOmgQVFUWelRGFisfwCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:StevenAShallcrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="Duration_1_3_2022_To_1_3_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6rAbrvfSCUWGUsBaubIWMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:StevenAShallcrossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2022-01-03</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2021_To_12_23_2021_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_ob3-lBLKQ0-1m3VgfFdc-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:Dr.SlimanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-23</startDate>
            <endDate>2021-12-23</endDate>
        </period>
    </context>
    <context id="Duration_12_30_2020_To_12_30_2020_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_5Rwg92J14EiVYGDVwneJ0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:StevenAShallcrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-11</startDate>
            <endDate>2017-09-11</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2021_p7WYQOUTpUi11HMdW1VRjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_3Kn9Wj-M-U2EBcPcpa_-tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_UcLPi0nU_k-Nrovhui30Ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_I2ym8-ECqUmzrLIL8pB_FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="As_Of_11_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_cCtXQSarIUqWy1ntHvFVqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-08</instant>
        </period>
    </context>
    <context id="As_Of_11_16_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_JKnuxTVzpU26lxfBbgZZXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="As_Of_11_16_2020_CZ8bHk5Mp0ir4tpe8uIf9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B1Z-wDViY0io9Y60hJ5IyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="As_Of_10_15_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_h58kDK3e0kC9mHm8SZusWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="As_Of_10_15_2018_zFSd_b_S1kyXW8-66Kwglw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="As_Of_11_18_2016_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_us-gaap_SeriesAMember_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_JdtyyC7Z80SCunUZpuqFNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AuctionMarketPreferredSecuritiesStockSeriesAxis">us-gaap:SeriesAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">syn:StockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-18</instant>
        </period>
    </context>
    <context id="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ZxaIHv3whUOoORl_cB5qNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-11-18</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_syn_MoneyMarketAccountsMember_RVHGBSefSU2di_Mp-C0IXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">syn:MoneyMarketAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_syn_MoneyMarketAccountsMember_sKG50uvlI0qAGAuG7zjYtg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">syn:MoneyMarketAccountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_BusinessAcquisitionAxis_syn_NewTechnologiesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WiHLxploBU2xe-zdv1Ih8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:NewTechnologiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_BusinessAcquisitionAxis_syn_GrifolsInnovationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4zfGfEAdcUanM58rCqi1Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:GrifolsInnovationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_CsW_sJTdhUmHG2HCpG3-rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_OptionMember_UcsU_7n8D0Gh9M_a12yMqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_p0e-bc-m1k-aY-9mEgL6FQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_OptionMember_w-qS4dRJ3U6O4DpjgVohSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_VjXYAcDWp02HBkXd6GYVAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_MCFQsLEw-UuxHL58RoxInQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_eQmeAnrjzk6zi6wV_bY3hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_ombmDTe2AkCAbJcUoj-n9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_-3VYIo1Se0a3VB9LflrxFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_thyNdGbiIUKfEg211NQAxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">syn:GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:ConsultantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_15_2018_To_10_15_2018_us-gaap_ClassOfWarrantOrRightAxis_syn_OctoberTwoThousandEighteenWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_syn_UnderwrittenPublicOfferingMember_Kff7vF4eSUKF3WYZhsclQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:OctoberTwoThousandEighteenWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">syn:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-15</startDate>
            <endDate>2018-10-15</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_mAkr-3jFnkW2bbxcAR8RYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice1820Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_Y6KWsIfrY0W-AXmu4z1SHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice0.69TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_nGWIzttATUuENHWAb_1Gxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice0.69Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_7WfemUuB9kSDPnEwicRDoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_VMLlPD7ENUWWhTbFeid_mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice1820Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_8CxCH8oNkEm74aCXq-VOTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice0.69TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_Qfjmc-RTiEuH6kugXZ51Iw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">syn:ExercisePrice0.69Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_26_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_MzByem4-e0OSJosV2hHEFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-26</instant>
        </period>
    </context>
    <context id="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_ThirdYearMember_pDW3ZJBjLEOCTDy7Fvp73A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="syn:QuarterlyInstallmentsPaymentPeriodAxis">syn:ThirdYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-19</instant>
        </period>
    </context>
    <context id="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_SecondYearMember_BTboTCNJsUKQRiy6cxkbug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="syn:QuarterlyInstallmentsPaymentPeriodAxis">syn:SecondYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-19</instant>
        </period>
    </context>
    <context id="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_FirstYearMember__Bn5hy98mU6mfmfCN95quw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="syn:QuarterlyInstallmentsPaymentPeriodAxis">syn:FirstYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-19</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_ISVZPzMHc0Ggvc_ZgMPJ2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:FbrCapitalMarketsCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_84bpVptC1E-TU2cJmJR7uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-15</instant>
        </period>
    </context>
    <context id="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Y8P_QWYzfky5T_au5O14bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-11</instant>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember_OdBA1XZNCkSZ2xDmj4iqwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:PrevAbrLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_HRovq6U78E-v3Zs9fQPjlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_XDETk7h4EEaL0z0ltMNi8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_gGcNUhXIPkSw2CheAQJBxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_MCMoFtcreUerjsPb8Xr3IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-18</startDate>
            <endDate>2016-11-18</endDate>
        </period>
    </context>
    <context id="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_qr4fxMiyiEuZKSyigooSJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">syn:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-18</startDate>
            <endDate>2016-11-18</endDate>
        </period>
    </context>
    <context id="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_QYEqV_MK-kaCxh0ejQsXbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_RegulatoryApprovalInAsianCountryMember_b29ls9jD-Eq0pdQkSHFuxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:RegulatoryApprovalInAsianCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-02</startDate>
            <endDate>2012-12-19</endDate>
        </period>
    </context>
    <context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_PhaseIiiClinicalTrialsMember_lswYHCn0iEGpMO6RGGHoqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:PhaseIiiClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-02</startDate>
            <endDate>2012-12-19</endDate>
        </period>
    </context>
    <context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_PhaseIClinicalTrialsMember_TUHpBF3yc0CkN3QUWLfWmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:PhaseIClinicalTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-02</startDate>
            <endDate>2012-12-19</endDate>
        </period>
    </context>
    <context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_NdaSubmissionInUsMember_iAOhW_VZcEGqi0gmByMIAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:NdaSubmissionInUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-02</startDate>
            <endDate>2012-12-19</endDate>
        </period>
    </context>
    <context id="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_EuropeanMedicinesAgencyApprovalMember_P8LwHIwz0kewI_WCPzgecA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:EuropeanMedicinesAgencyApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-02</startDate>
            <endDate>2012-12-19</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2012_To_12_19_2012_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_gp7VGPemIUmMsNTJacOkog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-01</startDate>
            <endDate>2012-12-19</endDate>
        </period>
    </context>
    <context id="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_AwBR-gCbEkOKHtktUYXQIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="As_Of_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_uAjHlff2ZEySANOAcEoi0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-10</instant>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_3SlaVldlt0uuxM4dd8Zq4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2018_To_9_5_2018_BLr1pn9j6UusGha5FDmjVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-05</endDate>
        </period>
    </context>
    <context id="Duration_8_7_2019_To_8_7_2019_us-gaap_TypeOfArrangementAxis_syn_ClinicalTrialAgreementMember_e8nSUVWVOUOzmBeVgBlJ_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">syn:ClinicalTrialAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-07</startDate>
            <endDate>2019-08-07</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2020_To_12_23_2020_lK-7ce7kgUKMLA_1odurJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2020-12-23</startDate>
            <endDate>2020-12-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nYSwPr0VKkqWTeFT1i_ttQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_iWZnfq9DoESxxwMr9XQsEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3rOlqxEP0ybyVhLBiTYEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8-WgejdDaEqgy2EWOSkLzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B8SS6pik5UydvtJcCB9dlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_US3t8HW7-0GmoQhdLHyCwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_u3tJQ_TKWUKU4AV_VlfaIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_fJelKMiPik68kesEofzomQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z7S1T7sWPU-5mMUOHtvhAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p4kGNEYs-UaBwLK97CJoow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_10_2022_To_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nY9W9p5hLEOy0btQJThIaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-10</startDate>
            <endDate>2022-03-10</endDate>
        </period>
    </context>
    <context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:OtherSecondIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:OtherFirstIndicationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6abns4wbvk2nLNMGsIo3mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">syn:VcnPrivateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="As_Of_8_5_2016_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_z5Ev0yENHUmoho2bPyB-eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">syn:FbrCapitalMarketsCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-08-05</instant>
        </period>
    </context>
    <context id="As_Of_3_29_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_19H4jFVReE6xfC5K5cBF2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-29</instant>
        </period>
    </context>
    <context id="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JT5YJdWctkSrgjj-7sNP_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-27</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYTAthCVn0yW8kcGh07aqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">syn:SYNBiomicsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">syn:CedarssinaiMedicalCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="Duration_11_2_2012_To_11_28_2012_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember__uZ5OPc6pka-czPBvUDXXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">syn:PrevAbrLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-11-02</startDate>
            <endDate>2012-11-28</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_MBsOhyAU1U-BqkratkUq7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_16_2022_umqElCEvQEmNaFMGvvZFPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <instant>2022-03-16</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000894158</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_yMnlz8fE9U-5tR1qkqQKuA">
        <measure>syn:item</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="0"
      id="Hidden__wOLoItMfEOut5trbqSU7g"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">121875042</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="0"
      id="Hidden_3sfOX5zm_UaozPORX6pCRg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">19011362</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_aDIZG6t2n0GZwd5yvkuYTA_2_1">0000894158</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_P_akI3DE1U26SA0hTdl8ZQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_WywGZbKdZEKPeSzBbDQ9WQ_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_zI_l_DiMgECyz19QANz4gg_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_LmSysYKNIEGOs74P9jPmJg_6_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Hidden_BQvinvRxo0eTGbNdzdVEkw">Synthetic Biologics, Inc.</dei:EntityRegistrantName>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      id="Hidden_pHpHOTsQ8k6yuHhORq5anA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      id="Hidden_ZQSm3RSFNUWe7-1pBlUnCQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Hidden_Fdq-HoAqqU2n8c5YodGVLg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="0"
      id="Hidden_f4gZt4BnFEalpG9LgsR3Xw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">120000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Hidden_e1t6MXX3JEGFq5wEFzIGlA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="0"
      id="Hidden_amWeR7lJNkqz2tqB1vva4w"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3973</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="INF"
      id="Hidden_tNvE2AVdREediPDrorC8RQ"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">-0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="INF"
      id="Hidden_7MwD_ebw_UmKjW6bRvU1Yw"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      id="Hidden_YmEvW5Sg1kyNFgYcXmib7A">http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_yl_iqzuwbE6YNxoKgQk5EA">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_igEh-5p84UO6ixlkErH2Ag">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_WJ8vzMZVtkirVRc3nGT5OA">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_rEh6dqkOcEiTsdAjXxoyzg">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_i48lUAHvV0SW8fVE-anq2Q">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_p9PKWbwcJUSLOaWvo30aCQ">001-12584</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_H0HqScr_fUSM3MmATWvHmw_1_0">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_keeYmNuox0KPfx9V4LaaUA_1_2">13-3808303</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_6vQPNIAUAEmAlDyNqBfM9g">9605 Medical Center Drive, Ste. 270</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_yIZKH3vYLEqFzWDSfx4Y2A">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_Q627kfPO6UW73iK1hFEEQA">MD</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_mc1QBtnKwEWoGsAPoFaPnw_1_2">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_xiNr4Q5EhEy4TwBBnlKBUA">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_vj1d6FK8ZUy8jQyBTT8wiQ">417-4364</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_nFa-5Y7L7Ue1qvXQZ6iUYw_2_0">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_uyg43PNvjUqKNEQ3YmQ1dg_2_2">SYN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_4hrRhqZiNUSj17XtFl6Nrg">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_UGJcEqxqGkG5q2Edh691Eg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_G_TbGiV-mk2BKZjij_taAw">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_r5ADZNlsSEOXcgWNBogkTw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_KNsZDxfWJEOQAPfCKiajWQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_rR3FRUyZ9US2pKOyiqMYSg_3_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_w4M9TrN2Q0-fMau5grodrA_3_4">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_KifUZ1VHC0eEnjmAXIJ7Zg_5_4">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_2BKukzij6kyRiEjTtb8lvw">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_rdkwoj4LnEOmwR1Yn_KzQw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2021_MBsOhyAU1U-BqkratkUq7w"
      decimals="-5"
      id="Narr_L8Gt-6XhZ0mVBfyFbdogJQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">79200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_16_2022_umqElCEvQEmNaFMGvvZFPQ"
      decimals="0"
      id="Narr_M5izBwoGRkSNMCmZ5OmGNg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">158437840</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_JoIwNyBaZEa118QuT_ZqIQ">243</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_19Q5F0CdYkabZL8g-g1rJw">BDO USA, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_zZWezzShcEy6PqQiN3Yg0Q">Potomac, Maryland</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc__lJhleaxWkWD9C7a388QhA_6_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">67325000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_IhmLzKzyGk6ymQm0B8cGnw_6_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">6227000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_jC8SFo5dT0WpQImbP5edGQ_7_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1533000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_XaBvtAcTIkuPIRNAwa-ijA_7_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1707000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_i-H79Uox0kmyqni-Oz3wKg_8_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">68858000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_P7bnqApJs0K2IdofZLrrbA_8_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">7934000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_QsdCNIHHIU6xp2lazl1I6Q_10_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">101000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_LEr9Am4zEkOLgp-o_U5lCQ_10_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">174000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_dGQXUPy4V0SSL4X0m7RCqw_12_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1383000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_APSnGvLvrUGeqPtWH7F6_g_12_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">279000</us-gaap:OperatingLeaseRightOfUseAsset>
    <syn:DepositsAndOtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_9KGf_p3uwUa6KtteDJQOWA_14_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">23000</syn:DepositsAndOtherAssetsNoncurrent>
    <syn:DepositsAndOtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_pkMnrIQH906qYnp9LY4gQA_14_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">23000</syn:DepositsAndOtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_yCRlYafJBUW5qBYkapJQ1g_16_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">70365000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_G6uEe5XAoECARBUVsQ1N6A_16_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">8410000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_zhpqeyRcuUmYM3uTr7mhnA_21_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">524000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_uehZkXyusUKD6Dk5AybX7w_21_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">886000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_BVcOBeah1UG4nbXB_Z_viQ_22_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1928000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_opKb27YpqEaMCUB5LEDQTw_22_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">925000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_vOBUzihzaEG-o0QJ7OXBrA_23_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">978000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_FtjAz8YFSke4SvQEXn9iEQ_23_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">868000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_6vbRcbTMNEeLuHhbjd7WQg_24_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">124000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_R0YzVY8Xz0m-IQ4O4ypHpw_24_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">287000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_ARYRAjjj3UuKohUFBcbriQ_25_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3554000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_gQK6IMglgkuMlqV9ndud-w_25_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2966000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_1zXxSlA1k0Okloo_6-7NCg_26_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1403000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_gGPI36vwYku6emEoHe1b_A_26_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">186000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc__mAfHYKXWU-rtgsNxZX8dw_27_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">4957000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_TalyIMAJFUic1RC4k_jNyg_27_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3152000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="3"
      id="Narr_XCPTLxGJiUuiusz_JWd1DA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="3"
      id="Narr_-ywaUWrjKkyr1lg8R-sLuA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="0"
      id="Narr_fjy_1E7Y_UCLYIFOtXyuBg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Narr_f6lP6fCkFUSFYIkuxf2_pQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">10000000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Narr_jtd7eQTpTEOYhsxM-FqWUA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="0"
      id="Narr_0LE6d80Fo0G8dvtbJyrGeg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">120000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_lmGX3NWDHkOZkxzjN9T41Q_30_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_6Xg4lkPtQU-CgQ2ZBVilSg_30_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">12798000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="4"
      id="Narr_Wq3oOh6GyUmroMkarzwyRA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="4"
      id="Narr_9weAVK5DfEqtxVEIo5Qw2Q"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="0"
      id="Narr_DpCLsmLUgkSzbYY__xeOlQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Narr_tiFisDwvr0-yJPoRN9JrQw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Narr_oeuykZxbF0CK2rcUDL2mXg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="0"
      id="Narr_CuBnlQg7okKJK8ZK77W4JA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3973</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_hrR9AAa_v0G8k36RSYX_Bw_32_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_Qq2tYr0Lr024Em15FSkKFw_32_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2477000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="3"
      id="Narr_yLRpncve9kOYqi2beMAUtQ"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="3"
      id="Narr_dzZBRE-8O0K3W43OI0mO6g"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="0"
      id="Narr_azRuMz524k-FEF02lHsfAA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Narr_pztgZwEVqEqReqME3XxS1g"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Narr_BSQPtdY2BUm6ogsZsHyw0Q"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">132044866</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Narr_YfenoYpdKUa10u2OuzEk2Q"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">132042538</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="0"
      id="Narr_75D7cJNjdUSiQenORIVKrw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">29252253</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="0"
      id="Narr__adGeaHuVk-ust1iiPFbdQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">29249925</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_5OH0Y6yHYU6LCKOmMpnBMg_33_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">132000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_EYJFCgq1KUat4DDLXoP2Ig_33_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">29000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_YsYbgkCHOkSErEI3KP0_Fw_34_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">336560000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_FF5dpQI_j0KPrc9SOUF5ZA_34_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">240821000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_GJ0pI0ESCk6EqCGU1HHc0Q_35_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-271284000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_sd--Bk3N5UKR1PTenNmLcg_35_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-248094000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_DFoibmQQAEqjqWmjAPBgwQ_36_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">65408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_w45LQUfnpUetCqXWOo_eWQ_36_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-4767000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_L51e-__fPEa-Sny4agcS2A_37_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-2773000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_ygT3wckGP06Klv7fP1hHBA_38_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">65408000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_S5bM82f4ZU2vPgGUbhkvaQ_38_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-7540000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_lR6-NJ6uTEyVy0sCOdUt3g_39_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">70365000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_rkMDINbJJ02xmq2wvmEx_A_39_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">8410000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_06AYPakes0mWKLrQQmdwaQ_4_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">6474000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_lJZgnQG9R0GLmM3581gTIw_4_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">5029000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_z04EWOcXX0-FEwYVpiiL1A_5_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">7800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_1is1AROzD0W0zSiH9Rql4A_5_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">5131000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_U4XxVEirPk6DIXnXZjdGeQ_6_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">14274000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_ScoEwhPNIUOkA6N_INBMDw_6_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">10160000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_h9bX_EUJV02ou3_1Rh3MrQ_7_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-14274000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_zDUqNfJ4SU-UVmWnQtajLA_7_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-10160000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_Nm8w2cLbjUCyYegEbTDzWA_9_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">6000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_wg4Ae5NPIEGXxfw7MQMbRA_9_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">44000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_R7bY-7-8oU60in0XIiwvvw_10_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">6000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_jo7YEXL3CEm6kvfCyx5NLA_10_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">44000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_g-BgJuo0AkaALr4kywJZ-g_12_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-14268000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_YswN2E6o70CRGFD4Klt6bw_12_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-10116000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_rRd9vxyjBkeArDvNLaFITw_14_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-1000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_5uZGXWDVC0y1BpRwxcWsDw_14_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-73000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_Gmw1maCtgUSR-bV-p3YaBA_16_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-14267000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_UfQPJpv_xE-AmOyJfDnbEQ_16_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-10043000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ"
      decimals="-3"
      id="Tc_FeVQVpH5ukWOCQOPbGT4pA_18_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">24000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig"
      decimals="-3"
      id="Tc_mXNms1UigEOa2pCcc7Y9aA_18_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">254000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B8SS6pik5UydvtJcCB9dlw"
      decimals="-3"
      id="Tc_pbekA9qxU0uUqI5GjBS_8Q_19_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1496000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA"
      decimals="-3"
      id="Tc_LeyfVXPQG0u28s8kco4P3A_19_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1380000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ"
      decimals="-3"
      id="Tc_UpBIFBVf8Umv2gVK3Gx4ww_20_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">7402000</syn:PreferredStockPriceAdjustment>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig"
      decimals="-3"
      id="Tc_85UiMwtxb0e73pZuPiuRFA_20_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:PreferredStockPriceAdjustment>
    <syn:WarrantExercisePriceAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_0_l_-0gHpUGOWOLG0QJC8Q_21_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:WarrantExercisePriceAdjustment>
    <syn:WarrantExercisePriceAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_tRU-SRkrxUKI1VHikcesHw_21_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">880000</syn:WarrantExercisePriceAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_n7mLT64GIUKCMY6Ssdpedw_22_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-23189000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_41NGWoKJ5EeWLKYs6GZkug_22_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-12557000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="INF"
      id="Tc_w-BbEaIpykuq_3anqftQWw_24_3"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">-0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="INF"
      id="Tc_tmxrERUH3k6ugYGWkkw-0w_24_6"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="0"
      id="Tc_C4KwpEaThEO-tywcsFtkXg_26_3"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">121875042</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="0"
      id="Tc_VxJ3fhbcoUeXNfyzXkIkrQ_26_6"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">19011362</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E9oQZ01YbkmNNdN49AavHw"
      decimals="0"
      id="Tc_ZBOydCz3EEqtnfPdGiBCbg_6_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">16806430</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_E9oQZ01YbkmNNdN49AavHw"
      decimals="-3"
      id="Tc_qY_Ki7CigUqgwYIkQ4cOzQ_6_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YJu4vcU5tUaCOKLeOjoE9g"
      decimals="0"
      id="Tc_mFUZONVSD0CThymU_B9Rlw_6_7"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">7638</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_YJu4vcU5tUaCOKLeOjoE9g"
      decimals="-3"
      id="Tc_On1k083_LUiIdw_rfxanpA_6_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">4761000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TY4ik2aZpkKjKDPnPKTE7g"
      decimals="-3"
      id="Tc_2F_HwulyfUaRCeQs5ABXcw_6_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">232580000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_w6f6JU4750WKM1AQ8ouQ7Q"
      decimals="-3"
      id="Tc_nTsFGh7hQ0WpJ-S9TysRMA_6_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-235537000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_nK4S9nYjdkezj6o91cTQfQ"
      decimals="-3"
      id="Tc_ZEULZHuOb0WllVa19KBsQQ_6_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-2878000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q"
      decimals="-3"
      id="Tc_Gn6zviUWT0GDWnD9b4pA8w_6_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-1057000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"
      decimals="-3"
      id="Tc_2RenfdXGU0yOF3bUzShnmQ_8_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g"
      decimals="-3"
      id="Tc_CySD4yNL30OCg9oWX-e00w_8_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw"
      decimals="-3"
      id="Tc_CD-C81TpyUqLBPbYRf4J0g_8_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ"
      decimals="-3"
      id="Tc_vHknjwVB2UGmyJzeUbDiZA_8_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg"
      decimals="-3"
      id="Tc_HR1JWkhSN0CrpqbVstTrUw_8_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_tkYIpVr4eE6gHHspS4OHVw_8_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <syn:StockIssuedDuringPeriodAtMarketOfferingShare
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"
      decimals="0"
      id="Tc_8S2DktcuAkOEECdIXO5JpQ_9_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">9256535</syn:StockIssuedDuringPeriodAtMarketOfferingShare>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"
      decimals="-3"
      id="Tc_EIxEzNWgakenL94vBLKnHQ_9_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">9000</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g"
      decimals="-3"
      id="Tc_XqSBTT7mf0C4AicEnsJ1Qw_9_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw"
      decimals="-3"
      id="Tc_uOq9-ju5Uk-Rb14E7ip2kw_9_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3350000</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ"
      decimals="-3"
      id="Tc_tYZSzDXOvEWOwfYZumkNKA_9_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg"
      decimals="-3"
      id="Tc_Uh5SiE__JUKD1ewX52RHXA_9_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_9gDSn1Amk0-sEbmBbq1_Zg_9_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3359000</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"
      decimals="-3"
      id="Tc_c5JH0TMaykiws9goRfSt9w_10_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g"
      decimals="-3"
      id="Tc_kJZob0k7hkCSrxxN5dwwkQ_10_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw"
      decimals="-3"
      id="Tc_Nue3FctjBE-f9vS-KuOqrw_10_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ"
      decimals="-3"
      id="Tc_rqb4hvL2TkevdFKP2tSKRg_10_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">254000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg"
      decimals="-3"
      id="Tc_L1fJqiCXVkuaaHd5TnmRZQ_10_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_G4udq3NbokeouYMfSkgiVw_10_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">254000</us-gaap:DividendsPreferredStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"
      decimals="-3"
      id="Tc_6bnNvhgGCUSbUf0tbIyeLQ_11_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g"
      decimals="-3"
      id="Tc_Cme4MMa1wk-luGPqK6OWYQ_11_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw"
      decimals="-3"
      id="Tc_ik451BYK30y92PlLz8B38w_11_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ"
      decimals="-3"
      id="Tc_q_b35sphDEWW6DDnIID80g_11_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg"
      decimals="-3"
      id="Tc_3GYsPDRq5UuCQJ3SxdkR5Q_11_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">178000</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:StockIssuedDuringPeriodValueOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_QO_wGXTztEiI8oXBOMLF8w_11_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">178000</syn:StockIssuedDuringPeriodValueOfSynBiomicsStock>
    <syn:AdjustmentsToEffectOfWarrantExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"
      decimals="-3"
      id="Tc_9WhZyHhoIEiuUieJ__9d7w_12_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:AdjustmentsToEffectOfWarrantExercisePrice>
    <syn:AdjustmentsToEffectOfWarrantExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g"
      decimals="-3"
      id="Tc_FutQEt_bfkeharrUu5i5_g_12_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:AdjustmentsToEffectOfWarrantExercisePrice>
    <syn:AdjustmentsToEffectOfWarrantExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw"
      decimals="-3"
      id="Tc_OcWqZ-eIMkeuh8wPGHKEfQ_12_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-880000</syn:AdjustmentsToEffectOfWarrantExercisePrice>
    <syn:AdjustmentsToEffectOfWarrantExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ"
      decimals="-3"
      id="Tc_XwxwIYdOqkC9E5ZaBu7AoA_12_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">880000</syn:AdjustmentsToEffectOfWarrantExercisePrice>
    <syn:AdjustmentsToEffectOfWarrantExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg"
      decimals="-3"
      id="Tc_YuvkZMG4uEyxMiOaVRfjsg_12_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:AdjustmentsToEffectOfWarrantExercisePrice>
    <syn:AdjustmentsToEffectOfWarrantExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_SnV3NJLbq0yuTfPzs65D5A_12_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:AdjustmentsToEffectOfWarrantExercisePrice>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"
      decimals="0"
      id="Tc_cKNAIVOJY025S108xNoFXw_13_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3186960</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"
      decimals="-3"
      id="Tc_RdhrwKRyX0Klm4pPqhjF8w_13_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g"
      decimals="0"
      id="Tc_3uoMDz-7r0yWd9ogmeKa6Q_13_7"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">-3665</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g"
      decimals="-3"
      id="Tc_iRcanFz9f0-7ZIFOxlWJBw_13_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-2284000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw"
      decimals="-3"
      id="Tc_xM1VdfwSLk-wOh1_j1diyQ_13_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3661000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ"
      decimals="-3"
      id="Tc_YF4FRR-jy0G1wHeSZV_4TQ_13_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-1380000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg"
      decimals="-3"
      id="Tc_OrpCDurO4U6AClfstLRGFg_13_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_elkFRZqK206fho5H07WfxQ_13_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g"
      decimals="-3"
      id="Tc_3-Of7JKwjU6nLJZBwAMszQ_14_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_mVzCOtn18EajnJ8MLkK_9g"
      decimals="-3"
      id="Tc_sISitfxmn0SI7YKzdoRPjA_14_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_4Pst0Rsyo0Kyf6USP9zKsw"
      decimals="-3"
      id="Tc_1Ooca4VYvkGVejjKSw4WDQ_14_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mzwKJt5F2kS0EhiqsBS2aQ"
      decimals="-3"
      id="Tc_FmIXbvKx80KJkJy9DiQKUw_14_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-10043000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_rCv3ufXigk6LPWwYiFPFPg"
      decimals="-3"
      id="Tc_zoN6FLNEzEiS1C5oQl7dXQ_14_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-73000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_XsxtaqrRwE6Y3u4VHz4QpA_14_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-10116000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BD7rNLuWk0iEFQwVRkploA"
      decimals="0"
      id="Tc_wh4mr11tBESaYvYe8SwxZA_16_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">29249925</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_BD7rNLuWk0iEFQwVRkploA"
      decimals="-3"
      id="Tc_s6RXSLduEEaaf4Cb7IZkLw_16_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">29000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VbneEhxFhkiVk48Qo2CSMg"
      decimals="0"
      id="Tc_YXdWQyY2gEO-5dfKcAaeJA_16_7"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3973</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_VbneEhxFhkiVk48Qo2CSMg"
      decimals="-3"
      id="Tc_tAT_CA70bEKvnsI4FOdXTw_16_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2477000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oR9rstllEUaUPKUvptIWbw"
      decimals="-3"
      id="Tc_Uu6WfKqgs0uAYu3CktoQAQ_16_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">240821000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lizShvTQnU27DK8SmxrMjg"
      decimals="-3"
      id="Tc_j6My3TAvJk2BRpXHhMrdwg_16_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-248094000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember__lq54v75EEqpd9AIZOp9HA"
      decimals="-3"
      id="Tc_2i9dZm8z5Uy0Un9SmIDqBg_16_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-2773000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_3idhAzEEPUGcL7V2T-xmoQ_16_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-7540000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"
      decimals="-3"
      id="Tc_OB0MPTkLEka2A57cxa_3gw_18_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"
      decimals="-3"
      id="Tc_u-bQBODp5EKiUXY9ltJSjQ_18_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA"
      decimals="-3"
      id="Tc_0ninDHf6rU-QeUXX9DAL9g_18_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">416000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ"
      decimals="-3"
      id="Tc_VOzmLcgNxUylE4wDBbXyZg_18_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA"
      decimals="-3"
      id="Tc_5ntpBl4tA0aqpssyMQbizg_18_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_kHYUmdr31kG_UwzHaKyiYQ_18_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">416000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <syn:StockIssuedDuringPeriodAtMarketOfferingShare
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"
      decimals="0"
      id="Tc_E0EhdMTtuEuCmI2HvsGW4w_19_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">78685315</syn:StockIssuedDuringPeriodAtMarketOfferingShare>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"
      decimals="-3"
      id="Tc_vF7b9fLINkqCFfP5XrI-uQ_19_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">79000</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"
      decimals="-3"
      id="Tc_01dIgVrhhEW0U_FN4R488g_19_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA"
      decimals="-3"
      id="Tc_44qgU0ePzky4S1eiTvb2eQ_19_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">65881000</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ"
      decimals="-3"
      id="Tc_MYXbcLyyCE-yUcoYDJMPOQ_19_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA"
      decimals="-3"
      id="Tc_d9-zXV8XQ06sAhQs80L8Kg_19_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <syn:StockIssuedDuringPeriodAtMarketOfferingValue
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_J5lXKKeCNUWecONX97CbcA_19_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">65960000</syn:StockIssuedDuringPeriodAtMarketOfferingValue>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"
      decimals="-3"
      id="Tc_C-KCTCQ8JkOSB2IWWx6yLQ_20_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"
      decimals="-3"
      id="Tc_71vmzg5WNUuK0aeEE3FT_A_20_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA"
      decimals="-3"
      id="Tc_zTB0IN9GCUat2IK1Mi155Q_20_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ"
      decimals="-3"
      id="Tc_WujQ99yWvU6ba6bYgZc50g_20_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">24000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA"
      decimals="-3"
      id="Tc_lbVOP_dUq0qo77Xn9lAQOA_20_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_TdEKcmYqrEikc_FmXr6UAA_20_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">24000</us-gaap:DividendsPreferredStock>
    <syn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"
      decimals="0"
      id="Tc_Wy0LynG1QkmFl2d9Z46KWw_21_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">11655747</syn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"
      decimals="-3"
      id="Tc__2UVHUJq3kWkszFshfA7wA_21_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">12000</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"
      decimals="-3"
      id="Tc_hdWy1F9h60KR5_NIspO1zw_21_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA"
      decimals="-3"
      id="Tc_7AH8yAtsekuYa1lv7h8FQg_21_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">8030000</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ"
      decimals="-3"
      id="Tc_namAuVGFoE6-Itoz797ZPQ_21_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA"
      decimals="-3"
      id="Tc_cISsn6e-sk-BJaV_MOwt6w_21_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_UJjrYE6PrUqplYfsD5ndCg_21_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">8042000</syn:StockIssuedDuringPeriodValueWarrantsExercised>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"
      decimals="-3"
      id="Tc_vNNAr2Q09kK1ScQE_bO_DQ_22_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"
      decimals="-3"
      id="Tc_rupBWmO_GE6UUFitLaUypQ_22_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA"
      decimals="-3"
      id="Tc_6nnRYBI-wUinA2YLPj0K7g_22_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">7402000</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ"
      decimals="-3"
      id="Tc_OJpw3XmVLUGaKcqfSCycpQ_22_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-7402000</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA"
      decimals="-3"
      id="Tc_LTj8NL8-AUe33VVK2iSdaA_22_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:AdjustmentsToEffectOfPreferredStockPrice
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_JUSNfiGsr0Sc3s9CPMlbHQ_22_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:AdjustmentsToEffectOfPreferredStockPrice>
    <syn:Conversionofseriesapreferredstocktocommonstockshares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p4kGNEYs-UaBwLK97CJoow"
      decimals="0"
      id="Tc_KA3yhfM1C0mWtbwAy3S6pQ_23_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">8996768</syn:Conversionofseriesapreferredstocktocommonstockshares>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p4kGNEYs-UaBwLK97CJoow"
      decimals="-3"
      id="Tc_Vtn1CtZe30u4Cg958gSpPQ_23_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">9000</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_u3tJQ_TKWUKU4AV_VlfaIA"
      decimals="-3"
      id="Tc_TRFah3AQ4EeUom32aJLKhA_23_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Z7S1T7sWPU-5mMUOHtvhAg"
      decimals="-3"
      id="Tc_NiIyAV7C3U6idcQdDjGk2w_23_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">12813000</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_US3t8HW7-0GmoQhdLHyCwQ"
      decimals="-3"
      id="Tc_xRitiwI_E0KdQ3LWi7pvdw_23_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_fJelKMiPik68kesEofzomQ"
      decimals="-3"
      id="Tc__k04QUzBM0CuvduB6yX8EQ_23_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:Conversionofseriesbpreferredstocktocommonstock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ"
      decimals="-3"
      id="Tc_vvaZvKTAW0aNbyWClE3siQ_23_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">12822000</syn:Conversionofseriesbpreferredstocktocommonstock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3rOlqxEP0ybyVhLBiTYEw"
      decimals="0"
      id="Tc_J5veoq8DSEueh5hN8648qg_24_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3454783</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_l3rOlqxEP0ybyVhLBiTYEw"
      decimals="-3"
      id="Tc_7Di4isoAiUWuAU4k1_xjUQ_24_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStockShares
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"
      decimals="0"
      id="Tc_HGnOhsB7FUqTN86pXZ8Rhg_24_7"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">-3973</syn:ConversionOfSeriesBPreferredStockToCommonStockShares>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"
      decimals="-3"
      id="Tc_bnRJjB--UUmleFsmDjbfjQ_24_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-2477000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_8-WgejdDaEqgy2EWOSkLzA"
      decimals="-3"
      id="Tc_rT1ZrsXpwU-WSCEVRef3DA_24_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3971000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nYSwPr0VKkqWTeFT1i_ttQ"
      decimals="-3"
      id="Tc_d7QBJpfxhE21EHUc6tuFtQ_24_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-1497000</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_iWZnfq9DoESxxwMr9XQsEw"
      decimals="-3"
      id="Tc_Cq_wMugcc0qSMhU_Vq5M8A_24_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <syn:ConversionOfSeriesBPreferredStockToCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B8SS6pik5UydvtJcCB9dlw"
      decimals="-3"
      id="Tc_X1NUxdmZ0EupoICKgeQHeQ_24_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:ConversionOfSeriesBPreferredStockToCommonStock>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"
      decimals="-3"
      id="Tc_maMRHTz0kEOhJsNH6cODow_25_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"
      decimals="-3"
      id="Tc_RWcXx3l6qESgAnPQemUAPw_25_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA"
      decimals="-3"
      id="Tc_OjPrWJwiMEO8Eu_KwECyxw_25_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ"
      decimals="-3"
      id="Tc_7xOgGm1KXUeKBowRqYZA2g_25_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-14267000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA"
      decimals="-3"
      id="Tc_swACYSLaIUOgDlOv_L4ULg_25_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-1000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_tqJf3IeVQUawzyu5gEQChg_25_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-14268000</us-gaap:ProfitLoss>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1Tyq9V7UTUmxlLoJ9_04AQ"
      decimals="-3"
      id="Tc_HoWbjdcJj0eQIt6qCkJFfg_26_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_Rg5xkJA0aEmRjqF15uPTwQ"
      decimals="-3"
      id="Tc_SAdkoXNCR0Ozo59YosOdxg_26_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Be9IxSfmV0OqT1W2Qb2MKA"
      decimals="-3"
      id="Tc_r15yegbWmEOcuSQhV1Glug_26_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-2774000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PqOKcb8fTE-hJAPAC9lgaQ"
      decimals="-3"
      id="Tc_DCdjHkevZU2Ml57Xh3C5jg_26_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember_bBJA9_hzFESGiBquq8ADLA"
      decimals="-3"
      id="Tc_sfSBgxdvNk2jkbgFkI7LLw_26_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2774000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_k0H9GfWxq0y-3i5vP1iLFg_26_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FpJzkt3PvkCZCGFfIrDKyA"
      decimals="0"
      id="Tc_2dnbb-oMuEehDqi1bmgW-A_27_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">132042538</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FpJzkt3PvkCZCGFfIrDKyA"
      decimals="-3"
      id="Tc_eAiMPXQUXEOSAniv-07MEg_27_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">132000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_tjgiVhZrI0OhzmtDQzO8PA"
      decimals="-3"
      id="Tc_p16_VnkhPkigjHdFHbm8FA_27_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Y8DpvdHRXUi1PZn6rztZ4w"
      decimals="-3"
      id="Tc_j1Xsomao8UipTkAIyklSHg_27_13"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">336560000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HesMEARWFkamUpDQQXE38g"
      decimals="-3"
      id="Tc_QdLulnBQCkykwHeHFcOqog_27_16"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-271284000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember__EXyzsLBqku0E4Q28xmdZQ"
      decimals="-3"
      id="Tc_mqlQXuInZk2P2B96jBYyww_27_19"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_pSF_boR-1ky52c5AS2XP2g_27_22"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">65408000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_O64SPO78mEuiJcrSNG_YFQ_4_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-14268000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_08HNJWJWh0Ch6bDrnyHXag_4_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-10116000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_PuyDBrMSYEWKRuONYdkuLw_6_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">416000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_SL1BH7smqUO2YOclz4vyKw_6_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">350000</us-gaap:ShareBasedCompensation>
    <syn:SubsidiaryStockIssuesToVendor
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_HLk_DjX9Q06AcZmM-QyI1A_7_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:SubsidiaryStockIssuesToVendor>
    <syn:SubsidiaryStockIssuesToVendor
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_93qu2mWDUkOgfTnpLUMolw_7_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">178000</syn:SubsidiaryStockIssuesToVendor>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_ImPqSJGxa0qS0xrp_7v_9g_8_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">87000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_Ir3Sgz05WUyjigcQGP9ktg_8_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">201000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_VDNPQAlRvEG7dt83G1qPfQ_10_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-174000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_l9Dwk49XsU2hbc3cm91QZA_10_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">326000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <syn:IncreaseDecreaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_tIghzbwdBUawGtcTvIdyfw_11_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">166000</syn:IncreaseDecreaseRightOfUseAssets>
    <syn:IncreaseDecreaseRightOfUseAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_fZP-pbm3VkePqIZLy3C_gA_11_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">141000</syn:IncreaseDecreaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_2Ot0osB7QUG4pHOO8OZEUw_12_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-363000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_fTNh_HKkUU2Er8O2Hn11mg_12_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-1429000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_d7g-ZTLXoEaOv00jp0k5Ug_13_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1004000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_kx0CFw1JdEmxPui-rUCVCw_13_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-851000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_ASu_4cXAHEG3r2ft-h3PUA_14_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">110000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_9BI79pRItkSGH5qAWVIdoQ_14_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-67000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <syn:IncreaseDecreaseLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_8HbsA02QxEyC0gFWIweZJg_15_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-216000</syn:IncreaseDecreaseLeaseLiability>
    <syn:IncreaseDecreaseLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_X-qpBldapkWxOiDoul6pBg_15_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-249000</syn:IncreaseDecreaseLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_GlK7cw9DMUG_auolK5UIWw_16_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-12890000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_tRxzgh7L8kWMkOQ7KjESaw_16_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-12168000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_bdoCxBwNpEmM4rI408Oh2w_19_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">14000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_PTPANZ71UESBzxsPIdnlKw_19_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_ucUVGVL-9EmExN5qX92BYg_20_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-14000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_SdRu8ywS-ECeXyQbcuO4eg_20_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-9000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_MyHd35Sx2069t9Ia_49OmA_23_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">65960000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_kvGT153hlkmyGAtdCgoyAA_23_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3359000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_L7Z2MVw-qEOaxcr1NqKp-Q_24_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">8042000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_ob58jizmXEOYFh79c1qiOQ_24_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_-9xNZD1TYkChHgqrO8eiow_25_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">74002000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_Q_6H7-3kcU22x5lv_oKg-g_25_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3359000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_Xw4CoDN3FUa9W3oVeoUSHA_26_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">61098000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_IJ4xeWN610WZ4rElRbWa0w_26_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-8818000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_ULTgwvSciE2zeed_GfSU2Q_27_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">6227000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q"
      decimals="-3"
      id="Tc_MSM3vAeGSEWYU5a_Z3GD-g_27_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">15045000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_SWo3pw9uiUuUBSVfbbmbPw_28_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">67325000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_Jn0_CIOhAUSx9ecfH0uSRA_28_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">6227000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ"
      decimals="-3"
      id="Tc_HL3ptuyk1EuS6UKtefBIvw_31_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">12822000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig"
      decimals="-3"
      id="Tc_iG705Wv_C0agCrH9FWsgFw_31_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ConversionOfStockAmountConverted1>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_5P84ryEQ3UimjccUPBvcCQ_32_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">7402000</syn:PreferredStockPriceAdjustment>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_oDei177RuEuMKf4Pje6MGQ_32_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:PreferredStockPriceAdjustment>
    <syn:ReturnOfSynBiomicsStock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_ZKlLAocuiEy-RHwl_tcOQQ_33_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2774000</syn:ReturnOfSynBiomicsStock>
    <syn:ReturnOfSynBiomicsStock
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_P8KTla6-AUKtjIqtaImgRQ_33_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:ReturnOfSynBiomicsStock>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B8SS6pik5UydvtJcCB9dlw"
      decimals="-3"
      id="Tc_hSelucVzH0KN7qMCKzTvEQ_34_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2477000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA"
      decimals="-3"
      id="Tc_WW7GHekdZkyvHxLi-I4M-Q_34_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2284000</us-gaap:ConversionOfStockAmountConverted1>
    <syn:DeemedDividendsWithBeneficialConversionFeature
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_M5AL9dSVfEyfgzGBYVQvng_35_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1496000</syn:DeemedDividendsWithBeneficialConversionFeature>
    <syn:DeemedDividendsWithBeneficialConversionFeature
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_OU5lJnfWBUqocj_EaSO-xQ_35_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1380000</syn:DeemedDividendsWithBeneficialConversionFeature>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_QpBUvwHPxEq-OjMoe11V5w_36_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1270000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_HlMUHODK_EOF3hfySixfkw_36_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DividendsPreferredStockPaidinkind
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_dXmnToKvwEShypr2da25eg_37_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">24000</us-gaap:DividendsPreferredStockPaidinkind>
    <us-gaap:DividendsPreferredStockPaidinkind
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_fuaGMe7vyUSKaQ51PxDvCg_37_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">254000</us-gaap:DividendsPreferredStockPaidinkind>
    <syn:WarrantExercisePriceAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_3iG2Zl8aAkCTWinSgx4MZA_38_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:WarrantExercisePriceAdjustment>
    <syn:WarrantExercisePriceAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_zYKd12AdBki1EeUIMXKW_w_38_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">880000</syn:WarrantExercisePriceAdjustment>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_VStRXgqK50iOP6zCpuVyhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. Organization and Nature of Operations and Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Description of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Synthetic Biologics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Synthetic Biologics&#x201d;) is a diversified clinical-stage company operating in one segment currently developing therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company&#x2019;s lead clinical development candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) &lt;i style="font-style:italic;"&gt;Clostridioides difficile&lt;/i&gt; infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under Current Good Manufacturing Practice (cGMP) conditions and intended to treat both local GI and systemic diseases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company was also developing SYN-010 to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). On September 30, 2020, Cedars Sinai Medical Center (CSMC) (the Company&#x2019;s SYN-010 clinical development partner) informed the Company that it agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients. Based on the results of a planned interim futility analysis, it was concluded that although SYN-010 was well tolerated, it was unlikely to meet its primary endpoint by the time enrollment is completed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Corporate Structure and Basis of Presentation &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2021, the Company had eight subsidiaries, Pipex Therapeutics,&#160;Inc. (&#x201c;Pipex Therapeutics&#x201d;), Effective Pharmaceuticals,&#160;Inc. (&#x201c;EPI&#x201d;), Solovax,&#160;Inc. (&#x201c;Solovax&#x201d;), CD4 Biosciences,&#160;Inc. (&#x201c;CD4&#x201d;), Epitope Pharmaceuticals,&#160;Inc. (&#x201c;Epitope&#x201d;), Healthmine,&#160;Inc. (&#x201c;Healthmine&#x201d;), Putney Drug Corp. (&#x201c;Putney&#x201d;) and Synthetic Biomics,&#160;Inc. (&#x201c;SYN Biomics&#x201d;). Pipex Therapeutics, EPI, Healthmine and Putney are wholly owned, and Solovax, CD4, Epitope and SYN Biomics are majority-owned.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For financial reporting purposes, the outstanding common stock of the Company is that of Synthetic Biologics,&#160;Inc. All statements of operations, (deficit) equity and cash flows for each of the entities are presented as consolidated. All subsidiaries were formed under the laws of the State of Delaware on January&#160;8, 2001, except for EPI, which was incorporated in Delaware on December&#160;12, 2000, Epitope which was incorporated in Delaware in January&#160;2002, Putney which was incorporated in Delaware in November&#160;2006, Healthmine which was incorporated in Delaware in December&#160; 2007 and SYN Biomics which was incorporated in Nevada in December&#160;2013.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Liquidity&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2021, the Company has a significant accumulated deficit, and with the exception of the three months ended June&#160;30, 2010 and the three months ended December&#160;31, 2017, the Company has experienced significant losses and incurred negative cash flows since inception. The Company expects to continue incurring losses for the foreseeable future, with the recognition of revenue being contingent on successful phase 3 clinical trials and requisite approvals by the FDA or foreign equivalents. Historically, the Company has financed its operations primarily through public and private sales of its common stock and a private placement of its preferred stock, and it expects to continue to seek to obtain required capital in a similar manner. The Company has spent, and expects to continue to spend, a substantial amount of funds in connection with implementing its business strategy, including planned product development efforts, clinical trials and research and discovery efforts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Organization and Nature of Operations and Basis of Presentation&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Cash and cash equivalents totaled approximately $67.3 million as of December 31, 2021, which includes the net proceeds of approximately $66 million from sales of its Common Stock in &#x201c;at-the-market&#x201d; (ATM) equity offerings during 2021 and cash proceeds of approximately $8.0 million through the exercise of a portion of the October 2018 warrants. With these additional sources of liquidity&lt;span style="color:#333333;background:#ffffff;"&gt;,&lt;/span&gt; the Company believes it will be able to fund its operations through the next twelve months from the issuance date of these financial statements. Management believes its plan, which includes the further development of SYN-020, additional testing of SYN-004 (ribaxamase) and the advancement of VCN-01 will allow the Company to meet its financial obligations, further advance key products, and maintain the Company&#x2019;s planned operations for at least one year from the issuance date of these consolidated financial statements. If necessary, the Company may attempt to utilize the ATM or seek to raise additional capital on the open market, neither of which is guaranteed. Use of the ATM is limited by certain restrictions and management&#x2019;s plan does not rely on additional capital from either of these sources. If the Company is not able to obtain additional capital (which is not assured at this time), our long-term business plan may not be accomplished and we may be forced to cease certain development activities. More specifically, the completion of any later stage clinical trial will require significant financing or a significant partnership.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="0"
      id="Narr_7dQAK-Ay_0GzcvHqS8468g"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-5"
      id="Narr_KId_huFtAESLl_Az5514qg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">67300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <syn:ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-5"
      id="Narr_9PzmUu2YMkC519-eVSspcA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">66000000</syn:ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-5"
      id="Narr_eznordvkD02fpKVCnes7Zw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">8000000.0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_HSA2bovUyUSrJt2bMNj7ug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;All intercompany transactions and accounts have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants, preferred stock and stock options granted for services or compensation, respectively, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Non-controlling Interest&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s non-controlling interest represents the minority stockholder&#x2019;s ownership interest related to the Company&#x2019;s subsidiary, SYN Biomics. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#x2019;s common stockholders on the face of the Consolidated Statements of Operations. On September&#160;5, 2018, the Company entered into an agreement with the minority stockholder for an investigator-sponsored Phase 2 clinical study of SYN-010. Prior to this agreement and IRB approval in December&#160;2018, the Company&#x2019;s equity interest in SYN Biomics was 88.5% and the non-controlling stockholder&#x2019;s interest was 11.5%. In consideration of the support, the Company issued additional shares of stock to the minority stockholder, resulting in the Company&#x2019;s equity interest in SYN Biomics being 83.0% and the non-controlling stockholder&#x2019;s interest is 17.0%. During 2021, the minority stockholder returned its shares of SYN Bionics to the Company for no consideration. The Company's interest in SYN Biomics is now 100%. This is reflected in the Consolidated Statements of Equity (Deficit).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Risks and Uncertainties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. These conditions may not only limit the Company&#x2019;s access to capital, but also make it difficult for its customers, its vendors and its ability to accurately forecast and plan future business activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Summary of Significant Accounting Policies&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three&#160;months or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"/&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/&gt;&lt;td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Office equipment and furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Leasehold improvements and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Lesser of estimated useful life or lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation and amortization expense was approximately $87,000 and $201,000 for the&#160;years ended December&#160;31, 2021 and 2020, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts with any gain or loss reported in the consolidated statement of operations. Repairs and maintenance are charged to expense as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews property and equipment for impairment to determine if assets are impaired due to obsolescence. As a result of this review, there was no impairment recognized for the&#160;years ended December&#160;31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the year ended December 31, 2021 includes the effect of the Series A preferred stock price adjustment of $7.4 million, the accretion of the Series B preferred discount of $1.5 million on converted shares and Series A preferred stock accrued dividends of $0.1 million. Net loss attributable to common stockholders for the year ended December 31, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $1.4 million on converted shares, the effect of warrant exercise adjustment of $1.0 million and Series A preferred stock accrued dividends of $0.3 million. The number of shares of common stock underlying Series A Preferred shares convertible to common stock that were excluded from the computation of the net loss per common share for the year ended December 31, 2020 was 678,258. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that was excluded from the computation of net loss per common share and for the year ended December 31, 2020 was 3,454,783. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share for the&#160;year ended December&#160;31, 2021 were 6,255,275 and 6,344,966, respectively, and for the&#160;year ended December&#160;31, 2020 were 3,997,418 and 18,000,713, respectively, because their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Summary of Significant Accounting Policies&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries, stock-based compensation and related employee costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of our product candidates. Research and development expenses include external contract research organization (&#x201c;CRO&#x201d;) services. The Company makes payments to the CROs based on agreed upon terms and may include payments in advance of study services. The Company reviews and accrues CRO expenses based on services performed and relies on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. At December&#160;31, 2021 and 2020, the Company has accrued CRO expenses of $0.7 million, that are included in accrued expenses. The Company has prepaid CRO costs at December&#160;31, 2021 and 2020 of $0.5 million that are included in prepaid expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt;, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are classified on a three-tier hierarchy as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 inputs: Inputs, other than quoted prices, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of the Company&#x2019;s short-term financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include money market accounts of $193,000 and $114,000 as of December&#160;31, 2021 and 2020, respectively, that are measured using Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In using this model, the fair value is determined by applying Level 3 inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions. The assumptions used in calculating the estimated fair value of the warrants represent the Company&#x2019;s best estimates; however, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different. In 2021 and 2020, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#x2019;s current stock price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2. Summary of Significant Accounting Policies&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Payment Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#x2019; grant date typically using the Black-Scholes option pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations, depending on the nature of the services provided.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Derivative Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The warrants issued in conjunction with the public offering of the Company&#x2019;s securities in November&#160;2016 include a provision that if the Company were to enter into a certain transaction, as defined in the warrant agreement, the warrants would be purchased from the holder for cash. The provisions of these warrants preclude equity accounting treatment under ASC 815, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging.&lt;/i&gt; Accordingly, the Company is required to record the warrants as liabilities at their fair value upon issuance and re-measure the fair value at each period end with the change in fair value recorded in the Consolidated Statement of Operations. When the warrants are exercised or cancelled, they are reclassified to equity. The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In November 2020, all liability-classified warrants expired. In 2019, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#x2019;s current stock price.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes deferred tax assets and liabilities based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the&#160;years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Management assesses the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex tax laws of multiple jurisdictions. The Company records the related interest expense and penalties, if any, as tax expense in the tax provision. At December&#160;31, 2021 and 2020, the Company did not record any liabilities for uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements and Developments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, &lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (subtopic 815-40)&lt;/i&gt;: &lt;i style="font-style:italic;"&gt;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/i&gt;. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity's own equity and improves and amends the related earnings per share guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company is currently assessing the impact of ASU 2020-06 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In October 2021, the FASB issued Accounting Standards Update 2021-08 that address the accounting for Contract Assets and Liabilities from Contracts with Customers in a business combination (&#x201c;ASU 2021-08&#x201d;), with an effective date for SYN of January 1,2 2024 (earlier adoption permitted). ASU 2021-08 provides that existing contract assets and liabilities (including deferred costs to obtain and deferred revenue) are measured in a business combination under the measurement and recognition requirements of ASC 606. ASU 2021-08 should generally &#x201c;result in an acquirer recognizing and measuring the acquired contract assets and liabilities consistent with how they were recognized and measured in the acquiree&#x2019;s financial statements.&#x201d; The Company is currently assessing the impact of ASU 2021-08 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_EQ9FYC9fBUqr8zJXsxv0jw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;All intercompany transactions and accounts have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_DJB0Dv9A50-QUifQtf4j6A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Such estimates and assumptions impact, among others, the following: the estimated useful lives for property and equipment, fair value of warrants, preferred stock and stock options granted for services or compensation, respectively, and the valuation allowance for deferred tax assets due to continuing and expected future operating losses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future confirming events. Accordingly, actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <syn:NoncontrollingInterestPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_gQW83zzV00-yubVmiszSYA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Non-controlling Interest&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s non-controlling interest represents the minority stockholder&#x2019;s ownership interest related to the Company&#x2019;s subsidiary, SYN Biomics. The Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#x2019;s common stockholders on the face of the Consolidated Statements of Operations. On September&#160;5, 2018, the Company entered into an agreement with the minority stockholder for an investigator-sponsored Phase 2 clinical study of SYN-010. Prior to this agreement and IRB approval in December&#160;2018, the Company&#x2019;s equity interest in SYN Biomics was 88.5% and the non-controlling stockholder&#x2019;s interest was 11.5%. In consideration of the support, the Company issued additional shares of stock to the minority stockholder, resulting in the Company&#x2019;s equity interest in SYN Biomics being 83.0% and the non-controlling stockholder&#x2019;s interest is 17.0%. During 2021, the minority stockholder returned its shares of SYN Bionics to the Company for no consideration. The Company's interest in SYN Biomics is now 100%. This is reflected in the Consolidated Statements of Equity (Deficit).&lt;/p&gt;</syn:NoncontrollingInterestPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_X7OTRMegzEONug23YJ7vFw"
      decimals="3"
      id="Narr_FZH6Xu_wLECn1-t24SndHw"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.885</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_X7OTRMegzEONug23YJ7vFw"
      decimals="3"
      id="Narr_Xe0gAHaT-EGtCV1tOogiSQ"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.115</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="3"
      id="Narr_9LSkUvA6w0uBjCFRvatWDw"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.830</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2021_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_cBapFdW9TUCTcjAUH7txKQ"
      decimals="3"
      id="Narr_ev3AQrXYxUuIoca9240LXg"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.170</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <syn:RisksAndUncertaintiesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_PfpOFHl2HEmq2UKsQnpuSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Risks and Uncertainties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s operations could be subject to significant risks and uncertainties including financial, operational and regulatory risks and the potential risk of business failure. These conditions may not only limit the Company&#x2019;s access to capital, but also make it difficult for its customers, its vendors and its ability to accurately forecast and plan future business activities.&lt;/p&gt;</syn:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_EG8sFimo1kaiI0zI6v2rhg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include cash and highly liquid short-term investments with original maturities of three&#160;months or less.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_Gatmj9FgZEKd6zWN7o41iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Property and equipment is recorded at cost and depreciated or amortized using the straight-line method over the estimated useful life of the asset or the underlying lease term for leasehold improvements, whichever is shorter. The estimated useful life by asset description is noted in the following table.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"/&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/&gt;&lt;td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Office equipment and furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Leasehold improvements and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Lesser of estimated useful life or lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation and amortization expense was approximately $87,000 and $201,000 for the&#160;years ended December&#160;31, 2021 and 2020, respectively. When assets are disposed of, the cost and accumulated depreciation are removed from the accounts with any gain or loss reported in the consolidated statement of operations. Repairs and maintenance are charged to expense as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews property and equipment for impairment to determine if assets are impaired due to obsolescence. As a result of this review, there was no impairment recognized for the&#160;years ended December&#160;31, 2021 and 2020.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <syn:EstimatedUsefulLifeOfAssetTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_qUk1kbx560KaRyW-RddY0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"/&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"/&gt;&lt;td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:48.99%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Asset Description&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated Useful Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Office equipment and furniture&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;3&#160;&#x2013;&#160;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Leasehold improvements and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Lesser of estimated useful life or lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:EstimatedUsefulLifeOfAssetTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_06odZ0po2U2Duco7oDcnHg"
      id="Narr_qHqpXrVrjEyKN-nI-sfDqA">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_qOfAb8XKjEiqZKgjiMEWCw"
      id="Narr_Z73_PD7TuE2JFiLIBbZV5w">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="0"
      id="Narr_w0lDfcjsp0G0jZ4Z1qBAyA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">87000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="0"
      id="Narr_qVVpzotRYkuOtfvQFPiKWg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">201000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_AUh0GONzNkCMwb8DAbZPdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such an event or change in circumstances occurs and potential impairment is indicated because the carrying values exceed the estimated future undiscounted cash flows of the asset, the Company will measure the impairment loss as the amount by which the carrying value of the asset exceeds its fair value.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_22nbGBafNU6BBkr18R_rYg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding including the effect of common share equivalents. Diluted net loss per share assumes the issuance of potential dilutive common shares outstanding for the period and adjusts for any changes in income and the repurchase of common shares that would have occurred from the assumed issuance, unless such effect is anti-dilutive. Net loss attributable to common stockholders for the year ended December 31, 2021 includes the effect of the Series A preferred stock price adjustment of $7.4 million, the accretion of the Series B preferred discount of $1.5 million on converted shares and Series A preferred stock accrued dividends of $0.1 million. Net loss attributable to common stockholders for the year ended December 31, 2020 excludes net loss attributable to non-controlling interest of $0.1 million and includes the accretion of Series B preferred discount of $1.4 million on converted shares, the effect of warrant exercise adjustment of $1.0 million and Series A preferred stock accrued dividends of $0.3 million. The number of shares of common stock underlying Series A Preferred shares convertible to common stock that were excluded from the computation of the net loss per common share for the year ended December 31, 2020 was 678,258. The number of shares of common stock underlying Series B Preferred shares convertible to common stock that was excluded from the computation of net loss per common share and for the year ended December 31, 2020 was 3,454,783. The number of options and warrants for the purchase of common stock that were excluded from the computations of net loss per common share for the&#160;year ended December&#160;31, 2021 were 6,255,275 and 6,344,966, respectively, and for the&#160;year ended December&#160;31, 2020 were 3,997,418 and 18,000,713, respectively, because their effect is anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <syn:PreferredStockPriceAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ"
      decimals="-5"
      id="Narr_arf4s6IOQUeDZeycspVmAA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">7400000</syn:PreferredStockPriceAdjustment>
    <us-gaap:PreferredStockDiscountOnShares
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_XT6XJ5XjDUuV4c_EGi70aw"
      decimals="-5"
      id="Narr_9bwPtVf_WUSTjk2DRYw7Yw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1500000</us-gaap:PreferredStockDiscountOnShares>
    <us-gaap:PreferredStockDiscountOnShares
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_E07f6QbiCEq3peUEus5GHQ"
      decimals="-5"
      id="Narr_SZD2Ew56vUWNo__yqBor5g"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">100000</us-gaap:PreferredStockDiscountOnShares>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_syn_SeriesAAndSeriesBPreferredStockMember_fpL3K7hVwEiXTKmMFfDtbQ"
      decimals="-5"
      id="Narr_oSnDqyZcCUGJ6v7wipwvEg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:PreferredStockDiscountOnShares
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_wVR9EwKxu0OMQoL-9aHnSw"
      decimals="-5"
      id="Narr_mQDfKDO6WUadxNA9kwUZUw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1400000</us-gaap:PreferredStockDiscountOnShares>
    <syn:WarrantExercisePriceAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig"
      decimals="-5"
      id="Narr_qNvTK8W5DkWAkN_bX05NHQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1000000.0</syn:WarrantExercisePriceAdjustment>
    <syn:AccretionOfPreferredStockDeemedDividend
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig"
      decimals="-5"
      id="Narr_Pfrt1a_RrECfjO1CIpAGjA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">300000</syn:AccretionOfPreferredStockDeemedDividend>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig"
      decimals="0"
      id="Narr_dA_PkSgtVU65D66JGjeFgw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">678258</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA"
      decimals="0"
      id="Narr_cmKecbbWoU6zrY7-S2cLvA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3454783</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_OptionMember_UcsU_7n8D0Gh9M_a12yMqQ"
      decimals="0"
      id="Narr_jbOJ4HYxu06b9uH8dsdVPA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6255275</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_CsW_sJTdhUmHG2HCpG3-rQ"
      decimals="0"
      id="Narr_oXj7gZahcU2CZvqzhcc-cg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6344966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_OptionMember_w-qS4dRJ3U6O4DpjgVohSQ"
      decimals="0"
      id="Narr_rKZTm5Vknk-kNO7tiglfBg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3997418</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_p0e-bc-m1k-aY-9mEgL6FQ"
      decimals="0"
      id="Narr_apH6VTF0HkClmU8geujv2A"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">18000713</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_PFxraIpTN0inXtqoM0g7Vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses research and development costs associated with developmental products not yet approved by the FDA to research and development expense as incurred. Research and development costs consist primarily of license fees (including upfront payments), milestone payments, manufacturing costs, salaries, stock-based compensation and related employee costs, fees paid to consultants and outside service providers for laboratory development, legal expenses resulting from intellectual property prosecution and other expenses relating to the design, development, testing and enhancement of our product candidates. Research and development expenses include external contract research organization (&#x201c;CRO&#x201d;) services. The Company makes payments to the CROs based on agreed upon terms and may include payments in advance of study services. The Company reviews and accrues CRO expenses based on services performed and relies on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. At December&#160;31, 2021 and 2020, the Company has accrued CRO expenses of $0.7 million, that are included in accrued expenses. The Company has prepaid CRO costs at December&#160;31, 2021 and 2020 of $0.5 million that are included in prepaid expenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-5"
      id="Narr_grIuZEdtOkepha0GXNglGQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">700000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-5"
      id="Narr_Cyc3s9VXMUC1qo92Syh-hQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">500000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-5"
      id="Narr_6Lx9HEz8sU-VIVPxVikJOw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">500000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_Ze8KZGjGNE6_JqRXY6Zsog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt;, defines fair value as the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants would use in pricing an asset or liability. Fair value measurements are classified on a three-tier hierarchy as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 1 inputs: Quoted prices (unadjusted) for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 2 inputs: Inputs, other than quoted prices, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Level 3 inputs: Unobservable inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In many cases, a valuation technique used to measure fair value includes inputs from multiple levels of the fair value hierarchy described above. The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of the Company&#x2019;s short-term financial instruments, including cash and cash equivalents, accounts payable and accrued liabilities, approximate fair value due to the relatively short period to maturity for these instruments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents include money market accounts of $193,000 and $114,000 as of December&#160;31, 2021 and 2020, respectively, that are measured using Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In using this model, the fair value is determined by applying Level 3 inputs for which there is little or no observable market data, requiring the Company to develop its own assumptions. The assumptions used in calculating the estimated fair value of the warrants represent the Company&#x2019;s best estimates; however, these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and different assumptions are used, the warrant liability and the change in estimated fair value could be materially different. In 2021 and 2020, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#x2019;s current stock price.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_syn_MoneyMarketAccountsMember_RVHGBSefSU2di_Mp-C0IXg"
      decimals="-3"
      id="Narr_zxBzpmaiP0aSGboLXQyIwA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">193000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_syn_MoneyMarketAccountsMember_sKG50uvlI0qAGAuG7zjYtg"
      decimals="-3"
      id="Narr_bUxJri87Ak2xBAGCxZFROA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">114000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <syn:StockBasedPaymentArrangementsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_oQd6v96yT0aWW_MS6y8CzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Stock-Based Payment Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Generally, all forms of stock-based payments, including stock option grants, warrants, restricted stock grants and stock appreciation rights are measured at their fair value on the awards&#x2019; grant date typically using the Black-Scholes option pricing model, based on the estimated number of awards that are ultimately expected to vest. Stock-based compensation awards issued to non-employees for services rendered are recorded at either the fair value of the services rendered or the fair value of the stock-based payment, whichever is more readily determinable. The expense resulting from stock-based payments is recorded in research and development expense or general and administrative expense in the Consolidated Statements of Operations, depending on the nature of the services provided.&lt;/p&gt;</syn:StockBasedPaymentArrangementsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_dzhQ6_sv60eyldIAs9ZeZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Derivative Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The warrants issued in conjunction with the public offering of the Company&#x2019;s securities in November&#160;2016 include a provision that if the Company were to enter into a certain transaction, as defined in the warrant agreement, the warrants would be purchased from the holder for cash. The provisions of these warrants preclude equity accounting treatment under ASC 815, &lt;i style="font-style:italic;"&gt;Derivatives and Hedging.&lt;/i&gt; Accordingly, the Company is required to record the warrants as liabilities at their fair value upon issuance and re-measure the fair value at each period end with the change in fair value recorded in the Consolidated Statement of Operations. When the warrants are exercised or cancelled, they are reclassified to equity. The Company uses Monte Carlo simulations to estimate the fair value of the warrants. In November 2020, all liability-classified warrants expired. In 2019, the Monte Carlo simulations were not used as the value of the warrants was deemed to be minimal based on the historical fair value of the warrants and the Company&#x2019;s current stock price.&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_7UB2a3YNZEOc138yryhe5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes deferred tax assets and liabilities based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rates in effect in the&#160;years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Management assesses the need to accrue or disclose uncertain tax positions for proposed potential adjustments from various federal and state authorities who regularly audit the Company in the normal course of business. In making these assessments, management must often analyze complex tax laws of multiple jurisdictions. The Company records the related interest expense and penalties, if any, as tax expense in the tax provision. At December&#160;31, 2021 and 2020, the Company did not record any liabilities for uncertain tax positions.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_WgR7M8NWC02JK1xQuhJilQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recent Accounting Pronouncements and Developments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2020-06, &lt;i style="font-style:italic;"&gt;Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (subtopic 815-40)&lt;/i&gt;: &lt;i style="font-style:italic;"&gt;Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/i&gt;. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity's own equity and improves and amends the related earnings per share guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company is currently assessing the impact of ASU 2020-06 on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In October 2021, the FASB issued Accounting Standards Update 2021-08 that address the accounting for Contract Assets and Liabilities from Contracts with Customers in a business combination (&#x201c;ASU 2021-08&#x201d;), with an effective date for SYN of January 1,2 2024 (earlier adoption permitted). ASU 2021-08 provides that existing contract assets and liabilities (including deferred costs to obtain and deferred revenue) are measured in a business combination under the measurement and recognition requirements of ASC 606. ASU 2021-08 should generally &#x201c;result in an acquirer recognizing and measuring the acquired contract assets and liabilities consistent with how they were recognized and measured in the acquiree&#x2019;s financial statements.&#x201d; The Company is currently assessing the impact of ASU 2021-08 on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_G6ZcRg50E0KMvZswRRyHzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. Selected Balance Sheet Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid clinical research organizations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 470&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid consulting, subscriptions and other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock sales receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Prepaid CRO expense is classified as a current asset. The Company makes payments to the CROs based on agreed upon terms that include payments in advance of study services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;PROPERTY AND EQUIPMENT (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 439&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (831)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,089)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ACCRUED EXPENSES (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vendor payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical consulting services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued manufacturing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ACCRUED EMPLOYEE BENEFITS (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued bonus expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 868&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_fBzTslO8HkCDtgMVGVOrTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 803&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 639&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid clinical research organizations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 470&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid consulting, subscriptions and other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock sales receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 469&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid manufacturing expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_opw2V_9SjkGxOqNsrph2gg_3_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">803000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_PixjeSfSxUODTe3R_jZTYw_3_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">639000</us-gaap:PrepaidInsurance>
    <syn:PrepaidClinicalResearchOrganizationsExpenseCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_3EdhgHPVJEKtNOXC1dhlhQ_4_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">458000</syn:PrepaidClinicalResearchOrganizationsExpenseCurrent>
    <syn:PrepaidClinicalResearchOrganizationsExpenseCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_SfwDN9G0jk69Pl9DiVaRcw_4_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">470000</syn:PrepaidClinicalResearchOrganizationsExpenseCurrent>
    <syn:PrepaidConsultingSubscriptionsAndOtherExpenses
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_hXcb9ZrKwUG9X8f5SG1QtQ_5_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">272000</syn:PrepaidConsultingSubscriptionsAndOtherExpenses>
    <syn:PrepaidConsultingSubscriptionsAndOtherExpenses
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_fd13on5GcEazOg11it4YMQ_5_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">90000</syn:PrepaidConsultingSubscriptionsAndOtherExpenses>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_QmfqfgqxzkKXp6GIt4nzWg_6_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_ZhztR82PpEyKL83Zt_N0WQ_6_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">469000</us-gaap:OtherReceivablesNetCurrent>
    <syn:PrepaidManufacturingExpense
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_OJPtNEhTzEWrRZF0Cg6LYQ_7_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</syn:PrepaidManufacturingExpense>
    <syn:PrepaidManufacturingExpense
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_Gd4GPvcg2UKf1cMv_HvfqA_7_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">39000</syn:PrepaidManufacturingExpense>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_LYSKIATeUEG8xzEOoccqyw_9_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1533000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_IssBv-uZ-Eq_ZgZA02pHJg_9_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1707000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_3C_Nb-FkJ06Jm8ScLtJ88g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;PROPERTY AND EQUIPMENT (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computers and office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 827&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 813&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 94&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 439&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,263&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (831)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,089)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 101&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_ZvDVzBKGkEueIM7aytJo4w"
      decimals="-3"
      id="Tc_-GUkKl0wJ02hP4zMn3DG6Q_3_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">827000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_syn_ComputersAndOfficeEquipmentMember_ThDy-dV5AU6IEh4MuJpfGw"
      decimals="-3"
      id="Tc_fTOxBgQOfky0NBUweBC-aw_3_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">813000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_mGRCO12RFEyXuQzUlkC0Ow"
      decimals="-3"
      id="Tc_FKIIKeO6_ESwxfZbXqLOjg_4_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">94000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_588QHXjz8kSla7aDWmJMXA"
      decimals="-3"
      id="Tc_qPFdDaOZokSrDxpDy_X-pA_4_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">439000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_IzIuFnR8zEGM4rQkXo15Fw"
      decimals="-3"
      id="Tc_RJAOQWb4NEu-pHL9fe9rSA_5_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">11000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerSoftwareIntangibleAssetMember_xIpjyVqOO0Og8SZMiELCjw"
      decimals="-3"
      id="Tc_M0wddhUo_EqUuH68djbHIQ_5_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">11000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_MsK-6VAtCkiOuRpzjrq5cg_6_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">932000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_b9EjvBnI30y8Y73QCDRpQw_6_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1263000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_5nBkyBErvk-yvJ_ClMaLgA_7_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">831000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_CM8C325ZjkW3gUT3BEYtjg_7_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1089000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_FSv8QfB7KEq9Hs7t3Cq2EA_9_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">101000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_QKaEnmvxpUSDQnikMHarsg_9_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">174000</us-gaap:PropertyPlantAndEquipmentNet>
    <syn:AccruedExpensesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_fWVkO4pVu06uZuHY2gYmZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ACCRUED EXPENSES (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vendor payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 225&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical consulting services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 696&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 700&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued manufacturing costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,928&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:AccruedExpensesTableTextBlock>
    <syn:AccruedVendorPayments
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_S-wa4crrBUO5BICeX1VTrw_3_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1028000</syn:AccruedVendorPayments>
    <syn:AccruedVendorPayments
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_g2PjpUe2h0WktNsCnDUl-A_3_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">225000</syn:AccruedVendorPayments>
    <syn:AccruedClinicalConsultingServices
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_5Q_mLIf2DEu-Wiite35BBQ_4_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">696000</syn:AccruedClinicalConsultingServices>
    <syn:AccruedClinicalConsultingServices
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_lMHkGNkCFkCpQnTyRiPr8Q_4_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">700000</syn:AccruedClinicalConsultingServices>
    <syn:AccruedManufacturingCosts
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_ZU4-SHOvD0S5rh5y1TPzLg_5_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">204000</syn:AccruedManufacturingCosts>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_TW4RQGlNTkej1PYaUytPWw_7_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1928000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_vghHt2gul0615UTYA6eTUA_7_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">925000</us-gaap:AccruedLiabilitiesCurrent>
    <syn:AccruedEmployeeBenefitsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_sCtakR8mPkiHjVh6YdgUFg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ACCRUED EMPLOYEE BENEFITS (in thousands)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued bonus expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued vacation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 868&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:AccruedEmployeeBenefitsTableTextBlock>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_V-ZfUQaOokCGHdN_vd9OJQ_3_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">886000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_DbjvLHHoJUiOS-_pvmzlUg_3_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">724000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_jnXondMtNU6-f3Fad9jX1Q_4_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">92000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_10DGZ7zVk06MfO6eA6wMgA_4_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">144000</us-gaap:AccruedVacationCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_NHgdPbMeFEWVeYnAVa6REQ_6_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">978000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_UWu5NYpss0uSZyK9M2qnFw_6_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">868000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_OzB6yYT9bUywRdLdEvW50w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. Stock-Based Compensation and Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March&#160;20, 2007, the Company&#x2019;s Board of Directors approved the 2007 Stock Incentive Plan (the &#x201c;2007 Stock Plan&#x201d;) for the issuance of up to 71,429 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. This plan was approved by the stockholders on November&#160;2, 2007. The exercise price of stock options under the 2007 Stock Plan was determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company&#x2019;s common stock on the date the option is granted. The total number of shares of stock with respect to which stock options and stock appreciation rights may be granted to any one employee of the Company or a subsidiary during any one-year period under the 2007 plan shall not exceed 7,143. Options become exercisable over various periods from the date of grant, and generally expire ten&#160;years after the grant date. As of December&#160;31, 2021, there were 5,145 options issued and outstanding under the 2007 Stock Plan. There are no shares available to be issued under this plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November&#160;2, 2010, the Board of Directors and stockholders adopted the 2010 Stock Incentive Plan (&#x201c;2010 Stock Plan&#x201d;) for the issuance of up to 85,714 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. From time to time the number of shares authorized for options was increased such that 4,000,000 million were authorized as of September 30, 2021. The exercise price of stock options under the 2010 Stock Plan is determined by the compensation committee of the Board of Directors and may be equal to or greater than the fair market value of the Company&#x2019;s common stock on the date the option is granted. Options become exercisable over various periods from the date of grant and expire between five and ten&#160;years after the grant date. As of December&#160;31, 2021, there were 2,450,130 options issued and outstanding under the 2010 Stock Plan. There are no shares available to be issued under this plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September 17, 2020, the stockholders approved and adopted the 2020 Stock Incentive Plan ("2020 Stock Plan") for the issuance of up to 4,000,000 shares of common stock to be granted through incentive stock options, nonqualified stock options, stock appreciation rights, dividend equivalent rights, restricted stock, restricted stock units and other stock-based awards to officers, other employees, directors and consultants of the Company and its subsidiaries. As of December 31, 2021, there were 3,800,000 options issued and outstanding under the 2010 Stock Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the event of an employee&#x2019;s termination, the Company will cease to recognize compensation expense for that employee. Stock forfeitures are recognized as incurred. There is no deferred compensation recorded upon initial grant date. Instead, the fair value of the stock-based payment is recognized over the stated vesting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has applied fair value accounting for all stock-based payment awards since inception. The fair value of each option or warrant granted is estimated on the date of grant using the Black-Scholes option pricing model. The assumptions used for the&#160;years ended December&#160;31, 2021 and 2020 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life of option (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected dividends&#160;&#x2014;&lt;/i&gt;The Company has never declared or paid dividends on its common stock and has no plans to do so in the foreseeable future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Stock-Based Compensation and Warrants&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected volatility&lt;/i&gt;&#x2014;Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The expected volatility assumption is derived from the historical volatility of the Company&#x2019;s common stock over a period approximately equal to the expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-free interest rate&lt;/i&gt;&#x2014;The assumed risk-free rate used is a zero coupon U.S. Treasury security with a maturity that approximates the expected term of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected life of the option&lt;/i&gt;&#x2014;The period of time that the options granted are expected to remain unexercised. Options granted during the&#160;year have a maximum term of seven&#160;years. The Company estimates the expected life of the option term based on the weighted average life between the dates that options become fully vested and the maximum life of options granted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company records stock-based compensation based upon the stated vesting provisions in the related agreements. The vesting provisions for these agreements have various terms as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;immediate vesting,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;in full on one-year anniversary date of grant date,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;half vesting immediately and remaining over three&#160;years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;quarterly over three&#160;years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;annually over three&#160;years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-third immediate vesting and remaining annually over two&#160;years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-half immediate vesting and remaining over nine&#160;months,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-quarter immediate vesting and remaining over three&#160;years,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one-quarter immediate vesting and remaining over 33&#160;months,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;monthly over one year, and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;monthly over three&#160;years.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the&#160;years ended December&#160;31, 2021 and 2020, the Company granted 2,260,000 and 1,540,000 options to employees and directors having an approximate fair value of $0.5 million and $0.4 million based upon the Black-Scholes option pricing model, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to employees for the&#160;years ended December&#160;31, 2021 and 2020 was $204,000 and $213,000, respectively. Stock-based compensation expense included in general and administrative expenses and research and development expenses relating to stock options issued to consultants for the&#160;years ended December&#160;31, 2021 and 2020 was $212,000 and $137,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Stock-Based Compensation and Warrants&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of stock option activity for the&#160;years ended December&#160;31, 2021 and 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Exercise&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance&#160;- December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,502,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.51 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 153,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,540,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance&#160;- December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,997,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.09 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,260,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,143)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance&#160;-December&#160;31, 2021&#160;- outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,255,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.58 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance&#160;-&#160;&#160;December&#160;31, 2021&#160;- exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,786,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.44 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Grant date fair value of options granted&#160;-&#160;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 501,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average grant date fair value - December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Grant date fair value of options granted&#160;- December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 412,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average grant date fair value&#160;- December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The options outstanding and exercisable at December&#160;31, 2021 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;width:62.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:24.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00&#160;&#x2013;&#160;$40.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,189,257&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,720,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;41.00&#160;&#x2013;&#160;$70.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;71.00&#160;&#x2013;&#160;$102.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2021, total unrecognized stock-based compensation expense related to stock options was $771,000, which is expected to be expensed through February 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The FASB&#x2019;s guidance for stock-based payments requires cash flows from excess tax benefits to be classified as a part of cash flows from operating activities. Excess tax benefits are realized tax benefits from tax deductions for exercised options in excess of the deferred tax asset attributable to stock compensation costs for such options. The Company did not record any excess tax benefits in 2021 or 2020. Cash received from option exercises under the Company&#x2019;s stock-based compensation plans for the&#160;years ended December&#160;31, 2021 and 2020 was zero.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Stock-Based Compensation and Warrants&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October&#160;15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i)&#160;2,520,000 Class&#160;A Units (the &#x201c;Class&#160;A Units&#x201d;), with each Class&#160;A Unit consisting of one share of common stock, and one five-year warrant to purchase one share of common stock at an initial exercise price of $1.38 per share, which subsequently was reduced to $0.69 per share (each a &#x201c;Warrant&#x201d; and collectively, the &#x201c;Warrants&#x201d;), with each Class&#160;A Unit to be offered to the public at a public offering price of $1.15, and (ii)&#160;15,723 Class&#160;B Units (the &#x201c;Class&#160;B Units&#x201d;, and together with the Class&#160;A Units, the &#x201c;Units&#x201d;), with each Class&#160;B Unit offered to the public at a public offering price of $1,000 per Class&#160;B Unit and consisting of one share of the Company&#x2019;s Series&#160;B Convertible Preferred Stock (the &#x201c;Series&#160;B Preferred Stock&#x201d;), with a stated value of $1,000 and convertible into shares of common stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series&#160;B Preferred Stock convertible into an aggregate of 13,672,173 shares of common stock, and issued with an aggregate of 13,672,173 Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of the Company&#x2019;s common stock, $0.001 par value per share (the &#x201c;Common Stock&#x201d;), to $0.69 per Warrant per full share of common stock in accordance with the anti-dilution terms of the Warrant. The reduction was the result of the issuance of shares of common stock by the Company through its &#x201c;at the market offering&#x201d; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend of $0.9 million during the year ended December 31, 2020, which reduces the income available to common stockholders. In addition, pursuant to the underwriting agreement that the Company had entered into with A.G.P./Alliance Global Partners (the &#x201c;Underwriters&#x201d;), as representative of the underwriters, the Company granted the Underwriters a 45 day option (the &#x201c;Over-allotment Option&#x201d;) to purchase up to an additional 2,428,825 shares of common stock and/or additional Warrants to purchase an additional 2,428,825 shares of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the Warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. The Company has concluded that the Warrants are required to be equity classified. The Warrants were valued on the date of grant using Monte Carlo simulations. During the year ended December 31, 2021, 11,655,747 warrants were exercised for cash proceeds of $8.0 million. There were no warrants exercised during the year ended December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 18, 2016, the Company completed a public offering of 714,286 shares of common stock in combination with accompanying warrants to purchase an aggregate of 1,428,571 shares of the common stock. The stock and warrants were sold in combination, with two warrants for each share of common stock sold, a Series A warrant and a Series B warrant, each representing the right to purchase one share of common stock. The purchase price for each share of common stock and accompanying warrants was $35.00. The shares of common stock were immediately separable from the warrants and were issued separately. The initial per share exercise price of the Series A warrants is $50.05 and the per share exercise price of the Series B warrants is $60.20, each subject to adjustment as specified in the warrant agreements. The Series A and Series B warrants could be exercised at any time on or after the date of issuance. The Series A warrants were exercisable until the four-year anniversary of the issuance date and expired November 16, 2020. The Series B warrants expired December 31, 2017 and none were exercised prior to expiration. The warrants included a provision, that if the Company were to enter into a certain transaction, as defined in the agreement, the warrants would be purchased from the holder for cash. Accordingly, the Company recorded the warrants as a liability at their estimated fair value on the issuance date of $15.7 million and changes in estimated fair value were recorded as non-cash income or expense in the Company&#x2019;s Statement of Operations at each subsequent period. At December 31, 2019, the fair value of the warrant liability was $100. The warrants were valued on the date of grant and on each remeasurement period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;4. Stock-Based Compensation and Warrants&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of all warrant activity for the Company for the years ended December 31, 2021 and 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,714,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (714,286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,000,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,655,747)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 26, 2017, the Company entered into a consulting agreement for advisory services for a period of six months. As compensation for such services, the consultant was paid an upfront payment, is paid a monthly fee and on January 24, 2018 was issued a warrant exercisable for 714 shares of the Company&#x2019;s common stock on the date of issue. The warrant is equity classified and the fair value of the warrant approximated $9,000 and was measured using the Black-Scholes option pricing model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A summary of all outstanding and exercisable warrants as of December 31, 2021 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.99&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.78&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.78 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_3_20_2007_us-gaap_PlanNameAxis_syn_StockPlan2007Member_sZjnQm5mlUKRuIz8LR01dg"
      decimals="INF"
      id="Narr_IDm6rJu-F0yTyZT-_jAa4Q"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">71429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_3_1_2007_To_3_20_2007_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_syn_StockPlan2007Member_6vT1SirORkqYa-QBH8UMpQ"
      decimals="INF"
      id="Narr_9SoLkpEr30-IawWCqrc9DA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">7143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockPlan2007Member_auU9NgALU0aCvHRUD6P_0Q"
      decimals="INF"
      id="Narr_lX6J-lg2sE6m1N0DTgqWqw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">5145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_11_2_2010_us-gaap_PlanNameAxis_syn_StockPlan2010Member_Zt_SyFnbm0e4SI86EXshXA"
      decimals="INF"
      id="Narr_z8zD1toLq0iC_7PRNjSWOA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">85714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="Duration_9_1_2021_To_9_30_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_YKWmzXomVU-N4eCGaM8B_w"
      decimals="-6"
      id="Narr_a7Wq0USk20y5Cijhapg2nQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">4000000000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_PlanNameAxis_syn_StockPlan2010Member_4D5WRURlwE63c5hlGLugSw"
      decimals="INF"
      id="Narr_ubHsqT6peEiNhdx5e4gR2w"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2450130</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_9_17_2020_us-gaap_PlanNameAxis_syn_StockPlan2020Member_KiYSEy59102VWky5jzVKvw"
      decimals="INF"
      id="Narr_GeVdUwhHDEWaRQ7YctY1zQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockPlan2010Member_8UEIx49YJkWPUL6XsZYSRw"
      decimals="INF"
      id="Narr_6lLfCYhHcEm2e68oJq4ofw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_-y3eFvN-BkSlzDYtKZ3oCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividends&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected life of option (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="2"
      id="Tc_ysx-_ETBGkeM-G4dDcuslA_3_3"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.33</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="2"
      id="Tc_4SbBRzF_WECuyI6aUdDevA_3_6"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.42</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="2"
      id="Tc_u2aU_BmnXEqBscPZUav2-Q_4_3"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="2"
      id="Tc_CzZkd7RZj0qQOz3GXn7jjQ_4_6"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="2"
      id="Tc_quBpVZgBa02hkHYO17C57A_5_3"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="2"
      id="Tc_xDorFklgk0KsqpFRDdpLZw_5_6"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="4"
      id="Tc_GZme9a8CdEqKkGKLqw5uyA_6_3"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.0112</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="4"
      id="Tc_nOhfK6XpukOtt2AkSpp4vw_6_6"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.0031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tc_EFswqIgXIEiI8NToyXtH-Q_7_3">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      id="Tc_pbYMhcsOUUiEHfclEiQpWw_7_6">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_EmployeesAndDirectorsMember_nY8Xr06tV0aNNWlTT_5fvw"
      decimals="INF"
      id="Narr_Y_UbxepkC02o8bb0P4dwxQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2260000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_EmployeesAndDirectorsMember_LECQK4-VqUWq2chzZjdaUA"
      decimals="INF"
      id="Narr_oNqgch1AgUeH38hMZ4KqHw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">1540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_VjXYAcDWp02HBkXd6GYVAg"
      decimals="-5"
      id="Narr_sOww47jwpk-IfArdfzIPGQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_ombmDTe2AkCAbJcUoj-n9g"
      decimals="-5"
      id="Narr_mvPKb3dsRk2kTAA6gjw2jQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_MCFQsLEw-UuxHL58RoxInQ"
      decimals="0"
      id="Narr_cfjj2XwhJ0CLySnBl5Iqew"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">204000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_EmployeeStockMember_-3VYIo1Se0a3VB9LflrxFQ"
      decimals="0"
      id="Narr_uzKkOATCfEa_2pSSTBobWg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">213000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_eQmeAnrjzk6zi6wV_bY3hg"
      decimals="0"
      id="Narr_dM6LRrYPa0urcgeN9nbC3w"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">212000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_ConsultantMember_thyNdGbiIUKfEg211NQAxQ"
      decimals="0"
      id="Narr_BgLB95JHKEKKaM-ZwFc3kw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">137000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_ahDpXAPfKkKDqESChoyS-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of stock option activity for the&#160;years ended December&#160;31, 2021 and 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&#160;Exercise&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance&#160;- December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,502,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.51 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 153,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,540,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,944)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.57&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29,650)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance&#160;- December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,997,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6.09 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,260,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,143)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 45.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance&#160;-December&#160;31, 2021&#160;- outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,255,275&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.58 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Balance&#160;-&#160;&#160;December&#160;31, 2021&#160;- exercisable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,786,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4.44 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Grant date fair value of options granted&#160;-&#160;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 501,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average grant date fair value - December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Grant date fair value of options granted&#160;- December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 412,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average grant date fair value&#160;- December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.27&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZD4aLXU3F02Cocoebc69mg"
      decimals="0"
      id="Tc_oHNQs1KiCkSP_9yBAZYuQw_4_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2502012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZD4aLXU3F02Cocoebc69mg"
      decimals="2"
      id="Tc_ldwP4oNo5UyWLcXEMqJwKA_4_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">3.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TmfP0gKxNEy5KmAuY3LXKg"
      id="Narr_69XuosZf3UyKO0DJKZ75Yw">P6Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_ZD4aLXU3F02Cocoebc69mg"
      decimals="0"
      id="Tc_JipiAMUuUkm4SC6tVXT_-g_4_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">153353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"
      decimals="0"
      id="Tc_Fj3wExvBYEKh67Z-Z97d2A_6_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">1540000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"
      decimals="2"
      id="Tc_dxezlVwA1kCT394t3WAfkg_6_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"
      decimals="0"
      id="Tc_zv-Dc9hWTESCGbWbRz-7bQ_8_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">14944</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"
      decimals="2"
      id="Tc_6IeSf0hEG0GcF_lVmIILLQ_8_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">17.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"
      decimals="0"
      id="Tc_Mc_QKL3CjEa-iJVDe8AFyA_9_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">29650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"
      decimals="2"
      id="Tc_h6kl8F4LmkSNk-ICf9iePA_9_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zVfa8-ihl0GXFzR6eyN9PA"
      decimals="0"
      id="Tc_5IE7lGplb0ija8o78dZhQQ_10_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3997418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zVfa8-ihl0GXFzR6eyN9PA"
      decimals="2"
      id="Tc_nWLaDcbB0U2Z4lOfnfXlqw_10_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">2.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"
      id="Narr_bERT4HlK3U2ciwl5KQ-DCQ">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_zVfa8-ihl0GXFzR6eyN9PA"
      decimals="0"
      id="Tc_5xqisTb4p0CrPmfuBtMJCA_10_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A"
      decimals="0"
      id="Tc_GQQ8GbidGEazpTfYeXBlig_12_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2260000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A"
      decimals="2"
      id="Tc_pw8nWhY5DUGlqVt0gPAsTw_12_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A"
      decimals="0"
      id="Tc_6640NelleUKDI-fCATvMyQ_14_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A"
      decimals="2"
      id="Tc_10hzyPzfuE22J4pHIimV2A_14_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">45.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA"
      decimals="0"
      id="Tc_E2nq_Mpr7UuZ4fSz1HFx9g_17_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6255275</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA"
      decimals="2"
      id="Tc_YozHlz10cke5cey8EBePQw_17_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A"
      id="Narr_LXLUIAQY-EmDGEsixmZZlg">P5Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA"
      decimals="0"
      id="Tc_-Nz8wISEEEiIll5y61KAKQ_17_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA"
      decimals="0"
      id="Tc_UOyXXa0sQEWJjVQNeLuzVQ_19_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2786934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA"
      decimals="2"
      id="Tc_lrwN7YC3SkCHUhiFdw-Ysw_19_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">3.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A"
      id="Narr_6JyXbOlYPEOHtajyNrF0_g">P4Y5M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hX2FwfrqGEenXwRZIxB3UA"
      decimals="0"
      id="Tc_g_tPCyG5ik2Ax2415XWIPA_19_10"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A"
      decimals="0"
      id="Tc_KCsu1GF5I0aY4tP2pMeSRQ_21_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">501000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A"
      decimals="2"
      id="Tc_vsXptH1V5kWfHGr0XbvWQQ_23_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"
      decimals="0"
      id="Tc_oOoO5cgQYEep--0R7jT6EA_25_5"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">412000</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_PHAJ8ClmdEiKZluxQ3jOYQ"
      decimals="2"
      id="Tc_LdN10xj7K0mT16bR4jdqcg_27_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_ekeerMJojEaW8nL8D5j_Uw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The options outstanding and exercisable at December&#160;31, 2021 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;width:62.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:35.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:24.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:24.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.00&#160;&#x2013;&#160;$40.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,189,257&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;6&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,720,916&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;4 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;41.00&#160;&#x2013;&#160;$70.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2&#160;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52.07&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;71.00&#160;&#x2013;&#160;$102.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59,797&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85.19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;2&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g"
      decimals="2"
      id="Narr__QXyRCpDNUumXYhmaDeQNw"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g"
      decimals="2"
      id="Narr_ReietgNrxEyCeAkUzQLkFg"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">40.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g"
      decimals="0"
      id="Tc_E7peh95PLUyujO5n6s3eeg_7_3"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6189257</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g"
      decimals="2"
      id="Tc_kbUhLz0-gEGFnZxCUp1XbQ_7_6"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.75</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g"
      id="Tc_WvvWmsUv0Uaoe2yHQ6yQuw_7_8">P6Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g"
      decimals="0"
      id="Tc_Q7X4EdRA2UCbsjQH-73Vbg_7_10"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2720916</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_H2pcQ_d7AUuVzDexGiRe6g"
      decimals="2"
      id="Tc_uysMCWBGvkWxE-sfPIF0oQ_7_13"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g"
      id="Tc_NMS1ZuIwD0quS7AWjHTKew_7_15">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA"
      decimals="2"
      id="Narr_BDKxrCiyPEemGzKIT-tg0A"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">41.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA"
      decimals="2"
      id="Narr_2mfJfAFcWEGEsKomcMH3MA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">70.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw"
      decimals="0"
      id="Tc_FIDD4yEQZEa0yHr2yGmx-w_8_3"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6221</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw"
      decimals="2"
      id="Tc_mjl8Qzfmr0K92rns0_-J9g_8_6"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">52.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA"
      id="Tc_GSJrzI_RWk2lGlGoXZ8KeQ_8_8">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw"
      decimals="0"
      id="Tc_srBzGC9ZgkOiVQ5XhZByJA_8_10"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6221</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_Td7HRO8nUkOFl1ESKUE_uw"
      decimals="2"
      id="Tc_0BDIl7dE7kKizgWmKuhhPA_8_13"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">52.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice41007000Member_JAti2j29WECRIovO8Y50yA"
      id="Tc_1Pkwg2WP6kWmt17G3-51jg_8_15">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w"
      decimals="2"
      id="Narr_H5XQFVEHj0SokMHSuZCbEA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">71.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w"
      decimals="2"
      id="Narr_cDfS6GVcIUez-cDu8Lvp0A"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">102.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA"
      decimals="0"
      id="Tc_1O_4pCuXRkSMi5wDsBJNDQ_9_3"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">59797</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA"
      decimals="2"
      id="Tc_y25Jebn4hESetTL0tZAmjw_9_6"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">85.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w"
      id="Tc_Z0JWz4QyZk--dmo8NDwS6A_9_8">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA"
      decimals="0"
      id="Tc_WncmHUtmSki7web6Ilqwvg_9_10"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">59797</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_8fFLLrgAO0SEvYx8jXFHwA"
      decimals="2"
      id="Tc_XnojmG17XEWIqP9TSsbrPw_9_13"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">85.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice710010200Member_jLgy7tK3RkePZyGFvRKC6w"
      id="Tc_DZq_-dATtkaIaLevNHgW8g_9_15">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="0"
      id="Narr_mn3TepQ9SEqXexXzb82kfQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">771000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="0"
      id="Narr_1XgdCm0r80qHNt-NhD8z_g"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="0"
      id="Narr_fZLxkREZHkyFxhHMi4Ak9g"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_10_15_2018_To_10_15_2018_XRwkhJ_Dmk-8YpsoxAckVw"
      decimals="-5"
      id="Narr_2L3ihd4lYESQg-7YBNiMCw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">18600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_e0SFi2g7CEyrvY0QNpCI5Q"
      decimals="0"
      id="Narr_YTEbpq32xU68dDmrpIT8dQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2520000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <syn:WarrantTerm
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_ClassOfWarrantOrRightAxis_syn_OctoberTwoThousandEighteenWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_syn_UnderwrittenPublicOfferingMember_Kff7vF4eSUKF3WYZhsclQg"
      id="Narr_gkIciZ7VvkeVQ5mfGBbueg">P5Y</syn:WarrantTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_15_2018_zFSd_b_S1kyXW8-66Kwglw"
      decimals="2"
      id="Narr_ZHuTyDzbsUOqQmZJizCNwA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_15_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_h58kDK3e0kC9mHm8SZusWg"
      decimals="2"
      id="Narr_QwV6otMEXU-iCrGppiPTDg"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_M20NXTQpLkugL1IJr-5fEg"
      decimals="2"
      id="Narr_uwBzHXPspEyGojRk3uSSEw"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_IfsKKTpoWkaVjjV1uYXCvQ"
      decimals="0"
      id="Narr_BXVQ62H75kSVJ7Jt6OWkgQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">15723</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA"
      decimals="0"
      id="Narr_s-Pfj2QNzkqM0zSeb9teSw"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA"
      decimals="0"
      id="Narr_aOHwdsbD4kum5UwGbUYGOw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <syn:PreferredStockConversionPricePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA"
      decimals="2"
      id="Narr_Vii7w5OLRECSSBhwz4YmcQ"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.15</syn:PreferredStockConversionPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA"
      decimals="0"
      id="Narr_PZVzHfhXukyP8arICYeFSQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">13672173</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_3Kn9Wj-M-U2EBcPcpa_-tA"
      decimals="0"
      id="Narr_8lWUmtG5xkCcU0yUD3s9gA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">13672173</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_16_2020_CZ8bHk5Mp0ir4tpe8uIf9A"
      decimals="2"
      id="Narr_HnvnQD8RUU2qsZ7O6XMAfQ"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_11_16_2020_CZ8bHk5Mp0ir4tpe8uIf9A"
      decimals="INF"
      id="Narr_xw46pZjdCEempCcUWPw9WA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_16_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_JKnuxTVzpU26lxfBbgZZXg"
      decimals="2"
      id="Narr_lbajP5BeZkOuNvMawBkf3A"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <syn:WarrantExercisePriceAdjustment
      contextRef="Duration_12_1_2020_To_12_31_2020_7WfemUuB9kSDPnEwicRDoA"
      decimals="-5"
      id="Narr_8Jdn1XnXT0SzCHnubTbPQw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">900000</syn:WarrantExercisePriceAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_16_2020_To_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_IPq28Mt1gUW_3j_-pwfbiQ"
      decimals="0"
      id="Narr_jaGXcOuRv0igUngecr7oGg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2428825</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_AwBR-gCbEkOKHtktUYXQIA"
      decimals="0"
      id="Narr_RV5Hp7g-qE-T5j8ztHpkMA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2428825</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <syn:IssueOfWarrantsToPurchaseCommonStock
      contextRef="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_AwBR-gCbEkOKHtktUYXQIA"
      decimals="0"
      id="Narr_zc9ayfdCMUiN9XLJklq8ew"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">1807826</syn:IssueOfWarrantsToPurchaseCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="0"
      id="Narr_lFLYRnJu9E6DTZmBZSMdfA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_UcLPi0nU_k-Nrovhui30Ew"
      decimals="INF"
      id="Narr__jLfWkniGUKmvCqvOm8IDw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">11655747</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-5"
      id="Narr_VZb2ZhIP2kCP3sPBWDIruQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">8000000.0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <syn:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_12_1_2020_To_12_31_2020_7WfemUuB9kSDPnEwicRDoA"
      decimals="0"
      id="Narr_vH4ibFVnYUOdcGuSYCcPRA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">0</syn:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MDjl32aA7Eup2n9x0SL85A"
      decimals="INF"
      id="Narr_PMrq28eTX0u_v5YuyzPztQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">714286</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_8_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_cCtXQSarIUqWy1ntHvFVqA"
      decimals="0"
      id="Narr_7Ms034dmeEWd7HGw3JQ2cg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">1428571</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <syn:NumberOfShareSold
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesWarrantsMember_qr4fxMiyiEuZKSyigooSJg"
      decimals="INF"
      id="Narr_Qqs6VbDSLEeV6kIgVl7wMg"
      unitRef="Unit_Standard_item_yMnlz8fE9U-5tR1qkqQKuA">2</syn:NumberOfShareSold>
    <syn:NumberOfSharesPurchase
      contextRef="Duration_11_18_2016_To_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_MCMoFtcreUerjsPb8Xr3IA"
      decimals="INF"
      id="Narr_wWv6aFuqnUiDrW_bs-FY1Q"
      unitRef="Unit_Standard_item_yMnlz8fE9U-5tR1qkqQKuA">1</syn:NumberOfSharesPurchase>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_18_2016_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_puysgE2QRkquEuEWCphmDg"
      decimals="2"
      id="Narr_Ra0eMw1W6EiloarJ5xfxQQ"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">35.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_18_2016_us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis_us-gaap_SeriesAMember_us-gaap_PlanNameAxis_syn_StockWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_JdtyyC7Z80SCunUZpuqFNw"
      decimals="2"
      id="Narr_J60vI-BzGEaFRuBVTyZtbQ"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">50.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_18_2016_us-gaap_ClassOfWarrantOrRightAxis_syn_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ZxaIHv3whUOoORl_cB5qNw"
      decimals="2"
      id="Narr_i7suSosfpkKWl627h7EQpQ"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">60.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_11_16_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_tO6QgfwYmUKrmumFN_QdXw"
      decimals="-5"
      id="Narr_WBJ745ghREG2loX8_m6mvg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">15700000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_31_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_ZNP2PWLgIUK7spcejRs3hQ"
      decimals="-6"
      id="Narr_qXdzunkkDEm433x2xJ4vwQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">100000000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <syn:ScheduleOfWarrantActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_fPhtjdK-802y68LgEDh9OA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;A summary of all warrant activity for the Company for the years ended December 31, 2021 and 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,714,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.24&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (714,286)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50.05&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,000,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,655,747)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance at December&#160;31,2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.74%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q"
      decimals="INF"
      id="Tc_EJ-tdWfqn06pCTbI_UrUfQ_3_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">18714999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q"
      decimals="2"
      id="Tc_3ImM-U5nIkCFETfqd_4QrQ_3_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">3.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="INF"
      id="Tc_42ZBNmi9n0y0u57lqsMHLw_6_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">714286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="2"
      id="Tc_E7GRbNDUUEmfWoiIpM1RbA_6_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">50.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="INF"
      id="Tc_4LqABqzzTU6VBtO5glGdKA_7_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">18000713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="2"
      id="Tc_xdxjRfQncUOu05B408e56Q_7_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="INF"
      id="Tc_eyNufAgL2UyA6tv3G3XkEw_9_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">11655747</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="2"
      id="Tc_SBEZ6Pg_WkyfgmWx8TybNQ_10_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="INF"
      id="Tc_jnZl_Ns4PkKrwJuW70ds3Q_11_2"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6344966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="2"
      id="Tc_yoMpj6VAtUGvacX6zR7dEg_11_5"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber
      contextRef="As_Of_12_26_2017_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_MzByem4-e0OSJosV2hHEFA"
      decimals="INF"
      id="Narr_jqglhGKfJECKg5_E27l21g"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">714</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="As_Of_12_26_2017_V_Q0QMOYikCPg8S4qD1ovg"
      decimals="0"
      id="Narr_faWvjMcoxEqdC1C55Mm9cg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">9000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_aIi27KZCE0GMYwq-ygxv_A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&#160;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;0.99&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 714&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.78&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.69&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,344,966&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1.78 years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock>
    <syn:WarrantsExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_nGWIzttATUuENHWAb_1Gxg"
      decimals="2"
      id="Tc_hned9R1FBU2-8uY1XxGymA_4_1"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.69</syn:WarrantsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_Qfjmc-RTiEuH6kugXZ51Iw"
      decimals="0"
      id="Tc_0ZLWtkrP6USCA-5zpFpMug_4_3"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6344252</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_Qfjmc-RTiEuH6kugXZ51Iw"
      decimals="0"
      id="Tc_wUdp4MkJFECxFYUqTMoDTQ_4_5"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6344252</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_nGWIzttATUuENHWAb_1Gxg"
      id="Narr_F_12Spjzp0WMBbrXBXo9og">P0Y11M26D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <syn:WarrantsExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_mAkr-3jFnkW2bbxcAR8RYQ"
      decimals="2"
      id="Tc_L04kz6A_D0S9eJOp016Vjg_5_1"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">18.20</syn:WarrantsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_VMLlPD7ENUWWhTbFeid_mw"
      decimals="0"
      id="Tc_xR_s11cCT0uLmvFRMK88ng_5_3"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">714</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_VMLlPD7ENUWWhTbFeid_mw"
      decimals="0"
      id="Tc_wAPDFFXaA0y-NQBVGoRh3A_5_5"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">714</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice1820Member_mAkr-3jFnkW2bbxcAR8RYQ"
      id="Narr_KfzLZdWCvEGenlpnNMiWQQ">P1Y9M10D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <syn:WarrantsExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_Y6KWsIfrY0W-AXmu4z1SHg"
      decimals="2"
      id="Tc_G28xn7CwFUGxwR3iz9NlpQ_6_1"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.69</syn:WarrantsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_8CxCH8oNkEm74aCXq-VOTA"
      decimals="0"
      id="Tc_F2OqvpWyg0yDikAg-YwkJA_6_3"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6344966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber
      contextRef="As_Of_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_8CxCH8oNkEm74aCXq-VOTA"
      decimals="0"
      id="Tc_ZhbA4spmKUWwgqmEqJ9IwA_6_5"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">6344966</syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69TwoMember_Y6KWsIfrY0W-AXmu4z1SHg"
      id="Narr_FC7fodRG3Uy2RfpAPXCX2w">P1Y9M10D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_6nUtADnyVkm5zRYI84HkFQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Series B Preferred Stock &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October&#160;15, 2018, the Company closed its underwritten public offering pursuant to which it received gross proceeds of approximately $18.6 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company and sold an aggregate of (i)&#160;2,520,000 Class&#160;A Units, with each Class&#160;A Unit offered to the public at a public offering price of $1.15, and (ii)&#160;15,723 Class&#160;B Units, with each Class&#160;B Unit offered to the public at a public offering price of $1,000 per Class&#160;B Unit and consisting of one share of the Company&#x2019;s Series&#160;B Preferred Stock, with a stated value of $1,000 and convertible into shares of common stock at the stated value divided by a conversion price of $1.15 per share, with all shares of Series&#160;B Preferred Stock convertible into an aggregate of 13,672,173 shares of common stock, and issued with an aggregate of 13,672,173 October&#160;2018 Warrants. Since the above units are equity instruments, the proceeds were allocated on a relative fair value basis which created the Series&#160;B Preferred Stock discount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In addition, pursuant to the Underwriting Agreement that the Company entered into with the Underwriters on October&#160;10, 2018, the Company granted the Underwriters a 45 day option (the &#x201c;Over-allotment Option&#x201d;) to purchase up to an additional 2,428,825 shares of common stock and/or additional warrants to purchase an additional 2,428,825 shares of common stock. Each Warrant is exercisable for one share of common stock. The Underwriters partially exercised the Over-allotment Option by electing to purchase from the Company additional Warrants to purchase 1,807,826 shares of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Stockholders&#x2019; Equity &#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The conversion price of the Series&#160;B Preferred Stock and exercise price of the October&#160;2018 Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the common stock. The exercise price of the Warrants is subject to adjustment in the event of certain dilutive issuances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 16, 2020, the exercise price of the Warrants was reduced from $1.38 per Warrant per full share of common stock to $0.69 per Warrant per full share of common stock. The reduction was the result of the issuance of shares of common stock by the Company through its &#x201c;at the market offering&#x201d; facility. The effect of the change in the exercise price of the warrants as a result of the triggering of the down round protection clause in the Warrants was recorded as a deemed dividend in accumulated deficit of $0.9 million, which reduces the income available to common stockholders for the year ended December 31, 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The October&#160;2018 Warrants are immediately exercisable at a price of $0.69  per share of common stock (which was 120% of the public offering price of the Class&#160;A Units) and will expire on October&#160;15, 2023. If, at the time of exercise, there is no effective registration statement registering, or no current prospectus available for, the issuance of the shares of common stock to the holder, then the October&#160;2018 warrants may only be exercised through a cashless exercise. No fractional shares of common stock will be issued in connection with the exercise of any October&#160;2018 warrants. In lieu of fractional shares, the holder will receive an amount in cash equal to the fractional amount multiplied by the fair market value of any such fractional shares. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Since the effective conversion price of the Series B Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is a beneficial conversion feature (&#x201c;BCF&#x201d;) at the issuance date. Because the Series B Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#x201c;deemed dividend&#x201d; and impacts earnings per share. During the years ended December 31, 2021 and 2020, 3,973 and 3,665 shares, respectively, were converted resulting in the recognition of deemed dividends of $1.5 million and $1.4 million, respectively, for the amortization of the Series B Preferred Stock discount upon conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Series A Preferred Stock &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;11, 2017, the Company entered into a share purchase agreement (the &#x201c;Purchase Agreement&#x201d;) with an investor (the &#x201c;Investor&#x201d;), pursuant to which the Company offered and sold in a private placement &#160; 120,000 shares of its Series&#160;A Convertible Preferred Stock, par value $0.001 per share (the &#x201c;Series&#160;A Preferred Stock&#x201d;) for an aggregate purchase price of $12 million, or $100 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Series&#160;A Preferred Stock ranks senior to the shares of the Company&#x2019;s common stock, and any other class or series of stock issued by the Company with respect to dividend rights, redemption rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. Holders of Series&#160;A Preferred Stock are entitled to a cumulative dividend at the rate of 2.0%&#160;per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series&#160;A Preferred Stock classifying the Series&#160;A Preferred Stock. The Series&#160;A Preferred Stock is convertible at the option of the holders at any time into shares of common stock at an initial conversion price of $0.54 per share which was increased to $18.90 after taking into account the 2018 reverse stock split, subject to certain customary anti-dilution adjustments, and was decreased to $1.50 on January 27, 2021, as described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Any conversion of Series&#160;A Preferred Stock may be settled by the Company in shares of common stock only.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The holder&#x2019;s ability to convert the Series&#160;A Preferred Stock into common stock is subject to(i)&#160;a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii)&#160;if so elected by the Investor, a 4.99% blocker provision that will prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#x2019;s common stock or voting power at any time, and (iii)&#160;applicable regulatory restrictions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Stockholders&#x2019; Equity &#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In the event of any liquidation, dissolution or winding-up of the Company, holders of the Series&#160;A Preferred Stock are entitled to a preference on liquidation equal to the greater of (i)&#160;an amount per share equal to the stated value plus any accrued and unpaid dividends on such share of Series&#160;A Preferred Stock (the &#x201c;Accreted Value&#x201d;), and (ii)&#160;the amount such holders would receive in such liquidation if they converted their shares of Series&#160;A Preferred Stock (based on the Accreted Value and without regard to any conversion limitation) into shares of the common stock immediately prior to any such liquidation, dissolution or winding-up (the greater of (i)&#160;and (ii), is referred to as the &#x201c;Liquidation Value&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Except as otherwise required by law, the holders of Series&#160;A Preferred Stock have no voting rights, other than customary protections against adverse amendments and issuance of&#160;&lt;i style="font-style:italic;"&gt;pari passu&lt;/i&gt;&#160;or senior preferred stock. Upon certain change of control events involving the Company, prior to the filing of the amendment to the Certificate of Designation for the Series A Preferred Stock described below, the Company will be required to repurchase all of the Series&#160;A Preferred Stock at a redemption price equal to the greater of (i)&#160;the Accreted Value and (ii)&#160;the amount that would be payable upon a change of control (as defined in the Certificate of Designation) in respect of common stock issuable upon conversion of such share of Series&#160;A Preferred Stock if all outstanding shares of Series&#160;A Preferred Stock were converted into common stock immediately prior to the change of control.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On or at any time after (i)&#160;the VWAP (as defined in the Certificate of Designation) for at least 20 trading&#160;days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6&#160;months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share of Series&#160;A Preferred Stock of $7,875.00, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&#160;A Convertible Preferred Stock or (ii)&#160;the five&#160;year anniversary of the issue date, the Company shall have the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Convertible Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Series&#160;A Preferred Stock was classified as temporary equity due to the shares being redeemable based on contingent events outside of the Company&#x2019;s control. Since the effective conversion price of the Series&#160;A Preferred Stock is less than the fair value of the underlying common stock at the date of issuance, there is BCF at the issuance date. Because the Series&#160;A Preferred Stock has no stated maturity or redemption date and is immediately convertible at the option of the holder, the discount created by the BCF is immediately charged to accumulated deficit as a &#x201c;deemed dividend&#x201d; and impacts earnings per share. During the&#160;year ended December&#160;31, 2017, the Company recorded a discount of $6.9 million. Because the Series A Preferred Stock is not currently redeemable, the discount arising from issuance costs was allocated to temporary equity and will not be accreted until such time that redemption becomes probable. The stated dividend rate of 2% per annum is cumulative and the Company accrues the dividend on a quarterly basis (in effect accreting the dividend regardless of declaration because the dividend is cumulative). During the years ended December 31, 2021 and 2020, the Company accrued dividends of $24,000 and $254,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 27, 2021, the Company filed an amendment to the Certificate of Designation for the Series A Preferred Stock to (i) lower the stated Conversion Price through September 30, 2021 and (ii) remove their change in control put. The Amendment to the Certificate of Designation for the Series A Convertible Preferred Stock (the &#x201c;Certificate of Amendment&#x201d;) that was filed with the Secretary of State of the State of Nevada adjusted the conversion price from $18.90 per share to $1.50 per share and removed the redemption upon change of control. The Company received notice from the holder of the Series A Preferred Stock that it was increasing the Maximum Percentage as defined in the &#x201c;Certificate of Designation&#x201d; from 4.99% to 9.99%, such increase to be effective 61 days from the date thereof. The holder of the Series A Preferred Stock converted all of its shares of Series A Preferred Stock and there are no remaining shares of the Series A Convertible Preferred stock outstanding. During January and February 2021, the Company issued 8,996,768 shares of its common stock upon the conversion effected on such date by the holder of 120,000 shares of its Series A Convertible Preferred Stock. The fair value of the consideration issued to the holder to induce conversion was accounted for as a deemed dividend and increased net loss available to common shareholders for purposes of calculating loss per share. The Company estimated the fair value of the inducement consideration of $7.4 million and as a result recorded a corresponding deemed dividend of $7.4 million during the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;5. Stockholders&#x2019; Equity &#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;B. Riley Securities Sales Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On August 5, 2016, the Company entered into the B. Riley FBR Sales Agreement with FBR Capital Markets &amp;amp; Co. (now known as B. Riley Securities), which enables the Company to offer and sell shares of the common stock from time to time through B. Riley Securities, Inc. as the Company&#x2019;s sales agent. Sales of common stock under the B. Riley Securities Sales Agreement are made in sales deemed to be &#x201c;at-the-market&#x201d; equity offerings as defined in Rule 415 promulgated under the Securities Act. B. Riley Securities, Inc. is entitled to receive a commission rate of up to 3.0% of gross sales in connection with the sale of the common stock sold on the Company&#x2019;s behalf. For the year ended December 31, 2020, the Company sold through the B. Riley Securities Sales Agreement an aggregate of 9.3 million shares of common stock and received net proceeds of approximately $3.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 9, 2021, the Company entered into an amended and restated sales agreement with B. Riley Securities, Inc. (&#x201c;B. Riley&#x201d;) and A.G.P./Alliance Global Partners (&#x201c;AGP&#x201d;) in order to include AGP as an additional sales agent for the Company&#x2019;s &#x201c;at the market offering&#x201d; program (the &#x201c;Amended and Restated Sales Agreement&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the year ended December 31, 2021, the Company sold through the At Market Issuance Sales Agreement and the Amended and Restated Sales Agreement approximately 78.7 million shares of the Company&#x2019;s common stock and received net proceeds of approximately $66.0 million.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_10_15_2018_To_10_15_2018_XRwkhJ_Dmk-8YpsoxAckVw"
      decimals="-5"
      id="Narr_9ApwoL6Y40ewsANyMhkp0A"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">18600000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassAMember_e0SFi2g7CEyrvY0QNpCI5Q"
      decimals="0"
      id="Narr_ZDCqPVZxzU-NEYNNWvuVWw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2520000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA"
      decimals="2"
      id="Narr_s7IXISQsS0a3OcfgiH0M5w"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.15</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_CommonClassBMember_IfsKKTpoWkaVjjV1uYXCvQ"
      decimals="0"
      id="Narr_IrmrsLzDC0KDc8Vw14UnYQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">15723</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA"
      decimals="0"
      id="Narr_XNQQ8Y4AMUCv2x96uOZciQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA"
      decimals="0"
      id="Narr_c76S7XkJfkCtVN9HcQFm2w"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <syn:PreferredStockConversionPricePerShare
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_C-dm9BfMgEC9P8RhAWgkjA"
      decimals="2"
      id="Narr_LUqjwpu8_UixyIP-awzAgw"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.15</syn:PreferredStockConversionPricePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="Duration_10_15_2018_To_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_b-kNj0AVWU6M5VJeDgVZWA"
      decimals="0"
      id="Narr_h_QHHL_U6keeI6LRzgPGLg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">13672173</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_15_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_WarrantMember_I2ym8-ECqUmzrLIL8pB_FQ"
      decimals="0"
      id="Narr_at_aNXw8Lka6DBIg07Gsxw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">13672173</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2018_To_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_g8yBpnY3o0iFqkOSqvylXg"
      decimals="0"
      id="Narr_tUuCUNTda0qWemyb9m4SDQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2428825</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_uAjHlff2ZEySANOAcEoi0A"
      decimals="0"
      id="Narr_uIfHZ9KlF0uD6dDH2dR_kQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2428825</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <syn:IssueOfWarrantsToPurchaseCommonStock
      contextRef="As_Of_10_10_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_uAjHlff2ZEySANOAcEoi0A"
      decimals="0"
      id="Narr_isoltVok2kCoYQbpc0rlkg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">1807826</syn:IssueOfWarrantsToPurchaseCommonStock>
    <syn:PreferredStockSharesConverted
      contextRef="Duration_11_16_2020_To_11_16_2020_84bpVptC1E-TU2cJmJR7uQ"
      decimals="2"
      id="Narr_8wtl7w_n1kGekwItAHF9_w"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">1.38</syn:PreferredStockSharesConverted>
    <us-gaap:PreferredStockConvertibleConversionPriceDecrease
      contextRef="Duration_11_16_2020_To_11_16_2020_84bpVptC1E-TU2cJmJR7uQ"
      decimals="2"
      id="Narr_36OqUkrCGkO0MxCfR4_gfg"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.69</us-gaap:PreferredStockConvertibleConversionPriceDecrease>
    <us-gaap:PreferredStockDiscountOnShares
      contextRef="As_Of_11_16_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_CBpL-RLdCE6YnRWt9ySuKg"
      decimals="-5"
      id="Narr_fJt-5quDj0m8CqBf_FgVZA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">900000</us-gaap:PreferredStockDiscountOnShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_B1Z-wDViY0io9Y60hJ5IyQ"
      decimals="2"
      id="Narr_OPHNKrM4qUGICwo9lOIn_g"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.69</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <syn:PercentageOfIssueOfThePublicOffering
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_3SlaVldlt0uuxM4dd8Zq4g"
      decimals="2"
      id="Narr_1B5tMBsgJkCwxb9qIufaew"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">1.20</syn:PercentageOfIssueOfThePublicOffering>
    <syn:InvestmentWarrantsExpirationDate1
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_3SlaVldlt0uuxM4dd8Zq4g"
      id="Narr_xI9uvhHlYEqyMaszkAzX2w">2023-10-15</syn:InvestmentWarrantsExpirationDate1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA"
      decimals="0"
      id="Narr_Cwqe83tdOUusRZp-w4iEKQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <syn:PreferredStockSharesConverted
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="INF"
      id="Narr_XZzyZudR6Uy3M8ht5kPPwg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3973</syn:PreferredStockSharesConverted>
    <syn:PreferredStockSharesConverted
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="INF"
      id="Narr_CJp3ByQs8U6YrxwRfR_7qw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">3665</syn:PreferredStockSharesConverted>
    <us-gaap:PreferredStockDiscountOnShares
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_XT6XJ5XjDUuV4c_EGi70aw"
      decimals="-5"
      id="Narr_tUfDCahkvU-DO48L0kzNpQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1500000</us-gaap:PreferredStockDiscountOnShares>
    <us-gaap:PreferredStockRedemptionDiscount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesBPreferredStockMember_N3liYas2vE2JY8U_wJY2yA"
      decimals="-5"
      id="Narr_2z-44B1B70CI83pKnhX5dg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1400000</us-gaap:PreferredStockRedemptionDiscount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_5WO4v6359U6n6BT9EUOLpA"
      decimals="0"
      id="Narr_SqMMpJ1I0kCEL9dgFJT9gg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">120000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_-JYGHuWq50WFYfi0Zl8OPg"
      decimals="3"
      id="Narr_0lIyfE6nNkamm3IhzwnmKA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_5WO4v6359U6n6BT9EUOLpA"
      decimals="-6"
      id="Narr_-eFqaO1uK0e1arMK65EpDw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">12000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_5WO4v6359U6n6BT9EUOLpA"
      decimals="0"
      id="Narr_Zq-rmADA6kernY_JTLo0Tg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">100</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g"
      decimals="3"
      id="Narr_sv_0fuv8bkWCrP44DfdJ4Q"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.020</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g"
      decimals="3"
      id="Narr_qICuPUhDHUiU_z9QXsa8Cg"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.020</us-gaap:PreferredStockDividendRatePercentage>
    <syn:PreferredStockConversionPricePerShare
      contextRef="As_Of_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_Y8P_QWYzfky5T_au5O14bg"
      decimals="2"
      id="Narr_cKo9zDJbXkmXwBqQt6A0FA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">0.54</syn:PreferredStockConversionPricePerShare>
    <us-gaap:PreferredStockConvertibleConversionPriceIncrease
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g"
      decimals="2"
      id="Narr_UrFERw4LBE2dwcPhJ63Zbw"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">18.90</us-gaap:PreferredStockConvertibleConversionPriceIncrease>
    <us-gaap:PreferredStockConvertibleConversionPriceDecrease
      contextRef="Duration_1_27_2021_To_1_27_2021_DAGJFo-tVEioslNEUzr8Og"
      decimals="2"
      id="Narr_koU4Knk8QEGcmOznEBr1-A"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.50</us-gaap:PreferredStockConvertibleConversionPriceDecrease>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g"
      id="Narr_g95RbpFJwEeMr401N9jP9g">(i)&#160;a 19.99% blocker provision to comply with NYSE American Listing Rules, (ii)&#160;if so elected by the Investor, a 4.99% blocker provision that will prohibit beneficial ownership of more than 4.99% of the outstanding shares of the Company&#x2019;s common stock or voting power at any time, and (iii)&#160;applicable regulatory restrictions. </us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:PreferredStockRedemptionTerms
      contextRef="Duration_9_11_2017_To_9_11_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_oFmCveKqJ0-Dx6gKxf-n1g"
      id="Narr_F03uxURHCkGyF6_57Szz0g">(i)&#160;the VWAP (as defined in the Certificate of Designation) for at least 20 trading&#160;days in any 30 trading day period is greater than $70.00, subject to adjustment in the case of stock split, stock dividends or the like the Company has the right, after providing notice not less than 6&#160;months prior to the redemption date, to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share of Series&#160;A Preferred Stock of $7,875.00, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series&#160;A Convertible Preferred Stock or (ii)&#160;the five&#160;year anniversary of the issue date, the Company shall have the right to redeem, in whole or in part, on a pro rata basis from all holders thereof based on the number of shares of Series&#160;A Convertible Preferred Stock then held, the outstanding Series&#160;A Preferred Stock, for cash, at a redemption price per share equal to the Liquidation Value.</us-gaap:PreferredStockRedemptionTerms>
    <us-gaap:PreferredStockDiscountOnShares
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_2eCFDmHGOUmlUJq481sbrQ"
      decimals="-5"
      id="Narr_hHH4I3s710K4LPzF9uE4fQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">6900000</us-gaap:PreferredStockDiscountOnShares>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_BQ77y5ola0aDzP3L6mwvjg"
      decimals="INF"
      id="Narr_gHbpxdtHaEmrGywBykALbQ"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.02</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_ByW72_Ny4k6XNv0h-JiWUQ"
      decimals="-3"
      id="Narr_yJgojw0cIE6v1Q383FXlEQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">24000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bihAHFSJx0yt3viAJYHnig"
      decimals="-3"
      id="Narr_Fde3pwTvkk6mBSAoecpm4Q"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">254000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockConvertibleConversionPriceIncrease
      contextRef="Duration_9_1_2021_To_9_30_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_k_-xpTQWD0GCQdXycMKDSg"
      decimals="2"
      id="Narr_c2kP5wlCK0azV5GMjKmz-g"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">18.90</us-gaap:PreferredStockConvertibleConversionPriceIncrease>
    <us-gaap:PreferredStockConvertibleConversionPriceDecrease
      contextRef="Duration_1_27_2021_To_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_bg6a5VAYZkmiWar8_qygxA"
      decimals="2"
      id="Narr__4u9Me0Am0G6zyAl96lgkA"
      unitRef="Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw">1.50</us-gaap:PreferredStockConvertibleConversionPriceDecrease>
    <syn:BeneficialOwnershipPercentage
      contextRef="As_Of_1_27_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_JT5YJdWctkSrgjj-7sNP_A"
      decimals="4"
      id="Narr_5H1NDCruUk-AbIEsNMw2hw"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.0499</syn:BeneficialOwnershipPercentage>
    <syn:BeneficialOwnershipPercentage
      contextRef="As_Of_3_29_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_19H4jFVReE6xfC5K5cBF2g"
      decimals="4"
      id="Narr_c_I4k-ZkQ02jTp5Gz0xoyA"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.0999</syn:BeneficialOwnershipPercentage>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_2_28_2021_p7WYQOUTpUi11HMdW1VRjQ"
      decimals="INF"
      id="Narr_m5QhZbikdEeBVy0Pm8dqsg"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">8996768</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_1_2021_To_2_28_2021_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesAPreferredStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zR9PSAiA3US5NsG8x7-7Ww"
      decimals="INF"
      id="Narr_Zs4eJ4DwXki9_bUnZdS9Lw"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">120000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <syn:EstimatedFairValueOfInducementConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-5"
      id="Narr_hl22SEoVW0GPRUooaeAzjg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">7400000</syn:EstimatedFairValueOfInducementConsideration>
    <syn:EstimatedFairValueOfInducementConsideration
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-5"
      id="Narr_WRbq2lZGvky-MZ-TMIFeCw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">7400000</syn:EstimatedFairValueOfInducementConsideration>
    <syn:BrokerageCommissionPercentage
      contextRef="As_Of_8_5_2016_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_z5Ev0yENHUmoho2bPyB-eQ"
      decimals="3"
      id="Narr_ovTm4IAHaUaS1V00g-FCyw"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.030</syn:BrokerageCommissionPercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_vVcxs-TyVEOrQ1i7bBXI3A"
      decimals="-5"
      id="Narr_nYpUBxVfc0GUF_SOUtUV7w"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">9300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <syn:ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_syn_FbrCapitalMarketsCoMember_ISVZPzMHc0Ggvc_ZgMPJ2A"
      decimals="-5"
      id="Narr_dvOUVXgp7UK6VzNYebuIQw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3400000</syn:ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_U6tWdREtxkuc90dTPJYBog"
      decimals="-5"
      id="Narr_didrsbaOq0iuGc4TPeOqXQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">78700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_U6tWdREtxkuc90dTPJYBog"
      decimals="-5"
      id="Narr_lBKXl4UIwkej6HklIXvx-Q"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">66000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_kHmI_Ep5jUeEYPVUDMNImw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Non-controlling Interest&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;5, 2018, the Company entered into an agreement (the &#x2018;Stock Purchase Agreement&#x201d;) with Cedars-Sinai Medical Center (CSMC) for an investigator-sponsored Phase 2b clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#x201c;Study&#x201d;). The Study will provide further evaluation of the efficacy and safety of SYN-010, the Company&#x2019;s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (&lt;i style="font-style:italic;"&gt;M. smithii&lt;/i&gt;) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In consideration of the support provided by CSMC for the Study, the Company paid $328,000 to support the Study and the Company entered into a Stock Purchase Agreement with CSMC pursuant to which the Company, upon the approval of the Study protocol by the Institutional Review Board (&#x201c;IRB&#x201d;) : (i)&#160;issued to CSMC 50,000 shares of common stock of the Company; and (ii)&#160;transferred to CSMC an additional 2,420,000 shares of common stock of its subsidiary SYN Biomics,&#160;Inc. (&#x201c;SYN Biomics&#x201d;) owned by the Company, such that after such issuance CSMC owned an aggregate of 7,480,000 shares of common stock of SYN Biomics, representing 17% of the issued and outstanding shares of SYN&#160;Biomics&#x2019; common stock.&#160;The services rendered are recorded to research and development expense in proportion with the progress of the study and are based overall on the fair value of the shares ($285,000) as determined at the date of IRB approval. During the years ended December 31, 2021 and 2020, research and development expense recorded related to this transaction approximated $1,000 and $225,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Stock Purchase Agreement also provides CSMC with a right, commencing on the six&#160;month anniversary of issuance of the stock under certain circumstances in the event that the shares of stock of SYN Biomics are not then freely tradeable, and subject to NYSE American, LLC approval, to exchange its SYN Biomics shares for unregistered shares of Common Stock, with the rate of exchange based upon the relative contribution of the valuation of SYN Biomics to the public market valuation of the Company at the time of each exchange. The Stock Purchase Agreement also provides for tag-along rights in the event of the sale by the Company of its shares of SYN Biomics.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September 30, 2020, CSMC Medically Associated Science and Technology Program (MAST) formally agreed to discontinue the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 following the results of a planned interim futility analysis. Although it was concluded that SYN-010 was well tolerated, SYN-010 was unlikely to meet its primary endpoint by the time enrollment is completed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;6. Non-controlling Interest &#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 9, 2020, the Company and its subsidiary, Synthetic Biomics, Inc. and CSMC mutually agreed to terminate the exclusive license agreement dated December 5, 2013 and all amendments thereto and the clinical trial agreement relating to SYN-010. The determination to terminate the SYN-010 license agreement was agreed to following the completion of a planned interim futility analysis of the Phase 2b investigator-sponsored clinical trial of SYN-010. On September 30, 2020, CSMC (the Company&#x2019;s SYN-010 clinical development partner) informed the Company that it discontinued the ongoing Phase 2b investigator-sponsored clinical study of SYN-010 IBS-C patients. During 2021, CSMC returned its shares of SYN Biomics to the Company. The Company&#x2019;s interest in SYN Biomics is now 100%. &#160;This is reflected in the Consolidated Statements of Equity (Deficit).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s non-controlling interest is accounted for under ASC 810, &lt;i style="font-style:italic;"&gt;Consolidation&lt;/i&gt; and represents the minority stockholder&#x2019;s ownership interest related to the Company&#x2019;s subsidiary, SYN Biomics. In accordance with ASC 810, the Company reports its non-controlling interest in subsidiaries as a separate component of equity in the Consolidated Balance Sheets and reports both net loss attributable to the non-controlling interest and net loss attributable to the Company&#x2019;s common stockholders in the face of the Consolidated Statements of Operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As of December&#160;31, 2020, the accumulated net loss attributable to the non-controlling interest was $2.8 million and includes $73,000 of prior&#160;year losses attributable to minority stockholders including the reversal of Dr.&#160;Pimentel&#x2019;s 2015 losses of $505,000 associated with the exchange of his shares of common stock in SYN Biomics for shares of the Company&#x2019;s common stock. During 2021, the minority stockholder returned its shares of SYN Biomics to the Company for no consideration. The Company&#x2019;s interest in SYN Biomics is now 100%.&lt;/p&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_9_5_2018_To_9_5_2018_uBFbvYxH-EmzEpTcsw0I4Q"
      decimals="0"
      id="Narr_0VqWvAopZEi6fNnj6A10jg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">328000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <syn:NumberOfCommonStockToBeIssued
      contextRef="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_QYEqV_MK-kaCxh0ejQsXbA"
      decimals="0"
      id="Narr_0HkxZ-GD7UGtAh38CmSq0A"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">50000</syn:NumberOfCommonStockToBeIssued>
    <syn:AdditionalNumberOfCommonStockToBeIssued
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SYNBiomicsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_LYTAthCVn0yW8kcGh07aqw"
      decimals="0"
      id="Narr_eT6_dDueYkWq1KuWJpLG3w"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">2420000</syn:AdditionalNumberOfCommonStockToBeIssued>
    <syn:NumberOfCommonStockToBeHeldByRelatedParty
      contextRef="As_Of_9_5_2018_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_QYEqV_MK-kaCxh0ejQsXbA"
      decimals="0"
      id="Narr_6md9QZ4JQE-vDABouCebew"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">7480000</syn:NumberOfCommonStockToBeHeldByRelatedParty>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_9_5_2018_srt_OwnershipAxis_syn_SyntheticBiomicsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_CedarssinaiMedicalCenterMember_Ub1M_a5LVE-DkomejQsGNQ"
      decimals="2"
      id="Narr_lZAwdmgDRkyXodK7UGrELg"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.17</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <syn:FairValueOfSharesIssued
      contextRef="Duration_9_1_2018_To_9_5_2018_BLr1pn9j6UusGha5FDmjVw"
      decimals="0"
      id="Narr_ERLBZo5mEkOpHtyoAvL9Tg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">285000</syn:FairValueOfSharesIssued>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_U6tWdREtxkuc90dTPJYBog"
      decimals="0"
      id="Narr_ajeZojSlH0GJFL-insIGIw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_syn_StockPurchaseAgreementMember_XdJgrqbMT0ShQF0kRBhn7Q"
      decimals="-3"
      id="Narr_jOeEV_5gfkab94NVmyJBiQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">225000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_12_31_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_2hlEGz94m0y871onqyMQIQ"
      decimals="2"
      id="Narr_sSBD-hkA8UaUvhXZzbvpkA"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_OwnershipAxis_syn_SYNBiomicsMember_lfF71se-CkmmyddDrmHIPQ"
      decimals="-5"
      id="Narr_ZTznWx2C_kWypBHcIjikaQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2800000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_DrPimentelsMember_6pUuXCugXk6NelClzj9WWw"
      decimals="-5"
      id="Narr_h5F4DUiXgUqS7FW3z0Pb_Q"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">73000000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ConsolidationItemsAxis_srt_ConsolidationEliminationsMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_DrPimentelsMember_0ZR0S_QqJE-CfP4OWtt76g"
      decimals="-3"
      id="Narr_fmfI257JDkKT_OnNnUCDQA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">505000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="As_Of_12_31_2021_srt_OwnershipAxis_syn_SYNBiomicsMember_2hlEGz94m0y871onqyMQIQ"
      decimals="2"
      id="Narr_3U_6aQFnx0uIORsnze-JtQ"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">1</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <syn:LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_2SLpeiHpLUKw70bCIgk0pw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. License, Collaborative and Employment Agreements and Commitments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;License and Collaborative Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As described below, the Company has entered into several license and collaborative agreements for the right to use research, technology and patents. Some of these license and collaborative agreements may contain milestones. The specific timing of such milestones cannot be predicted and is dependent on future developments as well as regulatory actions which cannot be predicted with certainty (including actions which may never occur). Further, under the terms of certain licensing agreements, the Company may have the obligation to pay certain milestones contingent upon the achievement of specific levels of sales. Due to the long-range nature of such commercial milestone amounts, they are neither probable at this time nor predictable and consequently are not included in this disclosure.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Washington University School of Medicine in St. Louis Clinical Trial Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In August 7, 2019, the Company entered into a clinical trial agreement (&#x201c;CTA&#x201d;) with Washington University School of Medicine in St. Louis (&#x201c;Washington University&#x201d;) to conduct a Phase 1b/2a single-center, randomized, double-blinded, placebo-controlled clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of oral SYN-004 (ribaxamase) in up to 36 adult allogeneic hematopoietic cell transplant (HCT) recipients (the &#x201c;Study&#x201d;). Under the terms of the CTA, the Company will serve as the sponsor of the Study and supply SYN-004 (ribaxamase), as well as compensate Washington University for all research services to be provided in connection with the Study which is estimated to cost approximately $3,200,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The CTA continues in effect until completion of all obligations under the CTA. Either party may terminate the CTA prior to completion of its obligations (i) if authorization of the study is withdrawn by the FDA; (ii) if the emergence of any adverse reaction or side effect with SYN-004 (ribaxamase) administered in the Study is of such magnitude or incidence in the opinion of either party to support termination; or (iii) upon a breach of the terms of the CTA if the breaching party fails to cure the breach within 30 days after receipt of notice. The Company has the right to terminate the CTA (i) effective immediately if Washington University fails to perform the study in accordance with the terms of the protocol, the CTA or applicable laws or regulations or if Washington University or the principal investigator become debarred or (ii) upon 14 days written notice and Washington University has the right to terminate the CTA upon 14 days notice if the principal investigator becomes unable to perform or complete the Study and the parties have not, prior to the expiration of such fourteen (14) day period, agreed to an alternative principal investigator.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. License, Collaborative and Employment Agreements and Commitments&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Cedars-Sinai Medical Center (&#x201c;CSMC&#x201d;) Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;5, 2013, the Company, through its newly formed, majority owned subsidiary, SYN Biomics, entered into a worldwide exclusive License Agreement with CSMC for the development of new treatment approaches to target non-bacterial intestinal microorganism life forms known as archaea that are associated with intestinal methane production and chronic diseases such as irritable bowel syndrome (IBS), obesity and type 2 diabetes. As part of the terms of the License Agreement, the Company issued 9,569 unregistered shares of the Company&#x2019;s common stock to CSMC, paid $150,000 for the initial license fee and $220,000 for patent reimbursement fees. The License Agreement also provides that, commencing on the second anniversary of the License Agreement, SYN Biomics will pay an annual maintenance fee, which payment shall be creditable against annual royalty payments owed under the License Agreement. In addition to royalty payments which are a&#160;percentage of net sales of license and technology products, SYN Biomics is obligated to pay CSMC a&#160;percentage of any non-royalty sublicense revenues, as well as additional consideration upon the achievement of milestones (the first two of which are payable in cash or unregistered shares of Company stock at the Company&#x2019;s option).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The License Agreement provided for termination: (i)&#160;automatically if SYN Biomics enters into a liquidating bankruptcy or other specified bankruptcy event or if the performance of any term, covenant, condition or provision of the License Agreement will jeopardize the licensure of CSMC, its participation in certain reimbursement programs, its full accreditation by the Joint Commission of Accreditation of Healthcare Organizations or any similar state organizations, its tax exempt status or is deemed illegal; (ii)&#160;upon 30&#160;days notice from CSMC if SYN Biomics fails to make a payment or use commercially reasonable efforts to exploit the patent rights; (iii)&#160;upon 60&#160;days notice from CSMC if SYN Biomics fails to cure any breach or default of any material obligations under the License Agreement; or (iv)&#160;upon 90&#160;days notice from SYN Biomics if CSMC fails to cure any breach or default of any material obligations under the License Agreement. SYN Biomics also has the right to terminate the License Agreement without cause upon six&#160;months notice to CSMC; however, upon such termination, SYN Biomics is obligated to pay a termination fee with the amount of such fee reduced: (i)&#160;if such termination occurs after an Investigational New Drug submission to the FDA but prior to completion of a Phase 2 clinical trial, (ii)&#160;reduced further if such termination occurs after completion of Phase 2 clinical trial but prior to completion of a Phase 3 clinical trial; and (iii)&#160;reduced to zero if such termination occurs after completion of a Phase 3 clinical trial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On September&#160;5, 2018, the Company entered into an agreement with CSMC for an investigator-sponsored Phase 2 clinical study of SYN-010 to be co-funded by the Company and CSMC (the &#x201c;Study&#x201d;). The Study was to provide further evaluation of the efficacy and safety of SYN-010, the Company&#x2019;s modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by CSMC. SYN-010 is designed to reduce methane production by certain microorganisms (&lt;i style="font-style:italic;"&gt;M. smithii&lt;/i&gt;) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;University of Texas Austin Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;19, 2012, the Company entered into a License Agreement with University of Texas Austin (&#x201c;UT&#x201d;) Austin for the exclusive license of the right to use, develop, manufacture, market and commercialize certain research and patents related to pertussis antibodies. The License Agreement provides that UT Austin is entitled to payment of past patent expenses, an annual payment of $50,000 per&#160;year commencing on the effective date through December&#160;31, 2014, a $25,000 payment on December&#160;31, 2015 and milestone payments of $50,000 upon commencement of Phase 1 clinical trials, $100,000 upon commencement of Phase 3 clinical trials, $250,000 upon NDA submission in the U.S., $100,000 upon European Medicines Agency approval and $100,000 upon regulatory approval in an Asian country. In&#160;addition, UT Austin is entitled to a running royalty upon net sales. The License Agreement terminates upon the expiration of the patent rights; provided, however that the License Agreement is subject to early termination by the Company in its discretion and by UT Austin for a breach of the License Agreement by the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. License, Collaborative and Employment Agreements and Commitments&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the License Agreement, the Company and UT Austin also entered into a Sponsored Research Agreement pursuant to which UT Austin will perform certain research work related to pertussis. The Sponsored Research Agreement may be renewed annually, in the sole discretion of the Company, after the first&#160;year for two additional one&#160;year terms with a fixed fee for the first&#160;year of $303,287. The Sponsored Research Agreement was renewed for the second and third&#160;years for a fixed fee of $316,438 and $328,758 respectively, all payable in quarterly installments. The Sponsored Research Agreement expires January 17, 2023; provided, however, the Sponsored Research Agreement is subject to early termination upon the written agreement of the parties, a default in the material obligations under the Research Agreement which remain uncured for 60&#160;days after receipt of notice, automatically upon the Company&#x2019;s bankruptcy or insolvency and by the Company in its sole discretion at any time after the one&#160;year anniversary of the date of execution thereof upon no less than 90&#160;days&#x2019; notice.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Prev ABR LLC (&#x201c;Prev&#x201d;) Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November&#160;28, 2012, the Company entered into an agreement (&#x201c;Prev Agreement&#x201d;) to acquire the C. diff program assets of Prev, including the pre-Investigational New Drug (IND) package, Phase 1 and Phase 2 clinical data, manufacturing process data and all issued and pending U.S. and international patents. Upon execution and closing of the Prev Agreement, the Company paid Prev cash payments of $235,000 and issued 17,858 unregistered shares of its common stock to Prev. As set forth in the Prev Agreement, Prev may be entitled to receive additional consideration upon the achievement of certain milestones, including: (i)&#160;commencement of an IND; (ii)&#160;commencement of a Phase 1 clinical trial; (iii)&#160;commencement of a Phase 2 clinical trial; (iv)&#160;commencement of a Phase 3 clinical trial; (v)&#160;filing a Biologic License Application (BLA) in the U.S. and for territories outside of the U.S. (as defined in the Prev Agreement); and (vi)&#160;approval of a BLA in the U.S. and for territories outside the U.S. With exception of the first milestone payment, the remaining milestones are payable 50% in cash and 50% in our stock, however, at Prev&#x2019;s option the entire milestone may be payable in shares of the Company&#x2019;s stock. As of December&#160;31, 2015, the first three milestones have been met, and at Prev&#x2019;s option, Prev elected to receive 18,724 shares of the Company&#x2019;s common stock. Currently, assets licensed under this agreement are used in the Company&#x2019;s &#160;Phase 1b/2a Clinical Study in Allogeneic HCT Recipients. No milestones were achieved or such payments were made during the&#160;years ended December&#160;31, 2021 and 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Employment Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;6, 2018, the Company entered into a three-year employment agreement with Steven A. Shallcross, (the &#x201c;Employment Agreement&#x201d;), to serve as the Chief Executive Officer and to continue to serve as the Chief Financial Officer of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Employment Agreement has a stated term of three&#160;years but may be terminated earlier pursuant to its terms. If Mr.&#160;Shallcross&#x2019; employment is terminated for any reason, he or his estate as the case may be, will be entitled to receive the accrued base salary, vacation pay, expense reimbursement and any other entitlements accrued by him to the extent not previously paid (the &#x201c;Accrued Obligations&#x201d;); provided, however, that if his employment is terminated (i)&#160;by the Company without Cause or by Mr.&#160;Shallcross for Good Reason (as each is defined in the Employment Agreement) then in addition to paying the Accrued Obligations, (a)&#160;the Company will continue to pay his then current base salary and continue to provide benefits at least equal to those that were provided at the time of termination for a period of twelve (12)&#160;months and (b)&#160;he shall have the right to exercise any vested equity awards until the earlier of six (6)&#160;months after termination or the remaining term of the awards; or (ii)&#160;by reason of his death or Disability (as defined in the Employment Agreement), then in addition to paying the Accrued Obligations, Mr.&#160;Shallcross would have the right to exercise any vested options until the earlier of six (6)&#160;months after termination or the remaining term of the awards. In such event, if Mr.&#160;Shallcross commenced employment with another employer and becomes eligible to receive medical or other welfare benefits under another employer-provided plan, the medical and other welfare benefits to be provided by the Company as described herein would terminate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 30, 2020, the Board of Directors of the Company awarded Steven A. Shallcross (i) a cash bonus equal to 62% of his prior base salary and (ii) an option to purchase 450,000 shares of the Company&#x2019;s common stock. On December 23, 2020, the Board of the Company awarded Steven A. Shallcross (i) a cash bonus equal to 62.5% of his prior base salary and (ii) an option to purchase 450,000 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 23, 2021, the Board of Directors of the Company awarded Steven A. Shallcross (i) a cash bonus equal to approximately 62.5% of his current base salary, and (ii) an option to purchase 650,000 shares of the Company&#x2019;s common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. License, Collaborative and Employment Agreements and Commitments&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Operating Lease&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s existing lease as of December 31, 2021 is classified as an operating lease. As of December 31, 2021, the Company has one operating lease for facilities with a remaining term expiring in 2027. During the quarter ended June 30, 2021, the Company renewed its facility lease by entering into a Second Lease Amendment which extends the lease term for 63 months beginning on September 1, 2022 and ending on December 31, 2027 at stated rental rates and including a 3 month rent abatement. The Second Amendment also has options for a Tenant Improvement Allowance and a Second Extension Term. The Second Amendment also gives the Company the right to expand their space by giving notice to the landlord before December 31, 2021. The Company did not give notice to expand the space during 2021. The Second Extension Term is offered at market rates and there is no economic incentive for the lessee, therefore the Company has determined that it is not part of the original lease term. There is an option in this Second Amendment to Lease for the Company to borrow funds for tenant improvements subject to an 8.5% interest rate. Operating lease costs are presented as part of general and administrative expenses in the condensed consolidated statements of operations, and for the years ended December 31, 2021 and 2020 approximated $280,000 and $209,000, respectively. For the years ended December 31, 2021 and 2020, operating cash flows used for operating leases approximated $321,000 and $309,000, respectively, and the right of use assets exchanged for operating the lease obligation was $1.3 million. The day one non-cash addition of right of use assets due to adoption of ASC 842 was $538,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A maturity analysis of our operating leases as of December 31, 2021 is as follows &lt;i style="font-style:italic;"&gt;(amounts in thousands of dollars)&lt;/i&gt;:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future undiscounted cash flow for the years ending December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 347&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 357&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Discount factor&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (456)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YmEvW5Sg1kyNFgYcXmib7A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability - long term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Consulting Fees&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In November&#160;2017, the Company engaged a regulatory consultant to assist in the Company&#x2019;s efforts to prepare, file and obtain FDA approval for ribaxamase.&#160;The term of the engagement is on a&#160;monthly basis, provided that either party may terminate the agreement at any time by providing the other party a six-month notice period. The Company was obligated to pay the consultant a&#160;monthly retainer in addition to success fee payments of up to an aggregate of $4,500,000 for attainment of certain regulatory milestones. The achievement of the milestones is not probable at this time.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 30, 2020, the World Health Organization (&#x201c;WHO&#x201d;) announced a global health emergency because of COVID-19 and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;7. License, Collaborative and Employment Agreements and Commitments&#160;&#x2013;&#160;(continued)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As COVID-19 continued to spread around the globe, the Company experienced disruptions that impacted its business and clinical trials, including the postponement of clinical site initiation of the Phase 1b/2a clinical trial of SYN-004. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s business, the clinical development of SYN-004 (ribaxamase) and SYN-020, the business of the Company&#x2019;s suppliers and other commercial partners, the Company&#x2019;s corporate development objectives and the value of and market for the Company&#x2019;s common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, especially in light of the new variants, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease. The global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic could have a material adverse effect on the Company's business, financial condition, results of operations and growth prospects. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties which the Company faces.&lt;/p&gt;</syn:LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock>
    <syn:EstimatedResearchCosts
      contextRef="Duration_8_7_2019_To_8_7_2019_us-gaap_TypeOfArrangementAxis_syn_ClinicalTrialAgreementMember_e8nSUVWVOUOzmBeVgBlJ_g"
      decimals="0"
      id="Narr_bGo9ezXRN0CiMcL5PB0FgA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3200000</syn:EstimatedResearchCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_GqTzjk6ZRUmQxuCuv8dWDQ"
      decimals="0"
      id="Narr_uo7LjZDTWkCuZtCtNgQQyA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">9569</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PaymentsForFees
      contextRef="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_GqTzjk6ZRUmQxuCuv8dWDQ"
      decimals="0"
      id="Narr_WhDbnohkIEqf6Qtfdp5eVw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">150000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="Duration_12_2_2013_To_12_5_2013_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_9Xpcg3JLq0uiDoVj62uKQg"
      decimals="0"
      id="Narr_c7vaVdaR4ESZw7tqKeJhAw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">220000</us-gaap:PaymentsForFees>
    <syn:LicenseAgreementAnnualPaymentsDue
      contextRef="Duration_12_1_2012_To_12_19_2012_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_gp7VGPemIUmMsNTJacOkog"
      decimals="0"
      id="Narr_mHKc7Khi8UO4lDwkCS-lTA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">50000</syn:LicenseAgreementAnnualPaymentsDue>
    <syn:LicenseAgreementFinalPaymentDue
      contextRef="Duration_12_1_2012_To_12_19_2012_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_gp7VGPemIUmMsNTJacOkog"
      decimals="0"
      id="Narr_GywWfTER10aWO0gA6yqSbw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">25000</syn:LicenseAgreementFinalPaymentDue>
    <syn:MilestonePayment
      contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_PhaseIClinicalTrialsMember_TUHpBF3yc0CkN3QUWLfWmw"
      decimals="0"
      id="Narr_bkV_IX-7UUKTxmUnmFRsJg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">50000</syn:MilestonePayment>
    <syn:MilestonePayment
      contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_PhaseIiiClinicalTrialsMember_lswYHCn0iEGpMO6RGGHoqQ"
      decimals="0"
      id="Narr_Cj1RgP_or0WaG5AGvGQbKg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">100000</syn:MilestonePayment>
    <syn:MilestonePayment
      contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_NdaSubmissionInUsMember_iAOhW_VZcEGqi0gmByMIAg"
      decimals="0"
      id="Narr_9bvy_V7m2kmclEaK8O8kpQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">250000</syn:MilestonePayment>
    <syn:MilestonePayment
      contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_EuropeanMedicinesAgencyApprovalMember_P8LwHIwz0kewI_WCPzgecA"
      decimals="0"
      id="Narr_sgLWl-jGxEiiilF_RLQXHQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">100000</syn:MilestonePayment>
    <syn:MilestonePayment
      contextRef="Duration_12_2_2012_To_12_19_2012_us-gaap_TypeOfArrangementAxis_syn_RegulatoryApprovalInAsianCountryMember_b29ls9jD-Eq0pdQkSHFuxw"
      decimals="0"
      id="Narr_9pPGuEXQAUaH6-X8tji4jQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">100000</syn:MilestonePayment>
    <syn:ResearchAgreementFixedFee
      contextRef="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_FirstYearMember__Bn5hy98mU6mfmfCN95quw"
      decimals="0"
      id="Narr_UTPREhKN3USHgtyE36tzvA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">303287</syn:ResearchAgreementFixedFee>
    <syn:ResearchAgreementFixedFee
      contextRef="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_SecondYearMember_BTboTCNJsUKQRiy6cxkbug"
      decimals="0"
      id="Narr_C9zXEw2lEkaXv1ubrwxQCQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">316438</syn:ResearchAgreementFixedFee>
    <syn:ResearchAgreementFixedFee
      contextRef="As_Of_12_19_2012_syn_QuarterlyInstallmentsPaymentPeriodAxis_syn_ThirdYearMember_pDW3ZJBjLEOCTDy7Fvp73A"
      decimals="0"
      id="Narr_91iG29b28kuFheksXvT79g"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">328758</syn:ResearchAgreementFixedFee>
    <syn:AdditionalCashPaymentForLicenseAgreement
      contextRef="Duration_11_2_2012_To_11_28_2012_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember__uZ5OPc6pka-czPBvUDXXw"
      decimals="0"
      id="Narr_rn3t1wfPc0y7jr6_gZKexg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">235000</syn:AdditionalCashPaymentForLicenseAgreement>
    <syn:UnregisteredSharesIssuedToLicenseAgreement
      contextRef="Duration_11_2_2012_To_11_28_2012_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember__uZ5OPc6pka-czPBvUDXXw"
      decimals="0"
      id="Narr_U3Lnvixt1kaYlKCwY1-f3w"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">17858</syn:UnregisteredSharesIssuedToLicenseAgreement>
    <syn:AdditionalConsiderationPayable
      contextRef="Duration_11_2_2012_To_11_28_2012_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember__uZ5OPc6pka-czPBvUDXXw"
      id="Narr_Ki2cHk2-Q02Ipd99LIFnOA">50% in cash and 50% in our stock</syn:AdditionalConsiderationPayable>
    <syn:OptionsToBeReceivedCommonStockShares
      contextRef="Duration_1_1_2015_To_12_31_2015_us-gaap_BusinessAcquisitionAxis_syn_PrevAbrLlcMember_OdBA1XZNCkSZ2xDmj4iqwg"
      decimals="0"
      id="Narr_7L8fcFCEE0mg77L22EHS6Q"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">18724</syn:OptionsToBeReceivedCommonStockShares>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
      contextRef="Duration_12_30_2020_To_12_30_2020_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_5Rwg92J14EiVYGDVwneJ0A"
      decimals="2"
      id="Narr_1H2u0RhvF0SDvV4ibBNlyQ"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.62</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_12_30_2020_To_12_30_2020_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_5Rwg92J14EiVYGDVwneJ0A"
      decimals="0"
      id="Narr_08AEf8mSNkSFoNsChkCFJQ"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <syn:CostOfLivingAdjustmentsPercentage
      contextRef="Duration_12_23_2020_To_12_23_2020_lK-7ce7kgUKMLA_1odurJw"
      decimals="4"
      id="Narr_n2M29U9JFE2W__j03hBF3w"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.625</syn:CostOfLivingAdjustmentsPercentage>
    <us-gaap:PaymentsToEmployees
      contextRef="Duration_12_23_2020_To_12_23_2020_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_CEW0YNQQwU-z7FPuSvxFMg"
      decimals="0"
      id="Narr_VtNvrHSM6k2me9gqobfmtQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">450000</us-gaap:PaymentsToEmployees>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
      contextRef="Duration_12_23_2021_To_12_23_2021_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_ob3-lBLKQ0-1m3VgfFdc-g"
      decimals="3"
      id="Narr_Q1ikMjQz2km3G-llybly3Q"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.625</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_12_23_2021_To_12_23_2021_srt_TitleOfIndividualAxis_syn_Dr.SlimanMember_ob3-lBLKQ0-1m3VgfFdc-g"
      decimals="0"
      id="Narr_bk65e_O0SkycOOj74vVVeA"
      unitRef="Unit_Standard_shares_RsriYutjxUuQSlocdtt04g">650000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="3"
      id="Narr_DyYjOhCiDUSh2oyHw0yOCQ"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="0"
      id="Narr_-vJo21Bs4E-DVEliOe4GtQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">280000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="0"
      id="Narr_bYcVILUEIUiGbU_nlT8QoA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">209000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="0"
      id="Narr_bExzAKTYx02-aEc21PlCbQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">321000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="0"
      id="Narr_4YKcpwYVfU6Fs5yH0LDAHg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">309000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LeaseAgreementsMember_FPxvWRsyyEuHDdGJz_4XaA"
      decimals="-5"
      id="Narr_1ItfuOVZGkKuD16-05kCPQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1300000</us-gaap:OperatingLeaseCost>
    <syn:NonCashAdditionOfRightOfUseAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="0"
      id="Narr_uAA45ZMU0kyeh7Y6QVTb-g"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">538000</syn:NonCashAdditionOfRightOfUseAssets>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_NKzciBSzIUa3HZlZ9IBH3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;A maturity analysis of our operating leases as of December 31, 2021 is as follows &lt;i style="font-style:italic;"&gt;(amounts in thousands of dollars)&lt;/i&gt;:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Future undiscounted cash flow for the years ending December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 247&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 327&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 347&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 357&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 368&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Discount factor&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (456)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_YmEvW5Sg1kyNFgYcXmib7A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lease liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability - current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (124)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability - long term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_dzc3FxPwdUqdjKLW_lVIbg_2_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">247000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_8Yf1JJACIEK0eNDPk3VyNg_3_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">327000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_vJ4Oy3x7EUqyWdrf0J_eGQ_4_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">337000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_gVo2W9mWa0mggrmzI41FFQ_5_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">347000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_w9UhaiRKKEKkIVHUZD3V0w_6_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">357000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <syn:LesseeOperatingLeaseLiabilityPaymentsDueYearSix
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_1IsRWx8Yz02HYOi3C7YpSg_7_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">368000</syn:LesseeOperatingLeaseLiabilityPaymentsDueYearSix>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_Dr8nSqX-aESlnmFU-sJsHA_8_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1983000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_YSytBnBeNkqVwK4QC_kywA_10_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">456000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_N8IMM0KUfEuDnQaXN1NSog_11_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1527000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_UeUeijSZQEeSIaFersKafA_12_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">124000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_p5NIoXPv9ESJV0sm_hPd8w_13_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1403000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PaymentsForFees
      contextRef="Duration_11_1_2017_To_11_30_2017_9RYWQN6O80iVs8ielspjNw"
      decimals="0"
      id="Narr_8PkglPO6k0WwvQj9nNPOYQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">4500000</us-gaap:PaymentsForFees>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_CuX8Zf18uEWJH9h09Q9gDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;There was no income tax expense for the&#160;years ended December 31, 2021 and 2020 due to the Company&#x2019;s net losses. The Company&#x2019;s tax expense differs from the &#x201c;expected&#x201d; tax expense for the years ended December 31, 2021 and 2020. For 2021, the &#x201c;expected&#x201d; tax expense is computed by applying the Federal corporate statutory tax rate of 21% and a net, after Federal benefit state tax rate of 6.46% (state blended rate was 8.18%) to loss before taxes. For 2020, the &#x201c;expected&#x201d; tax expense is computed by applying the Federal corporate statutory tax rate of 21% and a net, after Federal benefit state tax rate of 6.45% (state blended rate was 8.17.%) to loss before taxes. These results are as follows &lt;i style="font-style:italic;"&gt;(in thousands):&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &lt;/i&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Computed &#x201c;expected&#x201d; tax-benefit - Federal&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (3,045)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (2,124)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Computed &#x201c;expected&#x201d; tax-benefit - State&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (931)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (616)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Adjustment of &#x201c;expected&#x201d; tax-benefit to actual&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Meals, entertainment and other&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Non-deductible stock-based compensation&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 32&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 32&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;State Tax Rate Adjustment&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 932&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (1,221)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Federal and state NOL Adjustment&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Change in valuation allowance&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 3,012&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 3,929&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The effects of temporary differences that gave rise to significant portions of deferred tax assets at December&#160;31, 2021 and 2020 are as follows (&lt;i style="font-style:italic;"&gt;in thousands&lt;/i&gt;):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock issued for services&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,504&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,428&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accrued compensation&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 27&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 42&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock issued for acquisition of program&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,462&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,436&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock issued for license agreement&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,363&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,574&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock issued for milestone payment&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 236&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 262&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Amortizable License Fee&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 4&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 5&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Net operating loss carry-forward&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 16,884&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 12,540&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Total gross deferred tax assets&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 21,480&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 17,287&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Less: valuation allowance&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (21,480)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (17,287)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Total net deferred tax assets&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Income Taxes&#160;&#x2013;&#160;(continued)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At December 31, 2021, the Company has a gross Federal net operating loss carry-forward of approximately $58.3 million available to offset future taxable income. The Company&#x2019;s pre-2018 net operating losses expire on various dates through 2037. In addition, it was determined that the utilization of gross Federal net operating losses of approximately $198.8 million was limited by $155.6 million. due to change of control ownership changes that occurred under Section 382 of the Internal Revenue Code. State NOL&#x2019;s are also limited by Section 382 of the Internal Revenue Code and were limited accordingly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In 2020, the Company completed an Internal Revenue Code Section 382 analysis of its historical net operating loss carry-forward amount. As a result, the prior year net operating loss carry-forward of $188.6 million was limited by $155.6 million. The decrease in the prior year net operating loss is attributable to change of control ownership shifts which were determined for the years 2013 and 2018 which caused the reduction in the value of the historical net operating loss carry-forward amounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;An updated section 382 analysis was performed in 2021 to identify if any additional ownership shifts occurred in the current year. It was determined that an ownership shift occurred on January 20, 2021. The result of the updated 2021 analysis produced an IRC 382 limit due to the 2021 ownership shift. However, all previously limited net operating losses remain available for use in future periods. The Company&#x2019;s pre-2018 net operating losses expire on various dates through 2037 while the net operating loss carry-forward originating in the 2018 year and later carry-forward indefinitely and are subject to additional limitations based on taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, the FASB issued ASU 20109-12, &#x201c;Income Taxes Topic 740-Simplifying the Accounting for Income Taxes&#x201d; (&#x201c;ASU 2019-12&#x201d;), which intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application of Topic 740. This guidance is effective for fiscal years beginning after December 15, 2020, including interim periods therein, and early adoption is permitted. The Company adopted ASU 2019-12 in the current period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The valuation allowance at December 31, 2021 was approximately $21.5 million. The net change in valuation allowance during the year ended December 31, 2021, was an increase of approximately $4.2 million primarily due to increases in gross federal and state deferred tax assets in 2021. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2021.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Narr_DfwEYxp2nEqQ33YtHnd6Ug"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Narr_9EBopNpysUiB4b9cbKgSSg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Group_cqBW5xslPUu9Z5TA5xAREg">The Company&#x2019;s tax expense differs from the &#x201c;expected&#x201d; tax expense for the years ended December 31, 2021 and 2020. For 2021, the &#x201c;expected&#x201d; tax expense is computed by applying the Federal corporate statutory tax rate of 21% and a net, after Federal benefit state tax rate of 6.46% (state blended rate was 8.18%) to loss before taxes. For 2020, the &#x201c;expected&#x201d; tax expense is computed by applying the Federal corporate statutory tax rate of 21% and a net, after Federal benefit state tax rate of 6.45% (state blended rate was 8.17.%) to loss before taxes. These results are as follows &lt;i style="font-style:italic;"&gt;(in thousands):&lt;/i&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &lt;/i&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Computed &#x201c;expected&#x201d; tax-benefit - Federal&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (3,045)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (2,124)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Computed &#x201c;expected&#x201d; tax-benefit - State&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (931)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (616)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Adjustment of &#x201c;expected&#x201d; tax-benefit to actual&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Meals, entertainment and other&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Non-deductible stock-based compensation&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 32&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 32&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;State Tax Rate Adjustment&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 932&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (1,221)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Federal and state NOL Adjustment&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Change in valuation allowance&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 3,012&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 3,929&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_ppvkWxwF4027bvy1U_yy0Q"
      decimals="2"
      id="Narr_8ljnfKO4202UIOLIt9HZ0w"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="4"
      id="Narr_NBL9QdcCrkuO_ve77CmrNw"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.0646</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="4"
      id="Narr_B7W9qoo--0OyIdbApwy5HQ"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.0818</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_MRPkLh7Yjk6pd-zFujqF_A"
      decimals="2"
      id="Narr_-umAEsxtvkiEqepTB8TOdA"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="4"
      id="Narr_yTjPWSXwCU2MbB_e9Rpftw"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.0645</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="4"
      id="Narr_su-UiP1cVEapNWSBYEMuYQ"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.0817</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_s0EUhWWhE0GG-VpgRfYQSQ_2_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-3045000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_6Jsl3zvA5kS1oFzqDzStPA_2_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-2124000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_RQ9yb6YjekOj5NVaKrm-SQ_3_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-931000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_8i-ofmYK0Ui_Q2UDI_Wxfw_3_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-616000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_cgwRO1OrVk-s1_sfnykOnw_4_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_IHa4q0zQLkil_TNqo5HA2g_4_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_jonvvkE2GUmu6Kbfgploow_5_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_dG4RAPMU3UOZeKFIRS544w_5_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_yle8ppMnMEGg61g8frtvrw_6_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">32000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_U0Y-mB8EqkKOOXUYTw_0jQ_6_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">32000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_B0g90sISQEqgGAVhLYUaJA_7_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">932000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_XMBxcShJP0Gq7rk8fJ7M1w_7_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-1221000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_6f31Fdj4jEqkoLwbnp2veQ_8_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_r7L60W8pz0i_mWx986kKWA_8_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_OalBjmr1g0q-oR9YQExFZQ_9_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-3012000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_C26nJ4pxJUyDmd-a7PZJ-g_9_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">-3929000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      decimals="-3"
      id="Tc_OP7i8ojufkabOVE-TaCbMQ_10_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_4-i1204KM0aN-X4plFeyLQ"
      decimals="-3"
      id="Tc_tDPVFEV9_kK7HEXyhSbZ4g_10_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_ouhXX79kkE-LE9XtMaX3Cw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The effects of temporary differences that gave rise to significant portions of deferred tax assets at December&#160;31, 2021 and 2020 are as follows (&lt;i style="font-style:italic;"&gt;in thousands&lt;/i&gt;):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock issued for services&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,504&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,428&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accrued compensation&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 27&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 42&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock issued for acquisition of program&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,462&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,436&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock issued for license agreement&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,363&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 1,574&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Stock issued for milestone payment&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 236&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 262&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Amortizable License Fee&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 4&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 5&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Net operating loss carry-forward&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 16,884&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 12,540&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Total gross deferred tax assets&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 21,480&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; 17,287&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Less: valuation allowance&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (21,480)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; (17,287)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Total net deferred tax assets&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;$&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt; &#x2014;&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <syn:DeferredTaxAssetsStocksIssuedForServices
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_z6vv2ehULEmv9e5GnVcWKw_3_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1504000</syn:DeferredTaxAssetsStocksIssuedForServices>
    <syn:DeferredTaxAssetsStocksIssuedForServices
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_4SCzhL24ek-ceKm0un2hdg_3_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1428000</syn:DeferredTaxAssetsStocksIssuedForServices>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_GuTZ7JDJnUakt9HUGryxxg_4_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">27000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_rRBqVxZfwUCd0kavtiz1hQ_4_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">42000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_WqanQaU7EEu1zjmPr6J4bg_5_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1462000</syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram>
    <syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_T2r_bi9gRUyoaKFrEyT5kw_5_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1436000</syn:DeferredTaxAssetsStockIssuedForAcquisitionOfProgram>
    <syn:DeferredTaxAssetsStockIssuedForlicenseAgreement
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_SPs16QTtYEW3aGMP_Hg4Wg_6_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1363000</syn:DeferredTaxAssetsStockIssuedForlicenseAgreement>
    <syn:DeferredTaxAssetsStockIssuedForlicenseAgreement
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_UsM9QZNxk06Ka9pMmqTjuA_6_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">1574000</syn:DeferredTaxAssetsStockIssuedForlicenseAgreement>
    <syn:DeferredTaxAssetsStockIssuedForMilestonePayment
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_VcWGpXWNwUWIdwNTkjYzzw_7_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">236000</syn:DeferredTaxAssetsStockIssuedForMilestonePayment>
    <syn:DeferredTaxAssetsStockIssuedForMilestonePayment
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_V6ztuCY6I0WZeoCojqMRsg_7_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">262000</syn:DeferredTaxAssetsStockIssuedForMilestonePayment>
    <syn:DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_3eAypMYyYkuST74NtQ-fCQ_8_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">4000</syn:DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee>
    <syn:DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_xQ7EQevqb0SaO9issJNJ7g_8_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">5000</syn:DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_cFLYQw7_I0mOMJEHqDztPQ_9_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">16884000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_y0Lda3aBFkaBwoC8xruXFA_9_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">12540000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_sDb6lQm-l0Ccm_eo0QSOCg_10_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">21480000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_8MI9v2SQTUeENdeWlUmGlA_10_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">17287000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_0YRVb7LHOEGMY2rh8ZAslA_11_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">21480000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_T09pUeAoL02cXhfFiZXcLg_11_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">17287000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-3"
      id="Tc_sUZgGBIXaUaKG4qHW5lZwQ_12_3"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g"
      decimals="-3"
      id="Tc_fc_vUAtof0eUdMN4jwMSsg_12_6"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-5"
      id="Narr_UK3e-jtmmUmh8BzgvIYmHA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">58300000</us-gaap:OperatingLossCarryforwards>
    <syn:OperatingLossCarryforwardsExpireDate
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Narr_hPCsfpK0Ekeyz7Gov9KAmQ">2037</syn:OperatingLossCarryforwardsExpireDate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_HRovq6U78E-v3Zs9fQPjlA"
      decimals="-5"
      id="Narr_bfw97HOcY0Gaipo-2xl0tA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">198800000</us-gaap:OperatingLossCarryforwards>
    <syn:OperatingLossCarryforwardsLimitationOnUse
      contextRef="As_Of_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_HRovq6U78E-v3Zs9fQPjlA"
      decimals="-5"
      id="Narr_TJ0fHFAdj0itWq09xNc6-w"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">155600000</syn:OperatingLossCarryforwardsLimitationOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2020Member_FiWLkKZ3vEKpx7yg9MiRzw"
      decimals="-5"
      id="Narr_mUDguuKeJke_l9MofX9Rrw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">188600000</us-gaap:OperatingLossCarryforwards>
    <syn:OperatingLossCarryforwardsLimitationOnUse
      contextRef="As_Of_12_31_2020_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_XDETk7h4EEaL0z0ltMNi8Q"
      decimals="-5"
      id="Narr_xSa-a6n8n0GlQsZjFfVm3A"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">155600000</syn:OperatingLossCarryforwardsLimitationOnUse>
    <syn:OperatingLossCarryforwardsExpireDate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TaxPeriodAxis_us-gaap_TaxYear2018Member_gGcNUhXIPkSw2CheAQJBxw"
      id="Narr_au3j3td2M06o2hY8aH9kfg">2037</syn:OperatingLossCarryforwardsExpireDate>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-5"
      id="Narr_Uo3sHObH20CWlylQUkXBZw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">21500000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A"
      decimals="-5"
      id="Narr_RAs4JavyfE-SkYbHstVWzw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">4200000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA"
      id="Tb_zGvqaL-Nq0-0Z4UlRUWzDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On January 3, 2022, the Company entered into a three-year employment agreement with Steven A. Shallcross (the &#x201c;Employment Agreement&#x201d;), who has served as the Company&#x2019;s Chief Executive Officer since December 6, 2018 and as the Company&#x2019;s Chief Financial Officer since June 1, 2015, to continue to serve as the Chief Executive Officer and Chief Financial Officer of the Company. The Employment Agreement replaced the prior employment agreement with the Company that Mr. Shallcross entered into on December 6, 2018, as amended December 5, 2019. Pursuant to the Employment Agreement, Mr. Shallcross is entitled to an annual base salary of $585,000 and an annual cash performance bonus of up to fifty percent (50%) of his annual base salary as well as discretionary annual equity awards pursuant to the Company&#x2019;s incentive plans. The annual bonus will be based upon the assessment of the Board of Mr. Shallcross&#x2019;s performance. The Employment Agreement also includes confidentiality obligations and inventions assignments by Mr. Shallcross and non-solicitation and non-competition provisions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 10, 2022, the Company completed the acquisition of all the outstanding shares of VCN (the &#x201c;VCN Shares&#x201d;) from the shareholders of VCN. VCN is a private, clinical-stage biopharmaceutical company developing new oncolytic adenoviruses for the treatment of cancer. VCN&#x2019;s lead product candidate, VCN-01, is being studied in clinical trials for pancreatic cancer and retinoblastoma. VCN-01 is designed to be administered systemically, intratumorally or intravitreally, either as a monotherapy or in combination with standard of care, to treat a wide variety of cancer indications. VCN-01 is designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment, Degrading the tumor stroma has been shown to improve access to the tumor by the virus and additional therapies such as chemo- and immuno-therapies. Importantly, degrading the stroma exposes tumor antigens, turning &#x201c;cold&#x201d; tumors &#x201c;hot&#x201d; and enabling a sustained anti-tumor immune response. VCN has the rights to four exclusive patents for proprietary technologies, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional patents pending. As consideration for the purchase of the VCN Shares, the Comany paid $4,700,000 to Grifols Innovation and New Technologies Limited  the owner of approximately 86% of the equity of VCN, and issued to the remaining sellers and certain key employees and consultants of VCN the closing Shares, representing 19.99% of the outstanding shares of the Company&#x2019;s common stock on December 14, 2021, the date of the Purchase Agreement. In addition to the consideration described above, under the terms of the Purchase Agreement, the Company assumed up to $2,400,000 of existing liabilities of VCN and has agreed to make cash payments to Grifols upon the achievement of certain clinical and commercialization milestones, as described below. In connection with the Acquisition, prior to the closing the Company loaned VCN $425,000 to help finance the costs of certain of VCN&#x2019;s research and development activities and, at the Closing, VCN and Grifols entered into a sublease agreement for the sublease by VCN of the laboratory and office space currently occupied by it as well as a transitional services agreement. As a Purchase Agreement post-Closing covenant, Synthetic has agreed to commit to fund VCN&#x2019;s research and development programs, including but not limited to VCN01 PDAC phase 2 trial, VCN01 RB pivotal trial and necessary G&amp;amp;A within a budgetary plan of approximately $27.8 million.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;b style="font-weight:bold;"&gt;Milestone Payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;US$3MM upon VCN-01 US IND Safe to Proceed pancreatic ductal adenocarcinoma (&#x201c;PDAC&#x201d;, or other first indication)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;US$2.75MM upon VCN-01 US IND Safe to Proceed &#x2013; retinoblastoma (&#x201c;RB&#x201d;, or other second indication)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;US$3.25MM upon VCN-01 US first patient dosed&#x2013; PDAC (or other first indication) after receipt of VCN-01 US IND Safe to Proceed for PDAC being informed&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;US$3.25MM upon VCN-01 US first patient dosed &#x2013; RB (or other second indication) after receipt of VCN-01 US IND Safe to Proceed for RB being informed&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;US$6MM upon VCN-01 US Phase 2 trial meets the primary endpoint or if a Phase 2 trial is not conducted and only a Phase 3 trial is conducted then upon a Phase 3 being initiated &#x2013; PDAC (or other first indication)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;US$8MM upon VCN-01 Pivotal Trial meeting the primary endpoint or upon BLA Submission &#x2013; RB (or other second indication)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;US$12MM upon VCN-01 US Phase 3 trial meeting the primary endpoint or upon BLA Submission &#x2013; PDAC (or other first indication)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;US$16MM upon VCN-01 BLA Approval &#x2013; PDAC (or other first indication)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:100%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 18pt;"&gt;US$16MM upon VCN-01 BLA Approval &#x2013; RB (or other second indication)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1
      contextRef="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGuOmgQVFUWelRGFisfwCQ"
      id="Narr_ZlreESq4_EiwjcbsyEGypw">P3Y</us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGuOmgQVFUWelRGFisfwCQ"
      decimals="-3"
      id="Narr_MOtJK6dggUOQmJSB8hIo7A"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">585000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage
      contextRef="Duration_1_3_2022_To_1_3_2022_srt_RangeAxis_srt_MaximumMember_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6rAbrvfSCUWGUsBaubIWMQ"
      decimals="2"
      id="Narr_a4QuB8QAwUm9ukcWdkrmJA"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.50</us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage>
    <syn:ConsiderationPurchasePaid
      contextRef="Duration_3_10_2022_To_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nY9W9p5hLEOy0btQJThIaA"
      decimals="0"
      id="Narr_mifqZP2VD0G7tq0dgQ7Q1w"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">4700000</syn:ConsiderationPurchasePaid>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_BusinessAcquisitionAxis_syn_GrifolsInnovationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4zfGfEAdcUanM58rCqi1Pg"
      decimals="2"
      id="Narr_p4e21E8LfUiVnKZ40kkEmA"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.86</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_BusinessAcquisitionAxis_syn_NewTechnologiesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_WiHLxploBU2xe-zdv1Ih8Q"
      decimals="4"
      id="Narr_SH-2BgG14EetFKSqVqpyog"
      unitRef="Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg">0.1999</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <syn:CashPaymentsExistingLiabilities
      contextRef="Duration_3_10_2022_To_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nY9W9p5hLEOy0btQJThIaA"
      decimals="0"
      id="Narr_FQnzPXaDi0C8wna-DaPGZg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2400000</syn:CashPaymentsExistingLiabilities>
    <syn:ClosingFinanceCosts
      contextRef="Duration_3_10_2022_To_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nY9W9p5hLEOy0btQJThIaA"
      decimals="0"
      id="Narr_2IKKL4wj-0KLOa2N565smA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">425000</syn:ClosingFinanceCosts>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6abns4wbvk2nLNMGsIo3mg"
      decimals="-5"
      id="Narr_V7hwrwzwSUqjed3jMP-1Dw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">27800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <syn:BusinessCombinationMilestonePaymentsSafeToProceed
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ"
      decimals="-6"
      id="Narr_fsN348dMQUW9Kw6XzYEqhg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3000000</syn:BusinessCombinationMilestonePaymentsSafeToProceed>
    <syn:BusinessCombinationMilestonePaymentsSafeToProceed
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg"
      decimals="-4"
      id="Narr_u2no04GC2E-W8YD-mAVY8Q"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">2750000</syn:BusinessCombinationMilestonePaymentsSafeToProceed>
    <syn:BusinessCombinationMilestonePaymentsFirstPatientDosed
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ"
      decimals="-4"
      id="Narr_OPo0bnshsEW_pIfqZDkuuQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3250000</syn:BusinessCombinationMilestonePaymentsFirstPatientDosed>
    <syn:BusinessCombinationMilestonePaymentsFirstPatientDosed
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg"
      decimals="-4"
      id="Narr_40osaQonhEGu0BAUBV8coQ"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">3250000</syn:BusinessCombinationMilestonePaymentsFirstPatientDosed>
    <syn:BusinessCombinationMilestonePayments
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ"
      decimals="-6"
      id="Narr_rgIuScbStEe6PJjgcRBWgw"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">6000000</syn:BusinessCombinationMilestonePayments>
    <syn:BusinessCombinationMilestonePayments
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg"
      decimals="-6"
      id="Narr_W8WlqiU3m0qYeFgXvu381Q"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">8000000</syn:BusinessCombinationMilestonePayments>
    <syn:BusinessCombinationMilestonePayments
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_6abns4wbvk2nLNMGsIo3mg"
      decimals="-6"
      id="Narr_cuQmV0Jep0ecLdj3L2cfjA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">12000000</syn:BusinessCombinationMilestonePayments>
    <syn:BusinessCombinationMilestonePaymentsBlaApproval
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherFirstIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_nKoW3j61MEOn7sFbQcZEMQ"
      decimals="-6"
      id="Narr_4_9Ct-Kb_0q1oBGysLv9Yg"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">16000000</syn:BusinessCombinationMilestonePaymentsBlaApproval>
    <syn:BusinessCombinationMilestonePaymentsBlaApproval
      contextRef="As_Of_3_10_2022_srt_TitleOfIndividualAxis_syn_VcnPrivateMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_syn_OtherSecondIndicationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HtlMlKuyMk2sGFnO47vcYg"
      decimals="-6"
      id="Narr_8QeBAThZH0Cyd9hWXMlTBA"
      unitRef="Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q">16000000</syn:BusinessCombinationMilestonePaymentsBlaApproval>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M8TJUDN)X*T2M<D_M6!U_JG\WP:M@7I# <T;_DE!&4VMD@1"O4$;E$]O^P$5
MOM8+&!7F&VQS6W]H@2 3DL6%LR*(29+_HO?B("H.*M!F!U@XP*X.7N'@F4!S
M,A/6 Y)H-N%L"[BV5FIZ8,[&>*MH2*)OXU)R=94H/SF;LT0P2D(D<0CN$45)
M@,%2RPEPM4 <)S+"D@2(7H.OX NP@8C4JIC84NVN->R@V.D^WPD>V>D!!SW@
MN3< .M!M<)]W=W?J[K:*N0P<EH%#H^>='WB+NE>J>T:]?T3]-XY3QM5S ;Z]
M941^W !UEH!QL)1FPV=$,PP66"WHXVPZS7R#D=E /XR;F=-S''5RF^JAG;*J
MT?=+^OZ9](92@+M,1HR3?SAL(LY%_0J+Z^2?/>@.AC5NO^3V+^-^%")K9O8/
M4/9A#RU<>!QU4*(.+D/]E4DA41*29-W$.SC)>VC1QCLL>8>MO OU=L6<J]1=
M2A:\7I#/N?YP[Z;OP9\PJJ&/2O31>>B=DGG4-9D[&-:PQR7V^"+LX[D\/ID;
MAQ;>>.@U<[K.KH0X%Y&>2.5"M8VWP:0%N%+SW%;@.8MCU4*(G#95F;PQ^7M%
M$A R2A$7(%6Y;$K==2.[V^GM?-*L'L"N=KGPC  ZY7.A6#U*Z#1G="?3.OFN
M+KKMA;&1_'A*%VJUI\N#3K\_&@SVJ0]-X1CZ$/K'\F57#MWV>M@(?2J[&XJ<
M)E<XHWWR0U-%WA\K^CURN]+HZ2[[)^)KD@A \4JY.KVATN!YXYI/)$M-[_?"
MI.HDS3!2S3[FVD!=7S$F/R>ZG2S_/LS^ U!+ P04    "  [AG!4JHP+O3D%
M  #D%0  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;+U8WV_;-A#^5PBC
M#QO0Q")E2W;@&(B=;@O0=D'=+@_#'FB)MKE*HD?23@KLC]]14B1'(MFLS?9B
M_?#=\?N.Y'TGSNZ%_*QVC&GTD&>%NASLM-Y?#(<JV;&<JG.Q9P7\LQ$RIQH>
MY7:H]I+1M'3*LR$)@FB84UX,YK/RW:V<S\1!9[Q@MQ*I0YY3^67!,G%_.<"#
MQQ<?^':GS8OA?+:G6[9B^M/^5L+3L(F2\IP5BHL"2;:Y'%SABV58.I06OW%V
MKT[ND:&R%N*S>;A)+P>!0<0REF@3@L+ER)8LRTPDP/%7'730C&D<3^\?H_]4
MD@<R:ZK84F1W/-6[R\%D@%*VH8=,?Q#WO[":T-C$2T2FRE]T7]G&XP%*#DJ+
MO'8&!#DOJBM]J!-QXH CAP.I'4C78>1P"&N'L"1:(2MI75--YS,I[I$TUA#-
MW)2Y*;V!#2_,-*ZTA'\Y^.GY4A1*9#REFJ5HI>$"<Z05$AOTZYY):G*MT!GZ
MM+I&/[SZ$;U"O$ ?=^*@:)&JV5 #!A-IF-3C+:KQB&,\3- [4>B=0F^*E*5/
M PP!?,. /#)8$&_$:Y:<HQ"_1B0@V )H^7SWP ,G;!(:EO%"1[PZ:\46+86"
M1$*:T)L'V'6*J0M/_%$3?U3&'SGB_\P*&" KX](45@17V@QX9+;)J&+%92RS
MHX_S:!2/9L/C:8+Z1N. 3!NC)S#'#<RQ%^8'IAB5R:[$F;(CU(N]65DVD%6D
M\<GX\20(.B#[1F,<8CO(J $9>4%^%!HRZ9LQ&]RHAP2/2"^I%JL 1X$=<-P
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MN=B"P$#-(C1N$,B)!)P%GJO9O[@7I-BL2&$6<02RJ.I/',@LJK*/4.(IU0/
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M\/*^_=G=IY+S,F]?+EDB+OT-0'Q^6Y9\\]#\DF_[4^63?P%02P,$%     @
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M#M5Z98H5>V97\Y*609=P"(4$>&;'5-[![";B /0/&I;Y)JK!S6^':DY)'UO
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M?&FYJI'F7 *2Q+YO^L!K3+< YW2HZ(\F%RO00,>56F"6CPJHHTBC[[2BP<,
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M/H#]A?>I>V$!_1?)BW\!4$L#!!0    ( #N&<%0IIQ^ .Q0  %D[   8
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M6*7Y\4(;^!@AM^%Q@'MWQL;H,SR(#&^KA([[D/<4&W77L6(G3<G#O:KVNQ"
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M,:!648ANX+M10_$,EKXQFF^L18;L.!MJ@6TNR=T5M11L)#^:W6P)ZDT+NKS
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M<?I8)8EQAH8(C[U7?D^*P<N+<.:O9[.7O0[A,I@OS=-'#I!P0+3V%_-)?P!
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M]8H[I@'-L&9WQ(2[<D2+U6S8AKJCZ4GC:OI=X[[G)_[B1_4@,^F BSNUL5$
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MD"YK>@'/[ZNJ\1>T0/@)W9O_ E!+ P04    "  [AG!4J@!N74,(   ]%0
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M<IDUF2W*'&R7]<5'VRW3^^A*=)L<9L=4NZ^@5R[=WYK*[6^(NX,1OJ]!&BH
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MP9;\@6QF0[ %_UPJ['F.!/!\;FUH+LA ^\7T]K]02P,$%     @ .X9P5/1
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MKJ&JA<94-UC=K75JYB9-*@.=7=#,KDZ7T;@D545A*S @@3'-3%IAN[2>(?;
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MK-=5R@[9,E[R@2QE1=JGQ-?*.W3V8N+K5 3[B"92AEL25E:+PDL01Z6@WD4
M<Y^=Q7']J2V,2H9(2N)E'N7C9-%VLO[L0\F_\?3$?Q^R=Q49BRY*M7+RTKPF
M<4B]GO";'M+^:L$:\7$NT'C9&8@OWFH(VS*E@__$]OJO%N7PV1J(C0+[*L(5
M-AXBZU?J#GY&KP#\:$PM^(C2+* 6/@F1X4+ESR.@$U"CQR-SF&;1B-[Y-M!N
MI;ZP1GK;0 ()%K>I!8@&_)2S ED ( &'^46@CMR:R@,4L8D$EMSS&!V??R\]
MC(:).0%5ER%3'82&XB7VB?LCGATI\8#]UE/T; ]%'9LR]Y[[QU$T["S(_N$!
MO+D?8MBZ@AFA\^*=.7.7K"0_[3?G_=WS9 G[?<M),!Y(OCRR!P\;514/9[_8
M0'Y).+7(4Y-)A:W6V4\A7.RO)[FY$-K ;[UK$*?8W(^ 1Z_*>D%V.BB8![N(
M)9-971T*6$/*9=)+F Q$1SQE4&Q."CY,7'?V_7-_"SW3WCO/V<&)H@2B\/)?
MNK3?2]2A)8:$CZ_UNHH!\L5]F;0BRIUU(:PJ.E'!B<^^X,T=EDA\:.<2KH]'
M/EN2VI,YJ406+&@@@6,%6N>>--%-FTY1$I"*9VO.T:? (F<!2P5R4I\3XJ18
M1-1@KSM=V8R]V$FI<T*]5+J#Q_+!*:,3>ZO($E/.&-@<_GX097A"1 ";Z=%%
M%L0V['8F &78<(>M>9O+$UG8A\IG<98YB@  .)(/P\2M*&U@.O'R/+G1=V#8
M94U@_T#@1,E5",;DWA3K@1#GGL5"Z/;YI@W<Y$E VVT %:"8/[JX #((D1-%
M;$4]!]-ACNE#^457/EL=?!5!@-:M^ZQ=5"S!EWECU3"NAF6A8+4R,YS\803?
M >_)YYNP$\,XR51Y8R@#'%Q#2H)7A*.D^0A@-@@]&OK8!R$@*-F"Y#VQ09NV
MR<0A2%#;'*$4$,>G6 &QRIE,%U8H=L:=,4_:DD$+\EMJV$]X2AJ0Z[/9/3N#
MC3T>CQY\K6^>Z+5)O-I'6/;(WOODW.?A];"_P.NZM&L-;H8\/:2.THE;B:1O
MJ0A 85OGI;C<%$91%@MZX8PBJN'&RFTGD!D</FR5E#5B-1Q2B"EXE2:6.21+
MC5]W;2S13>#L 50!R ^"(Q=)W(\,# 7KLS\I;4HP397YMN-*>O:7ME9)-:?4
M3?R/0>W6V0/TTIR[ZW;G_7&)HW?[T^T/Y ]HYG9'C+EZ-NZZ\6F_!]L1F0!X
MWYJJ&Q@J!K^=3")PG\G;L3_4VK'7\'BW=M^JE*N?D1LJ](:+K&0\\NT@*(>S
MP.31R75S( ,/%]IXE.T+VU\$IE&,2U: GTE&AGFJ\,X=026M&Y,=S4*V8CJ:
M#B873[]A(QNN]\HNPF1-QH.2G*;,>%[GA:U=FQ<:GP].IQ>BU=/)Q>#IV05Q
M>"UFD3BB) L2HNNO->(]3:)/:0T\7$FU_$%*61>AG+_"VU 29LP5R,ETCQ**
M@-T[VT.ZV)B D)AN 5AC"3CW2Z8]1!W^\!^(.O:= @MNJ2D_A)$4V,AQG-]?
M:QCT<@4-U7T U<T-@/,VOQ6[7.S@/F]W^B),&4O*#%!MNA7?1D#WY,?8)U+M
MYDZGM:2?  DUOA&+;!.88_;=3?#G"6Y**;^5^C:Y?/E[\O[]58-<Z,O]2>>/
M]E8<*B3Q0>Q4["E(RWKAZ[ATK-*OM?'U(*!$X-%YR$E0%E>+EZ;W!TG; R$U
M!WUR,(XZ>O?QU3%D*?VB%CC.X,CI6'8 //BI8K3%):O2IL1$>L9OD;KYE"P#
M+%TP(>2MI1>D\)4%IJ-I5OE,)](>%,.WW#K?:$+;Z+*FRUC.VO( 3IYU<,MD
M*KA'&E&8,*CN!>S$@00;"5\_.4QS<Y8:C";%X%3Y7K+XLS?/,2Q@W2$7][T)
MQ-T.DNB )9+NXRH*G#^^\MF?G8<'T%K(SAP:WP]NGTOJY-#PW;CV"*/G)N=F
M&LHIY'9ATM8[2_F/67'T\OWE<8SS^/!\KA+VT)94]+)UQ95@+Q\\[DA1U#0W
M15OS[1[0L8^O;RG/&= >DXTUOWG)9M ?Y! 1K^AU[&;%&^[@:)%9L;+$A2@U
M'*> ST;_:-+ 1(3_;.M2Y#%R,[")P1A%:5^!CI ]3-H2X64R<H7WUT=X+99Y
M#-B)% ;11A%V:!WOALN1,ZHR(EP=B%G82ZE7%^YG[:K)&*Y\<OH=)9QA<E67
M)7<F#8)!;&+MX/PHJ&O++V!/[5I!Z<\>M^@T#4G7H<A]V7:]O+VZ@5,-72U#
M>(&8&1M=-CK-Q6=.X;35#WJ\4A"J3"PJD2* 1W-6I,?ZB1AG_#$:'L#*<1!_
M_G!R1\[OA+VH;B?L97RN*TK;)Y?#Y)JJ1&EI'0Q1G)K91TSP8 /NF8C;=*[
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M\D(&>7+L[$HXV@UI](-=Y=,P3AM*RDUP6-4X%TYNFKE7?S7*!/'N#O_ZXU&
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M:3(MRP>2_FR,$EP;DT.$QHH,Q:=-H^@WF]C)?<(B4OV4#KOHFS047_#P6'0
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M"9H0/YJJGA&3Z5-AGO7"_+.&_)-P3!XFG&2>$@;=P8K_G\0?#-9C'S!'O:_
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M!_#]K$:X]Q]H@_AO,;SZ?U!+ P04    "  [AG!4Q?(S+EH"   R!0  &0
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M4:#L =Q/I#2;B150?YA-_P902P,$%     @ .X9P5)$@G0FO @  *0<  !D
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M!>E,0L6'MX.Y74A6F=FV8U)-2F/FZBX#K@/4?LJ8/"QT@?YVC'X#4$L#!!0
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MC]S=,+N)%H5MTDNAL>7;88J7,DAC@.LK(?3[Q/3]^IH?_@502P,$%     @
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M;Q%V.-<7/1 F0#^/.5=O$W.5J*Z.PW]02P,$%     @ .X9P5"FK3=-T @
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MP,05VBAS9:VPQDDLQ1Y)&VW8[,!YX]"F&LKM*:9:FEUJ<#I)G:&0H5O,,">
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M!,&Y)* 6!?0780&U,*!-T("6<="F%;O+ H$V001:1D)0@01JF4 _" KT"!4
MJI;*,H$V P5:ID('6EX%LJCE FT>#"="PLE& 98,\$%D@#(9JLL-%@O0#!:@
MC(6:<H/E C3/A1,ASRBWY0*<PX6[4H\)-!?Z%]2#,\$ %@SPBX !+!B@"3!
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M&O/L/]@7;9T."+=<T*0 2P9)E.:?^+$P1 4 O08 *@"H+< M &Y;@%< O+8
MOP#X;0'] M!O"P@*0- 6,"@ @[: 80$8M@5 Y^ YIS6D='9K;\.#NV%K?\.#
MPV'F\5Z^%K.%/,$"CTX9W0.FVLO^U$46#1E>KM\H58$[%TR^C21.C.:"AM_?
M7\BEOP!CFLA\P'$>4>D"?,.,X51P\!YD[4"4AB15D08V,<[;4+$F3+[(<XA"
MOIL0@:.8_RYA7^83\.ZWWT][0G)5(_;"@M=%S@LU\+JENQ, !UV '-@WP,=V
M^)QL3H#K*#B"!OC$#K_![$1"%=P)#/"I'3XAH1P=-HY^V1[N&.!7;4S7;X1_
M;&$Z&#3"KUN3AT,#_),=?A<*.;J?P0<&^!\M1D?9W*')<9];F,YI7G4W;> H
M@_]@NIZ,RS(X41F<*.O/;7+%&C/R_J$>G.<J+E=$"J@ #T^@VFZ&G[+'YWO,
M%A8.;LG!S3AX#1RFR2:F3X2 .6&[*"2@B507W-)T1[B0S[/!>?<YZ5LJP),L
M1>Y)2%=I] ]9=(NT<K=1#;@IT')R049.%2&[41! QY'6W1DFY963\JR3FC$:
M$K+@8,EH\IP$F#X2%D9R=B8Z>;=^A8YFDH>V5R/<P-4ON?IV!Q1\P(8I\V]D
MMMWG>=F4&O*^AI7AX8D[>,[QTPN-GM'LES3[5IJE5B@WRWI/Q 0_Q$0J QAC
MONZ"2QPQ\!7'6P(F$0]CRK>,F"*\7[/@L-'A0<DNL+*[GMV!/V](\D#87Y:@
M&)3=#8X6F,.2P] ZI7S57G.^E9U/MBQ*5V!&6$156*EQ9?S=RL(Y:V&*K8MA
M;3$'T$.#OMG4T-$EA6-E-HXQYX N#_4#H QD.P)):*M<H-[-22@YBXAPN3[B
M6,Y!VJM<1 >$B??G8O@J<<7;#V #\THQ!.TVS>Q6&+4+9EG$2:/F!C56,;"V
M6EV_@89.^Q"]32Q=%0-5Z4$_<)QJ0!6J;FCI%'\-\]$2 NT:(J5#^?E"^_<0
MB^!?T#(TH<[MT#M:<$*=M>$KINT+6$_)?><$-1A>YV1H3\I7)"4,QUFA?KZ0
M&XB("X:S G[ZJ PCO:+>W1-., O7V<V$[.1^?I/9HVA5]=>A(."MO*83- R.
MYS6=U^' :K#S.*8A5B5,(Y_"),9=P: 60\CQ:K%V:6H'W>9 TY( [9J@?7.N
M'!DQ$@K*6GD*Z?2.G*-Y"NE4C5JDZE]AT3U4?%UPE2<EF5X/ GK%*#?6HP6K
MJO8@U*_GTTM#0^A[S=D4538%=G482\[;6"AAK83EJX>ZS4LZ\R/W>&M%*P*R
ME_N_%M6H7M(CB P>K[>#;M#L<"TEZ 4I*:/ZC=VL=0;UC^=F+2'(7N3_HIN#
MFOM\0Z%T:6CG6:HDI+4'V;5'G345>]&9.EUKXR&M#&AXO*,$+1VN?6?PFDG[
M;BNX3((+N>\Y["M,!WUN?;.@=CG#YUZ=&IKYT&NHY%VM4JY=I9I\*B/Y!C]&
MR3:QV55+@GO$@Z+*2=$+9?Y1)'E2L/K!PVZ#Z[1HN';14&=X/QF.KD[IKG\\
MA^FT[=JW!V\?CM."4=59[L"09F\,#=4.WVMPJQ8)URX2KS!G?8C!\_,"O!5K
MRM2)INF;BH*07Q,,Z^[:U;KAOJ0;YH4J<\P%E805T9_:"KA:5=SCJ8JG5<7[
MOZG*U*O+!?)\1V[B&@ZFM6)X+RD&^MFTXVF=\(ZG$Y[6">_M=**=OSYZ=8WP
MC-'7JWR5JGZY<(/9*DHYB,E2(IV30';!\A\#Y#>";K)O5Q^H$#3)+M<$+PA3
M#>3[):7B<*.^L"U_DC'Z#U!+ P04    "  [AG!4MQ/EV7L(  #X+@  &0
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M])M\\V(S]V%&QVG\1[3@JXM>T ,+N@RW,?^0[MY1M2$LY<W3.,O_@IT:Z_3
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MF'7QAJ>;_%'7^Y3S=)V_7-%0U$MR@/A^F:9\_T8^/5L^['[Y+U!+ P04
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M;-XT62#R'_IZ!Q*32GQ3<[\@%XD2<Q #5RJ->B4W;_6,&SW!"3U^@!X8E:5
M][2 8I_ 5>:LPV#K<!R<9;R#O(="_PH%7N!W")I\'.Z=D1/:@(>&+SP7<!O9
M,X21)8P,872"\->ZG@/7B=F27J$Q+ FEA"[1&%>8YM"5B(8V-K3Z:W\9^7W/
M\U(_'+@ONP'JFICZ499E=N*>\M@JCR]6?O\*/"?B,/.-XOA(R+7O)W&<1FFW
MDL0J22Y6HDZ)!1#9J622'"M1$0GZ2;>.U.I(+X\(+=Y)9'HD)@FC*$N2@SP>
MSSM*^)[JOE7=/ZOZR9R5Z@"Y?0&NSGZ;1#3E)(</;L=FC6Q'G==+^MG>[\#0
M,23L!5&WF<R:R3YGYMR^&#?<JJI=X*(#$WL]+^[VX7MO)[OW.2?O[ZQVA8N2
M<AFF\>;N%+ :^-+4=8%RMJ:R.>GMJ+T[W)J*>3 ^UG<*4QC?:)H+R0/F:A,*
M5,%"47J]5'T'O*GQ34>RE2F3<R95T37-4MV+@.L)ZOV",;GMZ 7L36OT'U!+
M P04    "  [AG!4Y;>BNW8#  "]#0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6S-5]^/XC80_E=&41^N4I?$!@*<  EVM^I)MRK:;;L/ISZ89 !K
MDYC:9EFD^^-K.R')M2% ?YR.AV [GF^^&?N;V..]D"]J@ZCA+4TR-?$V6F_?
M^[Z*-I@RU1%;S,R;E9 ITZ8KU[[:2F2Q,TH3GP9!Z*>,9]YT[,86<CH6.YWP
M#!<2U"Y-F3S,,1'[B4>\X\ C7V^T'?"GXRU;XQ/J7[<+:7I^B1+S%#/%1082
M5Q-O1M[/:6 -W(S?..Y5K0TVE*40+[;S(9YX@66$"4;:0C#S]XJWF"06R?#X
MHP#U2I_6L-X^HO_H@C?!+)G"6Y$\\UAO)M[0@QA7;)?H1['_"8N ^A8O$HER
M3]@7<P,/HIW2(BV,#8.49_D_>RL243/HGC*@A0%UO'-'CN4=TVPZEF(/TLXV
M:+;A0G76AAS/[*H\:6G><F.GIT]:1"\W<Q-7#+<B-8NM6)ZN+(9G)B7+M((;
M>,I7#<0*6)* 65^ES12>K=U,?$,9<<66"<+^:/7N#C7CB?I^[&M#U3KTHX+6
M/*=%3] B%!Y$IC<*[K,8XR\!?!-C&2@]!CJGK8AW&'6@2WX &E#R'?B@-DRB
MRI\M^-TRD5V'WSN!?Y]G &$A>800=,(1?'K =(GR]Q;X7@G?<_#=4^MD>=XL
M_[Y.,YOL-1JA:%@>H#YOP0YN>&96)(9/'PTD?-"8JC9"_9)0OS7>9[??C9?9
M*TJC7_A+ CY#E>2F]<_11P[=EH[7J4G9</3%;^R_-C ,2X9A.\/C/ORYVJQ-
M3'*4?HU)V.WU:)\VNQ^4[@>7N;^OM-'D?G"=^V'I?GC=^CRB+=)6L+=&6=*4
MPQU+X"-?(;SC&1R0R6:EMOLA!-)<J32$F!W:M#0JN8^NT1(9=FAPB9A(4%6]
MX-N0$ZD58O*_"JJ KRO*)JYY%Q%:T:+_B8H*F/H^'I#>">]5427M5?52$14P
MEWFO:B[I?24-G7%$G"F,CE(BP3DID:I.D_9"W?1A^F4O+M)356I)^(WHJ2J_
MY$S]_;=Z&OSC+Q2IBC0Y4Z4O5=>P\2LQ"L,3#*I22]IK[<4*&UW'@%:UF 9?
M265G'%VA,K]VHDY1KMV]04$D=IG.#]?E:'DWF>4G\FIZ?K%Y8'+-,P4)KHQI
MT!F8%,K\KI!WM-BZ\_E2:'/:=\V-N5^AM!/,^Y40^MBQ#LH;V_1/4$L#!!0
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M1>GNP5:OSUE/6,QI+F&7G0'9N^K ?T$41Y=BH/C2[/X3KN L86X7<-PC0K\
M\S/.U6Z@#Q35 ;+_#U!+ P04    "  [AG!4O_X(D9((  !$,   &0   'AL
M+W=O<FMS:&5E=',O<VAE970S.2YX;6S-FVMOXS86AO\*872!%DACD;JZ2 (X
M=C+C-LD$\:1%4?0#(S$V.[JXI.Q,@/WQ2TJR:4?R,3.+W7H^)';$0[TZET>'
ME.;LI1!?Y)RQ$GW-TER>]^9EN?BIWY?QG&54GA8+EJLCSX7(:*F^BEE?+@2C
M2664I7WB.$$_HSSO79Q5?[L7%V?%LDQYSNX%DLLLH^+UDJ7%RWD/]]9_>."S
M>:G_T+\X6] 9F[+R<7$OU+?^9I:$9RR7O,B18,_GO2'^Z2[TM$$UXE?.7N36
M9Z0OY:DHON@OD^2\YVA%+&5QJ:>@ZM>*C5B:ZIF4CK^;27N;<VK#[<_KV:^K
MBU<7\T0E&Q7I;SPIY^>]J(<2]DR7:?E0O'QDS07Y>KZX2&7U$[TT8YT>BI>R
M+++&6"G(>%[_IE\;1VP98&^/ 6D,B*V!VQBXM@9>8^#9&OB-@6]K$#0&@:U!
MV!B$M@918Q#9&@P:@X&M 7;6D7/>F+CN/I--L*VCC=?AQM;QQNN 8^N(XW7(
M<17S?IV^5>Z/:4DOSD3Q@H0>K^;3'ZH"JNQ5RO-<U_JT%.HH5W;EQ0V/5>&R
M$Z2*):5/A:"Z]A#-$W25+=+B5=5UB88SP9C^)*LCHR++>%E__Q$-DX3KNJ4I
MFN0U?705?S]F)>6I_$$->9R.T???_7#6+Y5D?>)^W,B[K.61/?+&+#Y%Q#U!
MQ"&XPWQD8>XZE;G383ZV/WN7^15L/ES.3I$3:G,\Z#"_ALVG;*',_<H\ZC#_
M8"&^,7<[S#_"YG?%:NTZ'':83RS.C@>5.>DP__F_,__%0CR)]IK?V*0-WIMU
MM_;F76ES9VV._5WSOJKN38F338F3:C[W?U7B?]RH&=&D9)G\$]#C;O2XE1YO
MCYY[^EK/JUB!/I5S)M U8[(K1>N)PFHBW;6L+CS?T?_.^JL.!=Y&@0<J&!6R
M1,4SNN$KGL\4P/Y2J*TUW3.AO%6J-J<+%_"T 3GUG7\!'O(W^GQPHFO*!?J5
MIDN&/CVCZ9P*)M%$RB5+NC#BM[Q$(G^ODX*-B  4\6G!=*8H_]PP6J>/++MJ
M*>@X_4Z,ZIKI&.8,]JH,-RK#]ZE<9U>7TGHJ?TN"2W!;:<<P0&FT41J!2N_4
M/7%$Y7QSO]096/76^L.C9&@H)>L6'K5\Y[O17D6#C:+!^WSW6]49LP0-5^K(
MC*$QEW&Q5'1XH*7V;5T<70KA,T4'"@,[IEUQP)D>F&14Q/,*4F.V4HN51<6O
MJZ\+3;E.V#LM]X61TY&BS<#MR/O8Q7L=C;>Z+ P3AR542,ESRM$M2WBLFJ61
MDJW8]\<MRYZ8@,B*#>KQ<; >&]ACF/9W2WUUFF/Z-"KKIV41?T&?"W3) *8U
ML^Z$8C_XL2$_AAD-ROG(T@1=OJ('EE)=!O=4E*^=ZKR6NM"+ 'V&_!A&OT6B
MH'^CZ>]WZ)(7&8^E5?X8YN/@./+'\!W#@-]:77QK*K5Y3CP"!,L0'<-(?P-0
MJU 8../!482"&/82F+VV'<$M:7,4NT#?1@Q'"<S1VBE5TV8NW,+M9*M9/@Z"
M$D-0 A-TF.=+E?V+==N<J+9PF2>J$M):*Z)K-5T++=)NH@&2$D-2 I/TFN=&
MU;M%M0%*]K>LQ."3P/BT7UM\(.VV&4..,0PE<.-<4ZGF$1HOA<Y6U3GQ(CEI
M>OD3=,=>ZA'=TH*6=P9^,-@CS*"4P"B]5S<UVWHQ#"31<=2+ 2>!F\WWY,"@
MO2@![@RN0:4+HW):JM8T1\-3'?$TC44A);1T-@!T\5&XVS7 = EXJ6/VS(1@
MU5ET"U[O_@V%H/FLTH!>>#E'DSQ1J^U$D>RD60:]4)%(]$&-4[W6";SR'AT0
MH9;>#KC"<+=V)V#<5B7ZHWY^ %S2TRO:'M>D7'U-)^C30ANH,J\N3B*>;P#P
MH9T)S06V&UX/P)%K..W"G!X+E80ISVAN4_BN0:WK'T<F&O"Z,'C_+YEX>4#$
MP4T@U_#:A7G]SV3BI=ONEP,H$\VMPH7;Y::1N=2M\I2F5'2MK<9N>[,#+ 1S
M7W /W!<$6Z'ADT W:6Q3"IZAO><<12EXYC;AP7WRUJJI2O%U6NA;8J/6Z.G:
M7V_FW[DSNOL[-,_<+CR8U(^Y8#,NU8)69>O.UB8J"TMMI+V\"",_VB/-D-\[
MT&AO.4T5#4^JY8ZJ-^4]^I1VT>"7 U,J%.B:BW4,=-";[\52(*G;1"C86[O9
M,.&;(F\6P@\L9BK[DMU%<NWIKH<17KL5QU%(O#W>-/<'[T K/M=U/D$C=:#:
MQO@L.$VMND_/(-\[COT*ST#;@Z%]RU.F0JLF;6JNZ]E9,X?EFLPSA/5@PC8^
MGWR;UPU)O>/8FO -@7VXW[;RNM^Q+0'L2OB&MCY,V[OQ$$V73QF7U2LPDQP]
M3FT\[AMJ^L>Q*^$;6/HPV>P\WFYJ"9#HOD&>#R/O:BF*!5,M;;5'J@Y*=?$L
MCU_1<+$0Q4HEOHW_MQ[('4>SZQOR^7"?:>?_]D8"F/&&<CY,N0<V6Z:T+,26
MPU7:#R57,1GI1T;JB$T$#-K\X]AG\ T%?;B?M(O X%T1" SQ@D,[#/JV?K\4
M<<7\S87;>#TP9 N.8[LA,"0,X/[Q6QX -E.&;X+P]@%U>Q0!-B4#@\H 1N7N
MO?B=H3)(#+SC")6!9@!W@%>RY%GU(&T3-/W$H*L+O0K:N[$N@0IEZS4&&)37
M7,@2_:[.;^5O@\ @/ Y_&T0&</>W\;+)L&O^5;G_FG65Q:29;O=%!Y=$X6YA
M_'QXW*Y@0]  )NB4Q85RBFUL0@/'\#@6Y*$!:0BWB.^-33/=CL]QX+G1F]@<
M'K<KV' VA#G[><[%.T)C8!BZQQ$: \X0[B7?'1JO U51Z+="<W!<+;B_]?:N
M?K_^EHH95\OYE#TK0^<T5,$5]2OK]9>R6%0O]#X595EDU<<YHPD3>H Z_EP4
MY?J+?D=X\Q\'+OX#4$L#!!0    ( #N&<%2-TCQP3P,  '(*   9    >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;*66VT[C,!"&7\6*N ")DL3I@:*V$I1%
MRP4K1&'WVDVF31;'[MH.[;[]CIT0>D@#TMZTMC/S^_/8'L]H+=6K3@$,V>1<
MZ+&7&K.Z\GT=IY S?2%7(/#+0JJ<&>RJI:]7"ECBG'+NTR#H^SG+A#<9N;%'
M-1G)PO!,P*,BNLASIO[> )?KL1=Z[P-/V3(U=L"?C%9L"3,P+ZM'A3V_5DFR
M'(3.I" *%F/O.KR:AM0Z.(N?&:SU5IO8I<RE?+6=^V3L!98(.,3&2C#\>X,I
M<&Z5D.-/)>K5<UK'[?:[^IU;/"YFSC1,)?^5)28=>Y<>26#!"FZ>Y/H[5 OJ
M6;U8<NU^R;JT[:)Q7&@C\\H9"?),E/]L4P5BRR'L'W&@E0/==^@><8@JA\@M
MM"1SR[IEADU&2JZ)LM:H9ALN-LX;5Y,)NXTSH_!KAGYF<B]BF0-Y9AO0Y/06
M#,NX/B,=\C*[):<G9^2$9((\I[+03"1ZY!N<U+KZ<37!33D!/3)!2,F#%";5
MY)M((-D5\)&V1J;OR#>T5?$6X@L2A>>$!C1L )I^W3UHP8GJ"$9.+_I"!%OD
MNK5<U\EUC\A-9;XJ#"3$@\T*SSHD:,@VG3D(6&0&=^8.$E",-VU%*3UPTO8"
MOTTZ4=#MC?RW[?@T6-&0=FNK'>Y>S=W[3^Z980::J$OAWC;/, KWH!N,^F&_
MF;E?,_=;F:^3WWC#,"D9(A?'P(VTN:9H#GC_@"K8XVZSV($>U-"#5N@'8%R?
M$X0&A;=5.'R\FT2:%%03Y.!3R#:+'<C+&O*R%?*'%!V\[04FZ3D'@FDL?NW8
M=)L0O"WX!FEFLW@3[>4!2T3W<%M-=GB'->^PE=>=3;OM1-D&JP]&$^'P8/KA
M >*A32>D-&RF#(./;!VT<E9WW^VW=LP"GWI\U!$[$TO"I=:?T%<SM!V'5I-=
M\JUW)FS/#RD32["/R1OC!2O?<(Y5!!-Q8U:H]'9V.0CWX]QD-:3#([3T@Y:V
MTE9)W1X(FQ6$;D:D!YGT()1M)B6<O_5ZYZ"6KJC1>$\*8<I7L1ZM"Z=K5R[L
MC=_8@LI5!1\R937VP-0R$YIP6*!D<#' >*FRP"D[1JY<C3"7!BL.UTRQ* 1E
M#?#[0DKSWK$3U&7FY!]02P,$%     @ .X9P5,%4OHQ  P  <@H  !D   !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&ULE9;;;MLX$(9?A1!ZT0)-)%''!+:!
M-$:Q!78709/N7C/2V"9"D2Y)V\D^_0XE154MVDAN;)&<^?G-\#2S@])/9@-@
MR7,CI)D'&VNWUV%HJ@TTS%RJ+4@<62G=,(M-O0[-5@.K6Z=&A#2*\K!A7 :+
M6=MWIQ<SM;."2[C3Q.R:ANF7+R#481[$P6O'=[[>6-<1+F9;MH9[L#^V=QI;
MX:!2\P:DX4H2#:MY<!-?W\;4.;06_W XF-$W<:$\*O7D&M_J>1 Y(A!062?!
M\&\/MR"$4T*.G[UH,,SI',??K^I?V^ QF$=FX%:)?WEM-_.@#$@-*[83]KLZ
M_ %]0)G3JY0P[2\Y=+9%%)!J9ZQJ>F<D:+CL_MESGXB10YR><*"] WVK0]([
M)&V@'5D;UI)9MIAI=2#:6:.:^VASTWIC-%RZ9;RW&D<Y^MG%-UFI!L@#>P9#
M+L@25J UU*Z#W!@#UI"/2[","_,)QW_<+\G'#Y_(!\(E>=BHG6&R-K/0(HH3
M#*M^VB_=M/3$M$NH+DD2?R8THK''_?;M[M'O[B$F8,@"';) 6[WDI%X?ML6P
M61OV]1G99)!-6MGTA.R]5=43X<;L4!J/'#&@][P";\(ZJ:*5<H=OOXBS*)V%
M^W%:/$8I+0>CWRC3@3(]2WE35=H!XD; R\$P=[Q\@)U*-IJ;%D=X4Y.4^N&R
M 2Y[7PI9]7/'#6_O +4B6ZW6FC4^WFP"$Z<Y/2+V&26YGSD?F//W,0M<<VF
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MNL,54/LF4-Q@KR^D-,\GQ8>OZLOH\#]02P,$%     @ .X9P5- ADOH; P
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M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-V;MNPD 0A>%707X
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M82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M (:M
M(:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"0M8$A:P)"EF3
M_R3KN]:KO_ZIT:YQK<KFZ,^Z/T?S3U!+ 0(4 Q0    ( #N&<%0'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ .X9P5$2 :]WO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ .X9P5)E<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  [
MAG!40.IXJP(&  #G&0  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ .X9P5(5<H8K'!0  8A8  !@
M         ("!1@X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( #N&<%1B!HG8+@,  $H,   8              " @4,4  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  [AG!4JHP+O3D%  #D%0
M&               @(&G%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ .X9P5#'D$]7N!P  MBP  !@              ("!%AT  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #N&<%3[#,4&V08
M !P>   8              " @3HE  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    "  [AG!4HL^7K'D(  "=%   &               @(%)
M+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ .X9P5"FG
M'X [%   63L  !@              ("!^#0  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( #N&<%2E]=;&0 0  )0,   8
M  " @6E)  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  [
MAG!45!6P1K$2  "210  &0              @('?30  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( #N&<%2?Z>P)_1   $XW   9
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M970Q-2YX;6Q02P$"% ,4    "  [AG!4")I#. ,5  "700  &0
M    @($9IP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M #N&<%3%\C,N6@(  #(%   9              " @5.\  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ .X9P5,Z#3.A)!   D0T  !D
M             ("!Y+X  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    "  [AG!4ZB<UT]X%  !A%P  &0              @(%DPP  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #N&<%2:@GU'V0(
M  $'   9              " @7G)  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ .X9P5!I(+G/9!   I T  !D              ("!
MB<P  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  [AG!4
MD2"=":\"   I!P  &0              @(&9T0  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( #N&<%16M=968@(  'L&   9
M      " @7_4  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ .X9P5):_5@^4!@  02   !D              ("!&-<  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  [AG!4L2<L/]P"  #R!P
M&0              @('CW0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( #N&<%32:+9>% ,  $8*   9              " @?;@  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ .X9P5"FK3=-T
M @  6P8  !D              ("!0>0  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    "  [AG!4V-@,\E("  #1!0  &0
M@('LY@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #N&
M<%01_@*]M (  %,(   9              " @77I  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ .X9P5,MP"QG+!   JA,  !D
M         ("!8.P  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    "  [AG!4P.P6+1D$  #K%0  &0              @(%B\0  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( #N&<%3VX]B;9@8  )XA
M   9              " @;+U  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ .X9P5+<3Y=E["   ^"X  !D              ("!3_P
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  [AG!4$G _
MX/D"  !U"0  &0              @($!!0$ >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( #N&<%3EMZ*[=@,  +T-   9
M  " @3$( 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M.X9P5(.,**&6"P  .34  !D              ("!W@L! 'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    "  [AG!4F/N?B-8$  "D%@  &0
M            @(&K%P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( #N&<%2C*M*6.0,  $P*   9              " @;@< 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ .X9P5+_^")&2"
M1#   !D              ("!*" ! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    "  [AG!4C=(\<$\#  !R"@  &0              @('Q
M* $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( #N&<%3!
M5+Z,0 ,  '(*   9              " @7<L 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ .X9P5)1*IN#[ P  -P\  !D
M     ("![B\! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #N&<%3N2=W_G@$   @:   :
M          "  0]! 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( #N&<%2HRH?9JP$  $$:   3              "  >5" 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     S #, W T  ,%$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>415</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>76</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Statements of Stockholders (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity</Role>
      <ShortName>Consolidated Statements of Stockholders (Deficit) Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation</Role>
      <ShortName>Organization, Nature of Operations and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Selected Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation</Role>
      <ShortName>Selected Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Stock-Based Compensation and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrants</Role>
      <ShortName>Stock-Based Compensation and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Non-controlling Interest</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest</Role>
      <ShortName>Non-controlling Interest</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - License, Collaborative and Employment Agreements and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitments</Role>
      <ShortName>License, Collaborative and Employment Agreements and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Selected Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables</Role>
      <ShortName>Selected Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Stock-Based Compensation and Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables</Role>
      <ShortName>Stock-Based Compensation and Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrants</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30703 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables</Role>
      <ShortName>License, Collaborative and Employment Agreements and Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30803 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Organization, Nature of Operations and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails</Role>
      <ShortName>Organization, Nature of Operations and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Selected Balance Sheet Information - Schedule of PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Selected Balance Sheet Information - Schedule of PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Selected Balance Sheet Information - Schedule of PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Selected Balance Sheet Information - Schedule of PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Selected Balance Sheet Information - Schedule of ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Selected Balance Sheet Information - Schedule of ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Selected Balance Sheet Information - Schedule of ACCRUED EMPLOYEE BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails</Role>
      <ShortName>Selected Balance Sheet Information - Schedule of ACCRUED EMPLOYEE BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Stock-Based Compensation and Warrants - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails</Role>
      <ShortName>Stock-Based Compensation and Warrants - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Stock-Based Compensation and Warrants - Summary of stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation and Warrants - Summary of stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Stock-Based Compensation and Warrants - Options outstanding and exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Stock-Based Compensation and Warrants - Options outstanding and exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40404 - Disclosure - Stock-Based Compensation and Warrants - Stock incentive plan and other information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails</Role>
      <ShortName>Stock-Based Compensation and Warrants - Stock incentive plan and other information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40405 - Disclosure - Stock-Based Compensation and Warrants - Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails</Role>
      <ShortName>Stock-Based Compensation and Warrants - Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40406 - Disclosure - Stock-Based Compensation and Warrants - Summary of all warrant activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails</Role>
      <ShortName>Stock-Based Compensation and Warrants - Summary of all warrant activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40407 - Disclosure - Stock-Based Compensation and Warrants - Summary of all outstanding and exercisable warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails</Role>
      <ShortName>Stock-Based Compensation and Warrants - Summary of all outstanding and exercisable warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Non-controlling Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails</Role>
      <ShortName>Non-controlling Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40701 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Maturity analysis of operating leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails</Role>
      <ShortName>License, Collaborative and Employment Agreements and Commitments - Maturity analysis of operating leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40702 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails</Role>
      <ShortName>License, Collaborative and Employment Agreements and Commitments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40802 - Disclosure - Income Taxes - Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40803 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="syn-20211231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.syntheticbiologics.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>43</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="syn-20211231x10k.htm">syn-20211231x10k.htm</File>
    <File>syn-20211231.xsd</File>
    <File>syn-20211231_cal.xml</File>
    <File>syn-20211231_def.xml</File>
    <File>syn-20211231_lab.xml</File>
    <File>syn-20211231_pre.xml</File>
    <File>syn-20211231xex10d32.htm</File>
    <File>syn-20211231xex10d33.htm</File>
    <File>syn-20211231xex10d34.htm</File>
    <File>syn-20211231xex10d35.htm</File>
    <File>syn-20211231xex10d4.htm</File>
    <File>syn-20211231xex21d1.htm</File>
    <File>syn-20211231xex23d1.htm</File>
    <File>syn-20211231xex31d1.htm</File>
    <File>syn-20211231xex32d1.htm</File>
    <File>syn-20211231xex4d4.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>syn-20211231x10k001.jpg</File>
    <File>syn-20211231x10k002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="523">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>73
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "syn-20211231x10k.htm": {
   "axisCustom": 1,
   "axisStandard": 27,
   "contextCount": 194,
   "dts": {
    "calculationLink": {
     "local": [
      "syn-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "syn-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "syn-20211231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "syn-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "syn-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "syn-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 511,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 11,
    "http://xbrl.sec.gov/dei/2021q4": 7,
    "total": 18
   },
   "keyCustom": 84,
   "keyStandard": 331,
   "memberCustom": 43,
   "memberStandard": 32,
   "nsprefix": "syn",
   "nsuri": "http://www.syntheticbiologics.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Stock-Based Compensation and Warrants",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrants",
     "shortName": "Stock-Based Compensation and Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Stockholders' Equity",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Non-controlling Interest",
     "role": "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest",
     "shortName": "Non-controlling Interest",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - License, Collaborative and Employment Agreements and Commitments",
     "role": "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitments",
     "shortName": "License, Collaborative and Employment Agreements and Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Income taxes",
     "role": "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Subsequent Events",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:EstimatedUsefulLifeOfAssetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:EstimatedUsefulLifeOfAssetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Selected Balance Sheet Information (Tables)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables",
     "shortName": "Selected Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Stock-Based Compensation and Warrants (Tables)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables",
     "shortName": "Stock-Based Compensation and Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Consolidated Balance Sheets",
     "role": "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - License, Collaborative and Employment Agreements and Commitments (Tables)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables",
     "shortName": "License, Collaborative and Employment Agreements and Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Organization, Nature of Operations and Basis of Presentation (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails",
     "shortName": "Organization, Nature of Operations and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "-5",
      "lang": null,
      "name": "syn:ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:EstimatedUsefulLifeOfAssetTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_06odZ0po2U2Duco7oDcnHg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Property and equipment (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:EstimatedUsefulLifeOfAssetTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_06odZ0po2U2Duco7oDcnHg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccruedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Selected Balance Sheet Information - Schedule of PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Selected Balance Sheet Information - Schedule of PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Selected Balance Sheet Information - Schedule of PROPERTY AND EQUIPMENT (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
     "shortName": "Selected Balance Sheet Information - Schedule of PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:AccruedExpensesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "syn:AccruedVendorPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Selected Balance Sheet Information - Schedule of ACCRUED EXPENSES (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
     "shortName": "Selected Balance Sheet Information - Schedule of ACCRUED EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:AccruedExpensesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "syn:AccruedVendorPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:AccruedEmployeeBenefitsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Selected Balance Sheet Information - Schedule of ACCRUED EMPLOYEE BENEFITS (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails",
     "shortName": "Selected Balance Sheet Information - Schedule of ACCRUED EMPLOYEE BENEFITS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:AccruedEmployeeBenefitsTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedBonusesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Stock-Based Compensation and Warrants - (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails",
     "shortName": "Stock-Based Compensation and Warrants - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "syn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TemporaryEquityParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_RsriYutjxUuQSlocdtt04g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Stock-Based Compensation and Warrants - Summary of stock option activity (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation and Warrants - Summary of stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_jmEkNr6ZXU2i-5WhZSeI1A",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_RsriYutjxUuQSlocdtt04g",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Stock-Based Compensation and Warrants - Options outstanding and exercisable (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails",
     "shortName": "Stock-Based Compensation and Warrants - Options outstanding and exercisable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_RangeOfExercisePrice0004000Member_26Rrgn2SZEaz1DmLOKv1_g",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40404 - Disclosure - Stock-Based Compensation and Warrants - Stock incentive plan and other information (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
     "shortName": "Stock-Based Compensation and Warrants - Stock incentive plan and other information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_10_15_2018_To_10_15_2018_XRwkhJ_Dmk-8YpsoxAckVw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40405 - Disclosure - Stock-Based Compensation and Warrants - Stock Warrants (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
     "shortName": "Stock-Based Compensation and Warrants - Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2020_v_kA2gAnv0aopQrFYHh0_g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_RsriYutjxUuQSlocdtt04g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40406 - Disclosure - Stock-Based Compensation and Warrants - Summary of all warrant activity (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails",
     "shortName": "Stock-Based Compensation and Warrants - Summary of all warrant activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2019_Fm7AtIyxXEuDtP4LXGLC9Q",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_RsriYutjxUuQSlocdtt04g",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_nGWIzttATUuENHWAb_1Gxg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "syn:WarrantsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40407 - Disclosure - Stock-Based Compensation and Warrants - Summary of all outstanding and exercisable warrants (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails",
     "shortName": "Stock-Based Compensation and Warrants - Summary of all outstanding and exercisable warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "syn:ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_syn_ExercisePrice0.69Member_nGWIzttATUuENHWAb_1Gxg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "syn:WarrantsExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_10_15_2018_To_10_15_2018_XRwkhJ_Dmk-8YpsoxAckVw",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_27_2021_To_1_27_2021_DAGJFo-tVEioslNEUzr8Og",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:PreferredStockConvertibleConversionPriceDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_rgIWMcm6mUyUqxtrjqk7rw",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "syn:NoncontrollingInterestPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Non-controlling Interest (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
     "shortName": "Non-controlling Interest (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:MinorityInterestDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_9_5_2018_To_9_5_2018_uBFbvYxH-EmzEpTcsw0I4Q",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Maturity analysis of operating leases (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails",
     "shortName": "License, Collaborative and Employment Agreements and Commitments - Maturity analysis of operating leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_11_1_2017_To_11_30_2017_9RYWQN6O80iVs8ielspjNw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - License, Collaborative and Employment Agreements and Commitments - Additional Information (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
     "shortName": "License, Collaborative and Employment Agreements and Commitments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_11_1_2017_To_11_30_2017_9RYWQN6O80iVs8ielspjNw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsForFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Consolidated Statements of Operations",
     "role": "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "i",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Income Taxes (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "i",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "i",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "syn:DeferredTaxAssetsStocksIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - Income Taxes - Deferred Tax Assets (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "i",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "As_Of_12_31_2021_ohEQJ-8DN02febyHOCUD2A",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "syn:DeferredTaxAssetsStocksIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_12_30_2020_To_12_30_2020_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_5Rwg92J14EiVYGDVwneJ0A",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_3JewgG-3vEWH89f_gBcazg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_3_2022_To_1_3_2022_srt_TitleOfIndividualAxis_syn_StevenAShallcrossMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_iGuOmgQVFUWelRGFisfwCQ",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualMaximumContractualTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Consolidated Statements of Stockholders (Deficit) Equity",
     "role": "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity",
     "shortName": "Consolidated Statements of Stockholders (Deficit) Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_VSIiLt_ajE2ZnZvtoSNs4g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_2l0DUH2Z3EyiMayschu0_Q",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Organization, Nature of Operations and Basis of Presentation",
     "role": "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation",
     "shortName": "Organization, Nature of Operations and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Selected Balance Sheet Information",
     "role": "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation",
     "shortName": "Selected Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "syn-20211231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_mJL1ikjZyEOxL_YbFbWrfA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 76,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationEliminationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Eliminations"
       }
      }
     },
     "localname": "ConsolidationEliminationsMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r77",
      "r121",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r134",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180",
      "r182",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r77",
      "r121",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130",
      "r131",
      "r134",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r179",
      "r180",
      "r182",
      "r184",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r187",
      "r193",
      "r230",
      "r233",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r412",
      "r451",
      "r452",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r187",
      "r193",
      "r230",
      "r233",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r412",
      "r451",
      "r452",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r187",
      "r193",
      "r227",
      "r230",
      "r233",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r412",
      "r451",
      "r452",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r187",
      "r193",
      "r227",
      "r230",
      "r233",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r412",
      "r451",
      "r452",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r87",
      "r92",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r87",
      "r92",
      "r171",
      "r231",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r135",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_AccretionOfPreferredStockDeemedDividend": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the amount of accretion of the Series B preferred stock deemed dividend.",
        "label": "Accretion of Preferred Stock Deemed Dividend",
        "terseLabel": "Accretion of Preferred Stock Deemed Dividend"
       }
      }
     },
     "localname": "AccretionOfPreferredStockDeemedDividend",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AccruedClinicalConsultingServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value of accrued clinical consulting services payable as on balance sheet date.",
        "label": "Accrued Clinical Consulting Services",
        "terseLabel": "Accrued clinical consulting services"
       }
      }
     },
     "localname": "AccruedClinicalConsultingServices",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AccruedEmployeeBenefitsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to accrued employee benefits.",
        "label": "Accrued Employee Benefits [Table Text Block]",
        "terseLabel": "Schedule of accrued employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_AccruedExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accrued expenses.",
        "label": "Accrued Expenses [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_AccruedManufacturingCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The manufacturing costs incurred in the production of goods for sale.",
        "label": "Accrued manufacturing costs",
        "terseLabel": "Accrued manufacturing costs"
       }
      }
     },
     "localname": "AccruedManufacturingCosts",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AccruedVendorPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to vendor payments.",
        "label": "Accrued Vendor Payments",
        "terseLabel": "Accrued vendor payments"
       }
      }
     },
     "localname": "AccruedVendorPayments",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AdditionalCashPaymentForLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional cash payment for license agreement.",
        "label": "Additional Cash Payment For License Agreement",
        "verboseLabel": "Additional Cash Payment for License Agreement"
       }
      }
     },
     "localname": "AdditionalCashPaymentForLicenseAgreement",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AdditionalConsiderationPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description related to additional consideration payable.",
        "label": "Additional Consideration Payable"
       }
      }
     },
     "localname": "AdditionalConsiderationPayable",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "syn_AdditionalNumberOfCommonStockToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional number of common stock to be issued under stock purchase agreement.",
        "label": "Additional Number Of Common Stock To Be Issued",
        "terseLabel": "Additional Number Of Common Stock To Be Issued"
       }
      }
     },
     "localname": "AdditionalNumberOfCommonStockToBeIssued",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_AdjustmentsToEffectOfPreferredStockPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of adjustment to effect of preferred stock price.",
        "label": "Adjustments To Effect Of Preferred Stock Price",
        "terseLabel": "Effect of Series A Preferred Stock price adjustment"
       }
      }
     },
     "localname": "AdjustmentsToEffectOfPreferredStockPrice",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_AdjustmentsToEffectOfWarrantExercisePrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount changes in effect of warrant exercise price.",
        "label": "Adjustments To Effect Of Warrant Exercise Price",
        "negatedLabel": "Effect of Warrant exercise price adjustment"
       }
      }
     },
     "localname": "AdjustmentsToEffectOfWarrantExercisePrice",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_BalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Selected Balance Sheet Information"
       }
      }
     },
     "localname": "BalanceSheetInformationAbstract",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "syn_BeneficialOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of beneficial ownership.",
        "label": "Beneficial Ownership Percentage",
        "verboseLabel": "Maximum percentage"
       }
      }
     },
     "localname": "BeneficialOwnershipPercentage",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "syn_BrokerageCommissionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent that percentage of commission revenue from buying and selling securities on behalf of customers.",
        "label": "Brokerage Commission percentage",
        "terseLabel": "Brokerage Commission percentage"
       }
      }
     },
     "localname": "BrokerageCommissionPercentage",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "syn_BusinessCombinationMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of business combination milestone payments.",
        "label": "Business Combination Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationMilestonePayments",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_BusinessCombinationMilestonePaymentsBlaApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of business combination milestone payments BLA approval .",
        "label": "Business Combination Milestone Payments BLA Approval",
        "terseLabel": "Milestone payments BLA approval"
       }
      }
     },
     "localname": "BusinessCombinationMilestonePaymentsBlaApproval",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_BusinessCombinationMilestonePaymentsFirstPatientDosed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of business combination milestone payments first patient dosed.",
        "label": "Business Combination Milestone Payments First Patient Dosed",
        "terseLabel": "Milestone payments first patient dosed"
       }
      }
     },
     "localname": "BusinessCombinationMilestonePaymentsFirstPatientDosed",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_BusinessCombinationMilestonePaymentsSafeToProceed": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of business combination milestone payments safe to proceed .",
        "label": "Business Combination Milestone Payments Safe to Proceed",
        "terseLabel": "Milestone payments safe to proceed"
       }
      }
     },
     "localname": "BusinessCombinationMilestonePaymentsSafeToProceed",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_CashPaymentsExistingLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments existing liabilities.",
        "label": "Cash Payments Existing Liabilities",
        "terseLabel": "Existing liabilities"
       }
      }
     },
     "localname": "CashPaymentsExistingLiabilities",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_CedarssinaiMedicalCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Cedarssinai Medical Center.",
        "label": "Cedarssinai Medical Center [Member]"
       }
      }
     },
     "localname": "CedarssinaiMedicalCenterMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ClinicalTrialAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to clinical trial agreement (\"CTA\").",
        "label": "Clinical Trial Agreement [Member]"
       }
      }
     },
     "localname": "ClinicalTrialAgreementMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ClosingFinanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of finance the costs.",
        "label": "Closing Finance Costs",
        "terseLabel": "Finance costs"
       }
      }
     },
     "localname": "ClosingFinanceCosts",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_ComputersAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computers and office equipment [Member]",
        "verboseLabel": "Computers and office equipment"
       }
      }
     },
     "localname": "ComputersAndOfficeEquipmentMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ConsiderationPurchasePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration for the purchase paid.",
        "label": "Consideration Purchase Paid",
        "terseLabel": "Consideration purchase paid"
       }
      }
     },
     "localname": "ConsiderationPurchasePaid",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_ConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a.",
        "label": "Consultant [Member]"
       }
      }
     },
     "localname": "ConsultantMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ConversionOfSeriesBPreferredStockToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents conversion of preferred stock to common stock",
        "label": "Conversion of Series B Preferred Stock to Common Stock",
        "verboseLabel": "Conversion of Series B Preferred Stock to Common"
       }
      }
     },
     "localname": "ConversionOfSeriesBPreferredStockToCommonStock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_ConversionOfSeriesBPreferredStockToCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of conversion of series B preferred stock to common stock issued.",
        "label": "Conversion of Series B Preferred Stock to Common Stock Shares",
        "verboseLabel": "Conversion of Series B Preferred Stock to Common (in shares)"
       }
      }
     },
     "localname": "ConversionOfSeriesBPreferredStockToCommonStockShares",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_Conversionofseriesapreferredstocktocommonstockshares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of preferred shares to common",
        "label": "ConversionOfSeriesAPreferredStockToCommonStockShares",
        "terseLabel": "Conversion of Series A Preferred Stock to Common (in shares)"
       }
      }
     },
     "localname": "Conversionofseriesapreferredstocktocommonstockshares",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_Conversionofseriesbpreferredstocktocommonstock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion Of Series B Preferred Stock To Common Stock",
        "label": "ConversionOfSeriesBPreferredStockToCommonStock",
        "terseLabel": "Conversion of Series A Preferred Stock to Common"
       }
      }
     },
     "localname": "Conversionofseriesbpreferredstocktocommonstock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_CostOfLivingAdjustmentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to cost of living adjustments percentage.",
        "label": "Cost of Living Adjustments Percentage"
       }
      }
     },
     "localname": "CostOfLivingAdjustmentsPercentage",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "syn_DeemedDividendsWithBeneficialConversionFeature": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Deemed Dividends With Beneficial Conversion Feature.",
        "label": "Deemed dividends for beneficial conversion features",
        "verboseLabel": "Deemed dividends for accretion of Series B Preferred Stock discount"
       }
      }
     },
     "localname": "DeemedDividendsWithBeneficialConversionFeature",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_DeferredTaxAssetsStockIssuedForAcquisitionOfProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stock issued for acquisition of program.",
        "label": "Deferred Tax Assets Stock Issued For Acquisition Of Program",
        "verboseLabel": "Stock issued for acquisition of program"
       }
      }
     },
     "localname": "DeferredTaxAssetsStockIssuedForAcquisitionOfProgram",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_DeferredTaxAssetsStockIssuedForMilestonePayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Stock Issued For Milestone Payment.",
        "label": "Deferred Tax Assets Stock Issued For Milestone Payment",
        "verboseLabel": "Stock issued for milestone payment"
       }
      }
     },
     "localname": "DeferredTaxAssetsStockIssuedForMilestonePayment",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_DeferredTaxAssetsStockIssuedForlicenseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stock issued for license agreement.",
        "label": "Deferred Tax Assets Stock Issued Forlicense Agreement",
        "verboseLabel": "Stock issued for license agreement"
       }
      }
     },
     "localname": "DeferredTaxAssetsStockIssuedForlicenseAgreement",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_DeferredTaxAssetsStocksIssuedForServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stocks issued for services.",
        "label": "Deferred Tax Assets Stocks Issued For Services",
        "verboseLabel": "Stock issued for services"
       }
      }
     },
     "localname": "DeferredTaxAssetsStocksIssuedForServices",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from amortizable license fee.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Amortizable License Fee",
        "verboseLabel": "Amortizable license fee"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseAmortizableLicenseFee",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_DepositsAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and also includes aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet due to materiality considerations. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).",
        "label": "Deposits and Other Assets Noncurrent",
        "verboseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsNoncurrent",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License, Collaborative and Employment Agreements and Commitments"
       }
      }
     },
     "localname": "DisclosureOfLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAbstract",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "syn_Dr.SlimanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Dr. Sliman [Member]"
       }
      }
     },
     "localname": "Dr.SlimanMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_DrPimentelsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dr. Pimentels [Member]"
       }
      }
     },
     "localname": "DrPimentelsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a.",
        "label": "Employees And Directors [Member]"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_EstimatedFairValueOfInducementConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Estimated Fair Value of Inducement Consideration.",
        "label": "Estimated Fair Value of Inducement Consideration",
        "terseLabel": "Estimated fair value of inducement consideration"
       }
      }
     },
     "localname": "EstimatedFairValueOfInducementConsideration",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_EstimatedResearchCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated research services cost provided.",
        "label": "Estimated Research Costs"
       }
      }
     },
     "localname": "EstimatedResearchCosts",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_EstimatedUsefulLifeOfAssetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of estimated useful life of assets.",
        "label": "Estimated Useful Life Of Asset [Table Text Block]",
        "terseLabel": "Schedule of Estimated Useful Life"
       }
      }
     },
     "localname": "EstimatedUsefulLifeOfAssetTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_EuropeanMedicinesAgencyApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "European Medicines Agency Approval [Member]"
       }
      }
     },
     "localname": "EuropeanMedicinesAgencyApprovalMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ExercisePrice0.69Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents information about  exercise price of warrant",
        "label": "Exercise Price 0.69 [Member]"
       }
      }
     },
     "localname": "ExercisePrice0.69Member",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ExercisePrice0.69TwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents information about  exercise price of warrant",
        "label": "Exercise Price 0.69 Two [Member]"
       }
      }
     },
     "localname": "ExercisePrice0.69TwoMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ExercisePrice1820Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price 18.20 [Member]"
       }
      }
     },
     "localname": "ExercisePrice1820Member",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_FairValueOfSharesIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents the fair value of shares issued.",
        "label": "Fair Value Of Shares Issued",
        "terseLabel": "Fair Value Of Shares Issued"
       }
      }
     },
     "localname": "FairValueOfSharesIssued",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_FbrCapitalMarketsCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FbrCapitalMarketsCoMember",
        "label": "Fbr Capital Markets Co [Member]"
       }
      }
     },
     "localname": "FbrCapitalMarketsCoMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_FirstYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "First Year [Member]"
       }
      }
     },
     "localname": "FirstYearMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expenses and Research and Development Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpensesAndResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_GrifolsInnovationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grifols Innovation.",
        "label": "Grifols Innovation"
       }
      }
     },
     "localname": "GrifolsInnovationMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "syn_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "syn_IncreaseDecreaseLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount of Increase decrease right of use assets",
        "label": "Increase decrease lease liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseLeaseLiability",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_IncreaseDecreaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount of increase decrease in lease liability.",
        "label": "Increase decrease Right of use assets",
        "verboseLabel": "Right of use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseRightOfUseAssets",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_InvestmentWarrantsExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of warrants held.",
        "label": "Investment Warrants Expiration Date1",
        "terseLabel": "Investment Warrants Expiration Date1"
       }
      }
     },
     "localname": "InvestmentWarrantsExpirationDate1",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "syn_IssueOfWarrantsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represent additional of warrant to purchase of common stock",
        "label": "Issue of warrants to purchase common stock",
        "terseLabel": "Issue of warrants to purchase common stock"
       }
      }
     },
     "localname": "IssueOfWarrantsToPurchaseCommonStock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_LesseeOperatingLeaseLiabilityPaymentsDueYearSix": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Six",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_LicenseAgreementAnnualPaymentsDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of annual payments due under the license agreement.",
        "label": "License Agreement Annual Payments Due",
        "terseLabel": "Annual payments due under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementAnnualPaymentsDue",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_LicenseAgreementFinalPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the final payment due under the license agreement.",
        "label": "License Agreement Final Payment Due",
        "terseLabel": "Final payment due under license agreement"
       }
      }
     },
     "localname": "LicenseAgreementFinalPaymentDue",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License, Collaborative and Employment Agreements and Commitments [Line Items]"
       }
      }
     },
     "localname": "LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsLineItems",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "License, Collaborative and Employment Agreements and Commitments [Table]"
       }
      }
     },
     "localname": "LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTable",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "syn_LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of license, collaborative and employment agreement and commitments.",
        "label": "License Collaborative And Employment Agreements And Commitments [Text Block]",
        "terseLabel": "License, Collaborative and Employment Agreements and Commitments"
       }
      }
     },
     "localname": "LicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A milestone payment is an authority payment made to a contractor which is linked to the contractor delivering a service or commodity such that, should the agreement be terminated at the point of payment.",
        "label": "Milestone Payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_MoneyMarketAccountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Accounts [Member]"
       }
      }
     },
     "localname": "MoneyMarketAccountsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_NdaSubmissionInUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NDA Submission In US [Member]"
       }
      }
     },
     "localname": "NdaSubmissionInUsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_NewTechnologiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Technologies",
        "label": "New technologies"
       }
      }
     },
     "localname": "NewTechnologiesMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_NonCashAdditionOfRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non cash addition to right of use assets.",
        "label": "Non Cash Addition of Right of Use Assets"
       }
      }
     },
     "localname": "NonCashAdditionOfRightOfUseAssets",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_NoncontrollingInterestPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy noncontrolling interest.",
        "label": "Noncontrolling Interest [Policy Text Block]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestPolicyTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_NumberOfCommonStockToBeHeldByRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional number of common stock to be held by the related party under stock purchase agreement.",
        "label": "Number Of Common Stock To Be Held By Related Party",
        "terseLabel": "Number Of Common Stock To Be Held By Related Party"
       }
      }
     },
     "localname": "NumberOfCommonStockToBeHeldByRelatedParty",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_NumberOfCommonStockToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of common stock to be issued under stock purchase agreement.",
        "label": "Number Of Common Stock To Be Issued",
        "terseLabel": "Number Of Common Stock To Be Issued"
       }
      }
     },
     "localname": "NumberOfCommonStockToBeIssued",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_NumberOfShareSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Number of Share sold.",
        "label": "Number of Share sold",
        "terseLabel": "Number of Share sold"
       }
      }
     },
     "localname": "NumberOfShareSold",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "syn_NumberOfSharesPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shares purchase",
        "label": "Number of Shares purchase",
        "terseLabel": "Number of Shares purchase"
       }
      }
     },
     "localname": "NumberOfSharesPurchase",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "syn_OctoberTwoThousandEighteenWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "October 2018 Warrants [Member]"
       }
      }
     },
     "localname": "OctoberTwoThousandEighteenWarrantsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_OperatingLossCarryforwardsExpireDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expiration date of each operating loss carryforward included in total operating loss carryforwards, or the applicable range of such expiration dates.",
        "label": "Operating Loss Carryforwards Expire Date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpireDate",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "syn_OperatingLossCarryforwardsLimitationOnUse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards Limitation On Use",
        "verboseLabel": "Limitation on Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationOnUse",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_OptionsToBeReceivedCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It Represents options to be received common stock shares reporting period.",
        "label": "Options To Be Received Common Stock Shares"
       }
      }
     },
     "localname": "OptionsToBeReceivedCommonStockShares",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_OtherFirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other First Indication.",
        "label": "Other First Indication [Member]"
       }
      }
     },
     "localname": "OtherFirstIndicationMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_OtherSecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other second indication.",
        "label": "Other Second Indication"
       }
      }
     },
     "localname": "OtherSecondIndicationMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_PercentageOfIssueOfThePublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of issue of public offering price",
        "label": "Percentage of issue of the public offering",
        "terseLabel": "Percentage of issue of the public offering"
       }
      }
     },
     "localname": "PercentageOfIssueOfThePublicOffering",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "syn_PhaseIClinicalTrialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase I Clinical Trials [Member]"
       }
      }
     },
     "localname": "PhaseIClinicalTrialsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_PhaseIiiClinicalTrialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Phase III Clinical Trials [Member]"
       }
      }
     },
     "localname": "PhaseIiiClinicalTrialsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_PreferredStockConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity can be converted.",
        "label": "Preferred Stock Conversion Price Per Share",
        "terseLabel": "Preferred Stock Conversion Price Per Share"
       }
      }
     },
     "localname": "PreferredStockConversionPricePerShare",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "syn_PreferredStockPriceAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents the effect of preferred stock price adjustment.",
        "label": "Preferred Stock Price Adjustment",
        "negatedLabel": "Effect of Series A Preferred Stock Price adjustment",
        "terseLabel": "Preferred stock price adjustment"
       }
      }
     },
     "localname": "PreferredStockPriceAdjustment",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_PreferredStockSharesConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The no of shares converted into common stock",
        "label": "Preferred Stock Shares Converted",
        "terseLabel": "Preferred Stock Shares Converted"
       }
      }
     },
     "localname": "PreferredStockSharesConverted",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_PrepaidClinicalResearchOrganizationsExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the amount paid in advance for clinical research organization.",
        "label": "Prepaid Clinical Research Organizations Expense Current",
        "terseLabel": "Prepaid clinical research organizations"
       }
      }
     },
     "localname": "PrepaidClinicalResearchOrganizationsExpenseCurrent",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_PrepaidConsultingSubscriptionsAndOtherExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the amount paid in advance for consulting, subscriptions and other expenses.",
        "label": "Prepaid Consulting Subscriptions And Other Expenses",
        "terseLabel": "Prepaid consulting, subscriptions and other expenses"
       }
      }
     },
     "localname": "PrepaidConsultingSubscriptionsAndOtherExpenses",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_PrepaidManufacturingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Prepaid Manufacturing Expense.",
        "label": "Prepaid Manufacturing Expense",
        "terseLabel": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidManufacturingExpense",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_PrevAbrLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prev Abr Llc [Member]"
       }
      }
     },
     "localname": "PrevAbrLlcMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of ATM offering, net of issuance cost during the period.",
        "label": "Proceeds From Issuance ATM Offering, Net Of Issuance Costs",
        "verboseLabel": "Proceeds from issuance ATM offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceAtmOfferingNetOfIssuanceCosts",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution for exclusive channel collaboration agreement to the entity.",
        "label": "Proceeds From Issuance Of Common Stock For Exclusive Channel Collaboration Agreement",
        "verboseLabel": "Proceeds from Issuance of Common Stock for Exclusive Channel Collaboration Agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockForExclusiveChannelCollaborationAgreement",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_QuarterlyInstallmentsPaymentPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Installments Payment Period [Axis]"
       }
      }
     },
     "localname": "QuarterlyInstallmentsPaymentPeriodAxis",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "syn_QuarterlyInstallmentsPaymentPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Installments Payment Period [Domain]"
       }
      }
     },
     "localname": "QuarterlyInstallmentsPaymentPeriodDomain",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_RangeOfExercisePrice0004000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price 0.00-40.00 [Member]"
       }
      }
     },
     "localname": "RangeOfExercisePrice0004000Member",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_RangeOfExercisePrice41007000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range of Exercise Price 41.00-70.00 [Member]"
       }
      }
     },
     "localname": "RangeOfExercisePrice41007000Member",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_RangeOfExercisePrice710010200Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range Of Exercise Price 71.09-102.00 [Member]"
       }
      }
     },
     "localname": "RangeOfExercisePrice710010200Member",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_RegulatoryApprovalInAsianCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Regulatory Approval In Asian Country [Member]"
       }
      }
     },
     "localname": "RegulatoryApprovalInAsianCountryMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ResearchAgreementFixedFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of research and development costs incurred for a fixed-price, all payable in quarterly installments.",
        "label": "Research Agreement Fixed Fee"
       }
      }
     },
     "localname": "ResearchAgreementFixedFee",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_ReturnOfSynBiomicsStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Return of SYN Biomics Stock",
        "label": "Return of SYN Biomics Stock"
       }
      }
     },
     "localname": "ReturnOfSynBiomicsStock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding risk and uncertainties.",
        "label": "Risks And Uncertainties [Policy Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_SYNBiomicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "S Y N Biomics",
        "label": "SYN Biomics [Member]"
       }
      }
     },
     "localname": "SYNBiomicsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ScheduleOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrant activity.",
        "label": "Schedule Of Warrant Activity [Table Text Block]",
        "terseLabel": "Summary of all warrant activity"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_ScheduleOfWarrantOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure relates to warrant outstanding and exercisable.",
        "label": "Schedule Of Warrant Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Summary of all outstanding and exercisable warrants"
       }
      }
     },
     "localname": "ScheduleOfWarrantOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_SecondYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second Year [Member]"
       }
      }
     },
     "localname": "SecondYearMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_SeriesAAndSeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A And Series B Preferred Stock",
        "label": "Series A and Series B Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAAndSeriesBPreferredStockMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]"
       }
      }
     },
     "localname": "SeriesBWarrantsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_SeriesWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]"
       }
      }
     },
     "localname": "SeriesWarrantsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the share warrants plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Warrants Exercisable Number",
        "verboseLabel": "Warrants Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsWarrantsExercisableNumber",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure relates to share based compensation arrangement by share based payment award options and warrants vested and expected to vest outstanding and exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award Options and Warrants Vested and Expected to Vest Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Schedule of assumptions used for awards"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of stock (or other type of equity) granted during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value",
        "terseLabel": "Grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share warrants exercised during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period",
        "negatedLabel": "Number of Warrants, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_ShareBasedPaymentArrangementEmployeeAndConsultantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee or employer-consultant relationships based on law of pertinent jurisdiction.",
        "label": "Employees and consultants"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeAndConsultantMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_StevenAShallcrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Steven A. Shallcross"
       }
      }
     },
     "localname": "StevenAShallcrossMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_StockBasedPaymentArrangementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding stock based payment arrangements for various stocks.",
        "label": "Stock Based Payment Arrangements [Policy Text Block]",
        "terseLabel": "Stock-Based Payment Arrangements"
       }
      }
     },
     "localname": "StockBasedPaymentArrangementsPolicyTextBlock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "syn_StockIssuedDuringPeriodAtMarketOfferingShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period at the market offering.",
        "label": "Stock Issued During Period At Market Offering Share",
        "terseLabel": "Stock issued under \"at-the-market\" offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAtMarketOfferingShare",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_StockIssuedDuringPeriodAtMarketOfferingValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period at the market offering.",
        "label": "Stock Issued During Period At Market Offering Value",
        "terseLabel": "Stock issued under \"at-the-market\" offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAtMarketOfferingValue",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Warrants Exercised (In shares)",
        "verboseLabel": "Warrants Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_StockIssuedDuringPeriodValueOfSynBiomicsStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of new stock of syn biomics stock issued.",
        "label": "Stock Issued During Period Value Of Syn Biomics Stock",
        "verboseLabel": "Issuance of SYN Biomics Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOfSynBiomicsStock",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Warrants Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_StockPlan2007Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2007 Stock Plan [Member]"
       }
      }
     },
     "localname": "StockPlan2007Member",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_StockPlan2010Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "2010 Stock Plan [Member]"
       }
      }
     },
     "localname": "StockPlan2010Member",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_StockPlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Stock Plan.",
        "label": "2020 Stock Plan [Member]"
       }
      }
     },
     "localname": "StockPlan2020Member",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "na",
        "label": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_StockWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Warrants"
       }
      }
     },
     "localname": "StockWarrantsAbstract",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "xbrltype": "stringItemType"
    },
    "syn_StockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Warrants [Member]"
       }
      }
     },
     "localname": "StockWarrantsMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_SubsidiaryStockIssuesToVendor": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of subsidiary stock issued in lieu of cash for services contributed to the entity. Value of the subsidiary stock issued includes, but is not limited to, services contributed by vendors.",
        "label": "Subsidiary Stock Issues To Vendor",
        "verboseLabel": "Subsidiary stock issuances to vendor"
       }
      }
     },
     "localname": "SubsidiaryStockIssuesToVendor",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "syn_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "syn_SyntheticBiomicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Synthetic Biomics Inc [Member]"
       }
      }
     },
     "localname": "SyntheticBiomicsIncMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_ThirdYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Third Year [Member]"
       }
      }
     },
     "localname": "ThirdYearMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwritten Public Offering [Member]"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_UnregisteredSharesIssuedToLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period for license agreement.",
        "label": "Unregistered Shares Issued To License Agreement",
        "verboseLabel": "Unregistered Shares Issued to License Agreement"
       }
      }
     },
     "localname": "UnregisteredSharesIssuedToLicenseAgreement",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "syn_VcnPrivateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VCN Private",
        "label": "VCN Private [Member]"
       }
      }
     },
     "localname": "VcnPrivateMember",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "syn_WarrantExercisePriceAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount represents the effect of warrant exercise price adjustment.",
        "label": "Warrant Exercise Price Adjustment",
        "negatedLabel": "Effect of Warrant exercise price adjustment",
        "verboseLabel": "Effect of Warrant exercise price adjustment"
       }
      }
     },
     "localname": "WarrantExercisePriceAdjustment",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "syn_WarrantTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrant term.",
        "label": "Warrant Term",
        "terseLabel": "Warrant Term"
       }
      }
     },
     "localname": "WarrantTerm",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "syn_WarrantsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price of the warrants.",
        "label": "Warrants Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WarrantsExercisePrice",
     "nsuri": "http://www.syntheticbiologics.com/20211231",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r30",
      "r377"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r32"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonus expense"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r32"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "verboseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedExpensesDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r433",
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r9",
      "r32",
      "r224"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Vacation, Current",
        "terseLabel": "Accrued vacation expense"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r29",
      "r165"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r269",
      "r270",
      "r271",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "APIC"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r237",
      "r265",
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Allocated Share-based Compensation Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r72",
      "r125",
      "r128",
      "r133",
      "r143",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r183",
      "r185",
      "r186",
      "r322",
      "r329",
      "r352",
      "r375",
      "r377",
      "r429",
      "r440"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r37",
      "r72",
      "r143",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r181",
      "r183",
      "r185",
      "r186",
      "r322",
      "r329",
      "r352",
      "r375",
      "r377"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesAxis": {
     "auth_ref": [
      "r17",
      "r190",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of series or issue of auction market preferred securities.",
        "label": "Auction Market Preferred Securities, Stock Series [Axis]"
       }
      }
     },
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesTitleDomain": {
     "auth_ref": [
      "r17",
      "r190",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of series or issue of auction market preferred securities based on rights (names are typically labeled by day of the week, duration between intervals, or combination of both).",
        "label": "Auction Market Preferred Securities, Stock Series, Title [Domain]"
       }
      }
     },
     "localname": "AuctionMarketPreferredSecuritiesStockSeriesTitleDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r238",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r229",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r229",
      "r232",
      "r309",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r315",
      "r316",
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Budgetary plan"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r26",
      "r62"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value.",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r56",
      "r62",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r56",
      "r353"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r70",
      "r72",
      "r96",
      "r97",
      "r98",
      "r101",
      "r103",
      "r110",
      "r111",
      "r112",
      "r143",
      "r172",
      "r177",
      "r178",
      "r179",
      "r185",
      "r186",
      "r191",
      "r192",
      "r195",
      "r199",
      "r352",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r222",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price per warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r170",
      "r434",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, Shares Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, Shares Outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r377"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 shares authorized, 132,044,866 issued and 132,042,538 outstanding at September 30, 2021 and 29,252,253 issued and 29,249,925 outstanding at December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r156",
      "r159",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Software [Member]",
        "verboseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of Stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r64",
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Conversion of Stock, Shares Converted"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r16",
      "r17",
      "r203",
      "r209",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "verboseLabel": "Common stock issued upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r16",
      "r17",
      "r209",
      "r213",
      "r214",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Convertible Preferred Stock, Terms of Conversion",
        "terseLabel": "Convertible Preferred Stock, Terms of Conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r295",
      "r301"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "verboseLabel": "Computed \"expected\" tax-benefit - Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r73",
      "r295",
      "r301"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "Computed \"expected\" tax-benefit - State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment made to pay deferred cash remuneration expressed as a percentage of the individual's base salary.",
        "label": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage",
        "terseLabel": "Annual cash performance bonus",
        "verboseLabel": "Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "auth_ref": [
      "r225",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement.",
        "label": "Deferred Compensation Arrangement with Individual, Compensation Expense",
        "terseLabel": "Annual base salary"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualMaximumContractualTerm1": {
     "auth_ref": [
      "r226",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum term of the deferred compensation arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Deferred Compensation Arrangement with Individual, Maximum Contractual Term",
        "terseLabel": "Employment agreement term"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualMaximumContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r287"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred Tax Assets, Net of Valuation Allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carry-forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r293",
      "r294"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r288"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r60",
      "r123"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r38",
      "r340",
      "r341",
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r76",
      "r336",
      "r337",
      "r338",
      "r339",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation and Warrants"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation and Warrants"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r216",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "terseLabel": "Series A Preferred Stock Dividends"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockPaidinkind": {
     "auth_ref": [
      "r216",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock, Paid-in-kind",
        "verboseLabel": "In-kind dividends paid in preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStockPaidinkind",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r47",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r93",
      "r96",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r347",
      "r348",
      "r436",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net Loss Per Share - Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r47",
      "r84",
      "r85",
      "r86",
      "r87",
      "r88",
      "r96",
      "r101",
      "r102",
      "r103",
      "r106",
      "r107",
      "r347",
      "r348",
      "r436",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net Loss Per Share - Dilutive"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r74",
      "r282",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r282",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r282",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfAccruedEmployeeBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employees [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Stock Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common and Preferred Stock"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r43",
      "r44",
      "r45",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r109",
      "r144",
      "r208",
      "r216",
      "r269",
      "r270",
      "r271",
      "r297",
      "r298",
      "r346",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r453",
      "r454",
      "r455",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity Method Investment, Ownership Percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r350",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r188",
      "r206",
      "r345",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r156",
      "r158",
      "r160",
      "r162",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r156",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r163",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r167",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r74",
      "r283",
      "r285",
      "r291",
      "r299",
      "r303",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r75",
      "r90",
      "r91",
      "r124",
      "r281",
      "r300",
      "r304",
      "r450"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r42",
      "r279",
      "r280",
      "r285",
      "r286",
      "r290",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal and state net operating loss adjustment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount",
        "verboseLabel": "Meals, entertainment and other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount",
        "verboseLabel": "Non-deductible stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r282"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax rate adjustment"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "verboseLabel": "Accrued employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r157",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r157",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r50",
      "r122"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Operating Lease [Member]"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements [Member]",
        "verboseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturity analysis of operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Discount factor"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r72",
      "r129",
      "r143",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r179",
      "r181",
      "r183",
      "r185",
      "r186",
      "r323",
      "r329",
      "r330",
      "r352",
      "r375",
      "r376"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r23",
      "r72",
      "r143",
      "r352",
      "r377",
      "r431",
      "r443"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r72",
      "r143",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r179",
      "r181",
      "r183",
      "r185",
      "r186",
      "r323",
      "r329",
      "r330",
      "r352",
      "r375",
      "r376",
      "r377"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r36",
      "r72",
      "r143",
      "r172",
      "r177",
      "r178",
      "r179",
      "r185",
      "r186",
      "r352",
      "r430",
      "r442"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "terseLabel": "Reversal of noncontrolling interest due to return of Syn Biomics shares"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterest"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Equity interest by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r36",
      "r48",
      "r320",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net Cash Provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net Cash Used in Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r56",
      "r58",
      "r61"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net Cash Used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r40",
      "r41",
      "r45",
      "r46",
      "r61",
      "r72",
      "r82",
      "r84",
      "r85",
      "r86",
      "r87",
      "r90",
      "r91",
      "r99",
      "r125",
      "r127",
      "r130",
      "r132",
      "r134",
      "r143",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r179",
      "r181",
      "r183",
      "r185",
      "r186",
      "r348",
      "r352",
      "r435",
      "r448"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r40",
      "r41",
      "r45",
      "r90",
      "r91",
      "r326",
      "r332"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Non-controlling interest",
        "verboseLabel": "Net Loss Attributable to Non-controlling Interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r87",
      "r93",
      "r94",
      "r100",
      "r103",
      "r125",
      "r127",
      "r130",
      "r132",
      "r134"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net Loss Attributable to Common Stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements and Developments"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "NONCASH FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r216",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-Controlling InterestAccumulated Non-Controlling Stockholders'"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total Other Income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other Income :"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment And Furniture"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total Operating Costs and Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating Costs and Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r125",
      "r127",
      "r130",
      "r132",
      "r134"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r365",
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Lease liability - current",
        "terseLabel": "Lease liability",
        "verboseLabel": "Operating Lease Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r362"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Lease liability - long term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r364",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use asset",
        "verboseLabel": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r368",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionMember": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).",
        "label": "Options [Member]"
       }
      }
     },
     "localname": "OptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Nature of Operations and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization, Nature of Operations and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Stock sales receivable"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToEmployees": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of cash to employees, including wages and salaries, during the current period.",
        "label": "Payments to Employees",
        "verboseLabel": "Annual Base Salary"
       }
      }
     },
     "localname": "PaymentsToEmployees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r238",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPriceDecrease": {
     "auth_ref": [
      "r201",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.",
        "label": "Preferred Stock, Convertible, Conversion Price, Decrease",
        "verboseLabel": "Preferred Stock, Convertible, Conversion Price, Decrease"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPriceIncrease": {
     "auth_ref": [
      "r201",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in conversion price of convertible preferred stock. Excludes change due to standard antidilution provision.",
        "label": "Preferred Stock, Convertible, Conversion Price, Increase",
        "terseLabel": "Preferred Stock, Convertible, Conversion Price, Increase"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockDiscountOnShares": {
     "auth_ref": [
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount on preferred shares, or any unamortized balance thereof, shown separately as a deduction from the applicable account(s) as circumstances require.",
        "label": "Preferred Stock, Discount on Shares",
        "terseLabel": "Accretion of preferred discount",
        "verboseLabel": "Preferred Stock Redemption Discount"
       }
      }
     },
     "localname": "PreferredStockDiscountOnShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Preferred Stock, Dividend Rate, Percentage"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Preferred Stock Dividends, Income Statement Impact",
        "terseLabel": "Preferred stock accrued dividends"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionDiscount": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The excess of (1) the carrying amount of the preferred stock in the registrant's balance sheet over (2) the fair value of the consideration transferred to the holders of the preferred stock, during the accounting period, which will be added to net earnings to arrive at net earnings available to common shareholders in the calculation of earnings per share.",
        "label": "Preferred Stock Redemption Discount",
        "terseLabel": "Preferred Stock Redemption Discount"
       }
      }
     },
     "localname": "PreferredStockRedemptionDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockRedemptionTerms": {
     "auth_ref": [
      "r190",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Terms",
        "terseLabel": "Preferred Stock, Redemption Terms"
       }
      }
     },
     "localname": "PreferredStockRedemptionTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17",
      "r377"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Series B Preferred Stock, $1,000 par value; 10,000,000 shares authorized, 0 issued and outstanding and 3,973 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r24",
      "r25"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r432",
      "r446"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r5",
      "r7",
      "r154",
      "r155"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from \"at the market\" stock issuance",
        "verboseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from Issuance of Convertible Preferred Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "verboseLabel": "Proceeds From Warrants Exercised"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from \"at the market\" stock issuance",
        "verboseLabel": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from Stock Options Exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from issuance of common stock for warrant exercises",
        "verboseLabel": "Cash proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureOrganizationNatureOfOperationsAndBasisOfPresentationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r40",
      "r41",
      "r45",
      "r55",
      "r72",
      "r82",
      "r90",
      "r91",
      "r125",
      "r127",
      "r130",
      "r132",
      "r134",
      "r143",
      "r172",
      "r173",
      "r174",
      "r177",
      "r178",
      "r179",
      "r181",
      "r183",
      "r185",
      "r186",
      "r321",
      "r325",
      "r327",
      "r332",
      "r333",
      "r348",
      "r352",
      "r437"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Loss",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r29",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r28",
      "r164"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r13",
      "r14",
      "r166",
      "r377",
      "r438",
      "r444"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r27",
      "r166",
      "r458",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r13",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r13",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r228",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r228",
      "r371",
      "r374",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r276",
      "r413",
      "r462"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r216",
      "r272",
      "r377",
      "r441",
      "r456",
      "r457"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit).",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r144",
      "r269",
      "r270",
      "r271",
      "r297",
      "r298",
      "r346",
      "r453",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]",
        "verboseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r367",
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets from operating lease"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of Stock, Consideration Received on Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Sale of Stock, Consideration Received Per Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScenarioPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The scenario under which facts represent plans as distinct from actual.",
        "label": "Scenario, Plan [Member]"
       }
      }
     },
     "localname": "ScenarioPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r29",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformationScheduleOfPropertyAndEquipmentDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r238",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r241",
      "r253",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A classification of auction market preferred securities that may have different rights to other classifications of auction market preferred securities, for example Series B.",
        "label": "Series A [Member]"
       }
      }
     },
     "localname": "SeriesAMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Number of Warrants, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Number of Warrants, Ending Balance",
        "periodStartLabel": "Number of Warrants, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllWarrantActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted Average Remaining Contractual Life (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk -free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r242",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "verboseLabel": "Warrants Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Options, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, Granted",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercise price of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r243",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options, Ending Balance",
        "periodStartLabel": "Options, Beginning Balance",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Schedule of options outstanding and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r236",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfAllOutstandingAndExercisableWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit",
        "verboseLabel": "Options Outstanding, Range of Exercise Price Lower"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options",
        "terseLabel": "Options Exercisable, Options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "verboseLabel": "Options Outstanding, Options"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit",
        "verboseLabel": "Options Outstanding, Range of Exercise Price Upper"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r235",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r260",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of option"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Life, Balance Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price",
        "terseLabel": "Options Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Exercisable, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price",
        "verboseLabel": "Options Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options Outstanding, Weighted Average Remaining Contractual Life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r68",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r70",
      "r72",
      "r96",
      "r97",
      "r98",
      "r101",
      "r103",
      "r110",
      "r111",
      "r112",
      "r143",
      "r172",
      "r177",
      "r178",
      "r179",
      "r185",
      "r186",
      "r191",
      "r192",
      "r195",
      "r199",
      "r208",
      "r352",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r35",
      "r43",
      "r44",
      "r45",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r91",
      "r109",
      "r144",
      "r208",
      "r216",
      "r269",
      "r270",
      "r271",
      "r297",
      "r298",
      "r346",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r453",
      "r454",
      "r455",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Accrued employee benefits",
        "verboseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Statements of Stockholders (Deficit) Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r109",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r208",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r208",
      "r216",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, Exercised",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock Issued During Period, Value, Issued for Services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r21",
      "r22",
      "r72",
      "r136",
      "r143",
      "r352",
      "r377"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Synthetic Biologics, Inc. and Subsidiaries Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' Equity (Deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r44",
      "r72",
      "r79",
      "r80",
      "r81",
      "r83",
      "r89",
      "r143",
      "r144",
      "r216",
      "r269",
      "r270",
      "r271",
      "r297",
      "r298",
      "r319",
      "r320",
      "r331",
      "r346",
      "r352",
      "r354",
      "r355",
      "r359",
      "r454",
      "r455",
      "r479"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r204",
      "r205",
      "r207",
      "r216",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r360",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r360",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r360",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r360",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r378",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails",
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Selected Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSelectedBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.",
        "label": "Tax Adjustments, Settlements, and Unusual Provisions",
        "terseLabel": "Adjustment of \"expected\" tax-benefit to actual"
       }
      }
     },
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2018Member": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2018.",
        "label": "Tax Year 2018 [Member]"
       }
      }
     },
     "localname": "TaxYear2018Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2020Member": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2020.",
        "label": "Tax Year 2020 [Member]"
       }
      }
     },
     "localname": "TaxYear2020Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r172",
      "r177",
      "r178",
      "r179",
      "r185",
      "r186"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "verboseLabel": "Series A Preferred Stock, $0.001 par value; 10,000,000 shares authorized; 0 and 120,000 issued and outstanding as of September 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r11",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r188",
      "r206",
      "r345",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureLicenseCollaborativeAndEmploymentAgreementsAndCommitmentsAdditionalInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureNonControllingInterestDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r118",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails",
      "http://www.syntheticbiologics.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "terseLabel": "Warrants Not Settleable in Cash, Fair Value Disclosure"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockIncentivePlanAndOtherInformationDetails",
      "http://www.syntheticbiologics.com/role/DisclosureStockBasedCompensationAndWarrantsStockWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r95",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Weighted average number of shares outstanding during the period - dilutive"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r93",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average number of shares outstanding during the period - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.syntheticbiologics.com/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=122038299&loc=d3e42851-122695"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-07)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187103-122770"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20487-108367"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28511-109314"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123452999&loc=d3e28446-109314"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "83",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125514181&loc=d3e34841-113949"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r463": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r464": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r465": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r466": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r467": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r468": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r469": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r470": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r471": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r472": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r473": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r474": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r475": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r476": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r477": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r478": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>74
<FILENAME>0001410578-22-000405-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-22-000405-xbrl.zip
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M4;B \E=(-L56>*+<N[(7$]\VQ9(KM8#W'X&4#:> -6]<CQ>Q1:L9N\3>LE_
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MV>*&4B \SS04 KRQ6?AV+)GQ'J/_]7\!4$L#!!0    ( #N&<%3U%M<+C@X
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M=!B3U)N!LSQO!KAPS9->U7;^V"9U-H-B(R\_7\;?Q![](E1R!!E/!O,?PC-
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MKDM)1$98H5*7+P_4+.;<)&V_,2]7:E\M ,VTY!I?^8!KL-=X) J9TQB][:F
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M1'P'##VASN85FT,<F=S9D4\*J:Y:8I6[>!2J0F4E;)F#12UP60IZ"$MMFF9
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M1:&ZJ*1 M^4FW+V72\"Z3M"29?/R&S)]8_RFMG'CN@1Y327QT^3DZZ1QV V
M47<>#^#2GR<"%,)N4M3YVA7H$^PES+;\]#!>:XN'K$H=PFG@W86!L_NE&C0G
MS'A7'(5_!%,?9_".T\7"<!!XQG<?#CJU0Y$Z&H/69>L-/?+#'_^=.E&"(G]#
MD^H<W\^@*:I?DG,>#CW6GB/=L:VCE;J:PY*]^RAT[8FICMVI#S="=0#-[5X*
M"&6[F2(B$':WZZ! &-W@-?*N@X2L?/K4VS2.$:U%>^O\&49=R:.*HPCB;)7'
M 4NZ':B=/LH>(_4E(6\L#0',?44@' R\A5!G163KX<^]D(2@+3X/UA0*(XAJ
M5NR'AA  JJ =%$?I0[;1M$(_=H>#@+919Z*?)NB!' 0ML'TMO;@0%J;TL1MW
M9-JPFD/"5R+%J-U< 6?MB44"^K=RBMB 6$HG:@/>SB1B PQAI1#(N(=79AN^
MKZC9"@!2X@)+]5;=B&F4>1Y)0^&TYGTS=3!K58G:X$&0YZQ68>HF*:TV<A'&
MM& T^0U%:]'U=$<O03IS9S_;;N$:B.+UP&O?X1[F]-!3OU.**:UW.S@@V:G
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MY3I($%'LB5K!VN_;!6O)L$?N;MQ).;#EHK6W.,@H7H(CJEW+:6M%FSX@GSK
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M*$[" !5BP.!$NXG-F.)Q&-#&$5S1BFHUG?N(4. >1=EOG*.ZH+W-2&3]_)-
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MNMC'>:1$\AG1K!Z?FFPI?3*GUIBS*+2,;+NJ@5@6M*(*SOTA@U5FQ$\#[X;
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M@O9 +B\ZY*R#,Y N-!K@B6].V6TA7&QTBIB );:KE._? Z6<2XXN975X>A2
M"CL\/6HTLF-_GA[]S0WN([PF1Q\NE=M-K%X*#2=O&R$(>_);?Z+G0[_MHP]V
MT-AY>'QGO-UB1L[MT6<<Q0E5!VZF KBJ3-08@D';_>B."(.1B/M([\T\6>KR
M6D.(QY$D+P\%6^;J [VIY!P/*M\LZ/2/_71Z W"K=&5+<_,K /.])04U2MJ6
MT5OG*UZF2RXU&]]M&^@,UI?D;$ *P98X3V,<H#B>NG^G.,ZIQ;<#N:TM*(CO
M^BF(3E2@<H7^,T)B1Z=$/R#V7X?<=7&J@91^\^37",]#/[X.@G M-DVX+2%8
M?=*"5%HI7&Q&*&R 7I^0NPBR6S'$=\5PVD&P^I3)R\$%@LYI*,X;3CQW=W/S
MD=VR*(BN4?8\UENI\&)AAUP0M")R[B:_/*%HR2NBJV=H",M513[T8 TNY.-0
M8U?>8:A//@[%<_>W>*Z<(T*CK)BIBLNIHE]]Y">-W$56Z0JS*N\)VMH,_%;A
M3P<:X!8HP]S<"<=L_EM(0Q"OZ4/I*$[BPA)M\F[H8#8#Q_LLOKYXCKW4=B_8
MQ5?DY)M%CV+G&?L$1.:#.9T]; :.*R^[+F3&)C\QV<F4]$';P$6\,FW,5C;C
MPI7)S$( K%XC^^,S@33+H2*F- &<X%93T*6(-(OW#AK)9GSY$(VFA.3(ZXD!
M4_.)W/C1F:.G\#X*7<2LY=MC#*NAYZJ+L0=^ +B6W0C?DV_DCTOJY^C).<8X
M9KDWP&DT $< '.S),-/\&>"TD4<) #O.?6>Z6D7A.O,P]N%,;02S3!K@.>F%
M7:_<G)^/<ZJ2_SR3T]Q__G]02P,$%     @ .X9P5":@J9P1=   M9$& !0
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ME;!0JF)@O*TF"D  %=%RH5./"G(E_D 4!]VF;CU*U?@%^?,V?\P^IT,"RI#
MJM%G6JD8#1B<6G1Y&%0*BD"G&HH"HA!\BAN42X!!JT*;7;4><!A )9 9&-8
M#@TQ^'=940;)_Q/OC2&K&AA8$92L*]6A!0FG% HV!E6#XR""Y#($I2YIG>-
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MH,XMP<B'0G'2(DOBB*T>:B3V1KW*ID< 0.^C5RQ5"6FRW3Y+6>:H+[$NZ]@
M#M3M<0M!VI?"#0@ =[T'N>GI5G6=M8%%OU/H7DX4A^K4X?XRVP5QMZKE "R,
M^A@9E]5&">A<70Q<#*H)^IV#0^I)>T?P \L'8+5Y*$!]V%INLZW?3^9PP)O(
M,A-#6ZWH=PX-J2&U0[Q(@J*XW3#&;":E/CSPA*030#D9=8'A)B(U)_T AX*Q
ME#M<<Z!G()EMX_2C @1:&&I9;BT'>U#N%X$:%@:5 G["X:FIUB/F'2,&D$L9
M%J+E5/3@[MW*$"_6*2Z]F)P8;^>CM4F# :E-1B'ZVJ0$!](F R_6J>FTVN3F
M9'P.07PH/W%5U6<;V'TRP .7F] )H"PST06&*R^AYL105D(@>)!"=;H0%UE1
M)2H7J)#Y4_^*4\)8LDZC=;2+TY@*0?-)5KQII!_$@C$(2V%DLQA <6X<5OST
MM*O"8EK5QA-*!F4GQ\L3M/! <\45F"CCELARB5]PDNW9EJ?14 9PH#+$60C2
M3@YG0 #("S?(C2(E',>I$NG66(N:QV  =3*26"6U.U*6J,'R*2BTG?^]"0*M
M@C_XH,\ZV(/)16'++T\^88KN?%!F?NQ[DQ6#ZBQ# BMTGVFE2C=@<$K=Y<&@
MUAP4?4N!>U=4'>OV(-OT$Z+#X\=Y_\<LS=J\5T8VL'*WP(/1=6N!9,T?1')N
M!Y8<J5(<9CW#J%"_6WJ1/QB=397JMMSB7(@#N;:_3E]PP0JC<68&$C#JP:&N
M5YG9;]^O4L,"7+ R,=+3E0:\4IC5LDD)+0+YT1+PSRAFT#[.#F/MV[O98-0L
MX(_WG^+U82*BL2)44;_DZ$&O(V6;N#0$]S( U-6C+HOM"T?B*\ UHW;3?67%
M93MD]RW-K,7[50L1$_(9QO2LV+M9BCVK"F(3&70Y]>&R6<L=D8-[ AV@J7*J
MP*TI="P1]U/K- Z'O9C?+FLVL2U3Z+MR)7,.)]N:48SBF<TP0KDFFW[QPJ4,
MN@M85S#9S"$KP=A*H-1L^[HPWCP,N(Q?X@BG4=%Y='6]V^NW*L>1\.$A@9V8
M^@<&9GS@AP<VS T^2*B)K(1UUG00)S2O0?[,I4SQ,WVX9XYM3U[8:6E\CA25
M/:5%01CFM&)H)(A-<3W%:\K<R=MWE3,A/W33/>9QB-?1?QSXMEQ'0 MXMV["
M6@#J$P:!%W$ 418>*'%VHC6V/W5[0EN,@EUV('J>XSWABCUJ)),6PIL-#DOZ
MHF#?T: ]I8R"FO0R)0E5[FZJE%US9UBH07/MR:;*<56/B?:J_EUG<-SZK>,'
M2*UBL_FHWX(\#^@-'YR'<8&'G=00@GLO92>"<%-F:! _9</2)$?UF1-&N*(,
M[*DFR5DA(8'EA:^:)$GCK'X;&A?76QL0,H%MK+X$<<*W:Z0L+%6-H?.@B,-.
MYTRFXL$.B+VP^BW501+ &ZJ6_-GLLPA2=*]"SAU445LA1L^#C9>CA%9NS2C$
MA4SB4175%JDD37:I@05*XF%BO)7$0P7H/HF'GHN^KQ=UV.O<HTO:@\5&_!CF
M:[VOF4=G:NX!M?PR3@ZE-I>B%MH/3>\P;]+U"A1<VUM\6.E[A>&+QIL%4.H\
M0X%]@O4;CI^WA.TUD3AXQA\/]*WQ[::7",_D]$?2@#&128+*AC.*@'-SFL!=
M?WE7T4 5$<2IL"V=7HI#X/EF5GF#2MZTEK?@\F8-(10=<OI_=%7/2S43 WX"
MGK0TO5"Y(MOLJ*.I>&7!0\):V+".A"]6;.;O6#L&GD=GEGFR+4?PDW%]:%8E
M56K5:AYXD6.)"YS\S$8P92(T$R)<4K1AKL9D@)5I-57IX2MM2[L:QJ1&"CCP
MU-KZ!$8](,@DVL8</_)V$'""HBDL VKN.HIB>M 3)'=!'%VG%\$^+H/$J,4#
M.# :;26(K-U&!.>:;L%-3X4:'$21SN(456C -C!)F+OK"]!$*V40IS@2>Q9&
M ] !0Z56,;'>SJFB@@1(IJ)GHZ\787C8'1(6#%03_K+:;95WY#@!8!\L*NY\
M&[7=C +V;'%0C,[+12T\Q./% 694KPI4=^R!_?PT0<XN%)+(5M*%D:/^?X)<
M?(H;WZ\/08(M,FSKX8$6F4,"M!:6.F#WBTDS)_V,GP3*HP3;$M,?@QWY\S$/
MTH*L?TF$9$RX;8,(I$C6(K4T:A#+O6I9LC2D8_#YNN_R^(5XS[LD"-E^R4")
M"#4PU-L.$^OM5QPJ2(#W&GHV%)=C&3"JH7W(Q]U<E2L>,\UR3=Q2P!&MA(*)
M65 @IO"W>Y:6Z1[_XQ 7<8D?</X2A[24:IQ%]SC,GM-8<7W4>>M06Q%..[>]
MJ>&D:8#M$8=R*39:ZM;IY;/.O@MJ]EVJ2G=G3Y0+)+.QJF:*BI,5JGE!%3.(
M<X,D=J#6M["]S6A471A*M&=[1< :X$4Z+]DQ%^=L77X(\C]P>;O98/HKJP[=
MZ:'QZ.Y?&$P13[PW&(,+\OI@/(.Z\EXQ>W9'8SAZR,F+>I-_I/AS]8HE9JTH
M3D*#DOUKQUHD.+Q)MZ\39N@'[I X#<2)"!^T+A&G@P0A7LC=_7.DV>2L1O.0
M1CA'WP3E&1G",SZ$W]1CZ-K%,"<Z7>H*W5L7TQ)OI(MAN#Z[&(G!_BY7?;7B
MZW(G)IG'N1-&R5MW,BRGE3M!WY+0D%^NZ269<[C8JQ^>M]]V:H(_+33,8FJ
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MPWND+L-7M[3P?BC,P*4L#3"XR@Q?M^KHC =.\F@98#-;-:],V"7AUR'5-Z.
MY;,:%*.3RDH+#Y'%:H 95;:G!F7%;W>_HM^K_P>WB D2W>5Q&L;[A%>M:Q$
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M SR,CQT40/:O6F#GOG6 DWZX1^'I?GB%03?3&0[\=*T4Q3A9&S$\4B/]1&T
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MY)MHYWP#;\&^>2B#O#RUWCG'SW&:&CK(_2%$5SBQ?"NN4WXI<LZ]&8O&3NB
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M_&H1_LXI>U/6F)<_K80,YY]=KXHRWM$DE'5&DMO-=1H=0G96V]I@5CBD4=@
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M,54_G*B3!FA@W,^L6D;%!-D#<)K47M-Z;UPO\^]1#3E_AN\+' 5Y4<1I$'_
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M]>^[(&*9<@/$:M.QA&WH\S8F6D%0* -$'\AW.IM)$!&F9W\Y2U.+"IR_$)M
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M2)WG8 @!)MF!'5='9#P@#;#J7*P)$F_4;5# JA'':0\FRGQ1B<(QD82*&ES
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M*J@@Y:?S&)95$3O(XR>+1?ZN6;@A?Y$?Q4_D?YZ" O_;_P=02P,$%     @
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M@!+J;AA'(7U5Z5V\?XV1=QN,BES:0S?!;SBAUBW;1=2\(;A4$:/./*G6(3N
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M3G1%L [)H.AR\>*HX39X0[&.>P6"AL!Q3?>] E79#6_/NIJ^R$ZB2$+A_KG
M$2)Z(J,L>1_[3I , X]>]YK3(KQ+"-(-@*.4)F8P+BFTTXD1/U#WT6#DU=UZ
M%ML=JK74B:Z+!$!7RAL<.(&K8:44- 2.:[I72E79C>8/Z6R=C$(7(2^F86?I
M^3G1"!I-^&'DI>N!HX\F%C"O[C50A=$;?5TYQ<NJ6,N](+CLR:VRFQR2T@*L
M#%=;7^U:KW*[0ZV6.C'@<^@^L@]5"/U?NE]Y<WRZIWE$-.:Z2S86] >REZG^
MH50RBU^X[BF\_I&'5"+_>'6"*7HDUDH6>)=#UNUV ASA&YMS /2F*W48<U!T
M90JVTJL)CG]0EJ\&3:=-HF!+'SQD G!T!CP]XG9XF*M!T^D7/_);9UZ],'")
M_"N'4^ M3:94Y74.%]GZ]K"KG<B:LJS!BA1>R3"6Q@":T8M.V9_)$-OGS5=U
M]<"QIAWXC*FJD08,>%4T7,%@Y-U8W2-GW, 0EK<6^6:2PW*$,.%_1,DB"F22
M]W)*6@VYBLQZ8RKH3CMRA<BRZ2U34/^&D]<+%* )=K'CK^:S&^00B5DIBM0:
ML)H5&E1ASV7/M7OVHY?$(::9=QL4[HJ;,%K>(1+>[]/0HK6T,Z4;35MU6*[Z
MY<A<6[$=[)%OX6 ]+Y]TO:H*C[N_7ZJ;7LTT8/B6J1Y#AY5N76CHBBM82X6&
MHAO)0\XP@DP&5[_"L>N',5FS1]'4"?('TP_I*CZ:Y--J&,1$M1=.C.,T:>'R
MJY\J*',"KN_OD?\9?!ZL/D7^H_RU?Q]DWZ/AUE=?'#B!-TB_2?]>^6H7$VRY
MPZMP\=E;\W+G1I.<@HZ_"B0O$;%=2_O?3D^Z2G+4JO\K:CP3$EWX_'LNNC\#
M9DXSQ(7-]6XK&C1ZF^9@NQ/CTV(V<Z)WLB/&TP"3'0^]6YL]D$PS]OAD#X3D
M<D_L[QUL3H5Y^W26*WUAL/K$8/F-3J*";8A:%]N+6X%29>_XZ/#\Y.S@8/_T
M^/SLM*/92@AEW1PD5QG,S-(0E\V9HX7<5LT'R$?T..["\>G5PJ=71*.-3,)H
MIF(3'3(F@KSA0=[R(&UZ4&Z[_9Z TVO.F):JT<T(7LSG?KHH.7ZYARN-UH]C
MA2; C&8%#"MCMZVL1D?PX99',-W@;\2O(_9/O@F47<R/&&.8-OTY;7M0;CS=
MS2R;[\9#M-SI3<H]RY]37X9Q$J>!_5YHYXNG11([EW8-?]OOZEZ+=+\OROVN
MFU1:MEH=>R<PTEUI0)CE=].O**.3U%:2W:U-4I4LH9*STC%G5LK;^K^#O#48
MB68?P@35;"CJ*@%)F4L[)>_(D*X/9D90PU"<\%9%5J.#>LM.UH?4Y\)+G%PS
ML$\V!S9I[W,I-_!@V6)75_0VA9.P(,05O^UWY26XQT%*DZ)'\J-;HB:8<:V(
MQ.;P;BJL34Z!.^S2Z(N71''.2TB/,-YH*,8L9A&U7(;3".4.VH!N.V8XBUHJ
M.?9/-\=^_LE_'U0^FFXT5I\=K+Z;_E+^LH8;-B4;KK$&!*X'K>UK\#XRE="X
M8[Q)1$^C8.:7[0!9/<TUI#Z;9JPL0/*S\T/Z[.)L<P[*&ADD:2L=Q=W+I%AU
MJS[8-;]&5[$#UWM49U^(JE29>]K],RT)C-8B_ZG)MIVG^]LZ;'R)T9\+TN#U
MFX)Y<,XZ5BQ:&N1-=>.FK\I3M]7G%N_HD*':G?H3!4YY<&.R#I?JV8&*5':-
M1IFC?Z4K (1I>P?-KP ,_E+\ZZ]VW08X.SZO'*EM^578ZAI,VLWWNI$NJ@)N
ML"MBL#D#*$N['4-YRS3Y&I/=RW6<X)F3<$.>5 O91P4)^8P^ 5,&G[EG9_NY
MQ$-?NIX]H+<3V6B -CT\>,3Q']0#\#5P443?E23%>BZD@4PUNUC06&)=H5E
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M-4:3A7^')\0"3UU%J>)$5JELU=Z.^US+58NTE=0V7<2MB2>@-,8/&6.\-JI
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M2.YQ@&>+&1>%RN]5&?8!X"#0;16)>CD 8.'\$&-1_KW/6-3*871NTF<.WN$
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MQ8+\JQ @KE4Y'R6!1";O8*:+..T#D?24>P6/40JL[@6*K-Z6DQ5J2^K?Y]^
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M#EK2*[ZJ@":AD3#/Q.M47T&0DDJ3!TC3-'<;N.$L-2_31>&.?HIJF;\Z"FJ
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M#X;NI>8T%:%@S6J&'LH" +"UK:@D*?="D=T/7P'@K(83 ^=F(L,:Q@W?2D*
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M5! <CFHX<&V1.A$A;APO5ANNVDB7@AK@()6$A+=AE!<2%JB7X6P6!JGP8I?
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M_6..@ABE5T3+V[O?</(JH):F5JTAG4E]&,T6U!T=8T1@>1T&WA5Z0WXXIWN
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MDFAT3)N&+-DU4@@Y ,0YW)@#%[XSG,^C\(UVO1$=2BWL&C/J1"](8MAARXR
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M]6*Q-5.[4[XSF708L_>46?@7%6\O4Z_'>"TX,(D0@Z8Y>@(<=A_U'1Q2#AP
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M<UG3Z$YQ.N^V0*[%P+YA^-8+_.5ZU6G91_MI_4V#&_P#\8JJX"YJJH2$]*B
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M=WFHI($"T&H-/RQ_;KGVT/4(Y+9+K1LF!US835-NV[SDW"<:TR8DW8DM/YC
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MOS"@CC(]LN*@3Y>*'F(<&]^(*)@0B"1OBA$72;HM@FW)^VK)P=6R>43?M<!
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M8',\T4+P8HOM!(T@BF!N8_/@WF/]!2T#B+]Q<+9M*9*G7B%SLQWRRF<>8##
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MF1*_+A;KE !TO[.^>4Q]N=545WMPJE-++LAN#?CTE;=JN:XDXZ2EVN4R7,-
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MH-3A'))Q0TZ^O:,VIY=CIYZR\8S !10!/NO&55A4'+T%[-U].W?!*1@02/&
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MW)E^N!Q?YPMN%@ZAN :H^&[WJ/\4Z<>I-(A]A#@X@RD^)-CM)Y@< K<UIR%
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M(11F QW-<4UP / ;>(RY*WD1O"?6)V _A)*")#*FVESI;?4NU]4<1PNW=!%
M]")BSO #TVDJ'@ Z&1H"U_5Y_KFHW9E_75=DBUA)F5KF9V0P%HNE@-K> 5I:
M7:_</3T[>=<[.SU[\?+MVP!OBX>'53?!1MJ,4$1 R]7_,V+A#K]AX;YAX>[
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M:%I .W"/-2#QQHA4Z^RFTT>W%PGONB*4#K![WM _LX6!)Z6G!^*+7>N1NE(
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ML57*C1-:E(46^6M:Z+*NQ0<7?11O(*.#;2_C.9Q7<V,5':[T31RF<7!RF4+
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M@JC;C>_]7*.!1R'Y=3A]@O5Q9;MA1-X%LFVB/D1/#\.<I8Y59KU1HBHF+>S
MI=&%O&3S)&RB N]/(ZIX\_I26H<X:V,1]%R-119+@ X]T0U"F#@IT7YE),BD
MQ[W6\KAX;G./%8B:B+DTK6^4%N(86<+&N8;UA3"_5X,<'-5 P2$B *O<66O
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MROU:*H/U(5H1#&P^2H)E:SM8HDYS^M\R<?Q0RHY^QR*80OD:&OV.FW/6U!G
M8><Y8BMI\AZ9RK4;]=44N!M-:QCV>FZC14_32WSG2LD]_O7J-NC[@ ( BS\R
MYYT*AT@<&/D32;?;K89^,MA)]P:'Z<[A@0D=D0^-"HB=WTD4I-9*L@EG>^]E
MD24%&^ 5XQVO\W(I[;)]2J9KU>B:%^+I=C+?A=W6^LD[5J]W;&XL.UEQZ\R<
MU2#Y'%K,H]]5KO[94M]'WU+?WU+?CS+U#0#,=26H>[IE6\6V9%DDIITZ?)!H
M@KPD63)RAEQPZR%C- ;"\)6T9<-Q8X2&G9!93H)AK VJI%X3W4GJ@HQ[8&#S
MT:1D78XO;Q4V(D>$BM<L&/O4Y*.:%1J>1-]T@Y]S M>)H**\0D2:<X<6\/(O
MY%,LRD>E8,VQTINJGHYIRW)&)#=Y_M$*LQB;2;]GS!UG:NLJ0\J*#7H7GIIK
M>*J]3L8!,:)A%P#NR?JX 16E:_&3&O/ ^O*L?.RF7<(F^3L91%9SH'/6$NQ?
ME0_G5\;R</:,(_H$W8VXO- \$(M :7 M&_W/LO"JDRS0[:\<]ONUI1]JFB8?
M_,Y\0$G@%9TE5]7PD+49[TJR'*]!$XQ0P>[.8*>S(./6\2=;08[[UF^Z3K>N
MCL.;\<ZZ1]LG1=UY8A_CCM %C5KF,F2P'94TZX]OL 'J,Y?L5"FE9(<7NSL[
MSW8&NZ"G*1;@G];7O>LV.?FM7%1'8D,J#!SNP:KV1E6ONBG5&==C(%$M(2UR
M/$4=DSQYMS9!-GP\_5C./=[IOV_?&6==LJMFPT";F5(GRML[Y9:44DE97!>+
MY/NDKE;9=+$RH5B43,,5])YGZ+LOG6,8KN\&[Z"*9&@P9MU]T3F 7EJEOE@$
M-N5*L BK!"4Y>8\,"GP[^\PV)D<1L8ZWC[G2&AX>M0/.ZZ#)6> DOA^\/R^=
MPPO*$NV)+HS4()$K@?!;GB%8:A <FPIA C;AUJ:_K40(LZ&K_SV#&L/V0P<[
MX!9J2?.%X4>A]0K.>G;TR>L81H@^NOWD2&4'=\]9SO40L$\4\>+K-5(UJ21(
MC3"."9L*JE#M69IAS@NG2UV62="W3)TU%&"2 JRJX+LH+<$BT8)?NQ $K0AS
M];2(?>RL&[[-R8$Z_U1]S,,%PK'B-'G.13I#L ]S#P;)3UNC^2Q1W@@XFM*$
MI[;?0+[P!=#Z(+^TMABZ8+<N>BI^:^L)G(2NIO&Z6RLJ/G,V5QH/B0YF_2);
MNG$&FBN8D=URYX+7[>YA)8]!D=*\SCE&@<F\E1D\L.(\1P7X(;3FS@;V.K6U
M<#Q>PS>FOZU-(M*>F*;]_1:M>0?Q7?S 2)5D08#4V&-G;DB![LSLM$ W'NWL
M'!X>M'3CL0\G\,"L!Y(K\L[H(DLP8EQQYV"NRE[XN@"V?>G++_=Z@V<?#?Y?
MU"'S6128B%4MUU.5I5K/BD;QXCA!0ZJ%@.)83!3:N(/4BC!&@ZZS&K>DMFL;
M0))L67('[CQJ/CIU*'VX?/P%Y7WS=\P5TZ-6WMXG;^_<XI:B7NCWUA2UTW!7
MK/_&U7(8Z#_#8I%^8-7I..Y$:3EUQRC J%UDL%3! IJ:;;_&U.MT.:.;MYS%
M_>F=/&95*P"!X*G&(X""5R?(F>M33+0I"'^FH$!8*!GM;);76JT#($<E=9CY
MU1538W@+<#ZMBD6'>DIEN#<%&FMA6;F^3[KQB4:0R&1P"-:WZL^G#Q^#U!;%
M]*3SS#^X](:'L<].SV&G^%Z_I9%DO6UNL<@.S7^]VND7>RZR+EH[E6L+FD;I
M"9E<8A[0S#<:P\^ZLGC)RPM0E^P]378'A[O]H\V"';%F-98]0+UGT-Y9-<T7
M*YVK7)F[)%NX%+P,6:/SYFILI4QT$J^9<'KI'@Y*5I8(:?Q(LN\R0RWZ%F/^
MKHJ@\>JM6[;]^_@V8N>'HW6B,/(G5'[>_B@8$-JGYX<NR1P0K#%R-MEC0S4L
M?N8C9P7OTNM!SUOFS=!9,6XO=\C=IJ[H'G;HZ#YOV."OL;#B,+7*V]OV1QAF
MW6FZ8N.[9AC)5?$9!:?J.$64W_97@)*XP4@\3IO_ND9TZZ_7A\F:N,7$4OUP
M8*'=)?L7+4\S5KH9W?-?\VIZE&MOJ6_>?,K".$#7VA7JN##O.:Y"L=#=NU4E
M;17;C-9=2I#0;8#3<>S /N?X*[YH]W===QE@ ZC&9LF$-S@30RNY8!&(=:2[
M@4YCB^"S438=:6&NW.VI R''=L,<A HE5R8T=#1$(3^7F*_S^!>L*<']AQX9
M0'\NI:)"CY#;98X&:TB47J>:7*.TON['9# 3HN:N7=G0026#N&YL&S#L":-=
MDG/@2RVP W7!Z'L70G)19KQFJ_BT_?6L ZL+TC(,]",;%VKG\DL*/&)K;V>;
MSV[+N?:G$"#MB5$E=/G8M]]I];Q5N$0>=F"<T^D1(9,-08D"#X,;"VF4L-40
M/G#;-]QEW G_I:R8*4%OAP4I!21A\:V55#3B/B^RCSDP]X$7=4.*KJE0;]$E
M->]>E*KV<8"VR\XY@F4]ESY*O-O2F ZMO:68C7M&W?V:/V>V].FW;.FW;.D?
ME2W]M6[/)>)N'E-DG>>B/!;;"(_-)W)DMH.#6_RB>!Y!R+C"?@K5:9O""[/5
M$%B9O.,<[*88V#V6:3TBMF')'<HK?(']T3W%_+(-#WD%>:*F4? 8_V=7R2F,
M>]="(.;&9N]+PUI0"]WYGZ,=^76FA/ 2I>&U9#7?JGSK9H85NS.HV-I,ON3Z
M*[2Z7+(M>8\=:+EUA3:QKY6C@XLN85S([?R4&^#0:#C SI@K)1*K?%:<MF(=
MI9GWZ]))9A\X=[V5ZI6TRRYIC'&(G+P%D5#<DU]7TAB)AMJ9S>=Z1[C!X8D?
MN;5R(<O(& $RXG,^6H9&A7<$N$NALU-^R[2',NW@6,%YGDXEG&G 3'2,LGA#
M&MB70D_E? 2+1%CP@2?!QE'7-KNP+6UV4T"RFW4< C_O-XW1-H]3A@[+'C\)
M+N 5SM*$_BE]J<A0Q.OAAC6</MT[W']^L+.3DL[?3D,WQQ.MB4NTD@K,D672
MY@"@TM111EMQL\!B;,'8,&V'V*%;TO:*VQR#J^O72U^$5Z_E_3C7I[[*$(VJ
MM3U7.8Z>00LTOF.!Q)]R*W1#CU]M6JB]75DH8 3SEGO:VN-D7GQB4G-F/4NM
MRQSS'((H8J&C3STMA*=)CS@("EXYP1#QF[SAK&7'O[127=85Q8;G'&$=G4$V
MS=^VKL>\J%;?1__ZS+Z[]RNN@!W9VM^V"(8]5CQS*_X.]W>2.<8XB773>>3^
MV-R#,-YNO7'/!8"4QU*) 9):HO\;9)%;'.XCLPHD4X&.[Y+=TWR"4X4(+>#5
M@7CACF$<@\ [-V5??JVJ4 DOKJZ Q%BB2(L[X?AGMI# 4UU+T1L=GM&572VG
M5P7H]-/;@QF6]-)>N-Y=SKR;C"LI>U?4,4!*KNR4]'(T/#042%UO'FTTRT\1
MCVPUY[_(RU+A"\=7Y0]2[8=WN[N2-1]%&][4Q4([PK!/O@I^Y^P4_6<AK4E'
MRWJSX[[I5.,O>!?):2Z]QP&\81\2 :5'D#KX1]9@H18TXH#K]7(TJ2HNJC36
M0VYQ1D-^6RUI/381QSX*B)5 +XY2;7=VD[<-ZY:1YV^S 8-./AS'IN^O6R5[
M7.>OW0O"S@5&G#M\LFN<ZSUK,Q72U$H\ND<W!>1H:<*4*\.JIP6BB.JW)MG9
M,LR;M!W-#A0.7[GR9J  43'56;-)$Y>Z]KU#4KND+E@/@<>'=/PD1]??>55P
M11238#-C/RAK:=7?G'R 43XJYF([A];_)?2@K56?UL^@%%+7IZJ -HPWFN6]
M0%05CV(DQ?K%2^%O!;FYB/+N(KR -@DRFP0MEJO[%+#DFTY]G,R!A41YJP4_
M[LJC^R&Y8"3J<&8&>AJA<H05TF?^(PWXN[UT5PPOYI27P_ZR+CXF[]'G93C,
M2<VGJ,N^RAN=N3N>#(RS@W'*_).0L!_\9IPQ,P07>9Q*/Y@&,;ONJ:\OMP/,
MQ"TX(HW-ZQ"J,^M5L>$MG##*KI>YGR_0'<EQ'S>PKO(QKL>Q(;.ZIY[2=#X5
M%OXW#$>:O$#7*GI<7=T$RQ"HV7SY,9\5V8,6D]'QCK5[I-/5 +3,1DO#>_ 1
M/:6?O R3X#"R7<+=ON-!@O&#VT%NAU,'6K#+HG0]"ZU94&GA\U>GQ\\#6+EZ
MM2TZ2C;?Z0CDS!PE#T:_@['KVBNT.EW2J-4*-[AG!<L,9DF:9=?DA2TE[(]C
M.^:7Z]>K.3U!)A,!!P+>G,#^>2ZI S<EQBZXK($=_Y;(,G>^;:Y<985P8XV6
MZJ#H<]3XV-N1E[#A(31;G-B<"Q\FR$8%,+^>,5C?;;>-/I=8S)04%9TMKC:)
M/1ND]H0+M[S4GGOL?#E!%TT?>9N*+F'J!@(Q&N!]LAO.^BA;DI4G;1R.(T3M
ME#_#G-._XQR,\7"DZN#X\5X-]H,U-8M-EI+E0/=;UU"/Z^N[_G1]:G%U]XAQ
M?8V4S-99_0CNJ1ZKM-#SX:VG-P68W\4:E(:O =RS!8SCK<$^&[/JNJ5B& DB
MJG2I0QR0[C$_TK80YR!'&DW(VUJ0!'O-S()3[Z:]=+B0=W->E\<6+#[/5G)X
M=MFD19'UFDD;!LOXOMTQ:;-,SU^_<78H1UL@A);:)2&(XG2@9Y@LKJO21EJ:
M.#!% .%FC(<X<7=6W5OX]O@B-)0=5?)U!G*ZX"E;K\\DP!RP)$^8H9VLY8*U
MP<2S[!?EU32;A?4]2E%\G?=LP-H.#SG9*XTM<LUESIT6+&;'K(@.":D8&0D[
MF3_/RZ<TQIZU+(A!&K< UMH5TFLEER^1RK7"B'X0,&@/R;BDM:-U2EP_3N&0
M"&@4@Y=M-*$#6,I-+B2<"M#T>Z]9^CAR$H0W;1WD"+Y^HT:$QQ7J0!P% P[%
M&C>T[RVD?3UDJQ!%'SN3M(7#SZZ96^?4YX$WM4&Y80Q3M2R9H[+DYK9CBS)C
MT>\Z^.V;)M.T\O3?<">"1=$&R F'P)*K8EB#F!S[VN1XN%N($(3SX_&KMZ?]
MQ#'1W^1."^#\TAXT&DV3*?XY,]//OF6FOV6F'WMF&DY;W#KI0_XY8T\:!!)%
MAY4A5(2N5:6KS7LL9L@I>1@HXA-;!(&UW9W!;E=X3?D>;H?URGK<D7'^Z8,M
MUQ>A>%/3,VE(4Y-J!J2%=D<MD:'37 @G*-(-A;7K6I $%+Z^1Z>J_VDVQ*A<
ML.+O>5D67.G3AS%79O5X8[CB9"(MCI*7RBS!:NWL'@[5A@7%_G""II40M8R8
MJB"WTC\$@$K&0#<+1YGW>:X\=%";@@,.OOK= 4>EL$@R;Z[=XH4F9\'7?;<P
MJU9!'9\OK9+=5XCG=[L'\FQ[7?L\ZO</K%BS>RUB:"NG;/P1:Q6!T*TBVY(;
MT[NJ03])]NIT;L[0LZYG<72<UNN[P<Z=/]OK^-EN^+8?3X^1@ID5 F+5P_93
MR74SEPNI88_?Y&"SOG>1MB5RK8VPOO&/0GYB^Y8P=QXWW-&2$96K#JAB(/'6
M*VJ6)=?'&4!;ID2W47LG*9H<PV%LN<10-V/,-VXQ+K<SA&GX_W)45,-<6%&V
M8! IEPGGOJH@I>[94+:W-T'M?TV-ROVGL/W<A8P=)[U/+VZ:]SWJ7Y9L0,+$
M#?"Y2AG<VC[)YL71JTUOYB<_)#%T5U!]PV#%_(<4:.FLVQ1OG(^XY8OK<*E@
M2>?+NEDJGL'G!MO!= ORK&DD\/QWJR(?X)6&4GH$U]6/ZIY^ KY4!&Y*XXLJ
MM2I"8;0<%O+I#(9 #//P?-UU RT5H_ #-QOG/X8T1X%CY'5I@.BEBUJ+HH\&
MQA'.N<!'HH7,M%#A*O>\2URF$:@EB/*]G;UT]^F1"YVIQRC_+.JQ_[J(?C!7
M[>\]%9&YM_LT/3IXFF(X<]%G4ZT\O/4L(?G++B=31B7O1HO**;'=75%B06L0
M!-W#:RPJLTK^3G9-5FM@2%&$1S_@B9?Y?!$H1GGD8?#(R-G7%$+7XYX^Q^/"
ME*J.[^B+'J9YV.?M9TE%V-,O>=8N*WF4I+)5 '[D]A '3R5&YMC%K!/5_<:Y
MN]<A?$6YW;JK=TE?IR8LLKRIVB-%,]'\*D,"U>%V%%/1G=6Y_;1)7X6<6T,L
M2X$PX$X<WB.%D"*M4R%()CTW>1+<^RTK/];+^6*TDLQ)4TT_B54ARL0K&OHD
MC[3-@A,[8-H/^H-4Z(KMKB99EGR5L]H5HE@-CT?X(2&3TU]X3&653*4/)YDG
MSX*9:7FP2XG\)%F9<&=\84F[QL-+%)]:YJKD(2.BL.R%4;M)_M?7S*JE+&I[
M7&D(1@IA61I]=N4VUI9%Q(X2/18EVS!=JCD*YZ^)AJN0K$*5"0HR;OO1@^EN
MRU"A<*IIEODX)'>,?#!C4S2CUU@7&>(J4^$CNG6[6P[21;C1&V@@';>CA(3Y
M0X#V8H9$?&2\A]80SVU<R$;C78M,FCPU.=T33F/YJD,XK*GIS'NM1JMWG16)
M>X-@!O;XF/_3#>414$Z=A\0(#TD;;YEC#KQ([/7!XBO++DJRI&.$?,J&CI^>
M#QZ0ABR4LC%*EQOF'FZXU\]PY6G?$NM)QL?,F5K/8ST7\U88IUS88I19;+N(
MK,-A EJ@O6:2*7C%IS0Z;;&R7J_OF2E/WOU\=MH;/'.V[O6T&@(/*W"=T02:
MC*\]-!"N -N!*F-! X$1*_E<:R[9".@FXYD)0*_>:_-M6L)]$,8XWW*&G4SW
M#U?BQB.ID36O!"$X[DE"W[".83BJUFMO_+ C0:B7_.L\_'DJF2_/MSP">)$[
MTF<WSCR@QZ%1-595&W<R+2TGQ_@##_"MHR:UK6XZ+5!]&RL73/;$Q="098&W
MK[6 4/'<-!N'#:1]TJM-4C^L1P684 EZV$V,%R/8)34G6@>8D]\K[V.].CT.
M: P#O( 3JY:OB[;&9<K;B[MI5JX<'9.2(MNK99C4LD@6#T@C)U$G=;MZS1*]
M/X!U:[VBZR(%[<@D)ZAMWD.D8&N36D_J^%7K%TV0?I)5@Y2!R^G*16B@4^-X
M\0?[$SAG:G^?6JS@0;_!NR<J81B3 U=+?DAX-*V7U?JQ?+CP@X*[I2.X$'W_
M44-1M;'6^E:[2+J^<5M,-2T#376,VU]?C6R ]3EN)NS::2!<(C,@><?-B7\Q
M:-G)Z?F[9MLULR.ONIY5R2LT\B(U]:*HWM.5$HKIUWEY]N+EAX#*5+MQC:N\
M^0I*H>I4S6D'P?L0-*<+>:_\(M?X!HGWB$7;>A3K@DH[LG H@!'/,Q IT0>.
MY(B!L_X!#=R)/V,.5^VL;SG<;SG<Q\;%W"RX]2LNV7D&_.B3?Z@61-!#Z5"4
M+Y?M*U-3)C*DG[ET"KQBPO^(!L[JBY0EDPE;8D_M<D.#R+[/#\4)3#&-7;73
M[V92\7@D>Z2&/6?%1-C"OFB^HHUE.N960ZLC4]5WK!%F<SM2N9LJ8;7"_H9R
MYM]P4>W"+#3M CNFZ4%3>,O#5MA1;*LYU39#E/;S :T1IRR6\P;0JAEOY)AT
MH/[3;[WGP9;L;&1'Z%IP%00'&^EF5"YUA;:9]+R5!4/\'^![C#/:>E965US]
M; =/:8GP?3(]&-5MQF-T36P9D:<(1TX?7KG 1TY'MEI9D<R26Q%-ES,-T%P5
MTX5SL>A, BR5"%CP&KZG#XUQA&W=HEUR69RW>JM:^ 6%* ?M-G$CS1'C[R'U
ML)#6JSIAQZS.UH.]'OF"8")K+K8[;7P8'097*\H[F\>Z^)Y-5??E$1Q(ADH
M+(Q%:02%/47461H<!<)1X[ N E#,YC <-7(>!@#ZR1G)"/G<LQ7K%Q= >W*'
M:A7.;5\'I-$N0[PL/Y9TQ!Y!7.Q]"#X)+.6'#)%Y/&68#).42A< 8U<,8H=2
M=G'L5@W34?\I !93RT!_=] ?V!_BE!J7?T:XG#!"88'V1[!]K\%M*=T;W[L8
MQ$/NW9F/E:>*_G'=(-+XZJ6DJ$<?&4.;@M-8_D:N'*E%_I0LDTJQTF-N#-OP
MWZ-6TRSALVG><IJLWU7 $&"K ]EK'86NW?)Q128@0S&ZE40<S;68N@HBL;0
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M>!Z2%/*L)4+B9I/68"IEF/0LZ3I>5F<+^L5*)YSD"PA+'^1U[&)&O]\/#IO
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M(^<4MD(N-JWEWJ)%7*K43C;5Y9A2C0YZJ)042J(TO'1VOMA*7/.>#\7*U-=
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MI%&.IT'JJ:.XMD%2L2ZFH3G3J.JR6GH)'W$]0XRI0XL8O.XX8O+1N=[)Y3H
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MMWGP?T,085V&JZSKIC"$+0(:,;5"-=PK7BHZ1C%,8\<<*3;D),^;8$7:Y$R
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M\>WSP,3Q$C.*;2:Y5083G@OH;"KAI LAYGLI9)#TGA_PO?OWSO[&<5,)]TB
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M_%=7W^RZBT6$U#\#+\GS/H3*$]U'<@3QYYMV$$0= 3 "$38+04J?RS:K%O#
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M8H2-PHR[7[NS#RJ6#G;0CE!64I0YNF&:<2/[0:]V],51 (*(2:F=8Q8E I9
M$K+K!64AK"B60I@>8,Z3U&@VEF-@-3+.<1?,#Q5X"=H"YIZ1X@BRD2ZDLA7G
MJMWP_&OR'';KL5S#^>1QHHZ1;P/6.F%=PW>D]B"G1TO"PE4:>7MZK'.21%;9
MD)#3Y#K>WXA!G?Q<7R?;WP'=V4LSR&R[@W<2%BFX,R8:M#'U/H36#T@N;Q>3
M&"0@X'-5BV@U5?/>[AU"('B$F>- =.].4?$^*,GD4>,N?D(^LS.BPFY-&W^O
M&8D#M2)&^9CG\;A@G'S/CD>V"&*[X#K?-;C*^&Q)-I!<48FI&4U18!@IKUMF
M2!XZ<VU(_:<L8^*/L*O%LY ,0#)&;,7R;S+"NE.\<&Z0E;D?^.45[ 3;]/5>
M3#Y> ,74^^=)*9^U K"+-?8CB>Z?\E1-R3SOHE-D9G)73Y')B)/0D "+4ZHM
MF"ICG2R5^S-#0T+*/7,!B:BYQFR=Y3 3FC884UA 3&01!+Y4=CP20Z:DY\<D
M'HQ?>DU+)CT7C,1^5VJ,C-<N9N0N%G)DZ(.<+ [0]F3-D6,AT 3]IB@W)I&9
M2TZJK/(R3]: &EU#Y+66G==9CX]NA,$LLFA%FJL^LU5R\,9?STGS%.Z*B4W)
MJ\8%\6CI3S*'],4IAW3*(7V4.:3W]S<>I\/(^0"'KU-C.D:+?);;!P 2O*\6
M)(?3G+?M00#@OT4ZJ)AS$:,BFLE@]3%Q@1J681#:W-15/5^S?L2U-:L7\=M[
M(3D"0H64+8WT=[E%4&6V(#T?0/_+STDODJ;F'8?$'$9$+FN_\D;WN"G^CM0*
M,-1GE:'/>_.1I+ZY!OG,TF>J=#$@"+"8Y$ V58LL<)#JY&*Y);8!)9\I?/[,
M!2S\L-F) DJP==66Q9J>LMB;(>RB>HM4GLO8;(M*L"4B0=AEV;3:,XW30U*M
MEW(ASPH/-G)+P5#O]?HLYJCT;2BQ8X"Y61Y3\:8..S@N8RBQ.@GPI9R5=/JP
MVB 7D7'^#I-_TC?ZQOO&HSFCK3U84\#2@)2.*=K<<)CZE*VGD>[V6ZF]Z,'5
MV.!< UO%D"&RW?TZ1>BM'X<$M>#R+/JK;4#<-(&CK22&6>!B<47+53CCR]4=
M8R^+R-V4@K9L?Y=@9[V8%PM. L77RAU.ZY)2 CC"",3;0=% F["9RBD0.M/X
MD+JYI.G][OP R?!)^:-AL)+=--)?S<%+C6H^:E&Q6M?[S-#D; ;</1%_73K1
M++M#PI.VPVMNEPM0:R]%VS0V.+5/?GA\D16ZC8#86;F0[/DSG#AF\W-IQ1:[
M3*$NV0Y<+JT&+J%X-:;;%IL@BP<[FX[.0LI96?0PO:8T2&^YY2R7TP2O!XL0
MX9+!,AJ[5MG8'4<)B]9Z+25%\V97=E%0F]"ENJG_(4\*T K4*V!8C+\0)1!A
M@JX3<SQ/%B/IU6D!<R:+JE6[WNL9Z14^]0/50U*X4 .6T-_)O81K# \F^"AK
M^PCE$*>3/20]B[6X\7E9P:.H8653XFEL,33\//FZ"LGV,6F1CI'"M)BPM>4Z
M7CC]Z%P=XW(=N'JZK);J NK5^1UIA8YDA/[R(KLO)2KT4[<XGUXTW8Y4 F>#
MC>1@*I\_K>;GT\G%[[OFY=OL3X^+R:\UT)!-0?^@0TH*9CIY1N?AC7SMWXO-
M]B&MT[G_%7U.J_G]^:_TWR^6=/4U_M.7 ;=VF;_H58"B/CBT5SNN7/6?R\?;
M-3[F&J^PP$Y.OB]K%EG E],C^EMY> /S37.[U/1+"^? UY(D+;LS!&9W[1GI
MLNY,#8?)':X]O.NV:$/+GZ]X"_0 B;ALVG3RUZ*B"[O")"#.V9>? 99=S=_0
M$.GLK>?3R<^DJYJN;$E/*F"5+::+'VW9L]^_K.<(V/W(J_6Z>$/KU1,67:3]
M!/+RX80?F(A=VY9M6HH?U\7;^A5MZ>IOHM@PG6=EU^YFI$1*&A[Y[D&'1R-I
MMC&\CQA>4=7+<O+J_()NPQ]9&<8CD2PW,Z+HO2A1[ET]UC)E?] V+)%UI/VN
M->Y2<VJ=3)/=VB[)R)T-TH+5OJ436E01VEPFC@+)B3+,>F!CEYKT'!1O:H17
MX<.Q>&6--(!DVH9S=J'HJ[+0E"=,E'KGPFC="G"HX$)56@AV9NJ9OOD9]U#'
MS](A:$/7L1&2W<S%(8O$(^5SA1TON>#S[QJU=959,61[[\L<H)6RAWEV]M6*
M<\=RG_!NU/D5OR.+0W'R4L+IP-[>#D,1K":1:!ZXWR.Q:[1O79*>>54VG,[7
MN%34%[B()=S(YH<83T.FLS[T2>KU.GWHX6<EP$U6:<4E^:WUXMNS?6@$&L\"
MK)&&53G^JUR07U"W''=K,_.PK%HRH3_%G**1^9.VDEV#EQHA?'V/@N8\'46@
MIY\PZ+SN<50,82$:*I3*ZUK$ZQT+5K;KHOHHLI!C>)!H-5GA1N; C0-=7;'@
M(%.6Y5!\?73&)XYU5[KPF%!A76I]Q _@:>]$KAA\OD9MZ0*A!%*1GQ\F$;B;
MJGOFG*&OG:"HGLI\+"Q "K:G3-M-,9CDNINAT9>.=UC=T0SVK:%#_DA94-86
M]'SR6ZK95  B+<N2$]I7'BNV5*X=G_9G<1*LYW@]*X-$.5G (1%? .V'$3EY
M4HRC4.&#J:6($<T8\"F.K3\,5T?38P:)'B[!CLWP8_?61.8ID)&4@M+D$ZP=
M>,R6BW)I*)4CSGOSI1<1W@/O2C!X;\B66-7U(E6C RPC8';XR#AF9"&LBX,W
MJ(&Q&)-8L2WQJA,85ZXBU!8S::?S_G?8-@,1GDY2AR=7\Z5O6_82O1)O88.(
MR]MVTIX[?Z1GE.H/2W!"VY 5U,J7N*HH*';'%SB/E1/6U[&(S'FF>\/ISQD^
M3,_#%1,IM8J4[]-:IY5[D&%^&J9D,!.--(%6E_(ZQ=]+K%4#60Y@[L0SPA+$
M8/;B)^P<&N[!AN8U<"/Z=>EDP\<V8FHT:RW3TZ-Z&JR 6E1U[[C,#=O(IE?1
M,0(PVEX&Q(V6XV"(GV:N[<M3KNV4:_LGR;4]-9BYMAVWYD(X_JP^=MOM>B]Z
MFZT_H,:+ZUYWTB/%V@93NZ'QJ7K32C,B;TWPD^11QA_ 6$EL/!P)%:CG_P
MPR#/LE,S43T]\)*439].8:S\YT#UST<$0_PMQ&(>7JPR-*V_N$>WZK E/JQ;
M5C;N]VQ6JU=+"-:S*]J0?,:F<:-X+XV\(O&I""65]+H=X\_T*5_V!H70+7&G
M]_J#+4"15<YVDM)\K;7*0+SUGYZ0;_0?7&,MRRHD$=UND8!)GJ$C@T,QR4J@
MN=8;>30OT!P"E:UF2$G&]^0 ML?Q;9R/BF'.RK"C7UM,XZ/P&F8-QLKJ$;&8
M_ C!#_O$Z_IZE%5*IQ6$]$S]-B[<LIA/$DG\A0:U,"NX5Q%RI[RK(6(5)/YU
M/B^,)6,I,%EQ?9'[$, I/3D^.C1,H2$U)@67G$9_I8<H5<7#;!LLY0.LKS;3
MH\?;\YNPD<K/5/\AOH_33UC=0:F\S?EF9:-X*562B4AJ ]B6<(OU+6X;?Z\G
MH[K.5L] Z[#@)@!,-R310]T[\4[X4-@6]J2X,</9E=@>5+.'R:@&,349?PHV
M,*N X]H0QX/[1@HSGC#A3$1;*H5_M7>KQM/TD_2SR(3T4.F2KS(<E$Q*R&G4
MW>P5VOF#'^N"LL"*+*,F*PNN@J:!RC+&GZ3$G^0$P03(-6T1*6W94SP&KN:X
M:WBK))>>?BK?#ZNG$5^B%Z=)6=C)G8L73P4PS#10=G!,GHXQ7$[>B>)2\#0>
MAS#_\=F+?+02Z0+VVT(9/9A (@&'3.WIE!]_8!Q_A+#'&7J5D-IA](K&1J,Q
ML?N'+_#54VUF@[^@4KA-&#GR5S#K'UR[3!LP\956'QQ9_P'!:-TD2M%8>N X
MAES,KG=N&^>_\K$/I7 A+HTMQWT[UO4)J5;C2KYTD%J:E%C&3$URZ226R-F9
M&M*(M1T&X T+19XJSZ 89'RM" 9[XV(<2J5#XUW7\,Y5><OY9K/;7/P0V\N*
M%HC ]JW$SUTCDPT=S!6]82&W@2AIOH&<ELW<=U8Z1IY->TVJ>FV5N'P299%%
M"T4.U /G)VVGON 03Z"D:OH\@9X-P?RJ(V0(>9++"'X.1,*88#E5?BBY8V8E
MQV7FI&BN>E+LR>&R\Q]'PT> BD:9[19=^2Y0WT..&* M_@%\M]VJ6NYI@0,.
M@XI?ABU+\5<#H;C3QX4!U1RU2J%)-K,6.:3U$=P8/F,.)KAYM/208Y+T]#4#
MU]!?Z.QO$CPQ>S)KO4S@+62Y1W.%-ODCRI7OL4')/4DQ8UZ&>$*[C+@Z,+\1
MV9 K&&7:,BK=U Z(XV S0@+.#Y"Z0JD.GRKOXL@5+E*O^3/7-@+$8X;JBS7[
MPD?.(C/6B+"WUXE0%Y>-*"WO[*@\<[924M%JE?7]>]XSSV?<18R:V(6NW@).
MY0&VY73J61$UT3[JUX=JD0+&].CYKT\?G]W_EL2HXGRW8M)R:4Q\WUMT,2'M
M\'O$U^9K$I]G[F]2 CK]X0^Y5#^M_%(QR <?=9XGZBL?L\!Q ?V;)FC<;3("
MX#*7M4]ZHQS28TD_2S;$O72A_5XUD$,9CI(-PQ^7Z)$<5VVU @F5] 4/:-JK
MR8KE83!U!\_L,@4SK-R:: N:5,3?>\9M9ML*:1>Q1;@>+@ ;2,C5B\C0Y+RY
M%"OH<U'MEYRSP9C9'*J>#@,FW0VH1?1:+63I=P-CFH)3SPS)/M2BHJZ(K^S@
M]-74>:1\G%2%"K?LT/Q*>)N^SLL8N].\3,5G<XW%7&/9PX$R'VII2_"Q#QTJ
M*_MNPKRV\-.BGN\X<QSOF>2JFL&&G?SY\44<CW32$XZ_95^-I,1A?^:#O90H
MRHC8R!KA1I3,J)#@C8K,N[^-!MJPL2W3UQDHMH1/+9P/N@WUTAS*KRB+D4%,
MNN(-FPDZC3)&_>A-C2)TE+1OJ70#Y4(PK('QV>4MLUU=>"+OWB'L2V5N["V9
MZX;G6EZ5*.DEA24,'>VNY6)H4<3>ZO&?-*JZ1X[D-$&%0_F[1A9I/;D KA9R
M@@59E)(V'1[H[-HLQ]PD\WD,P]:MXF0S<G<71!QVDL?D"T^2GZ-PZ-*=.S+*
MK DB^UIT<YO <7L08V'/0D1"0,(T+1[FSY1TGQ(6ZH>(/5;0@72U># "@5$"
M=/'S!#Y?ID@4^J+SHB(F*WV3F).J0TG%<:A/:OLA:/I961ED \E;5K-Q%RP$
MRR9(H2S<V@$F&N0)^\8VR^A/HB]K1Z<X;/F,F!Q9$N93RR)_=<HBG[+('V46
M>9(M!"C0Y/K^;E4NZ(KFCM7?/+CW^<-;SH'^T(LW&H+P1O5Y0'&*5AU5G^Z7
M ^5HQ83'U>-T<ADV<^;KK\)G=-N=;0L:8%>\#9JVU#@=)P=64OHC(5?V4PMS
M^RR\H(R!2[[))>DFW5:,XR]R*B97S.K=%T9OR/?T($ES6&$+/:-"WF$ 0F='
M(KB^]W8=HM>_S+&7&4WJ\9M)66>!>V(2-=L2X:D;[(;<*T!H+00EYY+:D0/.
MBKO&+R4I*V0'55YRJ+4.&2T1/77-GI)4H\0OZ'IS6(@_,B;$B)OK@4;%\8YQ
M6>FDHGQ_*4)0^EE@(WGU9?!2[Q$906A3I;FD,(;73>K 8S?U]) W?XRM_PBI
MW:=C>/V6)T.5GE ,:E3=N0"6C]Y5X]V[F=M?1"!")!BZ6,&Z*6ZAA\3 I>$!
M/>/BC_M?32</[CUX(#1%PO&SH+]R>[4SSA9$YA\?%4UT0)RQ"&SG<YO,S[]]
MB.<O#9[S/;TGH(AF.GFUI85EW:'EURTRJI>DQ19)\-Q"B?*]0B1Y%WO<>161
M0.Z^C=,-#U@$#B2WPRRI,L<<SY4.R9[TPCA.^32Y3;:GLOW0/$^VAW(I::G2
MS+F(Z2#Y&@&W-8S4CB_SE+ D>DN,CL&Z,Q)JQ:LF=M##E'(I;=HC AN6*UD'
M/P6KO#N;F]YR.1[^.;<DE&XD@C31B$N$NHN]T<1,E[MP#[1.J,(U4JV\GG*B
MF(!!A<\WD [%)DUD &H#:5PJB#+N'@\)T3A:&ZJR]D^^-2W^2/&"1IO$%>D,
MS/ USCC:_$>%6T3A@N9E$DA;MNF-CV#$6'I"))*:E74O_U<W!RM$!/?&16"S
MK.#2ES/ZKD]"O/!<XY>@SM/ZR5YO67!55F&P''S/ZQF)_+D<*O'\N?QGMG(X
M$:SUYDQ=\4;Z#'I==(A+)8.(H^+_E6#*.3ETB'$TWI-YG:3@_ER#FU9* =-7
M%+.&P3'!]L*6?CP9FXTVBR'.]A/'9)%6#I8H"<>Z-$[_+G:-2G8-=ZCM33Q&
MFP_OEK4O.4K!*C4$JDM,@%A?Q%@Z!S]"VSEC5$@VEZ0!NX2HC]^[M?/Z4\VQ
M:.;FCY<90"6T=-K!=&A-C=Z LO9D\H9%&/0\ZT0I]-4[%ZC04D?^=*Y?'K#9
M\-TPDHJUW>=\IQ: ">0FJ_02%(^S^WK@,"U\,((&<Z'&7CC@339-G7$:? 2H
M8O+0HO^8L8Y,CVA?($,5;1F)3<T4%K2F-R7I'"W6#EJN6+^",^/<&4-2,P/$
MH$/OIAMKFB=@IXD)QU'D#/Q7K@A65HY$CC?3-&C1DIO]BK&V-@W;?HFO#2IH
M=F/1<&Z7&#M.K,+FT_*16"3H+<+B*N*AE>VP=J0715+!TO] <P!T)*]V:P!N
MK#2^V-"&B>5<*/>4A7EOVS]RXO^.\P/7<]%VS4[P H:,!IF3ZYJ%[ Y9X.#C
MBBBF1-/20S^E\V$X7S8CUE;QGP"Z;GSGDXNH4O5:IFM26WJY"(A__'Q=[Q;&
M<XW3#'NT$[YM#'X9&J-;X!DMBJX0<_?XPF3X%O:&=<'T)L[!X48N+EQ10)MP
MBV[]2;(?8DYW*%+U3N V+'"5AV4T9?M&?7"<;58OD00-":Z94'>#16(GG1[H
M>9?LO,2FS]:AK(7\*Q&06_B?RC?AFFM.L4#6X8\ARVR,*$T1U\H&YK-+SD]<
M '4]-(&'BL(M(C@=^]=Q)+QZNC+(%"'IC!DJ68H-C\>A;AGINMIXW2OU9G^/
M-U)K\ EDGYAVB@1I,M_3LISARIV_2?WV/ Y#6Q)*9L;6\^8C,Y6.)'4;[=F(
MNCXN%!(0X[!!RA6E00@#.=QT+@&PER'3K*-$(ZM:@):\.@H#6';VERF7K[>6
M>!ITBU'J'/F_OXU$?XSZP8212PA4%.+FJPFC(^P_4PL)?+N27-"=V21-V^DE
MP!.G'N[@  %PA]-X7'V/#AEJD%_'0'&VUH[A7\E1T^2NBT;CQ%&>A? "7R)Y
MZ "Y8X>>O<S!E'C+N.B<T\A16*]-,KT4L)%O8\#!@QS&111YS-_ ;3T5?"TA
M7<1P+FMQO%AF>O%)?M\HDC0N1JSB:,)VIRB03S+#^/4IPWC*,'Z4&<;W-T-Q
MTAT>)^OL%E4$+9*_@&22XH-R?C#R"UB?=Q![9Y=Q5(VI-WDAV"Z^=6!*C"FE
MK&K KBM5<!)P0=>=2^T$YGI":5^2R J>NJ*VTJ^-X5-@%"A:Z2,LGS*\T_4%
M[JFQV&PP4V&WW;BNWR-$^?;.HC/'<XL89$]W.L9O.E(/&MVT5.C&6&6MOI/_
M#]L6%2"(IDBXB!.2SJ2SBRLVX&#S:\J1WR AIRB QL$D4<31!RH[Q!'<K-9@
M:TI:6!>#%HJ5U=1G8GI2ZDSM'BOBGFU;$4]&%/9)@-DL1>]Y:;EI1C-2S/5V
MA6Z]G-\YGSQE>C:PU#(<,;*"[9"B6-$+,K/-"+:8'),>KG=\/#))E.N1O\H]
M/N@,)7Y O)E9?"J4IS9Y $_6QZ6QQ<[M[0>0<;;8X^G=:;),#R@(Z[@6QY1[
M8WWC3XRH_>1-R1Q6T0D30CJMWH5P-36-8R+W+!<SQI6^*LE',3='-W:VMPWP
M S5MU(ZJ(EAAR1*&63Q]#_4T]0&9B&Q\9Z6EQ,W@SQM57P(B$W6+]:G"I=*;
ML'N2JB!S3N,1A3?-JE.E+$AU<9UX!]M5H>78<MBK ]5)_R2=6-D43P4V(@*>
M?#?W80LCF9OO56Q&6CWAF#W9P4\J.&-65Q&!_..ZGI%L/\9#7Z3V7R]C)8OW
M]NP]KLSEUEG6A#A)?8L1[J1U<9U.1+Q^4XFZ%,;L)W^G]6P7I=WP#.29-74!
MA:S^MUXNO N[UC29+@U'8/32&U-I4H0:WA:H\YB:3LQW9=I[3>1:\,\4[QC]
MD5@+&(@F^&:8NAP_2AW=L=V]@^]!&A[<>_CCXQ<O^3_O/[PKJ'K\!5&G2R44
M8Z5N_*AK%#6O]23W%_AR5RZTI:@.)I_J.>D>IN3B*JI6)Q,[LHTOIX0!4%./
M !3= SC]+@M=5XE)SJBQ=.]D)DFKH]-,WF7F.U =P)9  5SAX/!LCM")#-4\
M+W\0 0C5"M[[(OM(4MT17\N-[C@.S[QKL'CD&,L@VX=,AI#-I7,D4CT=P 8O
MB2S*<7Q*,$; ':.LT>5;42W7BL9^9+E0Z:J'Q4,A3QB.)Z]SZ0\K-=#K30XC
MN%->#1Y(5P$@#):(R$<30S*(]V6$[*Y81B*\Y%F5BQW@QB+J?JGZE34\\,@G
M_N3\E[XDID,=)99%HBF#U4CRE1O%BG\13T5_4:!_T@L1^=68NE%+I(A1?,;A
MPV17)OVJ36I)N=WV6E!@1R>./UM84D0'JR9&JY;B'#OKT1UNFF]>;>'CDINZ
M$EK@5(*AT'6%#39J3$2[Y4X:@P5'6_VU;^M^5=:V9"":XYKK+_X/_OM2KKBB
M0GC9J@]P7DC7??[5%P_1Q:Q<KY-!@DIMV-/:AN%N5@W*]2+KTA3$?%V4&Q4M
M)X@:),\E&GV$XQGKYP-BJ\9A35^L$3(L?N1A44.',Q',K'&K=<FR27#+:):K
M<L9-Q%<AY2H&&B>>2#Z'+(]VTNK\9N<O[*HU['C._"/8JE]',6;8I(LPROTC
M5/.W7+$C>1_N%QKY@YS4*K^V&QJS-LO:,PO$C#T@D2[8H 8EYB_'&6X"ZL[+
M=C.Y$\XOSZ<)P&HU6-Q:;0U;M[U[6%WM^<S'>KBQ( 1[74 6\#4X:*OA4O-Q
M=#'M$$M).=[KHS#9=%KQH]\$)NH"W4G&I,07L7J<[BV\5?EB=K'=]NT9Y+/L
MG;GM_?+)C[_\=/'Z^<O_FKQ\^NIOKR;_\=GLUFS:/T01E])PSK5.<([1YASZ
M+>P*I.RSF$A*I]#0B#TX181$-,IB_[$RL-%@& H C$^8[.M=SMP% +\2EKMU
MZ17%^X[BOO'.D')!:^'&6)JU[X94 ]KR98$1#FK)8@.$P,!7*VH=C./  'H[
MZN84-2T]]PR7//V5V<W'BY#+*F)M<\?HO4:"*S#[>9IC#X]J10@#(C/>+?V!
M[Y([PO,O5.&\GH*F,_LF=+)QPL+4F.72+U6;)'G9@K\(*"Z-,(\%!14^NI'V
MBIW"R@7$K_DV0?$?E1<ALO7!"XQT]%VSD/&5U=)T91YY%2HZ&\K-S97\#H0E
MS#^)SLL)P^0.W-(D$,<AUG=3Z/7(4F5PZ!0[QNO%I-?#%_/$4A&2,3.U"2Z-
M49HOU/(2NX1F*8VN\O),5[PBCBP>@8J=C,>K;.D6]+0- C+K59(?J"\W:D'A
MY>EU G4!NF3+QZZNSG$6PO/,\BTBRY%[(,:_K4G][V59ZOF<1:H4= !TBO;L
MW67$ E(O3G:&4-H@E'JL>4*K3:<T46Y5SF/4Z=-Q4'/CB8ZMTC=UB1T> O$.
M%R6O@1!@>4"N:_)EFAM#3 101D%EGP*U^FDF@[\Y)8-/R>"/,AG\1$E+KT,6
M, "HX_UO$+[W 8B>1N6.$XUL DI@.#WQ=XGK"REKG6BNF-"#_O;]3Q>)8:EB
M?WW(7LGKRA>DD10<;OC@8R*^NYUI_7IY@^DG1+ 8"6; J'Z4]^4)*+HD:$R<
MVMNU$4=6<.Y461?XP5,+MVB+R_A-8-R8_$Q@MZ)=T1Z[*Q'@B+'H7GVF,MC&
MD*"#8E<U>9I8IB[T6&UY5<=M?C-E#[[QUKR\K CSCUDX&KS*"9#$.LU*,0YE
MQ95E3'%[!K;>HJ59RHQ'$ES&+D0V4HYU8C,TI*/?SL305EOL$C,<A3*/P8@9
MW_* O\% =L.G9YQYMJ7K A>L(K3A(2+HS#E=B2!P8&-.Q@[-8P8992L881;%
MFV4%K</Q1\/,Q0C=6J6 2+_);GB[Y6RC"YFX C[_"%WKWBYI$MGF%^<^XTG1
M5F"B:LZ[-(YE2G/>'CA5,2+$,177@(0Q$3%[&]NQAF2:IK8E;V%FB0'/E#YQ
M;BMIX,B 08#>6]U2E Q*0-D7R?A-YUQ3HC3T&X?J%;4;;;\S3,<XVUO/N)P.
M'MF+*_M3@VV)HGF 54IRFKXK+(>X+,,3NX<.*&=N4^N,>LN"<0&CI0)C)=HP
M],,\>_8!CUSYAK6::QB52*1WJ5?*3.K9M<#4$"7B1G,^<J '>UY.<.U.(G^C
MPW)*QKD?L8YUN]G3%@P>601RNLH9]-0,Q)[(P\6738=R$.OQ<P]V9JT'8G=>
M[B/ :98>\, [NW;QW4CI_MZ!H5&S0/HS@&?Q8(.?VY/996^?0GO<Q+%TNMT'
MO5J>+;DGQ:7<%(;/N!('&$D^X=TD(:,-TV]T92N_I VJ'8<LB,[.WH2PM?:_
M&88LA4)B?K>N!$^,N0P$*!%J.#EGKCS&0,DKQ4E&X02' (:T>/0V"^#'MM;<
M7HM-Q?&(5M* H[Q_&4NHD6>X63FU*=Y_9D"X3*JQJ"/KR\%.H^DR %Q6@)^1
M [I*N53-T,6^Z8=;47RFS8[R(2>_'VQGJ!D0!K0!K=IHQ=AAYK6R^ONNLAN@
MT1P<_J-!V  %!44U=]$>1'G@9$@=Q+QF$FA^)NVT8)L,D!_)L"+]MLP]72O>
M\,@D6Q*-E6=*90= V:>7[.=4\_VTEP[M7VC=*N28R6[5\P3D.C?]FQ/(N2\G
M52>/^Y"ZY4.F*QZ-$+7P%DD.M$1O9.C]LWAO335(9,DG=D>X01O;/M:<^K83
M#G_9;8IA5Y3A]-YM-M/(2F"<V;2U>WZ<.W-->5DW:%U[C*.S3[1D04SP $+S
MY*LM)9BM^.,*)NW-Z4A+(2F>[;A\O8._VW8Y^7EDV[#@?(_ST$#DN*0ESFE5
MV<RUH3(?&YQK-D!0E)&^.IYK&;[#%A8S^DFM)#+;,)P<MVQFPEO?8]2Q\_87
M8Q@*UOE:=T&G0KYCV>Q81UM@CX-P9TQ:L6W#=_8?#S_ @;4()X3TH8NNL6AC
M$&<T9C).OEN6;\-B3-I=.,JBA7+LNX;^=V&3T*]](Y]]UBW\A_^KB;"E0*NM
MX^(ATA0>DID+6FJR.Q"0NVZ*[4,W"(T^ZF#__5^__>KK;Q_VQY5_::C(_NB0
MWS%4F$+Q]-ZG/S]FU*'F+7)+ND[4-RZ0X:F9>S*9B-\PX\^P5Y_Q?I]D[R1[
MD#UCX9CG^1R44FQ%0HJF040DT>Y,LXALZN=4(HMSDK>3O+V;KGOZ\GL(T9-'
M0WC#29&=!.M]!6N'V&QHP75FT=JVW9TTTDEP;A <H^",!6<+YDDZR<U);H[*
MS9HY-Y8)?L2I74VCG&ZODS"]CS"UZ_IZT!*J$7!@+($U>C:8XB>).DG4<<>N
M<GB\35V579UX%6+M U"S"AAL%#'0H=KE)&(G$;OY!GP7G74T9'I$Q#XUU.:W
M)]3F";5Y,VKSI#E/FK-W.2O.-/6*K U_D  DI6,JW:!W2G.ZG4\R]HXRQO3B
MP*;0:"IM8FULW65UA0SO92%XEGJR)/D 74^OC4-7D^!(D<9')'CW3G+WT<G=
M0-2.)B^96^KIR^^-D=JX*08%@ R+*L'=7DCKFD-".&Z0L(J*IM!M(]+![\F3
MUH*UP[E=8 H$$+48IR032 3#.TN A9%-$6"%8M. $V%6*8;W,J%0N34.\%WE
M,GVK4*S1Y%58I[@FD0?YV9-'[S#290E6UD60PL1YZ4A4=S,MOV^5?$W: <A-
M%QL$?BI5UAYN/]ZC.>+I?)^8D7(,X8Q(E!KQF=LFI+RJAZTK4F8 8(^@/X.F
MTL)922: 1O1,A83K6VX;(O6:*0;H&* 9^ADB\*,ULUS+BWF!/)<;V;A*6VDK
M-H)(NK'&YZH6IEY;<A74P&U[;<'KIK^=#.T$5$A>;9U_^E\'38@2:@.B+Q .
M[FES_][YQ(JH#K4JBSJNM^,@#9&V>=;+0X=DS">Q3M9F);5([R""S)PO0+ J
MDSVK8>$]X<7ICWA1AU9:@E2M]-0"V(L7YG#QLG72R=[+G:FT_D'Z M[G;G^#
MYH#-Y"4@DO5L78 ;M-]&?# DZ[87NPI.)P%-"TI%LT_6C "V3G/<+ZK:,160
MIQ_DN%A8I(IV0XF]2L^710X+/H0TT!?W+X;]\A"'JY4 G*XFH-H="XH^@O&I
MUA%I<J<I9\7;8D.K<C<N#C9EO($B6ND<7H2QA_:@=ZG:6KK3:Y,ZV=W10:$N
M!:_+CJ<[T2-MK,:J2O070O"UH&TJNY!6RP0[+M21]7DPZ\N%Z=D\X3?;]R L
M/9,X4M6G)AN)IW^?#IW2)?:AP:E*NPFQ.@>!H*T1MW"!P2).1571H4E<!U7T
M[" J"Y.G+. #9@>Q=ZT<.)=:)"28LS"\BU!</K998YJB8CM!7KW71[>TTNUR
M?Y!82FV*#!7/D'"MZ3B?])'"OA=@3KU0'$:K-T++P#?$"@C==H0^0!D#I.\F
M."Z=*D@M@'0?AWVGZ.=T]35Z<8&F@=M?^JJV-G0S9@3EOFM7PADW4*O2W<3E
M&+5PKLE-M@SJ@ 94'2Z;V$=*:%VER#_>=%#D98B&U^19W79C"V;LL:-X'#$X
MN#8TUE\)K9648#$Y*+=/BC#>G-U3@<,MDX6"\2IX4&XQ<E=)_1Q4M; 1]+K'
M'2A!I:&\<'*:%?_%#A\T/(7IHU*([&TLL!$:717-7HAWZ?1L4>KAB)>XW C#
MF2JQ7MU$WH118@4V@'LT"K):UDE>>B]DF(3QQI_7JIVY#??.\PQF55?&BF%M
M/\>7=NHJKZ=]/H>\QHDG_O'4^KZ_!?_8(/<XR\+A+,[14:;AR(,AIXA_9EVG
M4@*D\XTOLJ=DC:J@<:R@3UN<,&C<TY./MVR]5;,]\8=8?L>M0U[>DE>#3K10
M:-#EH2LWFGZL=]T<9:VX<[0_],"L\43!=LSR#).4 [I;:K2OA&]89NPYJS!0
M*0<<B-=H186RA'4HM#68+<OQ"@%'(.C[>0KE'Q]4E^+WUF>OK3#&^NCYKT\?
MG]W_EKY#9LFFG/?6?QDX.X?6+N21X[832<N:8 WYEO0>7_IL<:)8BH3GHT?D
M$U(!+V)7\57-!SAK5WW A&#63]JLIN0K<5?%4]^O=-=&/'([2T!%K]-T"19D
M),A6T9?+<44Q%2.+RVU=\?]A'JG([EKZ>R:54=^V GE^(%K"9BN'N:1/<0QJ
ML3_OC##H%%\Q>56OP=/+ 8\8*$OW9QC5Y&C+[=YQW:,/8MMU"S0IU_WD)I>T
MQJE'HI3'3NM--JZP&4E[750UA0V:5C9L\2$L6E2QBE$:9)F*>8>@($^G/\&#
M$231$JH8Y*2# +-9))H#K4^1",IX[7[F!AQ:2G<^;ES1C#7[:"2R'7=;R?>?
MH)EPG=S&(TZK]3;-O3GK/!_I;_\QKNU8*&08!?$.\.WXO'_4U]6VS@>"/B-F
MU__*.?ZS5!UZW\1+1*)F(QR0$'3U/H5C3>B?P134EA*5])<)EVVV/2H5JP/6
M?HQ3\P$:N5$&"WCPPDA%Q<EN.*JM'!$%B<7_S]Z;,*>-=6NC?T65K\^MY%YP
M,]B .^=]J_"0Q!D\.^[TK5N40 (4"XEHL$U^_=UKV(.$P';:#CA1G;=..R"D
MK;W77GN-SX-NT9 "1WF@P><(O;99*XMXRB*>M81>NX?UIS(?1+,G;**1F^1!
M,"\,)Q]!A#0IWQ*C%P,\G(--@VP4#0)E$$2*7,!7J.@F["PFA!D"T[#I'N&I
MD1'G@H6GW Z.GA'[D$IJAORQ1A?AK*74C3D2,)7P3"B$4V0O4?A%^8Y\FF6=
MS)2/9GLP%F84>ZPF[:O$J2+K)ABX]U*[63YE!<<]#[2)B$K/R+\Z6H =XQEX
M31(5IZ(2;(K/E:?0%G:99%X"%[9B5#"S92,+66#*@-H=+3=A!P#&'OA"$@Q5
M TD!MAJCI"GLO%6[10=#:JI=*#)>G)TWP[=#8"&&O+_'P5UA@W 4N:X&@,L)
M+FS*/*X6/,-<"MIX [")Q15#%S/\FB9-V(M5LA>G]BPT*$SA8B_#K"+.U!NQ
MA1E)F5RX(./UE0 *9<G1LA8^Z;^Q4UQ02E#62Y9"M%2(#-!+PE*"&+W0A@:#
ME3QS%)D'A'@Q><0IE@*;JY2[4NZ6RIUT+"#D)HP1"BU3P0T!@)JX\*4\E?)T
MASR1\G(Q%LJ2I.'HV+)CU\D,*I5R5<K54KGJIXXXVP"6SJ;B7=L)IV860M6W
M(9^W"WP-%(@%T&3@,/5*-(Y2RNZAO3A#C?YAA:H'LE#0!AD(R*&?N%% 9ZAJ
M7C9=10O9XC3J(GK_WH#H9DJ)+"5RJ41.A:@@]&CD>I-^*LY- PY2B&8&_T-6
MJ,QCXF; =X'UTR\EKY2\I9*719;A4S;7WF!'B5!FBNV10/&Q4M+@F)!$ Z7$
ME1)W#]\AR_A!%:WTF1>(VR<:WSP;=2Z(-V-_18Y,LFPB+07QH68@^1O,UVOF
M%KQ \C8@O#L"0T?9H_H9]HH.%]6.<$^GY&!273Z*TUA;P$AS*?Z@'WF8&>V+
MHP3Z,\&&IL2J^'SJ1ER78ZL:T;E+L3:+RD#GPY^9HN6Y,<E\+MTQJ2RH'Y_/
M#?Z;')?O7;E(N\"DM92W=>>S743W8-0#JU,7.RB!DD(&4:!PMR OQIUM"*"N
MLU=L-BH[L9JS$[5WDJM'EA5!N@4"ZM R9(AP;[>(=U%!26AZ4&.O+-XAUD*)
M,_..P-&B5E=.*'!@RXWI@UCB5M7)Q%S2,)>_S2<)YSH/YC*UDMS $*$;H]S
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MW+:/14A0]*4(S"3D"+Y2.I$5N0@5 @W"$G=+?&>(\Q!6ET&D]!@JU JEVIK
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M+V2T-_41B4U:J(J;.;,#BKR'818W*Q<GPW+^Y6^#CH2VU?4L2 .0H+$=LG"
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M:',)(*W&PH*C=,#L>PBN2GPLIKUM!%Y]"=1'+I 1%<_<D,IL*)3CWPWW&-D
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MC\R00UEMD"&YG%GBX,!.QKFL8A9618E<G*0.GN=B?"E"XD>J736F.E_;9QM
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M;H!,MRNUW\7C,$H0_H";3A=A%P'O;T#]W""#C=IK_NFWU'6_NQOX8?VUI80
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MZ8H&8\)ON!0M_S%U?\45(R8B*8?<6VK.P#= M ="HI.B(R$NH%;=1!ECK"0
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M)+=JAFE=L\=@Y9>BT,T*TX;%NOB]':"Q#%M<6<ZD@^OU2FMKJ]+>;&>6*F:
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M;2-$2<S*'ZWV/6>BD@%QAEELU4UH;5B[!:<8_;. $G:)248\86 $ ?$E<=;
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M)H_>['4I^GX-/F<("4496N :M7,^_:3-2,/ @PD2#V!+<ZY!O/58R$K?%H.
M.%X():0.V?^NAPZN&(0XBN&(A%L*:Y+-4UMG>Q(4,XRE]F=\%RG<H7$32'#=
M5O&A(*Q0]0H^8>B@,X"<\'SZ4H!BRE%=8\9R X]<F!***DA/7/HTPJ(9@!<Y
M=,&/F9%E(F8DG>*\BQ^,1I V3;A!HK)5JZD>"3N!&RLGCRT 8Q5-DTJ''J!&
M6 Y9&@CP?.R%$#X!J%\SMD ;S+8\YS\O>GW'Z6PVMIN]^K#5[VVZ]7K/;CNM
M7M-U&X-VPVZWZOT7I*OI%P>).VEW3R!I(_8*Z& A)N*?/O]KSXL'?ABG_*.5
MVO@P5JO=W4"=.[_A\?8-HUNZB#*%=OF#M84Y0;B1C"FRY!Q!M*G;A\3#)TJD
MG7KQU8H5"^SC76C.$+M+"(S8/N(8]Z&$ #U["BO3UX8.%UOP5"AOFK1ZHU]M
M2#VP?SL8@]ZWN@/*T8J;@M1R&([V'.D SJ9@E!XWE;I&&MCBMYY8TXP$MP>-
MIFWWG=Y@4'-ZFT(/]CK#>K/7'-9:@WK?J6^Y]3D)[KR1+NH99,QPGXK!G8&+
MCO^RH]G:2'!G0S,B%HCH@V53O;NE7YYJ_LW7M_;LQ#:%D:*$TOBFGD;T!*>Q
M^Y?\PWQO,%?9  <[;D#VGW0UT#*VTR24'Y!=C)]DK&>C+9*OF?=.DD@.S* >
M?G'?/O[MYL;6,R&9?CB?,R$5;&S6G^D+/A"3X<ZU7!D PX,1.8R5RZ%O;( .
M>2846R_^>RP,P8=2: F/-[N@SP-D0_O+IWA<AL.#0$6N3MV1,+LAB'>,15[=
MP2!,?\RIIKO#&6O<W](/L.@)%CXB(*?%BR:&ZVV]W-D[LB[.NA7KX\?CU]9Q
M*"3+'E3 %)D)O\T1'^UVCW:L@[W_8_VO=RN>'1RF$S%1 S0TQ42<PHL*GQ(/
MZUY=_!_XC;WSL%=O])K\K\G[CW7OZNL_L_VCVX^]+_TW_<MHV'UA!?9$O*[C
M>G]U4P=B\#"^ ^<%'M&'PEGLO0\/;@YG._8_^W:]WCE)SWO_?#LX>?'?QF;S
M?__,#.B_KWYP5RWLU8> RT_>97=UZD-$K/.OMM!:[Q=PKV&JP0_CZ D&3^)>
MJ[Y=;[1^;)^8=[4R09GY,-3CG:;/0!:>FSHU%U);K>'P2*6=>NUVN[/U"&)B
M&,5"O^H'_&N!62^81Y"A[=]#GY@"LT?-K/O"LTQFO4[CT07F)3_AE47/>.9Z
MIE4K]8P0FUT['K^!5NO>YG:]^?A2 _>W\ &_GIIIU7]=-6/7CZ*1'7C?\8P0
M9O.A#:EI\V 2'^[8/R8PAV$B,1B2T,J(3U$0Y[FKFL:3HDFM"704-$5599!E
MH]%>,J[,<W;%O/4C3]SWG>M?N["2\ P[B*OS#Q+W6A$>UN.]PP->XKE5-FR5
ME0UE9</=E0V<X=@<;O:;_8[3<SO]5F_3Z=B]3F<P[#5;;K\S;&_;@_[VHR8K
M,DN\N94_$/&3'TQH_'#@ZE&K)G(ON-$L>$?Z,*/8SLQ&)4B8[(1VA/T8>P@-
M'T;Q&@QR%B1C4*W6C@=5?=X@K@#6X&/65?P[ 3D5LWCM^;ZK@XUK,[;EE3U3
M+V#0+2R+O<L>L]:A;M2&\*KK2/0QRMUR=Y >?J96!SV2A7)DO81;P2G<J+WF
M5#'^J_[Z50X'R2HH)L)*5-?G#A=C"''&(<I43AO[#GDMVZ\E*%5%@S0Q$I:!
M/(1]! %5.554H;1\> #&M?42,I>NK =7,&=8)6,9+YH9:J:9GP<MIV!#3!*W
M<J&T5%0YR=*?0^U-C*4;MA?YV!,'31BJRQT+NZ$HF^ZG;V$VGR5&\MY.EBZ#
MG@U5P@V%XKGN>_CH7I/K(0X=I.X!V !K:FVMPJ>1)P8[A894:$"*J&D?6T\(
M2PIN>A%XRB_&\70QN&^OC^):JAQVH)X)9XC5Q"HW_SG6;-\M=%!9S5( 70-L
M:^=$B;<<E'<'7-.U81U1^;_Y*X_Z0VY!DD%\Y [0^C)[N[N'U[<1O97V$RHR
MHX=#025H.1L*4P$*IJ0QH3 MV*J0>\.P+HX .0(+X^DP?YD1PU?62][_F S3
M:HZKTLTJECX4KVB;!I_-FU:6AZG"&@38$Q8YZEPURHN-LPUKZ#I8VF^T6?OV
M3:PVK U=) ,T/;%>DIO:L$@,]ZT"EE2_ARM4'<XN-*C%L>QNP=F!=UMERS&T
MB:2J%XL6>M$D0:>Q(U9*O2B-WCH?A['YK>SSDWWXJIV;&X%I,N%11E\B0/2%
MU!BN._EM+-&2S7?WT^8(5@L89&*02H7#O,M+*NJ&#C53BW,'VI@C\3,Q*NJ9
M, JQ\C535&H; )X?U# :A9]04$6OB,"#](JLWK$'/Z#&'  N)=@T_0:JR L[
MN*""4K:>\J)P Y$Y$MG2&5"9%JX -WC<^W%67\PPO*)J(TZC:4B((:Q0L(=B
M3J=0IQ)T3;EQO$AO/>2M4>+$GXS>(K59$%*W"C]^I=B4:G\@KJP2: ;@&+@.
MM;%BG2^,G7I_  !HD3#*B;M3KN^0VDRG?7X\L _IQ'!('\+ZXK@VK#.86^-B
M]6[NK9C50-RJ@B7$5@( $EPZ["+V[, U@(AP3T] M\>J@5]66K*9<><[TMG&
MDVS[<6B,YMKV4ULU@!9;.&G,;4LF\*KLLH-#U,&297V89OKC<X^0D$]L'6;:
M/._Q)I<F.B3W3?.;R:)+VU1Z?67$&!;L,S' =N&T@TY7+"@1KF4B)'W%1I@U
MD(,B-3S!06&3> IMN>AZN<*VIEI;_MH6NR(#"\8=%ERYKE7Z_<XB.@'M./M8
M*.+/6B^9K]EBH4?)IG:)V6DG?UDOO5?L2I&NH;T0PWW-78</AR-#*1Z^\SUT
M#3SLI><!> $V'9-Y@"85X7X)DT8X;\$(]4.<]K_268#-IH2><&M]39T1[P9<
M$/62YDXJ7"4G=.G<M?V$R_W%67QCS\S-(0^B>[Q.8E^YV !M"RT:^KJ/AEMR
M*Z 6C/&Q"B@>'$I-Q6A\L(7%B(@H[MS0"F\ >SPPU=C\TDE,)B^1*[UA&56,
M:Z$1EA(J[+,RI976H."K)%CH0M5\+-:D3ZXOY/BL^@-VA>E(C%&:[D#X9C#P
M^"[(<0:K7XPRGL,DE\)@6JH$%!1GD(+HGHB52 ^21EX!YC??4K76YE]6[/T@
M,3&)LH]"4 CA@%5@5@Q4(K()")\)X$8H7!&XV.%+OH4"*4(L?W ^E^$4W0NC
MJ ACZ"Y\H9S9GVE[1H.$G6V%'E8 !J+/#09C(IRV. /*9,X9XNEDPS_/LV6X
M52;6RL3:6K8,"TL<O!5QE2?4AC;^E9/J9LZJ(C?6UZ06H/47&"VTHS%28JAX
M9051Z H V!D+!]V5C#\":@*L.^H&E>H0E/7 )OB^ M"D$/%-(+=7-'0G2D<9
M'7D'S(X)@Y5YC@S>2_-4 WC!N #3:\<+SP9XR(D[GFU\5!$\\:6*W\'9((Q?
M1E^3L)O4T98_F[<-0U2;6PS.118Q'+IH>9GF4VZH"U=S@QP6-O>$1E^\5LH.
M+K:!21+$X2KO8$I#@(5)?'(F[/23Z-#ADW$'A.*).'80NRQ;C]J:_>_,OO.Q
MYK@PP@8WK@P^Y-]"'*7%^T7Z]G\]M,?MWVE.U<JC:\M09:->@4%4?7L6ILE?
M0^_6=8I4C:'CY!%$^C=;7<>7=>B[7$78OWJ1?-T>#!&+]Q8R)';FZLK^K_^S
MW6IOO\Z/*U=\MK">Z*%#ON_YX\;:^^)]KL#!:*\/,$F" 4\?LZG"8K=)EQJ$
M-J O7:= 7?9GJ&&] -,#$JM18A"94 DR\.U%3I4ZVI7:5*9D:)0@,IZRQII2
MN@M<"W$$H4*7 04"_(F3[.C$&^3"4,;+H$#B#Z_%X8#[91#&2*#'A_1<_5ZY
MJ\I=!8YOS&%\RCC*H*.,W!?81%?N+'?^*4DD!J,%^\J(0$-X,V'P>'!G 9%/
MO)EXWE@AM:N;BNW"6V4B+9],._K2 UV"<Z*2,&$\"[S .7MHZDT1+A]N7C 1
MQB2H'>V]X@!_(7:H]MK-8WTH@1(9G$(%P C&-C+-3Z&.@I@PL)@N3OKM!5:7
M3"4:BB(/JJE!)PM'9,X&W52]/2@:0%'$61M >LG!8-0::9Q:J7#63N'LY[(U
MB+)-!W?!%M.F^[TS1;G$TV)_C>*ZK%(44RX;WS*+17E4B2Y.P#>NRK=A]M'4
M1AX54$"I@ZPVP*@WF!$ ;0> ,7>Y'L9++]E,Q<$%1DYA7WP=G((_XS]_2J?R
MH?C Z%.N;Y]LO:GM.E^N[/X_'SNCZJ@>O;]Y\5^SOSK?L+PVCI2L$A3W!K^2
M:]Z4P#2WX?!AKY+"OXU:O;$^CN#/6.^/(66+C#7__L^E^_W[V7BP/VL=?SOQ
M#IM?1K63%_^=ZZ)?VX4G4L%Z"PL#&S^E%>2G=J0L ZRX&PS.S"P_=-A"IT[%
MJ0^K_E 3P^P-^O<O@9.ASLL?>*7G%OUOE]'_,OI_[[::3KLU'&[W[5ZGMM7H
M;;IVLR<DQ.ZY+7>[:7><MM-L/VI;S8-V\[)*EZ+2?,J;8GT^07GU8V'BV4#B
MK6I@Z,7O@;3Q<][YSH*>9> =3U76\^]6YN4!N ["5[4AR^S>0J:<")4XU!99
MX)2H(K57N;7I"2>E4W>&F[WM[9K;V]QJN[WM0:/3&W;<YM!M=.IN6_9ZT2_.
M![W.97OZ9K!SN+]_Y)\<[(^ZC<O#Q@D8/?DKSVX^?KV=-B]:%^G[SV^"Z/U7
M?^OMC;AR*W]EF!Y=WHZ^=+PK[Y^ONY^C_E&RV1SU&O/WO+S^YZIZ==1L7.P.
M9E\NSK[-VI]F)^+*N7O6/N\=7K:&A]_VS\9[P?XL""<S^Z37[-7R5TX^-[:W
M:N'T;/_R0[ =>6\_S=P/-[VM^2OC9JV_LS\-9Q>SK_&T^CXZO'AWV>VUYJ\\
MKDZGYSO?#NM7WZ+KEC.^O$F[ES?BRKDWNFWU=L:#X&/KZL-HT/#>5K>=G3=P
MS[DW^M+>W&F%U^?-VH>]P&UWQW:U^O6DUYY_^F9UMGLU^7RR>?7VXLWA^65R
M=11Y)[W._)4?WC>W/I\?!,>UR][5^S>C6^$2?N[VZK6BF^Y.;\]FY]\NWG[_
M=M8]^^Q=..^[8./.72JTW?Z[S7K4V=\]^G)[&M3=\>Y;<>GF_*4'9Q>#=]]J
MVR?[;]/6Q^O3+[-_/FP)<2J8TV_5]+1[>CF)+^R:.XVK']U=>Q\OG9O4Z??T
M_?OKW;/]??OFP]59;5;[\,\4+YV;U8NOI[WKKVU[NC\;V-[W#V^_.=LU(:4%
MD]5X]WF8;GUIWES-:GZ8;A_\<UOK"S$MFJSIWN<C<=W!5;H??8G?[A[N'H!$
MU^<O;7:_;/H'8>M[S;7?G1U_C-O#P> &+IU[K>&[W>&[_4GXS\51_7SG[8>=
M\_KH[ 0NG7NM=/KYT\7G;Y>GM<8_NZVOFU]V+Y+OXM*"U?H4'>\=M<\.WM7>
M5FO#_<%9=-E.Q5@+MDKW^+AQTSU*/M;.)E_JG_\.+BZ:8W%IP<(>GKOO=[X.
MD\^UW>_M@X,#MSW8W>WV&@7;ZG,CW>ONO!LV+R9G7PZ[?[_=MJ<-,0,%,G!P
M=OG%F]T>G5^YS<OPY.AB_,_MK1A P288M29?WG_ZY]/1_F7O;';E=+Z]J7T4
M,[ ]?VDR_A1>7,1?+VH?4C>=?3Z<UK?:W5ZS:&$O+KHGTUEC?_]MZSQZ4_^V
MZX_<&W#SYBY-!\?#QLUI]/FB\>4FW#UP_IZ]^R3N6K $_=Z'K8LO?S<:M;..
MX_ICSW/.+X2RRB\!NH/7%]?U3;&TUU>ST?O)6:M[F(RW3@JN.[[H7WUJO/4O
MSH;5VN7'-WO3_O@D_^@@ZK6G[L%)<I5>']]<?_MG?]:;C'K-@B4]NOG[^NMP
M^*F][XV'WF[/[7\X'XA+"Y;T>[\_[7WZ$CE7E_L'[]SC3T?^IY&XM&!)FV]N
M_KF\[IP/][\YI_MG)R=?FOU(3%/!DIZUKSY>S@;_=/;MP7B[V?CN.5\<O+29
MO_1DLN<=[Z:'EQ<-WW[SX>;S29K C!9LZZO&]Z1VLG5P>F5':>)L77Z^KA^(
ML18(2K79/]UUOQ[4KR9;.YM^Q]E^7]L]@4OG]NK6^<7[]X.X&M<:GPZCP+T8
MB"GKPJ5RK_ZZ$*?M)KH/SP$!]$E<E-I&;>LN5_G!@!,/@6%=%$UO;#0WRW59
MOW6I;VR6^V4-UV4;PR[ENJS;NI1Z;#W7I=1CZ[DN0H\URG5YLG5Y(&K\G>;Q
MHX"H+YL#ZT=294^KLI_\G9>&4A=3LO2S+R_\,IB1_[QHO/A1'5G;:"_=C$\.
MH?_ N9EC[)J;E%(B_K5$_$("L7;:\$>/A,X#CH3UW@G_9@9^.)__V!HS1TLR
MO5T?4I(';B"H"'HN2O3YB\XO)CFUQ]"V/Q>V>_MQ)P%J^XVL_&-LH)\_'\O>
M_L'D3<O]\15@M/^ PMC^6:<M!?56N@/R>.2+1.#1!*&4\M]0RAO/5,K7TX%X
MX &VXN5_<KOP)^_NWWPK/_U:KOYT*H7U%Q'6IXUNKO2062\+:GE!,W?=E]Y2
M:4>6WE(IY:64E][23_&6%DMR"Y^ [(.*2 /0&:YMGUJOUM^27'M)?G(+]"Y%
M]<>OX/$TYRLFJ+7Z3<0@)6G@4><W4#CTSI@)H'=QMM=K^+6]BW>-?YK[,^^3
M/8L'X[36.WF1Z1?OQKVCH=D@'H[W3]Y7.WN'M<;0[<_>'>U>[#6Z+RS''7@3
MVX__\Z+:?&$1(L-_7GBWR5]!.G'"A+^7G>1I7!W9]O0OV&3=P('_[.L=UDUV
M[2@""*G/T!CVPHK%FHA?-5^HUAW__=AW[=O+J\N][=VVW>QT3L;0CM1\\=]6
MN])L;,DF<SD3SR):46[;G[1M5^O[_>QM6^M=]ZZZC5$WN*[9X?0D>O/EW;C6
M&_WT;7LPGGS\_N'[[.U5:S8YF=1V.H.W ?0;ML2VK30:[26[]GE[PF13' -Z
MJ,<P4!)>FH!O%/H<^\'/TCMX)OJK8%)6F'O_:2[50A]YQ2^_3JKRT2T<WO+[
MM..%TCR"[4[1+HY]%2C*K[N=LS?AEG->NYR>'$SZQUNN\Q::J(5]4Z]L-9M/
M9]Z4&J/4&'?&&TJ-\73&U8]IC+_MG>ND.S@_N$J/#TX/NS=VU?O:%1JC!1JC
M77M\TVHE BX1]I:E%,Y#X'=XPL1"J0]_$>561F_^E6USET[RJN_:VQ?A;>UJ
M,OL6>-6C[\V;#Z->!Z,TG4IGJU-&:<H]6H9JGM*:N&N/'K?[P;?N]'U<^] X
M<,+A/Q^CJ-\5>U38#>W*=G/SF8=DUGZSEE[7FF1_5Q^'^8FUH7>G<5<M N6^
M^ WW15G=\),6;:D#?1P!YR%PJ@$QUK?4FQ(E<^ FI1]=VNBE'_WH.0+:;\>^
M'23=P-F76^[0+3+93V)G]_#@W;N#B];MM.';W_WZ0>L$T% A.U"KETYUN6%+
MI_II0_0/VK ?]Z/M[F3S^_[5T<?1M!KV+K;\7=RP$)QOERYVZ4J4KL2S=[%_
MQW: 4LI7?Y _2RG_M1SF4_@'DM_&+E7P_0Y^\MQ$_!IV^/.;DM(#_[<>^)$P
MYY$5\Z-KQRYNYZ/A1>QB]JS HG?>GOQ]<3S;_%P[._NX^7=MTC[=_7:# X1R
MFV;G"0OTUE3TR\W_>S2N/WOG_:%[O7M\%KR]_G@=7;QUOQTGE^_:;UJ]$0Q0
M>.^-]G;IO9?>^V_AUZS]I)2)]7(_E?OI><,-K&P__5H1B3T7*0S,#D.[+(1_
M HWQ>W0!;:[\3=?))7FT\$,\"_Z2.S7;Z',8!H.%-;O;']X.>]-F>G-AMSXD
MB;OW_N3H$HE+F\(C*4,/Y7Y_C&._W.^/'H+XP?T^O?H41 <G[[9KK6]?@NGV
MQR^;HQ/<[ZT[]GL9@"@=IE_'82K+!\KR@5+*R_*!7\U9IX;UWZ=1?96% UFS
MMBG,6B=,@>%\#2SXI4+RQR-)1I$W__.GX4'F_=)Y>2Z^?K8AM\#*G^V>^E_L
MX?N=B\NM;SM?KNSI^Y/ZJ%='4,-VK=)L%8$:EMJBU!9/JRWF8@&EMOC9[?L%
MVN)M*]UWM_[NAON[W=.=B\_Q2?VPU05MT7KQWTYELUZ[0UF4H8'2:2J=IC(T
M4$IY*>5E:.#GO=>_I17]Z-DHVQ[#!Y\EX>!J++YSHQB$O-Y^;4$_8C*S7NZY
M0V_@):]^!S?AUZ@__GVZ]G_.H54*ZR\BK"5;V^\BMJ6U^1M:FZ5/54KYKR_E
MI4^U#K%QB0QN>%)_E1Y2:726'E(IK,]86$L/Z<D7C5B\NH.!&$H26U-[9O=]
MM[0&?Q]K\/%H0]?+$'RV+30J4<Z;\ICVY&+ ^^_CZ3=W=CI(+R9?/C73\Z@]
M&0?=GAA1\\5_MQK+P/C*[5UN[^?IYSW;CID';^_4'?]S]?<LC2\^[+7VKK:Z
ML_[?[1O8WE 7TVG]&C18RA")4E?3B98^0>D3K),#^RL8%;#!C$#18L6S\WEP
MM./:X_K%V\V@__=.[Y_>M7?2:S DV':C)+LJ]^MZ^_"_@I5P[_T:3C_T&^TO
MTV_[]J?=BYVMC_M[)^<WL%^%H;#=**JU_\6"&&0[3*9^.'-=J^\&[M KJ<=_
M)W?GE\[@_BK6QS[OT!W>H(M5VO71SL5W;_S=WG];#6LG[]M'?^]$W5ZC"2;(
M=OL)#9!RK_]6>[V,;SR1Y7+_O?XF^=K]WOGRYNS*W3R[/MG_.]CV]D]@KT.<
MH[5LKS^[. <"M5H^6W6STFWZ%>",UGZ&2MBSGXNZ+KVVV6*EU[KNGP[ZYY\.
M]]V/Z;MQ_ZO3OCP9]1H(?%9_RMS-[[P12E51(J:MVCYZL*HXK7WY_OE+Y^_O
MM4GUX&3S:',V?3>] 54!F&F=]B\;WJDWIO<$G"FH@WS4,LC2*?RMG,(R /38
M]M&]XMC=TR^GW:]?OS8OT@_A^.+-SJ ?0=YI"VRB9F5KJZQH*7=X&?993[/F
M7CM\=/*A=?!IY(^NTD_^M\_;@9,ZU1O8X6#*5+9;OTA12^UNPR47";*JUL<P
M&%F)&TU^APZ.N1GY/?R_$NG^ES%I%OAQ2^&OZ]__OCWSN_6KVM&5'X:]5K5]
MN#OJ-5I46;-9^_T0[TM%\%.,G5(1_.R SE)%,'I[?-!L7=]\N4I;[F0_?.?6
M^[TN* )A"-6?H+9WO4SY>X1TRE#.:AV]WT0W%DM$J2Y_2BBH0#'V)MWANR\?
M_KZ\J$;)*#Z\_>?OCB,\Q#982)N5[:UEX>Y2-92JX:EC1*5J^"DQI +5<&[[
MLX-/W?=O+KQ!_71W\ZKW]7 V M70@O!P?:OQG()':[_]U]IK+/LQGE?_U()7
M*P% 2F%=O^:A>PKK+^^([X:3B9=,W(#)=W?%)6)P;C HG?(R^_J<ZBONI.*>
MI]XP1:#Z_[/WI;V),UG;WQ_I^0^H9YY7,U+H\6[3]STM&3 [& -F^V(9;QAO
MX 4PO_ZU39).-V1GL4FUU.F$KMA5I\ZYZNSE*5)>W^;W._ZCEOPC+&O+&COP
M.,H@PJ V9WLK7+3IH^SSP?W8_Q0_)R)AI$.;OWG+[S^*U/RD63;RBP%!_U(@
MG-E)C3B+<$ZYOH7V^I4./U+(/+PLFKQ=XE(HG#=EF'[[V8\>IWA[?J1S75=1
M%==5[GO[W^4>EO_2(_[YLM>BK*]U64E\%MY<=!5/<+7ZJ"U9A,6'_&KKNXN5
M0;J;3[LNWN.Y&"C6TG%%-]S?5] 57=;M^Z*OR$/1#)2NXO;CN3YZ-:"]5Z,C
MNJXP+G4'K6VUH?.!'G@[H3&2X3(=T?G\9'B+<_=29,B'&Y$?N8NF$;JPJ5&]
MO-<*(C)$O ?!1SP[!Q^\SEFYI>CFUO%,_GH3)[[1?79/_Y[GZI/ 7VSY@.N;
MCB3[/H1IGV9#Z./T3XCMT8$_=]QH5?)1NJN+4( 9<B+PI=:D7F']<1@4M0LL
M_BW,=_;%$V:74$M&A>]7)G4CV*J(L.2^_82A.PA*_IZ"\YX>MTM7R2<';L2.
MN3WQ<N+C)%/"EQ?9FKKG!<]LR\*7284;+ <,.YE[VW:^LAKQ,19\3.QCXS45
M=+V(O+] 5ZC%$#(%51RH2LEK?]8(W:JBQ05GS_'Z&ZA[;-!QI:PBK_(UAUZM
M>,2F)'SBR-5A2[N"4J8G)/I#)?L0"QU?J(II4Q\KVA5&-)?50DOS>NAX<X6%
M.H'OQ6P;*8CO6JV7<]1<69$4:Z:X>VT.A>_VW\3XD-#C^?^'[G(1(RZ5B(O6
MBAF"H 3P\Z8P*)&%5(J=XCJRZ,U?0?Y2A.YA1#O:BGM+TK[OZK/ C_M+#IQ(
M"S^>A&9:U3':&95K!CLUMKM%IS# 8$Y H3C7XM%L_6+YJ$"(LQ6LR7S2PRDD
MF1AKF&ET?8[/ES0.F1:'NMG78DF.TTF1.[)P^BXJZ?* OAC(>LO%DJ>]-P7X
MS+^4SSQU!<.7R;< 7/ZEN#QU1;-G3=1(*2?_'F(I'H18'A:?G3@+]@YEZ7&U
MR6+?%5\8K5"'G1/5D+=<IVV([FX3]M(39KD0%0H;A1XV\;+*K/SMD*D[.+=!
M8H?WJ7S=7R#*\COYWQ1G*"]++<]J\9K1W\TF$T'8*JS)9="3_X&U^WI%]\J;
MM0OEPT;7Z74*#9?;G#K&$O'=033E;?'FF]B#%YS^CA*$QG0[JT"E)N)*?+F%
M6&,-!%,^2=924+1-3B,=H]EH4M,F28ZP!AU7(A3(8V7<)XVD*+!/M,=CM,%4
M*RM\PU1V]:IYC=RS<T=21&ND]$BST3%6.\1?%>'U6L1 ) 4X88$3%D123A))
M^1WV$PWZB(=U[O8*-"T*:ZA*&2C1ZT_&0G$CH B(E0 Q!;&2"\5*WB:KW KQ
M)R[4<B$$8RP8K_2-9B61U:3+&$;>;LO4_1OBPATGEME?#J&T.'O>L]O[9;S?
MQQ&V>DM;6BL%@YVL=&2FM&G>?]783F5"[4=)(.^FQ1Z3IUBHB8XPE*U#%DMH
M;TZF_<V%DS4[[@G-WN2?$'>]H+W#$<S(5Y@*A)@U3Z5?=0RFT"_PWH4O=[XV
MW3##%;/J*:LV@XZW?3AB$@1ZAV?FJ-<E\Y1[P>XO]KFN+T^0(F\1CN9-O5JX
M@6(/*HK<01AV1QUI8IG;F\E[VS?SQ&%_F<)'*311%=N9+.4F+\)0@+#!CC&0
M1PHA=SAZF(V0>V)?YT3_58LY^ZCT HN1>)F4&IV%S/=U3K'97GW8C Z>GTCA
M#L&1Z.^A?^FB''9VVKS&88(H5Q6Q%@R-?.#YL*YW*S.9VQ,(*]P=N_/P[0P&
M@?@XB(_?1!9(%MPR;P6&YXP]G*U!$R*L37BB56JR5GMI%]N:@"8W!48G#F@7
M!J3[-K-?,N_->8-T,Y-&I:2MX$B5]+%RN35VND@]D>[8E5/(4L.OUWB5CEX7
MKT$T(^M;E_.ZG9/$I>Z+)G C S<RB/:<\CKB1U'K1I)6MTM[.7N"1T>@:.)-
M9II1JK%&GW&9.MKL0D+L54YN[$-1X@XGCKE+@.@"T041H-/=+OP1T:U4<'G)
MU84%U.RZ4J'/\A5\2L>B&VL1&'1'(<><XK<4$J(E*; ",XX>1*1/2EZ (03Z
M)E_.#9+BOLD'U,C]*V,*34_Q1=U69$9T[8ARWA-IOZ]OBU Q6GOTV"/P6&U
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M"=VAQ&&M)@ @ $#I *"W>-$  %U.F?P  +E&NUSOS!H-"-E:*V2SMIBM0,<
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MW41T>E6=O%?ODQ<_#!5GT6D<^,J9-<OG31KX'0'"7[; I[UL+[>C !MQH8V
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M K$1$!L!DG2V1"KDHXE4A>_4>?6:$^=)#1Q?-(]=BP/\^T R@'L_LVR2+9H
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M?CUS?X$O^1WYG2#)+;[[#W1;CJCS([\?\Q*)<K^YE&[#B91Z-]IE\O?23 '
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MP.O(<:,5ZR7'CI;AQ2P0UZPG3KU]>X;B06]RW\GMXTT@G^HF*]F_\DW8O^2
M58^ZM@?.D]<G%V)[1V[$EIH=NCYD&Q,(P?LP1&T[3F6\$6!42*X_@"GBKD"
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M$"",?M<]M \1>EI>!)X?3\$;.,\D92>%8\48VTM/H#V9#[N,O_5Z2C1_+^*
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M6<AED5EI(<*,V+[1VGVLJ<BGC2UW $]=;[S<\/E1O\0,(Y*B93H!-72OJL'
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M"-*&D/6HU6E56]VPI@G4X4BQ41@W%')H,R.YQ=:#*L?G9YQ0.!PYF(U:([-
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MUT"?;+>EE=;@1VW(6Q9L#]DL-P)ZA%UL.J)/*V\&D<2VA@0Y<!;S 1<//9A
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MA"_<->_7[,:,+&7^OE=0Y6=]V:=*D_]$8,CY!!OK+@<95AAG]$+JKFN,[XC
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M/@UR0K,:6M>![P%"XR:2?*X!V>?S^#2 &$#-L0S$8"46F79?(FV.8-/4,:,
M(-S7,_DNJ=%\ 3'VW?T_[XSF2OBP.FH;B <FK Y-058!I-H!8+S3]*K#D@_
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MGE$T1(J,-7*#N-3Q%/ '#-%>\ D*%L"AH>2=GHHWDC%72%FZMBTA4Q*GL;F
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M+HPTII#M!5'CRSLW.0P/_F?##]$MH4%ALFZR(2I02>&ZW\FD'-<*M1N@<(:
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M^]U4D'=C[^9HE:VD\NS3-)ZJ*:FLW!$:X@JS-U90HHEC7/POZABQ>R[C=]]
M6UMHT.)@H1_U00Y\)U_:WG)B+H'1=;4*C<NL32^K\JI$LJ]MF6?X2+O)HSA,
M]?72JIU//29'L68^7#?K@Q@H,UR""UPK :L'K'Y5RLT?L_I("D<T-987<\*V
M.@Z'93/:*]=I65CJ_?6:2Y(Q@;YF#$$A$-30;QAJ' (_2V"(!8;8.ZHE6Z1K
MDF!,#MW 1!(U7+XS*L@\;6_59Z/%:+Q8;Z>EQWD\7S2CZK8+E841NJ]A[I_
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MUR&L6+,YT2?,V@RMA*BHZ^EV-98N9M!CN-/25Q0:-7S#<LD@!2-@YX"=+YE
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M8PK31G)6F\J%I\XDWI/&[;OQAT(JE&L/U5XNQZ1SE=Q=L15@*P38"I^^EB_
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M57$CHCL@Z2@2$QR#>4P#]^?T%[\6S_SA##)TY?]0?\-]-V@U'>WB<[S 7SG
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M'8QH0]_MNH1VT7_ &3(*D$X>)Y^,!5D0C%I9G]-L/Z554SER/F: 5!0 SU^
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M#JP)4PDL=@_/*:QI2E,)/ 9@'PN>95@0X4^?H"\$R-<U,0+O<R59DF ^1^B
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M4X+ ^8TT"L"'X+./GHK 8NF+WP3^G( *&/C3.Q4>?XY?"4XG,BVU-QO8R,R
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MD:6'+A?&(DZ2]R)>WA[F^\-=R>GBHZ0!; ,(O6(EQ4]M/,2_F:[P0#5ZCI0
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MUX;?R\+Y"^"BUIEV5,Q.:+E1*5JRQ0P'K=+G;:,@(>V7G78$SC90<G864(7
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MKU391[B#HX>G!&Y"9]3W@IIR([ UY!C89P'L1):;\(/V&9 >1IW8M!\S@#^
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M?;_6<X1"^3- WOO%7/[.=JD?YVDFBL2ZQKX7VI" 8@'L<!7EC2,_K^?@U0*
M= 4'VA=B<7L^8#42+7&Z'JI,Q5!M-5\?M_C!YZO4?2*OZU9'L"Q%@&A=TF"C
MJ#RX(936EI-,6/-O'V@7AUZW?J:<C)/BK$T7"$4?I,: DZZ@ 48^![@P_6P3
ME/&/,H?<SEE!@$%8=YC; YX417Y.+^$$]>%R&]1YR'960[(+3 & -MQ^8*CV
MW=IQ(J^J$PH;2><!JEEG1)9^VL<&=D&!0_:T1[7K]\/#TY\3(/4FT>Q7Q1)3
M29H+3IBWS=CL*/\BFOA>Q%D.^*VMR7*.5N.QV(;8E..K-4PX?5$I/6;$KT5%
MW,ITW^)3!1;N0CT \P_I&(6'':/"CE&W;[44=HSZ4L<H%C'%,<XF,3*6PL=3
M$A?&\2DY&:<(%A]STRE)3'DN$>-COUP<8/TFNGQ%6;0GRYHJ"\2"J=A,*Q83
M6S#6=+HRSZ4EHMBO96G'Z3JD+J_*D@E7QD]7-EM5<;A>Y;NR.E[2Z]$V6VCF
MQ#%Q_DP[K3.3='DXDJ/RL%OOK+"EG((KSY\YVG96K#K8THE%H;3H6+TM-J3&
ML3%VNG(X:5O$BDSEF#XCEOC%HC:D:;CR[)E%3.X9(Y&UY*A*X=JL4ZTO2^(X
M?O[,ZCR?C&8225GN1SO&*K_<-"=""ZP\.Q$Q87.-&4:79=NF8Z6J-&/(,EQ)
MGJY,5&HY!U]-=*Q2T/A\;MIA<EEQ3)Z_O1W%]-F0VNH 1D8\S[7TSC:S!BO/
MWIX;LK'1A*JT&'50M)=6I5 <,/"99V^O;=ME,Y;M<DRBVV6BK8K8&W'K<>+\
M[=-E)14=9%I3>;F:]:ML(3NFV^MQ\GQE22$HCHJOX[2MKNM-D6YIVK0U3IVO
MI%-V;]W:I+9TIS/KSSNK\58IKV&@X71E1EUO[-$XBLM"*9F>8+.B(,?AP-VS
M$TWDNES0Y^4*8UM.;!SCN.VT#P?)G;U=R2Q225N?=;!^O<DW$S3?MVFX\NR9
MHWE\$1?B,1GKC"I8OR-)[56-@O5C9P^M%2U6R61:0]FARHENLE@Q34V$2\^Q
M?E[/VNFR,*7M;%);<6U:IAMKJ-F?/74U:ZA+<:@7&&&='T:YDID7XQ1<>HS-
M8SX6)WDRQHW95)(<Q\ED; R$-T [,IY(L.E$BN33IP_'F'2.T2UI0/<G4DSM
M$[R>F8!]C).G*WO\H%'(M9936BAWS7DVU8HG6Q2@TS-^$B?&M49GY*PQ)]JG
MUL5V.D<WX<JSNXU.@,%/T32.%4QS3&YXBITEUV#EV=N7W:0X:2CKB=S1&N7Y
MB +4TA2#:'_0I>@H+C0YND^V>=.:4HN8LP8KS_8YJ>=3:E]LS>6H4.=KE!;-
MRVGXS+-]%K"QU8S36P6K6+GX;#TPTPI:>;;/@8TUV6R"G<M$K3CB\TTKH=;6
M0?RDH<4:FRT[H^@^8V(M:U18F5.X\NR9):O3,];K9A;+;E9\M[Q-3&G ]\CS
ME5H-V\I,:2G*G0%9B"8W\CRSHH(HNM%,I5?;0G7-$#VQ-R63,RT]$L%*_YD?
M[T#X33T%/R2-+]Q@\//M_U_*;#E(O>!F F\K>Z\9Y3:<=I BUP4ORB@HE=6#
MQ+0YL^9\)9K""">1JHIT;I9N@"<*P$Q:@&=:ABU\6Y='"EC!JNJYJV#I]L[I
MYAW";^V\<[KX?P=U>8Z<-WB6D$-FJBNP-??O6R5_')MO$ G_>YX/<CC!8@K^
M#YA*@2DB;@=OW\I"%A&TL!1V80J__7\<;A?:)9Y- C5"SM7K?9L2F4"L;>G^
M!ZX!A#XY,I,.YFAX:\[-4,OP-^8;0>YEO&]N>Y)XCB?^]<K<C@,U]^#Y.G@F
M;+WN7Z3_=Q0."?GMVI0PWOBF.>?!![W87\I.@")N6\)WV'$P(K'G3^>V&_I=
M(.X$3T':F^9?GAA#I$.XW!]<<.PY&0\!<W^ "0GF/N&"H]%7(5SN#BZ D9$A
M8*X&&#2L"OW_912Q+U]"ZHT[B'S_V,>W>/;5S_RJ1>I;FJ?_W3N"KZM)7.3T
M;WK+WW\?;K:@>P?Z]$*W\$-0 !B!D"A07LXGT0'<Q"-A@S\ T.ONZ8X!/+Z7
MNV.!GY4#J0_(@?NFAJ_<P!D2?,](9)=->EX7WY^SV$10M"[BA[@?B'!VHSX>
M@X'>$F4NQ59_#O;X:9LNVT7)FY=@NC<=37Q^!1E60<EYK'4^3Q#F1%V,;N[L
MW!>;T.QSS3L<T7QL<URY#AU/C_-JDK)*SF9 VSFK&:\."M5LNO6%&L3 ";(4
M9.HBRA3)./LE37?P*1HKZY:TES33,FR44=* O3:Z,U;S^C7LIM"ZFG; ]'*Z
M'+7X_G2I88E%MCLIC1F#F;;&,1BUQE-/L)8QG;[2!/,[))?OMUCQVP]R/[^&
M_[D0P[C3F>X?8!A?*O?X",OX</G6=1G&R33V E0P<ZPE[))S WA)K*36H@RI
ME>1LGNY.E_PXWC):;DY%[)F(O\)%'L^P*[BM^WZ$OGUI)>&^"!QE=A"7.-[M
M(74K^?1CL//5 ,5=8.>/,+=V;6)^JJ+XU]E5E^:B=P;/4/&_"J]]/+1^/$TT
MKQM300IUT;MS\[^)CF>'C_QS_5ZBIQWDXE$))[!XI8:Q]>@@OE#R@E.]2V_6
M#M%+FMNE*\ &C1.C3%V5TAKF8#:95)9FK5B%=2W$RXVY_OTC".=F$NS&!/:M
MXNR.F<GW>+:^SDWNP]'E\1(;MK;\A*N+3A;:DWJ.86AUVM>ETJ*&MR>PV(9\
MJ2G-#S/P7H^GP=8M/]-.^.OLOJOW=<;&J[%,$2*EK3!67[2,_+ XP\:O-A2\
MN7O\Q7A:O+JD,LOMMLLD>AFK08I*@:]0XZ073P-"XBF)G\_D^ZGD$IK5?Z=9
M??V@VKOXQGWH&E\*JFWXS;P];6D<T[ Q,A/'4@*9: &&0KXP6>Z171EA4"T,
MJOT]0NK'8&<85 N#:G>'E/=G7-W$W?OQ,2OO,[90VXK/JDRG&I*/V>8KGEW!
MJ=M32JP2C$,EK%6L$!O(]'J<1I;5RT-O+N?<O3-B"4VKO].T"B.6=Z8^_DT1
MR] 0"$-H80CMLB&TCVMH]^'6^F((K9.A1XFF..[+SE14^YM4UYG46[!AXK4\
M6W>FN;P10L-_JN+Z#5;>,9.) 2;#ZS;LN/:(7.8BLU/U&=TJ1U.Y.D9,A8E3
M;&29'/&5N7DWC+'-M9$RKIOQIEPQUF6[G\1X,]:"35&!*9AXBL7C3^G$>9K/
M3Z6G.S($;TYWMRMJN_G1;Z_8?(+IW(<F\Z4 G:/7%O-$C[*8PHKE!HEM.\G3
M(N1&[]1C_H.:@?[QEWD=9A^_Q^EMQN#N^L@2"7? T?&\']0L 0T7<F<0 >C#
M&>Z:N)\SA-K3LCPXN&[  77&2N($=YHDZXW_@)UN36D34<%>9^9SA#+1?-U=
M>V&X%@U\]W_]Y(T*16^#O7'AG)<%"^P></GV8FKH<+2(B[-/L.&M^YW[ L6)
M3 7!GTE29C4;-MLEXNA\*?0H;T(>N^N]>SAE"N[FBBH& <<1X<DO35RO;3..
MH,:C M;HE'6S1\R*=/Z[O=* #;@,X8QAG$R_AK<:K)V@P33SI:C,"I5IF<Y6
M1'),$TF%P$64?_S6,-G3^4-'PQ-/)M4@F!\-MH&((Z"]1S@XH<T=A>9/PWMY
M_!"[6!CZQAN@=+7I0SZ>],8MK%5K#"4YVQ13G?@RA^LK\;,S@3\Y2.@07E.V
MOYK7.'U#+_DLGB7)FIJ&(X#3,%TK>+H@I#EO*A ?L4U_%FQ& ;PQVN%FN@)A
MBI )C1R$"U2=%Y1OFUU^RAK/NG3KMF5"6"+>AT;*[3G&X2 TL/R\-W= 2^YO
M[8_>V&^>TO@#LGRA83I;DHAD992EL4)MN%Y&'7&S&E^K8?K!_""@=!UII2\W
M-\("9>W#- ]/?;%W^,NF!HG?D5/XX'?OA]?[3 [7P"2>4]=MVG<WYWW9QH[=
M4QC@%C<0(D&(!"$2A$CP@Y#@_1&;A],$+M[+]<Y!?[O.K5=G"/?<W?N;$.*#
MG45#% E1)$21$$6.3W^O7>%#W2+4+1[-V+CAE3P<K[AT(_P0)4*4"%'BAZ%$
M6U!920,;?%F+>/^4"/<*XL^Q'S51Q*_'B@2,@PAIY^*T\W,0YR N&V)-B#4?
M8S<PK!UB38@U[\2:+/@()N78K.(Z!ZK2]$J>@3O+^/Y()O,1[.^]MO46Y5:[
MM,7 M$'TJ4G9UDPWP*%X1@/4TX'I>&ZJ8%-A-3/C^ H3TI?:,-$0)3N:CC8^
M^@KF WLICUJA7]I:%M5E;+I>[%.3,5[8?+A[$<R..LE.=-\4D*D\TP0^W<;S
M&8:(INPA/M@4')4:Q\?XFXG*7V3$=T8_%ZM ^AET=9$"HUN146LZ5[EHNRO1
M=C$AV^)@1.*E]6>S2:^0.WR@$K]8T82-JGU+-IH)II.EHN1VD5_4;!%09LPO
M:")((B3/D#S_4O*\=5H_(-$UPR_B-;F<I[.;_)!9=FMZKML")$J&)/KS2?0+
MV>WWIE\>$%O4%+C?O&TX FM\7[7=@4 \J;?;>68/3+NN8*CF0;%&'MQM9S'?
M+K!^+3,Q!IF!GM9%J,#NQU3Z)70NEL+3F3\X6ORP\>'0-CSZ"@<@\VA7I60C
M&IOG-;E/3"8;CFJGVL,/=]'_B&U8Q>+R-D&-<U@G+90;"PQ/].;BF(2V(9YZ
M)L[KH'Z$E^[2<NR12.;Q],H#"NG5JDHSEZ3K3+\_ZT[R@L2/U4<S^S;ML8GC
M7+:+V55UE6_7*JF4!HDN%EPL&I)<2'*/3G+W8,I1S5P^/V IS(G66YE>06_/
M8A0@.S(DN\<DNT<QS]ZAXCVX>5:9;JLCOI]=T05!4Q9:O2;U6RV@0SXG4]]J
MGMV9PR0,V3VJ609=*MVU[I'M,%'IFZ6I,<3Z46J@VO$MWBE>-6I7(%(;+9E=
MYYG"9MV.2=MT75FTQHDP:G=YG^-/:D[Z>+KF,:6ELIML,:7795I-QMGL8!GM
M-;K4@UEX>:*Q7"WZCH@Y.4FFQ.AP+9?AG,#8U3L5AA0<4O!/H. [,!A'LPD5
M-Q=JA>FOQ:5*+\OITMJ;]AE2<1C[>R1%]<'MRWPV.=7Y=B'&.$1[NJ":@^R
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M5<"!K@>5+KM.[.C8P(Q"384\IZ8[_/DZWK;4& UW3XQY01I7!9%5:+@M!UG
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M<LY&J(N;I\:N,_1CI,J.)^$S[/778)B]S>&]N1J7FF%BE4*#'F..BRGGNNF
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MP]5<].1!@$>6=L\>SR,LXIEK&-T\:)!$X_W8EA.,W85F>H[.C<(P5Q;YS:W
M+R28<H\7"[& 6*ORO:3S%=HM#XZHY2FS/'<;AQRQ-)3T==-$+QG2GFI^-%-
MV]$ HYCI)_Y"DY+"Q:1 7&']1TP:]JK"![TY8EW?V&Q8'T0;H^(;5':HA%=3
M-$<-;N 5$T,X",;(E4 _+')P$?P$M6A<+M,AC+)4U/L5CUN8HAM52=3USAI<
MT=^61 <>^Y%(_MRHC:(*\9!_-R6\;M=O4^OGGY,5YI4[K  ,_2*XKQ@ZB[($
M_<3A/?@H:_']AE50VDKZD=UZ)7/"A0MX["W%.-C@A#]>=)@+&(?M.]$6?T04
MEY:D531'M.B,, @BV2'V+GZ(8LREZ>FC5U*/Z86?33=:,TW5!5JD&L.]&35R
M8<^-PKN6A>$,+E/H]_R($5W;"!!$XWW;A!R;\ZXP?LTLL-Z80L<+%F<:U?:#
MXSY?8]-3#D/ GX7OW/.PK<ZAVU5,X7[;Z,#%P"E=)5\>?6<M6 #C+H>Q=THF
MK!TU2<"\4<'VW-9BV>I2+*%=O8*V-528K34T#<\)1,E'PRB$T_Y2\@9"B!P@
MA'3Q,&J-&\9(@T6"H80PQG'XQ6#LW-K(7"\GA>19(EW5;N[JE9NE0<[DXGMA
M%BID3+#_85GTIT5+)\A 1!L^&!NZ (MT[]3A"L0>>0&%(7&:].3KZ:(F=RJ+
MF[0V+#7U-9@EV>0N"(,05ZPL<OM<H+T9%<.W<$U461@:].=VL_G:I7M3KQJ<
M4 GANO<L7FD=7,(]MW3UN)5)U]!I&"Q06<=Q1MJ6<KY8'>?GG>:L4S.;3GDZ
M*]?.8!'3^]*<WV)<AC=Z,A6YT0]\;R=38081G_3S>$XEN=FD=WYY41PD3+ _
MSS;<PNE7^@2P0W%K? $\9DR*(Q2=+,K\PM8SDI?)0J]P5JLF^X/!@YR:EFKH
M#LXF3S)?O_G>E2L=2=CG=U[%/NGH0$&#[[ARM2_?-=OM92_^E*M=>9W%JG;Y
MKYO:=$VF+.UK;'/C-A?V:><R.TO.26'R: ['<_>#=LQODLF;/V;R'C-YOS\%
M]IC)^Z\R>14J\P89)9?.%L;Y03Z3'P_2*="2"N-A=I!(*\/",)%7<HGA7XP'
MV!U==9 U;U=*P;;+/:)5G4+?MJUF;CE(#.2=*_-+M7AKY*][7G8^S">+QE.N
MN!PD=Z],+2J+YKQ_6JGV'TKCN'9Y6[FW)H/4[I69\U4J9SU=UZO]._4T?349
M6IVG]B"]>Z7B7)Q-.S?]0:_<ULK7^57YMM,K#C*[5S;G3[/.^=G@1L[J.7N:
MTVNM<Z4]R.Y>>5NXG%8ZV<Z@IU5J<?W,&%Y;QF20V[W2:*V;EW!B7LMQ+W[7
M\AYN+TA^.<CO7GD^SUGCNU2K+\>7U7[%?-+2S@3H*>]>6IO/M5DEH5DSY<Y,
M9.?GI>RX4\1#=N?2LI64KZK3=49.*LJ3&O>T8CH.ET:0M%?W2D[USEQ5'SN=
M57KZT)VT&_32)+_T[7G?J3?E?:>_)^\[0H5-?+*MNHGE\?G:;6)#"4N\40DS
MAZFX7KHX;\OQQ#QU,QG71FI\0PE["P#EYUJL[80VNWQH/R5G\U0]KNOKH;Y.
MM5]2FR.\F;'O-5N_9MT.T5P=SK(9,FC)G=E:;;4><NG%S0TIP@I^A+GZ;5!<
MOU-MR5MBH!P"W)A(%]C>Z)#0[0GL&SHRUGA)V4B4D/PH,HH'[*C!6B-BK [%
M@9@5O7<[R\*_>1< $3,YMNZF 8VQHJ)G'Q-Q>(7(ENN;)EPS#')\=,X'ML4W
M\#1N'@X_\^ EW.NZ-011XD#[(K)7KODHACSZRW'.:?T.*X"@*R<5@=%&H?QH
M&F4;L4 @>P(=)\V33DG<L3\DL" &;[;B=P>3&'F2E(MY1JAI[) OAU$@'A=%
M\8R-56FM;P ,SK*N^.OH19(RY&HRSV)G<PA&[_?B$U$*%D_JTNZ54F..[G86
M>,0DAB7M=$E#D.)159PXK?WOPH2?>\L$]K"S0?^MT(G%(5\T[+ZIJ'01)M13
M%.KL1PD,%X(9C=$)&"[9Y;1-?*"1-J+A3QQ Z$G!"_GK1@$V\L8\-J?(H)7&
M-#% <453IF I:/8X0S.6\'YL+XCK@Z':15#@A$GEV$V77DYGL;TY1H1%+C!X
M3(.M+GNJN]$PW00"TJ[M =?1P;,Q!(>U0&+<61N@Q(6_\396QP1%S;;-I81]
MXSCF*.,++>"+C5H%>-VGXS>;TVK[+)ZO-.7DF S7IZURKY(LOE?_\B4RI4&?
MGD2@G2,4ZX14-(?6[U_#XG)5*UK/JJSO'EK3LE;I=:9)<WVZE-<MK.G)1ZI9
M/@(V,LV)U-H2@(AOQ_,$L<C/<)F@%8N.B40VCY0)_"]^0(JN6R((BBO-4IO4
ML!'M^*8SQ3&T>(Z?$PLR(>'FJ)0B:2>;**R\?V:SB;>A/;]/I]OD!?141ZID
M\<69F4R4G'0U7KFIZEJ+I.OH#TWF]ZADG]N&@U%&WJ",/$C'M4123I]?RDHS
M?INV]!I97[R[ ?TK*3.\4V\:%[UJHZ?5A[V!H7?S;1.4U:1<B*1,;*,<ZT2J
MO8GU8B'5@9J58SB@'):LATR\I5@XOR^K"D]^]*)45T_%\^[=2D[&E:J:3%SI
MY2'6&X(V]$>PZ[/42=^=J];R[F;<R]:<S/I4OJ@43[& \%4L&_-1ZI@:@T5C
M5'FFB:5D!;8QF(/;[!CHB"%P:"RY_6JJB_S@VGNZZ.$$=CKHU:Y6B_ZULUY7
MO=/*J'[V-$C?*AM<'L]\C-S)A@/S#7?LM6[NZ[-SKY+(QN7,K'R%^<(GJ5WV
M!OM*AS^8AH?@@&B$8!-_EK(N$H-@*:/6=,22N921Z=<!%#ME*9].?LD*?HY4
MP<!LTS2H>XG/OS6^QMFWQCV'<T(T3$RQF,[<7_;DV9I,<W?9]DUW&,=6>:G\
M,Z"RKRE[>-M\-]GF@NK6F\QSH?%LL4L$1H?_T^!.%UY<TDUU]I?PWS;/GU2M
MU'EJ])34Z;U^7VB43E.P*@1F;\$[7-LCW^.9+6+Q+ATZ2!U%7SL,XQ4K*W:/
MNOWFNX*:O$Z/RN?;%O_@\/!,FS0]1T$K !X[0J^,[?S$;L9_TP5E+8I%M)-&
M)C'2J2N60_X6?X0GC_%!'AO$R(S*XFLBMDM#D5@X++Y@@4CZS4:X4J;1TG"P
M,@@'YUF4T;7%N$0LDKF@W)'X'G1]6I[,%X(%EL5#TB>%W'_"D&[\=0+>+11M
M"CT?;",;M1&!Z28^QY<VL"<+[2Z!3"]&57F4F[Y87*H,097W7/(5X53Y1,X$
M;KO=$"J][_4P=J$(^?_W7W?TBE68PL$4I^8YB RD'I]U\B1;.*[+X:U+XN2X
M70YQ6>23;/*X,)^V,/]U;3QJWGBL!'E!?_\?525D/'YFA3Z?+C4/^\QCTC;W
M>Z'C2!C6NWXA5#?"&@:CS =(]0,CBX@F;?_[ ?.ETO+ IKNQ.UZ['SY".!T8
M'5Y>]O=M^N^<$X:9/FR;_F%,^KQB\UM.^26EX<.-8&K#A:F0VJ;"1Z=HOR.\
M%']+?.E95T0(VZ,) ^K2TKU+&BOVO2VIOT1*VNA)3=565\M1[W'T<'[1'^@W
MC>%D $.'C9W>[?/W;P75@<EC[*?VNZH8WR3.#HP*'Z=6?9M"<91E(,NP+V1W
M:4:(L/S=.'%V5BPWJN<R:5:N9JF;=1-3FE,8C_IX$?;-\BI]U+6.NM91USI(
M^80=12(DU.(LW5JG5KEJ[W'=']EC^6Q ZEA*@1(J]2<H69FCDO4[*UE_DGOG
M*.VXM*N9GATA["8W9K)?F/<5>3Z9V/.G1CI1J[4'&2KL/L&B_&;)ECVJ8T=U
M[*B.':2 TA91VMBRT)LJVO7Y>?5\UK@Y[=U74C?R<I"E BKS)VACN:,V]MG:
M&,]7XB'JA+62:*J\))HT_.8NL>^>_F\I RD&]!OD7T=;18B_1,.Y[J_R=T]R
M\O2NI:7*N3NK@Y7U*/ZRNUW0?V7]K&NZBGY4T(X*VE%!.S0%+4(R5>R\T7F\
MC2O5CF[,:[VX<^:<%@=YE$R)6"&_FW?_FZEF7\_Q1RWNZ%,[<)_:QQ'FU]-?
M1*TP-A)P3?NHR?R+W7W !MGW;?4#-M-VJ"3]^)U4H5XH(;JZ0D2W(JV,BM"+
M[CIKMV242'/V>+,\3[?+@]EZ6<2^92ELF)G=48M^_LYZ4=PA:EQ;Q=GF^/N4
M_F]P-Z\N^IG.)#%;-VN3._5VK@USQ<B\_ _HR?-<?T?6]T(7Z^SOV:/*=E39
M_A"5[9<W8O?([ C9W,PW+B_E\]ZXZE6,MG+;3#0[Y@0QU:C1FOG-\L^VA)L4
M%WW]CJKI434]JJ:_NH#C.'81<JY'>D1[Z-RWJZ334&K$=LZ5,6V(BW(N C_O
M=]-!=R6?;O+&@4>E[FNCJ2D0!B/3P^X0AR B_^\71E*_8>I_HJ+7- UUKRBT
M,LV&>7NU*%0[9S>R,Q],KT;Y)7;QIBI?6GXQ3O%?VMKD?]NHM5_1_V5[6V\"
M7V!CF->6JW]]HUMLVN_IM"--C9!O@_EL&%(3^U3Z,)]).9';QOB<*-BB"UO,
M3CQ=<4U[3=LEPO YA"2VNW7<?0"PL/--F\&363:Q%)O$I+&FLS:IYI#B?=<J
M1<G'H,9">EL;*BMECMURV<"P&548U(T-2T JPNY40A!Q^AI[<VM.+$!#HQU"
MB4:1T[!3Y)HB4?K09PPH+@"U=2E G0N4QB:K["FB-9D9>HB" '5QUD^6=TYE
M4(.;'5:Q]17O9<:@+A$=D7>@%(3<FH!-D#+PHBTT/L=3T<,FC0D)@&^Q!Y?%
M&XPJ$Y@&O@B__;Q^6QQ2.<=AMRE4%GPJ7-_UV\UL*R]K-TY>([IC/327_Q:"
MIV;:M7WP._FKV42_:F5G<G^Y:#\4C.95ZP[A=V(9>4_#2=K#UT7Z;@//AW@\
M@!UF:[D%54]!^0)D8M%YUC:'M-<31:1$^$M@H6_#U=N'Z<+%4]CGQYN+7VO.
MC+7I[1F<)BY%0OEH8?E6S(4SQ? 0H&H3'K!OVOI(.B6*#ONO94\40WMB[0)_
M<-C6_FE+P+3"M S01U0JS"8Z+)0N3=FML*KVA!@J8M.J#'-U+)5;-XU*/%$(
M]3!$XO >R[1)+8.?5'3:-QZWUEJ W2XTVW,D!R2>,G+XVU LD35V%\:&VI:I
M,4YB'8HI/N6E8JO3\/Q.6^%VXE2\BE&9GDL;S- FXQ*V:B9S38U15(*1Q''A
M02W3:/=KF^K\P.%D99D.MC$18^)M[G]]D*G"$62*+\L19.H(,O6K@DR]'3;H
MFX" ?BN0CK<UVG2"4\@?$=5-Z7$G*53*TO,'#QFR95"L4$-F$,LCS;$]#JS
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M/-;,0?=!&^_0R'4 QQQ3F@^-,,_RT?_]()Y@]O6!-;!ZJ[KTT>U?/CQSY_D
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M-/(W,<'^?__/!O:9OT\1VM>T_Q:;,30MCKF6I/MR0N(,6DT9PYO_5O0EL+0
MY\V?)-/"R/O;W]!(""ESDL__1PK^1'+LT!)1@T,4VT %9G=MX@+S[U[ =^/+
MXIK6W\G$"8(4S^&C0))+GZ0_:9VV9'$^D"V*-+5QV_^?;JN\_T0S<'?K[*D<
MKX=_!18'+4<QQU+9I"#+CL^S"N/;3V8U,:D0\O6S"$.=M>%."9PC4DD#/IMH
MJA-C_H6&H9Y0X.J.-W2TD:;8&D(Z# ]R&DW3)0X;MVLB[:G[0G'!X*MI!IC0
M&MB!(/U=6G\>3.-YJ;')]%'<O(4F+V#0R]YM_GZ<R'O5_MEI82H7VH5)93+
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M@;^G3/V4$WCEA@TE3I)U9+;C36ZZM)=/RT[O\8&,4@^75_%$!;--<\]4B[(
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M"VGG'2$/Z0D^DB8F=BEEN@D%PS1=UL9;O!N/=(TW]Z3*)BK6H869PYG(,9%
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M162<)%5X_4L6$,A<I&&-Y!6<3D4@S[/),B,Z&K(.NYNC607;X2-F<Y!;[+/
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M(34J5]AS#+)0V18YLF/93_,S6+UF@0N(6+W3#@(#T[#EU>2QFBEEC)MOF\B
M\#9 .[:[C14X/W@?>()YQL+^!4($&W3,I93$-38O/655&U:R1OI;9,P02$D*
MU[T9*5C :&RX7)Q5:2L4=FHIDBY[Z^06F=+9*U9Y40ZB/$9I_LE :Q&D'^4I
M4QEZP[9UVYF"DN,K[,%4:?6UAJ'R;*C],WJI*U;OR,2[+MI3V@'UZ-@?8[AJ
MG[B[5X7]D25[NS;9:Y.]M4SVWC]Q9YZQJ,[<R2MPM,'#LW<R94>F>C9"B98N
M!1&PL3<5Q^#@E=R(;( U'Z=97K4%7':#?X< 3?0=J..U3-)06W3B*FTQY#%>
MZGB>.S%46Y5[7ZV!C)/A9IFV^-=XD.>7;\__V_ @E\MP*VJ42FM8,O7'<7:5
MF*X4W#^2'6>E2R0E/*F1PJJ_+)4PH=&4+W_[5)[,7%>E1-?YSZOIDJK+E#E#
M)65@S?>7JR;7++4R2W IQ/CL$SSH[PK1,DO ->)E(L4 7\"ST)LNDXKX@8E_
M67-EQ'>*S%E>YJ0"?-E< SG?JE[*T@8TN=!(K:QPB[1]L135POMR3@$>B-.S
M;%X,39"N%]+5)2#EMYB*!,$-E>2-E0PJTK P?$WJ!*R,>C,?3.2F@/F:?5U\
M^:'*#?'YG['N08!-KYY=X=57>*9@>YS1E2E%T.=1L)AA>\;-B]!4]IJ]"[)D
MD2S5=W,2C'^!YXC*Z,):#]D(2E W^EF$-EL016,P'6* %:QS&@'4*A:HUM<H
M6*"HY%CA%9EF^9T*29",B PX^^"#>%\/OUD$9I#(?P\"/J(@"XX+X-AWO[0H
MJFZYRZ(*@BH["&;@'&?,3_"L09Y'D/6 #;H2!;^\3H?(39^@J!S\@]\8_H-^
M]MH*1&-C5R 4,ZZGS+%I%*(ZP$%:X!E&,T"_L8OB; LOI>TT2^7" !M!3Z+
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MC$87*9?4IY]':.Z0T^ZC!4;,!+O!1P41^&?@&\[008=G("A(XJ]94&Y-S@M
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M15!]1MY<2)BS#)=&%,J14#K]BQ?DI<P5#^ J[JYBFG.:2[ &H*O#%<U9.?*
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MXM8IRY^P.D2.ES#B>U5#XBOG"B@!82;QE:N<][H'@RN8E\894^HYK]] =Y0
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M,7""D)D#KOQ"S)N:%)<C20RL</A/G-LTDPEX=2A_QKB[)<V8VT%@:F2AM'1
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MQS5LWYZ;\1'H/CE[*(] ,YZETRB&=X\I(4,"$$/?P'48-,5VTA("I6%-<X"
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MV=A/V44TF_EI*@1+ICP(6"RN?5A,%,*FX-^SJPB$#1OQQ$_8!'8WCU),*/&
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M%ZKIEK'VE/TK&U_-\ ]@?H_'\0*)/\I2\QE YG-<-#W*%TF3O>&(V@R^A?N
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M'90J+%W,)0Z*ZWC0J#S/HT^5)/FADA)5$K;HF@1E6Z&MXRP0B9J]'DJB0WO
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M50F<H,,\4_)^;F_,* QOG+X^'/]Q2&N&P5;0X$ &B?E(9-PKML@<_E>S +%
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M3R0@Z:F*0 (WUA&MV?#.72%P&2J%98<3NWT]('WJAK]C )/?AJYR?X;,+,C
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MZ4J=(K0JMD&_3I%K9\W"8F-]^&;["MII$,L0MY4/!454!Y4?[=[U2&%0'KY
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MRCD/TN>*!':HP W5B-1@A.,Q=$\4"6P2@O; E9"X,4A#YDYOYLPYBMJ&"A+
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MH-@QD4)^D/\L,+4J9OZ9_6(+N7J#1^7)%Z'ZA2!N.#=YW-Q$0O8*KX'T#CP
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M;0V<A:I[IT1'05Q7D,#.&Q=X@*1&$VC]S01.^T2H2V88JI"^>E.OD)U^HIC
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MWD7AS$=&>4:YF%6I)$G[!T:9?VNP3A"(;[HF75%5;_1,$51Z0V3@97\;G<V
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M4/;%L: SCT?#<T94#;L$ RN(+' ,^JDCZ"? CL9'K<+*2X=97#F:,BX]OY1
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M6=*RFU0QI6EJ)>?:JN-%_2ST7A :)%9@@/J+FN=7 N3;)MN_UYI;]SU@F;Y
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MK6D&?^H,-ZC.3:HK21KKD-M?:L7_JJM)7Y>@!M:O+8\[L<3R4%K15TI'MZE
MA[7.)^ QH3FI0.VKH^8^.&"5,<&F3F-+CSMO/SW4PGQ4-5697-=(IW_<9[GN
M>F/"GR=8=U1;JSOBV;!&AQU+K8T/(5L[:\2[S5;O'[DA\8UQ:?(W)F"TD_;1
M>E9NH=O<MO4O9"UJO^U.5=##;8EM0@3RY-V:XMHF6@KPU^-'E.I&=N^%+Y<&
M"K6)-OIRL:"-HE12+H6)4LQB#>WQL'+M\#(6FM7DEE?%:4D)&CJA)1#P[0.
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M)\P.WKL6IAD*?5%/>ER+ !H0P)7I4L."T'C#N@B2&6&!KK<N88QQ$U<8<P@
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M;Z;&&I,2%]?F";1 0T93R8[Z%"N:X_YYY"N]S#FTX)FWY8S5\#RDS]A]MQ$
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M)].RI&Y;C T+9Q"=$ .!/4F/#:TWIX<MZ /=I,O>4PSAU0I*Q7_["H#QIZ\
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M&$4M<9'9TMW#%2&Q36[9$KWK#EJ,1P $F^1C=2N!4_1!B_RQ)*>%/?BUSHP
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MX4-(QN&K5X-!X,-MDYN<U%7++UOM4E]45OLY+W>7(OA'O<:[EUZC1!02LV:
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MN]7 I%\@,M\-M".9_0,! Z0CR!QMO??0E60:2X0%RAA%]%O\CRTMQD@[RG#
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M?OB'X^3^U@HNOSE.>-O\'Z8GOW$<P@J('O[O#+A$SO.;Z9^QBOUFR8*4?S&
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MY&\'2LA/ZUHI2_>M%.JA!!/Y/-MS-<NO@W=.R(85T> 3_P=02P,$%     @
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ML!Z:1"*%8:5([7?VCA .)'S=?7M4L<^;B7I1!+B6<%SGY9:<-$6 LH"7+SN
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M=9L/LZK&\3 04HK)8>$*NB*N .2K%WM'#6U[2:!?F?L3F(4FI2"- ;-:D]F
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MWT5;+OG%DZ&TS\5FO,0@0@$CBH5$KVZ4 0XB@N%<C)'T,VP8(-N(88BE09H
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M#=ZX59J_E.M_#XD!L)].D&NG9 (-X!X Z4@838O"P;+"^L'Q*X9GZUV;8NX
MCPW#1@4 &BQ*_\8]9ZU^WK'3/M2X>/T EQ)<OIK!<D0R&*(E;A.>DSME%]0
M8Y(OM5: $=]7A':A+@"4+)=S8CKYJ0&MC"DI8TK*F)(RIN1QQ)3<5KWQ/BA7
MNZY;TH)-@2_HCH(=Z:+%[QN&,SQNLGX_^>%$V^J0X0)5F:QK]@4E1EFU482
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M0[5_E<>+%:VLF 3BL 8/_XUPH3 4(X"7PXJO9JH6.ZE4:E0>5J2G U-%&$F
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M/383)+08<U1GVERW7!(\%.H$*^ KNES7$I-#[)L)PM%^KGP)@9BJK3=V0SQ
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M" LVX%Q;,A[+EI0!:3<.2+MO]-FEX.'7@L]J Q'.X<]83J+W_P]02P,$%
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M_I@60[ T2I^:9#LW%BZZ'>D6):W1B7 Z!#TH#AVRPX:7@N-!/,';H(?4<+F
M(L5\$=0'+F9,/EB'_!FK)E)PFV9)^A7/R*0N;^;44T9?)3%[C>:J8"QA@)/4
M6 "JK5,J( [HLXIH]<(3U MKH1C.8G$6Y,E0I094X, %.R\[PG=)274<GXD,
M+H#"Z$3^V@3..R=8QV#8RR$&RG"S=2Z"T08"\S@K.QCE59>[&A0/^;Y"5T&C
MV<6Y9(KI*_"B88@'6_:XUI#^[N+W91VD[S?K$G<XB@+[11'EQA+5Z3(3LRJ4
M*) 4&$B&.>P[))<X0#:ZR=BE<*^Y,IN]7^'-1@H!IT.9$;K4! QA1\.K^.=Y
M%G#U5 SO#96*87M,]:4*ET4?LV+XAX)=&+9F,+-S1?LGAB8F"FQL:W!/87-'
M:W\ZC6Q<&G=8ODK]8=%]0(2;4/\NP 7X W-Z)L:=+<GZP6U1HI+R;JNJ*T^Q
MZ)\K\2Z8(#]."L,%76^#V:#A+M7CV^Z;&U*X'@7I"^6]HWWWGGGO@Y]P=WMW
MWQLV_W><VF$,9?#U(D6/>BL H4L/?MRA_QUZ#U7]8<Q:;P^N'H'\;YG/.\N>
MW7_WC)4VW_CPZ3H\>@K>^-80G(>O6V3J'\AH)N>9F<A7K[I[S_YVR!N109SN
M+ "N'P&,NP4A?Q\0<FO(W)2)7@<[IKY+APEXU KS4C/,PU(@3V4ZI63#18J)
MTB_'IY23I2,4N>\R"-0T=W8$IMH_F"2$3=06&6</U+=IE.A<^H&[3VQ'&(]^
M@*4U>9+.Q0;'/>!,4%\31A>%:D36DDU!@X,_P]1L%/'VGDU5D+N(()\&MT6,
MBN8@ #Q/D.JAA>J!M>,L!CH4(X1'<:R^P;.M[->8QZUFSM]AN"&2:9FVMVEJ
MMKGL'''ZAV:71A5$1:@R_Q!%0+5,D)[%XS,*OO#95\TNA3UQ)N %Q9C>U2GC
M=.8=+R.<1)@4_'<![YBFP":OW*TQPC,I8@KN\'RAM11>4F89_IS!VZ*L5^*=
M!D^.;U['\-])_=G5-UHNYGT'$O/V9.\A8HQ/$V\*.]NT;D,$E-%U#@BJ@5OF
M8>V7VLX+NCN2.#&#6=(1Y\:&W7NS7?S<FGE_SLQ[9U-\'$LG=!Z:S1TCQI0+
M11V"*P],>HPXU$1LP=N@9#DN?T*)EN ^ETYLN!G[\-G$X[,OO5/8_-<AC]BX
M$,ZUP2JLC^@2=.IZT"SN2=H@N!O_"EK##;RY[FZWX9;9.XMPL\@VLFD65:G3
MDV(&KS0S2!^'.<& #?Z8J1RW5MCUK=7#NV-'%'&$B#K"JTSD7) ?  8@Z&3:
M:K,\24*1H#4!%I]:$N\2%^ 3Q(10@2?A%(T>$1#<&#,A&VJ=*X:DHDP1R,3:
M!.X9UP]RYGE4=36UBQ<5=+^__X!?.C?*1A'8&T=\F)QFZL#^X8_[!5S$Q K0
M3:-)CVLJT=>1[)J7CO;K??*S<Q>Z,!?;Y2>^6LX3)\\ONR]?_LV?J9K8>%/@
M71SW]Q$L CM[]O,6JHH##E3@$KXQ@.!^ET.P7HL<#$$C2-\CE'!#G34?N+JA
MYH>/:LKGR@E_N=?=VVLG_(XFG/3(]5O:ZDO]?O30*A[H,5@?X$"Q*^3YH<NV
MN3^_TN[G>3G+0.!)]&IQ0S,[S8BJ>ZY/!:3)7$:NV TNL U;Z53.<3^!_3'7
MTX)A"7?K9NYW=]&W/*SM6.NUTOY4('^]%M>??L0U?)TKI>2Y.O%WL/H>A=K@
MF%*DXE"F8@Y/U>&8E@;%06&+?\BXD.F<X1*[&+<Z48&:."3%_FXKPPU_TZT,
MK\@1LHXOMQ3C$$/.Z"8FA0L7(RT5>H\+[G KM U_KZW05H7V/5PXB3+Q/DV*
MZ:.06?-$6'1[U/5-=\RI9<40'!0M">-DK')E:"FXN@G+XL*.4!IC32(D2H!H
M+B@A9#\15$BWPM[T!=$*>U78SVW"%O>N?APDD\>S3<M)4C"YBZ8'0] CU9W:
M2E?.ZKF$,EGAM92T12.6F46;'=\8%:A$4CI.RVBS@Q_<-2@PC7'D"0Y@:0+<
M9M9'14H'4Z:Z'DF7.:F6F9SS=>1DBFD2,#PPCAWIB:;:!KQDGG1*%"6H)44#
MMP4)9B0R%L441HFEUAQ[Z AX$2K+L4S7A2.,(G0Q"RZXMLEPEXPW$ D5_Y',
M,Q^3:>X::K  B90FP'=!.I9.!L4*[RZW-:(EN (F@1.P_EP36C*['KE@5ON2
M!6T1X? 2L$@?WK_ZQEB& X9 K;64MTK[R2EMBV5Y#)JZPY!KM*!JH*_6EFKX
M^VO%<BG8[G$84%^.3UL!;/B;:@7P)B*:=7RK9EN4-F4 ]B_B7X;*1^>"(6Q,
M=*MU#FG?_#.T.:V<-WQ%M')>7\!YM4!W'5]J&:? :&,*'CK="'UT+F#,+"5!
MJI.46 J\@D:=B5Z1)E.XR+)ZQ]XGL?M,[+\2>[LO]KHO.QCEG.B\2BE('356
MJ[H^@G4&OG]:9$2LD.J,&0F$C(;%!%&$& J%KR9)I%"YZ)(*#"D2+AC9[R$F
M? B^*1& :<3@ Q+62>3,13Q_/!=\7,<U/@'=.$V3BU1.^*^P"/ [K!4PE"^Y
MRNB;2QD5S&!,!^9)/I]BJ""C( KF7>'2123QJZD*7%2!#T=2+#P(2U2WQH02
MQ-I58HKA8HVI.=@.-X3WG&KX.5-!JG ('A,-?)JH?)R$+K@R1=XLC=PQEI#"
MU"JX*EVFOH.=@)&,J>:J##CF"OPAXXF^-^#I7D'53ZR@<Z\MZ&P+.MN"SKON
M*O-T\-/K9.P] =N=;=6.HZZ ?1\3-U4&BZ4EIK:DU-62QB;Q$D@L,!4*C)AD
MSE:#Y7Y&BV.$#)AX\$3JF.@WRDQ-ATDSK:T(:[0C8-ZWY-:ESFH9&XGF3V;X
M[54<(!W=*AD8OM-BTL46D'8H>P6WJR2PD@X9>U.T:3'OQB6E"]FW<CJ9IN^\
M@">A9!GREWXJI_08UP4-$FM44C(/+Q%^1V:99A(/&55_<I:WL=!0"G5L;$A\
M2YCK$Z8"ICRMXV?&U!PK#;G(Y#*)L HQAC.H\B6&907?HL%_J4KZ,5H38"AB
M!2P7%G,*C&MF\%)#59:LV-2:J^[JBB,8Z91<AULX!427EN<R&)NZ9:;>I1IC
MT>\*Y)&%":":6+BR3?4M)-',>U-;ZANL070"Z-UE'9ZHA&J!8=EBF31S.>;4
M@2%E3EHNA[9N02WW22<E,U-_B23&I10D112:B2D)TXF9UI9RMH&-ABO'-K!1
M(^"E\C64BT_LUZYYC(/S]K;2W_CJ!O9<2FV%4B L57P2*899F0PAQQ 86%%3
MU/"[(D@'<CBY[YP_7MU5,K'!RA0G&KU[ =[]9JLL&KZ8_JJRL*<:*_MY]\7T
MSDH+FZ-"G VYYJJC#(_.QL@%,DM2>#Z4[4?X8EOI;:67I/=4Y>(<?(I'D<,D
MZ<48/+$GUBB##"23'+M,1LKQ*2[80 O>,0(6XX+]CE!GA"RT=$J3*=S$!O'Q
M*Z2-(M;F5(4(]P;#(-)P#',J&?RVR.4W]F"QT&H1Y@C/]I4[MMTT2#!JD.PI
MX6Q("7HTYY4>/O$5A=@USL0!2HH9-H"ZO!#0> JQ*:,&KSE)L[)EBL>"P$Q-
MSD/T>*@]!\ZM+;'!KIOUO\!]M^)(,V4J=BG#@Q[V J"2\C@EU5/FD*S( (5<
MUY4!&W,,O%6PQ I83]EV@*\ WUGF-1^QE%SE9)LSL8IUY<6QV5V*Z6QD@J2E
M/$'*D[VF4Y[\-E;Q$CZ1++$$9: YF.3$!$<X2(,"4T0R-1)KI),E+BI2=E3$
M)39J@Q>92=LS:<FE$)I]H2AQ6[T8_LT_/&2KB';Y_X7EO]_TY3\HJQO=/A80
MMP!3'[IM!Q4X>?S8$*4D")+<D G#F)+J04W^/U<I+'&?<M&O?5B_Y;Q6'&+G
MU!YU!1(Q;%SL6SYFSP?K)$BFEMT1%D#6THRMC=+9:S[-V-LJ\7JU*@H7G4<%
M?R6EJBFTZI2824, 2?9JE<F4P961S+&_'=+(,GELYK/'QG:I8U+'V;^TH/#.
M<0(/99H]T9=&5CK.M#4Y%#P884^P>5=@3W5,U!K"H'PHT[T"HL1*B5:954/%
M-X2)'1TM4\.:C6J2H/'&Q_AY64;IHKL2NC?.B=ET)5YAHIB%VRYES?5"UG8U
MT&Z,>CR9Z*!ZM'D -ZP1KK5BBJGF?--O;V;O26GC0)5Y8Q4CD>ZR?/%BLOHO
MLQ&3T[B,A!C;-LC42BOF V'8[B=,I8+"N)#6S[0Y<5A!E&_%VFY#JLS)S0G%
M#*P$5?U/=+0+ZJ/,+3,Y\9AF8SVEPDDRNZMIAFL73^ED5Q8,SM](7B9%:M>#
M?1Z>"TX +V5D9B X.AWPV-0WFI.^?(KW6#F7L6H;8'%W: F&VSX22V&'^RWL
ML(4=MK##MH]$U4]H?&R.E]YIDJ.IEN4R=E%M[()UD<"GVA9J VA$B%"Q-(@=
M85X:]F1K6:\CZXH^&^*6/X8:!'0J7_DQ\0F,T>^?8.HNR$^AYI2YQA5F3$QP
M<"S9 =L5 LT*-&.',%W<U,"8"\:^*/LR>.:$?<JNZ%X7!5_?_;X52Q3+M8@9
MVO5\&P1H9,UD@:S OK?$3"CH"P<!O'T2"*XIBJT-#'9V" -ANI+0E#L-YY[S
M O[]#$4V1=<@(Y<.OZ6&]9[W9-S1,A'ED(TF'TB6M<L.V@;W9;\6;%6GL:ME
MASW,*G+34K'H"68:6;O@<;YO? 6JT4R&!YY4WU10^+0RUHN ,1@GHN90D2+*
MY5?.+4[@#R$OI8ZDF8J*ML0W8AV+,C!11@#*_GV+B;R;>^L\/G^DU4^HGYZM
MCWY*;$K-H>6EP9[#2J7,<TT1E?JJUK2=E4:.]-"D*LHF[J(_6NC'20#V%4ZN
M"2^WY<Q<^TWXJA3!0$YI^<'EC2XA\R<!-3?1_Z&_6>=0/#\%)2FGN54D-GY6
M;=Z \:N)-9I0D<X/UBXQ\U=E\EI!NP&8LZ[RV_@$P1()E@5<0-+T1R;&#R)G
M^Y%=$7;#R#_;$2*CC);&E!KM;;07PAY/Q&BU/F!+&K2Y+K7U_3Y5DR(V#/C?
MLZ'8?@>)WE%D9>K<H&K W:@"&]ZO6R"D$$RU2S58;8T=*FZA,"GVR.4*#Q-C
MIH@K<<_9WL&=LA]PJ:3*0'9GD<8NZ1C4TF2BT@##JIP@H=BT:TGLJH%6P&79
MUGDX0431F0FLCS((I,U2\[JVQ+5(>Z6RY38!8,R&&U=M6=5+:;C52U\V*Q4O
M3;"1GK_HOFR,B?04U7'CXS"#Q1 +Z0/)\C.94L6;ZQ/) G"=RV6$XB[5%[I]
M5$QW>Z5TQPJIX/Z8Q +:*J76<6N($.]UGS==S_1C"IY&N@P <0@FX8I>)_AW
M85>Y$+)I2H?FU77!E .Q(3>MX8E22N%@X@A.]24V#2ASM$XCI4IF20RK;V[A
MI X(7C(3UR(Z92\[&W1A]J^-X::]"#N8.LL*FBG24#IG^$.*2.Q9DGZ%*9*C
M$9?ZUK3WD% 74\2"HV#@""Q>A<+;-83&10TF9AZ]?%X"!J86&.+ZWN*$F9[)
MU+)U_6!_K>) Q?&BZ8IC<(74&HR0RO ]<F_QN?BJ$:$UJK,1(&=W(2GOLA@7
M\HK2/9AKYE"2'BZMZH!66UV2U03;^Z5."HZ98[B8F05*&77(-H*263.D1+ Y
M_#A[IBG&PF-TD,=):NPG1J75N;;1!L/$E7%3"3.#BJ06 Z[7;2 36 B*!W6<
MQQM1UV,8]T*H3V4@2]6/(3U(X)U<H)Y9B)_A:S*6#,RLT2TEMYF;6\3]F+NI
MZG-6WGK=3EILVFZK<HY0E149:-#ZT[F1.\P>I@C)3*5X!,(G&'&%64 =7X%\
M)KH(DZ7,G9DF4)1RYJSPRYRN@1.UJG0M5>G+]5&E2BU":5$;$!36P\JB-%?P
MLOS5<K"L%V WR%Z#,[2U!U141Q_/IZ#X.C=RB?@H]4OD%+ 9*K^)L1^+]SW+
MJOQW!&?:JD[7,NP?5MWA?:K@/P:+JKH#Y_PU'[CI&$X*4P8$BNZ/(F;#R9F^
M):9X&5C3XU_ARY51NM(!=+6"15J6VEWM"I:(USH[R_JIG.:.;+WP@\]:_&"+
M'VSQ@W=-6WA/U6 #;'BT0C'80C/GANO0UJ#\X>?]YN=R*:CGK2QGGY5>W**?
M-97SBM7Y@+B$AH:D>4GNO_@.6;+GW;WFK?+&K_,JM&:DOX'AS$WJLJ>*JC&9
MY<>?Q=W0FPU?G6R%;= _FT(5:8(%H').[YEJ!RF@"2>Y.'^M+#=;TET0"R1#
M@U]/X<<M_G6$#4NFX) W0&L_V^L^;YK6?D)RL=Z"D<]@D<^W1@AOV-A[OBE"
M<"(]+4\@!HS?,K,2!LT78- <+T96*STI3/@*::LV]C=+0M\_BE1GH0XLMU5V
MA<TT*J*1CFSD*J%B:!A<MJS-9RN"K0B2"#Y5&02Y.IK ,(.2,7OCU_/-JWG'
M;RUVN.M=WUO'B66&;7-:9,U3=V,:C_63:+T)UQUZ?OWR[@A<UA['?IZ8@-]4
MI0%)''W\VZ;=%&4<8U*EY"L<Z8LB5:6\+ZD"6P0!W1VP.A/[W3U*>NQW]Q$#
MU)AMLQ74AQ34QE=AU@6U(ZIB2$+#0B@O;&?V636%>'_"9AI/]*F(H:H*EG&0
MLE)8G7SFLVMECUOVU6WB,:R]V1Q=LWXIU3;HCNJA\;OX7:S9?GR9:'R/N%(/
MQ&^6=]@ZKQ,8Z-CAW12#ZK#&4;S3&998_:YDNC2ZS_TJP2FVV+5439,TK]8G
MN]IJ%.(-O0F_YK[A8$"QVOVR5(\8 ]X;45?\BN&N5 5*3QT Q(S T#,L4PH^
M?QM22P>,D&5\:PTX; !>658H [[PB:,U3>Q".7;K'#Q.9=%X2^(NE,4G#CJQ
MJCCB#!YCPRU5RD2&5*0WE/%7!PZS,D!?HM05Q)UGI2M9QKMNQ*=CF= S_2V?
MBXT7.]>&!EB$S9F6]M$@9&<:E5*NIP7"WNG7+T<#D[WQS25I:R7A+73%$5+U
M21VAI8),A'(N0A!XD_3QB=H)N$9WP?)3;,Q;!ZL&D=0<C# 3QW7>(XF(6(+U
M(RL<@G C.V>1NI!1^5MUF)8BKN,_(DQP6J@R[L%S$WLX87OS;%S#D]';@\?2
M4656I8'(\6FM.;.>&JKQC X40VA7UWJNKL:7G1T5V#RD04GZJ[?A-MCS719H
MX\$E2XIH'*4-O>6(>>J**5QGBW9G8TTQSTM ;2<,Q2[:!::!#E\*B?IU[-'O
MND8^63%%OP@OXE%3&]_)MMDAHRHK<?<R0W!\D8J-9YMB#BY7AE5 .K,%/^A!
MV1M/Z,:EZ0+N95)<@/617X/XQU-,P0P:0RY+4[FG;P=Z%3F62*MUMIZXS#<^
MAE.+)I M[B@BR6< AXA)!X3$+4PD1/)-R]\)!3;:=)7%F"*548!N#K$A!&,5
M?&7:@1#[U,"-K=^TM#,4'%5/W&0EZ<VPBMGT2__<4]BR/RX!0N:%(B9G#X4:
MPT%T_Z12#*FY!6A<>6@*(.-3=]C#M$[C$L<&9H;<GZ&M>T%D7LF2;@+E&85[
M4_;0Y@OUT9IK$?'>CE/(8CKB!(GMJ0!2(7/]QLM-,2Q@YK!&$WW25ML\=6W3
M^"!0GR,5N'Y+0JB2B<Y&22\UC .K $GA8(D87T(3QT&HX75=X!5<C.%Z+6%;
M<U18M,B\N%Q4*$L90CD^%',[CTQ161Y\O<#BU?&I#ZAU%TQ8:"X'[R":/SXA
M;:YGO%[U;\_;^K>V_JVM?[L[_ORGMONO1X#UT>U_[3*]W3)M?*3VB>8!GMHZ
M;#S?U#VLPSLJ#F^H9GT<F:W&K]-WAM@/;#=UB<2%5[3A*[MXI,HTO##D8JX_
M7ZUU!#/$8'<<@W:PD$JX [(2&C 7>."&OQI#!2X>63^I3K:E;ZP9QR>2&0<K
MD3I1(D$/!1TB+7D!<X8#F:Q-3',BQC*=$!N;93PLYX.)SN86B)&4O1?K[19+
M- H=IC&C0(/K'Y]=S=0#/WL-#86Y6X[<#&;T-0XT[W$=9>RJQ+H/WH#C3VZ4
MC5*=-WF'[Y(BS<<K$&M\MOR"J:)>\%%+KK$6"GX-&B4<N= L:Q)._=C8ZXE!
M:?6(LG(I1G4QJP2+-/FJZMH6%ZY-#94M;C$I8O@):;< 76@SMTZ7#Q6>9W!O
M(=^!XKND %'\)K'K2HQZL4* . .MFR5X>]>;MA:BMC=J D5( ZGTGX;7\&P=
M&$).F,D06_LB+J-(B@P3CSHAY'P^2\3&'H,7-JCU]!!D"I.2E4Y$U59B7B^A
M!2K#U/\1C!K,=N2+-@2<ML!CGQVVPO2TA:GQZ(@*(@J;QCO:YUC$B6<2ESM(
MI77V4EI1/V%X"!+42L'3EH+&9^U_0UR+:3AB[3+T9$ON6^.=RMBPQ2[VNBK=
MS%HWV_&2[I?KYU.VG@RNY<;K\[X!LG*_5FS'D_F.B><]=[S"P1) AJ;, EZ$
M3:(*?JQR;8E-0'!9P]FP[OE6#B>2%2/P2S01PY\CL_WRNQ+\+"N&V* ZUQ:"
M1OS/RG1V]MK84F-IK\3I;KO$@=*B"NL2V\L-2^K]!:S=Z3CR[WPD+V#)/:.Q
MV-@=Q<V":C?;1=01=38)=!H4$YQ0F#_32AA?5*B7]$_QZJQJ[Y,?\D_[O8[/
MNX:\3E5>I#%;XI&^+*O8RH*N4AL'V$IB8=257L.N.@U,=1EY.&?;@&\F*QV=
M-$YC-*\O=]^D,6S?N=])@L&0#+G.KAA7M5V# 8%[L&WJ[^)Z%U\W!>S<K]Z[
MJMIIL'Q:NQ<M=&2$67-U:W,77N:B.*0MQX!!YD6VB2(>-KYV!UO/':SQMM@'
M_57-]$)'[HK.P(6[5&(4A\-49!K>P7[R![6926[7 <[R]=>N;*6_+.@T'1G"
MNN!6BF,3KV$+M01UC5D8:^YK-/3!Z,JL2$W[4+]LPQUAZS'641C7*T6A1RME
M*#[8G)E=7QB3)1#\!54Z]T#_(G^" [4;)'R;R%@+Y;DF!6Z?9$JQRBM[U(&>
M81,'M5^0+S0+9$5[0>4M&#CUZ\I8RWD14=?C))!IBG8E9BZ661L=SXB0^*4I
M44%.@P*5<E2F,>9,@,)>MXQMD0OG,Y3_XP@48(P]1^ELYQI8;R&4$WE!!A;F
MK,D5(7.MD@,QQU+*.K.?0*\B(0&G748:<R[R DT^LC@GCP_EWDHX2O@Z./B+
M5)KLG9<.1G:%!.:E>NAXM$!\.C:[Q*YX*&\.OR(-+RXK$Y3QN3"Y2>TR(_-E
M%27*;'9>6^ I:)U 3['J[0J&(+Q))&=9C5S-]+#2,6$\-%;>I5P^MG:&SWJ5
M;+QH2S;:DHVV9..N6Q;==G]GFL=<;V'PKYAR>5^!>I3(T<A5)1TI-HY3C4YA
M)(Z34'$O/>/'.I;T7V-J;8K?G?6.3UQ\[A@$.= 105WHV,XRTZ\:&RPMP6[K
MP:R!?=/X\(\7.!6ARH)4#ZV]7HE=P@>;9[-X*8.R-2 .VZ/8^1WH!6";61WH
MW+-^.N".YQ2:*9MJ4FZ$KT89!TZ#.T LLZ![OCZB1[FW;V!Z_<)J2HD-Q*00
M<12NW26G$+WAEIY1)9[L/W ;XOFN(9YS_6VE$,])D3K,,/BA2!CCT:*T@9RU
M4(,OUB&04]%VEO1040Z6N'H"97D=&9>*4%!$JIHLE6'JN(0+A\:E(Y(@Y0Y&
M81EAMDQ%J-,LH,&5))A\6CTV?D7;!U3(.C8#,ZV]*\V(->5KZ8N!;5>\?DKM
M(<1G]WZD!WV#%<7GP:(D*X^Q)C^8$1T2#F="<3U/;<-2OM!(-^.MV)+SRD^A
M7\EMU^+!;J-[]YJO?=_.34R:(]75%N<4/CLT9E\;!G[B:[GQ >.W2]A_JKD/
M\'P4D@TB=#XK FK]A/GM%/,L&/PEEP7YZF4$6A-UIOO1$:%A+( :4: Q863%
M0[Q4*_$<T3.'';P2Q5:N6KDBN6I\H.)MG8!+VJQ(J+,@53D%V;R<9(U7ZR[[
MH;R$Z=ISB,6[N#)><9^[S*1$QV[#?\/,HC'!,<@-$+%2,[.R]=_*>BOK).N-
MY_4Y80'(D+V3=[X:'-E+O78P=H<-1*L&X^I-F$Y!'(\-)".GT^<85S*MES9!
MIXPZC!M+L555RN"S$(=G0_VUT_'KB9+<A^DJU/?*XQMX-,#'_B6JH\3++7D4
M@J_!O!HX'"B10*G05K1.5,A/8&;9@9(UGKJQO[.)!H>*0YG6NU34.M%<.<H_
M]Z!&!?H/%"C_@=M0QGI& AMO9U";)9]ZVRQP,)OS5 9Y@PCWV^WQNRS0QH=+
M='6G(W0T;8ZE_S=5W'7(PQK"IG0):KWPZBNH!N$*ANMI-&>,$/%06X8$BCI?
M)M$E9?*,Y<D(P-2 H.@;/XR'$7(!SX&LW&45#<7-6U/TB<M:X\,YOJ#5:B+F
MKKF$M,YGV6O/<1S!5H)8/$KS#%64Q!>.EHHAM6RF,2A$>N4&IN#"U3I,EE$M
M,3.\VZ:J\,,;<NYF5QMI3.+B&/OE^+VLEJM09Y-QE&):B[)1$TDL_ 7C?ZD$
M[A8S(@WW Q90)>N9<F^E_7;2WGCC;V!+*QDQZR-\:R3MV)PSS4#(J%BE(PC0
M(#:2&+9-?-1GX)*=4\P7?NSA)<=TR5[$7Q+R)":2NDI3&9?3)32E(WIPQBBQ
MWNE4+I?Y5H0>NP@U/G:#(I39+BRJ1(TABH* DJD*]%13N:#9Q!:)?);+!#)Z
M7<@T)"Y$5YANMA]?2FJL7IDJC=:*3.?)3&*'J4KE(]C)7XY/UT^2U@O_Q5IP
M!038)XN'(3["[ !6RX7.\M18&-1/#!5IH$R9Z@@#YEVQO#@0S+@6-+86H:*7
MS??#_97( $7KY+9^[1/>IE^N ZM?C1S$$8L0WP3A$:;)C,O],>VA,LO!9\,X
ML%.F%4T,#C$S"-?SCNQ+#A56,C#Y<@%;<TK0;I/6@>V92QS* M>UVW_7J]+L
M95MIUE::M95F#U-I]F*7]JP??C:8#J8=,1]\:GG+BEK6#A-N'!4P]:_/N;-M
M#.,S'RQ%NRG73U(NL:^"1SPJ%A.5J["UU"#HC[W2[*G9)HV/N0]\=]R%GYE/
MK;1'7/H)=H&.;6@ <J/S3$4C2R1,Y?;4G%E(X?4ML*T3KK9H2H(S9YN4XEJ1
M3SN0/XI49Z$.V!ZR 8AIJOX V0T<ILN), <5\9B[);%[B3A9!).M7Q"C]7Q1
M1ALOH1_+J,N36V)/:[M8@^J1"J=VS9VMDD"FBFJ$T1VEN*$TKJI)^5REWJ_T
M;*]T;)^>XGUJ4M%X%;W 46OZOR,[F:%HE-NX:$N*GXH!LUWIMJ60'2#086F%
MW4* ^$)8$^B%DG1:B=V[\M82X.\:99?LK%E63-"D(W*D)#-I6O5MRKDF\N<X
MUT1H!.\&7=&W',F4HQTJMBRS/$D,\J+^M&AR995'E5=-%O;.B@V<*L=Z';H]
MG('87QBPH0S6F8 !8EX7(5-+&3>'B/EG^@]Z6M6Q'6N262QB)+C$1R8:=//E
M4,5JI-TLEW-::ZTQ!'^X9-I=F#R\9'W6.H9_EMCK\+?*0[MW5E6(N$ ,$RZ>
M5V^X,Q<CA:"P-)G+B-DC#&CLNMYIK49][!IU+< A3EIKVFRIYVAY5?0(090@
M_#*$M4/+ JX0*ZS\D^E2-C>/",BCAB1=P)2XA+G4)>V[]-C*J<L?HS_K4O[T
MQ.AQ>(2-%XX3SKL_N>7UM+3T&H#CK_,&ER0WK9$%]A]:*=3GM590:HUDK]3I
M!O>/33$#1:&C%HLWKS>9GVJ5B>D;==>BU#R5OJ$W&RY("[P%XE(GD8.A@F I
MK!;QOEQE8>.G6@OAAZ]+;I?\_2SYQJ]Y<N,K>2*JQS!\Y#%EE(QOBI^6B0#G
M8:T4L#&/3,RT,8@0?GUZ-OA3,Y+6(3C(%!D$!AAA6,C4#"W5\?XA?UK-WZ(0
MG$[BNJ@O=CR+U>Y>+3IQ\[*QAY[SG!$J5PE:NYQOMYP;[WRZY>S"(U4=COH[
MJ^GO6R_[M*KG-2U^H]:-,/RI%7Z,?3!NM;H/>'FWV\@CE[O&U_I<JV6;NP[7
MJE*&:P=7*)3Q2WEMV<NG2MCADTHS @Z>R%RV93!KX32]:G[$K1\OM+2JP=Q@
M[9VE%S+6@?@@9V+W^?;NZ]>O"?U_H@(U&:KTIQ]W7^P<[NXCU5)UH?J+F$JY
M8*-%7GGNBD!,1%Z"Q*=>HH0KC')J?NY@89] ) ?"!&,&QU+?0'@@F2>IH;*O
M4=^[Y/#4#BO$85&VU] X>^0:EMW"=D&EPS!;A+UV,6$48Q-4<UZGS/IZ#4I#
M)IV69+>4;:UU6K86,\SX-"IFO"\[B^I*TKKCDWET1*@N591,\=LX3Y/(9(>0
M14 M>6VU\F)Q%GO,!6.)=/_:]NBNF6!Z5*:X.J)_TG_;^_#!AW/"(),AY=61
M[0FSO[9)*K\;?C6Y'(TL2IELNBVVZ1"6">_V M];ADT?L8$!OA=+Q9VGL Q&
M*C4,"OCJ-:[4.#:+R:W4&T@4'&3">#Y8:9J59&#&[[DJ8R=A<"HBN@/M-8OV
M&59*O+8'5RK3@RXQ;Y_HJ>ZX;=7.J[9JIZW:::MV'KH_U&+_][H5,=/9&-4\
M;"UIH+FG.>[?IM_Q" $?H-Z1T0 VHY'A2H1=&6VH*'(EE:'8R'2P6=]D&8X*
M,T)=1L'8H+;+=([)1\)VUREMCY)ZTH[$#I"VKC#$=CB*&N3BALP=@.ZP(F&@
M8JQ'P#1K+H,Q0?C$=)SD29!,':LG=T&W%$)@%5A#R?5,9/_&XFN;NZNTG@MZ
M+HT/@P_(^--9[O+T*  NR%WQ CP[#BUVG]E*?0O %,:(X5#E,\5(4,<:ADU@
MG('IR._(I.0^NEP 75Z.]1MWZ_7QF\Y5L$!)1>,M^;O\BZP<BJPP@*%>]EC
M;$32EE 9/A6R@(VCLWZV:"N;*)N-C^D/C C-F6G8;@)7,M8]5<3,TPB'OUH'
MZ-DY*6B$OR."+$)SC?SVJY8L*WB;IN+&A-2T4"Z&%Z@=.U<C&909=L5I>6:>
MN$PTWL1BF2#:4>/S6+/F>JE X5&3:93,%?D[2<?1"]?ZW 35O$<'R6,J5/W,
MC^SN;4ISROO92A,32$6+#6V;.+<CK3=_]^W"!Q3!=MNY%Q%KO*7$(E9PD.%J
ML6(S"D0",<[1W 3^#2 :&_0E9J%7A4%EN&!T-E[6%OCP84F\6PFX%PEH/ [A
MR)"3(67O8@9G L=9UN[5),12=WQ5:LJQ*@Y381YF,L&<3-YZO^OL_39^15,_
M51,\S9Q;P=C&/'E 7[>U^Q]\;>#R;;PO7#'H,4,"ZSDHTI3@#X2.F&$* XR.
MH0JPS]>4.*/%5YC\2(47RB=P)GJRU- P.0"R"PM1F*CUA9^Z3#3>%UZ0B27+
MF-)UH9HD,563$TD$TY=EQ6BD TV9L6J7C1GE)%(EPSG)#[G0.K>IP*'2EC@P
M+ -*)D35RD\K/T9^&N_H+K75B82D"O='4RDK*"5.);[U$)$?0*ISXBP5C0<O
M4&PEY,$7'TI(X]V&A1TF5BK,V,IR28FPA)2*2,X$%</X($<4F +KW7%==,0X
MF:E+Q9W,*7A:DA?5)85];;@7B* >:16ZQE"6*X7DS=O*9'A)L&$\ ?[)$F,M
MYA6&%9EEFKO)42?SU!0EIR:PS*VG>"Q%JCJVY)XW/&84QW9=[@AF_0RS:V)A
M,V.T>AA6[XD+MZ]ZBH;*@2@[7T1N;R8LK$O=9UY8^:0^>3X^U(7=..&N#>\3
MC3LOVVVYT:Q?)&*MJC!.]6K=2MY1[Z:/\@]5I&H-2BR:A)^S@)E QKB#^PCI
M$G:]",PQK8*1RA>O5_ 6/U3SA%KJ,6Q>(G ?-SL#>_<IM;DH$+2D_*IB-(\O
M$E!W,:-^+E0<&(ZR81)J)"Z;25**V%29LK .]1-;S#>(95ZD0]/]LIAF"N$[
M>:J_@FZ*DN K^+4=O"\]3R9!R\.-$.&3I/@7RS<"ROG.2*9V 0H(;E"D2- ]
M5C&VS).L!61V(/+Y=)S0S4=1DH3XKT[Q[F-PNF'KC?%O!3,\_G>!Z'O09ED1
MP_NN,8:[?DIP;="M2'0'EX9O8$J,,EOH/1HGY;12ZR5#AH>,F<@7"#KT A8'
M@:RX$9,*X6&6-.VVV'U7YQ I4VR/3E$D*08;R> K)_YLT4EGB;(W5Y;H DTX
M<L!XJ5!;,F=:+W2.FK =R0F0J 0<>MVBNN(W?"Z:<=,NV^XB-$0L#]$)[7@3
M=+M@)#@+L$S%QOXFUS<@"@PF#+R[?)PYTNK2\=.3B0HUN'VX!YF&5FHAH$V;
MZ]P"8OPNDF9?(+K!VE8M1R.NT_8VZBHL5&<>8^%BCTI:^R$RJ-KY,7*5-5S'
MK1?$_W4+\6\A_BW$_Z$A_JC2N1'GA(TYWMI(;4ZP&2ZZ1'.A1M@3E$K9X#,%
MLJF-0(:;G(&Q)$.PY0.LX:?-:9844>A\&--=VU@[J%B=P5/KZME<!;M6EOQ@
MQ;Z#'\&UPDJ,6"5%VS-P/1*[NSO-3XP]3>J.1[*ZUB#%5/>LB5D[<EURJ[XS
M?$"B<XE(R<M$8S5WQ%58U'E'Q;0%VHY4TD,A_U%@CA;]'DMZN;P+#GLA/I !
M(Y%X^] RR<,7);UFU=/!+=>#/Y +8Z ^9F3<XM6EA+'J'2-H2ZX5&YCG)<Q9
M2$!1>E(Z/5UR07_DYM'8&?(?\ '#;@W-"3P226]\,NPHGILHNZT=E5.,@LBH
M8[D4.F6KK! D(Z8N<R;,XSS_Q8JS1?(+&]77659P!KD2N7!R/9&A\F,(I?@.
MN3S6IXFCB#=<$ _4%,Q/N%/ 4,$IQ/F F&]J]AVJ"+R!E"&H3,.Q&*"8>R5R
M63&<Z-PTULL,(=T;77E?]/>!SF%F YC089$F(_GMS;;^66P$N(HI@0%?;7;P
MOS"M[DM0,Z0B%?W!) Z!A:Y8H#BE**>HQ4Q];>@ Y8[;RY7>/CY(U\.,_%T1
MAZ";?OIQ[]G^H>C'<$I>Y"+$ >Z^/.Q;UA!WR%N=3.#/_;U#4.D25IIX"PKN
M4N>PO6T8UI+-!WR@7Y)LBFM4G!2I! $1G]4\EE'6$?M23,$_02JG!QO=>QS3
M%TWS%IDYMB/&H/?NZ]=;L# ><(0?%D:%8_T0)<,4MO]<;.R\>KWS:E.\E;#]
M1TG\D+.IME"?^/1^#S..@>$%R/,2<O=_84S_[P''M+XJ"9F'WO;/SH_[O=/C
MWGE'G'<_W%M(9\EXCL YT"&+K!3OJ5,/3!UVB-I]OO>  SL'92:."Y1*V/#%
M%]C+43/O'V8HI;LOGS5#2M_);P?B?^\_8\JRU_O\[_.7N_S'WO[SUZT.6:I#
M'GI,K7]T9_Y1XZ%0I\9%F;KD*H*(+B@D,4R3"\QY@@4/B@;- &5:*R7<FPF]
M##BOP_#!2MM@C_N:/*HR05QESZF''XPGH[Y-T>"/7+>0_[!;$":(??)\)^,G
M>>Y-5PS(=P"[)7&(7NI<7(9(##M(GJ*?)C/&1[ET+0\;T9!,B[<P3 :"15X=
M;MG%RG(O*MLPN8U]/%+9?MYTV<;8AZD70:Q0$0>.H]O#YUT3U3#=$R]UH$$I
MY 7VM:0@!^%9A@CF\0053UO*[>.CB"H0)8;E7#TTR= D0U7J*#.)K\MB8"B8
MPD_92MHCE;0739>T@0?.(LB3#/(*4I9H34,U592091P8'(.<K/*&XO&N.*V$
M$>$W-:'&7 P/2ZGW"L;=:>,BZ!?E)KP^6T9*2: 1#89G(KMJJLS^SOV].'I?
MH8W ;[[J.+1-G5UKU22V$4B35?"WX%80'Z<@OEPG02Q#S;QB:8/RD(^T7J45
ML\RR)UO91 AKBL'QV/X"+W&(>0/# UW9ZR9T"Z^S<HUSNK:SE@C.:03OWL7[
M,Q0O"^6D0<-QCF3"=1(FH#M<%2Y%C5&1E +S<JW@/5+!>]5TP4-;<R1UA&8;
M^XMR;O<,Q^YJ]A.W3]FVZ,Q"9!-"=9;\ZJ8$<IIJJ@8QTE"1J]+%(_\.DQH@
M_&(F,2]65MG8 =QP9]K6W)UYLRTO52H1RU=;N2#CG>N7])'2K; ^3F%]O0["
M.DE"EQ1?LD'97/;27+5+41/WL!>A@>T,[$PNN;[D+A$(8+5;\E.MOFKA^KL[
M+5Z_Q>NW>/V[QNO?5W>MB*"2JP#"C\H&+U@U;=C"1_!=SH#_PK:I;+B";8T9
M4-N[S4>*5US^TL5?ZAB 0<-5JUY#HC( 4":FL"B3P*QAA[P:CEQCZO]\*F,L
M-X_4A<XX [1^5DV[M&EI-QZF?L727F@Y#^8\UEA;-Q4S*&")@],Y[S 8%5W3
M !NHH@HNHMQSGRM]O5*F$ ,C/K_",>A4"I%9JAA%:H->+NQ=08#;*#%19F3N
MDP&1.[S*^LG2/8WLNBT7#*??^H/3WOFY^.V7WN?>V3O<7JMO*DQL1S_TWA9>
M*BZI&?;AP<1%D$Q-T3JN$ZP_MXDX"D\JJB_ )C4<Y,0 IDT)$/<'YA3 UJ""
M:9<X&"M)"4!^\QEVT"-/,6MZV1[9>:PQK;/"1C_X(Y&<9NK _N&/!LE^C$N"
MUJ!IF%+Q1,!O3JJ."'U3,>E\&X^/J9O\@AX7S$\LTD]O5-6)5<G/7O_-GYOO
MJ/566<(('_[2'[SO(03P8^^D?PSV^^?>>>_H\_$O8+6?#_J#7\$:?W?VZ^D)
MF^\>ZMB:Y->S*;E'W[OG)V? V^)_;S7H9KVO*\":_HL@_=W8Q?AG(BX-75[?
M\UG6Y\7<=KD9)6XLLMWI-R2YTJ&P\:7FR-IVMDUN]S\DIN@_D]F'51E[AYG0
MXE.A+_Z0L4J?]!I=O[?Y$=Y9)(YE%C!^&XML/NE_%RJ5V5]>U>A5// DG%.2
MX$"TJW:=WM;W697W^BB?;+15G&AL&YH\[37V0'-OZF66O(-&+Y[6+FSHRKHW
MN[ YEL+QT>#HP]&IY_V>O1-GI\=G'\[>_]YXI[==?<U??:VR>V0OIM'+[8B(
M-RCSUBZEQC],HY=2J[G:Y7:/3X4QFY.T"WYQC,!F^#>*%%PH3+'P_N7A1:'^
MTZZQQC],H]>8C<"TZZPI;^1QKK-50C3MRFKHPU0P,8Q ;2YPHKDC6S/L_&Z+
MG6^Q\RUV_CMRW3-XZA:QV:/3T][_B/X!/-^GWW%R<"X^P3/#/!Q]^O2A?TSS
M=,<P]S51R??*7]7HF7@"F]->NSFUFU.[.35P<X+=Z?S7M[ 5]4[/^Z?O88J.
MSS[VQ+M>[WP-RJ_6#W9MQVGNO\N/?J7_.8&'CY2YZ/.=ZUQ0;S%Z%\="IE&4
MS.PTVL];6'ASP IN!G-VH^)QO\LAU>>I0]1!.*0\E7&&O5(/Z"\D-]G8Z6S!
M3YO?13U=O6J\ Z<K\Q'X6]+UP8#V9=S_RS!ALMID/MOK/G]^6]%9A'^&"=':
M6Z/"'$#"??7/J7F=5_UN@7JU7[]W[.BFO6#QU>#?EK)_R09Q3G1Y2$\97XA^
MC/VX5H^;M9/_UR;_<S*743XG=IA57D0K)K?65\Y'V7W6?<;9E<6)%LG05/LB
M,0]6^Q(Q)1:H[8LYF'R9UX "*]AZ5/>&A8TGH'I;2;G-_-M%;]FM;0'H4@%H
M5_[#K?RME^W:O^,W4-DB_!+Y::K(/*S*QPH"TNX0#RTGK92LIY1\C]QI\V+1
MRPQ5F*XVXO.P$9]5$0</$F'X7A'G!POIK(A5:2?[;B>[7=IW'2!K*(:II?-H
MZ3P:\W#?$1W8(AU;#.U?).AJ&3P>_@7>_FT] BZ$EH2CH2_D$:RMEF>C"7/?
M\FRT*ZL1#]/LY=;R;+2K;_V>JEUN#7V81B^WMEJ]26_C<:ZQ5J6UR^T>GZJE
M#FJ7TO=XJBMP)CX7QPW;:*O>UN-A&KTF6TZ.AW\'S>/D>&J5Q/OW74G\5\N&
M+Q,=WE0UO#U,PCG\,\XGT<__'U!+ P04    "  [AG!4AI;^AZTO  "+" (
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M(@UC"=2, 0<:<*#MQND$'.AZS'\0@( ##3C01X4#W0LXT( ##3C0@ /]LBB
M"V"XH(>-CZY!,(6]7B@^U/6V,R;R.E;9K8VRNKM2\7'I=3)>QFIM\-H](86Q
MIE)K:@A5'N5BW/#F*#2L#$]'C&&HL6/^H,@7,1<5^41E)<CDK,&S1LS)M2(Z
M,C?$*4=4RTQEN9?T\6*_I7>-DXD32+1F*J8>;7[]M_^<_DBHW]14+%<\FSIP
M\SXHR[3"K;^5!@QCO?^XXU59<ZV+Z<PDIBBJ[XW"2X#)#;@ 6),NEE=!_PXI
MW _?+[3@HG18CIFO].-2:-_,%";.9IGXLXCE<B&X70Q44 ^WF\W]94%WF#>N
M#&P:%HD:^57@&_T9(G?/VAZY&RQER"RX#>1H+%.JYTY5[F3*2*_!Q'%MLE&>
MSC8J,;&<#2B^,2[P&!&E$WZ#<D&T1N75&O)4'DD2I<V<][  ULL=N87G7E@]
MJ7VIJ[: DDNN1/4Y\@N:@3)/7@8>K=I8!//ZI*E>MJ[DNPBI\?64U>=MEU6O
M]YK9.BHA."Y;/8+\P0XSE;!NG2A['*34OI56]*B %9Q7$#R\W-/=#=CD4S ?
MB.8,[NZDHR(L892@5["'72_ 5CE9==@$"3\N-UN+6$4;#'X8S>M)>=P4&?H\
MT:11ET2@9FB;)3HV0QYADO\5T8N'%"P'@WRI6=Z@",I-W)\VJYM(*SCI-Q!]
M4H)IA)@ ))W!E 896B'3]E/J@!<_@0[P4.[H((P$.#T@,F#KT\;(8^-&63'T
ME8.UZ;T==07*)2S_GW/Y[[=]^5=T8"M],6]K\I%CR!I&Q11LM[O;W6MRY>V^
M:?QBC1M4-F=SP3,LE&(G(J)6X!O^IF(MP,K3MI1#!T% %@3DSE7_F>CX9X5I
M]WF[).FIW&BY()&GE?.\T'7PI,\L>[AB$8>E\$5+H?UKH>9B^P:!,QN<I1TI
MG>NR5XAAC\O4-"R4;[-06K]2/#/2!D?J]N(AKI2P&+[%8KAI^UI )'TNIG 5
MY$75Y#W(%)QDP:Y%*C)N6<NGKAG*PEKYCI5Z]'8_5Z9'!ZTPH[X=Z+PM<(0
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MBDQ/Y*PQ.&%(@U<&)-S=&AO83P.8,8 9 YBQW6"3 &9<C_D/ A# C ',^*C
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MQ+7*D;N2 KK72H&CQD&&$2F'K<9M6,STEM?FN3M6VDU?D#A W +$+4#<6HU
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M 0CQXQ _?ESQXV<A?GQW_/CO!HNQL\[G8L5;(Q7/X9])/DU^__]02P,$%
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M!,9M#7PT1C:C2 1I9H 1MTW/F4RG#EX6M$>0^^3=V-";;*.$P0C?-WC:F[/
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M,3B Z3,:>>HL2Y1F&T T[8.]8S@=&\ 1FR9#&89TUJ3F,G1CV6H&8":$!C(
M<Q91V/1U7"Q3HD>P34'Z18/[G*H!!DWH8AG4Q_/_K\[_8=WYOX1NFD/D%]Q*
MR?TEXIX)@#I+7B2B)")&,-KX+DG1WG62 H<FS_  '6DD*/*E.!2/H;Q1J452
M'3=P^@D48X, TF!]D"74 +P$]U%XQ/)4UMRACDD(5'#$\Z0A0AV#&6PV@(%7
M3GZ8DD$P.?LJD?_F99>;!4'&)*6A@UJ^>](F.S=HEZ86RZ )Q96^Z@$Z[AK5
MO7 540,>BGF09UV5)6QC;Y.-0;'6Q>PA-R4GYG'+&A?NF<4YH?6(.7 F!@?%
MIT!X(?=N0]1=R"W559][SRW6>N&X+R!_IGH5!#PF2T4:ISL**:ZQB OGHPOQ
M?9[XY<:L*]XT1W0S-I<^DK"G<7JTY>Y[>G3[Q>-L:Q'WKGO6_OE4O?T"PN#8
M;L"&P;'KP$^%PJL1,]M#Q >V_6GY*P2VGS4+F%K_/"0%&(9X1 +P/(_@O7F_
M]ZYB=>QZS][>S_Y4CU_5\)>Q:_\S8?&6('N6XJQ;+1O3,YQWL<^Q/D-5,P,T
M=W35TPQ]5.AY*KO&VXP/MQGK7OTZJ96*6\2GT4COP0_8W4B$/6$,,F* DM%8
M/<@X8MMT!96V4->M!1Y;FLZM%@.A1"LA8YR!3M"@HRS'2("YLP!+:\#,)!0N
M;%5+YRF6L <.KP'X_ 8Y$::-U0 _EZ%[+*>^HE1!#9UT7WR@\B8Y37P68L.Q
MFX6ZT9+7.;RAGAW6TVQWT+CE==_H"N2;[P@8V,@.$8=5Q_"B8VL?R05]5X1M
MN=+GUTY'W??IJ#X=U:>C^G14GX[JTU%].NK<=-3G+A2E!SU!=1<488X9#N04
MY4Z!+"N/V$!][#(H)UJ>4(0_#E!Q0\,/X9@#8PMR=L.C3.0(7HTB/P,46.K#
M:13H&=XC%8-:;@X!4*\1(584RN>T0M>XJV?<LKQ+=ZKI12WPB[S0^K1;>>3"
M<]) 8J!LE>FW[-*+*G1BTWI^+@NEP;*A0CH+A!SF=U!:(6(3$Z2=C&^4A-D0
MDKAH/%BLA6@PSP"J=#KGMZ+HF$Z X&#6#V"K0I.S9*RZZ:0EF*/#XQ\L!<[3
M7=/YIQI#1)K'1$C"<YY:TM&SO\_7A[]($LVAT2)JY-[8JKG[A:1Y?5Q]WK/W
M<,]>W4$]KJN' A[(%5>U!:M!IQX%>94*69>CCL"UDZF@WZ:)[)@3I"/2$:9^
M$EJJ+(Z6/*'#Y)^7&]$NRPO8<+^&$YI&$U6-^O#3BX>MU@$_9ZYCY6#58;&_
MV(P*YU,NITX;L& /EKVNE'U0?RB=9:04+@I9IT@G=*':4O;40ZS?Q1="M9RY
M:R)FFO".92C,-W,FMY5:ILYBB-:-*;"88<Q-%EHN/A^$CE%<\U3G5E,/B@'R
M3BD2EE>+FD)1G0>[&\9O$D29-BC0*HE"8#[SQC&;&4Q.X,[)+#*+CQ<I.9-T
MC.(B"6O:-,2Q<K&8"XS'!V3'+3R(9F5W)7)&E7E.J!?UM;0V\C[B4VMR)YD]
MZ(O)3:BD LW<C'P'J.OMV&08Q&/WG4\@ %2DX:?*ANBTFLS-JU%V@3\N'G%<
MU#T#'7LK&,Q+\N(ZO&;A<&,+LG8<DL?NX=7&PG6:]N2YDN19]V27\M&68[6"
MB6NTD=CT<,?*OUZ1HP''B58QO-Z\)Z+.SQK3CV.FV+;T_8S51(XB[JLF<O>M
M),VWZT7R<RV[UZMNFAHE Y7K0 "?Q+T&^\ICWA,Y.MX'T<7>AS4Q4%OU\;.O
M@SQ_77OK=$[RHJTC%]J950:5.R^0T2HB]V: )@+&J:P\SRE]4*7T 4=3-293
M,D?]-CHX_5EN2<&L"1QSVQ W[Q,%)ES^882VJC$7IL\EB]=A@\.IB9Z%*L@&
MIG4@W!@+7"M/QN7CZ G+Q\MFTC(<)DUJCT6T+&CL,*/&)%/SB@1^';C!J<DO
M#\#4EYA&N7X@T"^S\H^821YQ&,H5BPRS!$QB1#(@GT(%.H$L3Q.1O9%)FHF<
M3*WE[XK#7&$63\""IT:9Y68N:/M+X Z!&E#!3!25S1MD-E@7*#\R^ I9+%'S
M3X"@Q@U0F7H\R3M1VSRO!E)3*@+#>&72-$8P_*5+JI0CU**1&M:D8C%J) ?2
M&!DPC IA"^U,DK9*#F!IH0 >ET,S5]%[$POPE/%,;%.*?A:GB33)N"9>3<ZG
M;E<$QL.1"%@.9@3#W?@#Y^\(L]K0];!^J>S\1Z?,^D3>GT_D/?")O#Z1UR?R
M^D1>G\CK$WE](N]2<677PYZNN_O^B_PA1E*+Z4#@SUC68#Z:(EMK:E!8D%1]
M6_!&17)F6(2-,# 8Y%BBNPIC8=(BP/(^68Y0*\S5OI$JLK[8!.UF@1G5Q8=.
ME^^,:>(*8D6Y= _6;#I&!'G^+"'?=66$F)H]CBE0-(299G)Q)ML;MPUVI[P
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MVF9N>U/Z%^>0VH<%IDQI# QKFXKM$C7"$A!FQ$?H;>IF"7KV';=DF(^-5-%
M?(A&'@;#4HC&3!8Q48:.*<?H2A'FZ"46Z>N^^@VMK!\L)5/??:O4\@,;>22V
M-BVQ,793I676DB6$FAF:I>9V/8V*H8SB-HLTH><$!D?6)Y<CM#1*?:6+@8P/
MH21K3%-FS'G,(N>'T*7X^H?)?9N*R..^B=1E4[(4J&1[""2BP@+2(\UWMUA+
MDYU4'W+ 0Y&_:7B4!4*='C;;#NBT2/2<NPM3NU?L .8IB+2$$8*XME3%!P]9
M>AZ7>VHV8UL':BB>)Q[E4S5?*@I5_S*9R2A4AVIS@:N#,KRRPQR6<0G9L))9
M326N\=AB)/K"EU6DU[GNKS>K7_A2;G"ZAE4O+[/R,P['N#D)JSWO^[#M3.!5
M1;I9GR>#"!/[G*APL%SP5GB$N;$-.#8'W/88QDI3.#FU:S-,A;")Q/8(:#'%
M=+H/AI$T6',)%<*:P[?TN3NV9>*,)+RAL)_TPQJCS2@C(:2"HH=5)'K40:N7
MV<J2%T,!\P)O,?*BM;/J$N\:3FPOZ1:V\FJ]FBETIP $YC$HJS,95!%VEEL"
M'] 2,   1KVZ@2G1A$UE1*@EA#!0$D@HY%#G(C$WL^V%Z0- N=(&AH2R0",1
M-IA#+)%=M$1AO4YK$RB+$^RL][R-(%FK]:PM'[TT7)(T;*V#-+3VRUH*14_"
M2*6UKWK^I\U_&R;BKRRTT"^D#I.X1!%?,K2GDOD%^\)'C4F%U%:@E81]9\R$
M)+T[!X9)C([=&5O_EG%U!D5SU@GP+'QJE6F&F2.@Q2-(EE'T&SD^3M<A[,+.
M)#Q(LP+AVBC$I8,-#Z=\&@*E<:,8U^UX2)^8V1H&<PMO-1\4_K8<?8OK'V97
M1EA:9^J]$]B/$-O'LK%(Z58#SBMB<TG:AK=:PEISQY[Q#^/@&^V=3;!"QKHX
M?HTK+RY! >-\*8UH7<,PC;9@0%+G&8[3;Y@,GKP#$H+J2%'JDT5VR[B:,]:Q
M[:4C4R!EIZR+O] +K\4*K[J7=O^!7:"G'(&B@N(PLTV<*P!'C)U*96 EF%D*
MX\RPX2V&',%4Y<[*4IMTPSZ3MSMNM+6$-RK"K,R&0_$R@@@DF$R";&!"-=IV
M+W/@XR_OI/=:[9*TVMU5UVH_DM7YE?\ELF3YS5=^[;3?0Y_VZ]-^?=JO3_OU
M:;\^[=>G_=8F[;>]U]RE!YW=HMK9'@&/T1DP:2;DO90G?"IA9@UW,UYF4B\[
M8JSR+L1Y0TC3SRA14:/4FLB@A8-]SW^(&-TG/07,%)L(8D_$ 2X*2R552(Z9
M$:)E]14\9F0< P[<+G8.%"#:-$LZUD;)0#1CL7R:R!]@Z" %*\QVXX'I1*8Y
MO"V8"&[IJP1_,VE7&+0T,XM8)#V$7^$P+(_8L"]B!>OCMG&7/D*W3%^9QDZ1
M4B'^E G.WL^2!.1"C+\#9:3]?V48^07[3&<QO&Z:H'#OY-XM&%L",7#G\8$M
M*;E6W+NBX$:LBFVE"(IU"2%^/#IV6"QZ:/VAD6@L.PR!Q#/]7B5<8CU$2#]\
M:2X2'0+A4M5J!%J< :AQUF=C(A//]JX*I7FW U.\FK?'8K#G-R)/]$/@8^-)
MLC$:F3>E*GG&FNR?!##O/&TNO<_"QIOD.6PYA65_L K<!*!2MM'>I"0U"@_!
MK /8K#Z^#K,!A1-)#M#UQ5-*#G0^PBG4!?('NK99]K79W6NR\ZD42DXA+GCR
M4@+E% 1VU3LW-2[VY$JY=-MB&4H7_=W1N!D8X\;0 $U#/<>H0RNFW %MX^!(
M25ASC.\17C)2@T4F4AVPZP/L66;?"TXG4_-B9CD:)B 47T26K:I7;97:LK;:
MJV[^7Y1\^+H&8:V#Q0)'O(@_&_.0^818='T6;7##)GW/A5K*4\HID;DD"*G+
M9AFS+$^SQ-,.3N\<^L:>-\4-0)78>T7HHYK'TTN*8[4S-=J/N2&''[U:G!'Z
M  O3B*DWH)VWR-M@Y1U, M(,5K3[ZFZ'3O@&_W]\IT%$RK!=ON7QUO 6D_1E
MR)S7QUXWT$!W737KO?,RBHOIBR]NX=[CID3H?/*#S!!3#S3D=]\T#_?7>8^G
M>>4^V*CV%&;4:46('#W*IG^]TVSMK?,&+\54]F3\R%T^,<>8ITU/F[7;Y6L1
MB6$?3'I/G9XZ:[?+'_FMITM/E[7;Y;,!EY&GS&>DS%4))-7<$]"V;@ WJ1VL
M99[WX:Q_-S&5-J T.'JKNY$:N;US?V^A-_7(9&V,8 /NS:;(K_,.D'>63D8B
M%YM7\: $H,?F_]A_'R<W_(8O9,/+IYSW@CV#%PP=NI^5'LJ41ZZGL_GAG6/>
M.59OVO:JM'>.U737/&UZYUA]]\U3IW>.U7''K,KIJ<V[O%Z,WI;AR/IIX;NZ
M, #>W^;=/][?5ML-]_ZV%_"W?<0-O0OYQ>L[WKU6"U+VRKAWFKT\Q:VQ.K[D
MHLBZP16\\7 %'J[ PQ5XN (/5^#A"CQ<P3/ %?AD.>^\\\Z[]=UP;Y+[7 'O
M!JKQWOD, $]M/@.@SGOFZ>T%LL@\8:YB-=9/+\_#/]T#_[2WZO!/GPA1$)&!
MOO 1 0O](TND#F50HS8G"\2#\H#F2+6U[W%R74;\1SPLAYU8P<="-$$U&(@D
MP'96,C8PE*995H[O;S S34.3 JT3;RFA,!K,S1(((R%LI0QQ_RN]H@E9\&K(
MI>]0NJJT7_<6&>>Q:3UN^T*GD2"(481T[94:FX\0Q13A98N6EI-XG&7T4IUU
ML%\X?:$C4]-R#7D"&Z!;UG@KJ]XN_/T(RPQE .MZSQ,@$!5S=F)&B+"/7">+
M>?1V6[YK6!#6.V%2AT,E#7*FB@7;:&WF*\&V/N)V".3EFG^X#A\#GJ8.B;7Z
M;,"A#8=_5WXB9.J,4$7OZ%.79)$HT'K=$S3RWJ,6:;2;1=%X"NJW/%,H JF+
MUV$?&^%4)8P$"^A*&A@;C<+#"QX1_Z%HZ<@8J<V+D%44(?,UPOU5UPB_2HTO
MD<="9<L'!*T&J>S+OC=MT-[GR7D1)^+^:FF#<"J(6]#6M+Q!-&JNJ17:4!!M
MY'WD5((]F/1\@-4FK+R,= W7Q&"H\&1%&'"54/\W:DJ/',+RIG0\2_LJD=C(
M#LXMS!O$:Q)QH(4YEH)$4-<W./>TS@9BLE&5[5P'ITW>EB_F W,ZX+DL0'WM
M5KOD30!JU\ N\^TGE\",=5=/KR>53-431)BD),D4+L:QN-T0>K-!VE JTXS0
MW 4I543B"*&.AEINRF%O2%2,;,."/T\OZ&_\TKD= MDF ?9+0@?V/LR2(<*S
MV_9JC=+0(!D2,8S@G1M;3V>842Y"8?@Y%CV52MNXLE@%L*OI;(EFI4S- P)=
M=; 19>+:-C;N6Z9MXUB,:S1C!-(WS219T.<Q-IV#00<JE%UI]558VHB35 G$
M,)W$? XS>"P-KZ.P9JTD^C=\ L\+D@BFHS ZJ;C4#(!D6UW$A9<6BY46[9I+
M"X1"[W(9H5L&B-WTR7 ='F_1<U.T<<T/67L=6Y7*Q')F=ZK/0O5$G6I[7O$4
M&6^0:=Z22R0.O"9OC'E)[4KR!=PS,QW&^<Q&4Z"VKOEP1=L2&E-/#&HZ<TP.
M6V[H41-V]:?[@OEUK^;\6E:UK6J+2G;P _8V$F'/:*@\H..)'!]O,[=<&C 4
M@3(.DB/RJ&"VZ?'$E8F*@5?O3B-L[J/9?H,=--CK!CMLL#<-UMJ%_]KPWQ[-
MBK9U]L[RLLZ2&WDC<I=NI9]LA?==CQ[3&F;U?"[/L[)S:F0=HRDS<NI4V7\8
M*M(\&.X]%EKD+7:LTC'I=\3>N5;OD=B("B5SF/!1S+(A"?B18A)--F1J$(5#
MTV()Q6 L<J6*1A'4)ZCAFEF05N<,I;R_-GK4 IX67<[[@A<^MG5_N[]885)K
MQU<F^<HD7YGD*Y-\99*O3/*522M2F50W(?<0B38#8N5./MQ[LWP^K+R';;V-
M.]W>.69?>2PB=LHU+"SZ_;?=O?8Q^R;_E8F$ZT<)D]UG?@8#73S];V71J_46
M0O,F4AE%:G:F<JV?9ZX2]N?IQ5T1[MJ0U,^D.:_NFT'U\_/EU;?SZY)JN5J4
M=P'F_M'JBK*UI;OR>UEQX?;-J4CL$S8OYQ'[(!.!"0.>M%[V?0!Y\1ZZ":=?
MR.I0%_HFC]@5AY=UFO5X2NSRIY%C[=UCS3;R-,I-3W O\8J^*-.)^8B=@=V9
M]3)T;@OV)5(=S"Y(GU9:-A>38 E/\8&GCRR+WGM <=;*4-@Z<<N]+ZYY.!>
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M,1G GR/X!&^F"YB(;H,,],4B@GGA#D0)[8&'8JR?9K!HM)C\J&%))-8#$9'
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M,_I,4:IG9,@W\PO6_8V=^96VV3FR]L54V+%I.4&I:9BLFMZR$Y)--6T:4P[
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MIAF.+_FY$B"4Y#[*6?YG"=16J#ODEW2(-AC%7.5MR]'\9IW)QPRP?ID1*55
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M"#/5I#Q'[/N5/3X/*TJB$$\<)"95/N@5M3(,?Y(DFVF8T1J(4JFG-SGG=1*
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MLL&<2SLPG:+("$=9KDN1^BIG.$UL;1/EV"]E[7:0BH.T0'<CJ"DT%B(-G9!
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M3DG?Q.ELY["FFM1*9G*2WE6\[+0XD!YA::+ 7DQ"8M#2 E;_1._F'^L)8@R
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MKN5E<],:":VMNET*J]Q>%JL\IY#!7$5H1Y8]"(:9]CT1$)9K[E?JA+1^2@W
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M,/7^["L+&<_-.*5:^EL#_7770']?,2WEBCN8-+M U'@L:4MB%KD&70PD]\3
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MU"A 4HNHRC=P/8F>$<4!&,8Z-_O5PERI$L\GJ<Y4)CI2'#\ @:._1:8::PU
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MLL1Z>-_?GO]$PQ22&9)A.N5S'-OQE08V<#BG@:/*?N4$3346D_%[P*-[7,&
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MJ!F# !,%$H6XF%0*NQC1&=#\)IT[I/;SY >N&KZC=M;%. 2)(I6X1,*$TIP
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MBAFX=>H7.N]1FPU9J+/9V(&3?SR%I%%-EDD3FWC%^@%6I#YC:;+?6/]/N(5
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M%'DW)\>VH_00N9&;._J)."N8IP@WLAC]U&A4O@ZR-T&X G,&?@VT[]PKQTU
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M&=>&QL ^@">[(O^JCA%7SFX.6VSU7?])PTC_?8"SO3[)L/@3O//%<'7R.^_
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MITF3S2#0;7?7493,K)N%NC6KK^$F?P%02P,$%     @ .X9P5"M&!<L,"@
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M;Z(BX02%$E*1;\#N!3QQ<QISPSQ<@06)G"H*30_.^9SZY8$[-G(<%%HP,GA
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M5U(Z8I[+*>G0,!70B>11KBA'1Y7Z,L3*2U*V^N^^U,5^2\S)_P%02P,$%
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M4DJMV6-#G05$/7@K/-NV4\@B-.IXAYC@QZMN@R^1T1J)AWZ$!^7<4<X+N99
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MC*L3B!2+!=RG1)"SPV[NEO$K%40-Q:UP?R%(["BE<P@V@J:+A8&MX>"D(@&
MA84(R+4H;*'%@PKOJ/#K C'\/9<NVW>E,H1W8U!H[J<*GU7VJ-TJ[ G^@GB8
M!QYF=1Y^@0)7D<'PW_#(_7);\H^Z T!SV=D2+;_++;N<MO[3LG][=-V1<ZZ)
MP/U_I<-H<QY]7&H%J-N-5*+TZ*L!_3>N-0,T;ZS<U,"R<2(ST?5_#SS)77C%
MJM3U+OA+M;X$?Z7>EK#;\)#SI>C.M> ?N^1MC7BRX5LS=OT(IZ>]HY.OQW.E
M 6E]C\)@IY'A"VJ/V#/--L@@+V50!QDD][6MUC,!IS(#$ME, U[@[1RMTN-%
M_V.?PY^^ON%?"&)>J]8^<9:V.7E9Q0%F K 8G.GX:#!@YV#G]9:=@X?PD4T!
M@E;L0I.C,"VD%;YAXWC081<"'8<.D  BQF/%3@='@^=?(.+\IJ+#&]A>!'#E
M_("KGZ<3+'!I<(RR>U!UF+5(=()5_+B5([ZP3Q'6-@46AI+7].>KGJ]Y?7D<
M^TT"-JU"W-*B-3(57Z*,W<:Q]X4V!83=(?  4Y26GKZN<\D' 7R)(1&B<G#H
MJ:>(JN,P!K4W7F96BT^88,_0U<*  M9+M67*7$!8 >]M,$[2 E!;NZ ?'H*
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M,#(Q,3(S,5]L86(N>&UL4$L! A0#%     @ .X9P5 R/8IN24P  %Q$& !0
M             ( !U=0  '-Y;BTR,#(Q,3(S,5]P<F4N>&UL4$L! A0#%
M  @ .X9P5&=DH"75G@, =[0@ !0              ( !F2@! '-Y;BTR,#(Q
M,3(S,7@Q,&LN:'1M4$L! A0#%     @ .X9P5+V],9F!=   XI(  !<
M         ( !H,<$ '-Y;BTR,#(Q,3(S,7@Q,&LP,#$N:G!G4$L! A0#%
M  @ .X9P5! H2\@*>0  %)<  !<              ( !5CP% '-Y;BTR,#(Q
M,3(S,7@Q,&LP,#(N:G!G4$L! A0#%     @ .X9P5'<WGS3^&0  >\0  !@
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M+FAT;5!+ 0(4 Q0    ( #N&<%0:)+J&\@0  ,(R   7              "
M :L2!P!S>6XM,C R,3$R,S%X97@R,60Q+FAT;5!+ 0(4 Q0    ( #N&<%0%
M\7F9H00  %H4   7              "  =(7!P!S>6XM,C R,3$R,S%X97@R
M,V0Q+FAT;5!+ 0(4 Q0    ( #N&<%0K1@7+# H  /E&   7
M  "  :@<!P!S>6XM,C R,3$R,S%X97@S,60Q+FAT;5!+ 0(4 Q0    ( #N&
M<%05N#;M7 8  $0I   7              "  >DF!P!S>6XM,C R,3$R,S%X
M97@S,F0Q+FAT;5!+ 0(4 Q0    ( #N&<%31\E(&]Q$  #Q9   6
M      "  7HM!P!S>6XM,C R,3$R,S%X97@T9#0N:'1M4$L%!@     2 !(
*QP0  *4_!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
